1	Urine	B
2	specimens	O
3	containing	O
4	either	O
5	phencyclidine	O
6	(	O
7	PCP	O
8	)	O
9	or	O
10	11	O
11	-	O
12	nor	O
13	-	O
14	delta	O
15	9	O
16	-	O
17	tetrahydrocannabinol	O
18	-	O
19	9	O
20	-	O
21	carboxylic	O
22	acid	O
23	(	O
24	9	O
25	-	O
26	THC	O
27	-	O
28	COOH	O
29	)	O
30	were	O
31	adulterated	O
32	with	O
33	sodium	O
34	chloride	O
35	,	O
36	bleach	O
37	,	O
38	vinegar	O
39	,	O
40	potassium	O
41	hydroxide	O
42	,	O
43	liquid	O
44	soap	O
45	,	O
46	2	O
47	-	O
48	propanol	O
49	,	O
50	and	O
51	ammonia	O
52	.	O

1	The	O
2	appropriate	O
3	use	O
4	and	O
5	benefits	O
6	of	O
7	bile	O
8	acid	O
9	sequestrants	O
10	,	O
11	nicotinic	O
12	acid	O
13	,	O
14	fibric	O
15	acids	O
16	,	O
17	3	B
18	-	I
19	hydroxy	I
20	-	I
21	3	I
22	-	I
23	methylglutaryl	I
24	coenzyme	I
25	A	I
26	(	I
27	HMG	I
28	-	I
29	CoA	I
30	)	I
31	reductase	I
32	inhibitors	O
33	,	O
34	and	O
35	probucol	O
36	are	O
37	individually	O
38	discussed	O
39	,	O
40	whereas	O
41	nonpharmacologic	O
42	approaches	O
43	used	O
44	in	O
45	conjunction	O
46	with	O
47	the	O
48	drugs	O
49	are	O
50	recommended	O
51	emphatically	O
52	.	O

1	SPP	B
2	also	O
3	induced	O
4	transient	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	focal	B
9	adhesion	I
10	kinase	I
11	(	O
12	p125	O
13	(	O
14	FAK	B
15	)),	O
16	a	O
17	cytosolic	B
18	tyrosine	I
19	kinase	I
20	that	O
21	localizes	O
22	in	O
23	focal	O
24	adhesions	O
25	,	O
26	and	O
27	of	O
28	the	O
29	cytoskeleton	O
30	-	O
31	associated	O
32	protein	O
33	paxillin	B
34	.	O

1	Transcripts	B
2	characterized	O
3	include	O
4	(	O
5	i	O
6	)	O
7	abundant	O
8	monocistronic	O
9	L11e	O
10	and	O
11	tricistronic	O
12	L1e	B
13	-	I
14	L10e	I
15	-	I
16	L12e	I
17	transcripts	I
18	;	O
19	(	O
20	ii	O
21	)	O
22	less	O
23	abundant	O
24	bicistronic	O
25	NAB	O
26	-	O
27	L11e	O
28	and	O
29	monocistronic	O
30	NAB	O
31	transcripts	O
32	and	O
33	(	O
34	iii	O
35	)	O
36	a	O
37	very	O
38	rare	O
39	ORF	O
40	monocistronic	O
41	transcript	O
42	.	O

1	Comparison	O
2	was	O
3	made	O
4	with	O
5	other	O
6	neuroradiological	O
7	imaging	O
8	modalities	O
9	including	O
10	CT	O
11	,	O
12	myelography	O
13	,	O
14	CT	O
15	ventriculography	O
16	,	O
17	and	O
18	CT	O
19	myelocisternography	O
20	.	O

1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	O
6	prevention	O
7	in	O
8	Indian	O
9	country	O
10	:	O
11	visionary	O
12	,	O
13	complex	O
14	,	O
15	and	O
16	practical	O
17	.	O

1	Our	O
2	mapping	O
3	results	O
4	did	O
5	not	O
6	suggest	O
7	involvement	O
8	of	O
9	this	O
10	gene	O
11	in	O
12	previously	O
13	mapped	O
14	genetic	O
15	disorders	O
16	or	O
17	in	O
18	known	O
19	neoplasia	O
20	-	O
21	associated	O
22	translocation	O
23	breakpoints	O
24	.	O

1	Effect	O
2	of	O
3	bromazepam	O
4	on	O
5	growth	O
6	hormone	O
7	and	O
8	prolactin	B
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	The	O
2	authors	O
3	evaluated	O
4	the	O
5	potential	O
6	for	O
7	thrombotic	O
8	complications	O
9	arising	O
10	from	O
11	implantation	O
12	of	O
13	a	O
14	ventricular	O
15	assist	O
16	device	O
17	(	O
18	Sarns	O
19	/	O
20	3M	O
21	-	O
22	VAD	O
23	)	O
24	in	O
25	four	O
26	calves	O
27	.	O

1	GAP	B
2	JUNCTIONS	O
3	IN	O
4	THE	O
5	BRAIN	O
6	:	O
7	PREFACE	O
8	.	O

1	Microstructure	B
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O

1	Sequence	O
2	analysis	O
3	and	O
4	identification	O
5	of	O
6	two	O
7	hyp	B
8	regulatory	I
9	mutants	I
10	.	O

1	Morphine	B
2	-	I
3	dependent	I
4	and	O
5	control	O
6	rats	O
7	in	O
8	an	O
9	oral	O
10	free	O
11	-	O
12	choice	O
13	protocol	O
14	were	O
15	treated	O
16	with	O
17	gamma	B
18	-	I
19	vinyl	O
20	GABA	O
21	(	O
22	GVG	O
23	),	O
24	60	O
25	,	O
26	120	O
27	and	O
28	240	O
29	mg	O
30	/	O
31	kg	O
32	IP	O
33	,	O
34	for	O
35	3	O
36	days	O
37	over	O
38	three	O
39	successive	O
40	periods	O
41	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	O
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	O
22	-	O
23	IV	O
24	gene	O
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	I
50	gene	I
51	(	O
52	pBLCAT2	O
53	).	O

1	In	O
2	patients	O
3	with	O
4	osteomyelitis	O
5	and	O
6	joint	O
7	empyema	O
8	(	O
9	n	O
10	=	O
11	48	O
12	)	O
13	PMN	B
14	elastase	I
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	exceeded	O
25	by	O
26	that	O
27	of	O
28	the	O
29	unspecific	O
30	erythrocyte	O
31	sedimentation	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	Although	O
2	RAD17	O
3	,	O
4	RAD24	O
5	and	O
6	MEC3	O
7	are	O
8	not	O
9	required	O
10	for	O
11	cell	O
12	cycle	O
13	arrest	O
14	when	O
15	S	O
16	phase	O
17	is	O
18	inhibited	O
19	by	O
20	hydroxyurea	O
21	(	O
22	HU	O
23	),	O
24	they	O
25	do	O
26	contribute	O
27	to	O
28	the	O
29	viability	O
30	of	O
31	yeast	O
32	cells	O
33	grown	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	HU	O
39	,	O
40	possibly	O
41	because	O
42	they	O
43	are	O
44	required	O
45	for	O
46	the	O
47	repair	O
48	of	O
49	HU	O
50	-	O
51	induced	O
52	DNA	O
53	damage	O
54	.	O

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	O

1	High	B
2	-	I
3	frequency	O
4	electrical	O
5	stimulation	O
6	in	O
7	the	O
8	hippocampus	O
9	leads	O
10	to	O
11	an	O
12	increase	O
13	in	O
14	synaptic	O
15	efficacy	O
16	that	O
17	lasts	O
18	for	O
19	many	O
20	hours	O
21	.	O

1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	I
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O

1	A	I
2	strong	O
3	trithorax	B
4	binding	I
5	site	I
6	was	O
7	found	O
8	at	O
9	the	O
10	cytological	O
11	location	O
12	of	O
13	the	O
14	fork	B
15	head	I
16	gene	I
17	,	O
18	a	O
19	region	O
20	-	O
21	specific	O
22	homeotic	B
23	gene	I
24	not	O
25	located	O
26	within	O
27	a	O
28	homeotic	O
29	complex	O
30	.	O

1	While	O
2	Pt	O
3	;	O
4	cycH	O
5	;	O
6	1	O
7	and	O
8	Os	O
9	;	O
10	cycH	O
11	;	O
12	1	O
13	were	O
14	expressed	O
15	in	O
16	all	O
17	tissues	O
18	examined	O
19	,	O
20	the	O
21	transcripts	O
22	accumulated	O
23	abundantly	O
24	in	O
25	dividing	O
26	cells	O
27	.	O

1	For	O
2	228	O
3	of	O
4	425	O
5	deaths	O
6	(	O
7	54	O
8	%)	O
9	occurring	O
10	among	O
11	26	O
12	100	O
13	people	O
14	of	O
15	known	O
16	age	O
17	in	O
18	the	O
19	Malumfashi	O
20	area	O
21	of	O
22	northern	O
23	Nigeria	O
24	,	O
25	data	O
26	were	O
27	collected	O
28	on	O
29	symptoms	O
30	present	O
31	prior	O
32	to	O
33	death	O
34	.	O

1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O

1	99mTc	O
2	phytate	O
3	,	O
4	198Au	O
5	colloid	O
6	,	O
7	and	O
8	99mTc	O
9	antimony	O
10	sulfide	O
11	have	O
12	been	O
13	used	O
14	;	O
15	the	O
16	last	O
17	appears	O
18	to	O
19	have	O
20	been	O
21	the	O
22	most	O
23	satisfactory	O
24	.	O

1	Refined	B
2	Cox	O
3	models	O
4	using	O
5	a	O
6	CD4	B
7	count	O
8	of	O
9	150	O
10	/	O
11	microL	O
12	rather	O
13	than	O
14	200	O
15	/	O
16	microL	O
17	to	O
18	distinguish	O
19	I0	O
20	and	O
21	I1	O
22	yielded	O
23	a	O
24	simplified	O
25	model	O
26	with	O
27	better	O
28	fit	O
29	to	O
30	the	O
31	observed	O
32	data	O
33	.	O

1	A	I
2	high	O
3	mean	O
4	intensity	O
5	of	O
6	CLTPA	O
7	(	O
8	standardized	O
9	multivariate	O
10	regression	O
11	coefficient	O
12	beta	B
13	-	I
14	0	O
15	.	O
16	059	O
17	,	O
18	p	O
19	=	O
20	0	O
21	.	O
22	020	O
23	)	O
24	and	O
25	a	O
26	high	O
27	maximal	O
28	oxygen	O
29	uptake	O
30	(	O
31	beta	B
32	-	I
33	0	O
34	.	O
35	163	O
36	,	O
37	p	O
38	<	O
39	0	O
40	.	O
41	001	O
42	)	O
43	were	O
44	associated	O
45	with	O
46	reduced	O
47	plasma	O
48	fibrinogen	B
49	when	O
50	adjusting	O
51	for	O
52	the	O
53	strongest	O
54	covariates	O
55	.	O

1	A	I
2	DNA	I
3	motif	I
4	related	I
5	to	O
6	the	O
7	cAMP	B
8	-	I
9	responsive	I
10	element	I
11	and	O
12	an	O
13	exon	O
14	-	O
15	located	O
16	activator	B
17	protein	I
18	-	I
19	2	I
20	binding	I
21	site	I
22	in	O
23	the	O
24	human	B
25	tissue	I
26	-	I
27	type	I
28	plasminogen	I
29	activator	I
30	gene	I
31	promoter	I
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O

1	We	O
2	have	O
3	generated	O
4	various	O
5	base	O
6	substitutions	O
7	and	O
8	internal	O
9	deletions	O
10	in	O
11	and	O
12	around	O
13	DRE	O
14	(	O
15	nucleotide	O
16	positions	O
17	-	O
18	93	O
19	to	O
20	-	O
21	100	O
22	with	O
23	respect	O
24	to	O
25	the	O
26	transcription	O
27	initiation	O
28	site	O
29	)	O
30	of	O
31	the	O
32	PCNA	B
33	gene	I
34	in	O
35	vitro	O
36	and	O
37	subsequently	O
38	examined	O
39	their	O
40	effects	O
41	on	O
42	the	O
43	binding	O
44	to	O
45	DREF	O
46	(	O
47	DRE	O
48	-	O
49	binding	O
50	factor	O
51	)	O
52	and	O
53	PCNA	B
54	gene	I
55	promote	O
56	activity	O
57	in	O
58	cultured	O
59	Drosophila	O
60	Kc	O
61	cells	O
62	as	O
63	well	O
64	as	O
65	in	O
66	living	O
67	flies	O
68	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	In	O
2	contrast	O
3	,	O
4	cotransfection	O
5	of	O
6	TFIIB	O
7	and	O
8	IRF	B
9	-	I
10	1	I
11	into	O
12	NIH	O
13	3T3	O
14	cells	O
15	resulted	O
16	in	O
17	a	O
18	dose	O
19	-	O
20	dependent	O
21	repression	O
22	of	O
23	promoter	O
24	activation	O
25	which	O
26	occurred	O
27	in	O
28	a	O
29	TATA	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Expression	O
2	of	O
3	the	O
4	dibasic	O
5	proprotein	O
6	processing	O
7	enzyme	O
8	furin	O
9	is	O
10	directed	O
11	by	O
12	multiple	O
13	promoters	O
14	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	EDLF	O
10	has	O
11	clear	O
12	vasoconstrictor	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	O
29	in	O
30	the	O
31	vasoconstrictor	O
32	effects	O
33	of	O
34	EDLFs	O
35	with	O
36	respect	O
37	to	O
38	different	O
39	vascular	O
40	beds	O
41	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	O
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	B
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	O
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	O
33	,	O
34	fyn	O
35	,	O
36	and	O
37	btk	O
38	,	O
39	or	O
40	of	O
41	vav	O
42	-	O
43	and	O
44	ras	B
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	B
7	structural	I
8	homology	I
9	,	O
10	meq	O
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	I
20	fos	I
21	gene	I
22	family	I
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	We	O
2	measured	O
3	basal	O
4	plasma	O
5	prolactin	B
6	concentrations	O
7	(	O
8	in	O
9	samples	O
10	obtained	O
11	during	O
12	the	O
13	early	O
14	follicular	O
15	phase	O
16	)	O
17	in	O
18	25	O
19	normal	O
20	(	O
21	control	O
22	)	O
23	women	O
24	and	O
25	in	O
26	a	O
27	similar	O
28	group	O
29	of	O
30	40	O
31	patients	O
32	with	O
33	a	O
34	long	O
35	-	O
36	standing	O
37	history	O
38	of	O
39	infertility	O
40	.	O

1	Insulin	B
2	-	I
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	O
12	insulin	B
13	receptor	I
14	.	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	B
15	-	I
16	PAR	I
17	gene	I
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	Both	O
2	classes	O
3	of	O
4	MHBst	O
5	proteins	O
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O

1	Prostacyclin	B
2	formation	O
3	,	O
4	reflected	O
5	by	O
6	the	O
7	excretion	O
8	rate	O
9	of	O
10	its	O
11	stable	O
12	metabolite	O
13	6	O
14	-	O
15	keto	B
16	-	I
17	prostaglandin	I
18	F1	I
19	alpha	I
20	,	O
21	was	O
22	measured	O
23	by	O
24	means	O
25	of	O
26	radioimmunoassay	O
27	in	O
28	4	O
29	-	O
30	hour	O
31	urine	O
32	specimens	O
33	obtained	O
34	during	O
35	a	O
36	smoking	O
37	-	O
38	free	O
39	period	O
40	and	O
41	after	O
42	participants	O
43	had	O
44	inhaled	O
45	smoke	O
46	from	O
47	four	O
48	high	O
49	-	O
50	nicotine	O
51	cigarettes	O
52	.	O

1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O

1	Sequence	O
2	comparison	O
3	between	O
4	the	O
5	translated	O
6	ORF	O
7	and	O
8	a	O
9	protein	O
10	database	O
11	reveal	O
12	between	O
13	26	O
14	.	O
15	5	O
16	and	O
17	23	O
18	.	O
19	4	O
20	%	O
21	aa	O
22	sequence	O
23	homology	O
24	to	O
25	bacterial	B
26	transmembrane	I
27	(	I
28	TM	I
29	)	I
30	proteins	I
31	including	O
32	those	O
33	mediating	O
34	chloramphenicol	B
35	(	O
36	Cm	O
37	)	O
38	and	O
39	tetracycline	O
40	(	O
41	Tc	O
42	)	O
43	resistance	O
44	and	O
45	an	O
46	arabinose	B
47	-	I
48	proton	I
49	symport	I
50	protein	I
51	.	O

1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O

1	As	O
2	the	O
3	high	O
4	-	O
5	affinity	O
6	Mg2	B
7	+	I
8	binding	I
9	sites	I
10	are	O
11	filled	O
12	,	O
13	the	O
14	primer	O
15	terminus	O
16	migrates	O
17	from	O
18	the	O
19	exonuclease	O
20	site	O
21	to	O
22	a	O
23	highly	O
24	based	O
25	stacked	B
26	polymerase	I
27	active	O
28	site	O
29	.	O

1	In	O
2	spite	O
3	of	O
4	this	O
5	and	O
6	other	O
7	complications	O
8	of	O
9	corticosteroids	O
10	,	O
11	she	O
12	made	O
13	a	O
14	full	O
15	recovery	O
16	from	O
17	the	O
18	fungal	O
19	infection	O
20	following	O
21	treatment	O
22	with	O
23	amphotericin	O
24	B	O
25	and	O
26	surgical	O
27	excision	O
28	of	O
29	the	O
30	lung	O
31	abscess	O
32	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	O
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O

1	Routine	B
2	isotope	O
3	cystography	O
4	using	O
5	99M	O
6	Tc	O
7	sulfur	O
8	colloid	O
9	for	O
10	detection	O
11	and	O
12	follow	O
13	-	O
14	up	O
15	of	O
16	vesico	O
17	-	O
18	ureteral	O
19	reflux	O

1	Biologically	B
2	significant	O
3	amounts	O
4	of	O
5	platelet	B
6	activating	I
7	factor	I
8	were	O
9	eluted	O
10	from	O
11	the	O
12	sorbent	O
13	during	O
14	the	O
15	entire	O
16	treatment	O
17	time	O
18	.	O

1	Fourteen	B
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O

1	Tumours	B
2	of	O
3	the	O
4	cavum	O
5	oris	O
6	and	O
7	oropharynx	O
8	of	O
9	T1	O
10	-	O
11	stage	O
12	are	O
13	possible	O
14	only	O
15	in	O
16	1	O
17	of	O
18	3	O
19	cases	O
20	.	O

1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O

1	Interestingly	O
2	,	O
3	disruption	O
4	of	O
5	the	O
6	VPS34	O
7	locus	O
8	resulted	O
9	in	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	growth	O
15	defect	O
16	,	O
17	indicating	O
18	that	O
19	the	O
20	VPS34	B
21	gene	I
22	is	O
23	essential	O
24	for	O
25	vegetative	O
26	growth	O
27	only	O
28	at	O
29	elevated	O
30	growth	O
31	temperatures	O
32	.	O

1	Using	O
2	the	O
3	rap1t	O
4	alleles	O
5	to	O
6	generate	O
7	wild	B
8	-	I
9	type	I
10	cells	O
11	differing	O
12	only	O
13	in	O
14	telomere	O
15	tract	O
16	lengths	O
17	,	O
18	we	O
19	also	O
20	show	O
21	that	O
22	telomere	O
23	position	O
24	effects	O
25	are	O
26	highly	O
27	sensitive	O
28	to	O
29	changes	O
30	in	O
31	the	O
32	size	O
33	(	O
34	or	O
35	structure	O
36	)	O
37	of	O
38	the	O
39	telomeric	O
40	tract	O
41	.	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	The	O
2	scr	O
3	regulon	O
4	of	O
5	pUR400	O
6	and	O
7	the	O
8	chromosomally	O
9	encoded	O
10	scr	O
11	regulon	O
12	of	O
13	Klebsiella	O
14	pneumoniae	O
15	KAY2026	O
16	are	O
17	both	O
18	negatively	O
19	controlled	O
20	by	O
21	a	O
22	specific	O
23	repressor	O
24	(	O
25	ScrR	O
26	).	O

1	Number	B
2	and	O
3	size	O
4	of	O
5	the	O
6	myelin	O
7	structures	O
8	in	O
9	the	O
10	pneumocytes	O
11	typ	O
12	II	O
13	increased	O
14	simultaneously	O
15	.	O

1	IE2	B
2	-	I
3	IE2	I
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	B
14	-	I
15	turn	I
16	-	I
17	helix	I
18	motif	I
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	The	O
2	results	O
3	obtained	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	The	O
9	mitral	O
10	valve	O
11	orifice	O
12	area	O
13	(	O
14	MVA	O
15	)	O
16	was	O
17	significantly	O
18	smaller	O
19	in	O
20	patients	O
21	with	O
22	type	O
23	III	O
24	of	O
25	the	O
26	LVIT	O
27	flow	O
28	velocity	O
29	pattern	O
30	than	O
31	in	O
32	patients	O
33	with	O
34	type	O
35	I	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Tonsillectomy	B
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O

1	In	O
2	viral	O
3	infections	O
4	,	O
5	G	B
6	-	I
7	CSF	I
8	was	O
9	correlated	O
10	with	O
11	mononuclear	O
12	cells	O
13	(	O
14	rs	O
15	=	O
16	0	O
17	.	O
18	41	O
19	,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	05	O
25	),	O
26	white	O
27	blood	O
28	cell	O
29	counts	O
30	(	O
31	rs	O
32	=	O
33	0	O
34	.	O
35	56	O
36	,	O
37	P	O
38	<	O
39	0	O
40	.	O
41	01	O
42	),	O
43	neutrophils	O
44	(	O
45	rs	O
46	=	O
47	0	O
48	.	O
49	41	O
50	,	O
51	P	O
52	<	O
53	0	O
54	.	O
55	05	O
56	)	O
57	and	O
58	CRP	B
59	(	O
60	rs	O
61	=	O
62	0	O
63	.	O
64	47	O
65	,	O
66	P	O
67	<	O
68	0	O
69	.	O
70	05	O
71	).	O

1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O

1	Serum	B
2	antibody	I
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O

1	The	O
2	Wnt	B
3	signaling	O
4	pathway	O
5	functions	O
6	reiteratively	O
7	during	O
8	animal	O
9	development	O
10	to	O
11	control	O
12	cell	O
13	fate	O
14	decisions	O
15	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	O
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O

1	U4	B
2	/	I
3	U6	I
4	snRNP	I
5	is	O
6	one	O
7	of	O
8	four	O
9	essential	O
10	small	B
11	nuclear	I
12	ribonucleoprotein	I
13	(	I
14	snRNP	I
15	)	I
16	particles	I
17	(	I
18	U1	I
19	,	O
20	U2	B
21	,	O
22	U5	B
23	and	O
24	U4	B
25	/	I
26	U6	I
27	)	O
28	present	O
29	in	O
30	the	O
31	spliceosome	O
32	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	suppressor	I
5	of	O
6	sable	B
7	gene	I
8	,	O
9	su	O
10	(	O
11	s	O
12	),	O
13	encodes	O
14	a	O
15	novel	O
16	,	O
17	150	O
18	-	O
19	kDa	O
20	nuclear	B
21	RNA	I
22	binding	I
23	protein	I
24	,	O
25	SU	O
26	(	O
27	S	O
28	),	O
29	that	O
30	negatively	O
31	regulates	O
32	RNA	O
33	accumulation	O
34	from	O
35	mutant	O
36	alleles	O
37	of	O
38	other	O
39	genes	O
40	that	O
41	have	O
42	transposon	O
43	insertions	O
44	in	O
45	the	O
46	5	O
47	'	O
48	transcribed	O
49	region	O
50	.	O

1	At	O
2	1	O
3	,	O
4	5	O
5	,	O
6	and	O
7	9	O
8	months	O
9	after	O
10	initial	O
11	isolation	O
12	of	O
13	C	O
14	.	O
15	kutscheri	O
16	from	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	hamsters	O
22	were	O
23	euthanatized	O
24	,	O
25	and	O
26	attempts	O
27	were	O
28	made	O
29	to	O
30	culture	O
31	C	O
32	.	O
33	kutscheri	O
34	from	O
35	13	O
36	additional	O
37	sites	O
38	.	O

1	Glutathione	B
2	S	I
3	-	I
4	transferase	I
5	(	O
6	GST	B
7	)-	I
8	E2F	I
9	and	O
10	GST	B
11	-	O
12	DP	B
13	fusion	I
14	proteins	I
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	B
25	sites	I
26	in	O
27	the	O
28	DNA	B
29	polymerase	I
30	alpha	I
31	gene	I
32	promoter	I
33	in	O
34	vitro	O
35	.	O

1	SUP46	B
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	O
13	.	O

1	Atrial	B
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O

1	Human	B
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	B
11	-	I
12	75	I
13	cobalt	I
14	-	I
15	based	O
16	alloy	O
17	.	O

1	We	O
2	estimate	O
3	that	O
4	the	O
5	protease	O
6	activity	O
7	is	O
8	at	O
9	least	O
10	35	O
11	-	O
12	fold	O
13	greater	O
14	in	O
15	mature	O
16	B	O
17	cells	O
18	than	O
19	in	O
20	pre	O
21	-	O
22	B	O
23	cells	O
24	.	O

1	We	O
2	demonstrate	O
3	that	O
4	the	O
5	protein	O
6	is	O
7	a	O
8	murine	B
9	homologue	I
10	of	O
11	SAF	O
12	-	O
13	A	O
14	which	O
15	has	O
16	been	O
17	shown	O
18	to	O
19	bind	O
20	selectively	O
21	to	O
22	MARs	O
23	and	O
24	is	O
25	responsible	O
26	for	O
27	the	O
28	satMa	B
29	-	I
30	binding	I
31	activity	O
32	in	O
33	the	O
34	chromatographic	O
35	fractions	O
36	.	O

1	In	O
2	vivo	O
3	dimethyl	O
4	sulfate	O
5	footprinting	O
6	of	O
7	the	O
8	cyclin	B
9	E	I
10	promoter	I
11	revealed	O
12	several	O
13	regions	O
14	of	O
15	protection	O
16	and	O
17	hypersensitivity	O
18	that	O
19	were	O
20	unique	O
21	to	O
22	infected	O
23	cells	O
24	.	O

1	For	O
2	monocytes	O
3	,	O
4	as	O
5	measured	O
6	on	O
7	the	O
8	Hematrak	O
9	,	O
10	it	O
11	was	O
12	13	O
13	.	O
14	4	O
15	%.	O

1	Analysis	O
2	of	O
3	corticosteroids	O
4	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	super	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	DDT1MF	B
19	-	I
20	2	I
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	O
29	1B	O
30	-	O
31	AR	B
32	gene	I
33	bound	I
34	CRE	I
35	binding	I
36	protein	I
37	.	O

1	Increased	O
2	granulocyte	B
3	-	I
4	colony	I
5	stimulating	I
6	factor	I
7	(	I
8	G	I
9	-	I
10	CSF	I
11	)	O
12	levels	O
13	in	O
14	neonates	O
15	with	O
16	perinatal	O
17	complications	O
18	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	Paracrine	B
2	activation	O
3	of	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	LTR	I
9	promoter	I
10	by	O
11	the	O
12	viral	O
13	Tat	B
14	protein	I
15	is	O
16	mechanistically	O
17	similar	O
18	to	O
19	trans	O
20	-	O
21	activation	O
22	within	O
23	a	O
24	cell	O
25	.	O

1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	O
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	Spatiotemporal	B
2	expression	O
3	of	O
4	the	O
5	PAX3	B
6	gene	I
7	is	O
8	tightly	O
9	regulated	O
10	during	O
11	development	O
12	.	O

1	Here	O
2	,	O
3	a	O
4	case	O
5	of	O
6	Sjogren	O
7	'	O
8	s	O
9	syndrome	O
10	is	O
11	presented	O
12	that	O
13	was	O
14	initially	O
15	diagnosed	O
16	because	O
17	of	O
18	dental	O
19	complaints	O
20	,	O
21	and	O
22	long	O
23	-	O
24	term	O
25	treatment	O
26	of	O
27	Sjogren	O
28	'	O
29	s	O
30	patients	O
31	is	O
32	discussed	O
33	.	O

1	Promoter	O
2	activities	O
3	were	O
4	estimated	O
5	using	O
6	beta	B
7	-	I
8	glucuronidase	I
9	and	O
10	neomycin	B
11	phosphotransferase	I
12	II	I
13	reporter	I
14	gene	I
15	systems	O
16	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	O
8	target	O
9	gene	O
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	B
13	subtilis	I
14	,	O
15	ArgR	O
16	and	O
17	AhrC	O
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	B
30	-	I
31	dependent	I
32	DNA	I
33	-	I
34	binding	I
35	complexes	I
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	O
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	Thus	O
2	,	O
3	our	O
4	studies	O
5	suggest	O
6	that	O
7	pV	O
8	-	O
9	mediated	O
10	activation	O
11	of	O
12	HIV	B
13	-	I
14	1	I
15	LTR	I
16	activity	O
17	is	O
18	controlled	O
19	by	O
20	the	O
21	nuclear	O
22	translocation	O
23	of	O
24	the	O
25	NF	B
26	-	I
27	kappaB	I
28	transcription	I
29	factor	I
30	,	O
31	which	O
32	is	O
33	mediated	O
34	by	O
35	IkappaBalpha	B
36	serine	I
37	phosphorylation	O
38	and	O
39	degradation	O
40	,	O
41	but	O
42	also	O
43	by	O
44	a	O
45	still	O
46	undefined	O
47	NF	B
48	-	I
49	kappaB	I
50	-	I
51	independent	O
52	pathway	O
53	.	O

1	The	O
2	DSF	O
3	regimen	O
4	appears	O
5	to	O
6	have	O
7	significant	O
8	activity	O
9	in	O
10	patients	O
11	who	O
12	have	O
13	metastatic	O
14	pancreatic	O
15	islet	O
16	-	O
17	cell	O
18	carcinoma	O
19	,	O
20	and	O
21	patient	O
22	tolerance	O
23	of	O
24	the	O
25	regimen	O
26	is	O
27	excellent	O
28	,	O
29	thus	O
30	warranting	O
31	further	O
32	investigation	O
33	.	O

1	Commercially	B
2	available	O
3	formulations	O
4	of	O
5	2	O
6	.	O
7	5	O
8	%	O
9	and	O
10	5	O
11	%	O
12	lambdacyhalothrin	O
13	can	O
14	be	O
15	diluted	O
16	either	O
17	with	O
18	water	O
19	for	O
20	ULV	O
21	cold	O
22	aerosol	O
23	space	O
24	-	O
25	spraying	O
26	or	O
27	with	O
28	diesel	O
29	/	O
30	kerosene	O
31	for	O
32	thermal	O
33	fogging	O
34	at	O
35	recommended	O
36	application	O
37	rates	O
38	of	O
39	0	O
40	.	O
41	5	O
42	-	O
43	1	O
44	g	O
45	ai	O
46	/	O
47	ha	O
48	for	O
49	mosquito	O
50	control	O
51	and	O
52	2	O
53	g	O
54	ai	O
55	/	O
56	ha	O
57	for	O
58	housefly	O
59	control	O
60	.	O

1	RESULTS	O
2	:	O
3	Closure	O
4	time	O
5	of	O
6	fistulas	O
7	in	O
8	patients	O
9	receiving	O
10	TPN	O
11	+	O
12	somatostatin	B
13	was	O
14	significantly	O
15	shorter	O
16	(	O
17	13	O
18	.	O
19	86	O
20	+/-	O
21	1	O
22	.	O
23	84	O
24	versus	O
25	20	O
26	.	O
27	4	O
28	+/-	O
29	2	O
30	.	O
31	89	O
32	days	O
33	)	O
34	than	O
35	in	O
36	those	O
37	receiving	O
38	TPN	O
39	alone	O
40	.	O

1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	O
9	orphan	B
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	B
26	beta	I
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O

1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O

1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	O
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	O
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	O
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	The	O
2	science	O
3	of	O
4	tissue	O
5	engineering	O
6	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	The	O
2	mean	O
3	day	O
4	of	O
5	diagnosis	O
6	of	O
7	periventricular	O
8	echodensities	O
9	was	O
10	3	O
11	+/-	O
12	2	O
13	days	O
14	(	O
15	range	O
16	1	O
17	-	O
18	11	O
19	days	O
20	),	O
21	and	O
22	of	O
23	cystic	O
24	PVL	O
25	21	O
26	+/-	O
27	8	O
28	days	O
29	(	O
30	range	O
31	2	O
32	-	O
33	47	O
34	days	O
35	).	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	data	O
6	establish	O
7	that	O
8	the	O
9	previously	O
10	reported	O
11	human	B
12	MAdCAM	I
13	-	I
14	1	I
15	cDNA	I
16	does	O
17	indeed	O
18	encode	O
19	the	O
20	human	B
21	homologue	I
22	of	O
23	mouse	B
24	MAdCAM	I
25	-	I
26	1	I
27	,	O
28	despite	O
29	gross	O
30	dissimilarities	O
31	in	O
32	the	O
33	MAdCAM	B
34	-	I
35	1	I
36	C	I
37	-	I
38	terminal	I
39	structures	O
40	.	O

1	Recently	O
2	,	O
3	roles	O
4	also	O
5	have	O
6	been	O
7	suggested	O
8	for	O
9	the	O
10	nuclear	B
11	trans	I
12	-	I
13	factor	I
14	GATA	I
15	-	I
16	1	I
17	in	O
18	regulating	O
19	progenitor	O
20	cell	O
21	proliferation	O
22	.	O

1	The	O
2	human	O
3	RAD30B	O
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O

1	High	B
2	-	I
3	resolution	O
4	computed	O
5	tomography	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	miliary	O
11	tuberculosis	O
12	.	O

1	Hepatitis	B
2	B	I
3	and	O
4	liver	O
5	transplantation	O
6	.	O

1	Abp1	B
2	preferentially	O
3	binds	O
4	to	O
5	multiple	O
6	sites	O
7	in	O
8	ARS	O
9	3002	O
10	and	O
11	to	O
12	the	O
13	DNA	O
14	polymer	O
15	poly	O
16	[	O
17	d	O
18	(	O
19	A	O
20	.	O
21	T	O
22	)].	O

1	Six	O
2	putative	O
3	MDV	O
4	genome	O
5	products	O
6	,	O
7	including	O
8	one	O
9	Rep	B
10	and	O
11	five	O
12	non	O
13	-	O
14	Rep	B
15	proteins	I
16	,	O
17	show	O
18	high	O
19	(	O
20	70	O
21	.	O
22	4	O
23	-	O
24	90	O
25	.	O
26	9	O
27	%)	O
28	amino	O
29	acid	O
30	identity	O
31	to	O
32	the	O
33	corresponding	O
34	six	O
35	FBNYV	O
36	proteins	O
37	,	O
38	whereas	O
39	two	O
40	other	O
41	Rep	B
42	proteins	I
43	encoded	I
44	by	O
45	MDV	B
46	-	I
47	C2	I
48	and	O
49	C3	B
50	are	O
51	82	O
52	.	O
53	3	O
54	%	O
55	and	O
56	73	O
57	.	O
58	0	O
59	%	O
60	identical	O
61	to	O
62	those	O
63	encoded	O
64	by	O
65	SCSV	B
66	-	I
67	C2	I
68	and	O
69	C6	O
70	,	O
71	respectively	O
72	.	O

1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	B
33	-	I
34	endothelium	O
35	.	O

1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O

1	Mutagenesis	B
2	of	O
3	the	O
4	pecT	O
5	regulatory	O
6	region	O
7	revealed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	sites	O
13	in	O
14	which	O
15	insertions	O
16	reproduced	O
17	the	O
18	pec	B
19	-	I
20	1	I
21	phenotype	O
22	.	O

1	In	O
2	contrast	O
3	,	O
4	dig1	O
5	dig2	O
6	cells	O
7	constitutively	O
8	invade	O
9	agar	O
10	medium	O
11	,	O
12	whereas	O
13	a	O
14	dig1	O
15	dig2	O
16	ste12	O
17	triple	O
18	mutant	O
19	does	O
20	not	O
21	,	O
22	indicating	O
23	that	O
24	Dig1	O
25	and	O
26	Dig2	O
27	share	O
28	a	O
29	role	O
30	in	O
31	negatively	O
32	regulating	O
33	the	O
34	invasive	O
35	growth	O
36	pathway	O
37	.	O

1	From	O
2	sequence	O
3	alignments	O
4	with	O
5	phylogenetically	O
6	related	O
7	viruses	O
8	,	O
9	including	O
10	tymoviruses	O
11	,	O
12	we	O
13	predicted	O
14	that	O
15	p223	O
16	contained	O
17	a	O
18	papain	B
19	-	I
20	like	I
21	proteinase	I
22	domain	I
23	with	O
24	a	O
25	putative	O
26	catalytic	O
27	cysteine994	O
28	and	O
29	histidine1075	O
30	.	O

1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	O
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	O
15	-	O
16	17	O
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O

1	Higher	B
2	fasting	O
3	serum	O
4	gastrin	B
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	O
16	.	O
17	3	O
18	+/-	O
19	8	O
20	.	O
21	3	O
22	ng	O
23	.	O
24	l	O
25	-	O
26	1	O
27	),	O
28	and	O
29	greater	O
30	postprandial	O
31	gastrin	B
32	release	O
33	(	O
34	AUC0	O
35	-	O
36	120	O
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	O
63	.	O

1	Cells	B
2	differentiate	O
3	in	O
4	response	O
5	to	O
6	various	O
7	extracellular	O
8	stimuli	O
9	.	O

1	Recurrence	B
2	of	O
3	oxalate	O
4	deposition	O
5	in	O
6	a	O
7	renal	O
8	transplant	O
9	during	O
10	ciclosporin	O
11	A	O
12	therapy	O
13	.	O

1	The	O
2	yeast	O
3	retrotransposon	O
4	Ty5	O
5	preferentially	O
6	integrates	O
7	into	O
8	regions	O
9	of	O
10	silent	O
11	chromatin	O
12	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	region	O
9	revealed	O
10	several	O
11	GC	O
12	boxes	O
13	but	O
14	no	O
15	identifiable	O
16	TATA	O
17	box	O
18	.	O

1	Cyclin	B
2	-	I
3	dependent	I
4	kinase	I
5	-	I
6	2	I
7	(	O
8	Cdk2	B
9	)	O
10	forms	O
11	an	O
12	inactive	O
13	complex	O
14	with	O
15	cyclin	B
16	D1	I
17	since	O
18	Cdk2	B
19	associated	I
20	with	O
21	cyclin	B
22	D1	I
23	is	O
24	not	O
25	phosphorylated	O
26	by	O
27	Cdk7	O
28	-	O
29	cyclin	B
30	-	I
31	H	I
32	.	O

1	I	I
2	.	O

1	There	O
2	were	O
3	45	O
4	to	O
5	56	O
6	nt	O
7	differences	O
8	between	O
9	the	O
10	virulent	O
11	and	O
12	avirulent	O
13	groups	O
14	while	O
15	there	O
16	were	O
17	6	O
18	to	O
19	14	O
20	nt	O
21	differences	O
22	among	O
23	four	O
24	avirulent	O
25	strains	O
26	.	O

1	GW	B
2	Gamma	O
3	approximation	O
4	for	O
5	electron	O
6	self	O
7	-	O
8	energies	O
9	in	O
10	semiconductors	O
11	and	O
12	insulators	O
13	.	O

1	The	O
2	12S	O
3	E1A	B
4	product	I
5	does	O
6	not	O
7	activate	O
8	a	O
9	TRE	O
10	sequence	O
11	,	O
12	but	O
13	cotransfection	O
14	with	O
15	c	B
16	-	I
17	jun	I
18	circumvents	O
19	this	O
20	lack	O
21	of	O
22	stimulation	O
23	.	O

1	Presentation	B
2	of	O
3	a	O
4	horse	B
5	cytochrome	I
6	c	I
7	peptide	I
8	by	O
9	multiple	O
10	H	B
11	-	I
12	2b	I
13	class	I
14	I	I
15	major	I
16	histocompatibility	I
17	complex	I
18	(	I
19	MHC	I
20	)	I
21	molecules	I
22	to	O
23	C57BL	O
24	/	O
25	6	O
26	-	O
27	and	O
28	bm1	O
29	-	O
30	derived	O
31	cytotoxic	O
32	T	O
33	lymphocytes	O
34	:	O
35	presence	O
36	of	O
37	a	O
38	single	O
39	MHC	B
40	anchor	I
41	residue	O
42	may	O
43	confer	O
44	efficient	O
45	peptide	O
46	-	O
47	specific	O
48	CTL	O
49	recognition	O
50	.	O

1	The	O
2	proliferation	O
3	potential	O
4	protein	B
5	-	I
6	related	I
7	(	I
8	P2P	I
9	-	I
10	R	I
11	)	I
12	gene	I
13	with	O
14	domains	O
15	encoding	O
16	heterogeneous	B
17	nuclear	I
18	ribonucleoprotein	I
19	association	O
20	and	O
21	Rb1	O
22	binding	O
23	shows	O
24	repressed	O
25	expression	O
26	during	O
27	terminal	O
28	differentiation	O
29	.	O

1	Cotransfection	O
2	analyses	O
3	of	O
4	the	O
5	T	B
6	/	I
7	EBP	I
8	promoter	I
9	-	I
10	reporter	I
11	constructs	I
12	with	O
13	a	O
14	T	B
15	/	I
16	EBP	I
17	expression	O
18	vector	O
19	into	O
20	human	O
21	HepG2	O
22	cells	O
23	,	O
24	which	O
25	do	O
26	not	O
27	express	O
28	T	B
29	/	I
30	EBP	I
31	,	O
32	suggested	O
33	that	O
34	autoregulation	O
35	may	O
36	be	O
37	involved	O
38	in	O
39	controlling	O
40	both	O
41	rat	O
42	and	O
43	human	B
44	T	I
45	/	I
46	EBP	I
47	gene	I
48	expression	O
49	.	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	O
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	O
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	O
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	human	B
10	DSG3	I
11	gene	I
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O

1	Morphologic	B
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	histologic	O
8	grade	O
9	,	O
10	capsular	O
11	penetration	O
12	,	O
13	seminal	O
14	vesicle	O
15	invasion	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O

1	In	O
2	controls	O
3	,	O
4	most	O
5	of	O
6	the	O
7	output	O
8	from	O
9	the	O
10	conduit	O
11	occurred	O
12	during	O
13	type	O
14	I	O
15	activity	O
16	(	O
17	73	O
18	+/-	O
19	14	O
20	%).	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	C25	O
11	,	O
12	C30	O
13	and	O
14	C35	O
15	complexes	O
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	SAA	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	relevance	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	functioning	O
44	of	O
45	the	O
46	rat	O
47	APP	O
48	promoter	O
49	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	O
25	HDC	O
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O

1	Bacterially	B
2	expressed	O
3	protein	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	in	O
10	vitro	O
11	reticulocyte	O
12	lysate	O
13	translation	O
14	product	O
15	,	O
16	comigrated	O
17	with	O
18	the	O
19	purified	O
20	37	O
21	-	O
22	kDa	O
23	protein	O
24	on	O
25	sodium	O
26	dodecyl	O
27	sulfate	O
28	-	O
29	polyacrylamide	O
30	gels	O
31	.	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	O
13	function	O
14	and	O
15	substrate	O
16	specificity	O
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	O
29	RNase	B
30	MRP	I
31	RNA	I
32	and	O
33	RNase	B
34	P	I
35	RNA	I
36	of	O
37	S	O
38	.	O
39	cerevisiae	O
40	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	-	O
6	119	O
7	to	O
8	-	O
9	81	O
10	fragment	O
11	of	O
12	the	O
13	CCK	O
14	promoter	O
15	contains	O
16	a	O
17	transcriptional	O
18	enhancer	O
19	that	O
20	potentiates	O
21	the	O
22	transcription	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	virus	I
28	thymidine	I
29	kinase	I
30	promoter	I
31	in	O
32	a	O
33	position	O
34	-	O
35	and	O
36	orientation	O
37	-	O
38	independent	O
39	manner	O
40	.	O

1	The	O
2	plant	O
3	protein	O
4	maintains	O
5	all	O
6	the	O
7	functional	O
8	domains	O
9	found	O
10	in	O
11	the	O
12	other	O
13	proteins	O
14	,	O
15	including	O
16	nuclear	O
17	localization	O
18	signal	O
19	,	O
20	DNA	B
21	-	I
22	binding	I
23	domain	I
24	and	I
25	helicase	I
26	motifs	O
27	,	O
28	suggesting	O
29	that	O
30	it	O
31	might	O
32	also	O
33	act	O
34	as	O
35	part	O
36	of	O
37	the	O
38	RNA	O
39	transcription	O
40	apparatus	O
41	,	O
42	as	O
43	well	O
44	as	O
45	nucleotide	O
46	excision	O
47	repair	O
48	in	O
49	plant	O
50	cells	O
51	.	O

1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O

1	Leptinaemia	B
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	Respiratory	B
2	chain	I
3	enzyme	I
4	activity	O
5	was	O
6	normal	O
7	.	O

1	A	I
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O

1	Me	B
2	(	I
3	2	I
4	)	I
5	SO	I
6	-	I
7	induced	O
8	neuronal	O
9	differentiation	O
10	of	O
11	N1E	O
12	-	O
13	115	O
14	neuroblastoma	O
15	cells	O
16	increased	O
17	both	O
18	the	O
19	expression	O
20	of	O
21	the	O
22	endogenous	O
23	Ntr	B
24	-	I
25	1	I
26	gene	I
27	and	I
28	reporter	I
29	genes	I
30	driven	O
31	by	O
32	NTR	B
33	-	I
34	1	I
35	promoter	I
36	sequences	I
37	by	O
38	3	O
39	-	O
40	4	O
41	-	O
42	fold	O
43	.	O

1	Dialyzable	B
2	transfer	I
3	factor	I
4	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	O
13	4	O
14	industrial	O
15	farms	O
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	Treatment	O
2	with	O
3	oxyphenylbutazone	O
4	and	O
5	hydrocortisone	O
6	failed	O
7	to	O
8	inhibit	O
9	the	O
10	raised	O
11	serum	O
12	CPN	O
13	levels	O
14	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Five	O
2	-	O
3	year	O
4	survivals	O
5	amounted	O
6	to	O
7	100	O
8	%,	O
9	86	O
10	.	O
11	2	O
12	%,	O
13	59	O
14	.	O
15	4	O
16	%,	O
17	29	O
18	.	O
19	8	O
20	%,	O
21	and	O
22	20	O
23	%	O
24	for	O
25	stages	O
26	I	O
27	,	O
28	II	O
29	,	O
30	III	O
31	,	O
32	IVA	O
33	and	O
34	IVB	O
35	respectively	O
36	.	O

1	A	I
2	canonical	O
3	TATA	O
4	box	O
5	was	O
6	not	O
7	detected	O
8	.	O

1	Clone	B
2	4c	O
3	(	O
4	2681	O
5	bp	O
6	)	O
7	had	O
8	a	O
9	coding	O
10	region	O
11	identical	O
12	to	O
13	that	O
14	of	O
15	clone	O
16	22c	O
17	but	O
18	it	O
19	included	O
20	a	O
21	putative	O
22	intron	O
23	of	O
24	959	O
25	bp	O
26	.	O

1	Mean	O
2	weighted	O
3	skin	O
4	temperature	O
5	(	O
6	Tsk	O
7	)	O
8	was	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	01	O
17	)	O
18	following	O
19	acclimation	O
20	than	O
21	before	O
22	,	O
23	and	O
24	acclimation	O
25	resulted	O
26	in	O
27	a	O
28	larger	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	02	O
36	)	O
37	Tre	O
38	-	O
39	to	O
40	-	O
41	Tsk	O
42	gradient	O
43	.	O

1	One	O
2	unit	O
3	encodes	O
4	traA	O
5	,	O
6	traF	O
7	,	O
8	and	O
9	traB	O
10	,	O
11	while	O
12	the	O
13	second	O
14	encodes	O
15	traC	O
16	,	O
17	traD	O
18	,	O
19	and	O
20	traG	O
21	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	Sterols	B
2	in	O
3	pollen	O
4	.	O

1	Patulin	B
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	Next	B
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	O
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	A	I
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	B
13	RNA	I
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	B
15	-	I
16	specific	I
17	genes	I
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	I
26	Mcm1	I
27	-	I
28	dependent	I
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	Closeup	B
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	Revascularization	B
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	Marinol	B
2	/	I
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O

1	While	O
2	this	O
3	Saccharomyces	B
4	cerevisiae	I
5	SIN4	I
6	gene	I
7	product	I
8	is	O
9	a	O
10	component	O
11	of	O
12	a	O
13	mediator	O
14	complex	O
15	associated	O
16	with	O
17	RNA	B
18	polymerase	I
19	II	I
20	,	O
21	various	O
22	studies	O
23	suggest	O
24	the	O
25	involvement	O
26	of	O
27	Sin4	O
28	in	O
29	the	O
30	alteration	O
31	of	O
32	higher	O
33	-	O
34	order	O
35	chromatin	O
36	structure	O
37	.	O

1	Cardiac	B
2	disease	O
3	was	O
4	not	O
5	detected	O
6	with	O
7	M	O
8	-	O
9	mode	O
10	,	O
11	2	O
12	-	O
13	dimensional	O
14	real	O
15	-	O
16	time	O
17	or	O
18	pulsed	O
19	-	O
20	wave	O
21	Doppler	O
22	echocardiography	O
23	.	O

1	The	O
2	bearing	O
3	of	O
4	season	O
5	and	O
6	sequence	O
7	of	O
8	calving	O
9	on	O
10	frequency	O
11	of	O
12	male	O
13	,	O
14	female	O
15	and	O
16	total	O
17	calvings	O
18	in	O
19	Hariana	O
20	cows	O
21	.	O

1	Although	O
2	the	O
3	OC	O
4	promoter	O
5	is	O
6	activated	O
7	in	O
8	a	O
9	C	O
10	terminus	O
11	dependent	O
12	manner	O
13	,	O
14	the	O
15	MDR	O
16	,	O
17	LTR	O
18	and	O
19	BSP	O
20	promoters	O
21	are	O
22	repressed	O
23	by	O
24	three	O
25	distinct	O
26	mechanisms	O
27	,	O
28	either	O
29	independent	O
30	of	O
31	or	O
32	involving	O
33	the	O
34	AML	O
35	C	O
36	terminus	O
37	,	O
38	or	O
39	requiring	O
40	only	O
41	the	O
42	conserved	O
43	C	O
44	-	O
45	terminal	O
46	pentapeptide	O
47	VWRPY	O
48	.	O

1	Serial	B
2	levels	O
3	of	O
4	troponin	O
5	T	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	B
11	-	I
12	MB	I
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	unclamping	O
26	.	O

1	Comprising	B
2	a	O
3	126	O
4	-	O
5	nucleotide	O
6	5	O
7	'	O
8	untranscribed	O
9	genomic	O
10	sequence	O
11	and	O
12	a	O
13	466	O
14	-	O
15	nucleotide	O
16	5	O
17	'	O
18	noncoding	O
19	cDNA	O
20	sequence	O
21	,	O
22	the	O
23	592	O
24	-	O
25	nucleotide	O
26	5	O
27	'	O
28	CpG	O
29	island	O
30	lacked	O
31	TATA	O
32	and	O
33	CAAT	O
34	boxes	O
35	but	O
36	displayed	O
37	a	O
38	high	O
39	G	B
40	+	I
41	C	I
42	content	O
43	,	O
44	was	O
45	enriched	O
46	for	O
47	CpG	O
48	dinucleotides	O
49	,	O
50	and	O
51	contained	O
52	a	O
53	potential	O
54	Sp1	B
55	-	I
56	binding	I
57	site	I
58	,	O
59	i	O
60	.	O
61	e	O
62	.,	O
63	features	O
64	compatible	O
65	with	O
66	a	O
67	housekeeping	O
68	gene	O
69	.	O

1	METHODS	O
2	:	O
3	Ten	O
4	influenza	O
5	A	O
6	(	O
7	H3N2	O
8	)	O
9	viruses	O
10	isolated	O
11	during	O
12	the	O
13	outbreaks	O
14	were	O
15	examined	O
16	for	O
17	resistance	O
18	to	O
19	amantadine	O
20	and	O
21	rimantadine	O
22	by	O
23	means	O
24	of	O
25	an	O
26	enzyme	O
27	immunoassay	O
28	and	O
29	by	O
30	sequencing	O
31	of	O
32	the	O
33	viral	O
34	nucleic	O
35	acid	O
36	that	O
37	encodes	O
38	the	O
39	transmembrane	O
40	domain	O
41	of	O
42	the	O
43	M2	O
44	protein	O
45	.	O

1	Ki	B
2	-	I
3	ras4BVal	I
4	-	I
5	12	O
6	transfectant	O
7	cells	O
8	expressed	O
9	2	O
10	-	O
11	fold	O
12	elevated	O
13	protein	O
14	levels	O
15	of	O
16	the	O
17	lysosomal	O
18	cysteine	B
19	protease	I
20	cathepsin	I
21	B	I
22	but	O
23	did	O
24	not	O
25	up	O
26	-	O
27	regulate	O
28	cathepsin	B
29	B	I
30	mRNA	I
31	expression	O
32	.	O

1	Fisher	B
2	'	O
3	s	O
4	exact	O
5	test	O
6	or	O
7	Pearson	O
8	'	O
9	s	O
10	chi2	O
11	test	O
12	were	O
13	used	O
14	for	O
15	statistical	O
16	analysis	O
17	.	O

1	Moreover	O
2	,	O
3	Lck	B
4	was	O
5	reversibly	O
6	co	O
7	-	O
8	immunoprecipitated	O
9	with	O
10	p95Vav	O
11	,	O
12	and	O
13	the	O
14	stoichiometry	O
15	of	O
16	binding	O
17	increased	O
18	in	O
19	anti	B
20	-	I
21	CD3	I
22	-	I
23	treated	O
24	Jurkat	O
25	cells	O
26	.	O

1	A	I
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	B
11	pylori	I
12	-	I
13	specific	I
14	serum	I
15	immunoglobulin	I
16	G	I
17	(	I
18	IgG	I
19	)	O
20	are	O
21	now	O
22	commercially	O
23	available	O
24	.	O

1	In	O
2	the	O
3	first	O
4	,	O
5	homologous	O
6	sequences	O
7	were	O
8	deleted	O
9	from	O
10	a	O
11	mouse	B
12	enhancer	I
13	,	O
14	resulting	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	loss	O
21	of	O
22	activity	O
23	when	O
24	assayed	O
25	in	O
26	transgenic	O
27	mice	O
28	.	O

1	Maternal	B
2	seizures	O
3	had	O
4	occurred	O
5	during	O
6	pregnancy	O
7	in	O
8	52	O
9	per	O
10	cent	O
11	.	O

1	Interestingly	O
2	,	O
3	an	O
4	increase	O
5	of	O
6	distance	O
7	per	O
8	se	O
9	did	O
10	not	O
11	have	O
12	a	O
13	deleterious	O
14	effect	O
15	on	O
16	translation	O
17	efficiency	O
18	.	O

1	This	O
2	complex	O
3	interacts	O
4	at	O
5	the	O
6	GTPase	B
7	domain	I
8	in	O
9	the	O
10	large	O
11	subunit	O
12	rRNA	O
13	,	O
14	overlapping	O
15	the	O
16	binding	O
17	site	O
18	of	O
19	the	O
20	protein	O
21	L11	B
22	-	I
23	like	I
24	eukaryotic	O
25	counterpart	O
26	(	O
27	Saccharomyces	B
28	cerevisiae	I
29	protein	I
30	L15	O
31	and	O
32	mammalian	B
33	protein	I
34	L12	I
35	).	O

1	Multiple	O
2	chemical	O
3	sensitivity	O
4	(	O
5	MCS	O
6	)	O
7	is	O
8	a	O
9	syndrome	O
10	in	O
11	which	O
12	multiple	O
13	symptoms	O
14	reportedly	O
15	occur	O
16	with	O
17	low	O
18	-	O
19	level	O
20	chemical	O
21	exposure	O
22	.	O

1	Although	O
2	methods	O
3	to	O
4	align	O
5	the	O
6	control	O
7	and	O
8	activation	O
9	fMR	O
10	images	O
11	may	O
12	correct	O
13	for	O
14	some	O
15	of	O
16	this	O
17	motional	O
18	error	O
19	,	O
20	they	O
21	will	O
22	be	O
23	incomplete	O
24	in	O
25	correcting	O
26	for	O
27	those	O
28	that	O
29	depend	O
30	on	O
31	spatial	O
32	orientation	O
33	.	O

1	Cerebrospinal	B
2	fluid	I
3	transferrin	I
4	II	I
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	B
30	alpha	I
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	Deletion	O
2	of	O
3	the	O
4	apeA	B
5	gene	I
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	B
15	(	I
16	protease	I
17	IV	I
18	and	O
19	aminopeptidase	O
20	N	O
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O

1	Experiments	O
2	on	O
3	narcotized	O
4	cats	O
5	demonstrated	O
6	that	O
7	the	O
8	derivatives	O
9	of	O
10	2	O
11	-	O
12	mercaptobenzimidazole	O
13	possessing	O
14	the	O
15	properties	O
16	of	O
17	specific	O
18	bradycardic	O
19	agents	O
20	and	O
21	coded	O
22	as	O
23	CM	O
24	-	O
25	251	O
26	,	O
27	CM	O
28	-	O
29	266	O
30	,	O
31	and	O
32	CM	O
33	-	O
34	345	O
35	,	O
36	reduce	O
37	the	O
38	mean	O
39	rise	O
40	of	O
41	segment	O
42	ST	O
43	on	O
44	numerous	O
45	leads	O
46	of	O
47	the	O
48	epicardial	O
49	electrogram	O
50	during	O
51	5	O
52	-	O
53	min	O
54	occlusion	O
55	of	O
56	the	O
57	anterior	O
58	descending	O
59	branch	O
60	of	O
61	the	O
62	left	O
63	coronary	O
64	artery	O
65	.	O

1	2	I
2	patients	O
3	(	O
4	11	O
5	%)	O
6	had	O
7	significant	O
8	morbidity	O
9	502	O
10	and	O
11	529	O
12	days	O
13	respectively	O
14	after	O
15	transplantation	O
16	.	O

1	The	O
2	clinical	O
3	tolerance	O
4	and	O
5	pharmacokinetics	O
6	of	O
7	FCE	O
8	22101	O
9	(	O
10	sodium	O
11	(	O
12	5R	O
13	,	O
14	6S	B
15	)-	I
16	6	I
17	-[(	I
18	1R	I
19	)-	I
20	hydroxyethyl	I
21	]-	I
22	2	I
23	-	I
24	carbamoyloxymethyl	I
25	-	I
26	2	I
27	-	I
28	penem	I
29	-	I
30	3	I
31	-	I
32	carboxylate	O
33	),	O
34	a	O
35	new	O
36	penem	O
37	antibiotic	O
38	,	O
39	have	O
40	been	O
41	studied	O
42	after	O
43	giving	O
44	a	O
45	single	O
46	i	O
47	.	O
48	v	O
49	.	O
50	dose	O
51	of	O
52	4	O
53	mg	O
54	.	O
55	kg	O
56	-	O
57	1	O
58	to	O
59	ten	O
60	healthy	O
61	male	O
62	volunteers	O
63	.	O

1	Each	O
2	of	O
3	these	O
4	spliced	O
5	mRNAs	O
6	has	O
7	an	O
8	untranslated	O
9	leader	O
10	sequence	O
11	of	O
12	249	O
13	bases	O
14	and	O
15	a	O
16	single	O
17	intron	O
18	of	O
19	approximately	O
20	540	O
21	bases	O
22	which	O
23	are	O
24	contained	O
25	entirely	O
26	within	O
27	TRs	O
28	/	O
29	IRs	O
30	sequences	O
31	.	O

1	Removal	O
2	of	O
3	lipid	O
4	fractions	O
5	of	O
6	plant	O
7	extractions	O
8	with	O
9	hexane	O
10	is	O
11	recommended	O
12	to	O
13	avoid	O
14	damage	O
15	to	O
16	the	O
17	HPLC	O
18	column	O
19	.	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	The	O
2	invasive	O
3	pattern	O
4	of	O
5	squamous	O
6	cell	O
7	carcinoma	O
8	in	O
9	the	O
10	mandibular	O
11	gingiva	O

1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	Pharmacologic	B
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	Electrocardiographic	B
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	SV	B
2	increased	O
3	less	O
4	in	O
5	SHR	O
6	,	O
7	mainly	O
8	reflecting	O
9	the	O
10	reduced	O
11	diastolic	O
12	compliance	O
13	of	O
14	the	O
15	hypertrophied	O
16	SHR	O
17	left	O
18	ventricle	O
19	and	O
20	the	O
21	consequent	O
22	rightward	O
23	shift	O
24	of	O
25	its	O
26	Frank	O
27	-	O
28	Starling	O
29	curve	O
30	.	O

1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	O
8	AM	O
9	gene	O
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	O
21	gene	O
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O

1	The	O
2	relative	O
3	abundance	O
4	of	O
5	each	O
6	alternatively	O
7	spliced	O
8	mRNA	O
9	was	O
10	determined	O
11	by	O
12	reverse	B
13	transcription	I
14	-	I
15	polymerase	I
16	chain	I
17	reaction	O
18	in	O
19	various	O
20	human	O
21	tissues	O
22	and	O
23	cell	O
24	lines	O
25	.	O

1	GETS	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	many	O
8	tissues	O
9	,	O
10	but	O
11	is	O
12	enriched	O
13	in	O
14	retina	O
15	and	O
16	brain	O
17	.	O

1	The	O
2	well	O
3	-	O
4	known	O
5	Rel	B
6	/	I
7	NF	I
8	-	I
9	kappaB	I
10	family	I
11	of	O
12	vertebrate	O
13	transcription	O
14	factors	O
15	comprises	O
16	a	O
17	number	O
18	of	O
19	structurally	O
20	related	O
21	,	O
22	interacting	O
23	proteins	O
24	that	O
25	bind	O
26	DNA	O
27	as	O
28	dimers	O
29	and	O
30	whose	O
31	activity	O
32	is	O
33	regulated	O
34	by	O
35	subcellular	O
36	location	O
37	.	O

1	We	O
2	postulate	O
3	that	O
4	CaM	B
5	binding	I
6	by	O
7	HIV	B
8	envelope	I
9	proteins	I
10	is	O
11	likely	O
12	to	O
13	exert	O
14	diverse	O
15	modulatory	O
16	effects	O
17	,	O
18	and	O
19	the	O
20	mechanism	O
21	for	O
22	HIV	O
23	-	O
24	induced	O
25	cytotoxicity	O
26	may	O
27	involve	O
28	,	O
29	in	O
30	part	O
31	,	O
32	inhibition	O
33	of	O
34	CaM	B
35	-	I
36	regulated	O
37	cellular	O
38	functions	O
39	.	O

1	The	O
2	upstream	O
3	promoter	O
4	is	O
5	located	O
6	within	O
7	the	O
8	coding	O
9	sequence	O
10	of	O
11	a	O
12	divergent	O
13	gene	O
14	expressing	O
15	a	O
16	protein	O
17	of	O
18	Mr	O
19	39	O
20	kDa	O
21	of	O
22	unknown	O
23	function	O
24	.	O

1	Distinguishing	B
2	roles	O
3	of	O
4	the	O
5	membrane	O
6	-	O
7	cytoskeleton	O
8	and	O
9	cadherin	O
10	mediated	O
11	cell	O
12	-	O
13	cell	O
14	adhesion	O
15	in	O
16	generating	O
17	different	O
18	Na	B
19	+,	I
20	K	I
21	(+)-	I
22	ATPase	I
23	distributions	O
24	in	O
25	polarized	O
26	epithelia	O
27	.	O

1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O

1	Isolation	O
2	of	O
3	Weeksella	O
4	virosa	O
5	(	O
6	formerly	O
7	CDC	O
8	group	O
9	IIf	O
10	)	O
11	from	O
12	a	O
13	vaginal	O
14	sample	O
15	.	O

1	Kodak	B
2	XV	I
3	-	I
4	2	I
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	Biol	O
2	.	O

1	Ten	O
2	days	O
3	of	O
4	cefadroxil	O
5	therapy	O
6	was	O
7	used	O
8	to	O
9	treat	O
10	44	O
11	children	O
12	with	O
13	urinary	O
14	tract	O
15	infection	O
16	and	O
17	CRP	B
18	values	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	28	O
25	microgram	O
26	/	O
27	ml	O
28	(	O
29	CRP	B
30	-	I
31	positive	O
32	group	O
33	).	O

1	Possible	B
2	pathogenetic	O
3	mechanisms	O
4	of	O
5	hemopoietic	O
6	changes	O
7	in	O
8	response	O
9	to	O
10	space	O
11	flight	O
12	effects	O
13	are	O
14	described	O
15	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	A	I
2	Golgi	O
3	study	O
4	of	O
5	the	O
6	sixth	O
7	layer	O
8	of	O
9	the	O
10	cerebral	O
11	cortex	O
12	.	O

1	Such	O
2	an	O
3	intervention	O
4	may	O
5	be	O
6	of	O
7	considerable	O
8	use	O
9	for	O
10	the	O
11	treatment	O
12	of	O
13	angiogenesis	O
14	-	O
15	dependent	O
16	diseases	O
17	involving	O
18	FGF	B
19	-	I
20	2	I
21	.	O

1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	O
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	O
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O

1	Derepression	B
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	B
15	lyase	I
16	gene	I
17	of	O
18	Candida	O
19	tropicalis	O
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	There	O
2	was	O
3	a	O
4	2	O
5	.	O
6	4	O
7	-	O
8	fold	O
9	difference	O
10	in	O
11	CAT	B
12	produced	O
13	from	O
14	these	O
15	transcripts	O
16	in	O
17	HeLa	O
18	cells	O
19	,	O
20	which	O
21	contain	O
22	a	O
23	greater	O
24	natural	O
25	abundance	O
26	of	O
27	PTB	O
28	.	O

1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	O
6	lambda	O
7	pseudogene	O
8	,	O
9	called	O
10	psi	B
11	V	I
12	lambda	I
13	1	I
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	B
21	lambda	I
22	gene	I
23	.	O

1	Mapping	O
2	the	O
3	cAMP	B
4	receptor	I
5	protein	I
6	contact	I
7	site	I
8	on	O
9	the	O
10	alpha	B
11	subunit	I
12	of	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	Immunologic	B
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	O
21	approximately	O
22	IgG2	O
23	>	O
24	IgG3	O
25	>	O
26	IgG4	O
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O

1	We	O
2	cloned	O
3	a	O
4	complete	O
5	cDNA	O
6	(	O
7	2	O
8	.	O
9	9	O
10	kb	O
11	)	O
12	for	O
13	HET	O
14	from	O
15	an	O
16	MCF	O
17	-	O
18	7	O
19	cDNA	O
20	library	O
21	.	O

1	RT	B
2	-	I
3	PCR	O
4	using	O
5	1	O
6	.	O
7	D	O
8	-	O
9	specific	O
10	primers	O
11	showed	O
12	that	O
13	kidney	O
14	,	O
15	brain	O
16	and	O
17	prostate	O
18	do	O
19	not	O
20	express	O
21	1	O
22	.	O
23	D	O
24	mRNA	O
25	even	O
26	though	O
27	kidney	O
28	and	O
29	brain	O
30	are	O
31	the	O
32	most	O
33	abundant	O
34	source	O
35	for	O
36	aFGF	O
37	protein	O
38	.	O

1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O

1	A	I
2	G22V	I
3	mutant	I
4	of	I
5	M	I
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	I
20	IL	I
21	-	I
22	3	I
23	)-	I
24	dependent	I
25	mast	I
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Expression	O
2	of	O
3	the	O
4	mouse	O
5	TSH	B
6	beta	I
7	gene	I
8	,	O
9	therefore	O
10	,	O
11	gives	O
12	rise	O
13	to	O
14	multiple	O
15	mRNAs	O
16	,	O
17	each	O
18	with	O
19	a	O
20	unique	O
21	5	O
22	'-	O
23	untranslated	O
24	region	O
25	.	O

1	In	O
2	summary	O
3	,	O
4	p56	O
5	(	O
6	lck	O
7	)	O
8	activity	O
9	stimulates	O
10	G1	O
11	/	O
12	S	O
13	transition	O
14	in	O
15	immature	O
16	thymoblasts	O
17	and	O
18	maintains	O
19	cell	O
20	viability	O
21	via	O
22	transduction	O
23	of	O
24	constitutive	O
25	activation	O
26	signals	O
27	downstream	O
28	to	O
29	components	O
30	of	O
31	the	O
32	Ras	B
33	/	I
34	Raf	I
35	/	I
36	MAPK	I
37	pathway	O
38	.	O

1	Antihistamines	B
2	in	O
3	asthma	O
4	.	O

1	3	I
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	We	O
2	failed	O
3	to	O
4	find	O
5	these	O
6	data	O
7	to	O
8	be	O
9	useful	O
10	in	O
11	predicting	O
12	the	O
13	time	O
14	of	O
15	onset	O
16	of	O
17	initial	O
18	seizures	O
19	after	O
20	acute	O
21	ischemic	O
22	stroke	O
23	and	O
24	recurrence	O
25	.	O

1	Characterization	O
2	of	O
3	the	O
4	alpha	B
5	4	I
6	integrin	I
7	gene	I
8	promoter	I
9	.	O

1	The	O
2	2	O
3	kb	O
4	of	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	and	O
10	the	O
11	1	O
12	.	O
13	1	O
14	kb	O
15	of	O
16	the	O
17	entire	O
18	sGTH	B
19	alpha	I
20	subunit	I
21	coding	O
22	region	O
23	were	O
24	sequenced	O
25	from	O
26	the	O
27	genomic	O
28	clone	O
29	,	O
30	sGTH	B
31	alpha	I
32	-	I
33	G1	O
34	.	O

1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	B
11	-	I
12	R1	I
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	B
38	-	I
39	R1	I
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	chiefly	O
8	by	O
9	electromyography	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	auxiliary	O
20	indicators	O
21	.	O

1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	O
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	O
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O

1	Oncogenic	B
2	capacity	O
3	of	O
4	the	O
5	E2F1	B
6	gene	I
7	.	O

1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O

1	Thrombocyte	B
2	function	O
3	was	O
4	impaired	O
5	in	O
6	all	O
7	patients	O
8	,	O
9	characterized	O
10	by	O
11	a	O
12	diminished	O
13	platelet	O
14	shape	O
15	change	O
16	.	O

1	RESULTS	O
2	:	O
3	For	O
4	E1	B
5	,	O
6	itraconazole	O
7	plasma	O
8	drug	O
9	concentration	O
10	extrapolated	O
11	to	O
12	time	O
13	zero	O
14	(	O
15	IV	O
16	dose	O
17	)	O
18	was	O
19	5	O
20	.	O
21	2	O
22	+/-	O
23	1	O
24	.	O
25	4	O
26	micrograms	O
27	/	O
28	ml	O
29	,	O
30	and	O
31	mean	O
32	residence	O
33	time	O
34	(	O
35	MRT	O
36	)	O
37	was	O
38	37	O
39	+/-	O
40	16	O
41	hours	O
42	.	O

1	SUMMARY	B
2	BACKGROUND	O
3	DATA	O
4	:	O
5	Melanoma	O
6	care	O
7	has	O
8	not	O
9	changed	O
10	significantly	O
11	in	O
12	the	O
13	last	O
14	20	O
15	years	O
16	,	O
17	and	O
18	the	O
19	controversy	O
20	of	O
21	elective	O
22	lymph	O
23	node	O
24	dissections	O
25	in	O
26	this	O
27	disease	O
28	continues	O
29	to	O
30	be	O
31	discussed	O
32	.	O

1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	I
10	2	I
11	but	O
12	not	O
13	an	O
14	Egr	B
15	-	I
16	1	I
17	expression	O
18	vector	O
19	activated	O
20	VPF	O
21	/	O
22	VEGF	B
23	transcription	I
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	I
30	2	I
31	protein	I
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	B
37	alpha	I
38	-	I
39	induced	O
40	VPF	O
41	/	O
42	VEGF	B
43	gene	I
44	expression	O
45	.	O

1	Krox	B
2	-	I
3	20	O
4	,	O
5	a	O
6	zinc	B
7	finger	I
8	gene	I
9	,	O
10	has	O
11	a	O
12	highly	O
13	conserved	O
14	pattern	O
15	of	O
16	expression	O
17	in	O
18	r3	O
19	and	O
20	r5	O
21	and	O
22	is	O
23	functionally	O
24	required	O
25	for	O
26	their	O
27	maintenance	O
28	in	O
29	mouse	O
30	embryos	O
31	.	O

1	Comparison	O
2	of	O
3	frequencies	O
4	of	O
5	atrial	O
6	fibrillation	O
7	after	O
8	coronary	O
9	artery	O
10	bypass	O
11	grafting	O
12	with	O
13	and	O
14	without	O
15	the	O
16	use	O
17	of	O
18	cardiopulmonary	O
19	bypass	O
20	.	O

1	Since	O
2	the	O
3	stability	O
4	of	O
5	TF1	O
6	resides	O
7	in	O
8	its	O
9	primary	O
10	structure	O
11	,	O
12	we	O
13	cloned	O
14	a	O
15	gene	O
16	coding	O
17	for	O
18	TF1	O
19	,	O
20	and	O
21	the	O
22	primary	O
23	structure	O
24	of	O
25	the	O
26	beta	B
27	subunit	I
28	was	O
29	deduced	O
30	from	O
31	the	O
32	nucleotide	O
33	sequence	O
34	of	O
35	the	O
36	gene	O
37	to	O
38	compare	O
39	the	O
40	sequence	O
41	with	O
42	those	O
43	of	O
44	beta	O
45	'	O
46	s	O
47	of	O
48	three	O
49	major	O
50	categories	O
51	of	O
52	F1	O
53	'	O
54	s	O
55	;	O
56	prokaryotic	O
57	membranes	O
58	,	O
59	chloroplasts	O
60	,	O
61	and	O
62	mitochondria	O
63	.	O

1	Regulation	O
2	of	O
3	parathyroid	B
4	hormone	I
5	-	I
6	related	I
7	protein	I
8	(	I
9	PTHrP	I
10	)	I
11	gene	I
12	expression	O
13	.	O

1	Intravenous	O
2	versus	O
3	oral	O
4	administration	O
5	of	O
6	amitriptyline	O
7	in	O
8	patients	O
9	with	O
10	major	O
11	depression	O
12	.	O

1	LY290181	B
2	appears	O
3	to	O
4	inhibit	O
5	uPA	B
6	promoter	I
7	activation	O
8	by	O
9	blocking	O
10	phorbol	O
11	ester	O
12	-	O
13	stimulated	O
14	binding	O
15	of	O
16	nuclear	O
17	proteins	O
18	to	O
19	the	O
20	uPA	B
21	PEA3	B
22	/	I
23	12	I
24	-	I
25	0	O
26	-	O
27	tetradecanoylphorbol	O
28	13	O
29	-	O
30	acetate	O
31	responsive	O
32	element	O
33	(	O
34	TRE	O
35	).	O

1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O

1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	Abl	O
9	SH3	B
10	domain	I
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	O
5	locus	O
6	at	O
7	Xp11	O
8	.	O
9	3	O
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	ELISA	O
2	was	O
3	found	O
4	to	O
5	make	O
6	a	O
7	contribution	O
8	to	O
9	the	O
10	diagnosis	O
11	of	O
12	tuberculosis	O
13	similar	O
14	to	O
15	that	O
16	of	O
17	sputum	O
18	smear	O
19	.	O

1	M	B
2	.,	O
3	and	O
4	D	O
5	.	O

1	50	O
2	kDa	O
3	and	O
4	130	O
5	-	O
6	170	O
7	kDa	O
8	were	O
9	detected	O
10	.	O

1	Pentachlorophenol	B
2	accelerates	O
3	the	O
4	onset	O
5	of	O
6	HCB	O
7	porphyria	O
8	,	O
9	in	O
10	other	O
11	words	O
12	it	O
13	increases	O
14	the	O
15	total	O
16	urinary	O
17	porphyrin	O
18	excretion	O
19	and	O
20	causes	O
21	an	O
22	earlier	O
23	disturbance	O
24	of	O
25	the	O
26	porphyrin	O
27	pattern	O
28	.	O

1	A	I
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O

1	One	O
2	form	O
3	of	O
4	the	O
5	SBEI	B
6	gene	I
7	transcript	I
8	in	O
9	12	O
10	-	O
11	day	O
12	old	O
13	kernels	O
14	contained	O
15	the	O
16	exon	O
17	I	B
18	+	I
19	II	I
20	+	I
21	III	I
22	combination	O
23	at	O
24	the	O
25	5	O
26	'	O
27	end	O
28	,	O
29	whereas	O
30	other	O
31	forms	O
32	differed	O
33	by	O
34	inclusion	O
35	of	O
36	intron	O
37	1	O
38	or	O
39	exclusion	O
40	of	O
41	exon	O
42	II	O
43	sequences	O
44	.	O

1	This	O
2	article	O
3	describes	O
4	the	O
5	collaborative	O
6	care	O
7	of	O
8	the	O
9	woman	O
10	participating	O
11	in	O
12	maternal	O
13	blood	O
14	donation	O
15	for	O
16	intrauterine	O
17	transfusion	O
18	.	O

1	100	O
2	and	O
3	14	O
4	p	O
5	.	O

1	Rapid	B
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	O
7	GnRHR	O
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	O
18	human	O
19	GnRHR	O
20	(	O
21	hGnRHR	O
22	)	O
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	Risk	O
2	factors	O
3	associated	O
4	with	O
5	a	O
6	high	O
7	seroprevalence	O
8	of	O
9	hepatitis	O
10	C	O
11	virus	O
12	infection	O
13	in	O
14	Egyptian	O
15	blood	O
16	donors	O
17	.	O

1	Association	B
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O

1	Antenatal	B
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O

1	Elledge	B
2	,	O
3	P	O
4	.	O

1	It	O
2	is	O
3	also	O
4	homologous	O
5	to	O
6	other	O
7	sugar	O
8	carriers	O
9	from	O
10	human	O
11	,	O
12	mouse	O
13	and	O
14	Escherichia	O
15	coli	O
16	.	O

1	Thus	O
2	,	O
3	while	O
4	the	O
5	genomic	O
6	organization	O
7	of	O
8	mHuA	O
9	is	O
10	similar	O
11	to	O
12	the	O
13	neural	O
14	-	O
15	restricted	O
16	members	O
17	of	O
18	the	O
19	Elav	B
20	family	I
21	,	O
22	the	O
23	promoter	O
24	element	O
25	differs	O
26	substantially	O
27	both	O
28	by	O
29	sequence	O
30	analysis	O
31	and	O
32	transcriptional	O
33	activity	O
34	in	O
35	non	O
36	-	O
37	neural	O
38	cell	O
39	types	O
40	.	O

1	These	O
2	clones	O
3	overlapped	O
4	and	O
5	contained	O
6	the	O
7	structural	O
8	gene	O
9	encoding	O
10	the	O
11	complete	O
12	C5	B
13	alpha	I
14	-	I
15	chain	I
16	and	O
17	90	O
18	%	O
19	of	O
20	the	O
21	beta	B
22	-	I
23	chain	I
24	.	O

1	Oligonucleotide	B
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	Band	B
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	METHODS	O
2	:	O
3	We	O
4	determined	O
5	an	O
6	odds	O
7	ratio	O
8	(	O
9	OR	O
10	),	O
11	as	O
12	a	O
13	measure	O
14	of	O
15	the	O
16	relative	O
17	risk	O
18	of	O
19	being	O
20	exposed	O
21	to	O
22	a	O
23	potential	O
24	interaction	O
25	,	O
26	comparing	O
27	the	O
28	use	O
29	of	O
30	the	O
31	H2	B
32	-	I
33	receptor	I
34	antagonist	O
35	,	O
36	cimetidine	O
37	,	O
38	with	O
39	that	O
40	of	O
41	the	O
42	noninteracting	O
43	agents	O
44	ranitidine	O
45	,	O
46	famotidine	O
47	and	O
48	nizatidine	O
49	in	O
50	users	O
51	and	O
52	nonusers	O
53	of	O
54	warfarin	O
55	,	O
56	phenytoin	O
57	and	O
58	theophylline	O
59	.	O

1	Characterization	O
2	of	O
3	CR1	O
4	repeat	O
5	random	O
6	PCR	O
7	markers	O
8	for	O
9	mapping	O
10	the	O
11	chicken	O
12	genome	O
13	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	O
12	preferentially	O
13	infects	O
14	CD4	B
15	+	I
16	T	I
17	lymphocytes	O
18	and	O
19	may	O
20	exist	O
21	as	O
22	a	O
23	latent	O
24	provirus	O
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	SGPT	B
2	,	O
3	SGOT	O
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Thus	O
2	,	O
3	SOX8	O
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O

1	A	I
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	1	I
2	.	O

1	Thus	O
2	,	O
3	SAG	O
4	appears	O
5	to	O
6	control	O
7	cell	O
8	cycle	O
9	progression	O
10	in	O
11	yeast	O
12	by	O
13	promoting	O
14	ubiquitination	O
15	and	O
16	degradation	O
17	of	O
18	cell	O
19	cycle	O
20	regulatory	O
21	proteins	O
22	.	O

1	Lack	B
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	yeast	O
5	CEG1	O
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	O
12	conserved	O
13	motifs	O
14	are	O
15	essential	O
16	for	O
17	capping	O
18	enzyme	O
19	function	O
20	in	O
21	vivo	O
22	.	O

1	In	O
2	the	O
3	multivariate	O
4	analysis	O
5	,	O
6	six	O
7	variables	O
8	were	O
9	independently	O
10	correlated	O
11	with	O
12	survival	O
13	:	O
14	blood	O
15	urea	O
16	nitrogen	O
17	level	O
18	,	O
19	serum	B
20	aspartate	I
21	aminotransferase	I
22	level	O
23	,	O
24	community	O
25	-	O
26	acquired	O
27	vs	O
28	.	O
29	hospital	O
30	-	O
31	acquired	O
32	peritonitis	O
33	,	O
34	age	O
35	,	O
36	Child	O
37	-	O
38	Pugh	O
39	score	O
40	and	O
41	ileus	O
42	.	O

1	Although	O
2	the	O
3	RAD23	O
4	equivalents	O
5	are	O
6	well	O
7	conserved	O
8	during	O
9	evolution	O
10	,	O
11	the	O
12	mammalian	B
13	genes	I
14	did	O
15	not	O
16	express	O
17	the	O
18	UV	O
19	-	O
20	inducible	O
21	phenotype	O
22	of	O
23	their	O
24	yeast	O
25	counterpart	O
26	.	O

1	Acute	O
2	type	O
3	A	O
4	hepatitis	O
5	in	O
6	three	O
7	patients	O
8	with	O
9	chronic	O
10	HBV	O
11	infection	O
12	.	O

1	Titration	B
2	of	O
3	the	O
4	human	O
5	and	O
6	porcine	B
7	proteins	I
8	with	O
9	2	O
10	-	O
11	nitro	B
12	-	I
13	5	I
14	-	I
15	thiosulfabenzoate	O
16	indicates	O
17	that	O
18	membrane	O
19	dipeptidase	O
20	additionally	O
21	possesses	O
22	two	O
23	intrachain	O
24	disulfide	O
25	bonds	O
26	.	O

1	Modification	B
2	of	O
3	enteral	O
4	resorption	O
5	by	O
6	cytostatic	O
7	therapy	O

1	Future	B
2	analysis	O
3	of	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	measures	O
9	of	O
10	performance	O
11	with	O
12	the	O
13	implant	O
14	will	O
15	confirm	O
16	or	O
17	dispute	O
18	the	O
19	benefit	O
20	of	O
21	ear	O
22	selection	O
23	using	O
24	the	O
25	Prom	O
26	-	O
27	EABR	O
28	.	O

1	In	O
2	particular	O
3	,	O
4	unc	O
5	-	O
6	86	O
7	encodes	O
8	a	O
9	POU	B
10	-	I
11	type	I
12	homeodomain	I
13	protein	I
14	needed	O
15	for	O
16	the	O
17	production	O
18	of	O
19	the	O
20	touch	O
21	cells	O
22	,	O
23	while	O
24	mec	B
25	-	I
26	3	I
27	encodes	O
28	a	O
29	LIM	B
30	-	I
31	type	I
32	homeodomain	I
33	protein	I
34	needed	O
35	for	O
36	the	O
37	differentiation	O
38	of	O
39	the	O
40	touch	O
41	cells	O
42	.	O

1	Antibiotic	B
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	O

1	This	O
2	coat	B
3	protein	I
4	consists	O
5	of	O
6	Sar1p	O
7	,	O
8	the	O
9	Sec23p	B
10	protein	I
11	complex	I
12	containing	O
13	Sec23p	O
14	and	O
15	Sec24p	O
16	,	O
17	and	O
18	the	O
19	Sec13p	B
20	protein	I
21	complex	I
22	containing	O
23	Sec13p	O
24	and	O
25	a	O
26	novel	O
27	150	O
28	-	O
29	kDa	O
30	protein	O
31	,	O
32	p150	O
33	.	O

1	A	I
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O

1	Experiments	O
2	showed	O
3	that	O
4	temporary	O
5	arrest	O
6	of	O
7	pulmonary	O
8	circulation	O
9	under	O
10	conditions	O
11	of	O
12	extracorporeal	O
13	circulation	O
14	is	O
15	attended	O
16	by	O
17	the	O
18	development	O
19	of	O
20	ischemia	O
21	of	O
22	the	O
23	respiratory	O
24	pulmonary	O
25	tissue	O
26	.	O

1	An	O
2	essential	O
3	role	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	and	O
9	c	B
10	-	I
11	Fos	I
12	in	O
13	basal	O
14	and	O
15	PMA	O
16	-	O
17	stimulated	O
18	transcription	O
19	of	O
20	the	O
21	PAI	B
22	-	I
23	1	I
24	gene	I
25	is	O
26	demonstrated	O
27	by	O
28	our	O
29	finding	O
30	that	O
31	antisense	O
32	c	B
33	-	I
34	jun	I
35	and	O
36	c	B
37	-	I
38	fos	I
39	oligodeoxynucleotides	O
40	both	O
41	strongly	O
42	reduced	O
43	basal	O
44	and	O
45	PMA	O
46	-	O
47	stimulated	O
48	PAI	B
49	-	I
50	1	I
51	synthesis	O
52	.	O

1	Anatomy	B
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	Formalin	B
2	activated	I
3	both	O
4	SNO	O
5	NS	O
6	and	O
7	NnS	O
8	neurones	O
9	,	O
10	but	O
11	,	O
12	when	O
13	they	O
14	responded	O
15	,	O
16	NS	O
17	neurones	O
18	(	O
19	n	O
20	=	O
21	5	O
22	)	O
23	showed	O
24	only	O
25	the	O
26	first	O
27	phase	O
28	of	O
29	activity	O
30	while	O
31	NnS	O
32	neurones	O
33	showed	O
34	either	O
35	one	O
36	(	O
37	n	O
38	=	O
39	13	O
40	)	O
41	or	O
42	two	O
43	phases	O
44	(	O
45	n	O
46	=	O
47	6	O
48	).	O

1	Overexpression	O
2	of	O
3	Sed5p	O
4	allowed	O
5	growth	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	Vti1p	O
11	.	O

1	AP	B
2	was	O
3	induced	O
4	by	O
5	intraductal	O
6	infusion	O
7	of	O
8	two	O
9	different	O
10	concentrations	O
11	of	O
12	glycodeoxycholic	O
13	acid	O
14	(	O
15	GDOC	O
16	17	O
17	mmol	O
18	and	O
19	34	O
20	mmol	O
21	).	O

1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O

1	Propagation	B
2	and	I
3	hormone	I
4	production	O
5	by	O
6	human	O
7	normal	O
8	and	O
9	malignant	O
10	trophoblast	O
11	in	O
12	rats	O
13	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	OND	B
2	8	O
3	mg	O
4	tid	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	tid	O
14	prn	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	prednisolone	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	qds	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	MCP	O
34	30	O
35	mg	O
36	/	O
37	metylprednisolone	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	MCP	O
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O

1	In	O
2	ICE	B
3	gamma	I
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	B
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O

1	J	O
2	.	O

1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	Nerve	B
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	3225	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	BPV	B
25	-	I
26	1	I
27	pre	I
28	-	I
29	mRNAs	I
30	in	O
31	BPV	B
32	-	I
33	1	I
34	-	I
35	transformed	O
36	C127	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	productively	O
46	infected	O
47	warts	O
48	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	the	O
6	sensitivity	O
7	of	O
8	the	O
9	3	O
10	given	O
11	guinea	O
12	pig	O
13	strains	O
14	was	O
15	comparable	O
16	.	O

1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O

1	Value	B
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	I
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	B
11	-	I
12	1	I
13	regulatory	I
14	element	I
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	B
30	-	I
31	response	I
32	element	I
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	114	O
41	).	O

1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O

1	Ti	B
2	exhibited	O
3	a	O
4	feather	B
5	-	I
6	like	I
7	morphology	O
8	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	Bacteria	B
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O

1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O

1	The	O
2	persistent	O
3	fetal	O
4	dispersion	O
5	of	O
6	nodal	O
7	and	O
8	Hiss	O
9	bundle	O
10	fragments	O
11	within	O
12	the	O
13	ventricular	O
14	septum	O
15	is	O
16	proposed	O
17	as	O
18	a	O
19	possible	O
20	explanation	O
21	.	O

1	Electronic	B
2	structure	O
3	of	O
4	delta	O
5	-	O
6	plutonium	O
7	and	O
8	of	O
9	single	O
10	Al	O
11	,	O
12	Ga	O
13	,	O
14	and	O
15	Sc	O
16	impurities	O
17	in	O
18	delta	O
19	-	O
20	plutonium	O
21	.	O

1	Several	O
2	lines	O
3	of	O
4	evidence	O
5	demonstrate	O
6	that	O
7	this	O
8	growth	O
9	inhibition	O
10	requires	O
11	active	O
12	PKA	B
13	subunits	I
14	and	O
15	cAMP	O
16	:	O
17	(	O
18	i	O
19	)	O
20	this	O
21	phenotype	O
22	is	O
23	dependent	O
24	on	O
25	cAMP	O
26	since	O
27	it	O
28	is	O
29	not	O
30	seen	O
31	in	O
32	a	O
33	strain	O
34	lacking	O
35	adenylyl	B
36	cyclase	I
37	activity	O
38	,	O
39	but	O
40	the	O
41	growth	O
42	rate	O
43	of	O
44	these	O
45	transformants	O
46	is	O
47	slower	O
48	when	O
49	exogenous	O
50	cAMP	O
51	is	O
52	added	O
53	;	O
54	(	O
55	ii	O
56	)	O
57	normal	O
58	growth	O
59	occurs	O
60	when	O
61	wild	O
62	-	O
63	type	O
64	RI	B
65	cDNA	I
66	is	O
67	replaced	O
68	by	O
69	a	O
70	mutant	O
71	RI	B
72	cDNA	I
73	encoding	O
74	a	O
75	RI	B
76	protein	I
77	with	O
78	reduced	O
79	cAMP	O
80	binding	O
81	;	O
82	and	O
83	(	O
84	iii	O
85	)	O
86	the	O
87	growth	O
88	-	O
89	inhibited	O
90	phenotype	O
91	of	O
92	the	O
93	transformed	O
94	BL21	O
95	(	O
96	DE3	O
97	)	O
98	cells	O
99	requires	O
100	soluble	O
101	,	O
102	active	O
103	C	B
104	alpha	I
105	protein	I
106	.	O

1	The	O
2	length	O
3	scales	O
4	of	O
5	the	O
6	turbulence	O
7	were	O
8	also	O
9	estimated	O
10	:	O
11	at	O
12	a	O
13	Reynolds	O
14	number	O
15	near	O
16	4	O
17	,	O
18	000	O
19	the	O
20	macroscale	O
21	is	O
22	about	O
23	1	O
24	.	O
25	25	O
26	mm	O
27	,	O
28	the	O
29	Taylor	O
30	microscale	O
31	is	O
32	about	O
33	0	O
34	.	O
35	85	O
36	mm	O
37	,	O
38	and	O
39	the	O
40	Kolmogoroff	O
41	scale	O
42	is	O
43	near	O
44	0	O
45	.	O
46	075	O
47	mm	O
48	.	O

1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	7R	I
10	alpha	I
11	chains	I
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	JAKs	O
20	and	O
21	STATs	O
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	proliferative	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	Spontaneous	B
2	burst	O
3	firing	O
4	in	O
5	cat	O
6	primary	O
7	auditory	O
8	cortex	O
9	:	O
10	age	O
11	and	O
12	depth	O
13	dependence	O
14	and	O
15	its	O
16	effect	O
17	on	O
18	neural	O
19	interaction	O
20	measures	O
21	.	O

1	A	I
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	B
16	gene	I
17	(	O
18	named	O
19	porCa	O
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

1	Motivational	B
2	factors	I
3	focusing	O
4	on	O
5	attitudes	O
6	,	O
7	perceived	O
8	susceptibility	O
9	to	O
10	pregnancy	O
11	,	O
12	and	O
13	normative	O
14	factors	O
15	were	O
16	also	O
17	relevant	O
18	.	O

1	The	O
2	RING	B
3	finger	I
4	,	I
5	B2	I
6	box	I
7	,	O
8	and	O
9	coiled	O
10	-	O
11	coil	O
12	region	O
13	are	O
14	required	O
15	for	O
16	oligomerization	O
17	of	O
18	KAP	B
19	-	I
20	1	I
21	-	I
22	RBCC	O
23	and	O
24	KRAB	B
25	binding	I
26	,	O
27	as	O
28	mutations	O
29	in	O
30	these	O
31	domains	O
32	concomitantly	O
33	abolished	O
34	these	O
35	functions	O
36	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	with	O
6	nuclear	O
7	extracts	O
8	and	O
9	oligonucleotide	O
10	sequences	O
11	spanning	O
12	the	O
13	0	O
14	.	O
15	125	O
16	-	O
17	kb	O
18	promoter	O
19	region	O
20	detected	O
21	an	O
22	ETS	B
23	-	I
24	immunoreactive	I
25	complex	I
26	,	O
27	present	O
28	most	O
29	abundantly	O
30	in	O
31	cells	O
32	overexpressing	O
33	HER2	O
34	,	O
35	whose	O
36	high	O
37	-	O
38	affinity	O
39	binding	O
40	depended	O
41	on	O
42	the	O
43	GAGGAA	O
44	response	O
45	element	O
46	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	O
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	O
18	.	O

1	This	O
2	study	O
3	provides	O
4	a	O
5	direct	O
6	demonstration	O
7	of	O
8	a	O
9	role	O
10	for	O
11	G	O
12	betagamma	O
13	in	O
14	mediating	O
15	the	O
16	agonist	O
17	-	O
18	stimulated	O
19	translocation	O
20	of	O
21	GRK2	O
22	and	O
23	GRK3	O
24	in	O
25	an	O
26	intact	O
27	cellular	O
28	system	O
29	and	O
30	demonstrates	O
31	isoform	O
32	specificity	O
33	in	O
34	the	O
35	interaction	O
36	of	O
37	these	O
38	components	O
39	.	O

1	The	O
2	transcription	O
3	of	O
4	most	O
5	RP	O
6	genes	O
7	is	O
8	activated	O
9	by	O
10	two	O
11	Rap1p	B
12	binding	I
13	sites	I
14	,	O
15	250	O
16	to	O
17	400	O
18	bp	O
19	upstream	O
20	from	O
21	the	O
22	initiation	O
23	of	O
24	transcription	O
25	.	O

1	Type	B
2	I	I
3	cysts	O
4	(	O
5	with	O
6	a	O
7	high	O
8	K	O
9	+/	O
10	Na	O
11	+	O
12	ratio	O
13	)	O
14	tend	O
15	to	O
16	have	O
17	higher	O
18	total	O
19	PSA	B
20	than	O
21	Type	O
22	II	O
23	cysts	O
24	.	O

1	Like	O
2	humans	O
3	,	O
4	the	O
5	PITSLRE	O
6	PK	O
7	genes	O
8	in	O
9	chickens	O
10	must	O
11	be	O
12	closely	O
13	linked	O
14	,	O
15	based	O
16	on	O
17	fluorescent	O
18	in	O
19	situ	O
20	hybridization	O
21	(	O
22	FISH	O
23	)	O
24	localization	O
25	of	O
26	these	O
27	genes	O
28	to	O
29	a	O
30	single	O
31	chicken	O
32	microchromosome	O
33	.	O

1	GnRH	B
2	treatment	O
3	was	O
4	found	O
5	to	O
6	increase	O
7	the	O
8	phosphorylation	O
9	of	O
10	tyrosine	O
11	residues	O
12	of	O
13	MAPK	B
14	and	O
15	to	O
16	increase	O
17	MAPK	B
18	activity	O
19	,	O
20	as	O
21	determined	O
22	by	O
23	an	O
24	immune	B
25	complex	I
26	kinase	I
27	assay	O
28	.	O

1	Stimulation	B
2	of	O
3	the	O
4	caudate	O
5	nucleus	O
6	'	O
7	dophamine	B
8	-	I
9	reactive	I
10	system	O
11	in	O
12	dogs	O
13	by	O
14	means	O
15	of	O
16	administration	O
17	of	O
18	dophamine	O
19	(	O
20	60	O
21	micrograms	O
22	)	O
23	and	O
24	phenamine	O
25	led	O
26	to	O
27	deterioration	O
28	of	O
29	conditioned	O
30	and	O
31	unconditioned	O
32	components	O
33	of	O
34	feeding	O
35	behaviour	O
36	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	O
9	type	O
10	peptides	O
11	were	O
12	observed	O
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	Splenectomized	B
2	patients	O
3	are	O
4	predisposed	O
5	toward	O
6	developing	O
7	overwhelming	O
8	bacterial	O
9	infections	O
10	.	O

1	Significantly	B
2	,	O
3	two	O
4	proximal	O
5	GATA	B
6	-	I
7	1	I
8	-	I
9	binding	I
10	sites	I
11	(-	O
12	118	O
13	/-	O
14	113	O
15	and	O
16	-	O
17	98	O
18	/-	O
19	93	O
20	)	O
21	and	O
22	a	O
23	region	O
24	located	O
25	within	O
26	-	O
27	518	O
28	to	O
29	-	O
30	315bp	O
31	of	O
32	the	O
33	mouse	O
34	ALAS2	O
35	promoter	O
36	were	O
37	essential	O
38	for	O
39	transcriptional	O
40	activation	O
41	during	O
42	chemically	O
43	induced	O
44	differentiation	O
45	of	O
46	MEL	O
47	cells	O
48	,	O
49	implying	O
50	their	O
51	importance	O
52	in	O
53	conferring	O
54	erythroid	O
55	specificity	O
56	to	O
57	the	O
58	ALAS2	O
59	transcriptional	O
60	activation	O
61	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	(	I
2	2	I
3	)	O
4	Erythroid	O
5	32D	O
6	Epo1	O
7	cells	O
8	showed	O
9	a	O
10	lower	O
11	level	O
12	of	O
13	bulk	O
14	PKC	B
15	catalytic	O
16	activity	O
17	,	O
18	lacked	O
19	the	O
20	expression	O
21	of	O
22	epsilon	O
23	and	O
24	eta	O
25	PKC	B
26	isoforms	I
27	,	O
28	and	O
29	showed	O
30	a	O
31	weak	O
32	or	O
33	absent	O
34	upregulation	O
35	of	O
36	the	O
37	remaining	O
38	isoforms	O
39	,	O
40	except	O
41	betaI	O
42	,	O
43	upon	O
44	readdition	O
45	of	O
46	Epo	B
47	to	O
48	growth	B
49	factor	I
50	-	I
51	starved	O
52	cells	O
53	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	the	O
6	predictive	O
7	ability	O
8	of	O
9	the	O
10	selected	O
11	attitudes	O
12	and	O
13	orientations	O
14	increased	O
15	considerably	O
16	from	O
17	1975	O
18	to	O
19	1982	O
20	.	O

1	Gluzman	B
2	,	O
3	EMBO	O
4	J	O
5	.	O

1	If	O
2	the	O
3	haemoglobin	O
4	concentration	O
5	(	O
6	Hb	B
7	)	O
8	was	O
9	less	O
10	than	O
11	12	O
12	g	O
13	dL	O
14	-	O
15	1	O
16	they	O
17	were	O
18	given	O
19	a	O
20	four	O
21	week	O
22	course	O
23	of	O
24	ferrous	O
25	sulphate	O
26	.	O

1	Based	O
2	on	O
3	the	O
4	current	O
5	literature	O
6	,	O
7	the	O
8	mechanisms	O
9	involved	O
10	in	O
11	the	O
12	toxicity	O
13	of	O
14	OA	O
15	indicate	O
16	three	O
17	major	O
18	effects	O
19	:	O
20	(	O
21	1	O
22	)	O
23	inhibition	O
24	of	O
25	mitochondrial	O
26	respiration	O
27	correlated	O
28	with	O
29	a	O
30	depletion	O
31	of	O
32	ATP	O
33	;	O
34	(	O
35	2	O
36	)	O
37	inhibition	O
38	of	O
39	tRNA	B
40	-	I
41	synthetase	I
42	accompanied	O
43	by	O
44	a	O
45	reduced	O
46	protein	O
47	synthesis	O
48	;	O
49	and	O
50	(	O
51	3	O
52	)	O
53	enhanced	O
54	lipid	O
55	peroxidation	O
56	.	O

1	In	O
2	contrast	O
3	to	O
4	full	O
5	-	O
6	length	O
7	E2F	B
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	O
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	The	O
2	mobility	O
3	shift	O
4	assay	O
5	of	O
6	the	O
7	65	O
8	bp	O
9	(-	O
10	318	O
11	/	O
12	-	O
13	254	O
14	)	O
15	fragment	O
16	with	O
17	nuclear	O
18	extract	O
19	from	O
20	the	O
21	dark	O
22	-	O
23	adapted	O
24	sample	O
25	showed	O
26	an	O
27	additional	O
28	band	O
29	,	O
30	not	O
31	seen	O
32	with	O
33	the	O
34	light	O
35	-	O
36	grown	O
37	sample	O
38	.	O

1	Individuals	B
2	attending	O
3	the	O
4	GUM	O
5	Department	O
6	in	O
7	the	O
8	Royal	O
9	Infirmary	O
10	of	O
11	Edinburgh	O
12	between	O
13	1990	O
14	and	O
15	1994	O
16	with	O
17	the	O
18	diagnosis	O
19	of	O
20	HIV	O
21	infection	O
22	,	O
23	genital	O
24	warts	O
25	,	O
26	genital	O
27	herpes	O
28	,	O
29	non	O
30	-	O
31	specific	O
32	genital	O
33	infection	O
34	(	O
35	NSGI	O
36	),	O
37	gonorrhoea	O
38	and	O
39	syphilis	O
40	were	O
41	included	O
42	in	O
43	the	O
44	study	O
45	.	O

1	The	O
2	P	O
3	-	O
4	wr	O
5	and	O
6	P	O
7	-	O
8	rr	O
9	cDNA	O
10	sequences	O
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O

1	The	O
2	routine	O
3	administration	O
4	of	O
5	fat	O
6	-	O
7	soluble	O
8	vitamins	O
9	appears	O
10	unnecessary	O
11	but	O
12	it	O
13	is	O
14	prudent	O
15	to	O
16	measure	O
17	prothrombin	B
18	time	O
19	and	O
20	serum	O
21	vitamins	O
22	A	O
23	and	O
24	E	O
25	at	O
26	intervals	O
27	.	O

1	Concurrent	B
2	with	O
3	ligand	O
4	-	O
5	dependent	O
6	uptake	O
7	,	O
8	we	O
9	now	O
10	show	O
11	that	O
12	the	O
13	receptor	O
14	undergoes	O
15	ligand	O
16	-	O
17	induced	O
18	ubiquitination	O
19	,	O
20	suggesting	O
21	that	O
22	receptor	O
23	ubiquitination	O
24	may	O
25	function	O
26	in	O
27	the	O
28	ligand	O
29	-	O
30	dependent	O
31	endocytosis	O
32	of	O
33	the	O
34	a	O
35	-	O
36	factor	B
37	receptor	I
38	as	O
39	well	O
40	as	O
41	in	O
42	its	O
43	constitutive	O
44	endocytosis	O
45	.	O

1	To	O
2	test	O
3	the	O
4	role	O
5	of	O
6	ML	O
7	in	O
8	human	O
9	reproductive	O
10	axis	O
11	,	O
12	128	O
13	healthy	O
14	children	O
15	,	O
16	68	O
17	boys	O
18	and	O
19	60	O
20	girls	O
21	,	O
22	were	O
23	studied	O
24	.	O

1	The	O
2	present	O
3	treatment	O
4	strategy	O
5	in	O
6	progressive	O
7	disorders	O
8	is	O
9	mainly	O
10	based	O
11	on	O
12	the	O
13	complementary	O
14	effect	O
15	of	O
16	intensive	O
17	radiochemotherapy	O
18	,	O
19	autologous	O
20	stem	O
21	-	O
22	cell	O
23	transplantation	O
24	and	O
25	the	O
26	rational	O
27	use	O
28	of	O
29	cytokines	O
30	,	O
31	mostly	O
32	colony	B
33	-	I
34	stimulating	I
35	factors	I
36	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	O
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O

1	Moreover	O
2	,	O
3	when	O
4	added	O
5	to	O
6	the	O
7	osteoclast	O
8	cultures	O
9	,	O
10	mrIhh	O
11	-	O
12	N	O
13	markedly	O
14	stimulated	O
15	the	O
16	formation	O
17	of	O
18	resorption	O
19	pits	O
20	on	O
21	dentine	O
22	slices	O
23	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	O
5	and	O
6	Sonic	O
7	hedgehog	O
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	O
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	O
32	expression	O
33	domain	O
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	We	O
2	purified	O
3	a	O
4	Ca2	O
5	+/	O
6	calmodulin	B
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	I
14	CaM	I
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O

1	Examination	O
2	of	O
3	DNA	O
4	:	O
5	protein	O
6	binding	O
7	complexes	O
8	by	O
9	gel	O
10	-	O
11	shift	O
12	analysis	O
13	indicated	O
14	that	O
15	nuclear	O
16	factors	O
17	from	O
18	both	O
19	proliferative	O
20	and	O
21	growth	O
22	-	O
23	arrested	O
24	cells	O
25	bound	O
26	to	O
27	the	O
28	DNA	O
29	fragment	O
30	spanning	O
31	-	O
32	949	B
33	-	I
34	-	I
35	722	O
36	bp	O
37	.	O

1	Functional	O
2	and	O
3	regulatory	O
4	analysis	O
5	of	O
6	the	O
7	two	O
8	copies	O
9	of	O
10	the	O
11	fixNOQP	B
12	operon	I
13	of	O
14	Rhizobium	O
15	leguminosarum	O
16	strain	O
17	VF39	O
18	.	O

1	Interestingly	O
2	,	O
3	these	O
4	response	O
5	elements	O
6	display	O
7	dramatically	O
8	reduced	O
9	affinity	O
10	for	O
11	retinoic	B
12	acid	I
13	receptor	I
14	-	O
15	retinoid	B
16	-	I
17	X	I
18	receptor	I
19	heterodimers	I
20	.	O

1	Furthermore	O
2	,	O
3	a	O
4	mutant	B
5	receptor	I
6	(	O
7	Y977F	O
8	/	O
9	Y989F	O
10	[	O
11	PLC	B
12	gamma	I
13	-	I
14	binding	I
15	sites	I
16	])	I
17	could	O
18	fully	O
19	activate	O
20	Ras	B
21	,	O
22	and	O
23	the	O
24	direct	O
25	activation	O
26	of	O
27	protein	B
28	kinase	I
29	C	I
30	and	O
31	calcium	O
32	mobilization	O
33	had	O
34	almost	O
35	no	O
36	effect	O
37	on	O
38	the	O
39	GDP	O
40	/	O
41	GTP	O
42	state	O
43	of	O
44	Ras	B
45	in	O
46	this	O
47	cell	O
48	line	O
49	.	O

1	Fewer	B
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	Screening	B
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	O
16	IgE	B
17	antibodies	O

1	The	O
2	transit	O
3	time	O
4	was	O
5	significantly	O
6	shortened	O
7	.	O

1	Paf1p	B
2	may	O
3	therefore	O
4	be	O
5	required	O
6	for	O
7	both	O
8	positive	O
9	and	O
10	negative	O
11	regulation	O
12	of	O
13	subsets	O
14	of	O
15	yeast	O
16	genes	O
17	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	Preferential	B
2	heterodimeric	O
3	parallel	O
4	coiled	O
5	-	O
6	coil	O
7	formation	O
8	by	O
9	synthetic	O
10	Max	B
11	and	O
12	c	B
13	-	I
14	Myc	I
15	leucine	I
16	zippers	O
17	:	O
18	a	O
19	description	O
20	of	O
21	putative	O
22	electrostatic	O
23	interactions	O
24	responsible	O
25	for	O
26	the	O
27	specificity	O
28	of	O
29	heterodimerization	O
30	.	O

1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O

1	The	O
2	Tullio	O
3	phenomenon	O
4	,	O
5	fistula	O
6	test	O
7	,	O
8	and	O
9	Hennebert	O
10	'	O
11	s	O
12	sign	O
13	:	O
14	clinical	O
15	significance	O
16	.	O

1	Increasing	B
2	mean	O
3	arterial	O
4	pressure	O
5	by	O
6	phenylephrine	O
7	infusion	O
8	to	O
9	levels	O
10	much	O
11	greater	O
12	than	O
13	produced	O
14	by	O
15	NMA	O
16	and	O
17	NNA	O
18	caused	O
19	only	O
20	small	O
21	reductions	O
22	in	O
23	cardiac	O
24	output	O
25	.	O

1	Toxicity	B
2	during	O
3	the	O
4	therapeutic	O
5	period	O
6	was	O
7	not	O
8	significant	O
9	in	O
10	the	O
11	study	O
12	group	O
13	compared	O
14	with	O
15	the	O
16	historical	O
17	control	O
18	,	O
19	treated	O
20	with	O
21	the	O
22	same	O
23	regimen	O
24	without	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	We	O
2	used	O
3	two	O
4	approaches	O
5	to	O
6	ascertain	O
7	whether	O
8	CDP	O
9	/	O
10	cut	O
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	gp91	B
17	-	I
18	phox	I
19	gene	I
20	expression	O
21	.	O

1	In	O
2	XO	O
3	males	O
4	,	O
5	two	O
6	her	B
7	-	I
8	1	I
9	mRNAs	I
10	,	O
11	her	B
12	-	I
13	1a	I
14	and	O
15	her	B
16	-	I
17	1b	I
18	,	O
19	are	O
20	transcribed	O
21	from	O
22	two	O
23	separate	O
24	promoters	O
25	:	O
26	P1	O
27	,	O
28	located	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	flanking	O
34	region	O
35	,	O
36	and	O
37	P2	O
38	,	O
39	located	O
40	in	O
41	the	O
42	large	O
43	second	O
44	intron	O
45	.	O

1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O

1	Smoking	B
2	history	O
3	and	O
4	awake	O
5	oxygen	O
6	saturation	O
7	(	O
8	SaO2	O
9	)	O
10	was	O
11	recorded	O
12	in	O
13	all	O
14	of	O
15	them	O
16	.	O

1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O

1	The	O
2	acids	O
3	were	O
4	obtained	O
5	by	O
6	hydrolysis	O
7	of	O
8	the	O
9	corresponding	O
10	esters	O
11	,	O
12	and	O
13	their	O
14	anti	B
15	-	I
16	inflammatory	O
17	activity	O
18	was	O
19	tested	O
20	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	autophosphorylation	O
6	of	O
7	Thr286	B
8	(	I
9	alpha	I
10	subunit	I
11	)	O
12	and	O
13	Thr287	B
14	(	I
15	beta	I
16	subunit	I
17	)	O
18	is	O
19	responsible	O
20	for	O
21	transition	O
22	of	O
23	CaM	B
24	-	I
25	kinase	I
26	II	I
27	to	O
28	the	O
29	Ca2	O
30	+-	O
31	independent	O
32	form	O
33	.	O

1	Tyrosine	B
2	112	O
3	of	O
4	latent	B
5	membrane	I
6	protein	I
7	2A	I
8	is	O
9	essential	O
10	for	O
11	protein	B
12	tyrosine	I
13	kinase	I
14	loading	O
15	and	O
16	regulation	O
17	of	O
18	Epstein	B
19	-	I
20	Barr	I
21	virus	I
22	latency	O
23	.	O

1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O

1	Protein	B
2	tyrosine	I
3	kinases	I
4	(	O
5	PTKs	O
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	virtue	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	transducers	O
31	,	O
32	and	O
33	as	O
34	growth	B
35	factor	I
36	receptors	I
37	or	O
38	components	O
39	thereof	O
40	.	O

1	Our	O
2	purpose	O
3	was	O
4	to	O
5	determine	O
6	if	O
7	intact	O
8	perianal	B
9	(	I
10	S4	I
11	-	I
12	5	O
13	)	O
14	pin	O
15	sensation	O
16	(	O
17	PPS	O
18	)	O
19	and	O
20	bulbocavernosus	O
21	(	O
22	S2	B
23	-	I
24	4	I
25	)	O
26	reflex	O
27	(	O
28	BCR	B
29	)	O
30	shortly	O
31	after	O
32	spinal	O
33	cord	O
34	injury	O
35	(	O
36	SCI	O
37	)	O
38	are	O
39	predictive	O
40	of	O
41	bladder	O
42	function	O
43	recovery	O
44	.	O

1	Transformation	B
2	of	O
3	the	O
4	sconC3	O
5	mutant	O
6	with	O
7	sconB	O
8	+	O
9	restores	O
10	the	O
11	wild	B
12	-	I
13	type	I
14	phenotype	O
15	.	O

1	Canine	B
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O

1	A	I
2	5	O
3	.	O
4	8S	B
5	-	I
6	like	I
7	structure	O
8	is	O
9	present	O
10	within	O
11	the	O
12	5	O
13	'-	O
14	terminal	O
15	region	O
16	of	O
17	all	O
18	three	O
19	fungal	O
20	mitochondrial	O
21	LSU	O
22	rRNAs	O
23	;	O
24	in	O
25	contrast	O
26	,	O
27	no	O
28	4	O
29	.	O
30	5S	B
31	-	I
32	like	I
33	structure	O
34	is	O
35	evident	O
36	at	O
37	the	O
38	3	O
39	'	O
40	end	O
41	of	O
42	these	O
43	molecules	O
44	.	O

1	A	I
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	Replacement	B
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	We	O
2	used	O
3	deletion	O
4	analysis	O
5	and	O
6	transfection	O
7	assays	O
8	with	O
9	reporter	O
10	gene	O
11	constructs	O
12	to	O
13	examine	O
14	the	O
15	transcription	O
16	control	O
17	elements	O
18	in	O
19	the	O
20	5	O
21	'	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	EpoR	I
28	gene	I
29	.	O

1	The	O
2	chick	O
3	axon	B
4	-	I
5	associated	I
6	surface	I
7	glycoprotein	I
8	neurofascin	O
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O

1	The	O
2	possible	O
3	mechanisms	O
4	underlying	O
5	differences	O
6	in	O
7	post	O
8	-	O
9	tetanic	O
10	effects	O
11	from	O
12	muscle	O
13	and	O
14	cutaneous	O
15	afferents	O
16	in	O
17	adults	O
18	and	O
19	neonates	O
20	are	O
21	discussed	O
22	.	O

1	Reverse	B
2	transcriptase	I
3	-	I
4	polymerase	I
5	chain	I
6	reaction	O
7	(	O
8	RT	O
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	Several	O
2	7SL	B
3	RNA	I
4	-	I
5	encoding	I
6	sequences	I
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	B
17	fragments	I
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	upstream	O
7	region	O
8	of	O
9	pepX	O
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	O
24	were	O
25	shown	O
26	to	O
27	be	O
28	able	O
29	to	O
30	encode	O
31	proteins	O
32	with	O
33	high	O
34	homology	O
35	to	O
36	GlnR	O
37	and	O
38	GlnA	O
39	proteins	O
40	,	O
41	respectively	O
42	.	O

1	About	B
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O

1	Finding	B
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	Antithrombin	B
2	III	I
3	in	O
4	hip	O
5	surgery	O

1	Group	O
2	A	O
3	was	O
4	treated	O
5	with	O
6	three	O
7	or	O
8	four	O
9	doses	O
10	of	O
11	hepatitis	B
12	B	I
13	immune	I
14	globulin	I
15	(	O
16	HBIG	O
17	)	O
18	in	O
19	one	O
20	of	O
21	three	O
22	different	O
23	schedules	O
24	.	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	CONCLUSIONS	O
2	.	O

1	A	I
2	group	O
3	of	O
4	66	O
5	DSM	O
6	-	O
7	IV	O
8	paranoid	O
9	schizophrenic	O
10	in	O
11	-	O
12	patients	O
13	were	O
14	assessed	O
15	three	O
16	times	O
17	using	O
18	the	O
19	SAPS	O
20	,	O
21	SANS	O
22	,	O
23	BPRS	O
24	and	O
25	PAS	O
26	.	O

1	We	O
2	identified	O
3	telSMN	O
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	SMA	B
11	-	I
12	like	I
13	individuals	O
14	who	O
15	carry	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	telSMN	O
21	:	O
22	these	O
23	include	O
24	two	O
25	frameshift	O
26	mutations	O
27	(	O
28	800ins11	O
29	and	O
30	542delGT	O
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	A2G	O
38	,	O
39	S262I	O
40	,	O
41	and	O
42	T274I	O
43	).	O

1	Cardiovascular	B
2	risk	O
3	factors	O
4	were	O
5	measured	O
6	by	O
7	standardized	O
8	techniques	O
9	.	O

1	One	O
2	of	O
3	the	O
4	most	O
5	relevant	O
6	aspects	O
7	in	O
8	achieving	O
9	the	O
10	consistent	O
11	survival	O
12	of	O
13	an	O
14	animal	O
15	undergoing	O
16	the	O
17	experimental	O
18	implantation	O
19	of	O
20	a	O
21	total	O
22	artificial	O
23	heart	O
24	is	O
25	obviously	O
26	related	O
27	to	O
28	the	O
29	correct	O
30	anatomic	O
31	placement	O
32	of	O
33	prosthetic	O
34	ventricles	O
35	inside	O
36	the	O
37	chest	O
38	.	O

1	The	O
2	application	O
3	of	O
4	ISH	O
5	and	O
6	IHC	O
7	did	O
8	not	O
9	change	O
10	significantly	O
11	the	O
12	routine	O
13	histologic	O
14	classification	O
15	of	O
16	pneumonias	O
17	into	O
18	CMV	O
19	-	O
20	IP	O
21	and	O
22	IIP	O
23	.	O

1	The	O
2	cDNA	O
3	has	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	900	O
10	amino	O
11	acids	O
12	capable	O
13	of	O
14	encoding	O
15	a	O
16	97	O
17	-	O
18	kDa	O
19	protein	O
20	.	O

1	The	O
2	recombinant	O
3	purified	O
4	protein	O
5	expressed	O
6	in	O
7	the	O
8	baculovirus	O
9	system	O
10	had	O
11	an	O
12	approximate	O
13	molecular	O
14	size	O
15	20	O
16	kDa	O
17	with	O
18	amino	O
19	-	O
20	terminal	O
21	sequence	O
22	of	O
23	AVQGP	O
24	.	O

1	Monitoring	B
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	B
8	-	I
9	1	I
10	and	O
11	TNF	B
12	levels	O
13	throughout	O
14	the	O
15	clinical	O
16	course	O
17	of	O
18	disease	O
19	may	O
20	help	O
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	A	I
2	total	O
3	of	O
4	117	O
5	EVS	O
6	treatments	O
7	were	O
8	performed	O
9	on	O
10	34	O
11	patients	O
12	.	O

1	In	O
2	a	O
3	longitudinal	O
4	study	O
5	,	O
6	14	O
7	low	O
8	-	O
9	risk	O
10	fetuses	O
11	were	O
12	studied	O
13	at	O
14	2	O
15	-	O
16	week	O
17	intervals	O
18	from	O
19	32	O
20	weeks	O
21	of	O
22	gestation	O
23	onward	O
24	.	O

1	STUDY	B
2	DESIGN	O
3	:	O
4	Salivary	O
5	immunoglobulin	B
6	A	I
7	levels	O
8	of	O
9	each	O
10	of	O
11	20	O
12	subjects	O
13	were	O
14	determined	O
15	on	O
16	3	O
17	occasions	O
18	:	O
19	first	O
20	,	O
21	while	O
22	the	O
23	subject	O
24	was	O
25	still	O
26	smoking	O
27	;	O
28	second	O
29	,	O
30	7	O
31	days	O
32	after	O
33	cessation	O
34	of	O
35	smoking	O
36	;	O
37	third	O
38	,	O
39	on	O
40	the	O
41	14th	O
42	day	O
43	after	O
44	cessation	O
45	.	O

1	Patients	O
2	with	O
3	apparently	O
4	minor	O
5	CT	O
6	abnormalities	O
7	may	O
8	have	O
9	significant	O
10	epidural	O
11	disease	O
12	.	O

1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	Sex	B
2	selection	O
3	via	O
4	albumin	B
5	columns	O
6	:	O
7	20	O
8	years	O
9	of	O
10	results	O
11	.	O

1	These	O
2	data	O
3	demonstrate	O
4	the	O
5	presence	O
6	of	O
7	a	O
8	single	O
9	binding	O
10	site	O
11	for	O
12	vinculin	O
13	,	O
14	and	O
15	at	O
16	least	O
17	two	O
18	binding	O
19	sites	O
20	for	O
21	FAK	B
22	that	O
23	are	O
24	separated	O
25	by	O
26	an	O
27	intervening	O
28	stretch	O
29	of	O
30	100	O
31	amino	O
32	acids	O
33	.	O

1	Statistics	B
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	O
8	-	O
9	34	O
10	transcript	O
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	The	O
2	role	O
3	of	O
4	supercritical	O
5	fluid	O
6	chromatography	O
7	(	O
8	SFC	O
9	)	O
10	as	O
11	a	O
12	viable	O
13	technique	O
14	for	O
15	analyzing	O
16	agricultural	O
17	products	O
18	has	O
19	been	O
20	investigated	O
21	using	O
22	packed	O
23	and	O
24	capillary	O
25	column	O
26	methodology	O
27	.	O

1	Reproducing	B
2	populations	O
3	of	O
4	this	O
5	aphid	O
6	were	O
7	first	O
8	detected	O
9	in	O
10	Puerto	O
11	Rico	O
12	in	O
13	April	O
14	1992	O
15	.	O

1	To	O
2	the	O
3	problem	O
4	of	O
5	the	O
6	stimulation	O
7	of	O
8	the	O
9	growth	O
10	of	O
11	transplantable	O
12	tumors	O
13	of	O
14	animals	O
15	previously	O
16	treated	O
17	with	O
18	antineoplastic	O
19	antibiotics	O

1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	O
16	.	O

1	The	O
2	exon	O
3	:	O
4	intron	O
5	structure	O
6	of	O
7	chicken	O
8	IL8	O
9	corresponds	O
10	almost	O
11	exactly	O
12	to	O
13	that	O
14	of	O
15	human	O
16	IL8	O
17	and	O
18	differs	O
19	from	O
20	those	O
21	of	O
22	other	O
23	known	O
24	mammalian	O
25	CXC	O
26	chemokine	O
27	genes	O
28	.	O

1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	O
5	genes	O
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	O
24	coxI	O
25	intron	O
26	aI4	O
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	B
32	-	I
33	amino	I
34	-	I
35	acid	I
36	site	I
37	-	I
38	specific	I
39	DNA	I
40	endonuclease	I
41	.	O

1	Value	B
2	of	O
3	urine	O
4	glucose	O
5	tests	O
6	in	O
7	the	O
8	management	O
9	of	O
10	type	O
11	II	O
12	diabetes	O
13	mellitus	O
14	.	O

1	The	O
2	cDNA	O
3	encoded	O
4	a	O
5	mature	O
6	protein	O
7	of	O
8	240	O
9	amino	O
10	acids	O
11	,	O
12	including	O
13	a	O
14	29	O
15	-	O
16	amino	O
17	acid	O
18	signal	O
19	sequence	O
20	.	O

1	In	O
2	AcMNPV	O
3	-	O
4	infected	O
5	Sf9	O
6	cells	O
7	,	O
8	late	O
9	transcription	O
10	initiation	O
11	is	O
12	detected	O
13	from	O
14	only	O
15	two	O
16	upstream	O
17	TAAG	O
18	sites	O
19	and	O
20	not	O
21	from	O
22	three	O
23	downstream	O
24	TAAG	O
25	sites	O
26	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	sGTH	B
6	alpha	I
7	subunit	I
8	promoter	I
9	by	O
10	the	O
11	transient	O
12	transfection	O
13	of	O
14	several	O
15	sGTH	B
16	alpha	I
17	/	I
18	CAT	I
19	chimeric	O
20	plasmids	O
21	into	O
22	rainbow	O
23	trout	O
24	pituitary	O
25	cells	O
26	suggests	O
27	that	O
28	its	O
29	pituitary	B
30	-	I
31	specific	I
32	expression	O
33	is	O
34	GSE	O
35	-	O
36	dependent	O
37	.	O

1	Purified	B
2	P7	O
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	O
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	O
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	O
21	.	O

1	Cognate	B
2	promoter	I
3	elements	I
4	implicated	O
5	in	O
6	glucocorticoid	B
7	-	I
8	and	O
9	cAMP	O
10	-	O
11	mediated	O
12	regulation	O
13	as	O
14	well	O
15	as	O
16	in	O
17	liver	O
18	-,	O
19	myeloid	O
20	-,	O
21	and	O
22	lymphocyte	O
23	-	O
24	specific	O
25	expression	O
26	are	O
27	located	O
28	within	O
29	the	O
30	5	O
31	'	O
32	flanking	O
33	sequence	O
34	.	O

1	The	O
2	gene	O
3	is	O
4	essential	O
5	for	O
6	yeast	O
7	vegetative	O
8	growth	O
9	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O

1	The	O
2	role	O
3	of	O
4	calcitonin	B
5	,	O
6	and	O
7	other	O
8	agonists	O
9	which	O
10	activate	O
11	the	O
12	cAMP	O
13	pathway	O
14	,	O
15	in	O
16	regulating	O
17	transcription	O
18	of	O
19	the	O
20	human	B
21	parathyroid	I
22	hormone	I
23	-	I
24	related	I
25	protein	I
26	(	I
27	PTHrP	I
28	)	I
29	gene	I
30	was	O
31	investigated	O
32	in	O
33	a	O
34	human	O
35	lung	O
36	cancer	O
37	cell	O
38	line	O
39	(	O
40	BEN	O
41	).	O

1	All	O
2	patients	O
3	had	O
4	abnormal	O
5	von	B
6	Willebrand	I
7	factor	I
8	(	O
9	vWF	O
10	)	O
11	fragmentation	O
12	as	O
13	reflected	O
14	by	O
15	decreased	O
16	high	O
17	molecular	O
18	weight	O
19	and	O
20	increased	O
21	low	O
22	molecular	O
23	weight	O
24	vWF	O
25	multimers	O
26	in	O
27	the	O
28	circulation	O
29	.	O

1	Because	O
2	the	O
3	deletion	O
4	included	O
5	the	O
6	TK	B
7	gene	I
8	,	O
9	selection	O
10	with	O
11	gancyclovir	O
12	against	O
13	cells	O
14	not	O
15	having	O
16	undergone	O
17	recombination	O
18	was	O
19	possible	O
20	.	O

1	The	O
2	rCBF	O
3	and	O
4	vasomotion	O
5	were	O
6	recorded	O
7	by	O
8	laser	O
9	-	O
10	doppler	O
11	fluxmetry	O
12	.	O

1	A	I
2	sequence	I
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	B
7	/	I
8	enhancer	I
9	binding	I
10	protein	I
11	(	I
12	C	I
13	/	I
14	EBP	I
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	zippers	O
26	1	O
27	and	O
28	2	O
29	(	O
30	bZIP1	O
31	and	O
32	bZIP2	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	Grb2	B
9	-	I
10	mediated	O
11	activation	O
12	of	O
13	Ras	B
14	,	O
15	PLC	B
16	-	I
17	gamma1	I
18	-	I
19	mediated	O
20	DAG	O
21	production	O
22	is	O
23	required	O
24	for	O
25	EGF	B
26	-	I
27	and	O
28	PDGF	B
29	-	I
30	induced	O
31	S	O
32	-	O
33	phase	O
34	entry	O
35	and	O
36	gene	O
37	expression	O
38	,	O
39	possibly	O
40	through	O
41	activation	O
42	of	O
43	PKC	B
44	.	O

1	The	O
2	present	O
3	investigation	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	distribution	O
9	of	O
10	the	O
11	main	O
12	fatty	O
13	acids	O
14	in	O
15	Leptospira	O
16	phospholipids	O
17	is	O
18	similar	O
19	to	O
20	their	O
21	distribution	O
22	in	O
23	Leptospira	O
24	neutral	O
25	lipids	O
26	with	O
27	the	O
28	exception	O
29	of	O
30	unsaturated	O
31	fatty	O
32	acid	O
33	with	O
34	14	O
35	carbon	O
36	atoms	O
37	,	O
38	occurring	O
39	mainly	O
40	in	O
41	phospholipids	O
42	.	O

1	The	O
2	histopathology	O
3	and	O
4	neovascularization	O
5	did	O
6	not	O
7	appreciably	O
8	differ	O
9	between	O
10	xenograft	O
11	tumors	O
12	derived	O
13	from	O
14	FGF4	O
15	over	O
16	-	O
17	expressing	O
18	versus	O
19	control	O
20	transfectants	O
21	.	O

1	XXI	B
2	.	O

1	The	O
2	ligand	O
3	for	O
4	RXR	B
5	,	O
6	9	O
7	-	O
8	cis	O
9	retinoic	O
10	acid	O
11	,	O
12	has	O
13	the	O
14	opposite	O
15	effect	O
16	of	O
17	destabilizing	O
18	the	O
19	heterodimeric	B
20	-	I
21	DNA	I
22	complex	I
23	.	O

1	BACKGROUND	O
2	:	O
3	Defensins	O
4	,	O
5	also	O
6	known	O
7	as	O
8	human	O
9	neutrophil	O
10	peptides	O
11	,	O
12	are	O
13	antimicrobial	O
14	peptides	O
15	present	O
16	in	O
17	the	O
18	azurophil	O
19	granules	O
20	of	O
21	neutrophils	O
22	.	O

1	On	O
2	d	O
3	112	O
4	,	O
5	progesterone	O
6	was	O
7	higher	O
8	(	O
9	P	O
10	less	O
11	than	O
12	.	O
13	05	O
14	)	O
15	in	O
16	hysterectomized	O
17	heifers	O
18	than	O
19	in	O
20	other	O
21	treatment	O
22	groups	O
23	.	O

1	Nine	B
2	DNA	I
3	fragments	I
4	that	O
5	were	O
6	specifically	O
7	recognized	O
8	and	O
9	bound	O
10	by	O
11	histidine	O
12	-	O
13	tagged	O
14	AdpA	O
15	were	O
16	isolated	O
17	by	O
18	cycles	O
19	of	O
20	a	O
21	gel	O
22	mobility	O
23	shift	O
24	-	O
25	PCR	O
26	method	O
27	.	O

1	Alternative	O
2	processing	O
3	of	O
4	the	O
5	tryptophanyl	B
6	-	I
7	tRNA	I
8	synthetase	I
9	mRNA	I
10	from	O
11	interferon	B
12	-	I
13	treated	O
14	human	O
15	cells	O
16	.	O

1	Thrombosis	B
2	of	O
3	the	O
4	renal	O
5	vein	O
6	may	O
7	be	O
8	dramatic	O
9	and	O
10	include	O
11	renal	O
12	failure	O
13	.	O

1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	B
11	transcriptase	I
12	-	I
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	O
31	and	O
32	Y88L	O
33	RNAs	O
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	O
16	-	O
17	binding	O
18	protein	O
19	gene	O
20	.	O

1	Manganese	B
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	O
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	The	O
2	detection	O
3	of	O
4	ORF	B
5	-	I
6	1	I
7	sequences	I
8	in	O
9	human	O
10	tumors	O
11	,	O
12	while	O
13	not	O
14	proof	O
15	per	O
16	se	O
17	,	O
18	is	O
19	a	O
20	prerequisite	O
21	for	O
22	establishing	O
23	its	O
24	role	O
25	in	O
26	tumor	O
27	development	O
28	.	O

1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O

1	The	O
2	codon	O
3	usage	O
4	is	O
5	particularly	O
6	marked	O
7	for	O
8	the	O
9	gag	B
10	,	O
11	pol	B
12	,	O
13	and	O
14	env	B
15	genes	I
16	.	O

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	O
7	insulin	B
8	I	I
9	gene	I
10	5	O
11	'-	O
12	flanking	O
13	DNA	O
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	B
38	-	I
39	cell	I
40	-	I
41	specific	I
42	transcriptional	I
43	enhancer	I
44	.	O

1	Phosphopeptide	B
2	mapping	O
3	revealed	O
4	the	O
5	same	O
6	autophosphorylation	O
7	sites	O
8	utilized	O
9	by	O
10	EGFR	O
11	-	O
12	IC	O
13	as	O
14	those	O
15	identified	O
16	in	O
17	wild	B
18	-	I
19	type	I
20	EGFR	O
21	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O

1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	O
9	Leu	B
10	-	I
11	tRNA	I
12	precursor	I
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	O
18	tau	O
19	element	O
20	.	O

1	High	B
2	-	I
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	O
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O

1	A	I
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	O
8	-	O
9	3a	O
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	The	O
2	CVA16	O
3	.	O
4	4	O
5	proteolipid	O
6	transcript	O
7	is	O
8	the	O
9	most	O
10	prevalent	O
11	of	O
12	the	O
13	two	O
14	proteolipid	O
15	messages	O
16	in	O
17	expanding	O
18	ovules	O
19	harvested	O
20	10	O
21	d	O
22	post	O
23	-	O
24	anthesis	O
25	.	O

1	The	O
2	simultaneous	O
3	recording	O
4	of	O
5	electrical	O
6	activity	O
7	from	O
8	the	O
9	surface	O
10	electrocardiogram	O
11	,	O
12	right	O
13	ventricular	O
14	apex	O
15	,	O
16	His	O
17	bundle	O
18	,	O
19	high	O
20	right	O
21	atrium	O
22	,	O
23	coronary	O
24	sinus	O
25	,	O
26	with	O
27	or	O
28	without	O
29	a	O
30	roving	O
31	mapping	O
32	catheter	O
33	,	O
34	enables	O
35	us	O
36	to	O
37	precisely	O
38	map	O
39	the	O
40	electrical	O
41	activation	O
42	sequence	O
43	in	O
44	the	O
45	heart	O
46	.	O

1	A	I
2	possible	O
3	role	O
4	for	O
5	the	O
6	mixed	O
7	function	O
8	oxidase	B
9	enzyme	I
10	system	O
11	in	O
12	the	O
13	requirement	O
14	for	O
15	selenium	O
16	in	O
17	the	O
18	rat	O
19	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	negative	O
7	inotropic	O
8	action	O
9	of	O
10	nicorandil	O
11	is	O
12	caused	O
13	by	O
14	inhibition	O
15	of	O
16	Ca	O
17	influx	O
18	and	O
19	intracellular	O
20	mobilization	O
21	of	O
22	Ca	O
23	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O

1	The	O
2	retention	O
3	index	O
4	of	O
5	201Tl	O
6	SPECT	O
7	is	O
8	a	O
9	useful	O
10	indicator	O
11	of	O
12	metastatic	O
13	potential	O
14	,	O
15	thereby	O
16	facilitating	O
17	the	O
18	prediction	O
19	of	O
20	prognosis	O
21	,	O
22	and	O
23	provides	O
24	insight	O
25	into	O
26	the	O
27	relationship	O
28	between	O
29	201Tl	O
30	uptake	O
31	and	O
32	malignancy	O
33	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	Hepatitis	B
2	B	I
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	O
15	hepatitis	O
16	B	O
17	endemicity	O
18	.	O

1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O

1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O

1	Output	B
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O

1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	B
9	-	I
10	SH2	I
11	domain	I
12	,	O
13	because	O
14	PECAM	B
15	-	I
16	1	I
17	can	O
18	be	O
19	precipitated	O
20	by	O
21	a	O
22	GST	B
23	-	I
24	Src	I
25	-	I
26	SH2	I
27	affinity	O
28	matrix	O
29	.	O

1	This	O
2	shows	O
3	that	O
4	the	O
5	characteristically	O
6	diffuse	O
7	banding	O
8	pattern	O
9	of	O
10	plant	O
11	nuclear	O
12	proteins	O
13	interacting	O
14	with	O
15	the	O
16	G	B
17	-	I
18	box	I
19	is	O
20	also	O
21	observed	O
22	in	O
23	a	O
24	binding	O
25	assay	O
26	using	O
27	only	O
28	one	O
29	recombinant	O
30	GBF	O
31	.	O

1	An	O
2	egg	B
3	protein	I
4	,	I
5	lysozyme	I
6	,	O
7	is	O
8	a	O
9	still	O
10	unlabeled	O
11	additive	O
12	currently	O
13	used	O
14	in	O
15	cheese	O
16	preparation	O
17	.	O

1	During	O
2	the	O
3	conditioning	O
4	procedure	O
5	,	O
6	the	O
7	C	O
8	-	O
9	fiber	O
10	reflex	O
11	was	O
12	facilitated	O
13	(	O
14	wind	O
15	-	O
16	up	O
17	)	O
18	in	O
19	a	O
20	stimulus	O
21	-	O
22	dependent	O
23	fashion	O
24	in	O
25	intact	O
26	,	O
27	anesthetized	O
28	animals	O
29	during	O
30	the	O
31	application	O
32	of	O
33	the	O
34	first	O
35	seven	O
36	conditioning	O
37	stimuli	O
38	;	O
39	thereafter	O
40	,	O
41	the	O
42	magnitude	O
43	of	O
44	the	O
45	responses	O
46	reached	O
47	a	O
48	plateau	O
49	and	O
50	then	O
51	decreased	O
52	.	O

1	Lack	B
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	O
11	105	O
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	B
17	-	I
18	RNA	I
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	Routine	B
2	psychometric	O
3	screening	O
4	of	O
5	IHD	O
6	patients	O
7	may	O
8	provide	O
9	a	O
10	cost	O
11	-	O
12	effective	O
13	means	O
14	of	O
15	alerting	O
16	cardiologists	O
17	and	O
18	internists	O
19	to	O
20	the	O
21	relatively	O
22	high	O
23	levels	O
24	of	O
25	distress	O
26	among	O
27	their	O
28	patients	O
29	.	O

1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	B
6	acts	O
7	by	O
8	stimulating	O
9	AP	B
10	-	I
11	1	I
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	O
20	AP	B
21	-	I
22	1	I
23	with	O
24	NF	B
25	-	I
26	kappaB	I
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	transactivates	O
35	the	O
36	HIV	B
37	-	I
38	1	I
39	LTR	I
40	.	O

1	A	I
2	second	O
3	isotype	O
4	of	O
5	Raja	O
6	immunoglobulin	B
7	heavy	I
8	chain	I
9	genes	I
10	has	O
11	been	O
12	detected	O
13	by	O
14	screening	O
15	a	O
16	spleen	O
17	cDNA	O
18	library	O
19	with	O
20	homologous	O
21	Raja	O
22	VH	B
23	-	I
24	and	O
25	CH1	O
26	-	O
27	specific	O
28	probes	O
29	complementing	O
30	the	O
31	respective	O
32	regions	O
33	of	O
34	the	O
35	mu	B
36	-	I
37	like	I
38	isotype	O
39	.	O

1	The	O
2	fast	O
3	real	O
4	-	O
5	time	O
6	digital	O
7	processing	O
8	of	O
9	the	O
10	N2	O
11	and	O
12	flow	O
13	signals	O
14	incorporated	O
15	filtering	O
16	,	O
17	delay	O
18	compensation	O
19	,	O
20	and	O
21	corrections	O
22	for	O
23	the	O
24	effects	O
25	of	O
26	changes	O
27	in	O
28	gas	O
29	composition	O
30	and	O
31	temperature	O
32	.	O

1	In	O
2	all	O
3	instances	O
4	the	O
5	apparent	O
6	alcohol	O
7	responses	O
8	were	O
9	very	O
10	small	O
11	and	O
12	never	O
13	exceeded	O
14	a	O
15	reading	O
16	of	O
17	1	O
18	microgram	O
19	/	O
20	100ml	O
21	for	O
22	breath	O
23	samples	O
24	more	O
25	than	O
26	10min	O
27	post	O
28	-	O
29	exposure	O
30	.	O

1	It	O
2	may	O
3	be	O
4	dependent	O
5	on	O
6	location	O
7	of	O
8	a	O
9	focus	O
10	(	O
11	according	O
12	to	O
13	EEG	O
14	)	O
15	as	O
16	well	O
17	as	O
18	on	O
19	the	O
20	character	O
21	and	O
22	manifestation	O
23	of	O
24	the	O
25	accompanying	O
26	neuropsychologic	O
27	symptomatology	O
28	.	O

1	A	I
2	second	O
3	study	O
4	group	O
5	,	O
6	with	O
7	intact	O
8	cardiac	O
9	innervation	O
10	,	O
11	consisted	O
12	of	O
13	19	O
14	patients	O
15	with	O
16	stable	O
17	angina	O
18	pectoris	B
19	class	I
20	I	I
21	to	O
22	III	O
23	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	these	O
6	nicks	O
7	occur	O
8	in	O
9	both	O
10	the	O
11	wild	B
12	-	I
13	type	I
14	and	O
15	the	O
16	mutant	O
17	sites	O
18	.	O

1	The	O
2	pre	B
3	-	I
4	mRNA	I
5	splicing	I
6	factor	I
7	U2AF	I
8	(	I
9	U2	I
10	small	I
11	nuclear	I
12	ribonucleoprotein	I
13	particle	I
14	[	I
15	snRNP	I
16	]	O
17	auxiliary	B
18	factor	I
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	alpha	I
5	,	O
6	the	O
7	cytokine	O
8	that	O
9	participates	O
10	in	O
11	the	O
12	autocrine	O
13	growth	O
14	control	O
15	of	O
16	hairy	O
17	cell	O
18	leukemia	O
19	has	O
20	strong	O
21	bone	O
22	resorptive	O
23	properties	O
24	.	O

1	Stereotactic	B
2	radiofrequency	O
3	lesioning	O
4	of	O
5	the	O
6	hamartoma	O
7	resulted	O
8	in	O
9	seizure	O
10	remission	O
11	without	O
12	complications	O
13	20	O
14	months	O
15	after	O
16	surgery	O
17	.	O

1	Effect	O
2	of	O
3	thrombotic	O
4	and	O
5	antithrombotic	O
6	drugs	O
7	on	O
8	the	O
9	surface	O
10	charge	O
11	characteristics	O
12	of	O
13	canine	O
14	blood	O
15	vessels	O
16	:	O
17	in	O
18	vivo	O
19	and	O
20	in	O
21	vitro	O
22	studies	O
23	.	O

1	Depleted	B
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	gagging	O
7	induced	O
8	by	O
9	oropharyngeal	O
10	irritation	O
11	is	O
12	unclear	O
13	.	O

1	Computerized	B
2	detection	O
3	of	O
4	abnormal	O
5	asymmetry	O
6	in	O
7	digital	O
8	chest	O
9	radiographs	O
10	.	O

1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	I
8	F	I
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	B
20	4	I
21	,	O
22	5	O
23	bisphosphate	O
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O

1	Mycoplasma	B
2	pneumoniae	I
3	was	O
4	isolated	O
5	from	O
6	the	O
7	pleural	O
8	fluid	O
9	of	O
10	this	O
11	patient	O
12	.	O

1	Candidate	B
2	tumor	I
3	suppressor	I
4	genes	I
5	,	O
6	Mts1	O
7	(	O
8	p16INK4a	O
9	)	O
10	and	O
11	Mts2	O
12	(	O
13	p15INK4b	O
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O

1	Efficacy	B
2	of	O
3	cervical	O
4	spine	O
5	immobilization	O
6	methods	O
7	.	O

1	These	O
2	results	O
3	demonstrate	O
4	the	O
5	existence	O
6	of	O
7	different	O
8	PI	B
9	3	I
10	-	I
11	kinase	I
12	isoforms	I
13	and	O
14	define	O
15	a	O
16	family	O
17	of	O
18	genes	O
19	encoding	O
20	distinct	O
21	PI	B
22	3	I
23	-	I
24	kinase	I
25	catalytic	I
26	subunits	I
27	that	O
28	can	O
29	associate	O
30	with	O
31	p85	B
32	.	O

1	Upstream	O
2	of	O
3	-	O
4	37	O
5	,	O
6	the	O
7	5	O
8	'	O
9	untranslated	O
10	sequences	O
11	of	O
12	the	O
13	isolates	O
14	differ	O
15	in	O
16	both	O
17	length	O
18	and	O
19	sequence	O
20	.	O

1	Signal	B
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	O
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O

1	The	O
2	juxtamembrane	O
3	region	O
4	of	O
5	the	O
6	insulin	B
7	receptor	I
8	(	I
9	IR	I
10	)	I
11	beta	I
12	-	I
13	subunit	I
14	contains	O
15	an	O
16	unphosphorylated	O
17	tyrosyl	O
18	residue	O
19	(	O
20	Tyr960	O
21	)	O
22	that	O
23	is	O
24	essential	O
25	for	O
26	insulin	B
27	-	I
28	stimulated	O
29	tyrosyl	O
30	phosphorylation	O
31	of	O
32	some	O
33	endogenous	O
34	substrates	O
35	and	O
36	certain	O
37	biological	O
38	responses	O
39	(	O
40	White	O
41	,	O
42	M	O
43	.	O
44	F	O
45	.,	O
46	Livingston	O
47	,	O
48	J	O
49	.	O
50	N	O
51	.,	O
52	Backer	O
53	,	O
54	J	O
55	.	O
56	M	O
57	.,	O
58	Lauris	O
59	,	O
60	V	O
61	.,	O
62	Dull	O
63	,	O
64	T	O
65	.	O
66	J	O
67	.,	O
68	Ullrich	O
69	,	O
70	A	O
71	.,	O
72	and	O
73	Kahn	O
74	,	O
75	C	O
76	.	O
77	R	O
78	.	O

1	Triumph	B
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	anthraquinone	O
6	sennoside	O
7	B	O
8	and	O
9	rhein	O
10	are	O
11	weakly	O
12	genotoxic	O
13	.	O

1	These	O
2	latter	O
3	results	O
4	showed	O
5	that	O
6	the	O
7	ABFI	O
8	protein	O
9	,	O
10	like	O
11	the	O
12	RAP1	O
13	protein	O
14	,	O
15	bound	O
16	sequences	O
17	required	O
18	for	O
19	positive	O
20	as	O
21	well	O
22	as	O
23	negative	O
24	regulation	O
25	of	O
26	gene	O
27	expression	O
28	.	O

1	Like	O
2	scrotal	O
3	testes	O
4	,	O
5	undescended	O
6	testes	O
7	were	O
8	hypointense	O
9	to	O
10	fat	O
11	on	O
12	sequences	O
13	with	O
14	a	O
15	short	O
16	repetition	O
17	time	O
18	(	O
19	TR	B
20	)	O
21	and	O
22	echo	O
23	time	O
24	(	O
25	TE	O
26	)	O
27	in	O
28	all	O
29	cases	O
30	,	O
31	and	O
32	hyperintense	O
33	or	O
34	isointense	O
35	to	O
36	fat	O
37	on	O
38	long	O
39	TR	B
40	/	I
41	TE	O
42	sequences	O
43	in	O
44	all	O
45	but	O
46	two	O
47	cases	O
48	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	O
19	human	B
20	AC	I
21	gene	I
22	from	O
23	FD	O
24	patients	O
25	.	O

1	NUP145	B
2	was	O
3	previously	O
4	identified	O
5	by	O
6	using	O
7	a	O
8	genetic	O
9	synthetic	O
10	lethal	O
11	screen	O
12	(	O
13	E	O
14	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	O
10	anemia	O
11	group	O
12	C	O
13	protein	O
14	(	O
15	FANCC	O
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	Ectopic	B
2	ACTH	I
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	The	O
2	T	B
3	-	I
4	box	I
5	motif	I
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	Taken	O
2	together	O
3	,	O
4	we	O
5	provide	O
6	evidence	O
7	for	O
8	the	O
9	existence	O
10	of	O
11	an	O
12	activator	O
13	,	O
14	NFE	O
15	,	O
16	which	O
17	in	O
18	combination	O
19	with	O
20	the	O
21	p50	B
22	and	O
23	c	B
24	-	I
25	Rel	I
26	proteins	I
27	,	O
28	are	O
29	part	O
30	of	O
31	the	O
32	transcription	O
33	factor	O
34	machinery	O
35	that	O
36	regulates	O
37	3	O
38	'	O
39	enhancer	O
40	activity	O
41	,	O
42	and	O
43	thus	O
44	the	O
45	control	O
46	of	O
47	the	O
48	IgH	O
49	locus	O
50	in	O
51	late	O
52	B	O
53	lymphocyte	O
54	development	O
55	.	O

1	Transcription	O
2	from	O
3	adenovirus	B
4	E2	I
5	-	I
6	early	I
7	promoter	I
8	is	O
9	controlled	O
10	by	O
11	a	O
12	unique	O
13	array	O
14	of	O
15	four	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	which	O
21	include	O
22	an	O
23	atypical	O
24	TBP	B
25	site	I
26	,	O
27	two	O
28	E2F	B
29	sites	I
30	present	O
31	in	O
32	an	O
33	inverted	O
34	orientation	O
35	relative	O
36	to	O
37	each	O
38	other	O
39	,	O
40	and	O
41	an	O
42	ATF	B
43	site	I
44	.	O

1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O

1	Transfecting	B
2	the	O
3	cloned	O
4	bovine	O
5	PBR	O
6	/	O
7	IBP	O
8	cDNA	O
9	into	O
10	COS	O
11	-	O
12	7	O
13	cells	O
14	resulted	O
15	in	O
16	an	O
17	11	O
18	-	O
19	fold	O
20	increase	O
21	in	O
22	the	O
23	density	O
24	of	O
25	high	O
26	affinity	O
27	[	O
28	3H	O
29	]	O
30	PK	O
31	11195	B
32	binding	I
33	sites	I
34	which	O
35	had	O
36	only	O
37	low	O
38	affinity	O
39	for	O
40	Ro5	O
41	-	O
42	4864	O
43	.	O

1	Cryoglobulinemia	B
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	xtRNA	O
6	(	O
7	Sec	O
8	)	O
9	gene	O
10	needs	O
11	the	O
12	binding	O
13	of	O
14	the	O
15	seven	O
16	Staf	O
17	zinc	O
18	fingers	O
19	,	O
20	but	O
21	not	O
22	Oct	B
23	-	I
24	1	I
25	,	O
26	for	O
27	optimal	O
28	transcriptional	O
29	capacity	O
30	.	O

1	CONCLUSIONS	O
2	:	O
3	A	O
4	comparison	O
5	of	O
6	the	O
7	LysU	O
8	crystal	O
9	structure	O
10	with	O
11	the	O
12	structures	O
13	of	O
14	seryl	O
15	-	O
16	and	O
17	aspartyl	B
18	-	I
19	tRNA	I
20	synthetases	O
21	enables	O
22	a	O
23	conserved	O
24	core	O
25	to	O
26	be	O
27	identified	O
28	.	O

1	SL1	B
2	trans	I
3	-	I
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	B
20	elegans	I
21	pre	I
22	-	I
23	mRNA	I
24	.	O

1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	B
18	-	I
19	type	I
20	HLF	O
21	and	O
22	chimeric	O
23	E2A	B
24	-	I
25	HLF	I
26	proteins	I
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O

1	Some	O
2	of	O
3	the	O
4	PCR	O
5	products	O
6	contained	O
7	mutations	O
8	in	O
9	ATG1	O
10	and	O
11	/	O
12	or	O
13	ATG2	O
14	.	O

1	Chlamydial	B
2	agents	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	semen	O
8	near	O
9	the	O
10	end	O
11	of	O
12	the	O
13	chlamydemic	O
14	phase	O
15	.	O

1	Observation	B
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O

1	Samples	B
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O

1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O

1	I	I
2	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	showed	O
5	that	O
6	site	O
7	A	O
8	is	O
9	necessary	O
10	and	O
11	sufficient	O
12	for	O
13	RXR	B
14	alpha	I
15	-	I
16	mediated	O
17	transactivation	O
18	of	O
19	the	O
20	apoAI	B
21	gene	I
22	basal	I
23	promoter	I
24	in	O
25	human	O
26	hepatoma	O
27	HepG2	O
28	cells	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	RA	O
34	and	O
35	that	O
36	this	O
37	transactivation	O
38	is	O
39	abolished	O
40	by	O
41	increasing	O
42	amounts	O
43	of	O
44	cotransfected	O
45	ARP	B
46	-	I
47	1	I
48	.	O

1	Twenty	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	these	O
7	patients	O
8	had	O
9	neurologic	O
10	disease	O
11	that	O
12	appeared	O
13	to	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	tinnitus	O
19	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	I
25	IGF	I
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	SCL	B
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	In	O
2	addition	O
3	,	O
4	anti	B
5	-	I
6	phosphotyrosine	I
7	antibodies	I
8	immunoprecipitated	O
9	80K	B
10	-	I
11	H	I
12	from	O
13	cell	O
14	lysates	O
15	of	O
16	FGF	B
17	-	I
18	stimulated	O
19	but	O
20	not	O
21	from	O
22	control	O
23	fibroblasts	O
24	.	O

1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	B
20	sarcoma	I
21	associated	I
22	virus	I
23	and	I
24	proto	I
25	-	I
26	sis	O
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	B
38	-	I
39	sis	I
40	messenger	I
41	RNA	I
42	.	O

1	To	O
2	identify	O
3	the	O
4	DNA	O
5	sequences	O
6	that	O
7	cis	O
8	-	O
9	regulate	O
10	the	O
11	expression	O
12	of	O
13	the	O
14	rat	O
15	liver	O
16	pyruvate	B
17	kinase	I
18	(	I
19	L	I
20	-	I
21	PK	I
22	)	I
23	genes	I
24	,	O
25	a	O
26	series	O
27	of	O
28	constructs	O
29	in	O
30	which	O
31	the	O
32	chloramphenicol	B
33	acetyltransferase	I
34	reporter	I
35	genes	I
36	is	O
37	driven	O
38	by	O
39	various	O
40	deleted	O
41	fragments	O
42	of	O
43	the	O
44	3200	O
45	base	O
46	pairs	O
47	(	O
48	bp	O
49	)	O
50	upstream	O
51	of	O
52	the	O
53	L	B
54	-	I
55	PK	I
56	gene	I
57	cap	I
58	site	I
59	have	O
60	been	O
61	assayed	O
62	for	O
63	transient	O
64	expression	O
65	after	O
66	introduction	O
67	into	O
68	hepatoma	O
69	HepG2	O
70	cells	O
71	,	O
72	rat	O
73	hepatocytes	O
74	in	O
75	primary	O
76	culture	O
77	,	O
78	fibroblast	O
79	LTK	O
80	-	O
81	cells	O
82	,	O
83	myogenic	O
84	C2C12	O
85	cells	O
86	,	O
87	and	O
88	CHO	O
89	cells	O
90	.	O

1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	O
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	O
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O

1	Metabolism	B
2	of	O
3	calcium	O
4	and	O
5	vitamin	O
6	D3	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	tubulointerstitial	O
12	nephritis	O
13	:	O
14	a	O
15	study	O
16	of	O
17	41	O
18	patients	O
19	with	O
20	nephropathia	O
21	epidemica	O
22	.	O

1	The	O
2	gene	O
3	organization	O
4	of	O
5	CRSV	B
6	RNA	I
7	-	I
8	1	I
9	is	O
10	similar	O
11	to	O
12	those	O
13	of	O
14	red	O
15	clover	O
16	necrotic	O
17	mosaic	O
18	(	O
19	RCNMV	O
20	)	O
21	and	O
22	sweet	O
23	clover	O
24	necrotic	O
25	mosaic	O
26	(	O
27	SCNMV	O
28	)	O
29	dianthoviruses	O
30	with	O
31	the	O
32	exception	O
33	that	O
34	CRSV	B
35	RNA	I
36	-	I
37	1	I
38	contains	O
39	the	O
40	additional	O
41	3	O
42	'-	O
43	terminal	O
44	ORF	O
45	.	O

1	Furthermore	O
2	,	O
3	unlike	O
4	the	O
5	case	O
6	for	O
7	HIS3	B
8	where	O
9	only	O
10	a	O
11	limited	O
12	subset	O
13	of	O
14	TATA	B
15	-	I
16	like	I
17	sequences	I
18	can	O
19	activate	O
20	transcription	O
21	in	O
22	conjunction	O
23	with	O
24	GCN4p	O
25	,	O
26	many	O
27	divergent	O
28	TATA	B
29	-	I
30	like	I
31	sequences	I
32	allowed	O
33	GCN4p	O
34	activation	O
35	of	O
36	TRP3	O
37	.	O

1	Perilunar	B
2	luxation	O
3	--	O
4	an	O
5	unusual	O
6	injury	O
7	demanding	O
8	immediate	O
9	and	O
10	correct	O
11	treatment	O

1	MEASUREMENTS	B
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	The	O
7	two	O
8	groups	O
9	were	O
10	similar	O
11	on	O
12	entry	O
13	into	O
14	the	O
15	study	O
16	,	O
17	including	O
18	mean	O
19	FEV1	O
20	measurements	O
21	(	O
22	0	O
23	.	O
24	70	O
25	L	O
26	atropine	O
27	/	O
28	0	O
29	.	O
30	60	O
31	L	O
32	metaproterenol	O
33	,	O
34	P	O
35	greater	O
36	than	O
37	.	O
38	05	O
39	).	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	O
15	carboxyhemoglobin	O
16	(	O
17	COHb	O
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	A	I
2	malignant	O
3	true	O
4	teratoma	O
5	of	O
6	liver	O
7	in	O
8	childhood	O
9	.	O

1	Glutamic	B
2	acid	I
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O

1	Moreover	O
2	,	O
3	the	O
4	same	O
5	mutations	O
6	alter	O
7	the	O
8	structure	O
9	of	O
10	junB	B
11	5	O
12	'	O
13	flanking	O
14	DNA	O
15	within	O
16	chromatin	O
17	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	B
12	box	I
13	-,	I
14	ssDNA	I
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	Several	O
2	Src	B
3	SH3	I
4	-	I
5	binding	I
6	proteins	I
7	were	O
8	phosphorylated	O
9	in	O
10	Src	B
11	-	I
12	transformed	O
13	cells	O
14	.	O

1	62	O
2	:	O
3	2491	O
4	-	O
5	2499	O
6	,	O
7	1987	O
8	).	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	O
7	and	O
8	tyrosine	B
9	kinases	I
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	O
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	Plasma	B
2	NE	O
3	was	O
4	also	O
5	low	O
6	in	O
7	the	O
8	anephric	O
9	group	O
10	(	O
11	289	O
12	mg	O
13	/	O
14	liter	O
15	+/-	O
16	126	O
17	(	O
18	1	O
19	SD	O
20	)	O
21	vs	O
22	612	O
23	+/-	O
24	189	O
25	,	O
26	P	O
27	=	O
28	0	O
29	.	O
30	033	O
31	,	O
32	resting	O
33	).(	O
34	ABSTRACT	O
35	TRUNCATED	O
36	AT	O
37	250	O
38	WORDS	O
39	)	O

1	Somatostatin	B
2	gene	I
3	expression	O
4	in	O
5	pancreatic	O
6	islet	O
7	cells	O
8	is	O
9	directed	O
10	by	O
11	cell	O
12	-	O
13	specific	O
14	DNA	O
15	control	O
16	elements	O
17	and	O
18	DNA	B
19	-	I
20	binding	I
21	proteins	I
22	.	O

1	Schizosaccharomyces	B
2	pombe	I
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	O
9	altering	O
10	G2	O
11	/	O
12	M	O
13	cell	O
14	size	O
15	control	O
16	.	O

1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	O
13	ARS1	B
14	DNA	I
15	-	I
16	binding	I
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	I
25	-	I
26	binding	I
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Interspecific	B
2	mouse	O
3	back	O
4	-	O
5	cross	O
6	analysis	O
7	identified	O
8	the	O
9	loci	O
10	for	O
11	mouse	O
12	3Ost	O
13	genes	O
14	and	O
15	syntenic	O
16	assignments	O
17	of	O
18	corresponding	O
19	human	O
20	isologs	O
21	were	O
22	confirmed	O
23	by	O
24	the	O
25	identification	O
26	of	O
27	mapped	O
28	sequence	O
29	-	O
30	tagged	O
31	site	O
32	markers	O
33	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	We	O
2	introduced	O
3	the	O
4	gel	O
5	technique	O
6	as	O
7	a	O
8	routine	O
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	aortic	O
7	explants	O
8	isolated	O
9	from	O
10	PPARalpha	B
11	-	I
12	null	I
13	mice	O
14	display	O
15	an	O
16	exacerbated	O
17	response	O
18	to	O
19	inflammatory	O
20	stimuli	O
21	,	O
22	such	O
23	as	O
24	lipopolysaccharide	O
25	(	O
26	LPS	O
27	),	O
28	as	O
29	demonstrated	O
30	by	O
31	increased	O
32	IL	B
33	-	I
34	6	I
35	secretion	O
36	.	O

1	Significance	B
2	of	O
3	the	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	reaction	O
8	to	O
9	physical	O
10	loading	O
11	in	O
12	evaluating	O
13	the	O
14	effectiveness	O
15	of	O
16	mitral	O
17	commissurotomy	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	Scm	B
10	mutant	I
11	alleles	I
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O

1	For	O
2	85Sr	O
3	,	O
4	larger	O
5	-	O
6	than	O
7	-	O
8	expected	O
9	distribution	O
10	coefficients	O
11	were	O
12	obtained	O
13	in	O
14	the	O
15	desorption	O
16	experiments	O
17	,	O
18	an	O
19	indication	O
20	of	O
21	the	O
22	irreversible	O
23	formation	O
24	of	O
25	metal	O
26	-	O
27	oxyhydroxides	O
28	during	O
29	a	O
30	slow	O
31	reaction	O
32	.	O

1	Members	O
2	of	O
3	the	O
4	JAK	O
5	/	O
6	Tyk	B
7	family	I
8	of	I
9	tyrosine	I
10	kinases	I
11	mediate	O
12	phosphorylation	O
13	of	O
14	STAT3	B
15	at	O
16	Tyr705	O
17	during	O
18	CNTF	O
19	signaling	O
20	;	O
21	however	O
22	,	O
23	the	O
24	kinase	O
25	responsible	O
26	for	O
27	phosphorylation	O
28	at	O
29	STAT3	B
30	Tyr727	O
31	appears	O
32	to	O
33	depend	O
34	on	O
35	both	O
36	the	O
37	extracellular	O
38	stimulus	O
39	and	O
40	the	O
41	cellular	O
42	context	O
43	.	O

1	A	I
2	TATA	I
3	-	I
4	less	O
5	promoter	O
6	containing	O
7	binding	O
8	sites	O
9	for	O
10	ubiquitous	O
11	transcription	O
12	factors	O
13	mediates	O
14	cell	O
15	type	O
16	-	O
17	specific	O
18	regulation	O
19	of	O
20	the	O
21	gene	O
22	for	O
23	transcription	B
24	enhancer	I
25	factor	I
26	-	I
27	1	I
28	(	I
29	TEF	I
30	-	I
31	1	I
32	).	O

1	Human	B
2	bcl3	I
3	protein	I
4	specifically	O
5	displaces	O
6	(	O
7	p50	B
8	)	I
9	2	I
10	-	I
11	DNA	I
12	complexes	I
13	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	(	O
5	TNF	B
6	)	O
7	is	O
8	reported	O
9	to	O
10	cause	O
11	a	O
12	shock	O
13	syndrome	O
14	similar	O
15	to	O
16	that	O
17	produced	O
18	by	O
19	endotoxin	O
20	(	O
21	LPS	O
22	).	O

1	Analysis	O
2	of	O
3	the	O
4	sequences	O
5	with	O
6	the	O
7	BLAST	O
8	and	O
9	GRAIL	O
10	programs	O
11	provided	O
12	additional	O
13	independent	O
14	evidence	O
15	that	O
16	15	O
17	of	O
18	these	O
19	17	O
20	clones	O
21	contain	O
22	coding	O
23	sequences	O
24	and	O
25	that	O
26	nine	O
27	other	O
28	clones	O
29	are	O
30	likely	O
31	to	O
32	contain	O
33	sequences	O
34	coding	O
35	for	O
36	portions	O
37	of	O
38	new	O
39	genes	O
40	.	O

1	3	I
2	.	O

1	Opposite	B
2	effects	O
3	of	O
4	CYP1	O
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O

1	MEF	B
2	and	O
3	AML1B	O
4	synergistically	O
5	transactivated	O
6	an	O
7	interleukin	B
8	3	I
9	promoter	I
10	reporter	I
11	gene	I
12	construct	I
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	B
20	was	O
21	abolished	O
22	when	O
23	MEF	B
24	was	O
25	coexpressed	O
26	with	O
27	AML1	O
28	/	O
29	ETO	O
30	.	O

1	Before	B
2	turnout	O
3	,	O
4	a	O
5	morantel	O
6	sustained	O
7	release	O
8	bolus	O
9	(	O
10	MSRB	O
11	)	O
12	was	O
13	administered	O
14	to	O
15	each	O
16	animal	O
17	in	O
18	the	O
19	"	O
20	treated	O
21	"	O
22	category	O
23	.	O

1	We	O
2	have	O
3	carried	O
4	out	O
5	a	O
6	comprehensive	O
7	and	O
8	systematic	O
9	mutagenesis	O
10	of	O
11	the	O
12	Cse4p	O
13	N	O
14	terminus	O
15	to	O
16	analyze	O
17	its	O
18	function	O
19	.	O

1	Elevated	B
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O

1	Incorporation	B
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	a	O
5	DNA	O
6	sequence	O
7	involved	O
8	in	O
9	linking	O
10	gene	O
11	expression	O
12	to	O
13	the	O
14	cell	O
15	cycle	O
16	.	O

1	After	O
2	the	O
3	application	O
4	of	O
5	RS	O
6	86	O
7	,	O
8	REM	O
9	latency	O
10	was	O
11	shortened	O
12	in	O
13	all	O
14	groups	O
15	under	O
16	investigation	O
17	.	O

1	The	O
2	COOH	O
3	-	O
4	terminal	O
5	46	O
6	codons	O
7	of	O
8	slyD	O
9	encode	O
10	a	O
11	remarkable	O
12	histidine	O
13	-	O
14	rich	O
15	peptide	O
16	sequence	O
17	which	O
18	is	O
19	at	O
20	least	O
21	partly	O
22	dispensable	O
23	for	O
24	slyD	O
25	function	O
26	in	O
27	E	O
28	-	O
29	mediated	O
30	lysis	O
31	.	O

1	This	O
2	study	O
3	evaluates	O
4	the	O
5	feasibility	O
6	of	O
7	indirect	O
8	mesenteric	O
9	lymphangiography	O
10	as	O
11	a	O
12	colonoscopic	O
13	technique	O
14	in	O
15	a	O
16	canine	O
17	model	O
18	.	O

1	One	O
2	site	O
3	,	O
4	PAL	O
5	,	O
6	occurs	O
7	within	O
8	the	O
9	10	O
10	bp	O
11	sequence	O
12	GGGGAGGAGG	O
13	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	O
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O

1	Three	O
2	monopolar	O
3	electrodes	O
4	were	O
5	inserted	O
6	into	O
7	the	O
8	left	O
9	and	O
10	right	O
11	lateral	O
12	vestibulospinal	O
13	tract	O
14	(	O
15	LVST	O
16	)	O
17	and	O
18	medial	O
19	vestibulospinal	O
20	tract	O
21	(	O
22	MVST	O
23	)	O
24	of	O
25	the	O
26	C1	O
27	segment	O
28	,	O
29	to	O
30	determine	O
31	the	O
32	pathway	O
33	of	O
34	axons	O
35	.	O

1	This	O
2	strategy	O
3	was	O
4	used	O
5	to	O
6	place	O
7	both	O
8	the	O
9	Tn903	O
10	neo	B
11	gene	I
12	and	O
13	the	O
14	Rhodosporidium	O
15	toruloides	B
16	phenylalanine	I
17	ammonia	I
18	lyase	I
19	(	I
20	PAL	I
21	)-	I
22	encoding	I
23	gene	I
24	under	O
25	the	O
26	transcriptional	O
27	control	O
28	of	O
29	pPGK	O
30	::	O
31	REP2	O
32	.	O

1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	B
32	-	I
33	terminal	I
34	domain	I
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O

1	A	I
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	O
15	Tea	O
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	O
27	retrovirus	O
28	receptor	O
29	/	O
30	cationic	O
31	amino	O
32	acid	O
33	transporter	O
34	(	O
35	ecoR	O
36	/	O
37	CAT1	O
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	O
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O

1	In	O
2	addition	O
3	serum	O
4	IgE	B
5	concentrations	O
6	were	O
7	not	O
8	statistically	O
9	different	O
10	.	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	O
16	p53	B
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	O
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	O
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	O
28	.	O

1	Ras2p	B
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	B
16	(	O
17	Cdc42p	O
18	/	O
19	Ste20p	O
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	O
33	/	O
34	cAMP	O
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	As	O
2	is	O
3	deduced	O
4	from	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	the	O
10	cDNA	O
11	,	O
12	CBS	B
13	-	I
14	1	I
15	contains	O
16	an	O
17	open	O
18	reading	O
19	frame	O
20	consisting	O
21	of	O
22	182	O
23	amino	O
24	acids	O
25	,	O
26	with	O
27	a	O
28	molecular	O
29	weight	O
30	of	O
31	19	O
32	.	O
33	5kDa	O
34	.	O

1	The	O
2	first	O
3	open	O
4	reading	O
5	frame	O
6	of	O
7	the	O
8	blueberry	O
9	scorch	O
10	carlavirus	O
11	(	O
12	BBScV	O
13	)	O
14	genome	O
15	encodes	O
16	a	O
17	putative	O
18	replication	O
19	-	O
20	associated	O
21	protein	O
22	of	O
23	223	O
24	kDa	O
25	(	O
26	p223	O
27	).	O

1	The	O
2	active	O
3	derivatives	O
4	of	O
5	the	O
6	present	O
7	series	O
8	were	O
9	also	O
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	A	I
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	O
10	chemokine	B
11	receptor	I
12	5	O
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	B
18	-	I
19	tropic	I
20	HIV	I
21	-	I
22	1	I
23	strains	O
24	.	O

1	A	I
2	significant	O
3	degree	O
4	of	O
5	homology	O
6	was	O
7	also	O
8	found	O
9	among	O
10	these	O
11	genes	O
12	and	O
13	the	O
14	Mtase	B
15	gene	I
16	of	O
17	related	O
18	phage	O
19	SPR	O
20	,	O
21	which	O
22	codes	O
23	for	O
24	an	O
25	enzyme	O
26	with	O
27	different	O
28	modification	O
29	specificity	O
30	.	O

1	The	O
2	authors	O
3	proposed	O
4	that	O
5	the	O
6	highly	O
7	convergent	O
8	inputs	O
9	to	O
10	the	O
11	entorhinal	O
12	cortex	O
13	indicate	O
14	this	O
15	region	O
16	may	O
17	be	O
18	particularly	O
19	important	O
20	for	O
21	selecting	O
22	or	O
23	compressing	O
24	information	O
25	.	O

1	The	O
2	sequence	O
3	contains	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1744	O
10	nt	O
11	in	O
12	the	O
13	virus	O
14	-	O
15	sense	O
16	strand	O
17	,	O
18	a	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	1360	O
25	nt	O
26	and	O
27	a	O
28	3	O
29	'	O
30	poly	O
31	(	O
32	A	O
33	)	O
34	tail	O
35	.	O

1	Primary	B
2	invasive	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	disease	O
8	:	O
9	a	O
10	population	O
11	-	O
12	based	O
13	assessment	O
14	of	O
15	risk	O
16	factors	O
17	.	O

1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	O
6	haemoglobin	O
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	I
28	SP1	I
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	Eleven	B
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	instruments	O
6	allows	O
7	occlusion	O
8	of	O
9	the	O
10	ascending	O
11	aorta	O
12	traversed	O
13	by	O
14	the	O
15	perfusion	O
16	cannula	O
17	inserted	O
18	directly	O
19	or	O
20	through	O
21	the	O
22	apex	O
23	of	O
24	the	O
25	heart	O
26	as	O
27	well	O
28	as	O
29	simultaneous	O
30	left	O
31	ventricular	O
32	venting	O
33	.	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	One	O
2	gene	O
3	appears	O
4	ubiquitously	O
5	expressed	O
6	while	O
7	the	O
8	other	O
9	is	O
10	prominently	O
11	expressed	O
12	in	O
13	muscle	O
14	.	O

1	These	O
2	results	O
3	support	O
4	a	O
5	model	O
6	in	O
7	which	O
8	p53	B
9	protein	I
10	contributes	O
11	to	O
12	the	O
13	maintenance	O
14	of	O
15	genomic	O
16	integrity	O
17	through	O
18	recombinational	O
19	repair	O
20	.	O

1	Developmental	B
2	toxicity	O
3	of	O
4	the	O
5	class	O
6	III	O
7	antiarrhythmic	O
8	agent	O
9	almokalant	O
10	in	O
11	mice	O
12	.	O

1	Effects	O
2	of	O
3	posteroventral	O
4	pallidotomy	O
5	on	O
6	Parkinson	O
7	'	O
8	s	O
9	disease	O
10	.	O

1	This	O
2	E	O
3	box	O
4	sequence	O
5	(	O
6	CACGTG	O
7	)	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	binding	O
13	element	O
14	for	O
15	USF	B
16	(	I
17	upstream	I
18	stimulatory	I
19	factor	I
20	),	O
21	a	O
22	member	O
23	of	O
24	the	O
25	helix	B
26	-	I
27	loop	I
28	-	I
29	helix	I
30	family	I
31	of	O
32	transcription	O
33	factors	O
34	.	O

1	DNA	O
2	sequence	O
3	and	O
4	functions	O
5	of	O
6	the	O
7	actVI	O
8	region	O
9	of	O
10	the	O
11	actinorhodin	O
12	biosynthetic	O
13	gene	O
14	cluster	O
15	of	O
16	Streptomyces	O
17	coelicolor	B
18	A3	I
19	(	I
20	2	I
21	).	O

1	Acetoin	B
2	-	I
3	dependent	I
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	O
15	.	O
16	coli	O
17	acoK	O
18	mutants	O
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	O
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	This	O
2	indicates	O
3	that	O
4	recruitment	O
5	of	O
6	large	O
7	T	B
8	antigen	I
9	to	O
10	the	O
11	rRNA	O
12	promoter	O
13	by	O
14	SL1	O
15	constitutes	O
16	a	O
17	crucial	O
18	step	O
19	in	O
20	the	O
21	activation	O
22	process	O
23	.	O

1	The	O
2	ORF	O
3	was	O
4	analyzed	O
5	for	O
6	secondary	O
7	structural	O
8	features	O
9	,	O
10	and	O
11	the	O
12	sequence	O
13	data	O
14	bases	O
15	were	O
16	searched	O
17	for	O
18	homologies	O
19	.	O

1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O

1	The	O
2	cryptococcal	B
3	antigen	I
4	test	O
5	was	O
6	positive	O
7	at	O
8	1	O
9	:	O
10	125	O
11	by	O
12	latex	O
13	agglutination	O
14	.	O

1	Functional	O
2	tests	O
3	using	O
4	a	O
5	reporter	O
6	gene	O
7	,	O
8	containing	O
9	Stat5	B
10	-	I
11	binding	I
12	elements	I
13	,	O
14	confirmed	O
15	that	O
16	while	O
17	the	O
18	variant	O
19	form	O
20	was	O
21	inactive	O
22	by	O
23	itself	O
24	,	O
25	it	O
26	could	O
27	inhibit	O
28	the	O
29	function	O
30	of	O
31	the	O
32	full	B
33	-	I
34	length	I
35	receptor	I
36	.	O

1	Another	O
2	long	O
3	insertion	O
4	in	O
5	the	O
6	cathepsin	O
7	X	O
8	amino	O
9	acid	O
10	sequence	O
11	forms	O
12	a	O
13	beta	B
14	-	I
15	hairpin	O
16	pointing	O
17	away	O
18	from	O
19	the	O
20	active	O
21	site	O
22	.	O

1	Survey	B
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O

1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O

1	This	O
2	effect	O
3	was	O
4	abolished	O
5	once	O
6	the	O
7	EM	O
8	motif	O
9	in	O
10	the	O
11	promoter	O
12	-	O
13	reporter	O
14	construct	O
15	was	O
16	mutated	O
17	,	O
18	thus	O
19	suggesting	O
20	that	O
21	the	O
22	synergistic	O
23	transactivation	O
24	function	O
25	of	O
26	the	O
27	TEF	B
28	-	I
29	1	I
30	-	O
31	Max	B
32	heterotypic	I
33	complex	I
34	is	O
35	mediated	O
36	through	O
37	binding	O
38	of	O
39	the	O
40	complex	O
41	to	O
42	the	O
43	EM	O
44	motif	O
45	.	O

1	CONCLUSIONS	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	pre	O
8	-	O
9	treatment	O
10	with	O
11	coenzyme	O
12	Q10	O
13	may	O
14	play	O
15	a	O
16	protective	O
17	role	O
18	during	O
19	routine	O
20	vascular	O
21	procedures	O
22	requiring	O
23	abdominal	O
24	aortic	O
25	cross	O
26	clamping	O
27	by	O
28	attenuating	O
29	the	O
30	degree	O
31	of	O
32	peroxidative	O
33	damage	O
34	.	O

1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O

1	Impaction	B
2	of	O
3	gastrostomy	O
4	tube	O
5	in	O
6	the	O
7	abdominal	O
8	wall	O
9	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	A	O
2	larval	B
3	albumin	I
4	-	I
5	like	I
6	protein	I
7	was	O
8	not	O
9	detectable	O
10	by	O
11	silver	O
12	staining	O
13	in	O
14	serum	O
15	of	O
16	tadpoles	O
17	before	O
18	the	O
19	beginning	O
20	of	O
21	metamorphosis	O
22	at	O
23	stage	O
24	48	O
25	.	O

1	The	O
2	treatments	O
3	were	O
4	60	O
5	mg	O
6	t	O
7	.	O
8	i	O
9	.	O
10	d	O
11	.	O
12	and	O
13	120	O
14	mg	O
15	t	O
16	.	O
17	i	O
18	.	O
19	d	O
20	.	O
21	during	O
22	14	O
23	days	O
24	'	O
25	treatment	O
26	,	O
27	with	O
28	the	O
29	last	O
30	dose	O
31	pulsed	O
32	with	O
33	1	O
34	.	O
35	85	O
36	MBq	O
37	[	O
38	14C	O
39	]	O
40	diltiazem	O
41	.	O

1	Delta	B
2	-	I
3	aminolevulinic	O
4	acid	O
5	in	O
6	physiological	O
7	conditions	O
8	and	O
9	some	O
10	diseases	O
11	in	O
12	children	O

1	Between	B
2	the	O
3	subgroups	O
4	of	O
5	dementia	O
6	disorders	O
7	there	O
8	were	O
9	no	O
10	significant	O
11	differences	O
12	in	O
13	basal	O
14	cortisol	O
15	levels	O
16	.	O

1	Induction	O
2	of	O
3	Fas	B
4	ligand	O
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	O
13	with	O
14	the	O
15	T	B
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	situation	O
6	in	O
7	mammalian	O
8	cells	O
9	,	O
10	prolonged	O
11	exposure	O
12	of	O
13	the	O
14	agonist	O
15	(	O
16	24	O
17	h	O
18	)	O
19	does	O
20	not	O
21	result	O
22	in	O
23	down	O
24	regulation	O
25	of	O
26	the	O
27	remaining	O
28	70	O
29	%	O
30	of	O
31	the	O
32	receptors	O
33	.	O

1	Serum	B
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	O
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	B
17	peptide	I
18	transport	I
19	gene	I
20	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	AML1a	O
6	,	O
7	which	O
8	solely	O
9	has	O
10	no	O
11	effects	O
12	as	O
13	a	O
14	transcriptional	O
15	regulator	O
16	,	O
17	dominantly	O
18	suppresses	O
19	transcriptional	O
20	activation	O
21	by	O
22	AML1b	O
23	,	O
24	and	O
25	that	O
26	AML1a	O
27	exhibits	O
28	the	O
29	higher	O
30	affinity	O
31	for	O
32	DNA	O
33	-	O
34	binding	O
35	than	O
36	AML1b	O
37	.	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	B
42	-	I
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	Isolation	O
2	by	O
3	PCR	O
4	of	O
5	a	O
6	cDNA	O
7	clone	O
8	from	O
9	pea	O
10	petals	O
11	with	O
12	similarity	O
13	to	O
14	petunia	O
15	and	O
16	wheat	B
17	zinc	I
18	finger	I
19	proteins	I
20	.	O

1	Well	B
2	-	I
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	Tctex	B
2	-	I
3	1	I
4	binding	I
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	B
35	tyrosine	I
36	-	I
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	B
42	)	I
43	of	I
44	lymphocyte	I
45	Ag	I
46	receptors	I
47	.	O

1	Voluntary	B
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	analyses	O
9	revealed	O
10	two	O
11	hepatocyte	B
12	nuclear	I
13	factor	I
14	-	I
15	1	I
16	(	O
17	HNF1	O
18	),	O
19	three	O
20	CCAAT	B
21	/	I
22	enhancer	I
23	-	I
24	binding	I
25	protein	I
26	(	I
27	C	I
28	/	I
29	EBP	I
30	),	O
31	and	O
32	one	O
33	consensus	O
34	palindromic	O
35	thyroid	O
36	hormone	O
37	response	O
38	elements	O
39	within	O
40	the	O
41	first	O
42	215	O
43	base	O
44	pairs	O
45	(	O
46	bp	O
47	)	O
48	of	O
49	the	O
50	promoter	O
51	sequence	O
52	of	O
53	rat	O
54	Std	O
55	.	O

1	Coimmunoprecipitation	B
2	experiments	O
3	performed	O
4	in	O
5	transfected	O
6	cells	O
7	showed	O
8	that	O
9	BCMA	O
10	associates	O
11	with	O
12	TNFR	B
13	-	I
14	associated	I
15	factor	I
16	(	I
17	TRAF	I
18	)	I
19	1	I
20	,	O
21	TRAF2	B
22	,	O
23	and	O
24	TRAF3	O
25	adaptor	O
26	proteins	O
27	.	O

1	To	O
2	facilitate	O
3	the	O
4	investigation	O
5	of	O
6	parameters	O
7	that	O
8	govern	O
9	selective	O
10	export	O
11	in	O
12	adenovirus	O
13	-	O
14	infected	O
15	cells	O
16	,	O
17	we	O
18	constructed	O
19	a	O
20	marked	O
21	human	B
22	beta	I
23	-	I
24	actin	I
25	minigene	O
26	under	O
27	the	O
28	control	O
29	of	O
30	the	O
31	glucocorticoid	B
32	-	I
33	inducible	I
34	enhancer	I
35	-	I
36	promoter	I
37	of	O
38	mouse	O
39	mammary	O
40	tumor	O
41	virus	O
42	and	O
43	introduced	O
44	it	O
45	into	O
46	the	O
47	left	O
48	end	O
49	of	O
50	the	O
51	adenovirus	O
52	type	O
53	5	O
54	(	O
55	Ad5	O
56	)	O
57	genome	O
58	.	O

1	Additional	B
2	exonuclease	I
3	III	I
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	B
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	Along	B
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	O
12	,	O
13	OSBP	O
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O

1	Hyperthyroidism	B
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	The	O
2	4	O
3	degrees	O
4	stimuli	O
5	were	O
6	found	O
7	to	O
8	elicit	O
9	scalp	O
10	distributions	O
11	for	O
12	the	O
13	pattern	O
14	reversal	O
15	P100	O
16	and	O
17	the	O
18	pattern	O
19	onset	O
20	C1	O
21	consistent	O
22	with	O
23	striate	O
24	and	O
25	extrastriate	O
26	visual	O
27	cortical	O
28	origins	O
29	respectively	O
30	.	O

1	A	I
2	complementary	O
3	study	O
4	,	O
5	showing	O
6	a	O
7	good	O
8	agreement	O
9	between	O
10	surface	O
11	and	O
12	oesophageal	O
13	EMGd	O
14	seems	O
15	to	O
16	confirm	O
17	that	O
18	surface	O
19	EMGd	O
20	is	O
21	a	O
22	useful	O
23	and	O
24	promising	O
25	tool	O
26	for	O
27	clinical	O
28	investigation	O
29	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	O
5	protein	O
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	Serum	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	I	I
8	(	I
9	IGF	I
10	-	I
11	I	I
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	O
6	-	O
7	C	O
8	and	O
9	pregenomic	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	B
21	receptor	I
22	superfamily	I
23	.	O

1	Overexpression	O
2	of	O
3	H411	O
4	cDNA	O
5	in	O
6	the	O
7	RAW	O
8	264	O
9	.	O
10	7	O
11	macrophage	O
12	cell	O
13	line	O
14	promoted	O
15	an	O
16	increased	O
17	growth	O
18	rate	O
19	,	O
20	suggesting	O
21	that	O
22	expression	O
23	of	O
24	H411	O
25	is	O
26	part	O
27	of	O
28	the	O
29	proliferative	O
30	cell	O
31	response	O
32	to	O
33	LPS	O
34	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	B
5	-	I
6	1	I
7	or	O
8	sentrin	O
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	B
13	-	I
14	sensitive	I
15	L929	I
16	fibroblast	I
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	B
24	-	I
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	O
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	O
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	O
32	.	O

1	The	O
2	human	B
3	CD38	I
4	gene	I
5	consists	O
6	of	O
7	8	O
8	exons	O
9	that	O
10	extend	O
11	more	O
12	than	O
13	77	O
14	kb	O
15	on	O
16	the	O
17	human	O
18	genome	O
19	.	O

1	The	O
2	human	O
3	U4	B
4	/	I
5	U6	I
6	snRNP	I
7	contains	O
8	60	O
9	and	O
10	90kD	O
11	proteins	O
12	that	O
13	are	O
14	structurally	O
15	homologous	O
16	to	O
17	the	O
18	yeast	O
19	splicing	O
20	factors	O
21	Prp4p	O
22	and	O
23	Prp3p	O
24	.	O

1	OUTCOME	B
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O

1	Research	O
2	on	O
3	ethylene	O
4	glycol	O
5	and	O
6	diethylene	O
7	glycol	O
8	for	O
9	carcinogenic	O
10	effects	O

1	When	O
2	introduced	O
3	into	O
4	recJ	O
5	+	O
6	strains	O
7	,	O
8	srjA	O
9	mutations	O
10	conferred	O
11	hyperrecombinational	O
12	and	O
13	hyper	O
14	-	O
15	UVr	O
16	phenotypes	O
17	.	O

1	However	O
2	,	O
3	although	O
4	deletion	O
5	of	O
6	Fp1	O
7	in	O
8	the	O
9	hCRBP1	B
10	gene	I
11	yielded	O
12	increased	O
13	CAT	B
14	activity	O
15	,	O
16	pointing	O
17	toward	O
18	a	O
19	negative	O
20	regulatory	O
21	function	O
22	exerted	O
23	by	O
24	this	O
25	element	O
26	,	O
27	its	O
28	insertion	O
29	upstream	O
30	of	O
31	the	O
32	p12	O
33	basal	O
34	promoter	O
35	results	O
36	in	O
37	an	O
38	impressive	O
39	positive	O
40	stimulation	O
41	of	O
42	CAT	B
43	gene	I
44	expression	O
45	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Plasma	B
2	lactoferrin	O
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O

1	The	O
2	27	O
3	-	O
4	base	O
5	element	O
6	interacts	O
7	with	O
8	a	O
9	PDGF	B
10	-	I
11	activated	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	that	O
17	is	O
18	detected	O
19	only	O
20	within	O
21	the	O
22	nucleus	O
23	of	O
24	PDGF	B
25	-	I
26	treated	O
27	3T3	O
28	cells	O
29	.	O

1	The	O
2	emerging	O
3	view	O
4	based	O
5	on	O
6	studies	O
7	in	O
8	yeast	O
9	is	O
10	that	O
11	each	O
12	class	O
13	of	O
14	snoRNPs	O
15	is	O
16	composed	O
17	of	O
18	a	O
19	unique	O
20	set	O
21	of	O
22	proteins	O
23	.	O

1	Relations	B
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	O
7	cardiac	O
8	mechanical	O
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	O
15	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	O
12	and	O
13	hepatic	O
14	leukemia	O
15	factor	O
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	I
28	DBP	I
29	fusion	I
30	proteins	I
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Efficient	B
2	phosphorylation	O
3	of	O
4	BRDG1	O
5	by	O
6	Tec	O
7	required	O
8	the	O
9	PH	B
10	and	O
11	SH2	B
12	domains	I
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O

1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O

1	RVEF	B
2	and	O
3	LVEF	O
4	both	O
5	increased	O
6	by	O
7	about	O
8	14	O
9	%	O
10	(	O
11	p	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	and	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	01	O
24	).	O

1	19	I
2	-	I
3	32	O
4	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	Dynamic	B
2	decision	O
3	making	O
4	:	O
5	human	O
6	control	O
7	of	O
8	complex	O
9	systems	O
10	.	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	B
6	promoter	I
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	O
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	Protein	B
2	kinases	I
3	play	O
4	pivotal	O
5	roles	O
6	in	O
7	the	O
8	control	O
9	of	O
10	many	O
11	cellular	O
12	processes	O
13	.	O

1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	O
11	non	O
12	-	O
13	O1	O
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O

1	A	I
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	Studies	O
2	are	O
3	necessary	O
4	to	O
5	assess	O
6	the	O
7	source	O
8	of	O
9	contamination	O
10	and	O
11	potential	O
12	role	O
13	of	O
14	MRSA	O
15	-	O
16	contaminated	O
17	milk	O
18	in	O
19	the	O
20	transmission	O
21	of	O
22	MRSA	O
23	to	O
24	neonates	O
25	.	O

1	Two	O
2	mutants	O
3	,	O
4	each	O
5	representative	O
6	of	O
7	a	O
8	separate	O
9	pet	O
10	complementation	O
11	group	O
12	,	O
13	have	O
14	been	O
15	analyzed	O
16	.	O

1	The	O
2	hormonal	O
3	response	O
4	to	O
5	a	O
6	standardized	O
7	bicycle	O
8	exercise	O
9	test	O
10	was	O
11	studied	O
12	in	O
13	11	O
14	male	O
15	cadets	O
16	exposed	O
17	to	O
18	a	O
19	course	O
20	of	O
21	107	O
22	h	O
23	of	O
24	continuous	O
25	activity	O
26	with	O
27	less	O
28	than	O
29	2	O
30	h	O
31	sleep	O
32	.	O

1	Vascular	B
2	endothelial	I
3	growth	I
4	factor	I
5	(	I
6	VEGF	I
7	),	O
8	a	O
9	potent	O
10	agonist	O
11	secreted	O
12	by	O
13	virtually	O
14	all	O
15	cells	O
16	,	O
17	controls	O
18	migration	O
19	and	O
20	division	O
21	of	O
22	vascular	O
23	endothelial	O
24	cells	O
25	.	O

1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	O
6	proliferator	O
7	-	O
8	activated	B
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O

1	The	O
2	influenza	O
3	virus	O
4	NS1	B
5	protein	I
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O

1	DPA	B
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O

1	How	B
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Ras	B
2	-	I
3	and	O
4	ultra	B
5	-	I
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	I
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	B
7	regulatory	I
8	protein	I
9	,	O
10	CYS3	O
11	,	O
12	of	O
13	Neurospora	B
14	crassa	I
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	The	O
2	measurement	O
3	of	O
4	NO	O
5	in	O
6	biological	O
7	systems	O
8	using	O
9	chemiluminescence	O
10	.	O

1	The	O
2	same	O
3	trend	O
4	was	O
5	noted	O
6	between	O
7	YG	O
8	4	O
9	.	O
10	5	O
11	heifers	O
12	and	O
13	YG	O
14	5	O
15	.	O
16	5	O
17	steers	O
18	,	O
19	indicating	O
20	a	O
21	sex	O
22	-	O
23	related	O
24	deposition	O
25	of	O
26	seam	O
27	fat	O
28	in	O
29	fed	O
30	cattle	O
31	.	O

1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O

1	The	O
2	c	B
3	-	I
4	Ets	I
5	-	I
6	1	I
7	oncoprotein	I
8	is	O
9	a	O
10	transcription	O
11	activator	O
12	that	O
13	specifically	O
14	binds	O
15	to	O
16	DNA	O
17	.	O

1	Twenty	O
2	-	O
3	four	O
4	hours	O
5	later	O
6	,	O
7	the	O
8	animals	O
9	were	O
10	randomized	O
11	to	O
12	subretinal	O
13	treatment	O
14	with	O
15	2	O
16	.	O
17	5	O
18	micrograms	O
19	of	O
20	tissue	B
21	plasminogen	I
22	activator	I
23	or	O
24	a	O
25	similar	O
26	volume	O
27	of	O
28	physiologic	O
29	saline	O
30	.	O

1	Interestingly	O
2	,	O
3	the	O
4	interaction	O
5	of	O
6	ZAP	B
7	-	I
8	70	I
9	with	O
10	the	O
11	motif	O
12	was	O
13	dependent	O
14	on	O
15	the	O
16	presence	O
17	of	O
18	both	O
19	ZAP	B
20	-	I
21	70	I
22	SH2	I
23	domains	I
24	and	O
25	both	O
26	of	O
27	the	O
28	tyrosine	O
29	residues	O
30	in	O
31	the	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	ZAP	B
37	-	I
38	70	I
39	interacts	O
40	with	O
41	two	O
42	phosphotyrosine	O
43	residues	O
44	and	O
45	that	O
46	the	O
47	binding	O
48	of	O
49	the	O
50	two	O
51	SH2	B
52	domains	I
53	is	O
54	cooperative	O
55	.	O

1	Anterior	B
2	body	O
3	pattern	O
4	in	O
5	Drosophila	O
6	is	O
7	specified	O
8	by	O
9	the	O
10	graded	O
11	distribution	O
12	of	O
13	the	O
14	bicoid	O
15	protein	O
16	(	O
17	bcd	O
18	),	O
19	which	O
20	activates	O
21	subordinate	O
22	genes	O
23	in	O
24	distinct	O
25	anterior	O
26	domains	O
27	.	O

1	Hypothermia	B
2	After	O
3	Cardiac	O
4	Arrest	O
5	(	O
6	HACA	O
7	)	O
8	Study	O
9	Group	O
10	.	O

1	RNase	B
2	protection	O
3	analysis	O
4	of	O
5	two	O
6	rRNA	O
7	fragments	O
8	whose	O
9	genes	O
10	are	O
11	adjacent	O
12	provided	O
13	evidence	O
14	for	O
15	a	O
16	polycistronic	O
17	transcript	O
18	containing	O
19	sequences	O
20	from	O
21	both	O
22	,	O
23	as	O
24	well	O
25	as	O
26	separate	O
27	small	O
28	RNAs	O
29	.	O

1	Tyrosine	B
2	phosphorylation	O
3	of	O
4	cellular	O
5	proteins	O
6	is	O
7	the	O
8	earliest	O
9	identifiable	O
10	event	O
11	following	O
12	T	B
13	-	I
14	cell	I
15	antigen	I
16	receptor	I
17	(	I
18	TCR	I
19	)	O
20	stimulation	O
21	and	O
22	is	O
23	essential	O
24	for	O
25	activating	O
26	downstream	O
27	signaling	O
28	machinery	O
29	.	O

1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	O
20	gamma	B
21	-	I
22	globin	I
23	gene	I
24	(	I
25	A	I
26	gamma	I
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	B
39	gamma	I
40	-	I
41	globin	I
42	mRNA	I
43	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	polypeptide	O
6	component	O
7	of	O
8	the	O
9	Rel	B
10	-	I
11	related	I
12	human	I
13	p75	I
14	nucleoprotein	I
15	complex	I
16	has	O
17	revealed	O
18	its	O
19	identity	O
20	with	O
21	the	O
22	65	O
23	-	O
24	kDa	O
25	(	O
26	p65	B
27	)	I
28	subunit	I
29	of	O
30	NF	B
31	-	I
32	kappa	I
33	B	I
34	.	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	V	I
2	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	B
8	-	I
9	1	I
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	O
21	length	O
22	UGT2B7	O
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	A	I
2	much	O
3	less	O
4	expensive	O
5	solution	O
6	than	O
7	UW	O
8	,	O
9	containing	O
10	only	O
11	K	O
12	(+)-	O
13	lactobionate	O
14	,	O
15	KH2PO4	O
16	,	O
17	MgSO4	O
18	and	O
19	raffinose	O
20	,	O
21	can	O
22	be	O
23	used	O
24	successfully	O
25	for	O
26	preservation	O
27	of	O
28	rat	O
29	hepatocytes	O
30	for	O
31	24	O
32	hr	O
33	for	O
34	drug	O
35	transport	O
36	studies	O
37	.	O

1	Regulation	O
2	of	O
3	urokinase	B
4	plasminogen	I
5	activator	I
6	gene	I
7	transcription	I
8	in	O
9	the	O
10	RAW264	O
11	murine	B
12	macrophage	I
13	cell	O
14	line	O
15	by	O
16	macrophage	B
17	colony	I
18	-	I
19	stimulating	I
20	factor	I
21	(	I
22	CSF	I
23	-	I
24	1	I
25	)	O
26	is	O
27	dependent	O
28	upon	O
29	the	O
30	level	O
31	of	O
32	cell	O
33	-	O
34	surface	O
35	receptor	O
36	.	O

1	The	O
2	final	O
3	predicted	O
4	structure	O
5	has	O
6	an	O
7	overall	O
8	backbone	O
9	deviation	O
10	of	O
11	0	O
12	.	O
13	7	O
14	A	O
15	from	O
16	that	O
17	of	O
18	ras	B
19	-	O
20	p21	B
21	.	O

1	Sodium	B
2	-	I
3	taurocholate	I
4	-	I
5	induced	O
6	acute	O
7	necrotizing	O
8	pancreatitis	O
9	does	O
10	not	O
11	affect	O
12	jejunal	O
13	oxygenation	O
14	in	O
15	pigs	O
16	.	O

1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	Mutations	O
2	in	O
3	the	O
4	small	O
5	subunit	O
6	of	O
7	ribulosebisphosphate	O
8	carboxylase	O
9	affect	O
10	subunit	O
11	binding	O
12	and	O
13	catalysis	O
14	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	O
16	of	O
17	proteins	O
18	required	O
19	for	O
20	the	O
21	initiation	O
22	of	O
23	RNA	O
24	replication	O
25	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	Whipple	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	284	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	B
6	pre	I
7	-	I
8	mRNA	I
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O

1	The	O
2	concentration	O
3	of	O
4	mite	O
5	allergen	O
6	was	O
7	very	O
8	low	O
9	(	O
10	mean	O
11	0	O
12	.	O
13	18	O
14	micrograms	O
15	Der	O
16	p	O
17	milligrams	O
18	sieved	O
19	house	O
20	dust	O
21	),	O
22	whereas	O
23	that	O
24	of	O
25	cat	O
26	allergen	O
27	was	O
28	high	O
29	in	O
30	homes	O
31	with	O
32	a	O
33	cat	O
34	(	O
35	80	O
36	.	O
37	8	O
38	micrograms	O
39	Fel	O
40	d	O
41	milligrams	O
42	)	O
43	but	O
44	also	O
45	in	O
46	homes	O
47	with	O
48	no	O
49	cat	O
50	(	O
51	3	O
52	.	O
53	2	O
54	micrograms	O
55	Fel	O
56	d	O
57	milligrams	O
58	).	O

1	TH	B
2	-	I
3	SH3	I
4	binding	I
5	in	O
6	vitro	O
7	is	O
8	abolished	O
9	by	O
10	specific	O
11	,	O
12	single	O
13	amino	O
14	acid	O
15	substitutions	O
16	within	O
17	the	O
18	Btk	O
19	TH	O
20	domain	O
21	or	O
22	the	O
23	Fyn	B
24	SH3	I
25	domain	I
26	.	O

1	Constitutive	B
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	O
6	protein	O
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O

1	Various	O
2	transcripts	O
3	are	O
4	generated	O
5	from	O
6	the	O
7	VCSA1	B
8	gene	I
9	by	O
10	alternative	O
11	splicing	O
12	and	O
13	poly	O
14	(	O
15	A	O
16	)	O
17	processing	O
18	in	O
19	the	O
20	rat	O
21	submandibular	O
22	gland	O
23	.	O

1	The	O
2	objective	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	examine	O
9	the	O
10	influence	O
11	of	O
12	HHCA	O
13	and	O
14	other	O
15	serological	O
16	factors	O
17	upon	O
18	the	O
19	development	O
20	of	O
21	VGS	O
22	.	O

1	Of	O
2	the	O
3	153	O
4	patients	O
5	studied	O
6	,	O
7	CK	B
8	-	I
9	MB	I
10	results	O
11	were	O
12	positive	O
13	in	O
14	91	O
15	(	O
16	59	O
17	%)	O
18	patients	O
19	;	O
20	ECG	O
21	revealed	O
22	AMI	O
23	in	O
24	72	O
25	(	O
26	47	O
27	%)	O
28	patients	O
29	.	O

1	A	I
2	new	O
3	hypothesis	O
4	on	O
5	mechanisms	O
6	for	O
7	inhibiting	O
8	catalytic	O
9	subunits	O
10	by	O
11	gamma	B
12	-	I
13	subunits	I
14	and	O
15	activation	O
16	of	O
17	a	O
18	holoenzyme	O
19	by	O
20	transducin	O

1	Although	O
2	the	O
3	binding	O
4	of	O
5	IE2	B
6	86	O
7	to	O
8	nonphosphorylated	O
9	full	O
10	-	O
11	length	O
12	CREB	B
13	or	O
14	deltaCREB	O
15	is	O
16	minimal	O
17	,	O
18	IE2	B
19	86	O
20	does	O
21	form	O
22	complexes	O
23	with	O
24	p300	B
25	and	O
26	the	O
27	CREB	B
28	-	I
29	binding	I
30	protein	I
31	(	O
32	CBP	B
33	),	O
34	which	O
35	in	O
36	turn	O
37	bind	O
38	to	O
39	CREB	B
40	and	O
41	can	O
42	serve	O
43	as	O
44	adaptor	O
45	proteins	O
46	for	O
47	CREB	B
48	function	O
49	.	O

1	Using	O
2	mutated	O
3	IL2R	B
4	alpha	I
5	promoter	I
6	constructs	I
7	in	O
8	transient	O
9	transfection	O
10	and	O
11	DNA	O
12	binding	O
13	assays	O
14	,	O
15	we	O
16	now	O
17	demonstrate	O
18	that	O
19	sequences	O
20	located	O
21	immediately	O
22	upstream	O
23	and	O
24	downstream	O
25	of	O
26	the	O
27	kappa	B
28	B	I
29	enhancer	I
30	also	O
31	contribute	O
32	to	O
33	the	O
34	regulation	O
35	of	O
36	IL2R	B
37	alpha	I
38	gene	I
39	expression	O
40	.	O

1	Mn2	B
2	+	I
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O

1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	Mutagenesis	B
2	of	O
3	each	O
4	NRF	B
5	-	I
6	1	I
7	motif	I
8	in	O
9	the	O
10	ALAS	O
11	promoter	O
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	NRF	B
26	-	I
27	1	I
28	motifs	O
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O

1	Mitomycin	B
2	-	I
3	C	I
4	can	O
5	cause	O
6	severe	O
7	necrosis	O
8	and	O
9	ulceration	O
10	when	O
11	extravasated	O
12	inadvertently	O
13	into	O
14	skin	O
15	and	O
16	soft	O
17	tissues	O
18	following	O
19	IV	O
20	drug	O
21	administration	O
22	.	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	Value	B
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	O
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	The	O
2	mean	O
3	plasma	O
4	sodium	O
5	concentration	O
6	which	O
7	was	O
8	135	O
9	.	O
10	95	O
11	(+/-	O
12	SD	O
13	4	O
14	.	O
15	14	O
16	)	O
17	mEq	O
18	/	O
19	kg	O
20	before	O
21	diuretic	O
22	treatment	O
23	was	O
24	significantly	O
25	decreased	O
26	during	O
27	treatment	O
28	to	O
29	129	O
30	.	O
31	19	O
32	(+/-	O
33	SD	O
34	2	O
35	.	O
36	77	O
37	)	O
38	mEq	O
39	/	O
40	kg	O
41	,	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	.	O

1	Extracellular	B
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	O
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	A	I
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O

1	A	I
2	positive	O
3	correlation	O
4	between	O
5	serum	B
6	myoglobin	I
7	and	I
8	CA	I
9	III	I
10	concentrations	O
11	(	O
12	rs	O
13	=	O
14	0	O
15	.	O
16	933	O
17	,	O
18	P	O
19	<	O
20	0	O
21	.	O
22	001	O
23	)	O
24	was	O
25	observed	O
26	in	O
27	hemodialyzed	O
28	patients	O
29	with	O
30	chronic	O
31	renal	O
32	failure	O
33	.	O

1	Experimental	O
2	data	O
3	showed	O
4	that	O
5	these	O
6	abnormal	O
7	proteins	O
8	are	O
9	constitutively	O
10	localized	O
11	in	O
12	the	O
13	nucleus	O
14	,	O
15	have	O
16	lost	O
17	the	O
18	transcriptional	O
19	repressor	O
20	functions	O
21	typical	O
22	of	O
23	normal	O
24	NF	B
25	-	I
26	kappa	I
27	B2p52	O
28	and	O
29	may	O
30	be	O
31	capable	O
32	of	O
33	transactivation	O
34	activity	O
35	.	O

1	Analysis	O
2	of	O
3	the	O
4	intact	O
5	hGH	B
6	gene	I
7	or	O
8	hGH	O
9	5	O
10	'-	O
11	flanking	O
12	DNA	O
13	(	O
14	5	O
15	'-	O
16	FR	O
17	)	O
18	coupled	O
19	to	O
20	the	O
21	hGh	O
22	cDNA	O
23	or	O
24	chloramphenicol	B
25	acetyltransferase	I
26	or	O
27	luciferase	B
28	genes	I
29	,	O
30	indicated	O
31	that	O
32	cAMP	O
33	primarily	O
34	stimulated	O
35	hGH	O
36	promoter	O
37	activity	O
38	.	O

1	In	O
2	simpler	O
3	organisms	O
4	,	O
5	the	O
6	ATP	O
7	sulfurylase	O
8	and	O
9	APS	B
10	kinase	I
11	reactions	O
12	are	O
13	catalyzed	O
14	by	O
15	separate	O
16	enzymes	O
17	encoded	O
18	by	O
19	two	O
20	or	O
21	three	O
22	genes	O
23	,	O
24	suggesting	O
25	that	O
26	a	O
27	fusion	O
28	of	O
29	separate	O
30	genes	O
31	during	O
32	the	O
33	course	O
34	of	O
35	evolution	O
36	generated	O
37	the	O
38	bifunctional	O
39	enzyme	O
40	.	O

1	AMY	B
2	-	I
3	1	I
4	was	O
5	localized	O
6	in	O
7	the	O
8	cytoplasm	O
9	in	O
10	cells	O
11	expressing	O
12	c	B
13	-	I
14	myc	I
15	at	O
16	low	O
17	levels	O
18	,	O
19	but	O
20	in	O
21	the	O
22	nucleus	O
23	in	O
24	the	O
25	cells	O
26	of	O
27	a	O
28	high	O
29	c	B
30	-	I
31	myc	I
32	expression	O
33	in	O
34	transiently	O
35	transfected	O
36	cells	O
37	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	O
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	O
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	O
31	.	O

1	Thus	O
2	,	O
3	Esigma54	O
4	promoters	O
5	are	O
6	responsive	O
7	to	O
8	CRP	B
9	,	O
10	a	O
11	protein	O
12	unrelated	O
13	to	O
14	sigma54	O
15	activators	O
16	,	O
17	and	O
18	the	O
19	repression	O
20	exerted	O
21	is	O
22	the	O
23	direct	O
24	result	O
25	of	O
26	an	O
27	interaction	O
28	between	O
29	Esigma54	O
30	and	O
31	the	O
32	CRP	B
33	-	I
34	cAMP	I
35	complex	I
36	.	O

1	In	O
2	contrast	O
3	,	O
4	gel	O
5	mobility	O
6	shift	O
7	experiments	O
8	have	O
9	failed	O
10	to	O
11	reveal	O
12	that	O
13	HAP2	O
14	or	O
15	HAP3	O
16	binds	O
17	to	O
18	domain	O
19	1	O
20	or	O
21	that	O
22	hap3	O
23	mutations	O
24	affect	O
25	the	O
26	complexes	O
27	bound	O
28	to	O
29	it	O
30	.	O

1	1	I
2	A	I
3	colonic	O
4	delivery	O
5	system	O
6	is	O
7	described	O
8	to	O
9	deliver	O
10	orally	O
11	ingested	O
12	drugs	O
13	to	O
14	the	O
15	colon	O
16	and	O
17	release	O
18	them	O
19	at	O
20	that	O
21	site	O
22	by	O
23	coating	O
24	with	O
25	an	O
26	acrylic	O
27	based	O
28	resin	O
29	(	O
30	Eudragit	O
31	S	O
32	).	O

1	Pharmacological	B
2	desympathization	O
3	leads	O
4	to	O
5	the	O
6	development	O
7	of	O
8	hyper	O
9	-	O
10	reactivity	O
11	of	O
12	the	O
13	true	O
14	pacemakers	O
15	to	O
16	noradrenaline	O
17	and	O
18	dopamine	O
19	and	O
20	triggers	O
21	off	O
22	changes	O
23	in	O
24	the	O
25	regulation	O
26	of	O
27	the	O
28	electric	O
29	activity	O
30	of	O
31	these	O
32	cells	O
33	by	O
34	catecholamines	O
35	.	O

1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O

1	When	O
2	used	O
3	subcutaneously	O
4	or	O
5	intravenously	O
6	in	O
7	maximum	O
8	tolerated	O
9	doses	O
10	the	O
11	antibiotic	O
12	inhibited	O
13	the	O
14	development	O
15	of	O
16	lymphadenosis	O
17	NK	O
18	/	O
19	Li	O
20	by	O
21	90	O
22	and	O
23	70	O
24	per	O
25	cent	O
26	respectively	O
27	.	O

1	The	O
2	aspirate	O
3	from	O
4	a	O
5	parathyroid	O
6	cyst	O
7	was	O
8	watery	O
9	clear	O
10	and	O
11	contained	O
12	high	O
13	amount	O
14	of	O
15	parathyroid	B
16	hormone	I
17	.	O

1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O

1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	B
8	-	I
9	1	I
10	kinase	I
11	contains	O
12	zinc	O
13	,	O
14	translocates	O
15	to	O
16	liposomes	O
17	,	O
18	and	O
19	is	O
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	O
25	binds	O
26	GTP	B
27	-	I
28	ras	I
29	.	O

1	Ang	B
2	II	I
3	-	I
4	induced	O
5	fibronectin	B
6	mRNA	I
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	O
28	negative	O
29	EGF	B
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	Studies	O
2	using	O
3	a	O
4	reporter	O
5	plasmid	O
6	with	O
7	a	O
8	functionally	O
9	disrupted	O
10	sterol	B
11	-	I
12	responsive	I
13	element	I
14	(	O
15	SRE	O
16	)-	O
17	1	O
18	revealed	O
19	a	O
20	reduced	O
21	stimulatory	O
22	response	O
23	to	O
24	IL	B
25	-	I
26	6	I
27	.	O

1	Reaction	B
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O

1	DNA	I
2	binding	I
3	and	O
4	glutathione	B
5	S	I
6	-	I
7	transferase	I
8	pull	I
9	-	I
10	down	O
11	assays	O
12	demonstrate	O
13	that	O
14	binding	O
15	requires	O
16	Elk	B
17	-	I
18	1	I
19	(	I
20	1	I
21	-	I
22	212	O
23	)	O
24	but	O
25	not	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	transactivation	O
31	domain	O
32	.	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	Enhancers	B
2	containing	O
3	disrupted	O
4	Ets	B
5	-	I
6	1	I
7	binding	I
8	sites	I
9	were	O
10	tested	O
11	in	O
12	transient	O
13	expression	O
14	assays	O
15	in	O
16	the	O
17	murine	B
18	T	I
19	-	I
20	cell	O
21	line	O
22	EL4	O
23	.	O
24	E1	B
25	;	O
26	alterations	O
27	in	O
28	the	O
29	LVb	O
30	element	O
31	affected	O
32	constitutive	O
33	enhancer	O
34	activity	O
35	,	O
36	while	O
37	mutation	O
38	of	O
39	either	O
40	the	O
41	LVb	O
42	or	O
43	LVc	O
44	element	O
45	disrupted	O
46	phorbol	O
47	ester	O
48	-	O
49	induced	O
50	enhancer	O
51	activity	O
52	.	O

1	Upon	O
2	differentiation	O
3	with	O
4	retinoic	O
5	acid	O
6	(	O
7	RA	O
8	),	O
9	transcription	O
10	of	O
11	the	O
12	Rex	B
13	-	I
14	1	I
15	gene	I
16	decreases	O
17	rapidly	O
18	.	O

1	Three	O
2	cases	O
3	of	O
4	primary	O
5	signet	O
6	-	O
7	ring	O
8	cell	O
9	carcinoma	O
10	of	O
11	the	O
12	rectum	O
13	are	O
14	described	O
15	.	O

1	Feed	B
2	intake	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	dietary	O
8	KCl	O
9	or	O
10	NaHCO3	O
11	supplementation	O
12	,	O
13	but	O
14	average	O
15	daily	O
16	gain	O
17	increased	O
18	with	O
19	increased	O
20	K	O
21	and	O
22	tended	O
23	to	O
24	be	O
25	reduced	O
26	by	O
27	dietary	O
28	NaHCO3	O
29	.	O

1	The	O
2	effect	O
3	of	O
4	diffusion	O
5	limitation	O
6	was	O
7	quantified	O
8	in	O
9	terms	O
10	of	O
11	the	O
12	ratio	O
13	O2	O
14	uptake	O
15	/	O
16	O2	O
17	requirement	O
18	(=	O
19	fraction	O
20	of	O
21	cross	O
22	-	O
23	sectional	O
24	area	O
25	supplied	O
26	with	O
27	O2	O
28	),	O
29	assuming	O
30	local	O
31	O2	O
32	requirement	O
33	per	O
34	unit	O
35	volume	O
36	to	O
37	be	O
38	constant	O
39	and	O
40	independent	O
41	of	O
42	PO2	O
43	at	O
44	PO2	O
45	greater	O
46	than	O
47	0	O
48	.	O

1	1	I
2	,	I
3	3	I
4	-	I
5	bis	I
6	(	I
7	2	I
8	-	I
9	chloroethyl	I
10	)-	I
11	1	I
12	-	I
13	nitrosourea	O
14	(	O
15	bcnu	O
16	)	O
17	and	O
18	other	O
19	nitrosoureas	O
20	in	O
21	cancer	O
22	treatment	O
23	:	O
24	a	O
25	review	O
26	.	O

1	In	O
2	vitro	O
3	expression	O
4	levels	O
5	of	O
6	the	O
7	different	O
8	plasmids	O
9	differed	O
10	by	O
11	as	O
12	much	O
13	as	O
14	tenfold	O
15	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	rose	O
5	and	O
6	the	O
7	plasma	O
8	aldosterone	O
9	level	O
10	fell	O
11	after	O
12	taking	O
13	lisinopril	O
14	.	O

1	The	O
2	present	O
3	research	O
4	evaluated	O
5	the	O
6	possibility	O
7	that	O
8	polyethylene	O
9	glycol	O
10	400	O
11	(	O
12	PEG	O
13	400	O
14	)	O
15	might	O
16	be	O
17	efficacious	O
18	,	O
19	toxic	O
20	,	O
21	or	O
22	both	O
23	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	factors	O
8	present	O
9	in	O
10	nuclear	O
11	extracts	O
12	derived	O
13	from	O
14	differentiated	O
15	osteoblast	O
16	bound	O
17	to	O
18	oligonucleotide	O
19	probes	O
20	containing	O
21	the	O
22	E	B
23	-	I
24	box	I
25	1	I
26	and	I
27	E	I
28	-	I
29	box	I
30	2	I
31	elements	I
32	.	O

1	No	O
2	difference	O
3	in	O
4	elastin	O
5	peptide	O
6	concentration	O
7	was	O
8	observed	O
9	between	O
10	emphysematous	O
11	patients	O
12	and	O
13	control	O
14	subjects	O
15	(	O
16	mean	O
17	+/-	O
18	SD	O
19	=	O
20	2	O
21	.	O
22	39	O
23	+/-	O
24	1	O
25	.	O
26	18	O
27	micrograms	O
28	/	O
29	ml	O
30	in	O
31	patients	O
32	versus	O
33	2	O
34	.	O
35	55	O
36	+/-	O
37	1	O
38	.	O
39	34	O
40	micrograms	O
41	/	O
42	ml	O
43	in	O
44	policemen	O
45	and	O
46	2	O
47	.	O
48	59	O
49	+/-	O
50	1	O
51	.	O
52	20	O
53	micrograms	O
54	/	O
55	ml	O
56	in	O
57	coal	O
58	miners	O
59	).	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	B
5	-	I
6	III	I
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	O
7	proteins	O
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	O
15	NHP6A	O
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	Reconstitution	B
2	of	O
3	Raf	B
4	-	I
5	1	I
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	O
12	active	O
13	Jak1	O
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	A	I
2	value	O
3	of	O
4	1	O
5	.	O
6	1	O
7	l	O
8	/	O
9	kg	O
10	was	O
11	used	O
12	for	O
13	V	O
14	in	O
15	calculating	O
16	all	O
17	single	O
18	sample	O
19	estimates	O
20	of	O
21	clearance	O
22	(	O
23	CL	O
24	),	O
25	and	O
26	a	O
27	value	O
28	of	O
29	4	O
30	.	O
31	3	O
32	l	O
33	/	O
34	kg	O
35	was	O
36	used	O
37	to	O
38	calculate	O
39	single	O
40	sample	O
41	estimates	O
42	of	O
43	clearance	O
44	of	O
45	plasma	O
46	unbound	O
47	drug	O
48	(	O
49	CLunb	O
50	).	O

1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	O
6	mutants	O
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O

1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	O
8	ORL1	O
9	and	O
10	GAIP	O
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	Nitrogen	B
2	-	I
3	hydrogen	O
4	tautomerism	O
5	in	O
6	porphyrins	O
7	and	O
8	chlorins	O
9	.	O

1	In	O
2	addition	O
3	to	O
4	homologues	O
5	of	O
6	the	O
7	human	B
8	genes	I
9	PSMB5	O
10	through	O
11	PSMB9	O
12	,	O
13	two	O
14	new	O
15	genes	O
16	,	O
17	PSMB11	O
18	and	O
19	PSMB12	O
20	,	O
21	have	O
22	been	O
23	found	O
24	for	O
25	which	O
26	there	O
27	are	O
28	no	O
29	known	O
30	corresponding	O
31	genes	O
32	in	O
33	humans	O
34	.	O

1	The	O
2	3	O
3	'	O
4	stem	O
5	-	O
6	loop	O
7	is	O
8	highly	O
9	divergent	O
10	in	O
11	structure	O
12	among	O
13	species	O
14	and	O
15	lies	O
16	immediately	O
17	upstream	O
18	of	O
19	the	O
20	binding	O
21	site	O
22	for	O
23	Sm	O
24	proteins	O
25	.	O

1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	O
8	and	O
9	NBPhox	O
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	O
20	promoter	O
21	.	O

1	Simple	B
2	reaction	O
3	time	O
4	(	O
5	RT	O
6	)	O
7	to	O
8	a	O
9	peripheral	O
10	visual	O
11	target	O
12	(	O
13	S2	O
14	)	O
15	is	O
16	shortened	O
17	when	O
18	a	O
19	non	O
20	-	O
21	informative	O
22	cue	O
23	(	O
24	S1	B
25	)	O
26	is	O
27	flashed	O
28	at	O
29	the	O
30	S2	O
31	location	O
32	100	O
33	-	O
34	150	O
35	ms	O
36	before	O
37	target	O
38	onset	O
39	(	O
40	early	O
41	facilitation	O
42	).	O

1	Responsiveness	B
2	to	O
3	beta	B
4	-	I
5	2	I
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O

1	A	I
2	mutant	I
3	areA	I
4	product	I
5	truncated	I
6	immediately	O
7	after	O
8	the	O
9	last	O
10	residue	O
11	of	O
12	the	O
13	highly	O
14	conserved	O
15	GATA	B
16	(	I
17	DNA	I
18	-	I
19	binding	I
20	)	I
21	domain	I
22	retains	O
23	partial	O
24	function	O
25	.	O

1	To	O
2	investigate	O
3	the	O
4	effects	O
5	of	O
6	isotretinoin	O
7	on	O
8	HDL	B
9	,	O
10	we	O
11	measured	O
12	HDL	B
13	-	I
14	C	I
15	,	O
16	HDL	B
17	phospholipids	O
18	(	O
19	HDL	B
20	-	I
21	PL	O
22	),	O
23	apoprotein	B
24	A1	I
25	(	O
26	apo	B
27	A	I
28	-	I
29	1	I
30	),	O
31	and	O
32	HDL	B
33	-	I
34	C	I
35	subfractions	O
36	(	O
37	HDL2	B
38	-	I
39	C	I
40	and	O
41	HDL3	B
42	-	I
43	C	I
44	)	O
45	in	O
46	24	O
47	healthy	O
48	,	O
49	male	O
50	patients	O
51	receiving	O
52	a	O
53	16	O
54	-	O
55	week	O
56	course	O
57	of	O
58	isotretinoin	O
59	(	O
60	1	O
61	.	O
62	0	O
63	mg	O
64	/	O
65	kg	O
66	/	O
67	day	O
68	)	O
69	for	O
70	treatment	O
71	of	O
72	severe	O
73	acne	O
74	vulgaris	O
75	.	O

1	Further	O
2	,	O
3	the	O
4	ability	O
5	of	O
6	recombinant	B
7	beta	I
8	and	O
9	/	O
10	or	O
11	gamma	B
12	chains	I
13	to	O
14	function	O
15	in	O
16	defined	O
17	biochemical	O
18	assays	O
19	of	O
20	beta	B
21	gamma	I
22	activity	O
23	was	O
24	assessed	O
25	for	O
26	membrane	O
27	extracts	O
28	and	O
29	supernatant	O
30	fractions	O
31	from	O
32	infected	O
33	Sf9	O
34	cells	O
35	.	O

1	Study	O
2	on	O
3	micromelias	O
4	in	O
5	the	O
6	mouse	O
7	fetus	O
8	caused	O
9	by	O
10	x	O
11	-	O
12	radiation	O
13	,	O
14	hypoxia	O
15	,	O
16	trypan	O
17	blue	O
18	injection	O
19	of	O
20	hypervitaminosis	O
21	-	O
22	A	O
23	upon	O
24	mother	O
25	animals	O
26	during	O
27	pregnancy	O
28	.	O

1	CDNA	B
2	cloning	O
3	of	O
4	chick	O
5	brain	O
6	alpha	B
7	-	I
8	amino	I
9	-	I
10	3	I
11	-	I
12	hydroxy	I
13	-	I
14	5	I
15	-	I
16	methyl	I
17	-	I
18	4	I
19	-	I
20	isoxazolepropionic	I
21	acid	I
22	receptors	I
23	reveals	O
24	conservation	O
25	of	O
26	structure	O
27	,	O
28	function	O
29	and	O
30	post	O
31	-	O
32	transcriptional	O
33	processes	O
34	with	O
35	mammalian	B
36	receptors	I
37	.	O

1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	O
12	the	O
13	subjects	O
14	received	O
15	theophylline	O
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	O
48	7	O
49	days	O
50	.	O

1	The	O
2	rate	O
3	of	O
4	enzymic	O
5	stimulation	O
6	induced	O
7	by	O
8	a	O
9	given	O
10	nitrate	O
11	correlates	O
12	closely	O
13	with	O
14	the	O
15	rate	O
16	of	O
17	measured	O
18	NO	O
19	production	O
20	from	O
21	the	O
22	nitrate	O
23	molecule	O
24	.	O

1	Thus	O
2	,	O
3	multiple	O
4	myogenic	O
5	factors	O
6	that	O
7	vary	O
8	qualitatively	O
9	and	O
10	quantitatively	O
11	may	O
12	be	O
13	responsible	O
14	for	O
15	the	O
16	different	O
17	and	O
18	complex	O
19	modulatory	O
20	programs	O
21	of	O
22	actin	B
23	gene	I
24	expression	O
25	observed	O
26	during	O
27	in	O
28	vivo	O
29	muscle	O
30	differentiation	O
31	.	O

1	The	O
2	conserved	O
3	ninth	B
4	C	I
5	-	I
6	terminal	I
7	heptad	I
8	in	O
9	thyroid	O
10	hormone	O
11	and	O
12	retinoic	B
13	acid	I
14	receptors	I
15	mediates	O
16	diverse	O
17	responses	O
18	by	O
19	affecting	O
20	heterodimer	O
21	but	O
22	not	O
23	homodimer	O
24	formation	O
25	.	O

1	As	O
2	with	O
3	the	O
4	murine	O
5	and	O
6	human	B
7	mb	I
8	-	I
9	1	I
10	genes	I
11	,	O
12	the	O
13	5	O
14	'	O
15	region	O
16	of	O
17	the	O
18	bovine	B
19	mb	I
20	-	I
21	1	I
22	gene	I
23	lacked	O
24	a	O
25	TATA	O
26	box	O
27	.	O

1	Studies	O
2	of	O
3	lipoprotein	B
4	-	I
5	X	I
6	(	I
7	LP	I
8	-	I
9	X	I
10	)	O
11	and	O
12	bile	O
13	acids	O
14	in	O
15	familial	O
16	LCAT	O
17	deficiency	O
18	.	O

1	Feline	B
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	35	O
2	patients	O
3	with	O
4	acute	O
5	arterial	O
6	occlusions	O
7	[	O
8	27	O
9	]	O
10	and	O
11	graft	O
12	thromboses	O
13	[	O
14	8	O
15	],	O
16	responsible	O
17	for	O
18	severe	O
19	and	O
20	recent	O
21	ischemia	O
22	,	O
23	were	O
24	treated	O
25	by	O
26	fibrinolytic	O
27	therapy	O
28	(	O
29	Urokinase	O
30	:	O
31	1	O
32	000	O
33	units	O
34	/	O
35	kg	O
36	/	O
37	hour	O
38	,	O
39	and	O
40	Lys	O
41	Plasminogen	O
42	).	O

1	These	O
2	characteristic	O
3	structural	O
4	features	O
5	were	O
6	used	O
7	to	O
8	create	O
9	the	O
10	abbreviation	O
11	AZF1	O
12	(	O
13	Asparagine	B
14	-	I
15	rich	I
16	Zinc	I
17	Finger	I
18	protein	I
19	).	O

1	Use	O
2	of	O
3	Medi	O
4	-	O
5	Jector	O
6	EZ	O
7	dermojet	O
8	for	O
9	anesthesia	O
10	in	O
11	minor	O
12	surgery	O

1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	O
18	and	O
19	D4Mit147	O
20	in	O
21	both	O
22	progenies	O
23	.	O

1	A	I
2	system	O
3	is	O
4	described	O
5	in	O
6	which	O
7	the	O
8	volume	O
9	flow	O
10	rate	O
11	of	O
12	blood	O
13	in	O
14	a	O
15	vessel	O
16	is	O
17	determined	O
18	using	O
19	transverse	O
20	colour	O
21	Doppler	O
22	ultrasound	O
23	imaging	O
24	.	O

1	Cord	B
2	swelling	O
3	was	O
4	observed	O
5	in	O
6	2	O
7	patients	O
8	who	O
9	developed	O
10	complete	O
11	lesions	O
12	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	Intrastriatal	B
2	grafts	O
3	of	O
4	nigral	O
5	and	O
6	adrenal	O
7	tissues	O
8	have	O
9	been	O
10	found	O
11	to	O
12	be	O
13	effective	O
14	in	O
15	alleviating	O
16	many	O
17	of	O
18	the	O
19	simple	O
20	motor	O
21	and	O
22	sensorimotor	O
23	deficits	O
24	associated	O
25	with	O
26	lesions	O
27	of	O
28	the	O
29	nigrostriatal	O
30	dopamine	O
31	system	O
32	.	O

1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	B
8	-	I
9	adducin	I
10	isoform	I
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	NT	B
24	-	I
25	2	I
26	(	O
27	neuroepithelial	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O

1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O

1	Slowed	B
2	lysosomal	I
3	enzyme	I
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	The	O
2	MPS1	O
3	open	O
4	reading	O
5	frame	O
6	has	O
7	been	O
8	fused	O
9	to	O
10	those	O
11	that	O
12	encode	O
13	the	O
14	LexA	B
15	protein	I
16	or	O
17	the	O
18	GST	B
19	protein	I
20	and	O
21	both	O
22	of	O
23	these	O
24	constructs	O
25	function	O
26	in	O
27	yeast	O
28	.	O

1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O

1	Anti	B
2	-	O
3	PTB	B
4	antibodies	I
5	did	O
6	not	O
7	inhibit	O
8	the	O
9	binding	O
10	of	O
11	PTB	O
12	to	O
13	RNA	O
14	because	O
15	they	O
16	were	O
17	able	O
18	to	O
19	supershift	O
20	RNA	O
21	-	O
22	PTB	B
23	complexes	I
24	.	O

1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O

1	Expression	O
2	of	O
3	ME31B	O
4	cDNA	O
5	in	O
6	S	O
7	.	O
8	pombe	O
9	suppresses	O
10	the	O
11	ste13	O
12	mutation	O
13	.	O

1	Near	B
2	term	O
3	,	O
4	under	O
5	experimental	O
6	conditions	O
7	,	O
8	maternal	O
9	and	O
10	fetal	O
11	blood	O
12	gases	O
13	,	O
14	pH	O
15	,	O
16	uterine	O
17	and	O
18	umbilical	O
19	blood	O
20	flows	O
21	were	O
22	measured	O
23	or	O
24	calculated	O
25	.	O

1	We	O
2	have	O
3	found	O
4	out	O
5	that	O
6	one	O
7	-	O
8	year	O
9	-	O
10	old	O
11	carps	O
12	are	O
13	extremely	O
14	sensitive	O
15	to	O
16	ichthiomycin	O
17	in	O
18	concentrations	O
19	between	O
20	25	O
21	-	O
22	125	O
23	micrograms	O
24	/	O
25	dm3	O
26	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	B
27	-	I
28	3	I
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Interestingly	O
2	,	O
3	the	O
4	avirulent	O
5	strain	O
6	H37Ra	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	avirulent	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	opposed	O
36	to	O
37	those	O
38	in	O
39	the	O
40	virulent	O
41	strain	O
42	H37Rv	O
43	.	O

1	Also	O
2	,	O
3	the	O
4	deduced	O
5	amino	O
6	acids	O
7	of	O
8	the	O
9	antigenic	O
10	regions	O
11	A	O
12	,	O
13	B	O
14	and	O
15	C	O
16	of	O
17	VP7	O
18	were	O
19	nearly	O
20	conserved	O
21	within	O
22	the	O
23	phylogenetic	O
24	lineages	O
25	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	B
16	-	I
17	2	I
18	gene	I
19	transcription	I
20	.	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	O
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	Subcellular	B
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	O
9	and	O
10	the	O
11	CBFbeta	B
12	-	I
13	SMMHC	I
14	fusion	I
15	protein	I
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	B
27	-	I
28	type	I
29	or	O
30	fusion	O
31	protein	O
32	.	O

1	Reduced	B
2	NK	O
3	activity	O
4	correlates	O
5	with	O
6	active	O
7	disease	O
8	in	O
9	HIV	O
10	-	O
11	patients	O
12	with	O
13	multidrug	B
14	-	I
15	resistant	O
16	pulmonary	O
17	tuberculosis	O
18	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	O
13	.	O
14	5	O
15	-	O
16	kb	O
17	COR	O
18	segment	O
19	that	O
20	encompasses	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	B
28	,	O
29	UTR1	O
30	,	O
31	UTR3	O
32	,	O
33	OSM1	O
34	,	O
35	tRNA	O
36	(	O
37	Gly	O
38	)	O
39	and	O
40	RAD7	O
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O

1	3	I
2	)	O
3	and	O
4	one	O
5	distal	O
6	(-	O
7	11	O
8	.	O
9	8	O
10	/-	O
11	10	O
12	.	O
13	9	O
14	),	O
15	presented	O
16	an	O
17	enhancer	O
18	activity	O
19	in	O
20	pituitary	O
21	cells	O
22	when	O
23	placed	O
24	upstream	O
25	of	O
26	the	O
27	SV40	B
28	promoter	I
29	.	O

1	Laboratory	O
2	exam	O
3	:	O
4	IDR	O
5	of	O
6	the	O
7	tuberculin	O
8	was	O
9	high	O
10	positive	O
11	,	O
12	chest	O
13	radiography	O
14	shows	O
15	hilar	O
16	bilateral	O
17	calcifications	O
18	,	O
19	ORL	O
20	exam	O
21	shows	O
22	a	O
23	tumor	O
24	at	O
25	the	O
26	foot	O
27	of	O
28	the	O
29	epiglottis	O
30	and	O
31	anatomopathological	O
32	exam	O
33	shows	O
34	low	O
35	differentiated	O
36	epidermoid	O
37	carcinoma	O
38	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	Shh	O
6	can	O
7	drive	O
8	continued	O
9	cycling	O
10	in	O
11	immature	O
12	,	O
13	proliferating	O
14	CGNPs	O
15	.	O

1	These	O
2	results	O
3	suggested	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	fetus	O
9	played	O
10	some	O
11	role	O
12	in	O
13	the	O
14	production	O
15	of	O
16	E3	B
17	-	I
18	16	I
19	-	I
20	G	I
21	in	O
22	early	O
23	pregnancy	O
24	.	O

1	Ig	B
2	heavy	I
3	chain	I
4	class	I
5	switching	O
6	is	O
7	directed	O
8	by	O
9	cytokines	O
10	inducing	O
11	transcription	O
12	from	O
13	unrearranged	O
14	CH	O
15	genes	O
16	.	O

1	Inclusion	B
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	O
10	and	O
11	FliR	O
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O

1	Next	B
2	,	O
3	with	O
4	carcinoma	O
5	presenting	O
6	a	O
7	leather	O
8	bottle	O
9	(	O
10	linitis	O
11	plastica	O
12	type	O
13	)	O
14	of	O
15	the	O
16	stomach	O
17	itself	O
18	,	O
19	the	O
20	II	O
21	c	B
22	portion	O
23	of	O
24	the	O
25	stomach	O
26	consisted	O
27	of	O
28	fundic	O
29	glands	O
30	(	O
31	undifferentiated	O
32	carcinoma	O
33	)	O
34	shall	O
35	become	O
36	the	O
37	primary	O
38	focus	O
39	supporting	O
40	Nakamura	O
41	'	O
42	s	O
43	theory	O
44	.	O

1	Thirty	O
2	-	O
3	five	O
4	patients	O
5	were	O
6	included	O
7	.	O

1	We	O
2	present	O
3	the	O
4	preliminary	O
5	results	O
6	obtained	O
7	on	O
8	36	O
9	patients	O
10	which	O
11	were	O
12	followed	O
13	for	O
14	a	O
15	mean	O
16	period	O
17	of	O
18	12	O
19	months	O
20	.	O

1	Fibrinogen	B
2	determination	O
3	using	O
4	the	O
5	KZM	B
6	-	I
7	1	I
8	meter	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	O
7	/	O
8	mdr1b	B
9	gene	I
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	O
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	O
25	genes	O
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O

1	The	O
2	detectability	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	RCA	O
8	or	O
9	LAD	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O

1	Disorders	B
2	of	O
3	platelet	O
4	function	O
5	in	O
6	chronic	O
7	myeloid	O
8	leukemias	O

1	A	I
2	total	O
3	of	O
4	1459	O
5	men	O
6	aged	O
7	48	O
8	to	O
9	84	O
10	years	O
11	,	O
12	who	O
13	were	O
14	diagnosed	O
15	for	O
16	the	O
17	first	O
18	time	O
19	by	O
20	physicians	O
21	as	O
22	having	O
23	BPH	O
24	in	O
25	1994	O
26	and	O
27	who	O
28	had	O
29	not	O
30	received	O
31	treatment	O
32	,	O
33	participated	O
34	in	O
35	the	O
36	study	O
37	.	O

1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O

1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	Xaa	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	sequons	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O

1	A	I
2	full	I
3	-	I
4	length	I
5	cDNA	I
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	ANP	B
35	-	I
36	receptor	I
37	kinase	I
38	-	I
39	like	I
40	domain	I
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	B
50	-	I
51	serine	I
52	phosphatase	I
53	domain	I
54	.	O

1	Contrary	B
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	B
21	gene	I
22	transcript	I
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O

1	Rats	B
2	treated	O
3	with	O
4	8	O
5	-	O
6	OH	O
7	-	O
8	DPAT	O
9	were	O
10	not	O
11	impaired	O
12	in	O
13	their	O
14	ability	O
15	to	O
16	learn	O
17	a	O
18	visual	O
19	discrimination	O
20	in	O
21	a	O
22	water	O
23	maze	O
24	.	O

1	Isomers	B
2	were	O
3	differentiated	O
4	based	O
5	on	O
6	the	O
7	MS	O
8	-	O
9	MS	O
10	data	O
11	of	O
12	the	O
13	trofluoroacetyl	O
14	-	O
15	biphenylol	O
16	derivatives	O
17	.	O

1	These	O
2	introns	O
3	contain	O
4	only	O
5	single	O
6	snoRNA	O
7	genes	O
8	and	O
9	their	O
10	processing	O
11	involves	O
12	exonucleolytic	O
13	release	O
14	of	O
15	the	O
16	snoRNA	O
17	from	O
18	debranched	O
19	intron	O
20	lariats	O
21	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	O
16	IV	O
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O

1	Velocity	B
2	sedimentation	O
3	,	O
4	cross	O
5	-	O
6	linking	O
7	,	O
8	and	O
9	immunoprecipitation	O
10	analyses	O
11	of	O
12	detergent	O
13	-	O
14	solubilized	O
15	rat	O
16	brain	O
17	revealed	O
18	that	O
19	the	O
20	32	O
21	and	O
22	34	O
23	kDa	O
24	polypeptides	O
25	reside	O
26	within	O
27	heterotetramers	O
28	.	O

1	D5	B
2	/	I
3	D1	I
4	(	O
5	CT	O
6	)	O
7	or	O
8	D5	O
9	/	O
10	D1D	O
11	(	O
12	CT	O
13	)	O
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	B
29	-	I
30	type	I
31	(	O
32	wt	O
33	)	O
34	D1	O
35	receptors	O
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	O
56	D1	O
57	receptors	O
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	Transcription	O
2	factors	O
3	of	O
4	the	O
5	Stat	B
6	family	I
7	are	O
8	controlled	O
9	by	O
10	protein	B
11	kinases	I
12	.	O

1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	O
8	-	O
9	BP1	O
10	and	O
11	AT	O
12	-	O
13	BP2	O
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O

1	This	O
2	report	O
3	provides	O
4	further	O
5	evidence	O
6	for	O
7	the	O
8	riMLF	O
9	in	O
10	the	O
11	control	O
12	of	O
13	downgaze	O
14	,	O
15	and	O
16	a	O
17	synkinesis	O
18	is	O
19	postulated	O
20	for	O
21	the	O
22	development	O
23	of	O
24	the	O
25	convergence	O
26	retraction	O
27	nystagmus	O
28	.	O

1	Yang	B
2	and	O
3	H	O
4	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	HIR1	B
6	gene	I
7	predicts	O
8	an	O
9	88	O
10	-	O
11	kDa	O
12	protein	O
13	with	O
14	three	O
15	repeats	O
16	of	O
17	a	O
18	motif	O
19	found	O
20	in	O
21	the	O
22	G	B
23	beta	I
24	subunit	I
25	of	O
26	retinal	O
27	transducin	O
28	and	O
29	in	O
30	a	O
31	yeast	O
32	transcriptional	O
33	repressor	O
34	,	O
35	Tup1	O
36	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	cDNA	O
8	,	O
9	CHEMR1	O
10	,	O
11	encoding	O
12	a	O
13	chemokine	B
14	receptor	I
15	with	O
16	a	O
17	homology	O
18	to	O
19	the	O
20	human	B
21	C	I
22	-	I
23	C	I
24	chemokine	I
25	receptor	I
26	,	O
27	CCR	O
28	-	O
29	4	O
30	.	O

1	The	O
2	imprinted	O
3	expression	O
4	of	O
5	the	O
6	endogenous	B
7	gene	I
8	can	O
9	be	O
10	recapitulated	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	transgene	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	endoderm	O
42	-	O
43	specific	O
44	enhancers	O
45	,	O
46	and	O
47	an	O
48	internally	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O

1	In	O
2	the	O
3	former	O
4	cells	O
5	,	O
6	ets	B
7	-	I
8	2	I
9	was	O
10	a	O
11	CSF	B
12	-	I
13	1	I
14	immediate	I
15	-	I
16	early	I
17	response	I
18	gene	I
19	,	O
20	and	O
21	phosphorylated	O
22	ets	B
23	-	I
24	2	I
25	was	O
26	detected	O
27	after	O
28	2	O
29	to	O
30	4	O
31	h	O
32	,	O
33	coincident	O
34	with	O
35	expression	O
36	of	O
37	ets	B
38	-	I
39	2	I
40	protein	I
41	.	O

1	Type	B
2	II	I
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	IIA	O
12	and	O
13	IIB	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	underscribed	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O

1	USA	B
2	80	O
3	,	O
4	3618	O
5	-	O
6	3622	O
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	Sensitivity	B
2	and	O
3	specificity	O
4	was	O
5	established	O
6	for	O
7	the	O
8	Pharmacia	O
9	CAP	O
10	System	O
11	and	O
12	the	O
13	DPC	O
14	AlaSTAT	O
15	System	O
16	by	O
17	comparison	O
18	with	O
19	results	O
20	of	O
21	the	O
22	skin	O
23	prick	O
24	test	O
25	.	O

1	Cardiac	B
2	preservation	O
3	.	O

1	The	O
2	promoter	O
3	activity	O
4	was	O
5	measured	O
6	by	O
7	a	O
8	transient	O
9	expression	O
10	of	O
11	a	O
12	chloramphenicol	B
13	acetyltransferase	I
14	(	O
15	CAT	B
16	)	I
17	gene	I
18	connected	O
19	with	O
20	various	O
21	5	O
22	'-	O
23	deletion	O
24	mutants	O
25	of	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	.	O

1	We	O
2	inserted	O
3	genes	O
4	or	O
5	gene	O
6	segments	O
7	,	O
8	that	O
9	code	O
10	for	O
11	the	O
12	bacterial	O
13	chloramphenicol	B
14	acetyltransferase	I
15	,	O
16	the	O
17	bacterial	B
18	gene	I
19	conferring	O
20	resistance	O
21	against	O
22	hygromycin	O
23	,	O
24	and	O
25	the	O
26	ORF	O
27	E7	B
28	of	O
29	the	O
30	human	B
31	papillomavirus	I
32	type	I
33	18	O
34	into	O
35	these	O
36	vectors	O
37	.	O

1	Eleven	B
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	O
15	.	O
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	Studies	O
6	were	O
7	undertaken	O
8	in	O
9	9	O
10	isolated	O
11	guinea	O
12	pig	O
13	hearts	O
14	,	O
15	which	O
16	demonstrated	O
17	reverse	O
18	use	O
19	-	O
20	dependent	O
21	prolongation	O
22	of	O
23	cardiac	O
24	repolarization	O
25	by	O
26	100	O
27	nmol	O
28	/	O
29	L	O
30	domperidone	O
31	.	O

1	Using	O
2	appropriate	O
3	synthetic	O
4	HSE	O
5	oligonucleotides	O
6	,	O
7	three	O
8	types	O
9	of	O
10	clones	O
11	with	O
12	potential	O
13	HSE	O
14	binding	O
15	domains	O
16	were	O
17	isolated	O
18	from	O
19	a	O
20	tomato	O
21	lambda	O
22	gt11	O
23	expression	O
24	library	O
25	by	O
26	DNA	O
27	-	O
28	ligand	O
29	screening	O
30	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	Randomised	B
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	O
26	10	O
27	trial	O
28	.	O

1	Resting	B
2	VE	O
3	in	O
4	the	O
5	luteal	O
6	phase	O
7	was	O
8	7	O
9	.	O
10	8	O
11	%	O
12	greater	O
13	than	O
14	that	O
15	in	O
16	the	O
17	follicular	O
18	phase	O
19	.	O

1	Cutis	B
2	aplasia	O
3	.	O

1	Blood	O
2	pressure	O
3	also	O
4	was	O
5	increased	O
6	by	O
7	lidocaine	O
8	(	O
9	6	O
10	mg	O
11	kg	O
12	-	O
13	1	O
14	).	O

1	MAIN	B
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Associations	O
6	of	O
7	factor	O
8	analysis	O
9	-	O
10	derived	O
11	syndromes	O
12	with	O
13	risk	O
14	factors	O
15	for	O
16	chemical	O
17	interactions	O
18	that	O
19	inhibit	O
20	butyrylcholinesterase	O
21	and	O
22	neuropathy	O
23	target	O
24	esterase	B
25	.	O

1	Deletion	O
2	from	O
3	either	O
4	the	O
5	N	O
6	-	O
7	or	O
8	C	O
9	-	O
10	terminal	O
11	ends	O
12	of	O
13	repA	O
14	(	O
15	28	O
16	and	O
17	69	O
18	codons	O
19	,	O
20	respectively	O
21	,	O
22	out	O
23	of	O
24	the	O
25	286	O
26	-	O
27	codon	O
28	open	O
29	reading	O
30	frame	O
31	)	O
32	affected	O
33	the	O
34	initiator	O
35	but	O
36	not	O
37	the	O
38	inhibitory	O
39	activity	O
40	.	O

1	A	I
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	B
20	type	I
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	B
27	antigen	I
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	O
35	specific	O
36	IgE	B
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	B
57	antigen	I
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	O
72	specific	O
73	IgG	B
74	.	O

1	In	O
2	each	O
3	compartment	O
4	O2	O
5	is	O
6	removed	O
7	by	O
8	the	O
9	tissues	O
10	as	O
11	a	O
12	chemical	O
13	reaction	O
14	takes	O
15	place	O
16	between	O
17	O2	O
18	and	O
19	oxyhemoglobin	O
20	(	O
21	HbO2	O
22	).	O

1	Two	O
2	overlapping	O
3	clones	O
4	contained	O
5	the	O
6	complete	O
7	Adh	B
8	-	I
9	2	I
10	gene	I
11	composed	O
12	of	O
13	nine	O
14	exons	O
15	in	O
16	a	O
17	12	O
18	-	O
19	kb	O
20	region	O
21	,	O
22	with	O
23	the	O
24	placement	O
25	of	O
26	introns	O
27	matching	O
28	that	O
29	observed	O
30	in	O
31	other	O
32	mammalian	B
33	ADH	I
34	genes	I
35	.	O

1	Specific	O
2	class	B
3	I	I
4	and	I
5	II	I
6	histone	I
7	deacetylases	O
8	(	O
9	HDACs	O
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	O
16	,	O
17	suggesting	O
18	that	O
19	BCoR	O
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	O
28	.	O

1	The	O
2	background	O
3	processes	O
4	depending	O
5	on	O
6	the	O
7	etiological	B
8	factor	I
9	and	O
10	the	O
11	character	O
12	of	O
13	lesion	O
14	of	O
15	the	O
16	epithelium	O
17	are	O
18	divided	O
19	into	O
20	dyshormonal	O
21	,	O
22	inflammatory	O
23	,	O
24	and	O
25	posttraumatic	O
26	.	O

1	Erythrocyte	B
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	In	O
2	both	O
3	these	O
4	respects	O
5	,	O
6	however	O
7	,	O
8	the	O
9	DBP	O
10	mRNA	O
11	resembles	O
12	the	O
13	late	O
14	messengers	O
15	of	O
16	SV40	O
17	and	O
18	polyoma	O
19	viruses	O
20	.	O

1	We	O
2	find	O
3	that	O
4	beta	B
5	II	I
6	PKC	I
7	phosphorylates	O
8	nuclear	B
9	envelope	I
10	lamin	I
11	B	I
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	O
21	PKC	B
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	O
28	lamin	O
29	B	O
30	at	O
31	similar	O
32	rates	O
33	.	O

1	Oxfendazole	B
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	Electronic	B
2	data	O
3	processing	O
4	(	O
5	EDP	O
6	)	O
7	latex	O
8	immunoassay	O
9	using	O
10	anti	B
11	-	I
12	human	I
13	seminal	I
14	acid	I
15	phosphatase	I
16	(	I
17	anti	I
18	-	I
19	HSAP	O
20	)	O
21	immune	O
22	serum	O
23	was	O
24	applied	O
25	for	O
26	the	O
27	species	O
28	and	O
29	organ	O
30	identification	O
31	of	O
32	human	O
33	seminal	O
34	stains	O
35	.	O

1	Cells	B
2	respond	O
3	to	O
4	the	O
5	accumulation	O
6	of	O
7	unfolded	O
8	proteins	O
9	in	O
10	the	O
11	endoplasmic	O
12	reticulum	O
13	(	O
14	ER	O
15	)	O
16	by	O
17	increasing	O
18	the	O
19	transcription	O
20	of	O
21	the	O
22	genes	O
23	encoding	O
24	ER	B
25	-	I
26	resident	I
27	chaperone	I
28	proteins	I
29	.	O

1	The	O
2	hit1	B
3	-	I
4	1	I
5	mutation	I
6	caused	O
7	a	O
8	defect	O
9	in	O
10	synthesis	O
11	of	O
12	a	O
13	74	O
14	-	O
15	kD	O
16	heat	B
17	shock	I
18	protein	I
19	.	O

1	Chronic	O
2	renal	O
3	failure	O
4	patients	O
5	essentially	O
6	die	O
7	from	O
8	cardiovascular	O
9	causes	O
10	,	O
11	and	O
12	the	O
13	frequency	O
14	of	O
15	malignant	O
16	disease	O
17	responsible	O
18	for	O
19	death	O
20	is	O
21	estimated	O
22	to	O
23	be	O
24	10	O
25	%.	O

1	This	O
2	suggests	O
3	that	O
4	while	O
5	underpredictions	O
6	of	O
7	pain	O
8	do	O
9	not	O
10	hurt	O
11	more	O
12	,	O
13	disruption	O
14	on	O
15	primary	O
16	tasks	O
17	and	O
18	physiological	O
19	impact	O
20	are	O
21	higher	O
22	.	O

1	The	O
2	predicted	O
3	Pay4p	O
4	sequence	O
5	contains	O
6	two	O
7	putative	O
8	ATP	B
9	-	I
10	binding	I
11	domains	I
12	and	O
13	shows	O
14	structural	O
15	relationships	O
16	to	O
17	other	O
18	potential	O
19	ATP	B
20	-	I
21	binding	I
22	proteins	I
23	involved	O
24	in	O
25	biological	O
26	processes	O
27	as	O
28	diverse	O
29	as	O
30	peroxisome	O
31	biogenesis	O
32	,	O
33	vesicle	O
34	-	O
35	mediated	O
36	protein	O
37	transport	O
38	,	O
39	cell	O
40	cycle	O
41	control	O
42	,	O
43	and	O
44	transcriptional	O
45	regulation	O
46	.	O

1	Using	O
2	a	O
3	degenerate	O
4	oligodeoxyribonucleotide	O
5	(	O
6	oligo	O
7	)	O
8	based	O
9	on	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	aa	O
15	sequence	O
16	,	O
17	plus	O
18	an	O
19	internal	O
20	oligo	O
21	homologous	O
22	to	O
23	a	O
24	conserved	O
25	region	O
26	within	O
27	the	O
28	portion	O
29	of	O
30	CYP1	O
31	and	O
32	CYP2	O
33	that	O
34	had	O
35	been	O
36	deleted	O
37	in	O
38	the	O
39	genome	O
40	,	O
41	a	O
42	CYP3	B
43	-	I
44	specific	I
45	DNA	I
46	fragment	I
47	was	O
48	generated	O
49	by	O
50	the	O
51	polymerase	O
52	chain	O
53	reaction	O
54	(	O
55	PCR	O
56	)	O
57	using	O
58	GL81	O
59	genomic	O
60	DNA	O
61	as	O
62	a	O
63	substrate	O
64	.	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	O
13	,	O
14	but	O
15	activated	O
16	TC21	O
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	I
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	O
37	deoxynucleotidyltransferase	O
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	Transcription	O
2	from	O
3	the	O
4	promoter	O
5	containing	O
6	the	O
7	mutated	O
8	direct	O
9	repeats	O
10	was	O
11	increased	O
12	greatly	O
13	,	O
14	consistent	O
15	with	O
16	the	O
17	conclusion	O
18	that	O
19	these	O
20	motifs	O
21	functions	O
22	in	O
23	vivo	O
24	to	O
25	repress	O
26	GPT	B
27	gene	I
28	expression	O
29	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	interaction	O
6	between	O
7	Jak2	O
8	and	O
9	PRLR	O
10	requires	O
11	a	O
12	proline	O
13	-	O
14	rich	O
15	sequence	O
16	in	O
17	the	O
18	membrane	O
19	proximal	O
20	region	O
21	of	O
22	the	O
23	receptor	O
24	,	O
25	which	O
26	is	O
27	conserved	O
28	among	O
29	the	O
30	different	O
31	members	O
32	of	O
33	the	O
34	cytokine	O
35	receptor	B
36	superfamily	I
37	.	O

1	The	O
2	customary	O
3	coupling	O
4	reagent	O
5	sulfanilic	O
6	acid	O
7	has	O
8	been	O
9	replaced	O
10	by	O
11	1	O
12	,	O
13	3	O
14	-	O
15	dimethylbarbituric	O
16	acid	O
17	;	O
18	CNCl	O
19	is	O
20	produced	O
21	in	O
22	the	O
23	flow	O
24	through	O
25	system	O
26	directly	O
27	from	O
28	KCN	O
29	and	O
30	chloramine	O
31	T	O
32	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	Seventeen	B
2	of	O
3	the	O
4	35	O
5	patients	O
6	were	O
7	randomly	O
8	chosen	O
9	to	O
10	receive	O
11	a	O
12	training	O
13	program	O
14	(	O
15	lasting	O
16	approximately	O
17	1	O
18	month	O
19	)	O
20	designed	O
21	to	O
22	establish	O
23	a	O
24	systematic	O
25	strategy	O
26	of	O
27	organizing	O
28	complex	O
29	visual	O
30	material	O
31	.	O

1	Gap1	B
2	(	O
3	IP4BP	O
4	),	O
5	one	O
6	of	O
7	a	O
8	member	O
9	of	O
10	Ras	B
11	GTPase	I
12	-	I
13	activating	I
14	proteins	I
15	,	O
16	has	O
17	been	O
18	identified	O
19	as	O
20	a	O
21	specific	O
22	inositol	O
23	1	O
24	,	O
25	3	O
26	,	O
27	4	O
28	,	O
29	5	O
30	-	O
31	tetrakisphosphate	O
32	(	O
33	IP4	B
34	)-	I
35	binding	I
36	protein	I
37	(	O
38	Cullen	O
39	,	O
40	P	O
41	.	O

1	We	O
2	further	O
3	studied	O
4	the	O
5	effects	O
6	of	O
7	SIE	B
8	-	I
9	1	I
10	hypermethylation	O
11	on	O
12	p21WAF1	O
13	induction	O
14	by	O
15	STAT	B
16	activation	O
17	.	O

1	SBF	B
2	binds	O
3	to	O
4	the	O
5	promoter	O
6	prior	O
7	to	O
8	the	O
9	activation	O
10	of	O
11	transcription	O
12	in	O
13	late	O
14	G1	O
15	,	O
16	suggesting	O
17	that	O
18	Cln	O
19	/	O
20	Cdc28	B
21	kinase	I
22	regulates	O
23	the	O
24	ability	O
25	of	O
26	previously	O
27	bound	O
28	SBF	O
29	to	O
30	activate	O
31	transcription	O
32	.	O

1	Carboxy	B
2	-	I
3	terminal	I
4	Spc110p	O
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	I
10	site	I
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	O
5	/	O
6	RXRalpha	O
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	B
12	-	I
13	PPRE	I
14	luciferase	I
15	reporter	I
16	construct	I
17	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	O
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	I
21	ERRalpha1	I
22	fusion	I
23	protein	I
24	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	B
26	product	I
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	D3S1261	B
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	O
10	locus	O
11	,	O
12	while	O
13	D3S2465	O
14	and	O
15	D3S1766	O
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O

1	Replacement	B
2	of	O
3	the	O
4	spacer	O
5	sequence	O
6	between	O
7	the	O
8	two	O
9	ARMs	O
10	with	O
11	a	O
12	shorter	O
13	stretch	O
14	of	O
15	sequence	O
16	also	O
17	reduced	O
18	RNA	O
19	binding	O
20	in	O
21	vitro	O
22	.	O

1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O

1	At	O
2	physiological	O
3	doses	O
4	,	O
5	either	O
6	insulin	B
7	-	I
8	like	I
9	growth	I
10	factor	I
11	I	I
12	(	I
13	IGF	I
14	-	I
15	I	I
16	)	O
17	or	O
18	insulin	B
19	turned	O
20	out	O
21	to	O
22	be	O
23	as	O
24	potent	O
25	as	O
26	dibutyryl	O
27	cAMP	O
28	(	O
29	dbcAMP	O
30	)	O
31	in	O
32	increasing	O
33	UCP1	B
34	gene	I
35	transcription	I
36	rate	O
37	(	O
38	1	O
39	h	O
40	)	O
41	and	O
42	also	O
43	UCP1	O
44	mRNA	O
45	accumulation	O
46	(	O
47	3	O
48	h	O
49	),	O
50	their	O
51	maximal	O
52	effect	O
53	(	O
54	15	O
55	-	O
56	fold	O
57	increase	O
58	)	O
59	reached	O
60	upon	O
61	treatment	O
62	for	O
63	24	O
64	h	O
65	.	O

1	Two	O
2	scintigraphic	O
3	methods	O
4	,	O
5	resting	O
6	dipyridamole	O
7	and	O
8	exercise	O
9	thallium	O
10	-	O
11	201	O
12	myocardial	O
13	perfusion	O
14	imaging	O
15	,	O
16	to	O
17	detect	O
18	and	O
19	localize	O
20	coronary	O
21	artery	O
22	stenosis	O
23	were	O
24	compared	O
25	in	O
26	32	O
27	patients	O
28	suffering	O
29	from	O
30	coronary	O
31	artery	O
32	disease	O
33	.	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O

1	HA	B
2	resulted	O
3	in	O
4	decreased	O
5	(	O
6	p	O
7	less	O
8	than	O
9	0	O
10	.	O
11	05	O
12	)	O
13	Tre	O
14	(	O
15	0	O
16	.	O
17	4	O
18	degrees	O
19	C	O
20	)	O
21	and	O
22	HR	O
23	(	O
24	17	O
25	b	O
26	X	O
27	min	O
28	-	O
29	1	O
30	),	O
31	and	O
32	increased	O
33	(	O
34	p	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	)	O
41	Msw	O
42	(	O
43	16	O
44	g	O
45	X	O
46	m	B
47	-	I
48	2	I
49	X	I
50	h	O
51	-	O
52	1	O
53	)	O
54	during	O
55	the	O
56	saline	O
57	experiments	O
58	.	O

1	A	I
2	comparative	O
3	study	O
4	of	O
5	the	O
6	cortical	O
7	end	O
8	of	O
9	the	O
10	auditory	O
11	analyzer	O
12	during	O
13	postnatal	O
14	ontogenesis	O
15	in	O
16	lower	O
17	monkeys	O
18	and	O
19	man	O

1	Outcome	B
2	of	O
3	severe	O
4	congenital	O
5	hypothyroidism	O
6	.	O

1	For	O
2	comparison	O
3	conventional	O
4	heparin	O
5	was	O
6	used	O
7	during	O
8	18	O
9	dialyses	O
10	in	O
11	the	O
12	same	O
13	patients	O
14	.	O

1	Definite	B
2	JPsA	O
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	O
16	coincident	O
17	,	O
18	with	O
19	a	O
20	typical	O
21	psoriatic	O
22	rash	O
23	,	O
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O

1	The	O
2	first	O
3	exon	O
4	encodes	O
5	66	O
6	bp	O
7	of	O
8	the	O
9	5	O
10	'-	O
11	untranslated	O
12	sequence	O
13	,	O
14	while	O
15	exon	O
16	2	O
17	encodes	O
18	the	O
19	coding	O
20	and	O
21	3	O
22	'-	O
23	untranslated	O
24	sequences	O
25	.	O

1	Mutagenesis	B
2	of	O
3	the	O
4	CDE	O
5	/	O
6	CHR	O
7	elements	O
8	and	O
9	Sp1	B
10	sites	I
11	in	O
12	this	O
13	region	O
14	,	O
15	alone	O
16	or	O
17	in	O
18	combination	O
19	,	O
20	reduced	O
21	transcriptional	O
22	activity	O
23	by	O
24	40	O
25	-	O
26	60	O
27	%	O
28	in	O
29	asynchronously	O
30	growing	O
31	cells	O
32	and	O
33	abolished	O
34	cell	O
35	cycle	O
36	periodicity	O
37	in	O
38	G2	B
39	-	I
40	M	I
41	-	I
42	synchronized	O
43	cells	O
44	.	O

1	This	O
2	information	O
3	,	O
4	together	O
5	with	O
6	estimation	O
7	of	O
8	the	O
9	size	O
10	of	O
11	the	O
12	deglycosylated	B
13	A	I
14	subunit	I
15	relative	O
16	to	O
17	a	O
18	series	O
19	of	O
20	C	B
21	-	I
22	terminal	I
23	truncated	I
24	TSHR	O
25	ectodomain	O
26	variants	O
27	,	O
28	places	O
29	cleavage	O
30	Site	O
31	1	O
32	in	O
33	the	O
34	vicinity	O
35	of	O
36	,	O
37	or	O
38	closely	O
39	upstream	O
40	to	O
41	,	O
42	residue	O
43	317	O
44	.	O

1	Our	O
2	study	O
3	was	O
4	addressed	O
5	to	O
6	the	O
7	synthesis	O
8	of	O
9	some	O
10	derivatives	O
11	of	O
12	this	O
13	sequence	O
14	in	O
15	order	O
16	to	O
17	obtain	O
18	both	O
19	peptide	O
20	substrates	O
21	suitable	O
22	for	O
23	the	O
24	detection	O
25	of	O
26	the	O
27	Src	B
28	-	I
29	like	I
30	tyrosine	I
31	kinase	I
32	activity	O
33	and	O
34	active	O
35	site	O
36	-	O
37	directed	O
38	inhibitors	O
39	specific	O
40	for	O
41	this	O
42	class	O
43	of	O
44	enzymes	O
45	.	O

1	PURPOSE	O
2	/	O
3	OBJECTIVES	O
4	:	O
5	To	O
6	examine	O
7	the	O
8	question	O
9	of	O
10	whether	O
11	an	O
12	early	O
13	first	O
14	full	O
15	-	O
16	term	O
17	pregnancy	O
18	(	O
19	FFTP	O
20	)	O
21	protects	O
22	against	O
23	breast	O
24	cancer	O
25	and	O
26	whether	O
27	interruption	O
28	of	O
29	the	O
30	pregnancy	O
31	with	O
32	an	O
33	induced	O
34	abortion	O
35	increases	O
36	breast	O
37	cancer	O
38	risk	O
39	.	O

1	Cutaneous	B
2	necrosis	I
3	associated	I
4	with	O
5	protein	O
6	S	O
7	deficiency	O
8	.	O

1	Infectious	B
2	mutant	I
3	virus	I
4	progeny	O
5	was	O
6	obtained	O
7	only	O
8	on	O
9	complementing	O
10	gK	O
11	-	O
12	expressing	O
13	cells	O
14	,	O
15	suggesting	O
16	that	O
17	gK	O
18	has	O
19	an	O
20	important	O
21	function	O
22	in	O
23	the	O
24	replication	O
25	cycle	O
26	.	O

1	Using	O
2	site	O
3	-	O
4	directed	O
5	mutagenesis	O
6	,	O
7	we	O
8	show	O
9	that	O
10	the	O
11	RAREoct	O
12	contributes	O
13	to	O
14	the	O
15	transcriptional	O
16	activation	O
17	of	O
18	Oct	B
19	-	I
20	3	I
21	/	I
22	4	I
23	promoter	I
24	in	O
25	P19	O
26	cells	O
27	and	O
28	,	O
29	most	O
30	interestingly	O
31	,	O
32	mediates	O
33	the	O
34	RA	O
35	-	O
36	induced	O
37	repression	O
38	in	O
39	RA	O
40	-	O
41	differentiated	O
42	EC	B
43	cells	O
44	.	O

1	Deep	B
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	cDNA	I
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	O
18	eIF	B
19	-(	O
20	iso	O
21	)	O
22	4F	O
23	and	O
24	mammalian	B
25	eIF	I
26	-	I
27	4G	O
28	.	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	B
33	)	I
34	binding	I
35	proteins	I
36	of	O
37	the	O
38	alpha	B
39	-	I
40	complex	I
41	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	B
17	gene	I
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	B
29	-	I
30	chain	I
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O

1	The	O
2	goal	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	identify	O
9	neuronal	O
10	cell	O
11	cultures	O
12	that	O
13	express	O
14	RC3	O
15	/	O
16	neurogranin	O
17	,	O
18	to	O
19	check	O
20	whether	O
21	they	O
22	are	O
23	sensitive	O
24	to	O
25	T3	O
26	,	O
27	and	O
28	to	O
29	examine	O
30	the	O
31	mechanism	O
32	of	O
33	regulation	O
34	.	O

1	Intron	I
2	K1	O
3	cox1	O
4	.	O
5	2	O
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O

1	Thyrotropin	B
2	-	I
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	B
11	protein	I
12	related	I
13	to	O
14	the	O
15	trk	B
16	oncogene	I
17	.	O

1	Using	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	DNA	I
7	binding	I
8	assays	O
9	,	O
10	a	O
11	series	O
12	of	O
13	overlapping	O
14	alpha	B
15	promoter	I
16	DNA	O
17	sequences	O
18	between	O
19	-	O
20	170	O
21	to	O
22	29	O
23	basepairs	O
24	were	O
25	tested	O
26	,	O
27	but	O
28	each	O
29	failed	O
30	to	O
31	bind	O
32	GR	B
33	,	O
34	whereas	O
35	a	O
36	control	O
37	GRE	O
38	avidly	O
39	bound	O
40	receptor	O
41	.	O

1	In	O
2	10	O
3	control	O
4	sheep	O
5	mean	O
6	plasma	O
7	TXB2	O
8	concentration	O
9	increased	O
10	from	O
11	0	O
12	.	O
13	39	O
14	ng	O
15	/	O
16	ml	O
17	prebypass	O
18	to	O
19	about	O
20	1	O
21	.	O
22	1	O
23	ng	O
24	/	O
25	ml	O
26	at	O
27	8	O
28	and	O
29	16	O
30	min	O
31	of	O
32	bypass	O
33	.	O

1	A	I
2	Bub2p	I
3	-	I
4	dependent	I
5	spindle	I
6	checkpoint	I
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	B
11	kinase	I
12	in	O
13	budding	O
14	yeast	O
15	.	O

1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O

1	A	I
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O

1	CONCLUSIONS	O
2	:	O
3	Two	O
4	consecutive	O
5	sets	O
6	of	O
7	transrectal	O
8	ultrasound	O
9	guided	O
10	sextant	O
11	biopsies	O
12	of	O
13	the	O
14	prostate	O
15	performed	O
16	in	O
17	a	O
18	single	O
19	office	O
20	visit	O
21	represent	O
22	a	O
23	cost	O
24	-	O
25	effective	O
26	biopsy	O
27	strategy	O
28	for	O
29	men	O
30	presenting	O
31	with	O
32	an	O
33	abnormal	O
34	digital	O
35	rectal	O
36	examination	O
37	and	O
38	/	O
39	or	O
40	elevated	O
41	serum	B
42	PSA	I
43	.	O

1	No	O
2	differences	O
3	in	O
4	fixation	O
5	quality	O
6	were	O
7	observed	O
8	between	O
9	cochleas	O
10	fixed	O
11	by	O
12	intravascular	O
13	perfusion	O
14	and	O
15	cochleas	O
16	fixed	O
17	by	O
18	intralabyrinthine	O
19	perfusion	O
20	.	O

1	Clinical	O
2	research	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	post	O
12	-	O
13	transfusion	O
14	hepatitis	O

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	B
6	tRNA	I
7	3	I
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	O
19	activities	O
20	are	O
21	different	O
22	enzymes	O
23	.	O

1	Sequences	B
2	needed	O
3	for	O
4	iron	O
5	-	O
6	regulated	O
7	expression	O
8	of	O
9	sid1	O
10	were	O
11	localized	O
12	to	O
13	a	O
14	306	O
15	bp	O
16	region	O
17	mapping	O
18	2	O
19	.	O
20	3	O
21	and	O
22	2	O
23	.	O
24	6	O
25	kb	O
26	upstream	O
27	of	O
28	the	O
29	ATG	O
30	.	O

1	Thus	O
2	,	O
3	included	O
4	in	O
5	the	O
6	KG1a	O
7	EST	O
8	dataset	O
9	are	O
10	candidates	O
11	for	O
12	new	O
13	human	B
14	genes	I
15	that	O
16	may	O
17	play	O
18	roles	O
19	in	O
20	hematopoietic	O
21	differentiative	O
22	progression	O
23	and	O
24	lineage	O
25	commitment	O
26	.	O

1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	a	O
6	)	O
7	the	O
8	likelihood	O
9	of	O
10	detecting	O
11	carcinoma	O
12	or	O
13	atypical	O
14	hyperplasia	O
15	exclusively	O
16	in	O
17	the	O
18	adipose	O
19	tissue	O
20	component	O
21	of	O
22	grossly	O
23	benign	O
24	breast	O
25	biopsies	O
26	is	O
27	extremely	O
28	low	O
29	,	O
30	and	O
31	(	O
32	b	O
33	)	O
34	a	O
35	possible	O
36	cost	O
37	-	O
38	effective	O
39	method	O
40	of	O
41	sampling	O
42	grossly	O
43	benign	O
44	breast	O
45	biopsies	O
46	consists	O
47	of	O
48	initially	O
49	submitting	O
50	a	O
51	maximum	O
52	of	O
53	10	O
54	blocks	O
55	of	O
56	fibrous	O
57	parenchyma	O
58	for	O
59	each	O
60	case	O
61	,	O
62	then	O
63	examining	O
64	the	O
65	remaining	O
66	tissue	O
67	histologically	O
68	only	O
69	if	O
70	carcinoma	O
71	or	O
72	atypical	O
73	hyperplasia	O
74	is	O
75	found	O
76	among	O
77	these	O
78	blocks	O
79	.	O

1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	I
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O

1	Transcriptional	O
2	repression	O
3	mediated	O
4	by	O
5	LysR	B
6	-	I
7	type	I
8	regulator	I
9	CatR	O
10	bound	O
11	at	O
12	multiple	O
13	binding	O
14	sites	O
15	.	O

1	By	O
2	using	O
3	lambda	O
4	gt11	O
5	expression	O
6	cloning	O
7	with	O
8	oligonucleotides	O
9	corresponding	O
10	to	O
11	the	O
12	human	B
13	immunodeficiency	I
14	virus	I
15	1	I
16	TATA	I
17	element	I
18	,	O
19	we	O
20	report	O
21	the	O
22	identification	O
23	of	O
24	a	O
25	cellular	O
26	protein	O
27	with	O
28	a	O
29	calculated	O
30	molecular	O
31	mass	O
32	of	O
33	123	O
34	kDa	O
35	that	O
36	we	O
37	designate	O
38	TATA	B
39	element	I
40	modulatory	I
41	factor	I
42	(	O
43	TMF	O
44	).	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	O
14	IL	B
15	-	I
16	6	I
17	gene	I
18	promoter	I
19	coupled	I
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	O
32	.	O

1	Lack	B
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O

1	188	B
2	patients	O
3	received	O
4	cimetidine	O
5	400	O
6	mg	O
7	q	O
8	.	O
9	i	O
10	.	O
11	d	O
12	.	O
13	intravenously	O
14	and	O
15	1	O
16	,	O
17	000	O
18	mg	O
19	daily	O
20	orally	O
21	in	O
22	divided	O
23	doses	O
24	.	O

1	In	O
2	Experiments	O
3	1	O
4	and	O
5	2	O
6	,	O
7	infants	O
8	,	O
9	like	O
10	adults	O
11	,	O
12	initially	O
13	categorized	O
14	novel	O
15	objects	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	physical	O
21	appearance	O
22	,	O
23	but	O
24	only	O
25	if	O
26	trained	O
27	with	O
28	multiple	O
29	exemplars	O
30	,	O
31	after	O
32	delays	O
33	of	O
34	1	O
35	and	O
36	7	O
37	days	O
38	.	O

1	Immunohistochemical	B
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O

1	Hepatitis	B
2	-	I
3	B	I
4	vaccination	O
5	in	O
6	the	O
7	elderly	O
8	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	I
8	IGF	I
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	Recombinant	B
2	AROM	I
3	-	I
4	p64	O
5	displayed	O
6	high	O
7	binding	O
8	to	O
9	single	O
10	-	O
11	stranded	O
12	DNA	O
13	and	O
14	poly	O
15	(	O
16	A	O
17	)	O
18	homopolymers	O
19	suggesting	O
20	that	O
21	this	O
22	protein	O
23	could	O
24	play	O
25	a	O
26	role	O
27	in	O
28	mRNA	O
29	maturation	O
30	/	O
31	metabolism	O
32	.	O

1	Documentation	B
2	of	O
3	a	O
4	successful	O
5	intrauterine	O
6	fertilization	O
7	with	O
8	delivery	O
9	of	O
10	a	O
11	term	O
12	baby	O
13	supports	O
14	the	O
15	theoretical	O
16	feasibility	O
17	of	O
18	the	O
19	EP	O
20	;	O
21	however	O
22	,	O
23	anovulation	O
24	incurred	O
25	by	O
26	our	O
27	procedure	O
28	appears	O
29	to	O
30	be	O
31	the	O
32	major	O
33	drawback	O
34	.	O

1	Inspired	B
2	CO2	O
3	causing	O
4	changes	O
5	from	O
6	hypo	O
7	-	O
8	to	O
9	normocapnia	O
10	has	O
11	previously	O
12	been	O
13	shown	O
14	to	O
15	improve	O
16	arterial	O
17	O2	O
18	tension	O
19	(	O
20	PaO2	O
21	)	O
22	and	O
23	to	O
24	reduce	O
25	alveolar	O
26	-	O
27	arterial	O
28	O2	O
29	difference	O
30	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O

1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O

1	Normal	B
2	values	O
3	for	O
4	the	O
5	peripheral	O
6	blood	O
7	and	O
8	bone	O
9	marrow	O
10	of	O
11	the	O
12	grey	O
13	(	O
14	Armenian	O
15	)	O
16	hamster	O

1	The	O
2	application	O
3	of	O
4	these	O
5	microelectrodes	O
6	to	O
7	the	O
8	measurement	O
9	of	O
10	rapid	O
11	,	O
12	transient	O
13	changes	O
14	in	O
15	retinal	O
16	[	O
17	K	O
18	+]	O
19	o	O
20	is	O
21	presented	O
22	.	O

1	Using	O
2	an	O
3	oligomer	O
4	duplex	O
5	5	O
6	'-	O
7	A	O
8	(	O
9	GGGTTA	B
10	)(	I
11	5	I
12	)-	I
13	3	I
14	'/	I
15	5	I
16	'-(	I
17	TAACCC	I
18	)(	I
19	5	I
20	)	I
21	T	I
22	-	I
23	3	I
24	'	O
25	as	O
26	a	O
27	template	O
28	-	O
29	primer	O
30	,	O
31	we	O
32	show	O
33	that	O
34	both	O
35	the	O
36	Klenow	O
37	fragment	O
38	of	O
39	Escherichia	B
40	coli	I
41	DNA	I
42	polymerase	I
43	I	I
44	and	O
45	HIV	B
46	reverse	I
47	transcriptase	I
48	could	O
49	expand	O
50	telomere	O
51	DNA	O
52	sequences	O
53	as	O
54	well	O
55	,	O
56	giving	O
57	products	O
58	greater	O
59	than	O
60	the	O
61	size	O
62	of	O
63	the	O
64	template	O
65	DNA	O
66	.	O

1	The	O
2	mechanism	O
3	of	O
4	action	O
5	is	O
6	explored	O
7	in	O
8	some	O
9	detail	O
10	,	O
11	specifically	O
12	as	O
13	it	O
14	relates	O
15	to	O
16	reticuloendothelial	O
17	system	O
18	(	O
19	RES	O
20	)	O
21	Fc	B
22	receptor	I
23	blockade	O
24	and	O
25	suppression	O
26	of	O
27	antiplatelet	O
28	antibody	O
29	synthesis	O
30	.	O

1	Among	O
2	953	O
3	infants	O
4	in	O
5	22	O
6	neonatal	O
7	care	O
8	units	O
9	studied	O
10	,	O
11	23	O
12	%	O
13	(	O
14	median	O
15	value	O
16	,	O
17	range	O
18	0	O
19	-	O
20	78	O
21	)	O
22	were	O
23	found	O
24	to	O
25	be	O
26	faecally	O
27	colonized	O
28	with	O
29	one	O
30	of	O
31	21	O
32	distinct	O
33	nosocomial	O
34	strains	O
35	of	O
36	Escherichia	O
37	coli	O
38	,	O
39	Klebsiella	O
40	or	O
41	Enterobacter	O
42	spp	O
43	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	B
6	-	I
7	1	I
8	Gag	I
9	sequences	I
10	can	O
11	influence	O
12	the	O
13	viral	O
14	PR	B
15	-	I
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	O
21	TM	O
22	Env	B
23	protein	I
24	p15	O
25	(	O
26	E	O
27	).	O

1	HVH2	B
2	mRNA	I
3	showed	O
4	an	O
5	expression	O
6	pattern	O
7	distinct	O
8	from	O
9	CL100	O
10	(	O
11	human	B
12	homologue	I
13	of	O
14	mouse	O
15	MKP1	O
16	)	O
17	and	O
18	PAC1	O
19	,	O
20	two	O
21	previously	O
22	identified	O
23	MAP	B
24	kinase	I
25	phosphatases	I
26	.	O

1	In	O
2	12	O
3	cases	O
4	(	O
5	3	O
6	.	O
7	1	O
8	%),	O
9	a	O
10	change	O
11	in	O
12	stage	O
13	resulted	O
14	.	O

1	Reversal	B
2	of	O
3	the	O
4	increase	O
5	in	O
6	apomorphine	O
7	-	O
8	induced	O
9	stereotypy	O
10	and	O
11	aggression	O
12	in	O
13	REM	O
14	sleep	O
15	deprived	O
16	rats	O
17	by	O
18	dopamine	O
19	agonist	O
20	pretreatments	O
21	.	O

1	A	I
2	family	I
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O

1	Two	O
2	separate	O
3	NF1	B
4	-	I
5	binding	I
6	loci	I
7	were	O
8	also	O
9	found	O
10	in	O
11	the	O
12	equivalent	O
13	IE68	B
14	gene	I
15	of	O
16	HCMV	O
17	(	O
18	Towne	O
19	)	O
20	DNA	O
21	,	O
22	but	O
23	in	O
24	this	O
25	case	O
26	the	O
27	DNA	O
28	sequence	O
29	and	O
30	competition	O
31	filter	O
32	binding	O
33	experiments	O
34	indicated	O
35	a	O
36	maximum	O
37	of	O
38	only	O
39	four	O
40	to	O
41	five	O
42	consensus	O
43	binding	O
44	sites	O
45	encompassing	O
46	the	O
47	promoter	O
48	-	O
49	enhancer	O
50	region	O
51	.	O

1	Treatment	O
2	and	O
3	care	O
4	of	O
5	adult	O
6	diabetes	O
7	mellitus	O
8	without	O
9	coma	O

1	The	O
2	up	O
3	-	O
4	regulation	O
5	of	O
6	E	B
7	-	I
8	selectin	I
9	,	O
10	one	O
11	of	O
12	the	O
13	adhesion	O
14	molecules	O
15	on	O
16	the	O
17	endothelium	O
18	,	O
19	is	O
20	an	O
21	important	O
22	event	O
23	in	O
24	the	O
25	mediation	O
26	of	O
27	the	O
28	inflammatory	O
29	response	O
30	.	O

1	Co	O
2	-	O
3	immunoprecipitation	O
4	and	O
5	DNA	O
6	affinity	O
7	chromatography	O
8	prove	O
9	that	O
10	Sp1	B
11	heterodimerizes	O
12	with	O
13	ZBP	O
14	-	O
15	89	O
16	when	O
17	bound	O
18	to	O
19	the	O
20	silencer	O
21	element	O
22	to	O
23	yield	O
24	a	O
25	DNA	B
26	-	I
27	protein	I
28	complex	I
29	whose	O
30	mobility	O
31	is	O
32	indistinguishable	O
33	from	O
34	that	O
35	displayed	O
36	by	O
37	HeLa	O
38	nuclear	O
39	extract	O
40	in	O
41	band	O
42	shift	O
43	assays	O
44	.	O

1	The	O
2	glucose	O
3	areas	O
4	following	O
5	the	O
6	ingestion	O
7	of	O
8	the	O
9	foods	O
10	were	O
11	:	O
12	Study	O
13	1	O
14	:	O
15	glucose	O
16	11	O
17	.	O
18	7	O
19	,	O
20	orange	O
21	juice	O
22	7	O
23	.	O
24	3	O
25	,	O
26	sucrose	O
27	5	O
28	.	O
29	2	O
30	,	O
31	glucose	O
32	+	O
33	fructose	O
34	6	O
35	.	O
36	3	O
37	,	O
38	and	O
39	fructose	O
40	0	O
41	.	O
42	7	O
43	mmol	O
44	X	O
45	h	O
46	/	O
47	l	O
48	;	O
49	Study	O
50	2	O
51	:	O
52	glucose	O
53	14	O
54	.	O
55	6	O
56	,	O
57	orange	O
58	juice	O
59	7	O
60	.	O
61	3	O
62	,	O
63	apples	O
64	5	O
65	.	O
66	5	O
67	,	O
68	and	O
69	apple	O
70	juice	O
71	4	O
72	.	O
73	7	O
74	mmol	O
75	X	O
76	h	O
77	/	O
78	l	O
79	;	O
80	Study	O
81	3	O
82	:	O
83	glucose	O
84	12	O
85	.	O
86	6	O
87	,	O
88	ice	O
89	cream	O
90	8	O
91	.	O
92	1	O
93	,	O
94	milk	O
95	3	O
96	.	O
97	7	O
98	,	O
99	and	O
100	lactose	O
101	4	O
102	.	O
103	1	O
104	mmol	O
105	X	O
106	h	O
107	/	O
108	l	O
109	.	O

1	Position	B
2	-	I
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	O
8	nerve	B
9	growth	I
10	factor	I
11	-	I
12	luciferase	I
13	reporter	I
14	gene	I
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O

1	Evaluation	O
2	of	O
3	thyroid	O
4	function	O
5	.	O

1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	O
8	domain	O
9	of	O
10	the	O
11	Syrian	O
12	hamster	O
13	multifunctional	O
14	protein	O
15	CAD	O
16	.	O

1	G	B
2	.	O

1	Although	O
2	the	O
3	DSK2	B
4	-	I
5	1	I
6	mutation	I
7	alters	O
8	a	O
9	conserved	O
10	residue	O
11	in	O
12	the	O
13	Dsk2p	O
14	ubiquitin	B
15	-	I
16	like	I
17	domain	I
18	,	O
19	we	O
20	detect	O
21	no	O
22	differences	O
23	in	O
24	Dsk2p	O
25	or	O
26	Cdc31p	O
27	stability	O
28	.	O

1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	O
12	/	O
13	HDC	O
14	Ac	B
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O

1	The	O
2	medium	O
3	chains	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	mu1	O
9	and	O
10	mu2	O
11	,	O
12	have	O
13	been	O
14	implicated	O
15	in	O
16	two	O
17	types	O
18	of	O
19	interaction	O
20	:	O
21	assembly	O
22	with	O
23	the	O
24	beta1	B
25	and	O
26	beta2	O
27	chains	O
28	of	O
29	the	O
30	corresponding	O
31	complexes	O
32	and	O
33	recognition	O
34	of	O
35	tyrosine	O
36	-	O
37	based	O
38	sorting	O
39	signals	O
40	.	O

1	Quantitative	O
2	computed	O
3	tomography	O
4	for	O
5	measuring	O
6	vertebral	O
7	bone	O
8	mineral	O
9	content	O
10	offers	O
11	high	O
12	sensitivity	O
13	and	O
14	reproducibility	O
15	.	O

1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O

1	The	O
2	catenins	O
3	bind	O
4	to	O
5	APC	B
6	and	I
7	E	I
8	-	I
9	cadherin	O
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	APC	B
17	and	I
18	E	I
19	-	I
20	cadherin	O
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	catenins	O
35	.	O

1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	O
29	.	O

1	ATP	B
2	-	I
3	dependent	I
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	O
18	-	O
19	MSH6	O
20	and	O
21	MLH1	B
22	-	I
23	PMS1	I
24	protein	I
25	complexes	I
26	.	O

1	Secondly	B
2	,	O
3	an	O
4	ethanol	O
5	repression	O
6	autoregulation	O
7	(	O
8	ERA	O
9	)/	O
10	twelve	O
11	-	O
12	fold	O
13	TA	O
14	repeat	O
15	(	O
16	TAB	O
17	)	O
18	repressor	O
19	element	O
20	was	O
21	identified	O
22	within	O
23	the	O
24	promoter	O
25	region	O
26	of	O
27	the	O
28	GLK1	B
29	gene	I
30	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	O
30	mutants	O
31	.	O

1	The	O
2	congenital	O
3	forms	O
4	(	O
5	7	O
6	cases	O
7	)	O
8	all	O
9	occurred	O
10	in	O
11	female	O
12	infants	O
13	and	O
14	involved	O
15	the	O
16	mucosa	O
17	overlying	O
18	either	O
19	the	O
20	anterior	O
21	ridge	O
22	of	O
23	the	O
24	maxilla	O
25	or	O
26	the	O
27	mandible	O
28	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	O
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	B
11	-	I
12	1	I
13	-	I
14	dependent	I
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	I
24	AP1	I
25	(	I
26	activator	I
27	protein	I
28	1	I
29	)	I
30	element	I
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	I
48	protein	I
49	kinase	I
50	C	I
51	pathways	O
52	.	O

1	A	I
2	fusion	I
3	protein	I
4	composed	O
5	of	O
6	beta	B
7	-	I
8	galactosidase	I
9	and	O
10	full	O
11	-	O
12	length	O
13	Ahr	O
14	translocates	O
15	from	O
16	the	O
17	cytoplasm	O
18	to	O
19	the	O
20	nucleus	O
21	in	O
22	a	O
23	ligand	O
24	-	O
25	dependent	O
26	manner	O
27	.	O

1	Variation	B
2	in	O
3	the	O
4	temporal	O
5	-	O
6	spatial	O
7	distribution	O
8	of	O
9	228Ra	O
10	and	O
11	224Ra	O
12	in	O
13	the	O
14	RES	O
15	and	O
16	marrow	O
17	-	O
18	free	O
19	skeleton	O
20	after	O
21	incorporation	O
22	of	O
23	colloidal	O
24	ThO2	O

1	The	O
2	motility	O
3	of	O
4	sperm	O
5	,	O
6	except	O
7	for	O
8	those	O
9	adjacent	O
10	to	O
11	both	O
12	electrodes	O
13	,	O
14	did	O
15	not	O
16	change	O
17	after	O
18	stimulation	O
19	for	O
20	60s	O
21	,	O
22	despite	O
23	a	O
24	high	O
25	electrical	O
26	energy	O
27	.	O

1	During	O
2	the	O
3	cloning	O
4	by	O
5	reverse	B
6	transcriptase	I
7	-	I
8	polymerase	I
9	chain	I
10	reaction	O
11	of	O
12	the	O
13	human	B
14	HIF	I
15	-	I
16	1alpha	I
17	subunit	I
18	,	O
19	we	O
20	isolated	O
21	two	O
22	cDNA	O
23	clones	O
24	which	O
25	corresponded	O
26	to	O
27	alternative	O
28	splicing	O
29	of	O
30	the	O
31	HIF	B
32	-	I
33	1alpha	I
34	gene	I
35	.	O

1	The	O
2	lethal	O
3	toxicity	O
4	of	O
5	inorganic	O
6	(	O
7	HgCl2	O
8	)	O
9	and	O
10	organic	O
11	(	O
12	CH3HgCl	O
13	)	O
14	mercury	O
15	chloride	O
16	was	O
17	compared	O
18	for	O
19	Coturnix	O
20	(	O
21	Japanese	O
22	quail	O
23	,	O
24	Coturnix	O
25	japonica	O
26	)	O
27	of	O
28	different	O
29	ages	O
30	from	O
31	hatch	O
32	through	O
33	adulthood	O
34	by	O
35	single	O
36	-	O
37	dose	O
38	acute	O
39	oral	O
40	and	O
41	intramuscular	O
42	injections	O
43	and	O
44	by	O
45	a	O
46	5	O
47	-	O
48	d	O
49	dietary	O
50	trial	O
51	.	O

1	Dynamic	B
2	and	O
3	static	O
4	scintigrams	O
5	,	O
6	using	O
7	99mtechnetium	O
8	methylene	O
9	diphosphonate	O
10	,	O
11	were	O
12	obtained	O
13	at	O
14	zero	O
15	,	O
16	six	O
17	,	O
18	and	O
19	12	O
20	weeks	O
21	after	O
22	fracture	O
23	.	O

1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	inherited	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	Kruppel	B
20	-	I
21	related	I
22	sequences	I
23	to	O
24	isolate	O
25	zinc	B
26	finger	I
27	-	I
28	containing	I
29	cDNAs	I
30	.	O

1	Factor	B
2	V	I
3	Leiden	O
4	is	O
5	a	O
6	genetic	O
7	disorder	O
8	associated	O
9	with	O
10	an	O
11	increased	O
12	risk	O
13	of	O
14	venous	O
15	thrombosis	O
16	.	O

1	Plasma	B
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	O
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O

1	GRFI	B
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	O
16	mating	B
17	type	I
18	loci	I
19	HML	I
20	E	I
21	and	O
22	HMR	B
23	E	I
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O

1	Temporal	B
2	control	O
3	of	O
4	GUS	B
5	expression	O
6	was	O
7	found	O
8	to	O
9	involve	O
10	two	O
11	negative	O
12	regulatory	O
13	sequences	O
14	,	O
15	NRS1	O
16	(-	O
17	391	O
18	to	O
19	-	O
20	295	O
21	)	O
22	and	O
23	NRS2	O
24	(-	O
25	518	O
26	to	O
27	-	O
28	418	O
29	),	O
30	as	O
31	well	O
32	as	O
33	the	O
34	positive	O
35	domain	O
36	UAS1	O
37	.	O

1	Many	O
2	eukaryotic	O
3	cell	O
4	surface	O
5	proteins	O
6	are	O
7	anchored	O
8	in	O
9	the	O
10	lipid	O
11	bilayer	O
12	through	O
13	glycosylphosphatidylinositol	O
14	(	O
15	GPI	O
16	).	O

1	Treatment	O
2	was	O
3	well	O
4	-	O
5	tolerated	O
6	.	O

1	The	O
2	first	O
3	involved	O
4	measurements	O
5	of	O
6	the	O
7	steady	O
8	state	O
9	levels	O
10	of	O
11	mRNAs	O
12	for	O
13	subunit	O
14	5	O
15	of	O
16	cytochrome	B
17	oxidase	I
18	and	O
19	the	O
20	beta	B
21	subunit	I
22	of	I
23	F1	I
24	ATPase	I
25	in	O
26	wild	O
27	type	O
28	and	O
29	in	O
30	a	O
31	hem2	O
32	mutant	O
33	.	O

1	Mutations	O
2	within	O
3	conserved	O
4	region	O
5	2	O
6	(	O
7	CR2	O
8	)	O
9	of	O
10	E1A	B
11	that	O
12	inhibit	O
13	the	O
14	binding	O
15	of	O
16	E1A	B
17	to	O
18	the	O
19	retinoblastoma	B
20	gene	I
21	product	I
22	(	I
23	pRb	I
24	)	O
25	further	O
26	enhanced	O
27	the	O
28	stimulation	O
29	of	O
30	transcription	O
31	from	O
32	the	O
33	PEPCK	B
34	promoter	I
35	by	O
36	2	O
37	3	O
38	-	O
39	fold	O
40	compared	O
41	with	O
42	wild	B
43	type	I
44	E1A	I
45	.	O

1	Duch	B
2	,	O
3	and	O
4	F	O
5	.	O

1	Nodular	B
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	O
28	Type	O
29	Kappa	O
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	Radiolabelled	B
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	A	I
2	simplified	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	hippuric	O
10	acid	O
11	and	O
12	methylhippuric	O
13	acids	O
14	.	O

1	A	I
2	single	O
3	rectal	O
4	dose	O
5	of	O
6	25	O
7	mg	O
8	/	O
9	kg	O
10	will	O
11	obtain	O
12	this	O
13	lower	O
14	concentration	O
15	within	O
16	1	O
17	h	O
18	of	O
19	administration	O
20	and	O
21	maintain	O
22	it	O
23	for	O
24	up	O
25	to	O
26	6	O
27	h	O
28	.	O

1	Analysis	O
2	of	O
3	glucocorticoid	O
4	unresponsive	O
5	cell	O
6	variants	O
7	using	O
8	a	O
9	mouse	B
10	glucocorticoid	I
11	receptor	I
12	complementary	O
13	DNA	O
14	clone	O
15	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	The	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	I
8	ABC	I
9	-	I
10	P	O
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	O
31	-	O
32	Neelsen	O
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	O
4	levels	O
5	of	O
6	S	O
7	-	O
8	100beta	O
9	are	O
10	reliable	O
11	markers	O
12	for	O
13	adverse	O
14	neurologic	O
15	outcomes	O
16	after	O
17	cardiac	O
18	surgery	O
19	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	MEASUREMENTS	B
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O

1	Since	O
2	we	O
3	have	O
4	observed	O
5	effects	O
6	of	O
7	growth	O
8	factors	O
9	and	O
10	cAMP	O
11	as	O
12	well	O
13	as	O
14	estradiol	O
15	(	O
16	E2	O
17	)	O
18	on	O
19	regulation	O
20	of	O
21	expression	O
22	of	O
23	some	O
24	genes	O
25	stimulated	O
26	by	O
27	the	O
28	estrogen	B
29	receptor	I
30	(	I
31	ER	I
32	),	O
33	we	O
34	have	O
35	undertaken	O
36	studies	O
37	to	O
38	examine	O
39	directly	O
40	whether	O
41	activators	O
42	of	O
43	protein	B
44	kinases	I
45	can	O
46	modulate	O
47	transcriptional	O
48	activity	O
49	of	O
50	the	O
51	ER	O
52	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	B
19	lipase	I
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	Mitochondria	B
2	-	I
3	lytic	O
4	action	O
5	of	O
6	warfarin	O
7	in	O
8	lymphocytes	O
9	.	O

1	The	O
2	prevalence	O
3	and	O
4	incidence	O
5	of	O
6	human	B
7	immunodeficiency	I
8	virus	I
9	types	O
10	1	O
11	and	O
12	2	O
13	(	O
14	HIV	B
15	-	I
16	1	I
17	,	O
18	HIV	B
19	-	I
20	2	I
21	),	O
22	human	B
23	T	I
24	-	I
25	lymphotropic	I
26	virus	I
27	types	O
28	I	O
29	and	O
30	II	O
31	(	O
32	HTLV	B
33	-	I
34	I	I
35	/	I
36	II	I
37	),	O
38	and	O
39	syphilitic	O
40	infections	O
41	and	O
42	the	O
43	association	O
44	between	O
45	these	O
46	infections	O
47	were	O
48	determined	O
49	in	O
50	a	O
51	cohort	O
52	of	O
53	police	O
54	officers	O
55	in	O
56	Guinea	O
57	-	O
58	Bissau	O
59	.	O

1	Idiopathic	B
2	bilateral	O
3	recurrent	O
4	branch	O
5	retinal	O
6	arterial	O
7	occlusion	O
8	(	O
9	IBRBRAO	O
10	)	O
11	is	O
12	a	O
13	rare	O
14	syndrome	O
15	characterized	O
16	by	O
17	migraine	O
18	headaches	O
19	,	O
20	tinnitus	O
21	,	O
22	vertigo	O
23	,	O
24	hearing	O
25	loss	O
26	,	O
27	and	O
28	recurrent	O
29	branch	O
30	retinal	O
31	artery	O
32	occlusion	O
33	of	O
34	unknown	O
35	etiology	O
36	.	O

1	Finally	O
2	,	O
3	in	O
4	situ	O
5	RNA	O
6	hybridization	O
7	studies	O
8	revealed	O
9	a	O
10	very	O
11	specific	O
12	pattern	O
13	of	O
14	EphA8	B
15	gene	I
16	expression	O
17	restricted	O
18	to	O
19	the	O
20	rostral	O
21	region	O
22	of	O
23	midbrain	O
24	tectum	O
25	during	O
26	embryonic	O
27	development	O
28	.	O

1	Such	O
2	studied	O
3	acquired	O
4	with	O
5	low	O
6	energy	O
7	or	O
8	medium	O
9	energy	O
10	collimation	O
11	and	O
12	a	O
13	window	O
14	centered	O
15	on	O
16	the	O
17	159	O
18	keV	O
19	123I	O
20	photopeak	O
21	contain	O
22	appreciable	O
23	septal	O
24	breakthrough	O
25	signals	O
26	originating	O
27	from	O
28	Compton	O
29	scatter	O
30	of	O
31	high	O
32	energy	O
33	photons	O
34	primarily	O
35	from	O
36	124I	O
37	.	O

1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	I
11	abl	I
12	kinase	I
13	domain	I
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	O
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	O
33	mutant	O
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O

1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O

1	Furthermore	O
2	,	O
3	addition	O
4	of	O
5	B	B
6	-	I
7	Myb	I
8	-	I
9	glutathionine	I
10	S	I
11	-	I
12	transferase	I
13	fusion	I
14	protein	I
15	inhibited	O
16	complex	O
17	formation	O
18	.	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	O
9	4	O
10	(	O
11	myosin	B
12	from	O
13	rat	O
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	B
28	myosin	I
29	I	I
30	.	O

1	About	B
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	O
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	O
18	LAMB2	B
19	-	I
20	like	I
21	pseudogene	I
22	(	O
23	LAMB2L	O
24	).	O

1	POU	B
2	-	I
3	specific	I
4	and	I
5	POU	I
6	-	I
7	homeo	I
8	domains	I
9	of	O
10	Oct3	O
11	were	O
12	produced	O
13	in	O
14	Echerichia	O
15	coli	O
16	for	O
17	characterization	O
18	of	O
19	DNA	O
20	binding	O
21	to	O
22	the	O
23	octamer	O
24	sequence	O
25	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	O
8	is	O
9	a	O
10	distant	O
11	homolog	O
12	of	O
13	alphavirus	O
14	nonstructural	O
15	protein	O
16	nsP1	O
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	We	O
2	determined	O
3	whether	O
4	the	O
5	human	B
6	StAR	I
7	promoter	I
8	is	O
9	responsive	O
10	to	O
11	sterol	B
12	regulatory	I
13	element	I
14	-	I
15	binding	I
16	proteins	I
17	(	O
18	SREBPs	O
19	).	O

1	A	I
2	new	O
3	non	O
4	-	O
5	LTR	O
6	retrotransposon	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	O
16	in	O
17	Crithidia	O
18	fasciculata	O
19	miniexon	O
20	arrays	O
21	.	O

1	The	O
2	homologies	O
3	between	O
4	RAD16	O
5	,	O
6	RAD54	O
7	and	O
8	SNF2	O
9	are	O
10	also	O
11	shared	O
12	by	O
13	several	O
14	additional	O
15	,	O
16	recently	O
17	isolated	O
18	yeast	O
19	and	O
20	Drosophila	B
21	genes	I
22	.	O

1	The	O
2	gp330	O
3	/	O
4	Megalin	O
5	/	O
6	LRP	B
7	-	I
8	2	I
9	protein	I
10	belongs	O
11	to	O
12	the	O
13	low	B
14	-	I
15	density	I
16	lipoprotein	I
17	receptor	I
18	gene	I
19	family	I
20	and	O
21	is	O
22	believed	O
23	to	O
24	function	O
25	as	O
26	an	O
27	endocytic	O
28	receptor	O
29	for	O
30	the	O
31	uptake	O
32	of	O
33	lipoproteins	O
34	and	O
35	many	O
36	other	O
37	ligands	O
38	.	O

1	Patients	O
2	with	O
3	acute	O
4	myocardial	O
5	infarction	O
6	had	O
7	higher	O
8	plasma	O
9	concentrations	O
10	of	O
11	neutrophil	B
12	elastase	I
13	and	O
14	the	O
15	non	O
16	-	O
17	peroxide	O
18	diene	O
19	conjugated	O
20	isomer	O
21	of	O
22	linoleic	O
23	acid	O
24	than	O
25	normal	O
26	volunteers	O
27	or	O
28	patients	O
29	with	O
30	stable	O
31	ischaemic	O
32	heart	O
33	disease	O
34	.	O

1	Alternatively	B
2	,	O
3	PC12	O
4	-	O
5	E2	O
6	cells	O
7	were	O
8	submitted	O
9	to	O
10	treatment	O
11	with	O
12	antibodies	O
13	to	O
14	the	O
15	fibroblast	B
16	growth	I
17	factor	I
18	(	I
19	FGF	I
20	)	I
21	receptor	I
22	,	O
23	inhibitors	O
24	of	O
25	the	O
26	nonreceptor	B
27	tyrosine	I
28	kinase	I
29	p59	O
30	(	O
31	fyn	O
32	),	O
33	PLC	B
34	,	O
35	PKC	B
36	and	O
37	MEK	B
38	and	O
39	an	O
40	activator	O
41	of	O
42	PKC	B
43	,	O
44	phorbol	O
45	-	O
46	12	O
47	-	O
48	myristate	O
49	-	O
50	13	O
51	-	O
52	acetate	O
53	(	O
54	PMA	O
55	).	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	B
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	Kf	B
2	,	O
3	c	B
4	and	O
5	CT	O
6	(	O
7	referenced	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	linearly	O
16	with	O
17	reductions	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	Kf	O
24	,	O
25	c	B
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O

1	The	O
2	euglobulin	O
3	clot	O
4	lysis	O
5	time	O
6	was	O
7	slightly	O
8	longer	O
9	in	O
10	the	O
11	smokers	O
12	than	O
13	in	O
14	the	O
15	non	O
16	-	O
17	smokers	O
18	in	O
19	all	O
20	three	O
21	experimental	O
22	situations	O
23	,	O
24	but	O
25	the	O
26	differences	O
27	were	O
28	not	O
29	significant	O
30	.	O

1	CONCLUSION	O
2	:	O
3	Some	O
4	Gulf	O
5	War	O
6	veterans	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	neurotoxic	O
13	syndromes	O
14	from	O
15	wartime	O
16	exposure	O
17	to	O
18	combinations	O
19	of	O
20	chemicals	O
21	that	O
22	inhibit	O
23	butyrylcholinesterase	O
24	and	O
25	neuropathy	O
26	target	O
27	esterase	B
28	.	O

1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	or	O
9	the	O
10	ets	B
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O

1	The	O
2	toxicological	O
3	evaluation	O
4	of	O
5	chlorofluorocarbon	O
6	22	O
7	(	O
8	CFC	O
9	22	O
10	).	O

1	Environmental	B
2	factors	I
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	O
6	serum	O
7	fibrinogen	B
8	and	O
9	prolonged	O
10	prothrombin	B
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	B
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	Serum	B
2	TNF	I
3	concentrations	O
4	were	O
5	elevated	O
6	at	O
7	diagnosis	O
8	and	O
9	gradually	O
10	decreased	O
11	toward	O
12	the	O
13	reference	O
14	limits	O
15	by	O
16	week	O
17	16	O
18	.	O

1	However	O
2	,	O
3	if	O
4	EMPD	O
5	involves	O
6	the	O
7	glans	O
8	penis	O
9	or	O
10	perianal	O
11	area	O
12	,	O
13	a	O
14	search	O
15	for	O
16	internal	O
17	malignancy	O
18	is	O
19	still	O
20	warranted	O
21	.	O

1	Diagnosis	O
2	of	O
3	primary	O
4	sclerosing	O
5	cholangitis	O
6	in	O
7	a	O
8	blood	O
9	donor	O
10	with	O
11	elevated	O
12	serum	B
13	alanine	I
14	aminotransferase	I
15	.	O

1	Animal	B
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	The	O
2	full	O
3	protocol	O
4	was	O
5	completed	O
6	by	O
7	33	O
8	patients	O
9	(	O
10	45	O
11	%	O
12	of	O
13	original	O
14	cohort	O
15	).	O

1	The	O
2	roxithromycin	O
3	doses	O
4	that	O
5	were	O
6	chosen	O
7	for	O
8	these	O
9	studies	O
10	were	O
11	less	O
12	than	O
13	achievable	O
14	blood	O
15	levels	O
16	.	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	B
8	or	O
9	an	O
10	E2F	B
11	-	I
12	related	I
13	transcription	I
14	factor	I
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	B
22	myosin	I
23	expression	O
24	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	electrical	O
11	stimulation	O
12	generate	O
13	reactive	O
14	oxygen	O
15	species	O
16	and	O
17	affect	O
18	SOD	O
19	activity	O
20	,	O
21	which	O
22	in	O
23	part	O
24	are	O
25	responsible	O
26	for	O
27	decreased	O
28	sperm	O
29	motion	O
30	and	O
31	viability	O
32	.	O

1	Doppler	O
2	ultrasound	O
3	studies	O
4	of	O
5	long	O
6	-	O
7	term	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	children	O
13	with	O
14	hemolytic	O
15	-	O
16	uremic	O
17	syndrome	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	Recombinant	B
2	plasmids	O
3	containing	O
4	the	O
5	entire	O
6	322	O
7	nt	O
8	5	O
9	'	O
10	UTR	O
11	of	O
12	exon	O
13	1	O
14	and	O
15	a	O
16	1630	O
17	nt	O
18	segment	O
19	of	O
20	5	O
21	'	O
22	flanking	O
23	sequence	O
24	stimulated	O
25	luciferase	B
26	activity	O
27	nearly	O
28	70	O
29	times	O
30	higher	O
31	than	O
32	a	O
33	promoterless	O
34	control	O
35	plasmid	O
36	.	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	Fregnac	B
2	,	O
3	M	O
4	.	O

1	This	O
2	mutation	O
3	also	O
4	results	O
5	in	O
6	markedly	O
7	decreased	O
8	levels	O
9	of	O
10	CAD	O
11	mRNA	O
12	and	O
13	protein	O
14	in	O
15	the	O
16	mutant	O
17	.	O

1	The	O
2	LAMMER	B
3	protein	I
4	kinase	I
5	encoded	I
6	by	O
7	the	O
8	Doa	O
9	locus	O
10	of	O
11	Drosophila	O
12	is	O
13	required	O
14	in	O
15	both	O
16	somatic	O
17	and	O
18	germline	O
19	cells	O
20	and	O
21	is	O
22	expressed	O
23	as	O
24	both	O
25	nuclear	O
26	and	O
27	cytoplasmic	O
28	isoforms	O
29	throughout	O
30	development	O
31	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	DNA	O
6	fragment	O
7	showed	O
8	that	O
9	four	O
10	genes	O
11	are	O
12	present	O
13	encoding	O
14	proteins	O
15	of	O
16	16	O
17	,	O
18	18	O
19	.	O
20	5	O
21	,	O
22	21	O
23	and	O
24	89	O
25	kDal	O
26	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	Interferon	B
2	Regulatory	I
3	Factor	I
4	(	O
5	IRF	B
6	)-	I
7	1	I
8	has	O
9	been	O
10	characterized	O
11	as	O
12	an	O
13	important	O
14	growth	O
15	regulatory	O
16	and	O
17	immunomodulatory	B
18	transcription	I
19	factor	I
20	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	bovine	O
9	and	O
10	rat	B
11	GHF	I
12	-	I
13	1	I
14	cDNA	I
15	clones	O
16	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	O
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	Improvement	B
2	of	O
3	the	O
4	polypyrimidine	O
5	tract	O
6	also	O
7	increased	O
8	the	O
9	splicing	O
10	efficiency	O
11	,	O
12	but	O
13	to	O
14	a	O
15	degree	O
16	slightly	O
17	less	O
18	than	O
19	that	O
20	obtained	O
21	with	O
22	the	O
23	branchpoint	O
24	mutation	O
25	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	B
26	alpha	I
27	-	I
28	helix	I
29	(	I
30	L	I
31	-	I
32	61	O
33	to	O
34	F	O
35	-	O
36	97	O
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	O
49	.	O

1	Strikingly	B
2	,	O
3	stoichiometric	O
4	association	O
5	of	O
6	p107	O
7	or	O
8	p130	B
9	with	O
10	either	O
11	cyclin	B
12	E	I
13	-	I
14	cdk2	O
15	or	O
16	cyclin	B
17	A	I
18	-	I
19	cdk2	O
20	negated	O
21	the	O
22	activities	O
23	of	O
24	these	O
25	kinases	O
26	.	O

1	An	O
2	outbreak	O
3	of	O
4	hepatitis	O
5	A	O
6	among	O
7	homosexual	O
8	men	O
9	in	O
10	Amsterdam	O
11	,	O
12	1991	O
13	-	O
14	1993	O
15	.	O

1	After	O
2	hepatitis	O
3	B	O
4	vaccine	O
5	immunization	O
6	,	O
7	serum	O
8	antibody	O
9	response	O
10	was	O
11	of	O
12	primary	O
13	type	O
14	in	O
15	33	O
16	cases	O
17	with	O
18	anti	B
19	-	I
20	HBs	I
21	less	O
22	than	O
23	2	O
24	.	O
25	1	O
26	S	O
27	/	O
28	N	O
29	(	O
30	S	O
31	/	O
32	N	O
33	Ratio	O
34	Unit	O
35	)	O
36	at	O
37	T0	O
38	,	O
39	the	O
40	anti	B
41	-	I
42	HBs	I
43	positive	O
44	rate	O
45	was	O
46	39	O
47	.	O
48	4	O
49	%,	O
50	84	O
51	.	O
52	8	O
53	%,	O
54	96	O
55	.	O
56	7	O
57	%	O
58	and	O
59	96	O
60	.	O
61	7	O
62	%	O
63	in	O
64	T1	O
65	,	O
66	T2	O
67	,	O
68	T0	O
69	and	O
70	T12	O
71	respectively	O
72	.	O

1	Cocaine	B
2	-	I
3	treated	O
4	rats	O
5	acquired	O
6	a	O
7	preference	O
8	for	O
9	cocaine	O
10	-	O
11	associated	O
12	contextual	O
13	stimuli	O
14	(	O
15	CS	O
16	)	O
17	relative	O
18	to	O
19	saline	O
20	-	O
21	injected	O
22	control	O
23	rats	O
24	.	O

1	The	O
2	collection	O
3	of	O
4	mutants	O
5	displaying	O
6	TGN	O
7	sorting	O
8	defects	O
9	includes	O
10	members	O
11	with	O
12	mutations	O
13	in	O
14	previously	O
15	identified	O
16	vacuolar	B
17	protein	I
18	sorting	I
19	genes	I
20	(	O
21	VPS	O
22	),	O
23	including	O
24	the	O
25	dynamin	B
26	family	I
27	member	O
28	VPS1	O
29	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	the	O
6	Sp1	B
7	expression	O
8	plasmid	O
9	and	O
10	the	O
11	-	O
12	58	O
13	promoter	O
14	construct	O
15	into	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	revealed	O
20	that	O
21	Sp1	B
22	contributed	O
23	to	O
24	the	O
25	kinase	O
26	basal	O
27	promoter	O
28	activity	O
29	by	O
30	binding	O
31	to	O
32	the	O
33	non	O
34	-	O
35	consensus	O
36	site	O
37	in	O
38	the	O
39	-	O
40	58	O
41	region	O
42	.	O

1	All	O
2	six	O
3	ARF	B
4	cDNAs	I
5	are	O
6	more	O
7	similar	O
8	to	O
9	each	O
10	other	O
11	than	O
12	to	O
13	other	O
14	approximately	O
15	20	O
16	-	O
17	kDa	O
18	guanine	B
19	nucleotide	I
20	-	I
21	binding	I
22	proteins	I
23	.	O

1	Amikacin	B
2	concentrations	O
3	in	O
4	serum	O
5	and	O
6	blister	O
7	fluid	O
8	in	O
9	healthy	O
10	volunteers	O
11	and	O
12	in	O
13	patients	O
14	with	O
15	renal	O
16	impairment	O
17	.	O

1	Extreme	B
2	potency	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	O
8	accelerated	O
9	E1A	B
10	-	I
11	induced	O
12	apoptosis	O
13	.	O

1	[	O
2	Ala85	O
3	]	O
4	Dk	O
5	(	O
6	69	O
7	-	O
8	85	O
9	)	O
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	routinely	O
6	used	O
7	in	O
8	our	O
9	laboratory	O
10	for	O
11	1	O
12	year	O
13	and	O
14	has	O
15	proven	O
16	to	O
17	be	O
18	a	O
19	reliable	O
20	procedure	O
21	for	O
22	the	O
23	biological	O
24	control	O
25	of	O
26	occupational	O
27	exposure	O
28	to	O
29	toluene	O
30	and	O
31	/	O
32	or	O
33	xylene	O
34	.	O

1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O

1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	B
20	nuclear	I
21	protein	I
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	O
41	.	O

1	The	O
2	C4BP	B
3	alpha	I
4	gene	I
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	The	O
2	cDNA	O
3	of	O
4	cpm7	O
5	encodes	O
6	a	O
7	closely	O
8	related	O
9	protein	O
10	of	O
11	36	O
12	.	O
13	8	O
14	kDa	O
15	.	O

1	With	O
2	only	O
3	purified	O
4	T	B
5	antigen	I
6	in	O
7	the	O
8	presence	O
9	of	O
10	topoisomerase	I
11	I	I
12	to	O
13	unwind	O
14	purified	O
15	DNA	O
16	,	O
17	ori	O
18	-	O
19	auxiliary	O
20	sequences	O
21	strongly	O
22	facilitated	O
23	T	B
24	-	I
25	antigen	I
26	-	I
27	dependent	I
28	DNA	O
29	conformational	O
30	changes	O
31	consistent	O
32	with	O
33	melting	O
34	the	O
35	first	O
36	50	O
37	base	O
38	pairs	O
39	.	O

1	In	O
2	PC12	O
3	cells	O
4	,	O
5	nerve	B
6	growth	I
7	factor	I
8	induces	O
9	neuronal	O
10	differentiation	O
11	and	O
12	repressed	O
13	expression	O
14	of	O
15	nrg	B
16	-	I
17	1	I
18	.	O

1	BCL	B
2	-	I
3	2	I
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O

1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	O
10	up	O
11	-	O
12	regulated	O
13	during	O
14	death	O
15	(	O
16	mud	B
17	)-	I
18	1	I
19	-	I
20	8	O
21	.	O

1	We	O
2	analyzed	O
3	serial	O
4	biopsy	O
5	specimens	O
6	from	O
7	eight	O
8	patients	O
9	with	O
10	FL	O
11	for	O
12	secondary	O
13	alterations	O
14	of	O
15	the	O
16	rearranged	O
17	bcl	B
18	-	I
19	2	I
20	gene	I
21	in	O
22	the	O
23	breakpoint	O
24	and	O
25	open	O
26	reading	O
27	frame	O
28	(	O
29	ORF	O
30	)	O
31	regions	O
32	.	O

1	Nip7p	B
2	-	I
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	O
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	O
20	precursors	O
21	.	O

1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O

1	All	O
2	nuclear	O
3	receptors	O
4	have	O
5	several	O
6	well	O
7	-	O
8	characterized	O
9	structural	O
10	domains	O
11	,	O
12	including	O
13	a	O
14	conserved	O
15	DNA	B
16	-	I
17	binding	I
18	domain	I
19	,	O
20	and	O
21	a	O
22	ligand	O
23	binding	O
24	domain	O
25	at	O
26	the	O
27	carboxyl	O
28	terminus	O
29	of	O
30	the	O
31	receptor	O
32	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Rho1p	O
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	O
12	Bni1p	O
13	and	O
14	Pkc1p	O
15	.	O

1	Naloxone	B
2	(	I
3	2	I
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	X	O
16	h	O
17	-	O
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O

1	The	O
2	5	O
3	'-	O
4	terminus	O
5	of	O
6	the	O
7	p	O
8	-	O
9	gvpF	B
10	-	I
11	M	I
12	mRNA	I
13	was	O
14	located	O
15	169	O
16	nucleotides	O
17	upstream	O
18	of	O
19	p	O
20	-	O
21	gvpF	O
22	within	O
23	p	O
24	-	O
25	gvpE	O
26	.	O

1	DMI	B
2	and	I
3	2	I
4	-	I
5	OH	O
6	-	O
7	DMI	O
8	concentrations	O
9	were	O
10	determined	O
11	in	O
12	a	O
13	similar	O
14	group	O
15	of	O
16	61	O
17	DMI	O
18	-	O
19	treated	O
20	patients	O
21	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	greater	O
7	estrogenic	O
8	influence	O
9	associated	O
10	with	O
11	the	O
12	ethinyl	O
13	estradiol	O
14	-	O
15	containing	O
16	OC	O
17	resulted	O
18	in	O
19	inhibition	O
20	of	O
21	coronary	O
22	artery	O
23	atherosclerosis	O
24	despite	O
25	a	O
26	pronounced	O
27	progestin	O
28	-	O
29	induced	O
30	lowering	O
31	of	O
32	plasma	O
33	HDL	B
34	cholesterol	I
35	concentration	O
36	and	O
37	,	O
38	further	O
39	,	O
40	that	O
41	hormonal	O
42	balance	O
43	may	O
44	have	O
45	a	O
46	marked	O
47	influence	O
48	on	O
49	the	O
50	relationship	O
51	between	O
52	plasma	O
53	lipids	O
54	and	O
55	atherogenesis	O
56	.	O

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	B
9	matrix	I
10	glycoprotein	I
11	undulin	O
12	.	O

1	The	O
2	effect	O
3	of	O
4	acetazolamide	O
5	(	O
6	ACZ	O
7	)	O
8	on	O
9	HCO3	O
10	-	O
11	and	O
12	Cl	O
13	-	O
14	activities	O
15	in	O
16	inner	O
17	ear	O
18	fluid	O
19	was	O
20	investigated	O
21	by	O
22	ion	O
23	-	O
24	selective	O
25	microelectrode	O
26	methods	O
27	.	O

1	Combined	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	and	O
8	p65	B
9	induced	O
10	vigorous	O
11	transcription	O
12	of	O
13	IL	B
14	-	I
15	2	I
16	promoter	I
17	-	I
18	and	O
19	CD28RE	O
20	-	O
21	driven	O
22	reporter	O
23	constructs	O
24	in	O
25	both	O
26	LFA	B
27	-	I
28	3	I
29	-	I
30	and	O
31	B7	B
32	-	I
33	1	I
34	-	I
35	costimulated	O
36	Jurkat	O
37	cells	O
38	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	O
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	According	O
2	to	O
3	the	O
4	changes	O
5	of	O
6	perfusion	O
7	defects	O
8	between	O
9	Ex	O
10	,	O
11	RD	O
12	and	O
13	ReI	O
14	images	O
15	,	O
16	they	O
17	were	O
18	classified	O
19	into	O
20	3	O
21	types	O
22	:	O
23	Type	O
24	I	O
25	;	O
26	perfusion	O
27	defect	O
28	on	O
29	the	O
30	RD	O
31	image	O
32	was	O
33	identical	O
34	to	O
35	ReI	O
36	image	O
37	(	O
38	75	O
39	%)	O
40	Type	O
41	I	O
42	was	O
43	divided	O
44	into	O
45	2	O
46	subgroups	O
47	whether	O
48	perfusion	O
49	defect	O
50	at	O
51	Ex	O
52	was	O
53	unchanged	O
54	(	O
55	Ia	O
56	,	O
57	42	O
58	%)	O
59	or	O
60	improved	O
61	(	O
62	Ib	O
63	,	O
64	33	O
65	%)	O
66	on	O
67	the	O
68	RD	O
69	image	O
70	.	O

1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	TGACCT	O
12	motifs	O
13	or	O
14	truncation	O
15	of	O
16	the	O
17	entire	O
18	HD	O
19	PPRE	O
20	into	O
21	a	O
22	separate	O
23	DR1	B
24	and	O
25	DR2	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	O
34	PPRE	O
35	to	O
36	peroxisome	O
37	proliferators	O
38	.	O

1	Gastrointestinal	B
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	Ninety	B
2	-	I
3	four	O
4	percent	O
5	of	O
6	the	O
7	EPs	O
8	were	O
9	tubal	O
10	,	O
11	and	O
12	90	O
13	%	O
14	of	O
15	the	O
16	tubes	O
17	exhibited	O
18	some	O
19	pathologic	O
20	changes	O
21	,	O
22	including	O
23	chronic	O
24	salpingitis	O
25	(	O
26	49	O
27	.	O
28	5	O
29	%)	O
30	and	O
31	follicular	O
32	salpingitis	O
33	(	O
34	10	O
35	%),	O
36	among	O
37	others	O
38	.	O

1	New	O
2	beta	B
3	-	I
4	blocking	O
5	drugs	O
6	have	O
7	been	O
8	introduced	O
9	which	O
10	may	O
11	prove	O
12	beneficial	O
13	in	O
14	certain	O
15	clinical	O
16	situations	O
17	since	O
18	they	O
19	exert	O
20	more	O
21	selective	O
22	blockade	O
23	of	O
24	the	O
25	cardiac	B
26	receptors	I
27	(	I
28	beta1	I
29	)	O
30	as	O
31	opposed	O
32	to	O
33	smooth	O
34	muscle	O
35	receptors	O
36	(	O
37	beta2	O
38	).	O

1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O

1	Topics	B
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	Gonadotropin	B
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	O
12	twins	O
13	.	O

1	Silicosis	B
2	mortality	O

1	The	O
2	mean	O
3	duration	O
4	of	O
5	pain	O
6	relief	O
7	was	O
8	4	O
9	-	O
10	6	O
11	weeks	O
12	.	O

1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	I
6	-	I
7	phosphorylated	I
8	proteins	I
9	that	O
10	complexed	O
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	I
28	transformed	O
29	Rat	B
30	-	I
31	2	I
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	I
47	.	O

1	The	O
2	alternative	O
3	sigma	B
4	factor	I
5	sigmaB	O
6	in	O
7	Staphylococcus	O
8	aureus	O
9	:	O
10	regulation	O
11	of	O
12	the	O
13	sigB	B
14	operon	I
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	O
21	heat	O
22	shock	O

1	Light	B
2	microscopical	O
3	and	O
4	routine	O
5	immunohistochemical	O
6	studies	O
7	of	O
8	a	O
9	cervical	O
10	neoplasm	O
11	in	O
12	a	O
13	32	O
14	year	O
15	old	O
16	woman	O
17	initially	O
18	suggested	O
19	a	O
20	histiocytic	O
21	lymphoma	O
22	,	O
23	but	O
24	histochemical	O
25	staining	O
26	for	O
27	chloroacetate	B
28	esterase	I
29	established	O
30	the	O
31	correct	O
32	diagnosis	O
33	.	O

1	These	O
2	findings	O
3	and	O
4	the	O
5	differential	O
6	tissue	O
7	distribution	O
8	of	O
9	p54	O
10	suggest	O
11	that	O
12	this	O
13	novel	O
14	SR	B
15	protein	I
16	may	O
17	participate	O
18	in	O
19	regulation	O
20	of	O
21	alternative	O
22	splicing	O
23	in	O
24	a	O
25	tissue	O
26	-	O
27	and	O
28	substrate	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	B
10	-	I
11	dependent	I
12	DNA	I
13	binding	I
14	,	O
15	TraM	O
16	inhibited	O
17	TraR	O
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O

1	Large	B
2	scale	O
3	electronic	O
4	structure	O
5	calculations	O
6	.	O

1	A	I
2	hypothesis	O
3	.	O

1	In	O
2	control	O
3	patients	O
4	,	O
5	baseline	O
6	images	O
7	presented	O
8	Type	O
9	I	O
10	in	O
11	25	O
12	,	O
13	Type	O
14	II	O
15	in	O
16	7	O
17	,	O
18	and	O
19	the	O
20	Type	O
21	III	O
22	&	O
23	IV	O
24	in	O
25	0	O
26	,	O
27	and	O
28	the	O
29	Type	O
30	after	O
31	loading	O
32	was	O
33	the	O
34	same	O
35	as	O
36	the	O
37	Type	O
38	at	O
39	baseline	O
40	.	O

1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	B
9	family	I
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	Analysis	O
2	in	O
3	3	O
4	groups	O
5	of	O
6	patients	O
7	suffering	O
8	from	O
9	simple	O
10	acute	O
11	and	O
12	pernicious	O
13	malarial	O
14	flare	O
15	-	O
16	ups	O

1	Further	O
2	research	O
3	is	O
4	recommended	O
5	to	O
6	identify	O
7	the	O
8	coping	O
9	styles	O
10	associated	O
11	with	O
12	the	O
13	high	O
14	EE	O
15	/	O
16	low	O
17	EE	O
18	research	O
19	classification	O
20	.	O

1	The	O
2	distribution	O
3	of	O
4	body	O
5	fluids	O
6	following	O
7	hemorrhage	O
8	and	O
9	resuscitation	O
10	in	O
11	combat	O
12	casualties	O
13	.	O

1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	O
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	O
15	-	O
16	glycosidase	O
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	Enzyme	B
2	-	I
3	linked	O
4	immunosorbent	O
5	assay	O
6	for	O
7	screening	O
8	aflatoxin	O
9	B1	O
10	in	O
11	cottonseed	O
12	products	O
13	and	O
14	mixed	O
15	feed	O
16	:	O
17	collaborative	O
18	study	O
19	.	O

1	Regulation	O
2	of	O
3	the	O
4	Raf	B
5	kinase	I
6	in	O
7	T	O
8	cells	O
9	differs	O
10	from	O
11	findings	O
12	with	O
13	a	O
14	variety	O
15	of	O
16	cell	O
17	lines	O
18	that	O
19	the	O
20	catalytic	O
21	domain	O
22	of	O
23	Raf	B
24	(	I
25	Raf	I
26	(	I
27	delta26	I
28	-	I
29	303	O
30	))	O
31	shows	O
32	no	O
33	activity	O
34	.	O

1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	O
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	B
26	polymerases	I
27	I	I
28	,	O
29	II	O
30	,	O
31	and	O
32	III	O
33	in	O
34	vitro	O
35	.	O

1	These	O
2	transcripts	O
3	have	O
4	a	O
5	unique	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	and	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	and	O
16	encode	O
17	a	O
18	predicted	O
19	protein	O
20	of	O
21	121	O
22	kD	O
23	.	O

1	The	O
2	carcinoma	O
3	was	O
4	restricted	O
5	within	O
6	the	O
7	epithelium	O
8	in	O
9	one	O
10	,	O
11	the	O
12	mucosal	O
13	layer	O
14	in	O
15	five	O
16	,	O
17	and	O
18	the	O
19	submucosal	O
20	layer	O
21	in	O
22	two	O
23	.	O

1	Where	B
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	B
10	beta	I
11	receptor	I
12	blockader	O
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	We	O
2	found	O
3	a	O
4	direct	O
5	correlation	O
6	between	O
7	the	O
8	levels	O
9	of	O
10	transcription	O
11	of	O
12	the	O
13	acc	O
14	genes	O
15	and	O
16	the	O
17	rate	O
18	of	O
19	cellular	O
20	growth	O
21	.	O

1	It	O
2	was	O
3	also	O
4	suggested	O
5	that	O
6	the	O
7	biological	O
8	activities	O
9	of	O
10	5	O
11	-	O
12	FU	O
13	,	O
14	ADM	O
15	and	O
16	MMC	O
17	in	O
18	FAMLIP	O
19	were	O
20	stable	O
21	in	O
22	FULIP	O
23	,	O
24	ADRLIP	O
25	and	O
26	MMCLIP	O
27	.	O

1	False	B
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	O
5	-	O
6	inducible	O
7	HIV	B
8	-	I
9	1	I
10	gene	I
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O

1	The	O
2	highly	O
3	amyloidogenic	O
4	42	O
5	-	O
6	residue	O
7	form	O
8	of	O
9	Abeta	O
10	(	O
11	Abeta42	O
12	)	O
13	is	O
14	the	O
15	first	O
16	species	O
17	to	O
18	be	O
19	deposited	O
20	in	O
21	both	O
22	sporadic	O
23	and	O
24	familial	O
25	AD	O
26	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	LTR	B
3	-	I
4	binding	I
5	activities	O
6	of	O
7	VBP	O
8	,	O
9	a1	B
10	/	I
11	EBP	I
12	,	O
13	and	O
14	B	O
15	-	O
16	cell	O
17	nuclear	O
18	extract	O
19	protein	O
20	were	O
21	compared	O
22	and	O
23	mapped	O
24	by	O
25	gel	O
26	shift	O
27	,	O
28	DNase	B
29	I	I
30	footprinting	O
31	,	O
32	and	O
33	methylation	O
34	interference	O
35	assays	O
36	.	O

1	Interactions	B
2	between	O
3	adrenergics	O
4	,	O
5	adrenolytics	O
6	and	O
7	monoamine	B
8	oxidase	I
9	inhibitors	O

1	Among	O
2	unusual	O
3	features	O
4	,	O
5	we	O
6	report	O
7	numerous	O
8	large	O
9	G	B
10	+	I
11	C	I
12	-	I
13	rich	O
14	conserved	O
15	sequences	O
16	located	O
17	in	O
18	the	O
19	first	O
20	intron	O
21	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	NZ	O
6	-	O
7	107	O
8	may	O
9	be	O
10	a	O
11	useful	O
12	drug	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	bronchial	O
18	asthma	O
19	by	O
20	reducing	O
21	late	O
22	-	O
23	phase	O
24	airway	O
25	responses	O
26	and	O
27	airway	O
28	hyperreactivity	O
29	.	O

1	Other	B
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	O
9	12	O
10	and	O
11	Vinca	O
12	are	O
13	unaltered	O
14	.	O

1	Organization	O
2	of	O
3	the	O
4	bovine	B
5	gene	I
6	encoding	O
7	the	O
8	endothelial	O
9	nitric	B
10	oxide	I
11	synthase	I
12	.	O

1	12	I
2	-	I
3	O	I
4	-	I
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	O
26	and	O
27	myogenin	B
28	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	Recombinant	B
2	Ffh	O
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Point	B
2	mutations	O
3	in	O
4	the	O
5	third	O
6	SH3	B
7	domain	I
8	abolished	O
9	the	O
10	vinexin	O
11	-	O
12	Sos	B
13	interaction	O
14	.	O

1	A	I
2	decanucleotide	I
3	promoter	I
4	sequence	I
5	homologous	O
6	to	O
7	those	O
8	found	O
9	in	O
10	humans	O
11	and	O
12	mice	O
13	was	O
14	located	O
15	in	O
16	the	O
17	5	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	one	O
23	horse	B
24	gene	I
25	.	O

1	The	O
2	gene	O
3	ccpA	O
4	encoding	O
5	the	O
6	catabolite	O
7	control	O
8	protein	O
9	CcpA	O
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	O
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	O
12	trimeric	O
13	and	O
14	dimeric	O
15	complexes	O
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	O
22	function	O
23	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	The	O
2	weak	O
3	base	O
4	ketoconazole	O
5	showed	O
6	complete	O
7	dissolution	O
8	from	O
9	a	O
10	tablet	O
11	formulation	O
12	in	O
13	Simulated	O
14	Gastric	O
15	Fluid	O
16	without	O
17	pepsin	O
18	(	O
19	SGFsp	O
20	)	O
21	within	O
22	30	O
23	minutes	O
24	,	O
25	70	O
26	%	O
27	dissolution	O
28	in	O
29	2	O
30	hours	O
31	under	O
32	fed	O
33	state	O
34	simulated	O
35	upper	O
36	jejunal	O
37	conditions	O
38	but	O
39	only	O
40	6	O
41	%	O
42	dissolution	O
43	in	O
44	2	O
45	hours	O
46	under	O
47	fasted	O
48	state	O
49	conditions	O
50	.	O

1	Twelve	B
2	patients	O
3	without	O
4	abnormalities	O
5	in	O
6	the	O
7	PTT	O
8	are	O
9	assumed	O
10	to	O
11	harbor	O
12	missense	O
13	mutations	O
14	,	O
15	probably	O
16	in	O
17	TSC2	O
18	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	However	O
2	,	O
3	both	O
4	TPN	O
5	groups	O
6	showed	O
7	a	O
8	marked	O
9	increase	O
10	in	O
11	activities	O
12	of	O
13	liver	O
14	lysosomal	O
15	enzymes	O
16	.	O

1	Furthermore	O
2	,	O
3	competitor	O
4	containing	O
5	the	O
6	YY1	B
7	consensus	I
8	sequence	I
9	competed	I
10	for	I
11	protein	I
12	B	I
13	binding	I
14	,	O
15	whereas	O
16	competitor	O
17	containing	O
18	a	O
19	perfect	O
20	yeast	O
21	ABF	B
22	-	I
23	1	I
24	consensus	I
25	sequence	I
26	did	O
27	not	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	This	O
2	short	O
3	communication	O
4	compares	O
5	a	O
6	novel	O
7	fluorimetric	O
8	microplate	O
9	enzyme	O
10	immunoassay	O
11	(	O
12	FEIA	O
13	)	O
14	with	O
15	a	O
16	commercial	O
17	time	O
18	-	O
19	resolved	O
20	fluoroimmunoassay	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	thyrotropin	B
26	in	O
27	dried	O
28	blood	O
29	spots	O
30	.	O

1	It	O
2	is	O
3	clear	O
4	that	O
5	subclinical	O
6	and	O
7	silent	O
8	CD	O
9	exist	O
10	in	O
11	a	O
12	large	O
13	subgroup	O
14	of	O
15	the	O
16	celiac	O
17	population	O
18	.	O

1	In	O
2	summary	O
3	,	O
4	DDC	O
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	Significance	B
2	of	O
3	thin	O
4	glomerular	O
5	basement	O
6	membranes	O
7	in	O
8	hematuric	O
9	children	O
10	.	O

1	Analysis	O
2	of	O
3	its	O
4	genomic	O
5	region	O
6	revealed	O
7	that	O
8	the	O
9	13	O
10	-	O
11	kb	O
12	Cdc6	B
13	gene	I
14	is	O
15	divided	O
16	into	O
17	12	O
18	exons	O
19	by	O
20	11	O
21	introns	O
22	.	O

1	Wild	B
2	-	I
3	type	I
4	protein	I
5	bound	O
6	azido	O
7	-	O
8	ATP	O
9	well	O
10	,	O
11	but	O
12	mutants	O
13	with	O
14	substitutions	O
15	in	O
16	the	O
17	consensus	O
18	amino	O
19	acids	O
20	were	O
21	unable	O
22	to	O
23	bind	O
24	azido	O
25	-	O
26	ATP	O
27	.	O

1	Nitrofurazone	B
2	significantly	O
3	reduced	O
4	the	O
5	rise	O
6	in	O
7	LH	B
8	induced	O
9	by	O
10	LHRH	O
11	.	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	O
7	(	O
8	trp	B
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	O
15	mitochondria	O
16	is	O
17	also	O
18	reported	O
19	.	O

1	Gentamicin	B
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	Panlobular	B
2	emphysema	O

1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O

1	N	B
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	Six	O
2	patients	O
3	with	O
4	the	O
5	diagnosis	O
6	of	O
7	acute	O
8	mania	O
9	were	O
10	treated	O
11	with	O
12	high	O
13	doses	O
14	of	O
15	the	O
16	beta	B
17	-	I
18	adrenergic	I
19	blocking	O
20	agent	O
21	propranolol	O
22	.	O

1	Holger	B
2	v	O
3	.	O

1	The	O
2	1	O
3	.	O
4	9	O
5	-	O
6	kb	O
7	C	B
8	mu	I
9	RNA	I
10	contains	O
11	the	O
12	3	O
13	'	O
14	sequence	O
15	characteristic	O
16	of	O
17	secreted	O
18	mu	B
19	chain	I
20	,	O
21	whereas	O
22	the	O
23	longer	O
24	species	O
25	bear	O
26	that	O
27	of	O
28	membrane	O
29	-	O
30	bound	O
31	mu	O
32	chin	O
33	.	O

1	In	O
2	conclusion	O
3	,	O
4	IgM	B
5	class	I
6	CIC	O
7	is	O
8	the	O
9	predominant	O
10	CIC	O
11	in	O
12	acute	O
13	hepatitis	O
14	A	O
15	and	O
16	correlated	O
17	with	O
18	disease	O
19	activity	O
20	.	O

1	It	O
2	acts	O
3	on	O
4	Cdks	O
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	B
21	cell	I
22	nuclear	I
23	antigen	I
24	(	I
25	PCNA	I
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O

1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	B
18	DNA	I
19	polymerase	I
20	beta	I
21	(	I
22	beta	I
23	-	I
24	pol	I
25	)	I
26	gene	I
27	promoter	I
28	.	O

1	ERK	B
2	MAP	I
3	kinase	I
4	links	O
5	cytokine	O
6	signals	O
7	to	O
8	activation	O
9	of	O
10	latent	O
11	HIV	B
12	-	I
13	1	I
14	infection	O
15	by	O
16	stimulating	O
17	a	O
18	cooperative	O
19	interaction	O
20	of	O
21	AP	B
22	-	I
23	1	I
24	and	O
25	NF	B
26	-	I
27	kappaB	I
28	.	O

1	Zinc	B
2	fingers	O
3	(	O
4	Zf	O
5	)	O
6	are	O
7	a	O
8	common	O
9	structural	O
10	motif	O
11	found	O
12	in	O
13	many	O
14	nucleic	O
15	acid	O
16	-	O
17	binding	O
18	proteins	O
19	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	O
16	and	O
17	RNR3	O
18	genes	O
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O

1	The	O
2	resulting	O
3	clone	O
4	pKB11	O
5	,	O
6	which	O
7	has	O
8	a	O
9	1369	O
10	-	O
11	base	O
12	pair	O
13	(	O
14	bp	O
15	)	O
16	cDNA	O
17	insert	O
18	,	O
19	overlapping	O
20	pCAD142	O
21	by	O
22	781	O
23	bp	O
24	,	O
25	was	O
26	identified	O
27	by	O
28	hybridization	O
29	methods	O
30	and	O
31	sequence	O
32	analysis	O
33	and	O
34	found	O
35	to	O
36	contain	O
37	the	O
38	entire	O
39	cDNA	O
40	sequence	O
41	for	O
42	the	O
43	amino	O
44	end	O
45	of	O
46	the	O
47	CAD	O
48	polypeptide	O
49	.	O

1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	O
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O

1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	O
6	GCN2	B
7	mutations	O
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	B
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	Erythrocyte	B
2	delta	I
3	-	I
4	aminolevulinic	O
5	acid	O
6	dehydratase	O
7	(	O
8	ALAD	O
9	)	O
10	activity	O
11	,	O
12	erythrocyte	O
13	zinc	O
14	protoporphyrin	O
15	(	O
16	ZPP	O
17	)/	O
18	heme	O
19	ratio	O
20	,	O
21	and	O
22	urinary	O
23	coproporphyrin	O
24	(	O
25	UC	O
26	)	O
27	concentration	O
28	have	O
29	been	O
30	employed	O
31	as	O
32	biological	O
33	indicators	O
34	of	O
35	moderate	O
36	-	O
37	to	O
38	high	O
39	-	O
40	level	O
41	lead	O
42	exposure	O
43	,	O
44	corresponding	O
45	to	O
46	blood	O
47	levels	O
48	in	O
49	excess	O
50	of	O
51	50	O
52	micrograms	O
53	/	O
54	dl	O
55	,	O
56	in	O
57	human	O
58	subjects	O
59	.	O

1	A	I
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	B
7	-	I
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	Regulated	B
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	B
13	corticotropin	I
14	-	I
15	releasing	I
16	hormone	I
17	gene	I
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O

1	The	O
2	repression	O
3	domain	O
4	,	O
5	and	O
6	indeed	O
7	the	O
8	entire	O
9	Cdc68	O
10	protein	O
11	,	O
12	is	O
13	highly	O
14	conserved	O
15	,	O
16	as	O
17	shown	O
18	by	O
19	the	O
20	sequence	O
21	of	O
22	the	O
23	Cdc68	O
24	functional	O
25	homolog	O
26	from	O
27	the	O
28	yeast	O
29	Kluyveromyces	O
30	lactis	O
31	and	O
32	by	O
33	database	O
34	searches	O
35	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	B
38	factor	I
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	R	O
8	.	O
9	N	O
10	.	O

1	After	O
2	that	O
3	report	O
4	,	O
5	carboxypeptidase	O
6	D	O
7	(	O
8	CPD	O
9	)	O
10	was	O
11	subsequently	O
12	purified	O
13	from	O
14	bovine	O
15	pituitary	O
16	and	O
17	characterized	O
18	as	O
19	a	O
20	novel	O
21	carboxypeptidase	O
22	E	O
23	(	O
24	CPE	B
25	)-	I
26	like	I
27	enzyme	I
28	,	O
29	with	O
30	many	O
31	characteristics	O
32	in	O
33	common	O
34	with	O
35	duck	O
36	gp180	O
37	(	O
38	Song	O
39	,	O
40	L	O
41	.,	O
42	Fricker	O
43	,	O
44	L	O
45	.	O
46	D	O
47	.,	O
48	1995	O
49	.	O

1	Clones	B
2	33F	O
3	and	O
4	34B	O
5	encoded	O
6	identical	O
7	aromatase	B
8	proteins	I
9	of	O
10	503	O
11	amino	O
12	acids	O
13	,	O
14	but	O
15	differed	O
16	in	O
17	size	O
18	due	O
19	to	O
20	alternative	O
21	polyadenylation	O
22	signal	O
23	usage	O
24	for	O
25	the	O
26	corresponding	O
27	mRNAs	O
28	.	O

1	These	O
2	analyses	O
3	demonstrate	O
4	that	O
5	the	O
6	dUTPase	O
7	isoforms	O
8	are	O
9	encoded	O
10	by	O
11	the	O
12	same	O
13	gene	O
14	with	O
15	isoform	O
16	-	O
17	specific	O
18	transcripts	O
19	arising	O
20	through	O
21	the	O
22	use	O
23	of	O
24	alternative	O
25	5	O
26	'	O
27	exons	O
28	.	O

1	The	O
2	homeobox	B
3	gene	I
4	ATK1	O
5	of	O
6	Arabidopsis	O
7	thaliana	O
8	is	O
9	expressed	O
10	in	O
11	the	O
12	shoot	O
13	apex	O
14	of	O
15	the	O
16	seedling	O
17	and	O
18	in	O
19	flowers	O
20	and	O
21	inflorescence	O
22	stems	O
23	of	O
24	mature	O
25	plants	O
26	.	O

1	Chemotherapy	B
2	of	O
3	metastasizing	O
4	breast	O
5	cancer	O

1	The	O
2	algorithm	O
3	also	O
4	limited	O
5	TG	O
6	to	O
7	20	O
8	and	O
9	64	O
10	%,	O
11	apoB	O
12	to	O
13	6	O
14	and	O
15	20	O
16	%,	O
17	and	O
18	Lp	O
19	(	O
20	a	O
21	)	O
22	to	O
23	15	O
24	and	O
25	56	O
26	%,	O
27	of	O
28	low	O
29	-	O
30	and	O
31	high	O
32	-	O
33	risk	O
34	groups	O
35	,	O
36	respectively	O
37	.	O

1	Out	B
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	leprosy	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O

1	In	O
2	a	O
3	previous	O
4	study	O
5	(	O
6	Brandl	O
7	,	O
8	C	O
9	.	O

1	Nuclear	B
2	receptors	I
3	(	O
4	NRs	O
5	)	O
6	can	O
7	function	O
8	as	O
9	ligandinducible	O
10	transregulators	O
11	in	O
12	both	O
13	mammalian	O
14	and	O
15	yeast	O
16	cells	O
17	,	O
18	indicating	O
19	that	O
20	important	O
21	features	O
22	of	O
23	transcriptional	O
24	control	O
25	have	O
26	been	O
27	conserved	O
28	throughout	O
29	evolution	O
30	.	O

1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O

1	Argatroban	B
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	O
9	II	O
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O

1	A	I
2	cluster	I
3	of	O
4	basic	O
5	amino	O
6	acids	O
7	,	O
8	KKKR	O
9	,	O
10	generated	O
11	by	O
12	joining	O
13	of	O
14	the	O
15	sequences	O
16	encoded	O
17	by	O
18	the	O
19	constitutive	O
20	exon	O
21	13	O
22	and	O
23	the	O
24	alternative	O
25	exon	O
26	16	O
27	,	O
28	is	O
29	necessary	O
30	for	O
31	the	O
32	nuclear	O
33	targeting	O
34	of	O
35	4	O
36	.	O
37	1H	O
38	,	O
39	as	O
40	demonstrated	O
41	by	O
42	site	O
43	-	O
44	directed	O
45	mutagenesis	O
46	analysis	O
47	.	O

1	Indeed	B
2	,	O
3	A	O
4	-	O
5	MuLV	O
6	pseudotyped	O
7	with	O
8	some	O
9	viruses	O
10	,	O
11	such	O
12	as	O
13	the	O
14	Moloney	O
15	MuLV	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	be	O
22	highly	O
23	lymphogenic	O
24	,	O
25	whereas	O
26	A	O
27	-	O
28	MuLV	O
29	pseudotyped	O
30	with	O
31	other	O
32	viruses	O
33	,	O
34	such	O
35	as	O
36	the	O
37	BALB	O
38	/	O
39	c	B
40	endogenous	O
41	N	O
42	-	O
43	tropic	O
44	MuLV	O
45	,	O
46	has	O
47	been	O
48	shown	O
49	to	O
50	be	O
51	devoid	O
52	of	O
53	lymphogenic	O
54	potential	O
55	(	O
56	N	O
57	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	I
17	RBCC	O
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	O
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	I
20	gamma1	O
21	SH3	B
22	domain	I
23	.	O

1	Such	O
2	an	O
3	interaction	O
4	could	O
5	be	O
6	detected	O
7	using	O
8	a	O
9	GST	B
10	-	I
11	POU	I
12	fusion	I
13	protein	I
14	bound	O
15	to	O
16	glutathione	B
17	-	I
18	agarose	O
19	beads	O
20	.	O

1	Identification	O
2	of	O
3	the	O
4	plakoglobin	B
5	-	I
6	binding	I
7	domain	I
8	in	O
9	desmoglein	O
10	and	O
11	its	O
12	role	O
13	in	O
14	plaque	O
15	assembly	O
16	and	O
17	intermediate	O
18	filament	O
19	anchorage	O
20	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	O
19	chalcone	B
20	synthase	I
21	promoter	I
22	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	O
21	smegmatis	O
22	clones	O
23	.	O

1	Twelve	B
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	troponin	O
10	I	O
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	Axsym	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	Immuno	O
41	1	O
42	.	O

1	Incidences	B
2	of	O
3	nonfatal	O
4	stroke	O
5	,	O
6	myocardial	O
7	infarction	O
8	,	O
9	angina	O
10	pectoris	O
11	und	O
12	left	O
13	ventricular	O
14	hypertrophy	O
15	could	O
16	also	O
17	be	O
18	lowered	O
19	.	O

1	Reverse	B
2	transcription	I
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	B
22	kinases	I
23	.	O

1	Serum	B
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	Relaxation	B
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	Expression	O
2	of	O
3	p130	B
4	(	O
5	Cas	O
6	)	O
7	(	O
8	Cas	O
9	),	O
10	a	O
11	major	O
12	binding	O
13	protein	O
14	for	O
15	the	O
16	Crk	B
17	SH2	I
18	-	I
19	domain	I
20	,	O
21	also	O
22	induced	O
23	JNK	B
24	activation	O
25	,	O
26	which	O
27	was	O
28	blocked	O
29	by	O
30	the	O
31	SH2	B
32	-	I
33	mutant	I
34	of	O
35	Crk	B
36	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	showed	O
7	that	O
8	OxyR	O
9	-	O
10	C199S	O
11	protected	O
12	Pmom	O
13	from	O
14	-	O
15	104	O
16	to	O
17	-	O
18	46	O
19	on	O
20	the	O
21	top	O
22	strand	O
23	and	O
24	produced	O
25	a	O
26	protection	O
27	pattern	O
28	characteristic	O
29	of	O
30	reduced	O
31	wild	B
32	-	I
33	type	I
34	OxyR	O
35	.	O

1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	B
18	levels	O
19	.	O

1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	O
18	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	functionally	O
6	characterized	O
7	the	O
8	mouse	B
9	gene	I
10	for	O
11	the	O
12	C2	B
13	subunit	I
14	of	O
15	the	O
16	20S	B
17	proteasome	I
18	.	O

1	Citrate	B
2	synthase	I
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O

1	The	O
2	structural	O
3	similarity	O
4	between	O
5	Vav	O
6	and	O
7	other	O
8	guanine	B
9	nucleotide	I
10	exchange	I
11	factors	I
12	for	O
13	small	B
14	GTP	I
15	-	I
16	binding	I
17	proteins	I
18	,	O
19	together	O
20	with	O
21	the	O
22	recent	O
23	identification	O
24	of	O
25	biochemical	O
26	routes	O
27	specific	O
28	for	O
29	members	O
30	of	O
31	the	O
32	Ras	B
33	and	O
34	Rho	B
35	family	I
36	of	O
37	GTPases	O
38	,	O
39	prompted	O
40	us	O
41	to	O
42	explore	O
43	whether	O
44	MAPK	B
45	or	O
46	JNK	B
47	are	O
48	downstream	O
49	components	O
50	of	O
51	the	O
52	Vav	O
53	signaling	O
54	pathways	O
55	.	O

1	Bioplastique	B
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	Because	O
2	the	O
3	Pit	B
4	-	I
5	1	I
6	sites	I
7	in	O
8	the	O
9	hGH	B
10	-	I
11	N	I
12	gene	I
13	promoter	I
14	are	O
15	insufficient	O
16	for	O
17	such	O
18	gene	O
19	activation	O
20	in	O
21	vivo	O
22	,	O
23	these	O
24	data	O
25	suggested	O
26	a	O
27	unique	O
28	chromatin	O
29	-	O
30	mediated	O
31	developmental	O
32	role	O
33	for	O
34	Pit	B
35	-	I
36	1	I
37	in	O
38	the	O
39	hGH	O
40	LCR	O
41	.	O

1	TG	B
2	-	I
3	day	O
4	and	O
5	TG	B
6	-	I
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	In	O
2	the	O
3	predicted	O
4	transmembrane	O
5	domain	O
6	,	O
7	Casr	O
8	-	O
9	rs2	O
10	and	O
11	Casr	O
12	-	O
13	rs3	O
14	are	O
15	95	O
16	%	O
17	identical	O
18	to	O
19	Casr	O
20	-	O
21	rs1	O
22	.	O

1	We	O
2	cloned	O
3	the	O
4	third	O
5	human	B
6	gene	I
7	for	O
8	the	O
9	LD78	O
10	,	O
11	termed	O
12	LD78	B
13	gamma	I
14	and	O
15	the	O
16	sequence	O
17	analysis	O
18	showed	O
19	that	O
20	it	O
21	is	O
22	a	O
23	5	O
24	'-	O
25	truncated	O
26	pseudogene	O
27	.	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	These	O
2	patients	O
3	failed	O
4	to	O
5	respond	O
6	to	O
7	intravenous	O
8	cyclophosphamide	O
9	and	O
10	steroids	O
11	and	O
12	were	O
13	then	O
14	changed	O
15	to	O
16	receive	O
17	oral	O
18	cyclosporine	O
19	A	O
20	,	O
21	at	O
22	a	O
23	dose	O
24	of	O
25	5	O
26	mg	O
27	/	O
28	kg	O
29	/	O
30	day	O
31	.	O

1	This	O
2	Tbx6	B
3	-	I
4	subfamily	I
5	gene	I
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O

1	The	O
2	activity	O
3	of	O
4	serum	B
5	lipase	I
6	and	I
7	amylase	I
8	distinctly	O
9	increased	O
10	at	O
11	3	O
12	h	O
13	and	O
14	went	O
15	up	O
16	to	O
17	the	O
18	maximum	O
19	at	O
20	12	O
21	h	O
22	after	O
23	injection	O
24	of	O
25	Na	O
26	-	O
27	Tc	O
28	.	O

1	T	B
2	.,	O
3	Mahasneh	O
4	,	O
5	A	O
6	.,	O
7	and	O
8	Cote	O
9	,	O
10	G	O
11	.	O

1	Human	B
2	ULK1	O
3	,	O
4	a	O
5	novel	O
6	serine	B
7	/	I
8	threonine	I
9	kinase	I
10	related	I
11	to	O
12	UNC	B
13	-	I
14	51	I
15	kinase	I
16	of	O
17	Caenorhabditis	O
18	elegans	O
19	:	O
20	cDNA	O
21	cloning	O
22	,	O
23	expression	O
24	,	O
25	and	O
26	chromosomal	O
27	assignment	O
28	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	third	O
7	intracellular	O
8	loop	O
9	of	O
10	the	O
11	rat	O
12	GnRH	B
13	-	I
14	R	I
15	is	O
16	involved	O
17	in	O
18	receptor	O
19	G	B
20	(	I
21	q	I
22	/	I
23	11	I
24	)	I
25	protein	I
26	coupling	O
27	and	O
28	/	O
29	or	O
30	selectivity	O
31	,	O
32	and	O
33	in	O
34	the	O
35	GGH	O
36	(	O
37	3	O
38	)	O
39	1	O
40	'	O
41	cell	O
42	line	O
43	,	O
44	this	O
45	loop	O
46	is	O
47	also	O
48	involved	O
49	in	O
50	signal	O
51	transduction	O
52	mediated	O
53	through	O
54	the	O
55	Gs	O
56	protein	O
57	pathway	O
58	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	AACA	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	seed	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	barley	B
29	gibberellin	I
30	responsive	I
31	element	I
32	recognized	O
33	by	O
34	MYB	B
35	-	I
36	like	I
37	DNA	I
38	binding	I
39	proteins	I
40	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	B
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O

1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	O
17	of	O
18	the	O
19	MAO	B
20	-	I
21	B	I
22	inhibitor	I
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O

1	CASE	B
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O

1	Following	O
2	iv	O
3	injection	O
4	of	O
5	0	O
6	.	O
7	5	O
8	g	O
9	galactose	O
10	per	O
11	kg	O
12	body	O
13	weight	O
14	,	O
15	together	O
16	with	O
17	2	O
18	mu	O
19	Ci	O
20	generally	O
21	14C	O
22	-	O
23	labelled	O
24	galactose	O
25	,	O
26	14CO2	O
27	is	O
28	collected	O
29	in	O
30	regular	O
31	intervals	O
32	during	O
33	one	O
34	hour	O
35	.	O

1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O

1	The	O
2	Hagen	O
3	-	O
4	Poiseuille	O
5	equation	O
6	is	O
7	used	O
8	to	O
9	assess	O
10	the	O
11	effects	O
12	of	O
13	attached	O
14	parasites	O
15	in	O
16	the	O
17	foregut	O
18	of	O
19	Leishmania	O
20	-	O
21	infected	O
22	sandflies	O
23	on	O
24	blood	O
25	flow	O
26	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O

1	G	B
2	-	I
3	box	I
4	-	I
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	B
23	)	I
24	35S	I
25	promoter	I
26	.	O

1	Several	O
2	agents	O
3	have	O
4	been	O
5	tried	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O

1	D	I
2	-	I
3	cyclin	I
4	-	I
5	cdk	O
6	activity	O
7	is	O
8	required	O
9	for	O
10	Rb	B
11	phosphorylation	O
12	in	O
13	v	B
14	-	I
15	Jun	I
16	-	I
17	transformed	O
18	cells	O
19	,	O
20	since	O
21	ectopic	O
22	expression	O
23	of	O
24	the	O
25	cdk4	O
26	-	O
27	and	O
28	cdk6	O
29	-	O
30	specific	O
31	inhibitor	O
32	p16	B
33	(	O
34	INK4A	O
35	)	O
36	inhibits	O
37	both	O
38	DNA	O
39	synthesis	O
40	and	O
41	cell	O
42	proliferation	O
43	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	B
8	NAD	I
9	(	I
10	P	I
11	)	I
12	H	I
13	-	I
14	NR	O
15	sequence	O
16	in	O
17	comparison	O
18	to	O
19	NADH	O
20	-	O
21	NR	O
22	sequences	O
23	was	O
24	found	O
25	at	O
26	the	O
27	putative	O
28	pyridine	B
29	nucleotide	I
30	binding	I
31	site	I
32	.	O

1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	examine	O
7	the	O
8	effects	O
9	of	O
10	Msx2	O
11	expression	O
12	on	O
13	OC	O
14	promoter	O
15	activation	O
16	(	O
17	luciferase	B
18	reporter	I
19	)	O
20	by	O
21	FGF2	O
22	/	O
23	FSK	O
24	and	O
25	calcitriol	O
26	in	O
27	MC3T3	O
28	-	O
29	E1	B
30	osteoblasts	O
31	.	O

1	DNA	I
2	-	I
3	dependent	I
4	protein	I
5	kinase	I
6	(	I
7	DNA	I
8	-	I
9	PK	O
10	)	O
11	consists	O
12	of	O
13	a	O
14	heterodimeric	B
15	protein	I
16	(	O
17	Ku	O
18	)	O
19	and	O
20	a	O
21	large	O
22	catalytic	O
23	subunit	O
24	(	O
25	DNA	O
26	-	O
27	PKcs	O
28	).	O

1	Since	O
2	glutathione	B
3	peroxidase	I
4	(	O
5	GPX	O
6	)	O
7	and	O
8	superoxide	B
9	dismutase	I
10	(	O
11	SOD	O
12	)	O
13	play	O
14	a	O
15	significant	O
16	role	O
17	in	O
18	erythrocyte	O
19	antioxidative	O
20	defence	O
21	,	O
22	it	O
23	is	O
24	very	O
25	important	O
26	to	O
27	determine	O
28	their	O
29	activity	O
30	in	O
31	occupationally	O
32	exposed	O
33	workers	O
34	.	O

1	A	I
2	5	O
3	.	O
4	0	O
5	-	O
6	kb	O
7	transcript	O
8	detected	O
9	by	O
10	the	O
11	differential	O
12	display	O
13	amplicon	O
14	3G1	O
15	was	O
16	found	O
17	to	O
18	correlate	O
19	strongly	O
20	with	O
21	RAG1	O
22	mRNA	O
23	expression	O
24	in	O
25	various	O
26	human	O
27	cell	O
28	lines	O
29	.	O

1	Silencing	B
2	can	O
3	be	O
4	restored	O
5	by	O
6	creation	O
7	of	O
8	a	O
9	telomere	O
10	at	O
11	13	O
12	kb	O
13	from	O
14	the	O
15	reporter	O
16	construct	O
17	,	O
18	or	O
19	by	O
20	insertion	O
21	of	O
22	340	O
23	bp	O
24	of	O
25	yeast	O
26	telomeric	O
27	repeat	O
28	sequence	O
29	at	O
30	this	O
31	site	O
32	without	O
33	chromosomal	O
34	truncation	O
35	.	O

1	Shoulder	B
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	Eight	O
2	patients	O
3	received	O
4	1	O
5	.	O
6	5	O
7	mg	O
8	of	O
9	adefovir	O
10	dipivoxil	O
11	per	O
12	kg	O
13	of	O
14	body	O
15	weight	O
16	,	O
17	and	O
18	six	O
19	patients	O
20	received	O
21	3	O
22	.	O
23	0	O
24	mg	O
25	of	O
26	adefovir	O
27	dipivoxil	O
28	per	O
29	kg	O
30	.	O

1	Interspecific	B
2	complementation	O
3	tests	O
4	showed	O
5	that	O
6	the	O
7	P7	O
8	proteins	O
9	are	O
10	unable	O
11	to	O
12	complement	O
13	P1	O
14	parA	O
15	or	O
16	parB	O
17	mutants	O
18	,	O
19	and	O
20	the	O
21	P1	O
22	proteins	O
23	fail	O
24	to	O
25	complement	O
26	the	O
27	P7	O
28	mutations	O
29	.	O

1	Induction	O
2	of	O
3	Jurkat	O
4	leukemic	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	ionomycin	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	FKBP	O
24	mRNA	O
25	.	O

1	Thus	O
2	,	O
3	the	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	should	O
10	help	O
11	to	O
12	define	O
13	regulatory	O
14	elements	O
15	that	O
16	control	O
17	neuron	B
18	-	I
19	specific	I
20	and	O
21	developmental	O
22	expression	O
23	of	O
24	the	O
25	MAP1B	B
26	gene	I
27	.	O

1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	I
20	BTU2	I
21	)	I
22	gene	I
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O

1	A	I
2	method	O
3	is	O
4	described	O
5	for	O
6	the	O
7	simultaneous	O
8	determination	O
9	of	O
10	1	O
11	,	O
12	alpha	B
13	-	I
14	acetylmethadol	O
15	(	O
16	LAAM	O
17	)	O
18	and	O
19	five	O
20	active	O
21	metabolites	O
22	--	O
23	noracetylmethadol	O
24	,	O
25	dinoracetylmethadol	O
26	,	O
27	methadol	O
28	,	O
29	normethadol	O
30	,	O
31	and	O
32	dinormethadol	O
33	--	O
34	in	O
35	biofluids	O
36	by	O
37	high	O
38	-	O
39	performance	O
40	liquid	O
41	chromatography	O
42	using	O
43	a	O
44	normal	O
45	-	O
46	phase	O
47	column	O
48	and	O
49	a	O
50	UV	O
51	detector	O
52	at	O
53	218	O
54	nm	O
55	.	O

1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	Tec	B
6	family	I
7	kinases	I
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	effectors	O
20	of	O
21	these	O
22	enzymes	O
23	.	O

1	Pseudosubstrate	B
2	(	I
3	19	I
4	-	I
5	36	O
6	),	O
7	derived	O
8	from	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	of	O
14	Ca	B
15	-	I
16	dependent	I
17	PKC	I
18	isotypes	O
19	,	O
20	inhibited	O
21	beta	B
22	-	I
23	PKC	I
24	but	O
25	not	O
26	nPKC	O
27	activity	O
28	using	O
29	either	O
30	Histone	O
31	IIIS	O
32	or	O
33	peptide	O
34	(	O
35	19	O
36	-	O
37	31	O
38	)	O
39	as	O
40	substrate	O
41	.	O

1	Correlation	B
2	coefficients	O
3	between	O
4	the	O
5	reference	O
6	methods	O
7	and	O
8	NIT	O
9	were	O
10	>	O
11	or	O
12	=	O
13	0	O
14	.	O
15	95	O
16	for	O
17	water	O
18	,	O
19	fat	O
20	,	O
21	crude	O
22	protein	O
23	and	O
24	connective	B
25	-	I
26	tissue	I
27	-	I
28	protein	I
29	frei	O
30	meat	O
31	protein	O
32	,	O
33	and	O
34	>	O
35	or	O
36	=	O
37	0	O
38	.	O
39	86	O
40	for	O
41	connective	B
42	-	I
43	tissue	I
44	-	I
45	protein	I
46	.	O

1	Ultimate	B
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	O
30	tau	O
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O

1	Fufang	B
2	wuzi	O
3	yanzong	O
4	pills	O
5	have	O
6	strong	O
7	leukogenic	O
8	effect	O
9	on	O
10	cyclophosphamide	O
11	induced	O
12	leukopenia	O
13	in	O
14	mice	O
15	.	O

1	UPMC	B
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Phorbol	B
2	esters	O
3	stimulated	O
4	phosphorylation	O
5	of	O
6	CSK	O
7	35H	O
8	proteins	O
9	,	O
10	thus	O
11	emphasizing	O
12	that	O
13	sequences	O
14	isolated	O
15	according	O
16	to	O
17	PKC	B
18	binding	I
19	activity	O
20	in	O
21	vitro	O
22	are	O
23	also	O
24	PKC	B
25	substrates	O
26	in	O
27	vivo	O
28	.	O

1	The	O
2	parameters	O
3	of	O
4	nonspecific	O
5	humoral	O
6	immunity	O
7	--	O
8	serum	B
9	immunoglobulins	I
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	irradiated	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	cervix	O
24	carcinoma	O
25	(	O
26	Stages	O
27	IIB	O
28	and	O
29	IIIB	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O

1	These	O
2	natural	O
3	antisense	B
4	S	I
5	transcripts	I
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	O
15	transcripts	O
16	.	O

1	Biol	O
2	.	O

1	MK	O
2	-	O
3	927	O
4	:	O
5	a	O
6	topically	O
7	active	O
8	ocular	O
9	hypotensive	O
10	carbonic	B
11	anhydrase	I
12	inhibitor	I
13	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	suppression	O
6	of	O
7	elevated	O
8	prolactin	B
9	levels	O
10	in	O
11	progressive	O
12	metastatic	O
13	breast	O
14	cancer	O
15	patients	O
16	is	O
17	not	O
18	effective	O
19	in	O
20	restoring	O
21	tumor	O
22	sensitivity	O
23	to	O
24	chemotherapy	O
25	.	O

1	Significant	O
2	correlations	O
3	were	O
4	obtained	O
5	between	O
6	changes	O
7	in	O
8	SSEP	O
9	in	O
10	response	O
11	to	O
12	AS	O
13	and	O
14	the	O
15	presence	O
16	of	O
17	not	O
18	deep	O
19	residual	O
20	-	O
21	organic	O
22	disturbances	O
23	,	O
24	so	O
25	-	O
26	called	O
27	"	O
28	ground	O
29	"	O
30	in	O
31	psychogenic	O
32	disorders	O
33	.	O

1	Three	O
2	FGF	B
3	-	I
4	AS	I
5	cDNAs	I
6	were	O
7	isolated	O
8	;	O
9	the	O
10	full	B
11	-	I
12	length	I
13	FGF	I
14	-	I
15	AS	I
16	mRNA	I
17	and	O
18	two	O
19	alternative	O
20	splice	O
21	variants	O
22	lacking	O
23	exon	O
24	2	O
25	or	O
26	exons	O
27	2	O
28	and	O
29	3	O
30	of	O
31	the	O
32	FGF	B
33	-	I
34	AS	O
35	sequence	O
36	.	O

1	Spasmus	B
2	nutans	O
3	:	O
4	a	O
5	syndrome	O
6	of	O
7	auto	O
8	-	O
9	arousal	O
10	.	O

1	Reporter	B
2	gene	I
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	O
9	promoters	O
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	O
7	N2417	O
8	and	O
9	N2403	O
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	O
22	maltosa	O
23	cycloheximide	B
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	B
30	interleukin	I
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	I
36	ILF	I
37	-	I
38	2	I
39	).	O

1	In	O
2	the	O
3	Rett	O
4	syndrome	O
5	we	O
6	,	O
7	therefore	O
8	,	O
9	suspect	O
10	there	O
11	are	O
12	disturbances	O
13	in	O
14	the	O
15	brain	O
16	stem	O
17	functions	O
18	especially	O
19	in	O
20	the	O
21	ascending	O
22	reticular	O
23	activating	O
24	system	O
25	which	O
26	is	O
27	related	O
28	to	O
29	elevation	O
30	of	O
31	the	O
32	conscious	O
33	level	O
34	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	cosmid	O
6	containing	O
7	DNA	O
8	that	O
9	corresponds	O
10	to	O
11	the	O
12	site	O
13	of	O
14	transposon	O
15	insertion	O
16	in	O
17	257DH4	O
18	and	O
19	have	O
20	localized	O
21	Tn5	O
22	on	O
23	an	O
24	8	O
25	.	O
26	0	O
27	kb	O
28	EcoRI	B
29	fragment	I
30	.	O

1	The	O
2	neurohypophysial	B
3	vasopressin	I
4	and	O
5	oxytocin	O
6	content	O
7	was	O
8	bioassayed	O
9	by	O
10	pressor	O
11	effect	O
12	following	O
13	Dekanski	O
14	or	O
15	milk	O
16	-	O
17	ejection	O
18	activity	O
19	in	O
20	vitro	O
21	following	O
22	van	O
23	Dongen	O
24	and	O
25	Hays	O
26	,	O
27	respectively	O
28	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	vinculin	O
7	cDNA	O
8	from	O
9	chick	O
10	-	O
11	embryo	O
12	fibroblasts	O
13	.	O

1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	B
7	binding	I
8	transcription	I
9	factor	I
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	B
35	(	I
36	A	I
37	/	I
38	T	I
39	)(	I
40	T	I
41	/	I
42	A	I
43	)	I
44	GPyPyPy	I
45	-	I
46	3	I
47	'.	O

1	Antibodies	O
2	raised	O
3	against	O
4	GST	B
5	mSH2	I
6	-	I
7	B	I
8	identified	O
9	a	O
10	cellular	O
11	protein	O
12	of	O
13	92	O
14	kDa	O
15	that	O
16	was	O
17	not	O
18	found	O
19	to	O
20	be	O
21	phosphorylated	O
22	on	O
23	Tyr	O
24	.	O

1	Sodium	B
2	restriction	O
3	in	O
4	cardiac	O
5	failure	O
6	.	O

1	Primary	B
2	infection	O
3	is	O
4	usually	O
5	managed	O
6	conservatively	O
7	.	O

1	Can	B
2	thyroglobulin	O
3	assay	O
4	really	O
5	supplant	O
6	radioiodine	O
7	scans	O
8	in	O
9	patients	O
10	with	O
11	differentiated	O
12	thyroid	O
13	cancer	O
14	?	O

1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	O
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O

1	French	B
2	,	O
3	M	O
4	.	O

1	He	B
2	is	O
3	well	O
4	,	O
5	five	O
6	years	O
7	after	O
8	relapse	O
9	.	O

1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	O
10	identical	O
11	,	O
12	the	O
13	CArG	B
14	box	I
15	binding	I
16	proteins	I
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	O
27	,	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	,	O
33	and	O
34	c	B
35	-	I
36	fos	I
37	genes	I
38	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	O
6	cDNA	O
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O

1	After	O
2	selection	O
3	and	O
4	conversion	O
5	to	O
6	adipocytes	O
7	,	O
8	the	O
9	level	O
10	of	O
11	EGFR	O
12	expression	O
13	was	O
14	retained	O
15	in	O
16	infectant	O
17	adipocytes	O
18	(	O
19	150	O
20	,	O
21	000	O
22	and	O
23	250	O
24	,	O
25	000	O
26	/	O
27	cell	O
28	,	O
29	respectively	O
30	),	O
31	but	O
32	not	O
33	in	O
34	the	O
35	parental	O
36	3T3	O
37	-	O
38	L1	O
39	adipocytes	O
40	(<	O
41	5000	O
42	/	O
43	cell	O
44	).	O

1	Clinico	B
2	-	I
3	physiological	O
4	experiment	O

1	Studies	O
2	on	O
3	swine	O
4	enteroviruses	O
5	.	O

1	Contacts	B
2	between	O
3	Bacillus	B
4	subtilis	I
5	catabolite	O
6	regulatory	O
7	protein	O
8	CcpA	O
9	and	O
10	amyO	O
11	target	O
12	site	O
13	.	O

1	The	O
2	bactericidal	O
3	effect	O
4	of	O
5	disinfectants	O
6	against	O
7	biofilm	O
8	cells	O
9	was	O
10	found	O
11	to	O
12	be	O
13	considerably	O
14	enhanced	O
15	by	O
16	increasing	O
17	the	O
18	concentrations	O
19	of	O
20	the	O
21	disinfectants	O
22	.	O

1	These	O
2	observations	O
3	lead	O
4	to	O
5	the	O
6	proposal	O
7	that	O
8	the	O
9	RNAP	B
10	II	I
11	CTD	O
12	might	O
13	be	O
14	an	O
15	in	O
16	vivo	O
17	target	O
18	for	O
19	the	O
20	activated	O
21	p42mapk	O
22	and	O
23	p44mapk	B
24	MAP	I
25	kinases	I
26	.	O

1	The	O
2	sacT	B
3	gene	I
4	regulating	O
5	the	O
6	sacPA	B
7	operon	I
8	in	O
9	Bacillus	B
10	subtilis	I
11	shares	O
12	strong	O
13	homology	O
14	with	O
15	transcriptional	O
16	antiterminators	O
17	.	O

1	PCR	O
2	/	O
3	Southern	O
4	blot	O
5	analysis	O
6	of	O
7	human	O
8	kidney	O
9	cDNA	O
10	using	O
11	primers	O
12	flanking	O
13	the	O
14	hKID	O
15	coding	O
16	sequence	O
17	revealed	O
18	expression	O
19	of	O
20	a	O
21	full	B
22	-	I
23	length	I
24	mRNA	I
25	and	O
26	short	O
27	transcripts	O
28	with	O
29	partial	O
30	exon	O
31	1	O
32	and	O
33	partial	O
34	exon	O
35	4	O
36	deletions	O
37	.	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	O
7	in	O
8	pallid	O
9	bats	O
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	O
19	R2LC	O
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	VP	B
2	-	I
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O

1	Indirect	B
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Mutating	B
2	a	O
3	potential	O
4	cleavage	O
5	site	O
6	located	O
7	N	O
8	-	O
9	terminal	O
10	to	O
11	the	O
12	protease	O
13	domain	O
14	,	O
15	Gln2526	O
16	-	O
17	Asp2527	O
18	,	O
19	diminished	O
20	processing	O
21	.	O

1	Contractile	B
2	responses	O
3	to	O
4	norepinephrine	O
5	,	O
6	serotonin	O
7	and	O
8	potassium	O
9	(	O
10	K	O
11	+)	O
12	and	O
13	relaxant	O
14	responses	O
15	to	O
16	isoproterenol	O
17	and	O
18	papaverine	O
19	were	O
20	studied	O
21	in	O
22	vitro	O
23	with	O
24	spirally	O
25	cut	O
26	thoracic	O
27	aortic	O
28	strips	O
29	from	O
30	aortic	O
31	coarcted	O
32	hypertensive	O
33	rats	O
34	(	O
35	AHR	O
36	)	O
37	2	O
38	,	O
39	6	O
40	,	O
41	14	O
42	and	O
43	28	O
44	days	O
45	postoperatively	O
46	and	O
47	compared	O
48	to	O
49	time	O
50	-	O
51	matched	O
52	,	O
53	sham	O
54	-	O
55	operated	O
56	normotensive	O
57	controls	O
58	.	O

1	Qualitatively	B
2	,	O
3	the	O
4	results	O
5	are	O
6	similar	O
7	for	O
8	the	O
9	two	O
10	species	O
11	:	O
12	Both	O
13	rhesus	O
14	monkey	O
15	and	O
16	man	O
17	have	O
18	photopic	O
19	and	O
20	scotopic	O
21	branches	O
22	,	O
23	which	O
24	cross	O
25	at	O
26	approximately	O
27	the	O
28	same	O
29	time	O
30	in	O
31	the	O
32	dark	O
33	and	O
34	at	O
35	approximately	O
36	the	O
37	same	O
38	background	O
39	luminance	O
40	.	O

1	Thrombolytic	B
2	therapy	O
3	in	O
4	spontaneous	O
5	coronary	O
6	artery	O
7	dissection	O
8	.	O

1	An	O
2	intravenous	O
3	drip	O
4	infusion	O
5	of	O
6	AMK	O
7	in	O
8	adequate	O
9	dosage	O
10	would	O
11	be	O
12	beneficial	O
13	to	O
14	use	O
15	against	O
16	some	O
17	infectious	O
18	diseases	O
19	of	O
20	otorhinolaryngologic	O
21	field	O
22	.	O

1	The	O
2	alpha	B
3	2A	I
4	-	I
5	adrenergic	I
6	receptor	I
7	(	I
8	alpha	I
9	2AAR	O
10	)	O
11	is	O
12	coupled	O
13	to	O
14	a	O
15	variety	O
16	of	O
17	effectors	O
18	via	O
19	pertussis	B
20	toxin	I
21	-	I
22	sensitive	I
23	GTP	I
24	-	I
25	binding	I
26	proteins	I
27	.	O

1	ESS	B
2	type	I
3	1	I
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	Immunohistochemical	B
2	studies	O
3	revealed	O
4	positive	O
5	staining	O
6	for	O
7	S100	O
8	protein	O
9	in	O
10	all	O
11	the	O
12	granular	O
13	cell	O
14	tumors	O
15	of	O
16	the	O
17	adult	O
18	but	O
19	in	O
20	none	O
21	of	O
22	the	O
23	congenital	O
24	granular	O
25	cell	O
26	epulides	O
27	.	O

1	The	O
2	variability	O
3	is	O
4	most	O
5	likely	O
6	a	O
7	result	O
8	of	O
9	alternative	O
10	splicing	O
11	of	O
12	exons	O
13	from	O
14	the	O
15	primary	O
16	elastin	O
17	transcripts	O
18	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	O
28	mRNA	O
29	levels	O
30	.	O

1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	B
14	-	I
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	B
25	-	I
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O

1	Lens	B
2	aldose	I
3	reductase	I
4	in	O
5	diabetic	O
6	and	O
7	galactosemic	O
8	cataracts	O
9	.	O

1	Its	O
2	application	O
3	in	O
4	Madagascar	O
5	:	O
6	advantages	O
7	and	O
8	disadvantages	O

1	The	O
2	system	O
3	consisted	O
4	of	O
5	the	O
6	intact	O
7	canine	O
8	heart	O
9	connected	O
10	to	O
11	a	O
12	microcomputer	O
13	that	O
14	operated	O
15	as	O
16	the	O
17	modulated	O
18	parasystolic	O
19	pacemaker	O
20	.	O

1	The	O
2	ratio	O
3	of	O
4	P	O
5	-	O
6	31	O
7	NMR	O
8	-	O
9	S	O
10	derived	O
11	inorganic	O
12	phosphates	O
13	[	O
14	Pi	O
15	]	O
16	to	O
17	phosphocreatine	O
18	[	O
19	PCr	O
20	]	O
21	was	O
22	significantly	O
23	greater	O
24	at	O
25	rest	O
26	in	O
27	LVH	O
28	baboons	O
29	[	O
30	0	O
31	.	O
32	53	O
33	+/-	O
34	0	O
35	.	O
36	06	O
37	versus	O
38	controls	O
39	=	O
40	0	O
41	.	O
42	41	O
43	+/-	O
44	0	O
45	.	O
46	17	O
47	;	O
48	P	O
49	less	O
50	than	O
51	0	O
52	.	O
53	05	O
54	].	O

1	Neuromyelitis	B
2	optica	O
3	(	O
4	Devic	O
5	'	O
6	s	O
7	syndrome	O
8	):	O
9	not	O
10	always	O
11	multiple	O
12	sclerosis	O
13	.	O

1	Validation	B
2	of	O
3	the	O
4	survey	O
5	of	O
6	work	O
7	styles	O
8	:	O
9	a	O
10	profile	O
11	measure	O
12	of	O
13	the	O
14	type	O
15	A	O
16	behaviour	O
17	pattern	O
18	.	O

1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O

1	Potential	B
2	translational	O
3	start	O
4	signals	O
5	are	O
6	upstream	O
7	of	O
8	ORF1	O
9	and	O
10	ORF2	O
11	.	O

1	C	I
2	-	I
3	SP	I
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	We	O
2	measured	O
3	serum	O
4	hepatocyte	B
5	growth	I
6	factor	I
7	(	O
8	HGF	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	pectoris	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O

1	Movement	B
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	O
7	behavioral	O
8	requirements	O
9	.	O

1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O

1	METHODS	O
2	:	O
3	109	O
4	suspected	O
5	cases	O
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O

1	Expression	O
2	of	O
3	a	O
4	novel	O
5	murine	O
6	phospholipase	B
7	D	I
8	homolog	I
9	coincides	O
10	with	O
11	late	O
12	neuronal	O
13	development	O
14	in	O
15	the	O
16	forebrain	O
17	.	O

1	Contributions	B
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	I
13	activin	I
14	induces	O
15	the	O
16	gene	O
17	Mix	O
18	.	O
19	2	O
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	I
34	ARF	I
35	).	O

1	CONCLUSION	O
2	:	O
3	Rheumatic	O
4	fever	O
5	in	O
6	the	O
7	Nazareth	O
8	area	O
9	is	O
10	still	O
11	manifest	O
12	.	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	O
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	B
18	-	I
19	rich	I
20	site	I
21	mutation	I
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	O
36	(	O
37	Right	B
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	Lymphoproliferative	B
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O

1	Angiotensin	B
2	II	I
3	induces	O
4	nuclear	B
5	factor	I
6	(	O
7	NF	B
8	)-	I
9	kappaB1	I
10	isoforms	I
11	to	O
12	bind	O
13	the	O
14	angiotensinogen	B
15	gene	I
16	acute	O
17	-	O
18	phase	O
19	response	O
20	element	O
21	:	O
22	a	O
23	stimulus	O
24	-	O
25	specific	O
26	pathway	O
27	for	O
28	NF	B
29	-	I
30	kappaB	I
31	activation	O
32	.	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	B
18	-	I
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Possible	B
2	factors	I
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	O
16	blocks	O
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	O
24	and	O
25	rut	O
26	sites	O
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	Quantum	B
2	-	I
3	statistical	O
4	theory	O
5	of	O
6	high	O
7	-	O
8	field	O
9	transport	O
10	phenomena	O
11	.	O

1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	I
10	site	I
11	II	I
12	sequence	I
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O

1	Valuing	B
2	families	I
3	:	O
4	social	O
5	work	O
6	practice	O
7	with	O
8	families	O
9	from	O
10	a	O
11	strengths	O
12	perspective	O
13	.	O

1	A	I
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	B
16	-	I
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	I
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	Microwave	B
2	hyperthermia	I
3	-	I
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	signature	O
6	-	O
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	Development	B
2	of	O
3	basophilic	O
4	leukemia	O
5	with	O
6	trisomy	O
7	8	O
8	and	O
9	atypical	O
10	erythroblastosis	O
11	in	O
12	a	O
13	patient	O
14	with	O
15	a	O
16	history	O
17	of	O
18	aplastic	O
19	anemia	O
20	22	O
21	years	O
22	earlier	O

1	A	I
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	I
19	THZif	I
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	B
55	-	I
56	binding	I
57	protein	I
58	specific	I
59	for	O
60	the	O
61	nuclease	B
62	-	I
63	hypersensitive	I
64	element	I
65	(	O
66	NHE	O
67	)	O
68	of	O
69	the	O
70	human	O
71	c	B
72	-	I
73	myc	I
74	gene	I
75	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	strong	O
10	positive	O
11	cis	O
12	-	O
13	regulatory	O
14	element	O
15	at	O
16	-	O
17	70	O
18	bp	O
19	to	O
20	-	O
21	75	O
22	bp	O
23	in	O
24	the	O
25	LpS1	B
26	beta	I
27	promoter	I
28	with	O
29	the	O
30	sequence	O
31	(	O
32	G	O
33	)	O
34	6	O
35	and	O
36	a	O
37	similar	O
38	,	O
39	more	O
40	distal	O
41	cis	O
42	-	O
43	element	O
44	at	O
45	-	O
46	721	O
47	bp	O
48	to	O
49	-	O
50	726	O
51	bp	O
52	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	The	O
2	effect	O
3	of	O
4	ibopamine	O
5	and	O
6	furosemide	O
7	in	O
8	130	O
9	patients	O
10	with	O
11	NYHA	O
12	Class	O
13	I	O
14	and	O
15	II	O
16	heart	O
17	failure	O
18	were	O
19	studied	O
20	in	O
21	a	O
22	parallel	O
23	,	O
24	double	O
25	-	O
26	blind	O
27	,	O
28	randomized	O
29	placebo	O
30	-	O
31	controlled	O
32	multi	O
33	-	O
34	centre	O
35	trial	O
36	.	O

1	DNase	B
2	I	I
3	footprint	O
4	analysis	O
5	identified	O
6	a	O
7	protected	O
8	region	O
9	from	O
10	-	O
11	37	O
12	to	O
13	-	O
14	53	O
15	.	O

1	Helicobacter	B
2	pylori	I
3	and	O
4	stomach	O
5	diseases	O
6	:	O
7	from	O
8	clinical	O
9	point	O
10	of	O
11	view	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	beta	B
7	-	I
8	funaltrexamine	I
9	(	I
10	beta	I
11	-	I
12	FNA	O
13	)	O
14	and	O
15	naltrindole	O
16	(	O
17	NTI	O
18	)	O
19	(	O
20	nonequilibrium	B
21	mu	I
22	-	I
23	and	I
24	delta	I
25	-	I
26	antagonist	O
27	,	O
28	respectively	O
29	)	O
30	were	O
31	used	O
32	to	O
33	precipitate	O
34	withdrawal	O
35	in	O
36	butorphanol	O
37	-	O
38	dependent	O
39	rats	O
40	.	O

1	Thus	O
2	,	O
3	the	O
4	system	O
5	can	O
6	be	O
7	used	O
8	to	O
9	detect	O
10	and	O
11	study	O
12	dynamic	O
13	perfusion	O
14	changes	O
15	from	O
16	the	O
17	brain	O
18	surface	O
19	with	O
20	minimal	O
21	tissue	O
22	damage	O
23	.	O

1	In	O
2	spite	O
3	of	O
4	much	O
5	effort	O
6	,	O
7	no	O
8	one	O
9	has	O
10	succeeded	O
11	in	O
12	isolating	O
13	and	O
14	characterizing	O
15	the	O
16	enzyme	O
17	(	O
18	s	O
19	)	O
20	responsible	O
21	for	O
22	synthesis	O
23	of	O
24	cellulose	O
25	,	O
26	the	O
27	major	O
28	cell	O
29	wall	O
30	polymer	O
31	of	O
32	plants	O
33	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	O
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SAP	B
9	-	I
10	1	I
11	cDNA	I
12	showed	O
13	that	O
14	mature	O
15	SAP	B
16	-	I
17	1	I
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	O
26	-	O
27	type	O
28	PTP	B
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	B
35	-	I
36	conserved	O
37	domain	O
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	B
26	D2	I
27	(	O
28	hD2	O
29	)	O
30	cDNA	O
31	.	O

1	Mis3	B
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	The	O
2	highly	O
3	conserved	O
4	ninth	O
5	heptad	O
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	heterodimerization	O
12	,	O
13	appears	O
14	to	O
15	participate	O
16	in	O
17	the	O
18	receptor	O
19	-	O
20	inhibitor	O
21	interaction	O
22	,	O
23	suggesting	O
24	that	O
25	the	O
26	inhibitor	O
27	is	O
28	a	O
29	related	O
30	member	O
31	of	O
32	the	O
33	receptor	B
34	gene	I
35	family	I
36	.	O

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	O
10	-	O
11	AP	B
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	O
23	-	O
24	4	O
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	Cam	B
2	kinase	I
3	II	I
4	induces	O
5	in	O
6	vivo	O
7	phosphorylation	O
8	of	O
9	Smad2	O
10	and	O
11	Smad4	O
12	and	O
13	,	O
14	to	O
15	a	O
16	lesser	O
17	extent	O
18	,	O
19	Smad3	O
20	.	O

1	Effect	O
2	of	O
3	2	O
4	-(	O
5	p	O
6	-	O
7	chlorophenyl	O
8	)	O
9	cyclopropylamine	O
10	on	O
11	5	O
12	-	O
13	hydroxyindole	O
14	concentration	O
15	and	O
16	monoamine	B
17	oxidase	I
18	activity	O
19	in	O
20	rat	O
21	brain	O
22	.	O

1	A	I
2	computed	O
3	tomographic	O
4	scan	O
5	obtained	O
6	after	O
7	EOE	O
8	-	O
9	13	O
10	infusion	O
11	accurately	O
12	showed	O
13	the	O
14	perfusion	O
15	pattern	O
16	of	O
17	the	O
18	implanted	O
19	catheter	O
20	.	O

1	During	O
2	exercise	O
3	,	O
4	the	O
5	Pes	O
6	-	O
7	Ves	O
8	relation	O
9	was	O
10	shifted	O
11	toward	O
12	the	O
13	left	O
14	and	O
15	the	O
16	slope	O
17	[	O
18	end	O
19	-	O
20	systolic	O
21	elastance	O
22	(	O
23	Ees	O
24	)]	O
25	increased	O
26	from	O
27	7	O
28	.	O
29	7	O
30	+/-	O
31	2	O
32	.	O
33	8	O
34	to	O
35	12	O
36	.	O
37	7	O
38	+/-	O
39	4	O
40	.	O
41	2	O
42	(	O
43	SD	O
44	)	O
45	mmHg	O
46	/	O
47	ml	O
48	(	O
49	P	O
50	<	O
51	0	O
52	.	O
53	05	O
54	).	O

1	Serum	B
2	ferritin	I
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O

1	The	O
2	Oct	B
3	-	I
4	3	I
5	/	I
6	4	I
7	gene	I
8	product	I
9	,	O
10	which	O
11	belongs	O
12	to	O
13	the	O
14	POU	B
15	family	I
16	of	O
17	transcription	O
18	factors	O
19	,	O
20	is	O
21	a	O
22	good	O
23	candidate	O
24	for	O
25	regulating	O
26	initial	O
27	differentiation	O
28	decisions	O
29	.	O

1	To	O
2	dissect	O
3	these	O
4	mechanisms	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	and	I
10	mutant	I
11	Raf	I
12	-	I
13	1	I
14	proteins	I
15	were	O
16	studied	O
17	in	O
18	an	O
19	in	O
20	vitro	O
21	system	O
22	with	O
23	purified	O
24	plasma	O
25	membranes	O
26	from	O
27	v	B
28	-	I
29	Ras	I
30	-	I
31	and	O
32	v	B
33	-	I
34	Src	I
35	-	I
36	transformed	O
37	cells	O
38	(	O
39	transformed	O
40	membranes	O
41	).	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	Ca	O
6	entry	O
7	blocker	O
8	nitrendipine	O
9	,	O
10	the	O
11	antioxidant	B
12	superoxide	I
13	dismutase	I
14	(	O
15	SOD	O
16	),	O
17	and	O
18	a	O
19	combination	O
20	of	O
21	nitrendipine	O
22	and	O
23	superoxide	B
24	dismutase	I
25	on	O
26	postischemic	O
27	renal	O
28	function	O
29	was	O
30	studied	O
31	in	O
32	four	O
33	groups	O
34	(	O
35	n	O
36	=	O
37	24	O
38	)	O
39	of	O
40	rats	O
41	.	O

1	Patients	O
2	received	O
3	either	O
4	diltiazem	O
5	CD	O
6	180	O
7	mg	O
8	or	O
9	placebo	O
10	once	O
11	/	O
12	day	O
13	in	O
14	combination	O
15	with	O
16	existing	O
17	antianginal	O
18	therapy	O
19	.	O

1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	B
6	,	O
7	glutathione	B
8	peroxidase	I
9	and	I
10	superoxide	I
11	dismutase	I
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O

1	Altogether	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O

1	Grossly	B
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O

1	Overlapping	B
2	cDNA	I
3	clones	O
4	were	O
5	isolated	O
6	and	O
7	sequenced	O
8	.	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	Polyvinyl	B
2	alcohol	O
3	as	O
4	a	O
5	solution	O
6	mediator	O

1	Dermatology	B
2	is	O
3	no	O
4	exception	O
5	.	O

1	Axillary	B
2	nodal	O
3	status	O
4	,	O
5	tumour	O
6	progesterone	B
7	receptor	I
8	status	O
9	,	O
10	and	O
11	season	O
12	of	O
13	tumour	O
14	detection	O
15	significantly	O
16	influenced	O
17	survival	O
18	in	O
19	both	O
20	older	O
21	(	O
22	greater	O
23	than	O
24	50	O
25	yrs	O
26	)	O
27	and	O
28	younger	O
29	(	O
30	less	O
31	than	O
32	50	O
33	yrs	O
34	)	O
35	patients	O
36	.	O

1	The	O
2	effects	O
3	of	O
4	procedural	O
5	variations	O
6	on	O
7	lateralized	O
8	Stroop	O
9	effects	O
10	.	O

1	In	O
2	contrast	O
3	,	O
4	in	O
5	LL	O
6	patients	O
7	during	O
8	ENL	O
9	the	O
10	ConA	O
11	-	O
12	induced	O
13	suppressor	O
14	response	O
15	was	O
16	markedly	O
17	reduced	O
18	.	O

1	Transcervical	B
2	amnioinfusion	O
3	.	O

1	The	O
2	character	O
3	of	O
4	specific	O
5	immune	O
6	response	O
7	in	O
8	101	O
9	immunized	O
10	children	O
11	and	O
12	in	O
13	12	O
14	adults	O
15	belonging	O
16	to	O
17	a	O
18	high	O
19	risk	O
20	group	O
21	with	O
22	respect	O
23	to	O
24	VHB	O
25	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	O
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	B
19	+,	O
20	CD8	B
21	+,	I
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	EGV	B
2	had	O
3	no	O
4	detectable	O
5	effect	O
6	on	O
7	PP	O
8	secretion	O
9	under	O
10	basal	O
11	or	O
12	stimulated	O
13	conditions	O
14	.	O

1	Ceftazidime	B
2	shows	O
3	promise	O
4	as	O
5	single	O
6	-	O
7	agent	O
8	therapy	O
9	for	O
10	serious	O
11	gram	O
12	-	O
13	negative	O
14	bacillary	O
15	infections	O
16	.	O

1	Autoimmune	B
2	manipulation	O
3	aids	O
4	juvenile	O
5	diabetes	O
6	management	O
7	.	O

1	Neurospora	B
2	crassa	I
3	CYT	I
4	-	I
5	18	O
6	,	O
7	can	O
8	rescue	O
9	the	O
10	exonic	O
11	trap	O
12	and	O
13	intron	O
14	mutants	O
15	which	O
16	cause	O
17	a	O
18	structural	O
19	defect	O
20	.	O

1	From	O
2	Pap	O
3	to	O
4	ApUp	O
5	.	O

1	Band	B
2	-	I
3	shift	O
4	assays	O
5	were	O
6	performed	O
7	using	O
8	the	O
9	LPS	O
10	-	O
11	and	O
12	IL	B
13	-	I
14	1	I
15	-	I
16	responsive	I
17	element	I
18	(	O
19	LILRE	O
20	)	O
21	oligonucleotide	O
22	,	O
23	a	O
24	gamma	B
25	interferon	I
26	activation	I
27	site	I
28	-	I
29	like	I
30	site	I
31	that	O
32	is	O
33	present	O
34	in	O
35	the	O
36	human	O
37	IL	B
38	-	I
39	1beta	I
40	promoter	I
41	.	O

1	ATX	B
2	,	O
3	like	O
4	PC	B
5	-	I
6	1	I
7	,	O
8	was	O
9	found	O
10	to	O
11	hydrolyze	O
12	the	O
13	type	B
14	I	I
15	phosphodiesterase	I
16	substrate	I
17	p	I
18	-	I
19	nitrophenyl	I
20	thymidine	I
21	-	I
22	5	O
23	'-	O
24	monophosphate	O
25	.	O

1	The	O
2	nucleosomal	O
3	arrays	O
4	detected	O
5	by	O
6	MPE	O
7	X	O
8	Fe	O
9	(	O
10	II	O
11	)	O
12	were	O
13	characterized	O
14	by	O
15	a	O
16	considerable	O
17	loss	O
18	of	O
19	detail	O
20	and	O
21	significantly	O
22	enhanced	O
23	accessibility	O
24	,	O
25	the	O
26	extent	O
27	of	O
28	which	O
29	probably	O
30	reflected	O
31	the	O
32	relative	O
33	transcription	O
34	rate	O
35	of	O
36	each	O
37	gene	O
38	.	O

1	Such	O
2	transgenic	O
3	plants	O
4	should	O
5	enable	O
6	not	O
7	only	O
8	the	O
9	mutational	O
10	analysis	O
11	of	O
12	sequence	O
13	elements	O
14	within	O
15	the	O
16	replication	O
17	origin	O
18	region	O
19	,	O
20	but	O
21	also	O
22	the	O
23	construction	O
24	of	O
25	a	O
26	new	O
27	generation	O
28	of	O
29	vectors	O
30	for	O
31	gene	O
32	amplification	O
33	in	O
34	plants	O
35	,	O
36	based	O
37	on	O
38	a	O
39	minimal	O
40	virus	O
41	replicon	O
42	.	O

1	The	O
2	author	O
3	provides	O
4	a	O
5	rationale	O
6	for	O
7	an	O
8	interactional	O
9	view	O
10	and	O
11	presents	O
12	a	O
13	case	O
14	in	O
15	which	O
16	post	O
17	-	O
18	surgical	O
19	hiccups	O
20	were	O
21	successfully	O
22	treated	O
23	,	O
24	using	O
25	principles	O
26	developed	O
27	by	O
28	the	O
29	Mental	O
30	Research	O
31	Institute	O
32	.	O

1	These	O
2	data	O
3	strongly	O
4	implicate	O
5	the	O
6	normal	O
7	product	O
8	of	O
9	the	O
10	int	B
11	-	I
12	2	I
13	gene	I
14	,	O
15	which	O
16	is	O
17	related	O
18	to	O
19	the	O
20	fibroblast	B
21	growth	I
22	factor	I
23	family	I
24	,	O
25	as	O
26	a	O
27	contributory	B
28	factor	I
29	in	O
30	virally	O
31	induced	O
32	mammary	O
33	tumors	O
34	.	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	Characterisation	B
2	of	O
3	the	O
4	chicken	O
5	apolipoprotein	B
6	A	I
7	-	I
8	I	I
9	gene	I
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	.	O

1	From	O
2	S3	O
3	(	O
4	CBF	O
5	:	O
6	79	O
7	-	O
8	60	O
9	%)	O
10	to	O
11	S5	O
12	(	O
13	CBF	O
14	:	O
15	39	O
16	-	O
17	0	O
18	%),	O
19	%	O
20	WTh	O
21	,	O
22	1	O
23	/	O
24	TPC	O
25	and	O
26	1	O
27	/	O
28	T	O
29	were	O
30	significantly	O
31	decreased	O
32	from	O
33	those	O
34	of	O
35	the	O
36	control	O
37	levels	O
38	(	O
39	all	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	01	O
46	).	O

1	This	O
2	is	O
3	based	O
4	on	O
5	partitioning	O
6	an	O
7	underlying	O
8	multivariate	O
9	normal	O
10	distribution	O
11	.	O

1	Peroxydase	B
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	I
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	B
17	-	I
18	binding	I
19	protein	I
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	O
26	cell	O
27	cycle	O
28	control	O
29	protein	O
30	(	O
31	cdc	O
32	)	O
33	37	O
34	.	O

1	The	O
2	endodontal	O
3	treatment	O
4	need	O
5	has	O
6	been	O
7	forming	O
8	a	O
9	clinical	O
10	order	O
11	of	O
12	magnitude	O
13	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	Ultrastructure	B
2	of	O
3	the	O
4	heart	O
5	muscle	O
6	in	O
7	experimental	O
8	myocardial	O
9	infarct	O
10	following	O
11	physical	O
12	training	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	role	O
7	of	O
8	S	O
9	.	O
10	argyrostoma	O
11	in	O
12	the	O
13	dissemination	O
14	of	O
15	Trichinella	O
16	larvae	O
17	in	O
18	nature	O
19	is	O
20	limited	O
21	in	O
22	comparison	O
23	to	O
24	the	O
25	role	O
26	played	O
27	by	O
28	mammals	O
29	with	O
30	scavenger	O
31	and	O
32	cannibalistic	O
33	behavior	O
34	.	O

1	In	O
2	particular	O
3	,	O
4	71	O
5	and	O
6	69	O
7	%	O
8	amino	O
9	acid	O
10	sequence	O
11	similarities	O
12	were	O
13	identified	O
14	with	O
15	hsp70	B
16	of	O
17	Escherichia	O
18	coli	O
19	and	O
20	Bacillus	O
21	megaterium	O
22	,	O
23	respectively	O
24	.	O

1	Cycles	B
2	were	O
3	repeated	O
4	every	O
5	3	O
6	weeks	O
7	.	O

1	Similar	O
2	results	O
3	were	O
4	also	O
5	obtained	O
6	with	O
7	a	O
8	HepG2	O
9	hepatoblastoma	O
10	cell	O
11	line	O
12	carrying	O
13	wt	O
14	p53	B
15	.	O

1	General	B
2	formulae	O
3	for	O
4	estimating	O
5	heritability	O
6	in	O
7	a	O
8	population	O
9	with	O
10	related	O
11	parents	O
12	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	Renal	B
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	Piroximone	B
2	is	O
3	a	O
4	new	O
5	phosphodiesterase	B
6	III	I
7	inhibitor	I
8	that	O
9	combines	O
10	inotropic	O
11	and	O
12	vasodilator	O
13	properties	O
14	.	O

1	These	O
2	mutants	O
3	were	O
4	tested	O
5	for	O
6	ability	O
7	to	O
8	bind	O
9	each	O
10	of	O
11	the	O
12	Site	B
13	II	I
14	cognate	I
15	proteins	I
16	,	O
17	and	O
18	subsequently	O
19	evaluated	O
20	for	O
21	ability	O
22	to	O
23	confer	O
24	H4	O
25	transcriptional	O
26	activity	O
27	using	O
28	chimeric	B
29	H4	I
30	promoter	I
31	/	I
32	CAT	I
33	fusion	I
34	constructs	I
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	At	O
2	an	O
3	ambient	O
4	temperature	O
5	of	O
6	25	O
7	degrees	O
8	C	O
9	,	O
10	the	O
11	responses	O
12	to	O
13	spinal	O
14	cooling	O
15	are	O
16	reduced	O
17	during	O
18	the	O
19	dark	O
20	phase	O
21	.	O

1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O

1	Utilizing	B
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	I
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O

1	No	O
2	patient	O
3	had	O
4	a	O
5	history	O
6	of	O
7	excess	O
8	alcohol	O
9	intake	O
10	,	O
11	or	O
12	prolonged	O
13	intake	O
14	of	O
15	hepatotoxic	O
16	drugs	O
17	and	O
18	steroids	O
19	,	O
20	and	O
21	were	O
22	not	O
23	obese	O
24	or	O
25	malnourished	O
26	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	IgE	B
6	,	O
7	and	O
8	asIgE	O
9	and	O
10	IgG	B
11	-	I
12	4	I
13	against	O
14	14	O
15	common	O
16	food	O
17	allergens	O
18	were	O
19	determined	O
20	.	O

1	This	O
2	revealed	O
3	a	O
4	minimum	O
5	of	O
6	six	O
7	novel	O
8	OSBP	B
9	-	I
10	related	I
11	proteins	I
12	,	O
13	designated	O
14	ORP	B
15	-	I
16	1	I
17	to	O
18	ORP	O
19	-	O
20	6	O
21	.	O

1	To	O
2	discern	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	melatonin	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	IGD	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	B
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	pubertal	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	The	O
2	active	O
3	site	O
4	includes	O
5	the	O
6	acidic	O
7	triad	O
8	Asp53	O
9	(	O
10	the	O
11	site	O
12	of	O
13	phosphorylation	O
14	),	O
15	Asp10	O
16	and	O
17	Glu9	O
18	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	analysis	O
6	demonstrated	O
7	expression	O
8	of	O
9	human	B
10	PI	I
11	3	I
12	-	I
13	kinase	I
14	in	O
15	all	O
16	tissues	O
17	and	O
18	cell	O
19	lines	O
20	tested	O
21	.	O

1	The	O
2	role	O
3	of	O
4	pharmacological	O
5	profiling	O
6	in	O
7	safety	O
8	assessment	O
9	.	O

1	Phosphorylation	B
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	O
10	mitotic	O
11	regulatory	O
12	protein	B
13	kinase	I
14	in	O
15	budding	O
16	yeast	O
17	.	O

1	In	O
2	the	O
3	clinical	O
4	study	O
5	,	O
6	the	O
7	defect	O
8	size	O
9	shown	O
10	by	O
11	BMIPP	O
12	imaging	O
13	was	O
14	greater	O
15	in	O
16	anterior	O
17	than	O
18	in	O
19	inferior	O
20	infarcts	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	001	O
27	)	O
28	and	O
29	correlated	O
30	well	O
31	with	O
32	the	O
33	risk	O
34	area	O
35	revealed	O
36	by	O
37	contrast	O
38	ventriculography	O
39	(	O
40	r	O
41	=	O
42	0	O
43	.	O
44	80	O
45	,	O
46	p	O
47	<	O
48	0	O
49	.	O
50	0001	O
51	)	O
52	CONCLUSION	O
53	:	O
54	The	O
55	above	O
56	preliminary	O
57	data	O
58	,	O
59	admittedly	O
60	from	O
61	a	O
62	small	O
63	group	O
64	of	O
65	patients	O
66	,	O
67	suggest	O
68	that	O
69	tomographic	O
70	BMIPP	O
71	imaging	O
72	provides	O
73	an	O
74	accurate	O
75	quantification	O
76	of	O
77	defect	O
78	size	O
79	by	O
80	means	O
81	of	O
82	a	O
83	simple	O
84	threshold	O
85	technique	O
86	and	O
87	,	O
88	in	O
89	the	O
90	subacute	O
91	phase	O
92	,	O
93	permits	O
94	determination	O
95	of	O
96	the	O
97	amount	O
98	of	O
99	myocardium	O
100	at	O
101	risk	O
102	after	O
103	acute	O
104	myocardial	O
105	infarction	O
106	.	O

1	Presidential	B
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O

1	An	O
2	RNA	B
3	-	I
4	binding	I
5	protein	I
6	gene	I
7	(	O
8	rbp1	O
9	)	O
10	from	O
11	Drosophila	B
12	melanogaster	I
13	,	O
14	encoding	O
15	an	O
16	RNA	O
17	recognition	O
18	motif	O
19	and	O
20	an	O
21	Arg	O
22	-	O
23	Ser	O
24	rich	O
25	(	O
26	RS	O
27	)	O
28	domain	O
29	,	O
30	has	O
31	been	O
32	characterized	O
33	.	O

1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	O
27	.	O

1	The	O
2	slower	O
3	-	O
4	electrophoretic	O
5	-	O
6	mobility	O
7	form	O
8	of	O
9	p68	O
10	was	O
11	absent	O
12	in	O
13	human	O
14	cells	O
15	in	O
16	G1	O
17	/	O
18	S	O
19	and	O
20	appeared	O
21	as	O
22	the	O
23	cells	O
24	entered	O
25	G2	O
26	/	O
27	M	O
28	.	O

1	Grade	B
2	3	I
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	major	O
6	homology	O
7	region	O
8	of	O
9	Mason	B
10	-	I
11	Pfizer	I
12	monkey	I
13	virus	I
14	by	O
15	use	O
16	of	O
17	saturation	O
18	mutagenesis	O
19	.	O

1	To	O
2	get	O
3	further	O
4	insights	O
5	into	O
6	the	O
7	molecular	O
8	mechanisms	O
9	that	O
10	control	O
11	tal	B
12	-	I
13	1	I
14	expression	O
15	,	O
16	we	O
17	have	O
18	isolated	O
19	5	O
20	'	O
21	sequences	O
22	of	O
23	the	O
24	murine	B
25	gene	I
26	and	O
27	compared	O
28	them	O
29	to	O
30	their	O
31	human	O
32	counterparts	O
33	.	O

1	Prevalence	B
2	of	O
3	sleep	O
4	-	O
5	disordered	O
6	breathing	O
7	(	O
8	SDB	O
9	)	O
10	is	O
11	reported	O
12	to	O
13	increase	O
14	in	O
15	menopausal	O
16	women	O
17	.	O

1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	O
8	embryonic	O
9	Drosophila	B
10	melanogaster	I
11	cells	O
12	that	O
13	lack	O
14	MyoD1	O
15	and	O
16	Sp1	B
17	is	O
18	strictly	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	exogenously	O
32	supplied	O
33	Sp1	B
34	and	O
35	MyoD1	O
36	.	O

1	These	O
2	components	O
3	both	O
4	had	O
5	a	O
6	median	O
7	R2	O
8	of	O
9	0	O
10	.	O
11	84	O
12	,	O
13	compared	O
14	to	O
15	median	O
16	R2s	O
17	ranging	O
18	from	O
19	0	O
20	.	O
21	37	O
22	to	O
23	0	O
24	.	O
25	83	O
26	for	O
27	five	O
28	commonly	O
29	used	O
30	ad	O
31	hoc	O
32	EEG	O
33	components	O
34	.	O

1	The	O
2	ultrastructural	O
3	findings	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	urinary	O
10	C	B
11	-	I
12	peptide	I
13	excretion	O
14	,	O
15	confirmed	O
16	that	O
17	the	O
18	glycemic	O
19	effects	O
20	should	O
21	not	O
22	be	O
23	thought	O
24	to	O
25	be	O
26	due	O
27	to	O
28	a	O
29	direct	O
30	action	O
31	of	O
32	the	O
33	drugs	O
34	used	O
35	on	O
36	the	O
37	endocrine	O
38	pancreas	O
39	.	O

1	We	O
2	have	O
3	inactivated	O
4	Krox	O
5	-	O
6	20	O
7	by	O
8	homologous	O
9	recombination	O
10	in	O
11	ES	O
12	cells	O
13	and	O
14	demonstrated	O
15	that	O
16	the	O
17	mutation	O
18	leads	O
19	to	O
20	the	O
21	deletion	O
22	of	O
23	r3	O
24	and	O
25	r5	O
26	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	The	O
2	missing	O
3	5	O
4	'	O
5	sequences	O
6	were	O
7	obtained	O
8	by	O
9	5	O
10	'-	O
11	rapid	O
12	amplification	O
13	of	O
14	cDNA	O
15	ends	O
16	and	O
17	by	O
18	analysis	O
19	of	O
20	an	O
21	NHE5	O
22	genomic	O
23	clone	O
24	,	O
25	and	O
26	the	O
27	missing	O
28	3	O
29	'	O
30	sequences	O
31	were	O
32	obtained	O
33	by	O
34	3	O
35	'-	O
36	rapid	O
37	amplification	O
38	of	O
39	cDNA	O
40	ends	O
41	.	O

1	A	I
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	O
21	LRR	O
22	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	diverse	O
7	set	O
8	of	O
9	carboxyl	O
10	-	O
11	terminal	O
12	sequence	O
13	motifs	O
14	and	O
15	posttranslational	O
16	modifications	O
17	lead	O
18	to	O
19	functional	O
20	Ras	B
21	proteins	I
22	in	O
23	yeast	O
24	.	O

1	Analysis	O
2	of	O
3	viral	O
4	mutants	O
5	in	O
6	vivo	O
7	demonstrated	O
8	that	O
9	the	O
10	NFIII	O
11	/	O
12	OCT	B
13	-	I
14	1	I
15	binding	I
16	site	I
17	and	O
18	a	O
19	conserved	O
20	ATF	B
21	motif	I
22	were	O
23	important	O
24	for	O
25	efficient	O
26	viral	O
27	growth	O
28	.	O

1	In	O
2	comparison	O
3	with	O
4	normal	O
5	pregnant	O
6	women	O
7	and	O
8	normal	O
9	non	O
10	-	O
11	pregnant	O
12	women	O
13	,	O
14	women	O
15	with	O
16	PIH	O
17	showed	O
18	an	O
19	increase	O
20	in	O
21	heart	O
22	rate	O
23	,	O
24	suggesting	O
25	an	O
26	increased	O
27	peripheral	O
28	sympathetic	O
29	tone	O
30	,	O
31	and	O
32	an	O
33	initial	O
34	derangement	O
35	in	O
36	renal	O
37	function	O
38	as	O
39	shown	O
40	by	O
41	the	O
42	increase	O
43	in	O
44	serum	O
45	uric	O
46	acid	O
47	and	O
48	reduction	O
49	in	O
50	sodium	O
51	excretion	O
52	and	O
53	total	O
54	and	O
55	fractional	O
56	calcium	O
57	excretion	O
58	at	O
59	any	O
60	given	O
61	level	O
62	of	O
63	sodium	O
64	excretion	O
65	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	properties	O
6	of	O
7	sequences	O
8	surrounding	O
9	ARS1	O
10	left	O
11	open	O
12	the	O
13	possibility	O
14	that	O
15	ABFI	O
16	enhances	O
17	the	O
18	initiation	O
19	of	O
20	DNA	O
21	replication	O
22	at	O
23	ARS1	O
24	by	O
25	transcriptional	O
26	activation	O
27	.	O

1	CASE	B
2	REPORT	O
3	:	O
4	We	O
5	observed	O
6	a	O
7	congenital	O
8	skin	O
9	defect	O
10	located	O
11	exclusively	O
12	on	O
13	the	O
14	trunk	O
15	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	effects	O
6	of	O
7	a	O
8	preparation	O
9	with	O
10	50	O
11	micrograms	O
12	ethinyl	O
13	estradiol	O
14	and	O
15	2	O
16	mg	O
17	cyproterone	O
18	acetate	O
19	on	O
20	gonadotropins	O
21	,	O
22	prolactin	B
23	,	O
24	testosterone	O
25	,	O
26	sex	B
27	hormone	I
28	binding	I
29	globulin	I
30	(	O
31	SHBG	O
32	),	O
33	androstenedione	O
34	,	O
35	and	O
36	calculated	O
37	free	O
38	testosterone	O
39	index	O
40	before	O
41	and	O
42	after	O
43	six	O
44	months	O
45	of	O
46	treatment	O
47	.	O

1	Diacylglycerol	B
2	kinase	I
3	(	O
4	DGK	O
5	)	O
6	attenuates	O
7	levels	O
8	of	O
9	second	O
10	messenger	O
11	diacylglycerol	O
12	in	O
13	cells	O
14	and	O
15	produces	O
16	another	O
17	(	O
18	putative	O
19	)	O
20	messenger	O
21	,	O
22	phosphatidic	O
23	acid	O
24	.	O

1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	O
18	CRF	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	O
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O

1	In	O
2	both	O
3	groups	O
4	there	O
5	were	O
6	5	O
7	management	O
8	failure	O
9	of	O
10	therapy	O
11	,	O
12	so	O
13	that	O
14	alternative	O
15	medication	O
16	or	O
17	a	O
18	cesarean	O
19	section	O
20	lead	O
21	to	O
22	delivery	O
23	.	O

1	METHODS	O
2	:	O
3	All	O
4	these	O
5	30	O
6	non	O
7	-	O
8	responders	O
9	received	O
10	an	O
11	extra	O
12	dose	O
13	of	O
14	the	O
15	same	O
16	vaccine	O
17	2	O
18	months	O
19	after	O
20	primary	O
21	immunization	O
22	and	O
23	a	O
24	booster	O
25	dose	O
26	with	O
27	a	O
28	yeast	O
29	-	O
30	derived	O
31	vaccine	O
32	6	O
33	years	O
34	later	O
35	.	O

1	However	O
2	,	O
3	the	O
4	serum	O
5	TNF	B
6	-	I
7	a	O
8	concentration	O
9	decreased	O
10	significantly	O
11	in	O
12	patients	O
13	receiving	O
14	pentoxifylline	O
15	(	O
16	basal	O
17	623	O
18	+/-	O
19	366	O
20	pg	O
21	/	O
22	ml	O
23	;	O
24	6th	O
25	month	O
26	562	O
27	+/-	O
28	358	O
29	pg	O
30	/	O
31	ml	O
32	,	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	),	O
39	but	O
40	not	O
41	in	O
42	the	O
43	control	O
44	group	O
45	.	O

1	When	O
2	O2	O
3	therapy	O
4	was	O
5	controlled	O
6	for	O
7	,	O
8	the	O
9	association	O
10	between	O
11	RBT	O
12	and	O
13	RLF	O
14	did	O
15	not	O
16	achieve	O
17	statistical	O
18	significance	O
19	(	O
20	P	O
21	=	O
22	.	O
23	07	O
24	).	O

1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	vasectomized	O
6	rats	O
7	from	O
8	sham	O
9	rats	O
10	included	O
11	:	O
12	testicular	O
13	and	O
14	epididymal	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	pathologic	O
20	vas	O
21	deferens	O
22	granulomas	O
23	,	O
24	decreased	O
25	total	O
26	serum	B
27	protein	I
28	,	O
29	lowered	O
30	alpha	B
31	-	I
32	globulin	I
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	agglutinin	O
44	antibody	O
45	titers	O
46	.	O

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	TAR	B
7	-	I
8	binding	I
9	protein	I
10	is	O
11	very	O
12	similar	O
13	to	O
14	the	O
15	CREB2	O
16	protein	O
17	.	O

1	We	O
2	have	O
3	used	O
4	mutation	O
5	-	O
6	directed	O
7	chemical	O
8	cross	O
9	-	O
10	linking	O
11	with	O
12	bis	O
13	(	O
14	sulfosuccinimidyl	O
15	)	O
16	suberate	O
17	(	O
18	BS3	O
19	)	O
20	to	O
21	investigate	O
22	the	O
23	architecture	O
24	of	O
25	the	O
26	gp41	O
27	oligomer	O
28	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	crude	O
7	extracts	O
8	from	O
9	FREJ4	O
10	cells	O
11	revealed	O
12	the	O
13	binding	O
14	of	O
15	a	O
16	member	O
17	(	O
18	s	O
19	)	O
20	of	O
21	the	O
22	Ets	B
23	family	I
24	of	O
25	transcription	O
26	factors	O
27	to	O
28	the	O
29	P4	O
30	EBS	O
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	interaction	O
37	of	O
38	two	O
39	members	O
40	of	O
41	the	O
42	Sp1	B
43	family	I
44	,	O
45	Sp1	B
46	and	O
47	Sp3	B
48	,	O
49	with	O
50	the	O
51	adjacent	O
52	GC	O
53	box	O
54	.	O

1	The	O
2	SUP44	O
3	suppressor	O
4	mutation	O
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	S5	O
25	ram	O
26	mutations	O
27	.	O

1	Coronary	B
2	arteries	O
3	--	O
4	old	O
5	and	O
6	new	O
7	.	O

1	Yap1p	B
2	is	O
3	constitutively	O
4	nuclear	O
5	in	O
6	a	O
7	crm1	O
8	mutant	O
9	,	O
10	and	O
11	Crm1p	O
12	binds	O
13	to	O
14	a	O
15	nuclear	O
16	export	O
17	sequence	O
18	(	O
19	NES	B
20	)-	I
21	like	I
22	sequence	I
23	in	O
24	Yap1p	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	RanGTP	O
30	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	is	O
7	twofold	O
8	:	O
9	(	O
10	1	O
11	)	O
12	to	O
13	present	O
14	a	O
15	parallel	O
16	form	O
17	of	O
18	the	O
19	Gudjonsson	O
20	Suggestibility	O
21	Scale	O
22	(	O
23	GSS	O
24	,	O
25	Form	O
26	1	O
27	);	O
28	(	O
29	2	O
30	)	O
31	to	O
32	study	O
33	test	O
34	-	O
35	retest	O
36	reliabilities	O
37	of	O
38	interrogative	O
39	suggestibility	O
40	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	O
10	/	O
11	300	O
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	O
18	rich	O
19	ESE	O
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	B
33	doublesex	I
34	gene	I
35	.	O

1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	O
13	rbcS	O
14	promoters	O
15	.	O

1	In	O
2	14	O
3	of	O
4	21	O
5	infant	O
6	hearts	O
7	(	O
8	66	O
9	%)	O
10	with	O
11	aortic	O
12	arch	O
13	interruption	O
14	between	O
15	the	O
16	left	O
17	common	O
18	carotid	O
19	and	O
20	left	O
21	subclavian	O
22	arteries	O
23	(	O
24	type	O
25	B	O
26	of	O
27	Celoria	O
28	and	O
29	Patton	O
30	),	O
31	the	O
32	right	O
33	subclavian	O
34	artery	O
35	(	O
36	SA	O
37	)	O
38	arose	O
39	anomalously	O
40	.	O

1	PhoP	B
2	-	I
3	PhoQ	O
4	homologues	O
5	in	O
6	Pseudomonas	B
7	aeruginosa	I
8	regulate	O
9	expression	O
10	of	O
11	the	O
12	outer	O
13	-	O
14	membrane	O
15	protein	O
16	OprH	O
17	and	O
18	polymyxin	O
19	B	O
20	resistance	O
21	.	O

1	The	O
2	pel	B
3	gene	I
4	from	O
5	an	O
6	Amycolata	O
7	sp	O
8	.	O
9	encoding	O
10	a	O
11	pectate	B
12	lyase	I
13	(	O
14	EC	B
15	4	I
16	.	O
17	2	O
18	.	O
19	2	O
20	.	O
21	2	O
22	)	O
23	was	O
24	isolated	O
25	by	O
26	activity	O
27	screening	O
28	a	O
29	genomic	O
30	DNA	O
31	library	O
32	in	O
33	Streptomyces	O
34	lividans	O
35	TK24	O
36	.	O

1	Here	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	an	O
7	antagonistic	O
8	,	O
9	BMP	O
10	/	O
11	ALK2	O
12	/	O
13	Smad	O
14	-	O
15	mediated	O
16	signaling	O
17	pathway	O
18	is	O
19	active	O
20	on	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	Xenopus	O
27	embryo	O
28	.	O

1	Coronary	B
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O

1	Zebrafish	B
2	cyclops	O
3	(	O
4	cyc	O
5	)	O
6	encodes	O
7	a	O
8	Transforming	B
9	Growth	I
10	Factor	I
11	beta	I
12	(	O
13	TGFbeta	O
14	)	O
15	signaling	O
16	factor	O
17	closely	O
18	related	O
19	to	O
20	mouse	O
21	Nodal	O
22	.	O

1	These	O
2	kinases	O
3	belong	O
4	to	O
5	a	O
6	new	O
7	subfamily	O
8	related	O
9	to	O
10	the	O
11	Trk	O
12	subfamily	O
13	.	O

1	The	O
2	kinase	O
3	is	O
4	essential	O
5	in	O
6	vivo	O
7	for	O
8	normal	O
9	phosphorylation	O
10	of	O
11	the	O
12	CTD	O
13	and	O
14	for	O
15	normal	O
16	growth	O
17	and	O
18	differentiation	O
19	.	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	B
41	gene	I
42	.	O

1	Deletion	O
2	mapping	O
3	studies	O
4	revealed	O
5	that	O
6	the	O
7	upstream	O
8	DNA	O
9	sequences	O
10	up	O
11	to	O
12	-	O
13	86	O
14	were	O
15	sufficient	O
16	for	O
17	the	O
18	optimal	O
19	basal	O
20	level	O
21	transcription	O
22	in	O
23	HeLa	O
24	cells	O
25	and	O
26	also	O
27	for	O
28	the	O
29	EIA	O
30	-	O
31	induced	O
32	transcription	O
33	.	O

1	Plasma	B
2	levels	O
3	of	O
4	protein	O
5	C	O
6	,	O
7	protein	O
8	S	O
9	,	O
10	and	O
11	antithrombin	B
12	III	I
13	in	O
14	patients	O
15	with	O
16	subarachnoid	O
17	haemorrhage	O
18	.	O

1	Here	O
2	,	O
3	we	O
4	alter	O
5	the	O
6	dimerization	O
7	specificity	O
8	of	O
9	Fos	B
10	by	O
11	precisely	O
12	replacing	O
13	its	O
14	leucine	O
15	zipper	O
16	with	O
17	that	O
18	from	O
19	GCN4	B
20	.	O

1	Coronary	B
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	O
5	and	O
6	sigma	B
7	-	I
8	70	I
9	subunits	I
10	of	I
11	RNA	I
12	polymerase	I
13	affect	O
14	expression	O
15	of	O
16	the	O
17	mer	O
18	operon	O
19	.	O

1	The	O
2	synthetic	O
3	DNA	O
4	sequence	O
5	was	O
6	constructed	O
7	to	O
8	achieve	O
9	efficient	O
10	base	O
11	pairing	O
12	with	O
13	Escherichia	B
14	coli	I
15	16S	I
16	ribosomal	I
17	RNA	I
18	,	O
19	avoidance	O
20	of	O
21	internal	O
22	secondary	O
23	structure	O
24	,	O
25	and	O
26	optimal	O
27	codon	O
28	usage	O
29	for	O
30	high	O
31	-	O
32	level	O
33	protein	O
34	expression	O
35	in	O
36	accord	O
37	with	O
38	the	O
39	known	O
40	preferences	O
41	in	O
42	E	O
43	.	O
44	coli	O
45	.	O

1	Rapid	B
2	detection	O
3	of	O
4	this	O
5	mutation	O
6	is	O
7	achieved	O
8	by	O
9	restriction	O
10	digestion	O
11	of	O
12	PCR	O
13	-	O
14	amplified	O
15	genomic	O
16	DNA	O
17	;	O
18	a	O
19	mismatch	O
20	primer	O
21	combined	O
22	with	O
23	the	O
24	point	O
25	mutation	O
26	creates	O
27	a	O
28	Tru9I	O
29	restriction	O
30	site	O
31	.	O

1	Roles	B
2	of	O
3	the	O
4	Candida	O
5	albicans	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	I
12	,	O
13	Cek1p	O
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O

1	Component	B
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O

1	Using	O
2	an	O
3	opsonophagocytic	O
4	bacterial	O
5	assay	O
6	and	O
7	a	O
8	suckling	O
9	rat	O
10	model	O
11	of	O
12	GBS	O
13	sepsis	O
14	,	O
15	we	O
16	analyzed	O
17	a	O
18	modified	O
19	human	B
20	immunoglobulin	I
21	for	O
22	opsonic	O
23	and	O
24	protective	O
25	antibody	O
26	.	O

1	Except	B
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	Vitiligo	B
2	in	O
3	diabetes	O
4	mellitus	O
5	.	O

1	The	O
2	sites	O
3	targeted	O
4	for	O
5	mutagenesis	O
6	,	O
7	residues	O
8	60	O
9	,	O
10	61	O
11	,	O
12	and	O
13	66	O
14	,	O
15	are	O
16	located	O
17	within	O
18	a	O
19	putative	O
20	helical	O
21	loop	O
22	structure	O
23	which	O
24	may	O
25	be	O
26	involved	O
27	in	O
28	substrate	O
29	recognition	O
30	by	O
31	the	O
32	enzyme	O
33	.	O

1	Endoscopic	B
2	transthoracic	O
3	sympathectomy	O
4	as	O
5	adjuvant	O
6	treatment	O
7	for	O
8	critical	O
9	upper	O
10	-	O
11	limb	O
12	ischaemia	O
13	.	O

1	There	O
2	was	O
3	no	O
4	evident	O
5	inciting	O
6	agent	O
7	of	O
8	the	O
9	disease	O
10	.	O

1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	B
18	subtilis	I
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	TyrRS	O
21	activity	O
22	was	O
23	produced	O
24	.	O

1	Human	B
2	Duo	O
3	contains	O
4	a	O
5	guanine	B
6	nucleotide	I
7	exchange	I
8	factor	I
9	(	I
10	GEF	I
11	)	I
12	domain	I
13	that	O
14	is	O
15	likely	O
16	to	O
17	be	O
18	rac1	O
19	-	O
20	specific	O
21	,	O
22	a	O
23	pleckstrin	B
24	homology	I
25	(	O
26	PH	B
27	)	I
28	domain	I
29	and	I
30	spectrin	I
31	-	I
32	like	I
33	repeat	I
34	units	O
35	.	O

1	Two	O
2	-	O
3	way	O
4	analysis	O
5	of	O
6	variance	O
7	was	O
8	used	O
9	to	O
10	determine	O
11	whether	O
12	composite	O
13	knowledge	O
14	score	O
15	differed	O
16	among	O
17	patient	O
18	groups	O
19	.	O

1	Electron	B
2	microscopic	O
3	picture	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	cooled	O
11	to	O
12	22	O
13	degrees	O
14	C	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	The	O
2	Fas	B
3	receptor	I
4	mediates	O
5	a	O
6	signalling	O
7	cascade	O
8	resulting	O
9	in	O
10	programmed	O
11	cell	O
12	death	O
13	(	O
14	apoptosis	O
15	)	O
16	within	O
17	hours	O
18	of	O
19	receptor	O
20	cross	O
21	-	O
22	linking	O
23	.	O

1	CodY	B
2	does	O
3	not	O
4	have	O
5	any	O
6	homologues	O
7	in	O
8	the	O
9	data	O
10	-	O
11	bases	O
12	.	O

1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	hay	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	llamas	O
21	,	O
22	and	O
23	alfalfa	O
24	hay	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	unreliable	O
30	source	O
31	of	O
32	vitamins	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O

1	A	I
2	15	O
3	.	O
4	1	O
5	kb	O
6	fragment	O
7	of	O
8	the	O
9	yeast	O
10	genome	O
11	was	O
12	allocated	O
13	to	O
14	the	O
15	centromeric	O
16	region	O
17	of	O
18	chromosome	O
19	XIV	O
20	by	O
21	genetic	O
22	mapping	O
23	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	Alveolar	B
2	growth	I
3	,	O
4	contemporary	O
5	with	O
6	dental	O
7	eruption	O
8	,	O
9	is	O
10	sufficient	O
11	to	O
12	compensate	O
13	possible	O
14	hypotrophy	O
15	of	O
16	maxillary	O
17	bone	O
18	bases	O
19	.	O

1	RESULTS	O
2	:	O
3	Prevalence	O
4	of	O
5	obesity	O
6	(	O
7	BMI	O
8	SDS	O
9	>	O
10	2	O
11	.	O
12	0	O
13	)	O
14	was	O
15	<	O
16	2	O
17	%	O
18	at	O
19	diagnosis	O
20	,	O
21	but	O
22	increased	O
23	to	O
24	16	O
25	%	O
26	at	O
27	3y	O
28	.	O

1	Disruption	O
2	of	O
3	any	O
4	one	O
5	of	O
6	the	O
7	four	O
8	genes	O
9	encoding	O
10	the	O
11	newly	O
12	identified	O
13	SRP	B
14	proteins	I
15	results	O
16	in	O
17	slow	O
18	cell	O
19	growth	O
20	and	O
21	inefficient	O
22	protein	O
23	translocation	O
24	across	O
25	the	O
26	ER	O
27	membrane	O
28	.	O

1	The	O
2	TEA1	O
3	(	O
4	Ty	B
5	enhancer	I
6	activator	I
7	)	I
8	gene	I
9	sequence	I
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	I
33	type	I
34	family	I
35	of	I
36	DNA	I
37	-	I
38	binding	I
39	proteins	I
40	.	O

1	METHODS	O
2	:	O
3	Between	O
4	August	O
5	1991	O
6	and	O
7	June	O
8	1994	O
9	,	O
10	198	O
11	men	O
12	with	O
13	clinical	O
14	T2	O
15	or	O
16	T3	O
17	classified	O
18	(	O
19	TNM	O
20	)	O
21	prostate	O
22	carcinoma	O
23	(	O
24	bone	O
25	scan	O
26	negative	O
27	)	O
28	who	O
29	were	O
30	at	O
31	high	O
32	risk	O
33	of	O
34	lymph	O
35	node	O
36	involvement	O
37	underwent	O
38	a	O
39	111In	O
40	-	O
41	capromab	O
42	pendetide	O
43	scan	O
44	prior	O
45	to	O
46	staging	O
47	lymphadenectomy	O
48	.	O

1	Blood	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	was	O
7	measured	O
8	with	O
9	a	O
10	spectrophotometer	O
11	,	O
12	using	O
13	a	O
14	modification	O
15	of	O
16	a	O
17	previously	O
18	described	O
19	assay	O
20	.	O

1	Among	O
2	non	O
3	-	O
4	cirrhotics	O
5	,	O
6	lack	O
7	of	O
8	portal	O
9	vein	O
10	visualisation	O
11	had	O
12	a	O
13	90	O
14	%	O
15	sensitivity	O
16	,	O
17	88	O
18	%	O
19	specificity	O
20	,	O
21	94	O
22	%	O
23	negative	O
24	predictive	O
25	value	O
26	,	O
27	and	O
28	83	O
29	%	O
30	positive	O
31	predictive	O
32	value	O
33	in	O
34	the	O
35	diagnosis	O
36	of	O
37	pre	O
38	-	O
39	sinusoidal	O
40	portal	O
41	hypertension	O
42	.	O

1	An	O
2	8	O
3	-	O
4	h	O
5	exposure	O
6	to	O
7	10	O
8	mg	O
9	DMEA	O
10	/	O
11	m3	O
12	corresponds	O
13	to	O
14	a	O
15	postexposure	O
16	plasma	O
17	concentration	O
18	and	O
19	2	O
20	-	O
21	h	O
22	postexposure	O
23	urinary	O
24	excretion	O
25	of	O
26	4	O
27	.	O
28	9	O
29	mumol	O
30	/	O
31	l	O
32	and	O
33	75	O
34	mmol	O
35	/	O
36	mol	O
37	creatinine	O
38	,	O
39	respectively	O
40	.	O

1	Standardized	B
2	gastric	O
3	wall	O
4	specimens	O
5	from	O
6	the	O
7	area	O
8	of	O
9	grossly	O
10	healed	O
11	ulcers	O
12	were	O
13	obtained	O
14	,	O
15	processed	O
16	,	O
17	and	O
18	evaluated	O
19	by	O
20	light	O
21	microscopy	O
22	and	O
23	by	O
24	transmission	O
25	electron	O
26	microscopy	O
27	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	O
9	and	O
10	pelB	O
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	A	I
2	chromosome	O
3	transmission	O
4	fidelity	O
5	(	O
6	ctf	O
7	)	O
8	mutant	O
9	,	O
10	s138	O
11	,	O
12	of	O
13	Saccharomyces	O
14	cerevisiae	O
15	was	O
16	identified	O
17	by	O
18	its	O
19	centromere	O
20	(	O
21	CEN	O
22	)	O
23	transcriptional	O
24	readthrough	O
25	phenotype	O
26	,	O
27	suggesting	O
28	perturbed	O
29	kinetochore	O
30	integrity	O
31	in	O
32	vivo	O
33	.	O

1	Vestibular	B
2	adaptation	O
3	exercises	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	acoustic	O
11	neuroma	O
12	resection	O
13	.	O

1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	possible	O
7	involvement	O
8	of	O
9	p21	B
10	in	O
11	liver	O
12	cell	O
13	growth	O
14	,	O
15	the	O
16	expression	O
17	and	O
18	regulation	O
19	of	O
20	the	O
21	p21	B
22	gene	I
23	was	O
24	evaluated	O
25	in	O
26	rodent	O
27	models	O
28	of	O
29	liver	O
30	regeneration	O
31	and	O
32	specimens	O
33	of	O
34	human	O
35	liver	O
36	diseases	O
37	.	O

1	Specifically	O
2	,	O
3	by	O
4	the	O
5	type	O
6	of	O
7	adjuvant	O
8	therapy	O
9	,	O
10	the	O
11	median	O
12	disease	O
13	-	O
14	free	O
15	interval	O
16	and	O
17	survival	O
18	from	O
19	stage	O
20	IVA	O
21	for	O
22	23	O
23	patients	O
24	receiving	O
25	Corynebacterium	O
26	parvum	O
27	were	O
28	6	O
29	.	O
30	9	O
31	and	O
32	19	O
33	months	O
34	;	O
35	for	O
36	39	O
37	patients	O
38	receiving	O
39	BCG	O
40	,	O
41	eight	O
42	months	O
43	and	O
44	26	O
45	months	O
46	;	O
47	for	O
48	24	O
49	patients	O
50	receiving	O
51	BCG	O
52	+	O
53	DTIC	O
54	,	O
55	eight	O
56	and	O
57	17	O
58	.	O
59	4	O
60	months	O
61	;	O
62	and	O
63	for	O
64	all	O
65	51	O
66	DTIC	O
67	treated	O
68	patients	O
69	6	O
70	.	O
71	3	O
72	and	O
73	17	O
74	.	O
75	8	O
76	months	O
77	,	O
78	respectively	O
79	.	O

1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	I
43	gene	I
44	using	O
45	a	O
46	prokaryotic	B
47	gene	I
48	fusion	I
49	vector	O
50	(	O
51	pGEX	B
52	-	I
53	4T	I
54	-	I
55	2	I
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O

1	Quinone	B
2	-	I
3	binding	I
4	domain	I
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	B
12	binding	I
13	.	O

1	Nasal	B
2	absorption	O
3	was	O
4	rapid	O
5	,	O
6	nasal	O
7	bioavailability	O
8	was	O
9	43	O
10	%,	O
11	and	O
12	the	O
13	iv	O
14	and	O
15	nasal	O
16	elimination	O
17	profiles	O
18	were	O
19	similar	O
20	.	O

1	IL	B
2	-	I
3	1beta	I
4	(	O
5	10	O
6	ng	O
7	/	O
8	ml	O
9	)	O
10	drastically	O
11	increased	O
12	both	O
13	PDGFalphaR	O
14	and	O
15	CCAAT	B
16	/	I
17	enhancer	I
18	-	I
19	binding	I
20	protein	I
21	delta	I
22	(	I
23	C	I
24	/	I
25	EBPdelta	I
26	)	I
27	mRNA	I
28	levels	O
29	in	O
30	a	O
31	time	O
32	dependent	O
33	manner	O
34	.	O

1	Salazopyrine	B
2	desensitization	O

1	Strontium	B
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O

1	Climatic	B
2	treatment	O
3	of	O
4	children	O
5	with	O
6	respiratory	O
7	allergy	O

1	Several	O
2	studies	O
3	have	O
4	characterized	O
5	the	O
6	upstream	O
7	regulatory	O
8	region	O
9	of	O
10	c	B
11	-	I
12	fos	I
13	,	O
14	and	O
15	identified	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	termed	O
21	the	O
22	cyclic	O
23	AMP	O
24	(	O
25	cAMP	O
26	)	O
27	response	O
28	elements	O
29	(	O
30	CREs	O
31	)	O
32	that	O
33	are	O
34	critical	O
35	for	O
36	c	B
37	-	I
38	fos	I
39	transcription	I
40	in	O
41	response	O
42	to	O
43	a	O
44	variety	O
45	of	O
46	extracellular	O
47	stimuli	O
48	.	O

1	In	O
2	nondiabetics	O
3	the	O
4	response	O
5	of	O
6	tcPO2	O
7	but	O
8	not	O
9	of	O
10	LDF	O
11	was	O
12	influenced	O
13	by	O
14	the	O
15	values	O
16	at	O
17	rest	O
18	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	plasma	O
7	prolactin	B
8	response	O
9	to	O
10	12	O
11	.	O
12	5	O
13	micrograms	O
14	i	O
15	.	O
16	v	O
17	.	O

1	First	O
2	,	O
3	each	O
4	lung	O
5	was	O
6	cut	O
7	into	O
8	slices	O
9	,	O
10	from	O
11	which	O
12	primary	O
13	disectors	O
14	were	O
15	sampled	O
16	systematically	O
17	with	O
18	a	O
19	known	O
20	sampling	O
21	fraction	O
22	.	O

1	Gemfibrozil	B
2	in	O
3	hyperlipidaemic	O
4	patients	O
5	with	O
6	peripheral	O
7	arterial	O
8	disease	O
9	:	O
10	some	O
11	undiscovered	O
12	actions	O
13	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	O
7	and	O
8	Mus81p	O
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	The	O
2	UV	O
3	induction	O
4	of	O
5	c	B
6	-	I
7	jun	I
8	is	O
9	mediated	O
10	by	O
11	two	O
12	UV	O
13	response	O
14	elements	O
15	consisting	O
16	of	O
17	AP	B
18	-	I
19	1	I
20	-	I
21	like	I
22	sequences	I
23	within	O
24	its	O
25	5	O
26	'	O
27	control	O
28	region	O
29	.	O

1	The	O
2	value	O
3	of	O
4	different	O
5	sources	O
6	of	O
7	nitrogen	O
8	in	O
9	diets	O
10	for	O
11	the	O
12	early	O
13	-	O
14	weaned	O
15	calf	O
16	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	B
6	,	I
7	alpha	I
8	2AP	O
9	,	O
10	and	O
11	C1	B
12	-	I
13	INH	O
14	,	O
15	should	O
16	be	O
17	considered	O
18	equine	O
19	acute	O
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	The	O
2	determination	O
3	of	O
4	physical	O
5	performance	O
6	capacity	O
7	was	O
8	based	O
9	on	O
10	W170	O
11	,	O
12	W85	O
13	%	O
14	and	O
15	on	O
16	predicted	O
17	VO2	O
18	max	O
19	measured	O
20	with	O
21	continuously	O
22	increasing	O
23	work	O
24	load	O
25	on	O
26	a	O
27	bicycle	O
28	ergometer	O
29	.	O

1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	doxazosin	O
11	,	O
12	a	O
13	new	O
14	orally	O
15	active	O
16	selective	O
17	alpha	B
18	1	I
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	airflow	O
29	limitation	O
30	.	O

1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	O
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	O
42	-	O
43	TEFb	O
44	.	O

1	Among	O
2	them	O
3	,	O
4	26	O
5	cases	O
6	were	O
7	benign	O
8	and	O
9	34	O
10	malignant	O
11	.	O

1	We	O
2	have	O
3	now	O
4	identified	O
5	,	O
6	after	O
7	21	O
8	serial	O
9	undiluted	O
10	passages	O
11	of	O
12	MHV	O
13	,	O
14	a	O
15	small	O
16	DI	O
17	RNA	O
18	,	O
19	DIssF	O
20	,	O
21	which	O
22	is	O
23	efficiently	O
24	packaged	O
25	into	O
26	virions	O
27	.	O

1	We	O
2	demonstrate	O
3	that	O
4	a	O
5	VT	O
6	+	O
7	peptide	O
8	was	O
9	specifically	O
10	phosphorylated	O
11	by	O
12	protein	B
13	kinase	I
14	C	I
15	(	I
16	PKC	I
17	)	O
18	in	O
19	vitro	O
20	,	O
21	but	O
22	not	O
23	by	O
24	protein	B
25	kinase	I
26	A	I
27	(	O
28	PKA	B
29	).	O

1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	O
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	B
24	region	O
25	is	O
26	unaffected	O
27	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	Atopic	B
2	dermatitis	O
3	is	O
4	an	O
5	"	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	"	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O

1	1972	O
2	.	O

1	Ras	B
2	-	I
3	GRF1	O
4	transiently	O
5	expressed	O
6	with	O
7	v	B
8	-	I
9	Src	I
10	was	O
11	tyrosine	O
12	-	O
13	phosphorylated	O
14	and	O
15	showed	O
16	significant	O
17	GEF	B
18	activity	O
19	toward	O
20	Rac	B
21	,	O
22	but	O
23	not	O
24	Rho	B
25	and	O
26	Cdc42	B
27	,	O
28	which	O
29	was	O
30	comparable	O
31	with	O
32	that	O
33	induced	O
34	by	O
35	Gbetagamma	O
36	.	O

1	Consistent	O
2	with	O
3	these	O
4	findings	O
5	,	O
6	relatively	O
7	weak	O
8	transcriptional	O
9	silencing	O
10	by	O
11	the	O
12	native	O
13	VDR	B
14	was	O
15	observed	O
16	using	O
17	the	O
18	osteopontin	O
19	VDRE	O
20	.	O

1	Overall	O
2	agreement	O
3	between	O
4	rest	O
5	/	O
6	postnitroglycerin	O
7	technetium	O
8	-	O
9	99m	O
10	tetrofosmin	O
11	SPET	O
12	studies	O
13	and	O
14	rest	O
15	/	O
16	redistribution	O
17	or	O
18	rest	O
19	/	O
20	reinjection	O
21	thallium	O
22	-	O
23	201	O
24	SPET	O
25	studies	O
26	,	O
27	regarding	O
28	the	O
29	presence	O
30	of	O
31	myocardial	O
32	viability	O
33	,	O
34	was	O
35	87	O
36	%	O
37	and	O
38	90	O
39	%,	O
40	respectively	O
41	.	O

1	Having	B
2	an	O
3	LRR	O
4	domain	O
5	and	O
6	an	O
7	SH3	B
8	-	I
9	binding	I
10	domain	I
11	,	O
12	Acan125	O
13	and	O
14	the	O
15	C	O
16	.	O
17	elegans	O
18	homologue	O
19	define	O
20	a	O
21	novel	O
22	family	O
23	of	O
24	bifunctional	B
25	binding	I
26	proteins	I
27	.	O

1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	B
12	,	I
13	thioredoxin	I
14	reductase	I
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O

1	One	O
2	chimpanzee	O
3	reliably	O
4	selected	O
5	the	O
6	larger	O
7	numeral	O
8	4	O
9	during	O
10	testing	O
11	with	O
12	a	O
13	nonadjacent	O
14	pair	O
15	(	O
16	2	O
17	-	O
18	4	O
19	),	O
20	and	O
21	2	O
22	chimps	O
23	showed	O
24	no	O
25	preference	O
26	.	O

1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O

1	Serum	B
2	E2	I
3	concentrations	O
4	increased	O
5	numerically	O
6	two	O
7	-	O
8	to	O
9	threefold	O
10	from	O
11	d	O
12	56	O
13	to	O
14	140	O
15	in	O
16	controls	O
17	fed	O
18	MGA	O
19	,	O
20	compared	O
21	with	O
22	controls	O
23	not	O
24	fed	O
25	MGA	O
26	.	O

1	We	O
2	suggest	O
3	that	O
4	FlgN	O
5	and	O
6	FliT	O
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	flagellar	O
12	chaperones	O
13	that	O
14	prevent	O
15	oligomerization	O
16	of	O
17	the	O
18	HAPs	O
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O

1	Palindromic	B
2	rheumatism	O

1	The	O
2	odds	O
3	ratio	O
4	for	O
5	CHD	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	confidence	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	serostatus	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	I
32	after	O
33	adjustment	O
34	for	O
35	covariates	O
36	.	O

1	Its	O
2	neuromuscular	O
3	effects	O
4	are	O
5	similar	O
6	to	O
7	a	O
8	single	O
9	ED90	O
10	dose	O
11	of	O
12	vecuronium	O
13	.	O

1	The	O
2	high	O
3	density	O
4	lipoprotein	O
5	(	O
6	HDL	B
7	)	I
8	receptor	I
9	mediates	O
10	the	O
11	uptake	O
12	of	O
13	cholesterol	O
14	and	O
15	cholesteryl	O
16	esters	O
17	,	O
18	substrates	O
19	for	O
20	steroidogenesis	O
21	,	O
22	from	O
23	an	O
24	HDL	B
25	particle	I
26	in	O
27	the	O
28	adrenal	O
29	gland	O
30	and	O
31	gonads	O
32	.	O

1	A	I
2	high	O
3	reactor	O
4	pH	O
5	(+/-	O
6	8	O
7	),	O
8	a	O
9	short	O
10	solid	O
11	retention	O
12	time	O
13	(<	O
14	150	O
15	days	O
16	),	O
17	and	O
18	the	O
19	presence	O
20	of	O
21	a	O
22	substantial	O
23	SRB	O
24	population	O
25	in	O
26	the	O
27	inoculum	O
28	may	O
29	considerably	O
30	reduce	O
31	the	O
32	time	O
33	required	O
34	for	O
35	acetate	O
36	-	O
37	utilising	O
38	SRB	O
39	to	O
40	outcompete	O
41	MB	O
42	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	O
15	murine	O
16	gammaHV68	O
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	O
57	v	B
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	I
63	,	O
64	v	B
65	-	I
66	GCR	I
67	gene	I
68	,	O
69	and	O
70	gene	O
71	73	O
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	O
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	In	O
2	nine	O
3	patients	O
4	with	O
5	renal	O
6	failure	O
7	routine	O
8	haemodialysis	O
9	was	O
10	accompanied	O
11	by	O
12	a	O
13	30	O
14	per	O
15	cent	O
16	reduction	O
17	in	O
18	plasma	O
19	ANP	B
20	concentration	O
21	.	O

1	The	O
2	8	O
3	patients	O
4	receiving	O
5	Ir192	O
6	implant	O
7	in	O
8	addition	O
9	to	O
10	external	O
11	radiation	O
12	showed	O
13	improved	O
14	(	O
15	p	O
16	=	O
17	0	O
18	.	O
19	06	O
20	)	O
21	survival	O
22	compared	O
23	to	O
24	the	O
25	9	O
26	receiving	O
27	external	O
28	only	O
29	:	O
30	median	O
31	15	O
32	months	O
33	(	O
34	range	O
35	1	O
36	.	O
37	5	O
38	-	O
39	34	O
40	+	O
41	months	O
42	)	O
43	versus	O
44	7	O
45	months	O
46	(	O
47	range	O
48	2	O
49	.	O
50	5	O
51	-	O
52	21	O
53	months	O
54	).	O

1	However	O
2	,	O
3	parallax	O
4	measurements	O
5	showed	O
6	that	O
7	at	O
8	150K	O
9	,	O
10	collapse	O
11	of	O
12	Epon	O
13	sections	O
14	does	O
15	not	O
16	take	O
17	place	O
18	.	O

1	Critical	B
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	maturity	O
12	in	O
13	amniotic	O
14	fluid	O

1	It	O
2	is	O
3	thus	O
4	one	O
5	of	O
6	the	O
7	key	O
8	enzymes	O
9	involved	O
10	in	O
11	the	O
12	triiodothyronine	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	growth	O
18	,	O
19	differentiation	O
20	and	O
21	basal	O
22	metabolism	O
23	in	O
24	vertebrates	O
25	.	O

1	VII	I
2	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	O
9	and	O
10	CDKN2B	O
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	Then	B
2	we	O
3	correlated	O
4	HRCT	O
5	findings	O
6	with	O
7	the	O
8	clinical	O
9	features	O
10	,	O
11	pulmonary	O
12	functions	O
13	and	O
14	methacholine	O
15	PC20	O
16	(	O
17	PC20M	O
18	)	O
19	and	O
20	studied	O
21	their	O
22	clinical	O
23	significance	O
24	.	O

1	The	O
2	bovine	B
3	papillomavirus	I
4	E2	I
5	protein	I
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	I
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	B
27	papillomavirus	I
28	type	I
29	30	O
30	DNA	O
31	.	O

1	Natural	B
2	Haemophilus	I
3	influenzae	I
4	type	I
5	b	I
6	capsular	O
7	polysaccharide	O
8	antibodies	O
9	in	O
10	412	O
11	infants	O
12	and	O
13	children	O
14	from	O
15	West	O
16	Africa	O
17	(	O
18	Burkina	O
19	-	O
20	Faso	O
21	)	O
22	and	O
23	France	O
24	:	O
25	a	O
26	cross	O
27	-	O
28	sectional	O
29	serosurvey	O
30	.	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	The	O
2	data	O
3	provide	O
4	evidence	O
5	both	O
6	for	O
7	a	O
8	signal	O
9	transduction	O
10	pathway	O
11	independent	O
12	of	O
13	JNK	B
14	,	O
15	ERK	B
16	,	O
17	and	O
18	p38	B
19	MAP	I
20	kinase	I
21	to	O
22	be	O
23	involved	O
24	in	O
25	the	O
26	induction	O
27	of	O
28	rhoB	O
29	by	O
30	genotoxic	O
31	stress	O
32	,	O
33	and	O
34	furthermore	O
35	,	O
36	indicate	O
37	autoregulation	O
38	of	O
39	rhoB	O
40	.	O

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	Incubation	B
2	of	O
3	the	O
4	purified	O
5	fusion	O
6	proteins	O
7	with	O
8	[	O
9	gamma	B
10	-	I
11	32P	O
12	]	O
13	ATP	O
14	in	O
15	an	O
16	in	O
17	vitro	O
18	assay	O
19	showed	O
20	that	O
21	both	O
22	proteins	O
23	were	O
24	capable	O
25	of	O
26	autophosphorylation	O
27	.	O

1	SETTING	B
2	:	O
3	University	O
4	of	O
5	Paris	B
6	VII	I
7	hospital	O
8	.	O
9	Patient	O
10	(	O
11	s	O
12	):	O
13	Nine	O
14	women	O
15	had	O
16	embolization	O
17	for	O
18	symptomatic	O
19	myoma	O
20	,	O
21	with	O
22	12	O
23	pregnancies	O
24	observed	O
25	.	O

1	To	O
2	elucidate	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	Fyn	B
8	in	O
9	the	O
10	expression	O
11	of	O
12	viral	O
13	promoters	O
14	,	O
15	we	O
16	transfected	O
17	a	O
18	Fyn	B
19	-	I
20	expression	O
21	vector	O
22	together	O
23	with	O
24	a	O
25	reporter	O
26	plasmid	O
27	containing	O
28	the	O
29	chloramphenicol	B
30	acetyltransferase	I
31	gene	I
32	driven	O
33	by	O
34	HIV	B
35	LTR	I
36	into	O
37	a	O
38	human	O
39	T	O
40	cell	O
41	line	O
42	,	O
43	Jurkat	O
44	.	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	B
21	-	I
22	protein	I
23	interactions	O
24	.	O

1	The	O
2	Cut9	O
3	subunit	O
4	is	O
5	likely	O
6	to	O
7	be	O
8	a	O
9	target	O
10	for	O
11	regulating	O
12	APC	B
13	/	I
14	cyclosome	O
15	function	O
16	through	O
17	protein	B
18	-	I
19	protein	I
20	interactions	O
21	and	O
22	phosphorylation	O
23	.	O

1	Jembrana	B
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	B
20	immunodeficiency	I
21	virus	I
22	(	O
23	BIV	O
24	).	O

1	These	O
2	animals	O
3	were	O
4	viable	O
5	and	O
6	fertile	O
7	.	O

1	A	I
2	semiautomatic	O
3	digital	O
4	system	O
5	(	O
6	Videoplan	O
7	2	O
8	)	O
9	was	O
10	used	O
11	.	O

1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	I
6	-	I
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	STUDY	B
2	DESIGN	O
3	:	O
4	Fine	O
5	needle	O
6	aspiration	O
7	cytologic	O
8	smears	O
9	from	O
10	21	O
11	cases	O
12	of	O
13	invasive	O
14	lobular	O
15	carcinoma	O
16	(	O
17	ILC	O
18	)	O
19	of	O
20	breast	O
21	were	O
22	subjected	O
23	to	O
24	detailed	O
25	cytomorphologic	O
26	analysis	O
27	.	O

1	Dynamics	B
2	of	O
3	hospital	O
4	stay	O
5	in	O
6	peptic	O
7	ulcer	O
8	patients	O

1	In	O
2	wild	B
3	-	I
4	type	I
5	cells	O
6	,	O
7	SSM1b	O
8	transcripts	O
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	O
16	transcripts	O
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	O
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	O
29	pool	O
30	.	O

1	Interdomain	B
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	B
12	glucocorticoid	I
13	receptor	I
14	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	O
13	tRNA	O
14	can	O
15	confer	O
16	a	O
17	mutator	O
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	O
29	and	O
30	mutC	O
31	cells	O
32	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Cktsf1b1	O
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	O
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	The	O
2	standard	O
3	method	O
4	for	O
5	calculating	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	B
12	-	I
13	B	I
14	IV	I
15	excludes	O
16	subtests	O
17	with	O
18	a	O
19	raw	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	overestimates	O
26	cognitive	O
27	functioning	O
28	in	O
29	young	O
30	biologically	O
31	high	O
32	risk	O
33	children	O
34	.	O

1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	O
9	yr	O
10	)	O
11	with	O
12	doppler	O
13	-	O
14	proven	O
15	DVT	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	O
25	protein	O
26	C	O
27	(	O
28	APC	B
29	-	I
30	R	I
31	),	O
32	lupus	O
33	anticoagulant	O
34	(	O
35	LA	O
36	),	O
37	anticardiolipin	O
38	antibodies	O
39	and	O
40	deficiencies	O
41	of	O
42	protein	O
43	C	O
44	,	O
45	protein	O
46	S	O
47	,	O
48	ATIII	O
49	activities	O
50	.	O

1	Transcripts	B
2	from	O
3	a	O
4	second	O
5	POU	B
6	-	I
7	domain	I
8	gene	I
9	,	O
10	Oct	B
11	-	I
12	25	O
13	,	O
14	were	O
15	present	O
16	at	O
17	low	O
18	levels	O
19	in	O
20	oocytes	O
21	and	O
22	early	O
23	embryos	O
24	and	O
25	were	O
26	dramatically	O
27	upregulated	O
28	during	O
29	early	O
30	gastrulation	O
31	.	O

1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	O
10	and	O
11	Fv	O
12	fragments	O
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O

1	The	O
2	geometric	O
3	mean	O
4	hemagglutination	O
5	-	O
6	inhibition	O
7	antibody	O
8	titers	O
9	(	O
10	GMT	O
11	)	O
12	of	O
13	non	O
14	-	O
15	immunized	O
16	,	O
17	once	O
18	-	O
19	immunized	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	immunized	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	O
5	/	O
6	IRDelta960	O
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	O
13	/	O
14	IR	O
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O

1	Data	O
2	from	O
3	119	O
4	men	O
5	and	O
6	40	O
7	women	O
8	undergoing	O
9	coronary	O
10	angiography	O
11	provide	O
12	an	O
13	opportunity	O
14	to	O
15	compare	O
16	these	O
17	associations	O
18	in	O
19	relation	O
20	to	O
21	a	O
22	direct	O
23	and	O
24	continuous	O
25	measure	O
26	of	O
27	atherosclerosis	O
28	while	O
29	controlling	O
30	for	O
31	age	O
32	,	O
33	sex	O
34	,	O
35	income	O
36	,	O
37	hypertension	O
38	,	O
39	serum	O
40	cholesterol	O
41	,	O
42	smoking	O
43	,	O
44	angina	O
45	,	O
46	diabetes	O
47	,	O
48	family	O
49	history	O
50	of	O
51	heart	O
52	disease	O
53	,	O
54	Type	O
55	A	O
56	behavior	O
57	pattern	O
58	,	O
59	and	O
60	hostility	O
61	.	O

1	In	O
2	contrast	O
3	,	O
4	COUP	B
5	-	I
6	TF	I
7	alone	O
8	had	O
9	no	O
10	effect	O
11	on	O
12	repCRS2	B
13	-	I
14	dependent	I
15	reporter	I
16	gene	I
17	activity	O
18	.	O

1	In	O
2	a	O
3	blind	O
4	controlled	O
5	trial	O
6	,	O
7	15	O
8	patients	O
9	with	O
10	COCM	O
11	(	O
12	NYHA	B
13	II	I
14	-	I
15	III	I
16	)	O
17	with	O
18	sinus	O
19	rhythm	O
20	and	O
21	a	O
22	left	O
23	ventricular	O
24	ejection	O
25	fraction	O
26	(	O
27	LV	O
28	-	O
29	EF	O
30	)	O
31	of	O
32	34	O
33	.	O
34	5	O
35	+/-	O
36	2	O
37	.	O
38	6	O
39	%	O
40	received	O
41	consecutively	O
42	D	O
43	(	O
44	0	O
45	.	O
46	25	O
47	-	O
48	0	O
49	.	O
50	5	O
51	mg	O
52	/	O
53	d	O
54	),	O
55	placebo	O
56	(	O
57	PLAC	O
58	),	O
59	P	O
60	(	O
61	slow	O
62	releases	O
63	=	O
64	SR	O
65	)	O
66	(	O
67	80	O
68	mg	O
69	/	O
70	d	O
71	SR	O
72	)	O
73	and	O
74	both	O
75	drugs	O
76	combined	O
77	in	O
78	respective	O
79	doses	O
80	.	O

1	Stems	B
2	contain	O
3	distinctly	O
4	less	O
5	P	B
6	protein	I
7	mRNA	I
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O

1	Testing	B
2	for	O
3	serum	B
4	IgM	I
5	binding	I
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Histopathologic	B
2	observations	O
3	showed	O
4	that	O
5	both	O
6	somatostatin	B
7	and	O
8	triamcinolone	O
9	acetonide	O
10	reduced	O
11	the	O
12	inflammatory	O
13	signs	O
14	in	O
15	the	O
16	joint	O
17	structures	O
18	,	O
19	although	O
20	triamcinolone	O
21	acetonide	O
22	appeared	O
23	to	O
24	be	O
25	more	O
26	effective	O
27	.	O

1	The	O
2	same	O
3	rhythmic	O
4	structure	O
5	enables	O
6	a	O
7	prediction	O
8	to	O
9	be	O
10	made	O
11	concerning	O
12	when	O
13	vowels	O
14	of	O
15	stressed	O
16	syllables	O
17	will	O
18	be	O
19	auditorily	O
20	perceived	O
21	.	O

1	Maximum	B
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Keeping	B
2	in	O
3	mind	O
4	the	O
5	limited	O
6	range	O
7	of	O
8	age	O
9	and	O
10	dosages	O
11	,	O
12	advantages	O
13	and	O
14	disadvantages	O
15	of	O
16	the	O
17	drug	O
18	are	O
19	discussed	O
20	,	O
21	comparing	O
22	the	O
23	experimental	O
24	results	O
25	with	O
26	those	O
27	derived	O
28	from	O
29	the	O
30	literature	O
31	.	O

1	In	O
2	comparison	O
3	of	O
4	cDNA	O
5	and	O
6	genomic	O
7	sequences	O
8	four	O
9	RNA	O
10	editing	O
11	events	O
12	were	O
13	found	O
14	in	O
15	both	O
16	atp9	O
17	genes	O
18	.	O

1	It	O
2	was	O
3	shown	O
4	that	O
5	estradiol	O
6	concentrations	O
7	obtained	O
8	after	O
9	estradiol	O
10	valerate	O
11	and	O
12	micronized	O
13	estradiol	O
14	ingestion	O
15	were	O
16	dependent	O
17	on	O
18	the	O
19	patient	O
20	'	O
21	s	O
22	age	O
23	as	O
24	well	O
25	as	O
26	on	O
27	the	O
28	constitutional	O
29	type	O
30	.	O

1	Hybridization	O
2	signals	O
3	were	O
4	also	O
5	detected	O
6	with	O
7	total	O
8	DNAs	O
9	of	O
10	Rhizobium	O
11	leguminosarum	O
12	bv	O
13	.	O
14	phaseoli	O
15	,	O
16	Rhodobacter	O
17	capsulatus	O
18	and	O
19	Escherichia	O
20	coli	O
21	,	O
22	but	O
23	not	O
24	those	O
25	of	O
26	Xanthomonas	O
27	campestris	O
28	pv	O
29	.	O
30	campestris	O
31	and	O
32	Pseudomonas	O
33	putida	O
34	.	O

1	This	O
2	region	O
3	constitutes	O
4	the	O
5	DNA	B
6	-	I
7	binding	I
8	domain	I
9	with	O
10	basic	B
11	-	I
12	helix	I
13	-	I
14	loop	I
15	-	I
16	helix	I
17	and	I
18	leucine	I
19	-	I
20	zipper	I
21	motifs	O
22	,	O
23	features	O
24	common	O
25	to	O
26	the	O
27	myc	B
28	-	I
29	related	I
30	transcription	I
31	factor	I
32	family	I
33	.	O

1	Additionally	O
2	,	O
3	I	B
4	kappa	I
5	B	I
6	beta	I
7	,	O
8	but	O
9	not	O
10	I	B
11	kappa	I
12	B	I
13	alpha	I
14	,	O
15	also	O
16	prevented	O
17	the	O
18	binding	O
19	of	O
20	Rel	B
21	to	O
22	the	O
23	kappa	B
24	B	I
25	site	I
26	.	O

1	In	O
2	fact	O
3	,	O
4	families	O
5	of	O
6	polypeptides	O
7	were	O
8	produced	O
9	by	O
10	initiation	O
11	of	O
12	translation	O
13	at	O
14	AUG	O
15	codons	O
16	within	O
17	sequences	O
18	coding	O
19	for	O
20	VP1	B
21	and	O
22	T	O
23	,	O
24	presumably	O
25	as	O
26	a	O
27	result	O
28	of	O
29	transcription	O
30	initiation	O
31	events	O
32	that	O
33	generated	O
34	5	O
35	'	O
36	ends	O
37	immediately	O
38	upstream	O
39	from	O
40	these	O
41	AUGs	O
42	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	Acute	O
2	pancreatitis	O
3	:	O
4	a	O
5	multisystem	O
6	disease	O
7	.	O

1	The	O
2	psychologic	O
3	factors	O
4	associated	O
5	wth	O
6	serious	O
7	illness	O
8	,	O
9	terminal	O
10	prognoses	O
11	,	O
12	and	O
13	dying	O
14	complicate	O
15	the	O
16	scenario	O
17	even	O
18	more	O
19	as	O
20	compared	O
21	with	O
22	that	O
23	of	O
24	nonmalignant	O
25	pain	O
26	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O

1	The	O
2	radiation	O
3	burden	O
4	associated	O
5	with	O
6	the	O
7	majority	O
8	of	O
9	examinations	O
10	in	O
11	nuclear	O
12	medicine	O
13	expressed	O
14	as	O
15	the	O
16	effective	O
17	dose	O
18	is	O
19	comparable	O
20	with	O
21	the	O
22	radiation	O
23	burden	O
24	of	O
25	radiodiagnostic	O
26	examinations	O
27	,	O
28	only	O
29	after	O
30	administration	O
31	of	O
32	preparations	O
33	with	O
34	131I	O
35	,	O
36	201Tl	O
37	,	O
38	67Ga	O
39	and	O
40	111In	O
41	it	O
42	is	O
43	markedly	O
44	higher	O
45	.	O

1	The	O
2	other	O
3	hypoglycaemic	O
4	patient	O
5	showed	O
6	an	O
7	exaggerated	O
8	insulin	B
9	release	O
10	in	O
11	response	O
12	to	O
13	tolbutamide	O
14	.	O

1	Crystal	B
2	structure	O
3	of	O
4	an	O
5	oligomer	O
6	of	O
7	proteolytic	O
8	zymogens	O
9	:	O
10	detailed	O
11	conformational	O
12	analysis	O
13	of	O
14	the	O
15	bovine	O
16	ternary	O
17	complex	O
18	and	O
19	implications	O
20	for	O
21	their	O
22	activation	O
23	.	O

1	These	O
2	cells	O
3	averaged	O
4	17	O
5	microns	O
6	in	O
7	diameter	O
8	and	O
9	reproduced	O
10	by	O
11	fission	O
12	,	O
13	forming	O
14	clusters	O
15	of	O
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	A	I
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	O
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	I
24	RPTK	I
25	)	I
26	interacting	I
27	protein	I
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O

1	The	O
2	altered	O
3	amino	O
4	acid	O
5	residues	O
6	of	O
7	the	O
8	seven	O
9	mutant	O
10	9ORF1	O
11	polypeptides	O
12	clustered	O
13	within	O
14	three	O
15	separate	O
16	regions	O
17	referred	O
18	to	O
19	as	O
20	region	O
21	I	O
22	(	O
23	residues	O
24	34	O
25	to	O
26	41	O
27	),	O
28	region	O
29	II	O
30	(	O
31	residues	O
32	89	O
33	to	O
34	91	O
35	),	O
36	and	O
37	C	B
38	-	I
39	terminal	I
40	region	I
41	III	I
42	(	O
43	residues	O
44	122	O
45	to	O
46	125	O
47	).	O

1	Anastrozole	B
2	is	O
3	the	O
4	first	O
5	aromatase	B
6	inhibitor	I
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O

1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	O
8	c	B
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	I
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	B
26	cell	I
27	receptor	I
28	stimulation	O
29	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	Consequently	B
2	,	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	measured	O
8	and	O
9	calculated	O
10	methods	O
11	were	O
12	noted	O
13	in	O
14	oxygen	O
15	uptake	O
16	(	O
17	213	O
18	+/-	O
19	41	O
20	ml	O
21	/	O
22	min	O
23	vs	O
24	193	O
25	+/-	O
26	25	O
27	ml	O
28	/	O
29	min	O
30	,	O
31	p	O
32	<	O
33	0	O
34	.	O
35	001	O
36	),	O
37	oxygen	O
38	delivery	O
39	(	O
40	780	O
41	+/-	O
42	297	O
43	ml	O
44	/	O
45	min	O
46	vs	O
47	716	O
48	+/-	O
49	296	O
50	ml	O
51	/	O
52	min	O
53	,	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	),	O
60	and	O
61	cardiac	O
62	output	O
63	(	O
64	5	O
65	.	O
66	8	O
67	+/-	O
68	2	O
69	.	O
70	2	O
71	L	O
72	/	O
73	min	O
74	vs	O
75	5	O
76	.	O
77	3	O
78	+/-	O
79	1	O
80	.	O
81	8	O
82	L	O
83	/	O
84	min	O
85	,	O
86	p	O
87	<	O
88	0	O
89	.	O
90	001	O
91	).	O

1	To	O
2	clarify	O
3	whether	O
4	seizure	O
5	-	O
6	offset	O
7	patterns	O
8	are	O
9	reliable	O
10	in	O
11	predicting	O
12	seizure	O
13	outcome	O
14	,	O
15	we	O
16	studied	O
17	SEEG	O
18	/	O
19	ECoG	O
20	in	O
21	a	O
22	similar	O
23	group	O
24	of	O
25	patients	O
26	with	O
27	temporal	O
28	lobe	O
29	epilepsy	O
30	(	O
31	TLE	O
32	).	O

1	Differences	B
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	In	O
2	the	O
3	controls	O
4	,	O
5	it	O
6	was	O
7	found	O
8	that	O
9	all	O
10	right	O
11	-	O
12	handed	O
13	and	O
14	10	O
15	out	O
16	of	O
17	14	O
18	left	O
19	-	O
20	handed	O
21	control	O
22	subjects	O
23	showed	O
24	a	O
25	right	O
26	VHF	O
27	(	O
28	i	O
29	.	O
30	e	O
31	.,	O
32	left	O
33	hemisphere	O
34	)	O
35	advantage	O
36	.	O

1	In	O
2	the	O
3	PMR	O
4	target	O
5	area	O
6	but	O
7	not	O
8	in	O
9	the	O
10	nontreated	O
11	area	O
12	an	O
13	improvement	O
14	in	O
15	regional	O
16	myocardial	O
17	flow	O
18	reserve	O
19	occurs	O
20	in	O
21	wall	O
22	segments	O
23	with	O
24	initially	O
25	severely	O
26	or	O
27	moderately	O
28	reduced	O
29	stress	O
30	perfusion	O
31	.	O

1	Utilization	B
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	O
13	mRNAs	O
14	of	O
15	1	O
16	.	O
17	9	O
18	and	O
19	4	O
20	.	O
21	3	O
22	kb	O
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	report	O
6	that	O
7	ligand	O
8	binding	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	in	O
13	BaF3	O
14	cells	O
15	engineered	O
16	to	O
17	express	O
18	the	O
19	murine	B
20	Mpl	I
21	receptor	I
22	(	O
23	BaF3	O
24	/	O
25	mMpl	O
26	).	O

1	The	O
2	behavior	O
3	of	O
4	suf12	B
5	-	I
6	null	I
7	/	I
8	SUF12	I
9	+	I
10	heterozygotes	O
11	indicates	O
12	that	O
13	suf12	B
14	is	O
15	co	O
16	-	O
17	dominantly	O
18	expressed	O
19	and	O
20	suggests	O
21	that	O
22	suf12	B
23	allele	I
24	-	I
25	specific	I
26	suppression	O
27	may	O
28	result	O
29	from	O
30	functionally	O
31	distinct	O
32	mutant	O
33	proteins	O
34	rather	O
35	than	O
36	variation	O
37	in	O
38	residual	O
39	wild	B
40	-	I
41	type	I
42	SUF12	I
43	+	I
44	activity	O
45	.	O

1	Effects	O
2	of	O
3	intramammary	O
4	endotoxin	O
5	infusion	O
6	on	O
7	milking	O
8	-	O
9	induced	O
10	oxytocin	O
11	release	O
12	.	O

1	The	O
2	E	B
3	-	I
4	box	I
5	sequence	I
6	in	O
7	the	O
8	SE2	O
9	fragment	O
10	of	O
11	the	O
12	transferrin	B
13	promoter	I
14	was	O
15	CATCTG	O
16	and	O
17	was	O
18	similar	O
19	in	O
20	gel	O
21	shifts	O
22	to	O
23	the	O
24	consensus	O
25	E	B
26	-	I
27	box	I
28	elements	I
29	(	O
30	CANNTG	O
31	)	O
32	previously	O
33	characterized	O
34	.	O

1	Lung	O
2	function	O
3	tests	O
4	(	O
5	EFR	O
6	)	O
7	were	O
8	performed	O
9	on	O
10	these	O
11	patients	O
12	for	O
13	a	O
14	period	O
15	of	O
16	19	O
17	.	O
18	2	O
19	+/-	O
20	3	O
21	.	O
22	4	O
23	months	O
24	.	O

1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O

1	Patients	O
2	with	O
3	psychotropic	O
4	drugs	O
5	showed	O
6	significantly	O
7	higher	O
8	PRL	B
9	levels	O
10	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	role	O
6	of	O
7	cellular	O
8	p21ras	B
9	protein	I
10	in	O
11	insulin	B
12	and	O
13	insulin	B
14	-	I
15	like	I
16	growth	I
17	factor	I
18	-	I
19	I	I
20	(	I
21	IGF	I
22	-	I
23	I	I
24	)	O
25	signaling	O
26	pathways	O
27	.	O

1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	I
8	jun	I
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	I
62	jun	I
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	O
68	luciferase	B
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	O
26	group	O
27	of	O
28	the	O
29	esterase	B
30	/	I
31	lipase	I
32	family	I
33	.	O

1	Egd1p	B
2	is	O
3	homologous	O
4	to	O
5	human	O
6	BTF3b	O
7	,	O
8	recently	O
9	identified	O
10	as	O
11	the	O
12	beta	B
13	subunit	I
14	of	O
15	the	O
16	heterodimeric	B
17	nascent	I
18	-	I
19	polypeptide	I
20	-	I
21	associated	I
22	complex	I
23	(	O
24	NAC	O
25	)	O
26	involved	O
27	in	O
28	ensuring	B
29	signal	I
30	-	I
31	sequence	I
32	-	I
33	specific	I
34	protein	I
35	sorting	O
36	and	O
37	translocation	O
38	[	O
39	Wiedmann	O
40	et	O
41	al	O
42	.,	O
43	Nature	O
44	370	O
45	(	O
46	1994	O
47	)	O
48	434	O
49	-	O
50	440	O
51	].	O

1	Mammalian	B
2	M	I
3	-	I
4	Ras	I
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	O
34	p21	B
35	Ras	I
36	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	O
29	and	O
30	pulCp	O
31	promoters	O
32	.	O

1	Protein	B
2	phosphatase	I
3	2A	I
4	is	O
5	a	O
6	critical	O
7	regulator	O
8	of	O
9	protein	B
10	kinase	I
11	C	I
12	zeta	I
13	signaling	O
14	targeted	O
15	by	O
16	SV40	O
17	small	O
18	t	O
19	to	O
20	promote	O
21	cell	O
22	growth	O
23	and	O
24	NF	B
25	-	I
26	kappaB	I
27	activation	O
28	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	O
44	(	O
45	hsp27	O
46	).	O

1	Localized	B
2	fluorescence	O
3	was	O
4	detectable	O
5	only	O
6	in	O
7	cells	O
8	containing	O
9	a	O
10	visible	O
11	midcell	O
12	constriction	O
13	,	O
14	suggesting	O
15	that	O
16	FtsK	O
17	targeting	O
18	normally	O
19	occurs	O
20	only	O
21	at	O
22	a	O
23	late	O
24	stage	O
25	of	O
26	septation	O
27	.	O

1	25	I
2	-	I
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	Moxidectin	B
2	(	O
3	at	O
4	3	O
5	times	O
6	the	O
7	therapeutic	O
8	dose	O
9	)	O
10	did	O
11	not	O
12	have	O
13	deleterious	O
14	effects	O
15	on	O
16	cow	O
17	reproductive	O
18	performance	O
19	as	O
20	examined	O
21	(	O
22	eg	O
23	,	O
24	at	O
25	folliculogenesis	O
26	,	O
27	ovulation	O
28	,	O
29	and	O
30	the	O
31	early	O
32	embryonic	O
33	phase	O
34	of	O
35	development	O
36	).	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	In	O
2	some	O
3	of	O
4	the	O
5	cases	O
6	of	O
7	solitary	O
8	lesion	O
9	,	O
10	serum	O
11	TSH	B
12	levels	O
13	,	O
14	serum	O
15	thyroglobulin	O
16	values	O
17	,	O
18	and	O
19	131I	O
20	protein	O
21	bounded	O
22	iodine	O
23	(	O
24	131I	O
25	-	O
26	PBI	O
27	)	O
28	were	O
29	measured	O
30	,	O
31	but	O
32	there	O
33	were	O
34	no	O
35	significant	O
36	differences	O
37	between	O
38	successful	O
39	and	O
40	unsuccessful	O
41	therapy	O
42	.	O

1	The	O
2	quantitative	O
3	determination	O
4	of	O
5	HBSAG	O
6	--	O
7	a	O
8	valuable	O
9	aid	O
10	in	O
11	evaluating	O
12	the	O
13	infectiousness	O
14	of	O
15	hepatitis	O
16	B	O
17	virus	O
18	carriers	O

1	METHOD	B
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	O
42	serum	B
43	immunoglobulin	I
44	E	I
45	(	I
46	IgE	I
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	O
53	serum	O
54	IgE	B
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O

1	Lars	B
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	O
9	superoxide	B
10	dismutase	I
11	.	O

1	LH	B
2	/	I
3	CG	I
4	receptor	I
5	activation	O
6	of	O
7	ARNO	O
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	B
15	3	I
16	-	I
17	kinase	I
18	(	I
19	PI	I
20	3	I
21	-	I
22	kinase	I
23	)	O
24	or	O
25	by	O
26	G	B
27	protein	I
28	beta	I
29	gamma	I
30	subunits	I
31	.	O

1	Survival	O
2	of	O
3	111	O
4	Indium	O
5	-	O
6	labelled	O
7	autologous	O
8	platelets	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	shortened	O
24	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	genomic	O
8	RNA	O
9	of	O
10	rubella	O
11	virus	O
12	(	O
13	RUB	O
14	)	O
15	contains	O
16	a	O
17	14	O
18	-	O
19	nucleotide	O
20	(	O
21	nt	O
22	)	O
23	single	O
24	-	O
25	stranded	O
26	leader	O
27	(	O
28	ss	O
29	-	O
30	leader	O
31	)	O
32	followed	O
33	by	O
34	a	O
35	stem	O
36	-	O
37	and	O
38	-	O
39	loop	O
40	structure	O
41	[	O
42	5	O
43	'(+)	O
44	SL	O
45	]	O
46	(	O
47	nt	O
48	15	O
49	to	O
50	65	O
51	),	O
52	the	O
53	complement	O
54	of	O
55	which	O
56	at	O
57	the	O
58	3	O
59	'	O
60	end	O
61	of	O
62	the	O
63	minus	O
64	-	O
65	strand	O
66	RNA	O
67	[	O
68	3	O
69	'(-)	O
70	SL	O
71	]	O
72	has	O
73	been	O
74	proposed	O
75	to	O
76	function	O
77	as	O
78	a	O
79	promoter	O
80	for	O
81	synthesis	O
82	of	O
83	genomic	O
84	plus	O
85	strands	O
86	.	O

1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	O
15	in	O
16	Saccharopolyspora	O
17	erythraea	O
18	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	to	O
6	characterize	O
7	the	O
8	gene	O
9	for	O
10	protein	O
11	Z	O
12	,	O
13	its	O
14	organization	O
15	and	O
16	structure	O
17	were	O
18	determined	O
19	by	O
20	a	O
21	combination	O
22	of	O
23	PCR	O
24	amplification	O
25	of	O
26	leukocyte	O
27	DNA	O
28	and	O
29	isolation	O
30	of	O
31	phage	O
32	clones	O
33	from	O
34	a	O
35	human	O
36	genomic	O
37	library	O
38	.	O

1	Potential	B
2	consensus	I
3	sequences	I
4	for	O
5	early	O
6	and	O
7	late	O
8	regulatory	O
9	elements	O
10	were	O
11	identified	O
12	.	O

1	BACKGROUND	O
2	:	O
3	Fluoroquinolones	O
4	(	O
5	FQ	O
6	)	O
7	are	O
8	contraindicated	O
9	in	O
10	children	O
11	because	O
12	of	O
13	the	O
14	risk	O
15	of	O
16	cartilage	O
17	damage	O
18	.	O

1	In	O
2	studies	O
3	of	O
4	many	O
5	different	O
6	phenotypically	O
7	distinct	O
8	cells	O
9	,	O
10	the	O
11	CRE	O
12	of	O
13	the	O
14	somatostatin	B
15	gene	I
16	promoter	I
17	is	O
18	a	O
19	prototype	O
20	of	O
21	a	O
22	highly	O
23	cAMP	B
24	-	I
25	responsive	I
26	element	I
27	regulated	O
28	by	O
29	CREB	B
30	.	O

1	Ulcer	B
2	appeared	O
3	on	O
4	the	O
5	angulus	O
6	of	O
7	the	O
8	stomach	O
9	at	O
10	the	O
11	28th	O
12	week	O
13	and	O
14	resulted	O
15	in	O
16	ulcer	O
17	scar	O
18	at	O
19	the	O
20	42nd	O
21	week	O
22	.	O

1	Substitution	O
2	of	O
3	a	O
4	threonine	O
5	residue	O
6	by	O
7	an	O
8	alanine	O
9	residue	O
10	at	O
11	position	O
12	-	O
13	2	O
14	(	O
15	P2	O
16	)	O
17	of	O
18	this	O
19	cleavage	O
20	site	O
21	abolished	O
22	cleavage	O
23	,	O
24	whereas	O
25	substitution	O
26	of	O
27	a	O
28	tyrosine	O
29	residue	O
30	by	O
31	a	O
32	phenylalanine	O
33	residue	O
34	at	O
35	amino	O
36	acid	O
37	position	O
38	-	O
39	1	O
40	(	O
41	P1	O
42	)	O
43	of	O
44	the	O
45	cleavage	O
46	site	O
47	did	O
48	not	O
49	influence	O
50	processing	O
51	.	O

1	Evaluation	O
2	of	O
3	myocardial	O
4	perfusion	O
5	by	O
6	99mTc	O
7	-	O
8	tetrofosmin	O
9	SPECT	O
10	before	O
11	and	O
12	after	O
13	emergent	O
14	percutaneous	O
15	transluminal	O
16	coronary	O
17	angioplasty	O
18	for	O
19	acute	O
20	myocardial	O
21	infarction	O

1	Specific	O
2	IgG	B
3	,	O
4	specific	O
5	IgE	B
6	and	O
7	total	O
8	IgE	B
9	immunoglobulins	I
10	against	O
11	Toxocara	O
12	canis	O
13	excretory	O
14	/	O
15	secretory	O
16	antigens	O
17	(	O
18	TES	O
19	)	O
20	were	O
21	detected	O
22	by	O
23	using	O
24	ELISA	O
25	technique	O
26	.	O

1	Two	O
2	other	O
3	patients	O
4	underwent	O
5	PRFR	O
6	.	O

1	Telomeres	B
2	prevent	O
3	end	O
4	-	O
5	to	O
6	-	O
7	end	O
8	fusions	O
9	and	O
10	exonucleolytic	O
11	degradation	O
12	,	O
13	enable	O
14	the	O
15	end	O
16	of	O
17	the	O
18	linear	O
19	DNA	O
20	molecule	O
21	to	O
22	replicate	O
23	,	O
24	and	O
25	function	O
26	in	O
27	cell	O
28	division	O
29	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	GAP	B
2	-	I
3	N	I
4	bound	O
5	constitutively	O
6	to	O
7	p190	B
8	in	O
9	both	O
10	serum	O
11	-	O
12	deprived	O
13	and	O
14	growth	B
15	factor	I
16	-	I
17	stimulated	O
18	cells	O
19	.	O

1	During	O
2	1985	O
3	,	O
4	1990	O
5	,	O
6	and	O
7	1995	O
8	,	O
9	respectively	O
10	,	O
11	11	O
12	.	O
13	7	O
14	,	O
15	11	O
16	.	O
17	3	O
18	,	O
19	and	O
20	11	O
21	.	O
22	4	O
23	infants	O
24	per	O
25	100	O
26	,	O
27	000	O
28	live	O
29	births	O
30	had	O
31	a	O
32	diagnosis	O
33	of	O
34	HSV	O
35	(	O
36	P	O
37	=.	O
38	98	O
39	).	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	Cotransfection	O
2	of	O
3	the	O
4	helicase	B
5	-	I
6	primase	I
7	proteins	I
8	,	O
9	one	O
10	of	O
11	which	O
12	was	O
13	fused	O
14	to	O
15	a	O
16	heterologous	O
17	activation	O
18	domain	O
19	,	O
20	led	O
21	to	O
22	Zta	B
23	-	I
24	dependent	I
25	superactivation	O
26	of	O
27	CAT	B
28	expression	O
29	.	O

1	Kinetics	B
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	The	O
2	native	O
3	enzyme	O
4	purified	O
5	from	O
6	protease	B
7	-	I
8	B	I
9	-	I
10	deficient	O
11	URA2	O
12	-	O
13	transformed	O
14	cells	O
15	,	O
16	was	O
17	phosphorylated	O
18	in	O
19	vitro	O
20	using	O
21	catalytic	O
22	subunits	O
23	of	O
24	pure	O
25	cAMP	B
26	-	I
27	dependent	I
28	protein	I
29	kinase	I
30	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	O
22	core	O
23	promoter	O
24	through	O
25	liver	B
26	-	I
27	specific	I
28	enhancer	I
29	II	I
30	and	O
31	HBx	O
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O

1	Activated	B
2	areas	O
3	have	O
4	been	O
5	identified	O
6	by	O
7	means	O
8	of	O
9	cross	O
10	-	O
11	correlation	O
12	analysis	O
13	.	O

1	However	O
2	,	O
3	the	O
4	elderly	O
5	group	O
6	showed	O
7	significantly	O
8	longer	O
9	mean	O
10	residence	O
11	times	O
12	(	O
13	MRTs	O
14	)	O
15	and	O
16	lower	O
17	plasma	O
18	clearance	O
19	of	O
20	lidocaine	O
21	during	O
22	the	O
23	period	O
24	compared	O
25	with	O
26	the	O
27	adult	O
28	group	O
29	(	O
30	P	O
31	<	O
32	.	O
33	05	O
34	).	O

1	Indeed	B
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	it	O
8	mediates	O
9	the	O
10	formation	O
11	of	O
12	disulfide	O
13	-	O
14	linked	O
15	homodimers	O
16	and	O
17	that	O
18	the	O
19	formation	O
20	of	O
21	homo	O
22	-	O
23	and	O
24	heterodimers	O
25	are	O
26	mutually	O
27	excluded	O
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	low	O
6	concentrations	O
7	of	O
8	IL	B
9	-	I
10	1	I
11	beta	I
12	may	O
13	be	O
14	useful	O
15	for	O
16	nonsurgical	O
17	treatment	O
18	of	O
19	human	O
20	vitreous	O
21	hemorrhage	O
22	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	Cheung	B
2	and	O
3	S	O
4	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	I
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	The	O
2	MRS	O
3	II	O
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	ability	O
6	of	O
7	various	O
8	NF	B
9	-	I
10	kappa	I
11	B	I
12	subunits	I
13	to	O
14	bind	O
15	to	O
16	,	O
17	and	O
18	activate	O
19	transcription	O
20	from	O
21	,	O
22	the	O
23	IL	B
24	-	I
25	8	I
26	promoter	I
27	.	O

1	The	O
2	effect	O
3	of	O
4	emotional	O
5	-	O
6	painful	O
7	stress	O
8	(	O
9	EPS	O
10	)	O
11	on	O
12	myocardial	O
13	extensibility	O
14	and	O
15	contractility	O
16	was	O
17	studied	O
18	on	O
19	an	O
20	isolated	O
21	rat	O
22	atrium	O
23	.	O

1	The	O
2	characterized	O
3	Aplysia	O
4	Afurin2	O
5	is	O
6	a	O
7	candidate	O
8	PC	O
9	that	O
10	may	O
11	play	O
12	an	O
13	important	O
14	role	O
15	in	O
16	the	O
17	processing	O
18	of	O
19	egg	B
20	-	I
21	laying	I
22	hormone	I
23	(	I
24	ELH	I
25	)-	I
26	related	I
27	precursors	O
28	in	O
29	the	O
30	secretory	O
31	cells	O
32	of	O
33	the	O
34	atrial	O
35	gland	O
36	.	O

1	Underlying	B
2	the	O
3	clustering	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O

1	Atmospheric	B
2	benzene	O
3	,	O
4	urinary	O
5	muconic	O
6	acid	O
7	(	O
8	tt	B
9	-	I
10	MA	I
11	)	O
12	and	O
13	leukocyte	B
14	alkaline	I
15	phosphatase	I
16	activity	O
17	(	O
18	LAPA	O
19	)	O
20	were	O
21	evaluated	O
22	among	O
23	66	O
24	car	O
25	mechanics	O
26	,	O
27	34	O
28	road	O
29	tanker	O
30	drivers	O
31	,	O
32	and	O
33	28	O
34	nonexposed	O
35	workers	O
36	.	O

1	Possible	B
2	roles	O
3	of	O
4	RAD5	O
5	putative	O
6	ATPase	B
7	/	I
8	DNA	I
9	helicase	I
10	activity	O
11	in	O
12	DNA	O
13	repair	O
14	and	O
15	in	O
16	the	O
17	maintenance	O
18	of	O
19	wild	B
20	-	I
21	type	I
22	rates	O
23	of	O
24	instability	O
25	of	O
26	simple	O
27	repetitive	O
28	sequences	O
29	are	O
30	discussed	O
31	.	O

1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	Nuclease	B
2	probing	O
3	and	O
4	structure	O
5	-	O
6	directed	O
7	mutagenesis	O
8	revealed	O
9	that	O
10	the	O
11	105	O
12	-	O
13	nt	O
14	TE	O
15	(	O
16	TE105	O
17	)	O
18	forms	O
19	a	O
20	cruciform	O
21	secondary	O
22	structure	O
23	containing	O
24	four	O
25	helices	O
26	connected	O
27	by	O
28	single	O
29	-	O
30	stranded	O
31	regions	O
32	.	O

1	Measurement	O
2	of	O
3	gastric	O
4	acid	O
5	secretion	O
6	by	O
7	conductivity	O
8	.	O

1	Statins	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	Toluene	B
2	is	O
3	the	O
4	chemical	O
5	most	O
6	frequently	O
7	present	O
8	in	O
9	cases	O
10	involving	O
11	volatile	O
12	solvents	O
13	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	O
17	and	O
18	EXT2	O
19	genes	O
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O

1	Thus	O
2	,	O
3	ZNF74	O
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	O
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	Heart	B
2	rate	O
3	(	O
4	HR	O
5	),	O
6	rectal	O
7	temperature	O
8	(	O
9	Tre	O
10	),	O
11	blood	O
12	pressure	O
13	,	O
14	temperature	O
15	and	O
16	relative	O
17	humidity	O
18	changes	O
19	inside	O
20	clothing	O
21	were	O
22	measured	O
23	on	O
24	18	O
25	professional	O
26	firemen	O
27	(	O
28	mean	O
29	age	O
30	29	O
31	.	O
32	4	O
33	+/-	O
34	7	O
35	.	O
36	4	O
37	yr	O
38	,	O
39	VO2	O
40	max	O
41	41	O
42	.	O
43	4	O
44	+	O
45	8	O
46	.	O
47	8	O
48	ml	O
49	kg	O
50	-	O
51	1	O
52	min	O
53	-	O
54	1	O
55	)	O
56	wearing	O
57	fire	O
58	fighter	O
59	'	O
60	s	O
61	uniforms	O
62	(	O
63	SU	O
64	)	O
65	or	O
66	aluminized	O
67	,	O
68	fire	O
69	resistant	O
70	,	O
71	impermeable	O
72	clothing	O
73	with	O
74	self	O
75	contained	O
76	breathing	O
77	apparatus	O
78	(	O
79	FE	O
80	).	O

1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O

1	Moreover	O
2	,	O
3	it	O
4	is	O
5	the	O
6	assumptions	O
7	behind	O
8	steady	O
9	-	O
10	state	O
11	O2	O
12	uptake	O
13	that	O
14	do	O
15	not	O
16	permit	O
17	proper	O
18	interpretation	O
19	of	O
20	energy	O
21	expenditure	O
22	during	O
23	EPOC	O
24	;	O
25	1	O
26	l	O
27	O2	O
28	not	O
29	=	O
30	20	O
31	.	O
32	9	O
33	kJ	O
34	.	O

1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	B
16	domain	I
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O

1	Genes	B
2	belonging	O
3	to	O
4	the	O
5	ras	B
6	superfamily	I
7	encode	O
8	low	B
9	-	I
10	molecular	I
11	-	I
12	weight	I
13	GTP	I
14	/	I
15	GDP	I
16	-	I
17	binding	I
18	proteins	I
19	that	O
20	are	O
21	highly	O
22	conserved	O
23	in	O
24	wide	O
25	variety	O
26	of	O
27	organisms	O
28	.	O

1	Deleting	B
2	SNF1	O
3	repressed	O
4	meiosis	O
5	at	O
6	the	O
7	same	O
8	three	O
9	steps	O
10	that	O
11	were	O
12	inhibited	O
13	by	O
14	glucose	O
15	,	O
16	suggesting	O
17	that	O
18	glucose	O
19	blocks	O
20	meiosis	O
21	by	O
22	inhibiting	O
23	Snf1	O
24	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	O
9	,	O
10	NF	B
11	-	I
12	4FB	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	I
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O

1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O

1	Rabbit	B
2	skeletal	I
3	muscle	O
4	glycogenin	O
5	.	O

1	Urease	B
2	activity	O
3	of	O
4	97	O
5	%	O
6	of	O
7	these	O
8	organisms	O
9	became	O
10	evident	O
11	within	O
12	30	O
13	min	O
14	.	O

1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	I
8	Dig1	I
9	fusion	I
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	We	O
2	have	O
3	visualized	B
4	DNA	I
5	-	I
6	protein	I
7	complexes	I
8	by	O
9	electron	O
10	microscopy	O
11	and	O
12	a	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	site	O
18	of	O
19	WDV	O
20	Rep	B
21	protein	I
22	within	O
23	the	O
24	core	O
25	element	O
26	has	O
27	been	O
28	mapped	O
29	to	O
30	approximately	O
31	144	O
32	+/-	O
33	18	O
34	bp	O
35	upstream	O
36	from	O
37	the	O
38	initiation	O
39	site	O
40	,	O
41	between	O
42	the	O
43	start	O
44	site	O
45	for	O
46	complementary	O
47	-	O
48	sense	O
49	transcription	O
50	and	O
51	the	O
52	TATA	O
53	box	O
54	.	O

1	26	O
2	micrograms	O
3	PAF	B
4	or	O
5	placebo	O
6	was	O
7	sprayed	O
8	into	O
9	each	O
10	nasal	O
11	cavity	O
12	8	O
13	h	O
14	and	O
15	1	O
16	h	O
17	before	O
18	a	O
19	nasal	O
20	allergen	O
21	challenge	O
22	.	O

1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O

1	OBJECTIVES	O
2	:	O
3	1	O
4	)	O
5	to	O
6	determine	O
7	serum	O
8	ACE	B
9	activity	O
10	in	O
11	patients	O
12	with	O
13	COPD	O
14	treated	O
15	with	O
16	and	O
17	without	O
18	continuous	O
19	ambulatory	O
20	oxygen	O
21	therapy	O
22	(	O
23	CAOT	O
24	);	O
25	2	O
26	)	O
27	to	O
28	verify	O
29	whether	O
30	there	O
31	is	O
32	a	O
33	correlation	O
34	between	O
35	ACE	B
36	and	O
37	any	O
38	hematological	O
39	,	O
40	spirometric	O
41	or	O
42	gasometric	O
43	parameter	O
44	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	Tax	B
7	I	I
8	increased	O
9	the	O
10	extent	O
11	and	O
12	altered	O
13	the	O
14	profile	O
15	of	O
16	proteins	O
17	binding	O
18	TRE	B
19	-	I
20	2	I
21	in	O
22	vivo	O
23	.	O

1	We	O
2	examined	O
3	the	O
4	effects	O
5	of	O
6	long	O
7	-	O
8	term	O
9	perfusion	O
10	with	O
11	pyridoxalated	O
12	hemoglobin	B
13	polyoxyethylene	O
14	conjugate	O
15	(	O
16	PHP	O
17	)	O
18	solution	O
19	on	O
20	cardiac	O
21	function	O
22	of	O
23	isolated	O
24	rat	O
25	hearts	O
26	.	O

1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	I
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	B
14	E	I
15	-	I
16	box	I
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	I
24	promoter	I
25	region	I
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	B
44	-	I
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O

1	PAS1	B
2	,	O
3	a	O
4	yeast	B
5	gene	I
6	required	O
7	for	O
8	peroxisome	O
9	biogenesis	O
10	,	O
11	encodes	O
12	a	O
13	member	O
14	of	O
15	a	O
16	novel	O
17	family	O
18	of	O
19	putative	O
20	ATPases	O
21	.	O

1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	"	O
14	sperm	O
15	fall	O
16	"	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O

1	(	O
2	ii	O
3	)	O
4	An	O
5	AF	B
6	G	I
7	-	I
8	CSF	I
9	level	O
10	>	O
11	2000	O
12	pg	O
13	/	O
14	ml	O
15	is	O
16	a	O
17	strong	O
18	positive	O
19	predictor	O
20	of	O
21	CAM	O
22	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	a	O
6	common	O
7	mechanism	O
8	has	O
9	been	O
10	identified	O
11	to	O
12	coordinate	O
13	the	O
14	growth	O
15	-	O
16	and	O
17	FC	O
18	-	O
19	dependent	O
20	expression	O
21	of	O
22	caveolin	B
23	.	O

1	The	O
2	terminator	O
3	region	O
4	supported	O
5	termination	O
6	of	O
7	transcripts	O
8	initiated	O
9	by	O
10	RNA	B
11	polymerase	I
12	I	I
13	in	O
14	vivo	O
15	.	O

1	A	I
2	herpesvirus	I
3	proteinase	I
4	activity	O
5	has	O
6	been	O
7	identified	O
8	and	O
9	partially	O
10	characterized	O
11	by	O
12	using	O
13	the	O
14	cloned	O
15	enzyme	O
16	and	O
17	substrate	O
18	genes	O
19	in	O
20	transient	O
21	transfection	O
22	assays	O
23	.	O

1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	B
12	influenza	I
13	virus	I
14	protein	I
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	The	O
2	pia	O
3	mater	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O

1	The	O
2	mutant	O
3	protein	O
4	is	O
5	present	O
6	at	O
7	levels	O
8	slightly	O
9	greater	O
10	than	O
11	wild	B
12	-	I
13	type	I
14	,	O
15	but	O
16	exhibits	O
17	the	O
18	same	O
19	tissue	O
20	distribution	O
21	as	O
22	wild	B
23	-	I
24	type	I
25	protein	I
26	,	O
27	and	O
28	has	O
29	approximately	O
30	normal	O
31	affinity	O
32	for	O
33	known	O
34	target	O
35	sequences	O
36	(	O
37	though	O
38	no	O
39	DNA	O
40	targets	O
41	identified	O
42	to	O
43	date	O
44	require	O
45	the	O
46	first	O
47	cut	O
48	repeat	O
49	for	O
50	binding	O
51	).	O

1	This	O
2	inhibitory	O
3	domain	O
4	has	O
5	been	O
6	deleted	O
7	in	O
8	all	O
9	naturally	O
10	occurring	O
11	AHC	O
12	deletion	O
13	mutants	O
14	described	O
15	to	O
16	date	O
17	.	O

1	Either	B
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	(	O
2	1986	O
3	)	O
4	method	O
5	of	O
6	separation	O
7	of	O
8	Cryptosporidium	O
9	spp	O
10	.	O
11	oocysts	O
12	from	O
13	feces	O
14	by	O
15	using	O
16	a	O
17	percoll	O
18	discontinuous	O
19	density	O
20	gradient	O
21	appeared	O
22	a	O
23	method	O
24	of	O
25	choice	O
26	for	O
27	obtaining	O
28	large	O
29	numbers	O
30	of	O
31	oocysts	O
32	of	O
33	C	O
34	.	O
35	parvum	O
36	free	O
37	of	O
38	fecal	O
39	contamination	O
40	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	p65	B
6	binds	O
7	to	O
8	these	O
9	targets	O
10	with	O
11	almost	O
12	equal	O
13	affinity	O
14	and	O
15	that	O
16	different	O
17	residues	O
18	have	O
19	variable	O
20	roles	O
21	in	O
22	binding	O
23	different	O
24	kappaB	B
25	targets	O
26	.	O

1	This	O
2	dependence	O
3	,	O
4	however	O
5	,	O
6	can	O
7	be	O
8	overcome	O
9	to	O
10	a	O
11	large	O
12	extent	O
13	by	O
14	dividing	O
15	min	O
16	LVdP	O
17	/	O
18	dt	O
19	by	O
20	mean	O
21	aortic	O
22	pressure	O
23	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	O
8	could	O
9	activate	O
10	p96h2bk	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	O
16	Ras	B
17	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	O
16	alga	O
17	Scenedemus	O
18	obliquus	O
19	plastocyanin	O
20	.	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	cyclin	B
14	D2	I
15	suggested	O
16	that	O
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	B
28	/	I
29	EBP	I
30	,	O
31	PEA3	B
32	,	O
33	AP2	B
34	,	O
35	NF	B
36	-	I
37	Y	I
38	,	O
39	c	B
40	-	I
41	Myc	I
42	,	O
43	and	O
44	Sp1	B
45	may	O
46	have	O
47	a	O
48	major	O
49	positive	O
50	regulatory	O
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	The	O
2	hypothesis	O
3	of	O
4	Geisler	O
5	(	O
6	Brain	O
7	Res	O
8	.	O

1	Deadenylation	B
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	I
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	This	O
2	fraction	O
3	is	O
4	resistant	O
5	to	O
6	digestions	O
7	by	O
8	DNase	B
9	I	I
10	and	O
11	RNase	B
12	T1	O
13	and	O
14	disappears	O
15	completely	O
16	upon	O
17	alkali	O
18	hydrolysis	O
19	.	O

1	Both	O
2	the	O
3	presence	O
4	of	O
5	arginine	O
6	and	O
7	anaerobiosis	O
8	are	O
9	needed	O
10	to	O
11	trigger	O
12	induction	O
13	of	O
14	the	O
15	pathway	O
16	.	O

1	Steroids	B
2	in	O
3	germfree	O
4	and	O
5	conventional	O
6	rats	O
7	.	O

1	Neither	O
2	ethanol	O
3	nor	O
4	estrogen	O
5	has	O
6	been	O
7	shown	O
8	to	O
9	cause	O
10	UROD	O
11	-	O
12	deficiency	O
13	in	O
14	animals	O
15	.	O

1	In	O
2	vitro	O
3	,	O
4	Arix	O
5	and	O
6	NBPhox	O
7	form	O
8	DNA	O
9	-	O
10	independent	O
11	multimers	O
12	and	O
13	exhibit	O
14	cooperative	O
15	binding	O
16	to	O
17	the	O
18	DB1	O
19	regulatory	O
20	element	O
21	,	O
22	which	O
23	contains	O
24	two	O
25	homeodomain	B
26	recognition	I
27	sites	I
28	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	cortical	O
9	evoked	O
10	potentials	O
11	(	O
12	amplitude	O
13	of	O
14	the	O
15	N2	O
16	/	O
17	P2	O
18	peak	O
19	)	O
20	increased	O
21	from	O
22	5	O
23	.	O
24	1	O
25	+/-	O
26	0	O
27	.	O
28	7	O
29	microV	O
30	at	O
31	5	O
32	mA	O
33	to	O
34	16	O
35	.	O
36	3	O
37	+/-	O
38	1	O
39	.	O
40	1	O
41	microV	O
42	at	O
43	20	O
44	mA	O
45	.	O

1	It	O
2	is	O
3	believed	O
4	that	O
5	these	O
6	domains	O
7	are	O
8	important	O
9	for	O
10	directing	O
11	specific	O
12	protein	B
13	-	I
14	protein	I
15	interactions	O
16	necessary	O
17	for	O
18	the	O
19	proper	O
20	functioning	O
21	of	O
22	Src	B
23	.	O

1	Ongoing	B
2	and	O
3	future	O
4	investigations	O
5	may	O
6	better	O
7	define	O
8	the	O
9	optimal	O
10	approach	O
11	for	O
12	local	O
13	control	O
14	,	O
15	the	O
16	optimal	O
17	duration	O
18	of	O
19	maintenance	O
20	chemotherapy	O
21	,	O
22	and	O
23	the	O
24	possible	O
25	role	O
26	of	O
27	biologic	O
28	response	O
29	modifiers	O
30	and	O
31	growth	O
32	factors	O
33	in	O
34	further	O
35	improving	O
36	the	O
37	outcome	O
38	for	O
39	patients	O
40	with	O
41	this	O
42	disease	O
43	.	O

1	Intriguingly	B
2	,	O
3	three	O
4	hypomorphic	O
5	Scm	O
6	mutations	O
7	,	O
8	which	O
9	map	O
10	within	O
11	an	O
12	mbt	O
13	repeat	O
14	,	O
15	interact	O
16	with	O
17	PcG	O
18	mutations	O
19	more	O
20	strongly	O
21	than	O
22	do	O
23	Scm	O
24	null	O
25	alleles	O
26	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	significant	O
6	reduction	O
7	in	O
8	blood	O
9	pressure	O
10	,	O
11	the	O
12	angiotensin	B
13	converting	I
14	enzyme	I
15	(	I
16	ACE	I
17	)	I
18	inhibitor	I
19	ramipril	O
20	caused	O
21	a	O
22	significant	O
23	regression	O
24	of	O
25	pathologic	O
26	left	O
27	ventricular	O
28	hypertrophy	O
29	demonstrated	O
30	by	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	and	O
35	echocardiography	O
36	.	O

1	While	O
2	daily	O
3	food	O
4	intake	O
5	was	O
6	almost	O
7	constant	O
8	regardless	O
9	of	O
10	the	O
11	dietary	O
12	protein	O
13	level	O
14	,	O
15	water	O
16	intake	O
17	and	O
18	urine	O
19	volume	O
20	increased	O
21	with	O
22	increasing	O
23	the	O
24	dietary	O
25	protein	O
26	.	O

1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	A	I
2	favourable	O
3	response	O
4	was	O
5	achieved	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	amphotericin	O
11	B	O
12	and	O
13	cotrimoxazole	O
14	.	O

1	Biol	O
2	.	O

1	The	O
2	prevalence	O
3	of	O
4	CPAF	O
5	was	O
6	similar	O
7	in	O
8	type	O
9	1	O
10	and	O
11	type	O
12	2	O
13	diabetes	O
14	,	O
15	was	O
16	greater	O
17	in	O
18	women	O
19	than	O
20	in	O
21	men	O
22	,	O
23	and	O
24	was	O
25	significantly	O
26	greater	O
27	after	O
28	repeated	O
29	administrations	O
30	than	O
31	after	O
32	one	O
33	single	O
34	administration	O
35	of	O
36	chlorpropamide	O
37	.	O

1	L	B
2	-	I
3	canavanine	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	O
11	nitric	B
12	oxide	I
13	synthase	I
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	improving	O
24	venous	O
25	return	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O

1	The	O
2	residue	O
3	functions	O
4	,	O
5	R	O
6	(	O
7	t	O
8	),	O
9	for	O
10	C	O
11	-	O
12	11	O
13	CPZ	O
14	and	O
15	In	O
16	-	O
17	113m	O
18	transferrin	B
19	were	O
20	plotted	O
21	against	O
22	time	O
23	for	O
24	selected	O
25	areas	O
26	of	O
27	interest	O
28	,	O
29	and	O
30	the	O
31	CPZ	O
32	area	O
33	-	O
34	weighted	O
35	extraction	O
36	,	O
37	E	O
38	(	O
39	t	O
40	),	O
41	was	O
42	computed	O
43	for	O
44	the	O
45	same	O
46	areas	O
47	every	O
48	250	O
49	msec	O
50	using	O
51	the	O
52	formula	O
53	:	O
54	E	O
55	(	O
56	t	O
57	)	O
58	=	O
59	[	O
60	RT	O
61	(	O
62	t	O
63	)	O
64	-	O
65	RR	O
66	(	O
67	t	O
68	)]/[	B
69	1	I
70	-	I
71	RR	O
72	(	O
73	t	O
74	)],	O
75	where	O
76	RT	O
77	and	O
78	RR	O
79	are	O
80	the	O
81	normalized	O
82	residue	O
83	functions	O
84	for	O
85	CPZ	O
86	and	O
87	transferrin	B
88	,	O
89	respectively	O
90	.	O

1	This	O
2	binary	O
3	repeat	O
4	contains	O
5	repetitive	O
6	DNA	O
7	elements	O
8	that	O
9	include	O
10	LINES	O
11	,	O
12	SINES	O
13	,	O
14	medium	O
15	reiteration	O
16	frequency	O
17	repeats	O
18	,	O
19	and	O
20	a	O
21	transposon	O
22	-	O
23	like	O
24	element	O
25	.	O

1	Expense	B
2	limits	O
3	the	O
4	use	O
5	of	O
6	hepatitis	O
7	B	O
8	vaccines	O
9	,	O
10	but	O
11	low	O
12	-	O
13	dose	O
14	intradermal	O
15	immunization	O
16	has	O
17	been	O
18	evaluated	O
19	as	O
20	a	O
21	cost	O
22	-	O
23	saving	O
24	strategy	O
25	in	O
26	numerous	O
27	studies	O
28	.	O

1	Human	B
2	acid	I
3	ceramidase	I
4	((	I
5	AC	I
6	)	I
7	N	I
8	-	I
9	acylsphingosine	O
10	amidohydrolase	O
11	,	O
12	EC	B
13	3	I
14	.	O
15	5	O
16	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	Effect	O
2	of	O
3	hyperglycemia	O
4	on	O
5	pain	O
6	threshold	O
7	in	O
8	alloxan	O
9	-	O
10	diabetic	O
11	rats	O
12	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	O
23	GR	B
24	.	O

1	Oxygen	B
2	delivery	O
3	and	O
4	consumption	O
5	and	O
6	P50	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	myocardial	O
12	infarction	O
13	.	O

1	Absorption	B
2	of	O
3	electrolytes	O
4	from	O
5	the	O
6	colon	O
7	in	O
8	cases	O
9	of	O
10	ulcerative	O
11	colitis	O
12	and	O
13	in	O
14	control	O
15	subjects	O
16	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	mcs4	O
6	-	O
7	cells	O
8	are	O
9	defective	O
10	at	O
11	activation	O
12	of	O
13	Spc1	O
14	in	O
15	response	O
16	to	O
17	various	O
18	forms	O
19	of	O
20	stress	O
21	.	O

1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O

1	The	O
2	authors	O
3	report	O
4	a	O
5	case	O
6	in	O
7	which	O
8	stereotactic	O
9	irrigation	O
10	of	O
11	a	O
12	brain	O
13	cyst	O
14	was	O
15	temporally	O
16	associated	O
17	with	O
18	respiratory	O
19	distress	O
20	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	Semidominant	B
2	mutations	O
3	in	O
4	the	O
5	yeast	O
6	Rad51	O
7	protein	O
8	and	O
9	their	O
10	relationships	O
11	with	O
12	the	O
13	Srs2	B
14	helicase	I
15	.	O

1	A	I
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O

1	Then	B
2	,	O
3	pure	O
4	pancreatic	O
5	juice	O
6	was	O
7	infused	O
8	into	O
9	the	O
10	duodenum	O
11	.	O

1	Once	O
2	the	O
3	proliferation	O
4	of	O
5	fibroblasts	O
6	and	O
7	collagen	B
8	synthesis	O
9	had	O
10	led	O
11	to	O
12	an	O
13	increase	O
14	of	O
15	mechanical	O
16	strength	O
17	,	O
18	no	O
19	negative	O
20	effect	O
21	on	O
22	wound	O
23	healing	O
24	could	O
25	be	O
26	detected	O
27	applying	O
28	the	O
29	same	O
30	chemotherapeutic	O
31	agents	O
32	.	O

1	Dominant	B
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	O
12	ERK2	B
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	Aortic	B
2	diameters	O
3	in	O
4	infants	O
5	and	O
6	young	O
7	children	O
8	:	O
9	normative	O
10	angiographic	O
11	data	O
12	.	O

1	The	O
2	DNase	B
3	I	I
4	footprint	O
5	extended	O
6	5	O
7	'	O
8	in	O
9	the	O
10	silencer	O
11	region	O
12	to	O
13	include	O
14	an	O
15	inverted	O
16	repeat	O
17	of	O
18	a	O
19	six	B
20	-	I
21	nucleotide	I
22	motif	I
23	(	I
24	epsilon	I
25	-	I
26	267	O
27	to	O
28	-	O
29	278	O
30	bp	O
31	)	O
32	which	O
33	shares	O
34	5	O
35	of	O
36	6	O
37	bases	O
38	with	O
39	the	O
40	GATA	B
41	-	I
42	1	I
43	consensus	I
44	sequence	I
45	.	O

1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O

1	Apropos	B
2	of	O
3	a	O
4	case	O

1	The	O
2	relationship	O
3	of	O
4	human	O
5	umbilical	O
6	arterial	O
7	and	O
8	venous	O
9	plasma	O
10	levels	O
11	of	O
12	corticosteroids	O
13	to	O
14	gestational	O
15	age	O
16	.	O

1	Tolterodine	B
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	Pharmacodynamic	B
2	studies	O
3	on	O
4	the	O
5	cardiovascular	O
6	system	O
7	of	O
8	spontaneously	O
9	hypertensive	O
10	rats	O
11	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	I
7	E	I
8	-	I
9	specific	I
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	O
24	AMPD3	O
25	cDNA	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	differentiation	O
6	of	O
7	neoplastically	O
8	transformed	O
9	cells	O
10	does	O
11	not	O
12	repress	O
13	mitogenic	O
14	responsiveness	O
15	or	O
16	junB	B
17	or	O
18	c	B
19	-	I
20	fos	I
21	inducibility	O
22	.	O

1	On	O
2	parents	O

1	Studies	O
2	of	O
3	biochemical	O
4	and	O
5	morphological	O
6	changes	O
7	(	O
8	between	O
9	normal	O
10	and	O
11	treated	O
12	animals	O
13	)	O
14	show	O
15	that	O
16	chrysotile	O
17	induces	O
18	an	O
19	increase	O
20	in	O
21	the	O
22	lung	O
23	free	O
24	cell	O
25	population	O
26	and	O
27	pulmonary	O
28	surfactant	O
29	levels	O
30	.	O

1	Furthermore	O
2	,	O
3	45Ca	B
4	-	I
5	binding	I
6	assays	O
7	revealed	O
8	that	O
9	CCaMK	O
10	directly	O
11	binds	O
12	Ca2	O
13	+.	O

1	Overall	O
2	,	O
3	our	O
4	results	O
5	suggest	O
6	that	O
7	resistant	O
8	genotypes	O
9	exist	O
10	among	O
11	the	O
12	WAD	O
13	goat	O
14	population	O
15	.	O

1	Pit	B
2	-	I
3	1	I
4	is	O
5	a	O
6	tissue	B
7	-	I
8	specific	I
9	POU	I
10	domain	I
11	factor	I
12	obligatory	O
13	for	O
14	the	O
15	appearance	O
16	of	O
17	three	O
18	cell	O
19	phenotypes	O
20	in	O
21	the	O
22	anterior	O
23	pituitary	O
24	gland	O
25	.	O

1	We	O
2	found	O
3	that	O
4	total	O
5	PSA	B
6	can	O
7	be	O
8	detected	O
9	in	O
10	all	O
11	cyst	O
12	fluids	O
13	and	O
14	in	O
15	about	O
16	75	O
17	%	O
18	of	O
19	female	O
20	sera	O
21	.	O

1	EB	B
2	-	I
3	1	I
4	,	O
5	a	O
6	tyrosine	B
7	kinase	I
8	signal	I
9	transduction	I
10	gene	I
11	,	O
12	is	O
13	transcriptionally	O
14	activated	O
15	in	O
16	the	O
17	t	O
18	(	O
19	1	O
20	;	O
21	19	O
22	)	O
23	subset	O
24	of	O
25	pre	O
26	-	O
27	B	O
28	ALL	O
29	,	O
30	which	O
31	express	O
32	oncoprotein	O
33	E2a	O
34	-	O
35	Pbx1	O
36	.	O

1	Mutagenesis	B
2	of	O
3	IM1	O
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	I
10	Fos	I
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	I
16	promoter	I
17	.	O

1	Basal	O
2	promoter	O
3	activity	O
4	is	O
5	enhanced	O
6	by	O
7	a	O
8	functional	O
9	M1	O
10	domain	O
11	in	O
12	LHR	B
13	-	I
14	expressing	O
15	mouse	O
16	Leydig	O
17	tumor	O
18	cells	O
19	(	O
20	MLTC	O
21	)	O
22	but	O
23	not	O
24	in	O
25	non	O
26	-	O
27	expressing	O
28	CHO	O
29	cells	O
30	.	O

1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O

1	Clinical	O
2	course	O
3	and	O
4	nursing	O
5	care	O
6	of	O
7	patients	O
8	with	O
9	decubitus	O
10	ulcer	O
11	--	O
12	use	O
13	of	O
14	pillows	O
15	stuffed	O
16	with	O
17	buckwheat	O
18	chaff	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	B
12	protein	I
13	-	I
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	The	O
2	new	O
3	semi	O
4	-	O
5	synthetic	O
6	oral	O
7	cephalosporin	O
8	,	O
9	CGP	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	hospitalized	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O

1	Pentobarbital	B
2	(	I
3	1	I
4	,	O
5	3	O
6	,	O
7	10	O
8	,	O
9	and	O
10	17	O
11	.	O
12	5	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	was	O
18	also	O
19	tested	O
20	in	O
21	combination	O
22	with	O
23	rate	O
24	-	O
25	decreasing	O
26	doses	O
27	of	O
28	normeperidine	O
29	(	O
30	17	O
31	.	O
32	5	O
33	mg	O
34	/	O
35	kg	O
36	),	O
37	anileridine	O
38	(	O
39	10	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	alphaprodine	O
45	(	O
46	10	O
47	mg	O
48	/	O
49	kg	O
50	),	O
51	and	O
52	fentanyl	O
53	(	O
54	0	O
55	.	O
56	3	O
57	mg	O
58	/	O
59	kg	O
60	).	O

1	Behavioral	B
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	O
7	,	O
8	attB	O
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	O
15	and	O
16	attR	O
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O

1	A	I
2	114	I
3	-	I
4	base	O
5	pair	O
6	sequence	O
7	of	O
8	predominantly	O
9	repeating	O
10	purine	O
11	-	O
12	pyrimidine	O
13	nucleotides	O
14	separates	O
15	these	O
16	two	O
17	d	O
18	(	O
19	AC	O
20	)	O
21	repeats	O
22	.	O

1	Until	B
2	such	O
3	investigations	O
4	are	O
5	performed	O
6	,	O
7	we	O
8	conclude	O
9	that	O
10	the	O
11	role	O
12	for	O
13	adjuvant	O
14	treatment	O
15	is	O
16	questionable	O
17	and	O
18	that	O
19	TME	O
20	surgery	O
21	is	O
22	preferred	O
23	as	O
24	the	O
25	treatment	O
26	option	O
27	for	O
28	Stage	O
29	T1	O
30	-	O
31	T3	O
32	rectal	O
33	cancers	O
34	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	are	O
5	being	O
6	used	O
7	to	O
8	accelerate	O
9	the	O
10	recovery	O
11	of	O
12	myelopoiesis	O
13	following	O
14	high	O
15	-	O
16	dose	O
17	chemotherapy	O
18	in	O
19	cancer	O
20	patients	O
21	.	O

1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O

1	A	I
2	tobacco	I
3	homologue	I
4	(	O
5	trolC	O
6	)	O
7	of	O
8	the	O
9	rolC	B
10	gene	I
11	of	O
12	the	O
13	Agrobacterium	O
14	rhizogenes	O
15	Ri	O
16	-	O
17	plasmid	O
18	was	O
19	cloned	O
20	and	O
21	sequenced	O
22	from	O
23	Nicotiana	O
24	tabacum	O
25	L	O
26	.	O
27	cv	O
28	.	O

1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O

1	Synthetic	B
2	oligonucleotides	O
3	representing	O
4	the	O
5	19	O
6	bp	O
7	repeat	O
8	unit	O
9	strongly	O
10	reduced	O
11	the	O
12	activity	O
13	of	O
14	the	O
15	IE1	B
16	/	I
17	2	I
18	enhancer	I
19	/	I
20	promoter	I
21	in	O
22	cotransfection	O
23	assays	O
24	after	O
25	transient	O
26	expression	O
27	.	O

1	The	O
2	first	O
3	involved	O
4	complementation	O
5	of	O
6	a	O
7	nonphotosynthetic	O
8	mutant	O
9	of	O
10	Chlamydomonas	O
11	,	O
12	CC	O
13	-	O
14	2341	O
15	(	O
16	ac	B
17	-	I
18	u	I
19	-	I
20	g	O
21	-	O
22	2	O
23	.	O
24	3	O
25	),	O
26	which	O
27	has	O
28	a	O
29	frameshift	O
30	mutation	O
31	in	O
32	the	O
33	psaB	B
34	gene	I
35	,	O
36	and	O
37	selection	O
38	of	O
39	photosynthetic	O
40	transformants	O
41	on	O
42	minimal	O
43	medium	O
44	.	O

1	[	O
2	82Br	O
3	]	O
4	MISO	O
5	was	O
6	prepared	O
7	by	O
8	irradiating	O
9	samples	O
10	of	O
11	Br	O
12	-	O
13	MISO	O
14	in	O
15	a	O
16	SLOWPOKE	O
17	reactor	O
18	for	O
19	2	O
20	h	O
21	at	O
22	a	O
23	thermal	O
24	neutron	O
25	flux	O
26	of	O
27	10	O
28	(	O
29	12	O
30	)	O
31	n	O
32	cm	O
33	-	O
34	2	O
35	s	O
36	-	O
37	1	O
38	.	O

1	Estimation	B
2	of	I
3	renin	I
4	secretion	O
5	rate	O
6	and	O
7	renal	O
8	plasma	O
9	flow	O
10	from	O
11	peripheral	O
12	and	O
13	renal	O
14	vein	O
15	renin	B
16	levels	O
17	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	The	O
2	Nostoc	O
3	petBD	O
4	genes	O
5	are	O
6	not	O
7	closely	O
8	linked	O
9	to	O
10	the	O
11	psbB	B
12	gene	I
13	(	O
14	encoding	O
15	the	O
16	51	O
17	-	O
18	kDa	O
19	photosystem	B
20	II	I
21	polypeptide	I
22	)	O
23	and	O
24	do	O
25	not	O
26	contain	O
27	introns	O
28	as	O
29	do	O
30	the	O
31	closely	O
32	related	O
33	chloroplast	O
34	genes	O
35	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	This	O
2	report	O
3	presents	O
4	the	O
5	isolation	O
6	and	O
7	characterization	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	(	O
15	1	O
16	.	O
17	2	O
18	kb	O
19	)	O
20	and	O
21	exon	O
22	1	O
23	of	O
24	the	O
25	human	B
26	RII	I
27	alpha	I
28	gene	I
29	.	O

1	In	O
2	C	O
3	.	O
4	albicans	O
5	,	O
6	HST6	O
7	is	O
8	expressed	O
9	constitutively	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	the	O
15	different	O
16	cell	O
17	types	O
18	analysed	O
19	(	O
20	yeast	O
21	,	O
22	hyphae	O
23	,	O
24	white	O
25	and	O
26	opaque	O
27	),	O
28	demonstrating	O
29	that	O
30	HST6	O
31	transcription	O
32	is	O
33	not	O
34	repressed	O
35	in	O
36	this	O
37	diploid	O
38	yeast	O
39	,	O
40	unlike	O
41	in	O
42	diploid	O
43	S	O
44	.	O
45	cerevisiae	O
46	,	O
47	and	O
48	suggesting	O
49	a	O
50	basic	O
51	biological	O
52	function	O
53	for	O
54	the	O
55	Hst6p	B
56	transporter	I
57	in	O
58	C	O
59	.	O
60	albicans	O
61	.	O

1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O

1	During	O
2	flexion	O
3	whiplash	O
4	,	O
5	the	O
6	torque	O
7	at	O
8	the	O
9	occipital	O
10	condyle	O
11	reverses	O
12	its	O
13	direction	O
14	at	O
15	about	O
16	25	O
17	ms	O
18	after	O
19	impact	O
20	.	O

1	To	O
2	understand	O
3	further	O
4	the	O
5	expression	O
6	and	O
7	regulation	O
8	of	O
9	the	O
10	V1aR	O
11	,	O
12	we	O
13	now	O
14	describe	O
15	the	O
16	genomic	O
17	characteristics	O
18	,	O
19	tissue	O
20	expression	O
21	,	O
22	chromosomal	O
23	localization	O
24	,	O
25	and	O
26	regional	O
27	mapping	O
28	of	O
29	the	O
30	human	B
31	V1aR	I
32	gene	I
33	,	O
34	AVPR1A	O
35	.	O

1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O

1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O

1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O

1	Both	O
2	alleles	O
3	are	O
4	functionally	O
5	expressed	O
6	and	O
7	are	O
8	distributed	O
9	within	O
10	CD4	B
11	+/	O
12	CD8	B
13	+	I
14	T	I
15	cell	O
16	subsets	O
17	.	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Lysosomal	B
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O

1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	B
10	-	I
11	40	I
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	O
19	-	O
20	level	O
21	zeta	B
22	2	I
23	globin	I
24	promoter	I
25	activity	O
26	in	O
27	K562	O
28	cells	O
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	O
40	origin	O
41	.	O

1	1	I
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Although	O
2	a	O
3	carboxyl	O
4	-	O
5	terminal	O
6	HSF	B
7	transcriptional	O
8	activation	O
9	domain	O
10	is	O
11	critical	O
12	for	O
13	the	O
14	activation	O
15	of	O
16	CUP1	B
17	transcription	I
18	in	O
19	response	O
20	to	O
21	both	O
22	heat	O
23	shock	O
24	stress	O
25	and	O
26	glucose	O
27	starvation	O
28	,	O
29	this	O
30	region	O
31	is	O
32	dispensable	O
33	for	O
34	transient	O
35	heat	O
36	shock	O
37	activation	O
38	of	O
39	at	O
40	least	O
41	two	O
42	genes	O
43	encoding	O
44	members	O
45	of	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	hsp70	B
51	family	I
52	.	O

1	Flavonoids	B
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	O
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	O
13	heptamers	O
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O

1	The	O
2	differential	O
3	diagnosis	O
4	of	O
5	both	O
6	affections	O
7	is	O
8	based	O
9	on	O
10	the	O
11	clinical	O
12	course	O
13	,	O
14	sialography	O
15	and	O
16	CT	O
17	examination	O
18	which	O
19	along	O
20	with	O
21	modern	O
22	ATB	O
23	treatment	O
24	significantly	O
25	modify	O
26	hitherto	O
27	used	O
28	surgical	O
29	therapy	O
30	.	O

1	Mitochondrial	B
2	Mas70p	I
3	signal	I
4	anchor	I
5	sequence	I
6	.	O

1	Degenerate	B
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	O
11	sequences	O
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	B
22	I	I
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	B
34	-	I
35	terminal	I
36	region	I
37	of	I
38	I	I
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	B
47	-	I
48	protein	I
49	binding	I
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	B
94	-	I
95	like	I
96	region	I
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	Ischemia	B
2	and	O
3	reperfusion	O
4	markedly	O
5	increased	O
6	the	O
7	release	O
8	of	O
9	6	O
10	-	O
11	keto	B
12	-	I
13	PGF1	I
14	alpha	I
15	and	O
16	TXB2	O
17	.	O

1	Regulation	O
2	of	O
3	avian	B
4	fibroblast	I
5	growth	I
6	factor	I
7	receptor	I
8	1	I
9	(	I
10	FGFR	I
11	-	I
12	1	I
13	)	I
14	gene	I
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	To	O
2	assess	O
3	the	O
4	function	O
5	(	O
6	s	O
7	)	O
8	of	O
9	E74	O
10	during	O
11	metamorphosis	O
12	,	O
13	we	O
14	have	O
15	isolated	O
16	and	O
17	characterized	O
18	recessive	O
19	loss	O
20	-	O
21	of	O
22	-	O
23	function	O
24	mutations	O
25	specific	O
26	to	O
27	each	O
28	transcription	O
29	unit	O
30	.	O

1	The	O
2	diagnosis	O
3	of	O
4	amyloidosis	O
5	was	O
6	determined	O
7	from	O
8	a	O
9	labial	O
10	salivary	O
11	gland	O
12	biopsy	O
13	.	O

1	Materials	B
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	B
39	epsilon	I
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Effect	O
2	of	O
3	heparin	O
4	on	O
5	the	O
6	inactivation	O
7	of	O
8	serum	B
9	lipoprotein	I
10	lipase	I
11	by	O
12	the	O
13	liver	O
14	in	O
15	unanesthetized	O
16	dogs	O
17	.	O

1	Effect	O
2	of	O
3	alcohol	O
4	on	O
5	minimal	O
6	effective	O
7	nCPAP	O
8	pressure	O

1	Measurements	O
2	of	O
3	perfusion	O
4	also	O
5	showed	O
6	significantly	O
7	higher	O
8	values	O
9	under	O
10	active	O
11	therapy	O
12	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	B
16	beta	I
17	-	I
18	strand	I
19	I	I
20	(	O
21	betaI	O
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	The	O
2	C2C	O
3	-	O
4	Prx	O
5	is	O
6	encoded	O
7	as	O
8	a	O
9	preprotein	O
10	of	O
11	273	O
12	amino	O
13	acids	O
14	containing	O
15	a	O
16	putative	O
17	chloroplast	O
18	-	O
19	targeting	O
20	signal	O
21	of	O
22	65	O
23	amino	O
24	acids	O
25	at	O
26	its	O
27	N	O
28	-	O
29	terminus	O
30	.	O

1	Integrated	B
2	mapping	O
3	analysis	O
4	of	O
5	the	O
6	Werner	O
7	syndrome	O
8	region	O
9	of	O
10	chromosome	O
11	8	O
12	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Chirality	B
2	-	I
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	O
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	sequence	O
6	of	O
7	one	O
8	hydrophilic	O
9	peptide	O
10	of	O
11	the	O
12	FeS	O
13	protein	O
14	has	O
15	been	O
16	also	O
17	obtained	O
18	confirming	O
19	the	O
20	fbcF	O
21	reading	O
22	frame	O
23	.	O

1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O

1	Genes	B
2	for	O
3	ocs	B
4	element	I
5	binding	I
6	factors	I
7	(	O
8	OBFs	O
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O

1	Inhibitor	B
2	-	I
3	1	I
4	(	I
5	I	I
6	-	I
7	1	I
8	)	I
9	and	I
10	inhibitor	I
11	-	I
12	2	I
13	(	I
14	I	I
15	-	I
16	2	I
17	)	O
18	selectively	O
19	inhibit	O
20	type	B
21	1	I
22	protein	I
23	serine	I
24	/	I
25	threonine	I
26	phosphatases	I
27	(	O
28	PP1	O
29	).	O

1	Sequential	B
2	MR	O
3	examinations	O
4	of	O
5	the	O
6	nasal	O
7	cavity	O
8	and	O
9	paranasal	O
10	sinuses	O
11	were	O
12	performed	O
13	within	O
14	a	O
15	6	O
16	-	O
17	8	O
18	h	O
19	period	O
20	in	O
21	five	O
22	normal	O
23	volunteers	O
24	.	O

1	Competition	O
2	with	O
3	a	O
4	putative	O
5	MADS	B
6	box	I
7	consensus	I
8	binding	I
9	site	I
10	from	O
11	the	O
12	promoter	O
13	of	O
14	the	O
15	coordinately	O
16	regulated	O
17	opaque	B
18	-	I
19	phase	I
20	-	I
21	specific	I
22	gene	I
23	PEP1	O
24	(	O
25	SAP1	O
26	)	O
27	and	O
28	the	O
29	human	O
30	MADS	B
31	box	I
32	consensus	I
33	binding	I
34	site	I
35	for	O
36	serum	B
37	response	I
38	factor	I
39	demonstrated	O
40	that	O
41	one	O
42	of	O
43	the	O
44	three	O
45	complexes	O
46	formed	O
47	was	O
48	specific	O
49	to	O
50	the	O
51	OP4	O
52	sequence	O
53	.	O

1	The	O
2	effect	O
3	of	O
4	food	O
5	on	O
6	procainamide	O
7	absorption	O
8	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	O
19	monooxygenase	O
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	Immunoblotting	B
2	of	O
3	expressed	O
4	recombinant	B
5	proteins	I
6	with	O
7	the	O
8	monoclonal	O
9	08L	O
10	antibody	O
11	localized	O
12	the	O
13	08L	O
14	epitope	O
15	to	O
16	the	O
17	carboxyl	O
18	end	O
19	of	O
20	the	O
21	protein	O
22	.	O

1	Femoral	B
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Prevalence	B
2	of	O
3	rheumatoid	O
4	arthritis	O
5	and	O
6	rheumatoid	B
7	factor	I
8	in	O
9	women	O
10	:	O
11	evidence	O
12	for	O
13	a	O
14	secular	O
15	decline	O
16	.	O

1	Antisense	B
2	transcription	I
3	of	O
4	a	O
5	murine	O
6	FGFR	B
7	-	I
8	3	I
9	psuedogene	O
10	during	O
11	fetal	O
12	developement	O
13	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	O
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	virus	I
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	O
25	-	O
26	coding	O
27	sequence	O
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	B
38	type	I
39	-	I
40	like	I
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	sensorimotor	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	examining	O
13	the	O
14	acoustic	O
15	startle	O
16	response	O
17	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	N	O
6	-	O
7	nitroso	O
8	compounds	O
9	can	O
10	be	O
11	formed	O
12	in	O
13	vivo	O
14	in	O
15	the	O
16	infected	O
17	bladder	O
18	,	O
19	which	O
20	could	O
21	explain	O
22	the	O
23	association	O
24	between	O
25	urinary	O
26	-	O
27	tract	O
28	infections	O
29	and	O
30	increased	O
31	risk	O
32	for	O
33	bladder	O
34	cancer	O
35	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	B
19	-	I
20	block	O
21	group	O
22	.	O
23	beta	B
24	-	I
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	O
78	played	O
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	Up	B
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Both	O
2	examinations	O
3	are	O
4	sensitive	O
5	indicators	O
6	of	O
7	CNS	O
8	abnormalities	O
9	associated	O
10	with	O
11	bacterial	O
12	meningeal	O
13	infections	O
14	and	O
15	are	O
16	important	O
17	determinants	O
18	of	O
19	the	O
20	therapy	O
21	and	O
22	ultimate	O
23	prognosis	O
24	of	O
25	such	O
26	complications	O
27	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	The	O
2	ability	O
3	of	O
4	chronic	O
5	UM	O
6	-	O
7	272	O
8	(	O
9	dimethylpropranolol	O
10	)	O
11	treatment	O
12	to	O
13	prevent	O
14	the	O
15	induction	O
16	of	O
17	reentrant	O
18	ventricular	O
19	tachyarrhythmias	O
20	was	O
21	assessed	O
22	in	O
23	the	O
24	conscious	O
25	dog	O
26	subjected	O
27	to	O
28	serial	O
29	programmed	O
30	electrical	O
31	stimulation	O
32	on	O
33	days	O
34	3	O
35	--	O
36	5	O
37	after	O
38	myocardial	O
39	infarction	O
40	.	O

1	Histochemical	B
2	localization	O
3	of	O
4	GUS	B
5	revealed	O
6	promoter	O
7	function	O
8	in	O
9	leaf	O
10	epidermis	O
11	,	O
12	mesophyll	O
13	and	O
14	vascular	O
15	bundles	O
16	,	O
17	in	O
18	the	O
19	cortex	O
20	and	O
21	vascular	O
22	cylinder	O
23	of	O
24	the	O
25	root	O
26	.	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	On	O
2	the	O
3	other	O
4	side	O
5	,	O
6	when	O
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	O
21	)	O
22	or	O
23	methylene	O
24	blue	O
25	(	O
26	soluble	O
27	cGMPase	O
28	inhibitor	O
29	),	O
30	the	O
31	changes	O
32	could	O
33	be	O
34	attenuated	O
35	.	O

1	Sixteen	B
2	other	O
3	normal	O
4	subjects	O
5	with	O
6	2	O
7	g	O
8	of	O
9	Metyrapone	O
10	are	O
11	best	O
12	responses	O
13	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	II	I
7	(	O
8	IGFII	O
9	)	O
10	is	O
11	a	O
12	mitogenic	O
13	polypeptide	O
14	,	O
15	the	O
16	mRNAs	O
17	of	O
18	which	O
19	are	O
20	present	O
21	in	O
22	multiple	O
23	forms	O
24	,	O
25	despite	O
26	derivation	O
27	from	O
28	a	O
29	single	O
30	gene	O
31	.	O

1	The	O
2	RFX	B
3	protein	I
4	family	I
5	includes	O
6	members	O
7	from	O
8	yeast	O
9	to	O
10	humans	O
11	,	O
12	which	O
13	function	O
14	in	O
15	various	O
16	biological	O
17	systems	O
18	,	O
19	and	O
20	share	O
21	a	O
22	DNA	B
23	-	I
24	binding	I
25	domain	I
26	and	O
27	a	O
28	conserved	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O

1	99Tcm	O
2	-	O
3	DMP	O
4	-	O
5	HSA	O
6	showed	O
7	an	O
8	almost	O
9	identical	O
10	behaviour	O
11	to	O
12	in	O
13	vitro	O
14	labelled	O
15	red	O
16	blood	O
17	cells	O
18	(	O
19	RBCs	O
20	),	O
21	which	O
22	are	O
23	generally	O
24	considered	O
25	the	O
26	reference	O
27	standard	O
28	for	O
29	blood	O
30	pool	O
31	agents	O
32	.	O

1	Calmodulin	B
2	-	I
3	binding	I
4	peptide	I
5	(	O
6	CBP	B
7	),	O
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	O
17	myosin	B
18	light	I
19	chain	I
20	kinase	I
21	(	O
22	MLCK	O
23	),	O
24	binds	O
25	to	O
26	calmodulin	B
27	with	O
28	nanomolar	O
29	affinity	O
30	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	O
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	O
11	binding	O
12	of	O
13	NFI	O
14	proteins	O
15	,	O
16	and	O
17	the	O
18	addition	O
19	of	O
20	higher	O
21	concentrations	O
22	of	O
23	dithiothreitol	O
24	to	O
25	nuclear	O
26	extracts	O
27	from	O
28	TG	B
29	-	I
30	treated	O
31	cells	O
32	restores	O
33	NFI	B
34	-	I
35	DNA	I
36	binding	I
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	O
44	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	O
14	and	O
15	the	O
16	MUL	O
17	genes	O
18	.	O

1	In	O
2	this	O
3	case	O
4	the	O
5	degree	O
6	of	O
7	promoter	O
8	methylation	O
9	,	O
10	which	O
11	could	O
12	extend	O
13	beyond	O
14	the	O
15	T	O
16	-	O
17	DNA	O
18	borders	O
19	,	O
20	was	O
21	not	O
22	correlated	O
23	with	O
24	the	O
25	reduction	O
26	in	O
27	steady	O
28	-	O
29	state	O
30	poly	O
31	(	O
32	A	O
33	)+	O
34	mRNA	O
35	levels	O
36	,	O
37	the	O
38	silenced	O
39	state	O
40	was	O
41	transmitted	O
42	through	O
43	meiosis	O
44	and	O
45	reactivation	O
46	lasted	O
47	several	O
48	generations	O
49	.	O

1	Takahashi	B
2	,	O
3	H	O
4	.	O

1	313	O
2	,	O
3	98	O
4	-	O
5	102	O
6	).	O

1	Acupuncture	B
2	effect	O
3	on	O
4	deep	O
5	receptors	O
6	was	O
7	not	O
8	limited	O
9	to	O
10	one	O
11	point	O
12	but	O
13	within	O
14	a	O
15	certain	O
16	area	O
17	,	O
18	namely	O
19	distant	O
20	effect	O
21	existed	O
22	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	type	O
5	-	O
6	specific	O
7	capsular	O
8	polysaccharide	O
9	biosynthesis	O
10	genes	O
11	of	O
12	Streptococcus	O
13	agalactiae	O
14	type	O
15	Ia	O
16	.	O

1	However	O
2	,	O
3	cotransfection	O
4	studies	O
5	indicate	O
6	that	O
7	RVR	O
8	does	O
9	not	O
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	O
16	element	O
17	is	O
18	linked	O
19	to	O
20	a	O
21	reporter	O
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	B
33	alpha	I
34	function	O
35	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	B
10	p105	I
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	I
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O

1	Both	O
2	fusion	O
3	proteins	O
4	form	O
5	stable	O
6	specific	O
7	complexes	O
8	with	O
9	a	O
10	short	O
11	DNA	O
12	duplex	O
13	harboring	O
14	the	O
15	CTGT	O
16	(	O
17	at	O
18	)	O
19	4ACAG	O
20	consensus	O
21	sequence	O
22	of	O
23	the	O
24	LexA	B
25	repressor	I
26	.	O

1	The	O
2	evidence	O
3	in	O
4	support	O
5	of	O
6	this	O
7	was	O
8	derived	O
9	from	O
10	the	O
11	fact	O
12	that	O
13	the	O
14	affinity	O
15	or	O
16	interaction	O
17	between	O
18	the	O
19	two	O
20	subunits	O
21	was	O
22	impaired	O
23	as	O
24	indicated	O
25	by	O
26	the	O
27	first	O
28	order	O
29	rate	O
30	constant	O
31	of	O
32	hCG	B
33	alpha	I
34	1	I
35	beta	I
36	(	O
37	km	O
38	=	O
39	4	O
40	.	O
41	1	O
42	x	O
43	10	O
44	(-	O
45	2	O
46	)	O
47	min	O
48	-	O
49	1	O
50	)	O
51	at	O
52	pH	O
53	3	O
54	.	O
55	0	O
56	at	O
57	23	O
58	degrees	O
59	C	O
60	which	O
61	is	O
62	one	O
63	order	O
64	of	O
65	magnitude	O
66	greater	O
67	relative	O
68	to	O
69	rehCG	O
70	(	O
71	kw	O
72	=	O
73	4	O
74	.	O
75	6	O
76	x	O
77	10	O
78	(-	O
79	3	O
80	)	O
81	min	O
82	-	O
83	1	O
84	).	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	I
18	site	I
19	(	I
20	CAAT	I
21	box	I
22	)	O
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	B
31	-	I
32	2	I
33	.	O
34	CAT	B
35	reporter	I
36	gene	I
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	B
44	-	I
45	box	I
46	region	I
47	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	TGF	B
6	-	I
7	betaf	O
8	potentiates	O
9	the	O
10	c	B
11	-	I
12	fos	I
13	SRE	O
14	activated	O
15	by	O
16	PKC	B
17	through	O
18	the	O
19	SRF	B
20	binding	I
21	site	I
22	.	O

1	To	O
2	explore	O
3	the	O
4	function	O
5	of	O
6	human	O
7	SINA	O
8	-	O
9	homologous	O
10	(	O
11	Siah	O
12	)	O
13	proteins	O
14	,	O
15	expression	O
16	plasmids	O
17	encoding	O
18	Siah	B
19	-	I
20	1A	I
21	were	O
22	transiently	O
23	transfected	O
24	into	O
25	293	O
26	epithelial	O
27	cells	O
28	and	O
29	GM701	O
30	fibroblast	O
31	cells	O
32	,	O
33	resulting	O
34	in	O
35	growth	O
36	arrest	O
37	without	O
38	induction	O
39	of	O
40	apoptosis	O
41	.	O

1	Overproduction	B
2	,	O
3	purification	O
4	and	O
5	characterization	O
6	of	O
7	M	O
8	.	O
9	HinfI	B
10	methyltransferase	I
11	and	O
12	its	O
13	deletion	O
14	mutant	O
15	.	O

1	Hydropathy	B
2	analysis	O
3	of	O
4	KCC1	O
5	indicates	O
6	structural	O
7	homology	O
8	to	O
9	NKCC	O
10	,	O
11	including	O
12	12	O
13	transmembrane	O
14	domains	O
15	,	O
16	a	O
17	large	O
18	extracellular	O
19	loop	O
20	with	O
21	potential	O
22	N	O
23	-	O
24	linked	O
25	glycosylation	O
26	sites	O
27	,	O
28	and	O
29	cytoplasmic	O
30	N	O
31	-	O
32	and	O
33	C	O
34	-	O
35	terminal	O
36	regions	O
37	.	O

1	(	O
2	1996a	O
3	)	O
4	Biochemistry	O
5	35	O
6	,	O
7	1589	O
8	-	O
9	1598	O
10	].	O

1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O

1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O

1	Sample	B
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O

1	This	O
2	hypothesis	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	PEA3	B
10	binding	I
11	sites	I
12	in	O
13	the	O
14	PEA3	B
15	promoter	I
16	and	O
17	with	O
18	the	O
19	ability	O
20	of	O
21	PEA3	B
22	to	O
23	transactivate	O
24	this	O
25	promoter	O
26	.	O

1	Radionuclide	B
2	study	O
3	and	O
4	endomyocardial	O
5	biopsy	O
6	revealed	O
7	remarkable	O
8	degeneration	O
9	of	O
10	myocardium	O
11	.	O

1	The	O
2	stability	O
3	of	O
4	isoniazid	O
5	solutions	O
6	increases	O
7	markedly	O
8	with	O
9	increasing	O
10	NTA	O
11	or	O
12	EDTA	O
13	concentration	O
14	up	O
15	to	O
16	1	O
17	mmol	O
18	/	O
19	l	O
20	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	a	O
6	range	O
7	of	O
8	microenvironmental	O
9	conditions	O
10	exist	O
11	within	O
12	purified	O
13	water	O
14	systems	O
15	,	O
16	leading	O
17	to	O
18	variable	O
19	populations	O
20	of	O
21	bacteria	O
22	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	a	O
6	major	O
7	part	O
8	of	O
9	the	O
10	reduction	O
11	in	O
12	food	O
13	intake	O
14	in	O
15	hyperphagic	O
16	rats	O
17	eating	O
18	a	O
19	quinine	O
20	-	O
21	adulterated	O
22	diet	O
23	is	O
24	due	O
25	to	O
26	postingestional	O
27	events	O
28	.	O

1	A	I
2	subsequent	O
3	screen	O
4	for	O
5	the	O
6	loss	O
7	of	O
8	the	O
9	positively	O
10	selectable	O
11	target	O
12	locus	O
13	marker	O
14	detects	O
15	the	O
16	desired	O
17	replacement	O
18	at	O
19	modest	O
20	frequency	O
21	(>	O
22	2	O
23	%).	O

1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	O
20	nadir	O
21	33	O
22	%).	O

1	Gel	O
2	retardation	O
3	assays	O
4	detected	O
5	ZiaR	B
6	-	I
7	dependent	I
8	complexes	I
9	forming	O
10	with	O
11	the	O
12	zia	B
13	operator	I
14	-	I
15	promoter	I
16	and	O
17	ZiaR	B
18	-	I
19	DNA	I
20	binding	I
21	was	O
22	enhanced	O
23	by	O
24	treatment	O
25	with	O
26	a	O
27	metal	O
28	-	O
29	chelator	O
30	in	O
31	vitro	O
32	.	O

1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	B
13	-	I
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	B
26	,	O
27	suggesting	O
28	that	O
29	cdc17	O
30	/	O
31	pol1	O
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O

1	The	O
2	following	O
3	markers	O
4	were	O
5	looked	O
6	for	O
7	in	O
8	the	O
9	serum	O
10	,	O
11	skin	O
12	and	O
13	liver	O
14	of	O
15	all	O
16	patients	O
17	with	O
18	chronic	O
19	hepatitis	O
20	:	O
21	HBV	O
22	(	O
23	HBs	B
24	Ag	I
25	and	I
26	HBe	I
27	Ag	I
28	,	O
29	anti	B
30	-	I
31	HBs	I
32	,	O
33	anti	B
34	-	I
35	HBe	I
36	and	O
37	anti	B
38	-	I
39	HBc	O
40	in	O
41	the	O
42	serum	O
43	,	O
44	HBs	B
45	and	O
46	HBc	B
47	Ag	I
48	in	O
49	the	O
50	liver	O
51	);	O
52	non	B
53	-	I
54	A	I
55	non	I
56	-	I
57	B	I
58	(	I
59	non	I
60	-	I
61	A	I
62	,	I
63	non	I
64	-	I
65	B	I
66	Ag	I
67	and	O
68	antibody	O
69	,	O
70	anti	B
71	non	I
72	-	I
73	A	I
74	non	I
75	-	I
76	Bc	O
77	in	O
78	the	O
79	serum	O
80	,	O
81	non	O
82	-	O
83	A	O
84	,	O
85	non	O
86	-	O
87	Bc	B
88	Ag	I
89	in	O
90	the	O
91	liver	O
92	).	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	O
34	phosphatase	O
35	(	O
36	ACP	O
37	)	O
38	method	O
39	.	O

1	Influence	O
2	of	O
3	neural	O
4	regulation	O
5	on	O
6	anti	B
7	-	I
8	arrhythmic	O
9	effects	O
10	of	O
11	GABA	O
12	in	O
13	rats	O

1	Osteocalcin	B
2	(	I
3	serum	I
4	bone	I
5	-	I
6	Gla	I
7	protein	I
8	,	O
9	sBGP	O
10	),	O
11	serum	B
12	alkaline	I
13	phosphatase	I
14	(	O
15	sAP	O
16	)	O
17	and	O
18	urinary	O
19	hydroxyproline	O
20	/	O
21	creatinine	O
22	ratio	O
23	(	O
24	uOH	O
25	-	O
26	Prol	O
27	/	O
28	creatinine	O
29	)	O
30	have	O
31	been	O
32	measured	O
33	in	O
34	21	O
35	patients	O
36	with	O
37	primary	O
38	hyperparathyroidism	O
39	(	O
40	PHPT	O
41	)	O
42	and	O
43	in	O
44	nine	O
45	patients	O
46	with	O
47	hypercalcaemia	O
48	of	O
49	malignancy	O
50	(	O
51	HM	O
52	).	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	O
14	/	O
15	fix	B
16	gene	I
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O

1	By	O
2	DNase	B
3	I	I
4	footprint	O
5	analysis	O
6	of	O
7	the	O
8	PNR	O
9	element	O
10	,	O
11	a	O
12	palindrome	O
13	of	O
14	two	O
15	high	O
16	-	O
17	affinity	O
18	Ets	B
19	-	I
20	binding	I
21	sites	I
22	(	O
23	CTTCCCTGGAAG	O
24	)	O
25	was	O
26	identified	O
27	.	O

1	Ent	B
2	-	I
3	kaurene	I
4	synthase	I
5	from	O
6	the	O
7	fungus	O
8	Phaeosphaeria	O
9	sp	O
10	.	O

1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	O
15	factor	O
16	Sp1	B
17	.	O

1	The	O
2	high	O
3	density	O
4	of	O
5	tegumental	O
6	spines	O
7	on	O
8	posterior	O
9	half	O
10	of	O
11	the	O
12	body	O
13	and	O
14	the	O
15	distribution	O
16	of	O
17	type	O
18	II	O
19	papillae	O
20	on	O
21	dorsal	O
22	surface	O
23	are	O
24	considered	O
25	to	O
26	be	O
27	characteristic	O
28	of	O
29	C	O
30	.	O
31	armatus	O
32	.	O

1	Yusuf	B
2	Dawood	O
3	Docrat	O
4	L	O
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O

1	Bipolarity	B
2	in	O
3	Jungian	O
4	type	O
5	theory	O
6	and	O
7	the	O
8	Myers	O
9	-	O
10	Briggs	O
11	Type	O
12	Indicator	O
13	.	O

1	Possibilities	B
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	O

1	Further	O
2	,	O
3	Tax	B
4	-	I
5	mediated	O
6	apoptosis	O
7	was	O
8	effectively	O
9	prevented	O
10	by	O
11	ectopic	O
12	expression	O
13	of	O
14	the	O
15	p300	B
16	coactivator	I
17	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	the	O
6	fruA	O
7	transcript	O
8	is	O
9	well	O
10	conserved	O
11	with	O
12	the	O
13	D	O
14	.	O
15	melanogaster	O
16	type	O
17	A	O
18	protein	O
19	,	O
20	particularly	O
21	the	O
22	BTB	B
23	protein	I
24	-	I
25	protein	I
26	-	I
27	binding	I
28	domain	I
29	,	O
30	which	O
31	is	O
32	encoded	O
33	by	O
34	exons	O
35	I	O
36	and	O
37	II	O
38	and	O
39	is	O
40	100	O
41	%	O
42	conserved	O
43	.	O

1	LA	O
2	-	O
3	3848	O
4	-	O
5	MS	O
6	.	O

1	The	O
2	obtained	O
3	results	O
4	were	O
5	compared	O
6	with	O
7	control	O
8	group	O
9	(	O
10	10	O
11	female	O
12	volunteers	O
13	).	O

1	The	O
2	prognosis	O
3	of	O
4	seven	O
5	patients	O
6	who	O
7	received	O
8	ABSCT	O
9	was	O
10	significantly	O
11	better	O
12	than	O
13	that	O
14	of	O
15	13	O
16	patients	O
17	who	O
18	received	O
19	conventional	O
20	therapy	O
21	alone	O
22	.	O

1	These	O
2	cells	O
3	fail	O
4	to	O
5	generate	O
6	the	O
7	signals	O
8	to	O
9	phosphorylate	O
10	CREB	B
11	and	O
12	produce	O
13	significantly	O
14	less	O
15	of	O
16	the	O
17	cytokine	O
18	Interleukin	B
19	-	I
20	2	I
21	(	I
22	IL	I
23	-	I
24	2	I
25	)	O
26	in	O
27	response	O
28	to	O
29	agents	O
30	that	O
31	either	O
32	increase	O
33	intracellular	O
34	Ca2	O
35	+	O
36	and	O
37	/	O
38	or	O
39	activate	O
40	protein	B
41	kinase	I
42	C	I
43	.	O

1	A	I
2	case	O
3	of	O
4	M	O
5	hemoglobinosis	O

1	Constitutive	B
2	protection	O
3	of	O
4	E2F	B
5	recognition	I
6	sequences	I
7	in	O
8	the	O
9	human	B
10	thymidine	I
11	kinase	I
12	promoter	I
13	during	O
14	cell	O
15	cycle	O
16	progression	O
17	.	O

1	When	O
2	expressed	O
3	in	O
4	COS	O
5	-	O
6	7	O
7	cells	O
8	,	O
9	MKP	B
10	-	I
11	4	I
12	blocks	O
13	activation	O
14	of	O
15	MAP	B
16	kinases	I
17	with	O
18	the	O
19	selectivity	O
20	ERK	B
21	>	O
22	p38	B
23	=	O
24	JNK	B
25	/	O
26	SAPK	B
27	.	O

1	This	O
2	new	O
3	knowledge	O
4	has	O
5	contributed	O
6	to	O
7	the	O
8	development	O
9	of	O
10	a	O
11	successful	O
12	immunoprophylactic	O
13	strategy	O
14	for	O
15	eliminating	O
16	Hib	O
17	disease	O
18	.	O

1	Partial	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	B
8	platelet	I
9	cAMP	I
10	phosphodiesterase	I
11	,	O
12	PDE3A	O
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O

1	This	O
2	finding	O
3	represents	O
4	both	O
5	a	O
6	potentially	O
7	important	O
8	mechanism	O
9	by	O
10	which	O
11	HPV	B
12	gene	I
13	expression	O
14	can	O
15	be	O
16	regulated	O
17	and	O
18	an	O
19	interesting	O
20	model	O
21	for	O
22	the	O
23	study	O
24	of	O
25	transcriptional	O
26	cooperativity	O
27	.	O

1	The	O
2	most	O
3	frequent	O
4	causes	O
5	of	O
6	the	O
7	meningitis	O
8	was	O
9	the	O
10	external	O
11	ventricular	O
12	drainage	O
13	(	O
14	14	O
15	.	O
16	8	O
17	%),	O
18	post	O
19	-	O
20	neurosurgical	O
21	(	O
22	0	O
23	.	O
24	8	O
25	%)	O
26	and	O
27	head	O
28	injury	O
29	(	O
30	0	O
31	.	O
32	0007	O
33	%).	O

1	Successful	O
2	treatment	O
3	with	O
4	nasal	O
5	continuous	O
6	positive	O
7	airway	O
8	pressure	O
9	(	O
10	8	O
11	.	O
12	3	O
13	+/-	O
14	1	O
15	.	O
16	5	O
17	cmH2O	O
18	)	O
19	for	O
20	3	O
21	days	O
22	caused	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	mean	O
28	blood	O
29	pressure	O
30	in	O
31	OSAS	O
32	.	O

1	Secondary	B
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O

1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	B
8	kinase	I
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	B
23	-	I
24	2	I
25	.	O

1	With	O
2	constructs	O
3	containing	O
4	the	O
5	binding	O
6	site	O
7	of	O
8	one	O
9	gene	O
10	fused	O
11	to	O
12	the	O
13	promoter	O
14	of	O
15	the	O
16	other	O
17	,	O
18	we	O
19	demonstrated	O
20	that	O
21	the	O
22	positional	O
23	requirements	O
24	are	O
25	a	O
26	function	O
27	of	O
28	the	O
29	specific	O
30	binding	O
31	site	O
32	,	O
33	not	O
34	the	O
35	promoter	O
36	.	O

1	The	O
2	protein	O
3	predicted	O
4	by	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	human	B
10	pim	I
11	-	I
12	1	I
13	proto	I
14	-	I
15	oncogene	I
16	shares	O
17	extensive	O
18	homology	O
19	with	O
20	known	O
21	serine	B
22	/	I
23	threonine	I
24	protein	I
25	kinases	I
26	,	O
27	and	O
28	yet	O
29	the	O
30	human	B
31	Pim	I
32	-	I
33	1	I
34	enzyme	I
35	has	O
36	previously	O
37	been	O
38	reported	O
39	to	O
40	exhibit	O
41	protein	B
42	tyrosine	I
43	kinase	I
44	activity	O
45	both	O
46	in	O
47	vitro	O
48	and	O
49	in	O
50	vivo	O
51	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	O
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	B
21	stimulation	O
22	.	O

1	A	I
2	sharp	O
3	outbreak	O
4	of	O
5	influenza	O
6	A	O
7	occurred	O
8	on	O
9	the	O
10	base	O
11	during	O
12	February	O
13	that	O
14	was	O
15	due	O
16	to	O
17	an	O
18	A	O
19	/	O
20	Texas	B
21	/	I
22	1	I
23	/	I
24	77	O
25	-	O
26	like	O
27	virus	O
28	,	O
29	a	O
30	variant	O
31	of	O
32	the	O
33	A	O
34	/	O
35	Victoria	O
36	/	O
37	3	O
38	/	O
39	75	O
40	prototpye	O
41	.	O

1	Regulation	O
2	of	O
3	yeast	B
4	LEU2	I
5	.	O

1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	B
11	-	I
12	1	I
13	together	O
14	with	O
15	Sp1	B
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	B
31	protein	I
32	or	O
33	of	O
34	another	O
35	unidentified	O
36	erythroid	B
37	factor	I
38	.	O

1	The	O
2	COOH	O
3	-	O
4	terminus	O
5	of	O
6	this	O
7	new	O
8	isoform	O
9	,	O
10	which	O
11	we	O
12	designate	B
13	beta	I
14	4	I
15	,	O
16	lacks	O
17	a	O
18	22	O
19	amino	O
20	acid	O
21	lysine	O
22	-	O
23	rich	O
24	sequence	O
25	common	O
26	to	O
27	both	O
28	the	O
29	human	B
30	red	I
31	cell	I
32	alpha	I
33	-	I
34	and	I
35	beta	I
36	-	I
37	adducin	I
38	subunits	I
39	and	O
40	homologous	O
41	to	O
42	a	O
43	highly	O
44	conserved	O
45	region	O
46	in	O
47	MARCKS	O
48	,	O
49	a	O
50	filamentous	O
51	actin	B
52	-	I
53	cross	O
54	linking	O
55	protein	O
56	regulated	O
57	by	O
58	protein	B
59	kinase	I
60	C	I
61	and	O
62	calcium	O
63	/	O
64	calmodulin	B
65	.	I
66	beta	I
67	4	I
68	-	I
69	adducin	O
70	preserves	O
71	a	O
72	previously	O
73	identified	O
74	calmodulin	B
75	binding	I
76	domain	I
77	.	O

1	The	O
2	alternative	O
3	splice	O
4	sites	O
5	for	O
6	the	O
7	smallest	O
8	adducin	O
9	isoform	O
10	,	O
11	beta	B
12	-	I
13	3	I
14	,	O
15	are	O
16	alternative	O
17	donor	O
18	and	O
19	acceptor	O
20	sites	O
21	within	O
22	exons	O
23	7	O
24	and	O
25	12	O
26	.	O

1	For	O
2	each	O
3	night	O
4	,	O
5	the	O
6	diary	O
7	allowed	O
8	the	O
9	subjective	O
10	measurement	O
11	of	O
12	bedtime	O
13	,	O
14	wake	O
15	time	O
16	,	O
17	time	O
18	in	O
19	bed	O
20	(	O
21	TIB	O
22	),	O
23	sleep	O
24	efficiency	O
25	,	O
26	number	O
27	of	O
28	minutes	O
29	of	O
30	wake	O
31	after	O
32	sleep	O
33	onset	O
34	(	O
35	WASO	O
36	),	O
37	alertness	O
38	on	O
39	awakening	O
40	,	O
41	and	O
42	percentage	O
43	of	O
44	morning	O
45	needing	O
46	an	O
47	alarm	O
48	(	O
49	or	O
50	a	O
51	person	O
52	functioning	O
53	as	O
54	one	O
55	).	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	BMD	O
13	and	O
14	femoral	O
15	neck	O
16	BMD	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	exercises	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	swimming	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	BMD	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	swimming	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	building	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	shoulder	O
65	,	O
66	back	O
67	,	O
68	and	O
69	grip	O
70	muscle	O
71	strength	O
72	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O

1	Ruddell	B
2	,	O
3	M	O
4	.	O

1	Spontaneous	B
2	degradation	O
3	of	O
4	atracurium	O
5	in	O
6	plasma	O
7	is	O
8	the	O
9	major	O
10	route	O
11	of	O
12	elimination	O
13	in	O
14	man	O
15	and	O
16	contributes	O
17	to	O
18	a	O
19	short	O
20	elimination	O
21	half	O
22	-	O
23	life	O
24	(	O
25	approximatively	O
26	20	O
27	min	O
28	).	O

1	Only	O
2	one	O
3	of	O
4	these	O
5	bands	O
6	was	O
7	supershifted	O
8	by	O
9	antibody	O
10	to	O
11	p50	B
12	,	O
13	whereas	O
14	antibodies	O
15	to	O
16	p65	B
17	or	O
18	other	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	had	O
24	no	O
25	effect	O
26	.	O

1	The	O
2	cause	O
3	of	O
4	death	O
5	is	O
6	often	O
7	quite	O
8	apparent	O
9	from	O
10	the	O
11	pathological	O
12	and	O
13	toxicological	O
14	findings	O
15	;	O
16	however	O
17	,	O
18	the	O
19	manner	O
20	of	O
21	death	O
22	often	O
23	gives	O
24	the	O
25	examining	O
26	official	O
27	some	O
28	difficulty	O
29	.	O

1	Like	O
2	the	O
3	Tob	O
4	protein	O
5	,	O
6	Tob2	O
7	inhibited	O
8	cell	O
9	cycle	O
10	progression	O
11	from	O
12	the	O
13	G0	O
14	/	O
15	G1	O
16	to	O
17	S	O
18	phases	O
19	.	O

1	The	O
2	incidence	O
3	of	O
4	HSV	B
5	-	I
6	2	I
7	positive	O
8	subjects	O
9	(	O
10	HSV	B
11	-	I
12	2	I
13	/	I
14	HSV	I
15	-	I
16	1	I
17	antibody	I
18	ratio	O
19	>	O
20	or	O
21	=	O
22	1	O
23	)	O
24	was	O
25	low	O
26	in	O
27	the	O
28	Jewish	O
29	Israeli	O
30	population	O
31	,	O
32	compared	O
33	to	O
34	other	O
35	demographic	O
36	areas	O
37	.	O

1	In	O
2	the	O
3	present	O
4	report	O
5	,	O
6	66	O
7	hemochromatosis	O
8	families	O
9	yielding	O
10	151	O
11	hemochromatosis	O
12	chromosomes	O
13	and	O
14	182	O
15	normal	O
16	chromosomes	O
17	were	O
18	RFLP	O
19	-	O
20	typed	O
21	with	O
22	a	O
23	battery	O
24	of	O
25	probes	O
26	,	O
27	including	O
28	two	O
29	newly	O
30	derived	O
31	polymorphic	O
32	markers	O
33	from	O
34	the	O
35	6	O
36	.	O
37	7	O
38	and	O
39	HLA	B
40	-	I
41	F	I
42	loci	I
43	located	O
44	150	O
45	and	O
46	250	O
47	kb	O
48	telomeric	O
49	to	O
50	HLA	B
51	-	I
52	A	I
53	,	O
54	respectively	O
55	.	O

1	When	O
2	transiently	O
3	transfected	O
4	into	O
5	K562	O
6	cells	O
7	,	O
8	this	O
9	Lg	O
10	genomic	O
11	clone	O
12	is	O
13	actively	O
14	transcribed	O
15	,	O
16	suggesting	O
17	that	O
18	,	O
19	although	O
20	it	O
21	possesses	O
22	the	O
23	characteristics	O
24	of	O
25	a	O
26	processed	O
27	pseudogene	O
28	,	O
29	it	O
30	is	O
31	likely	O
32	to	O
33	correspond	O
34	to	O
35	the	O
36	gene	O
37	encoding	O
38	this	O
39	new	O
40	ferritin	B
41	subunit	I
42	.	O

1	Time	O
2	shifts	O
3	increase	O
4	growth	O
5	hormone	O
6	release	O
7	.	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	O
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	O
18	E1B	B
19	55	O
20	kDa	O
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	B
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	I
33	3	I
34	E1A	I
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	I
43	kDa	I
44	and	O
45	55	O
46	kDa	O
47	proteins	O
48	).	O

1	The	O
2	procedure	O
3	has	O
4	been	O
5	applied	O
6	to	O
7	three	O
8	materials	O
9	:	O
10	particle	O
11	board	O
12	with	O
13	carpet	O
14	;	O
15	gypsum	O
16	board	O
17	with	O
18	wallpaper	O
19	;	O
20	and	O
21	plywood	O
22	with	O
23	polyurethane	O
24	lacquer	O
25	,	O
26	for	O
27	which	O
28	the	O
29	steady	O
30	-	O
31	state	O
32	emission	O
33	factors	O
34	(	O
35	mg	O
36	m	B
37	-	I
38	2	I
39	h	O
40	-	O
41	1	O
42	)	O
43	of	O
44	several	O
45	compounds	O
46	are	O
47	given	O
48	.	O

1	Pokeweed	B
2	mitogen	I
3	(	O
4	PWM	O
5	)	O
6	or	O
7	anti	B
8	-	I
9	CD3	I
10	significantly	O
11	increases	O
12	c	B
13	-	I
14	jun	I
15	messenger	I
16	RNA	I
17	(	I
18	mRNA	I
19	)	O
20	levels	O
21	in	O
22	T	O
23	cells	O
24	.	O

1	The	O
2	average	O
3	values	O
4	were	O
5	199	O
6	and	O
7	424	O
8	revertants	O
9	/	O
10	g	O
11	for	O
12	the	O
13	hamburgers	O
14	and	O
15	hot	O
16	dogs	O
17	,	O
18	respectively	O
19	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	B
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O

1	The	O
2	UAS	O
3	of	O
4	the	O
5	AAC2	B
6	gene	I
7	contains	O
8	at	O
9	least	O
10	two	O
11	distinct	O
12	motifs	O
13	for	O
14	DNA	O
15	-	O
16	binding	O
17	transcriptional	O
18	activators	O
19	,	O
20	including	O
21	one	O
22	which	O
23	is	O
24	identical	O
25	with	O
26	the	O
27	core	O
28	HAP2	B
29	/	I
30	3	I
31	/	I
32	4	I
33	binding	I
34	motif	I
35	,	O
36	and	O
37	a	O
38	second	O
39	one	O
40	with	O
41	the	O
42	ABF1	O
43	consensus	O
44	binding	O
45	sequence	O
46	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	The	O
2	present	O
3	results	O
4	demonstrate	O
5	that	O
6	rats	O
7	with	O
8	relatively	O
9	small	O
10	remnants	O
11	of	O
12	one	O
13	olfactory	O
14	bulb	O
15	can	O
16	perform	O
17	a	O
18	variety	O
19	of	O
20	odor	O
21	detection	O
22	and	O
23	discrimination	O
24	tasks	O
25	as	O
26	well	O
27	or	O
28	nearly	O
29	as	O
30	well	O
31	as	O
32	controls	O
33	.	O

1	Binding	O
2	site	O
3	selection	O
4	using	O
5	in	O
6	vitro	O
7	-	O
8	synthesized	O
9	proteins	O
10	reveals	O
11	that	O
12	the	O
13	ROR	B
14	alpha	I
15	1	I
16	and	O
17	ROR	B
18	alpha	I
19	2	I
20	isoforms	I
21	bind	O
22	DNA	O
23	as	O
24	monomers	O
25	to	O
26	hormone	O
27	response	O
28	elements	O
29	composed	O
30	of	O
31	a	O
32	6	O
33	-	O
34	bp	O
35	AT	O
36	-	O
37	rich	O
38	sequence	O
39	preceding	O
40	a	O
41	half	O
42	-	O
43	site	O
44	core	O
45	motif	O
46	PuGGTCA	O
47	(	O
48	RORE	O
49	).	O

1	RNA	B
2	transcripts	I
3	that	O
4	hybridize	O
5	to	O
6	the	O
7	introduced	O
8	foreign	O
9	gene	O
10	have	O
11	been	O
12	identified	O
13	.	O

1	Five	O
2	women	O
3	(	O
4	15	O
5	.	O
6	6	O
7	%)	O
8	met	O
9	criteria	O
10	for	O
11	PMS	O
12	.	O

1	The	O
2	3	O
3	'	O
4	region	O
5	,	O
6	GA2	O
7	,	O
8	is	O
9	necessary	O
10	for	O
11	maximal	O
12	expression	O
13	.	O

1	Identity	B
2	of	O
3	GABP	B
4	with	O
5	NRF	B
6	-	I
7	2	I
8	,	O
9	a	O
10	multisubunit	O
11	activator	O
12	of	O
13	cytochrome	B
14	oxidase	I
15	expression	O
16	,	O
17	reveals	O
18	a	O
19	cellular	O
20	role	O
21	for	O
22	an	O
23	ETS	B
24	domain	I
25	activator	I
26	of	O
27	viral	O
28	promoters	O
29	.	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	O
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	O
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	O
25	Arabidopsis	O
26	,	O
27	Cdc2bAt	O
28	.	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	I
6	reporter	I
7	construct	I
8	,	O
9	(	O
10	PRDII	B
11	)(	I
12	4	I
13	)-	I
14	CAT	I
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	I
27	by	O
28	Tat	B
29	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	Relief	B
2	from	O
3	autoinhibition	O
4	and	O
5	a	O
6	subsequent	O
7	10	O
8	-	O
9	60	O
10	-	O
11	fold	O
12	increase	O
13	in	O
14	V	O
15	(	O
16	max	O
17	)	O
18	have	O
19	been	O
20	observed	O
21	upon	O
22	N	B
23	-	I
24	SH2	I
25	domain	I
26	engagement	O
27	by	O
28	a	O
29	specific	O
30	phosphotyrosyl	O
31	ligand	O
32	or	O
33	upon	O
34	deletion	O
35	of	O
36	the	O
37	SH2	B
38	domains	I
39	to	O
40	yield	O
41	the	O
42	catalytic	O
43	PTPase	O
44	domain	O
45	.	O

1	To	O
2	determine	O
3	the	O
4	function	O
5	of	O
6	VZV	O
7	gK	O
8	in	O
9	virus	O
10	growth	O
11	,	O
12	a	O
13	series	O
14	of	O
15	gK	O
16	deletion	O
17	mutants	O
18	were	O
19	constructed	O
20	with	O
21	VZV	O
22	cosmid	O
23	DNA	O
24	derived	O
25	from	O
26	the	O
27	Oka	O
28	strain	O
29	.	O

1	The	O
2	syncytial	O
3	microvillous	O
4	projections	O
5	seemed	O
6	to	O
7	be	O
8	more	O
9	numerous	O
10	and	O
11	longer	O
12	in	O
13	CNF	O
14	,	O
15	otherwise	O
16	the	O
17	structure	O
18	of	O
19	the	O
20	trophoblastic	O
21	layer	O
22	of	O
23	the	O
24	villi	O
25	and	O
26	the	O
27	lining	O
28	of	O
29	the	O
30	subtrophoblastic	O
31	vessels	O
32	were	O
33	identical	O
34	in	O
35	CNF	O
36	and	O
37	controls	O
38	.	O

1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O

1	Like	O
2	their	O
3	yeast	O
4	counterpart	O
5	,	O
6	the	O
7	mouse	O
8	GCN2	B
9	isoforms	I
10	contain	O
11	HisRS	B
12	-	I
13	related	I
14	sequences	I
15	juxtaposed	O
16	to	O
17	the	O
18	kinase	O
19	catalytic	O
20	domain	O
21	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	B
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	Immunohistochemical	B
2	staining	O
3	was	O
4	positive	O
5	for	O
6	S	O
7	-	O
8	100	O
9	in	O
10	all	O
11	9	O
12	cases	O
13	stained	O
14	,	O
15	positive	O
16	for	O
17	HMB	O
18	-	O
19	45	O
20	in	O
21	9	O
22	(	O
23	90	O
24	%)	O
25	of	O
26	10	O
27	,	O
28	and	O
29	negative	O
30	for	O
31	cytokeratin	O
32	in	O
33	all	O
34	9	O
35	cases	O
36	in	O
37	which	O
38	myxoid	O
39	melanoma	O
40	remained	O
41	in	O
42	the	O
43	block	O
44	after	O
45	previous	O
46	sections	O
47	.	O

1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O

1	The	O
2	effects	O
3	initiated	O
4	from	O
5	the	O
6	nucleus	O
7	accumbens	O
8	septi	O
9	were	O
10	most	O
11	marked	O
12	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	This	O
2	finding	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	notion	O
8	that	O
9	the	O
10	dsRNA	B
11	binding	I
12	domains	I
13	may	O
14	be	O
15	composed	O
16	of	O
17	two	O
18	separate	O
19	functional	O
20	subdomains	O
21	.	O

1	Rhizobium	B
2	meliloti	I
3	large	O
4	plasmid	O
5	pRmeGR4b	O
6	carries	O
7	the	O
8	nodulation	O
9	competitiveness	O
10	locus	O
11	nfe	O
12	responsible	O
13	for	O
14	the	O
15	nodulation	O
16	efficiency	O
17	and	O
18	competitive	O
19	ability	O
20	of	O
21	strain	O
22	GR4	O
23	on	O
24	alfalfa	O
25	roots	O
26	.	O

1	To	O
2	those	O
3	of	O
4	us	O
5	who	O
6	are	O
7	not	O
8	satisfied	O
9	with	O
10	the	O
11	present	O
12	outlook	O
13	there	O
14	is	O
15	much	O
16	to	O
17	be	O
18	investigated	O
19	and	O
20	much	O
21	to	O
22	be	O
23	contributed	O
24	.	O

1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O

1	Therefore	O
2	,	O
3	recombinant	O
4	human	O
5	Ads	O
6	that	O
7	express	O
8	noninfectious	O
9	HIV	O
10	or	O
11	other	O
12	microbial	O
13	proteins	O
14	are	O
15	attractive	O
16	vaccine	O
17	candidates	O
18	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	Introductory	B
2	remarks	O
3	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	CBF1	B
6	in	O
7	yeast	O
8	was	O
9	found	O
10	to	O
11	activate	O
12	transcription	O
13	of	O
14	reporter	O
15	genes	O
16	containing	O
17	the	O
18	C	B
19	-	I
20	repeat	I
21	/	I
22	DRE	O
23	as	O
24	an	O
25	upstream	O
26	activator	O
27	sequence	O
28	but	O
29	not	O
30	mutant	O
31	versions	O
32	of	O
33	the	O
34	DNA	O
35	element	O
36	.	O

1	Preheparin	B
2	LPL	O
3	mass	O
4	level	O
5	did	O
6	not	O
7	significantly	O
8	differ	O
9	in	O
10	individuals	O
11	from	O
12	19	O
13	to	O
14	70	O
15	years	O
16	old	O
17	,	O
18	for	O
19	both	O
20	men	O
21	and	O
22	women	O
23	.	O

1	Serum	B
2	-	I
3	ferritin	I
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O

1	Respiratory	B
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	This	O
2	regulation	O
3	requires	O
4	two	O
5	HMG	B
6	-	I
7	box	I
8	proteins	I
9	:	O
10	the	O
11	ubiquitous	O
12	Ste11	B
13	transcription	I
14	factor	I
15	and	O
16	the	O
17	M	O
18	cell	O
19	-	O
20	controlling	O
21	protein	O
22	Mat1	O
23	-	O
24	Mc	O
25	.	O

1	Increasing	B
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O

1	Recombinant	B
2	erythropoietin	I
3	(	O
4	r	O
5	-	O
6	HuEPO	O
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O

1	Overexpression	O
2	of	O
3	CARP	O
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	O
8	troponin	O
9	C	O
10	and	O
11	atrial	B
12	natriuretic	I
13	factor	I
14	transcription	I
15	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	opiate	O
6	antagonist	O
7	naloxone	O
8	was	O
9	evaluated	O
10	in	O
11	11	O
12	unselected	O
13	patients	O
14	with	O
15	cerebral	O
16	ischemia	O
17	.	O

1	Three	O
2	sequence	O
3	elements	O
4	are	O
5	shown	O
6	to	O
7	be	O
8	required	O
9	for	O
10	accurate	O
11	and	O
12	efficient	O
13	transcription	O
14	termination	O
15	by	O
16	RNA	B
17	polymerase	I
18	I	I
19	(	I
20	pol	I
21	I	I
22	)	O
23	assayed	O
24	both	O
25	in	O
26	a	O
27	cell	O
28	-	O
29	free	O
30	transcription	O
31	system	O
32	and	O
33	in	O
34	vivo	O
35	after	O
36	transfection	O
37	of	O
38	rDNA	O
39	minigene	O
40	constructs	O
41	into	O
42	3T6	O
43	cells	O
44	.	O

1	For	O
2	the	O
3	first	O
4	time	O
5	we	O
6	describe	O
7	deletion	O
8	and	O
9	point	O
10	mutations	O
11	within	O
12	the	O
13	plasma	O
14	membrane	O
15	family	O
16	of	O
17	guanylyl	B
18	cyclase	I
19	receptors	I
20	that	O
21	result	O
22	in	O
23	the	O
24	formation	O
25	of	O
26	effective	O
27	dominant	O
28	negative	O
29	proteins	O
30	.	O

1	Recovery	O
2	of	O
3	carbimazole	O
4	-	O
5	induced	O
6	agranulocytosis	O
7	following	O
8	recombinant	B
9	granulocyte	I
10	-	I
11	macrophage	I
12	colony	I
13	stimulating	I
14	factor	I
15	(	I
16	rhGM	I
17	-	I
18	CSF	I
19	)	O
20	administration	O
21	.	O

1	The	O
2	degree	O
3	of	O
4	lung	O
5	destruction	O
6	,	O
7	reflected	O
8	by	O
9	interstitial	O
10	hemorrhage	O
11	was	O
12	assessed	O
13	by	O
14	measuring	O
15	hemoglobin	B
16	content	O
17	in	O
18	the	O
19	fluid	O
20	of	O
21	the	O
22	lavaged	O
23	lungs	O
24	.	O

1	Heating	B
2	cells	O
3	to	O
4	43	O
5	degrees	O
6	C	O
7	decreased	O
8	the	O
9	amount	O
10	of	O
11	newly	O
12	synthesized	O
13	rRNA	O
14	to	O
15	less	O
16	than	O
17	5	O
18	%	O
19	of	O
20	the	O
21	control	O
22	level	O
23	and	O
24	led	O
25	to	O
26	greater	O
27	than	O
28	95	O
29	%	O
30	inhibition	O
31	of	O
32	transcription	O
33	termination	O
34	at	O
35	a	O
36	region	O
37	355	O
38	to	O
39	362	O
40	nucleotides	O
41	downstream	O
42	of	O
43	the	O
44	3	O
45	'	O
46	end	O
47	of	O
48	28S	B
49	rRNA	I
50	,	O
51	with	O
52	readthrough	O
53	continuing	O
54	into	O
55	the	O
56	next	O
57	transcription	O
58	unit	O
59	.	O

1	Thus	O
2	,	O
3	IRF	B
4	-	I
5	7	O
6	exhibits	O
7	functional	O
8	similarity	O
9	to	O
10	IRF	B
11	-	I
12	3	I
13	;	O
14	however	O
15	,	O
16	the	O
17	preferential	O
18	expression	O
19	of	O
20	IRF	B
21	-	I
22	7	O
23	in	O
24	lymphoid	O
25	cells	O
26	(	O
27	the	O
28	cell	O
29	type	O
30	that	O
31	expresses	O
32	IFNA	O
33	)	O
34	suggests	O
35	that	O
36	IRF	B
37	-	I
38	7	O
39	may	O
40	play	O
41	a	O
42	critical	O
43	role	O
44	in	O
45	regulating	O
46	the	O
47	IFNA	B
48	gene	I
49	expression	O
50	.	O

1	Structure	O
2	and	O
3	localization	O
4	of	O
5	the	O
6	human	B
7	gene	I
8	encoding	I
9	SR	I
10	-	I
11	BI	I
12	/	I
13	CLA	I
14	-	I
15	1	I
16	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	sequences	O
6	in	O
7	the	O
8	SH2	B
9	/	I
10	SH3	I
11	/	I
12	SH2	I
13	region	I
14	of	O
15	p120	O
16	GAP	B
17	are	O
18	required	O
19	for	O
20	full	O
21	catalytic	O
22	activity	O
23	toward	O
24	Ras	B
25	.	O

1	Identification	O
2	of	O
3	a	O
4	spliced	O
5	gene	O
6	from	O
7	Kaposi	O
8	'	O
9	s	O
10	sarcoma	O
11	-	O
12	associated	O
13	herpesvirus	O
14	encoding	O
15	a	O
16	protein	O
17	with	O
18	similarities	O
19	to	O
20	latent	B
21	membrane	I
22	proteins	I
23	1	I
24	and	I
25	2A	I
26	of	O
27	Epstein	B
28	-	I
29	Barr	I
30	virus	I
31	.	O

1	In	O
2	untreated	O
3	mice	O
4	,	O
5	bactericidal	O
6	activity	O
7	of	O
8	peritoneal	O
9	macrophages	O
10	decreased	O
11	from	O
12	one	O
13	day	O
14	to	O
15	3	O
16	days	O
17	after	O
18	ip	O
19	injection	O
20	of	O
21	killed	O
22	L	O
23	.	O
24	monocytogenes	O
25	.	O

1	Second	O
2	,	O
3	nitrate	O
4	induction	O
5	of	O
6	aeg	O
7	-	O
8	46	O
9	.	O
10	5	O
11	operon	O
12	expression	O
13	is	O
14	substantially	O
15	enhanced	O
16	in	O
17	narL	O
18	null	O
19	strains	O
20	(	O
21	M	O
22	.	O
23	H	O
24	.	O

1	Aspirin	B
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	O
9	mucosal	O
10	cyclooxygenase	O
11	(	O
12	COX	O
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O

1	A	I
2	cohort	O
3	of	O
4	Swedish	O
5	children	O
6	was	O
7	monitored	O
8	from	O
9	6	O
10	months	O
11	to	O
12	11	O
13	years	O
14	of	O
15	age	O
16	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	Expression	O
2	of	O
3	herpes	B
4	simplex	I
5	virus	I
6	beta	I
7	and	I
8	gamma	I
9	genes	I
10	integrated	O
11	in	O
12	mammalian	O
13	cells	O
14	and	O
15	their	O
16	induction	O
17	by	O
18	an	O
19	alpha	B
20	gene	I
21	product	I
22	.	O

1	Transcription	O
2	start	O
3	site	O
4	mapping	O
5	identified	O
6	the	O
7	presence	O
8	of	O
9	an	O
10	aphidicolin	O
11	-	O
12	sensitive	O
13	late	O
14	transcript	O
15	arising	O
16	from	O
17	a	O
18	TAAG	O
19	motif	O
20	located	O
21	at	O
22	-	O
23	352	O
24	nucleotides	O
25	and	O
26	an	O
27	aphidicolin	O
28	-	O
29	insensitive	O
30	early	O
31	transcript	O
32	originating	O
33	from	O
34	a	O
35	TTGT	O
36	motif	O
37	located	O
38	35	O
39	nucleotides	O
40	downstream	O
41	to	O
42	a	O
43	TATA	O
44	box	O
45	at	O
46	-	O
47	312	O
48	nucleotides	O
49	,	O
50	with	O
51	respect	O
52	to	O
53	the	O
54	+	O
55	1	O
56	ATG	O
57	of	O
58	lef2	O
59	.	O

1	Determination	O
2	of	O
3	potassium	O
4	iodide	O
5	in	O
6	Polish	O
7	edible	O
8	salt	O

1	Detailed	B
2	molecular	O
3	organization	O
4	of	O
5	the	O
6	coding	O
7	and	O
8	upstream	O
9	regulatory	O
10	regions	O
11	of	O
12	the	O
13	murine	B
14	homeodomain	I
15	-	I
16	containing	I
17	gene	I
18	,	O
19	Msx	B
20	-	I
21	1	I
22	,	O
23	is	O
24	reported	O
25	.	O

1	Mitogen	B
2	-	I
3	activated	I
4	protein	I
5	(	I
6	MAP	I
7	)	I
8	kinase	I
9	phosphatase	I
10	-	I
11	3	I
12	(	O
13	MKP	B
14	-	I
15	3	I
16	)	O
17	is	O
18	a	O
19	dual	O
20	specificity	O
21	phosphatase	O
22	that	O
23	inactivates	O
24	extracellular	B
25	signal	I
26	-	I
27	regulated	I
28	kinase	I
29	(	O
30	ERK	B
31	)	I
32	MAP	I
33	kinases	I
34	.	O

1	There	O
2	were	O
3	gene	O
4	clusters	O
5	encoding	O
6	photosynthesis	O
7	components	O
8	such	O
9	as	O
10	the	O
11	psbB	B
12	-	I
13	psbH	I
14	-	I
15	petB	I
16	-	I
17	petD	O
18	and	O
19	the	O
20	psbE	O
21	-	O
22	psbF	O
23	clusters	O
24	.	O

1	High	O
2	concentrations	O
3	of	O
4	tumor	B
5	-	I
6	associated	I
7	trypsin	I
8	inhibitor	I
9	in	O
10	hemodialyzed	O
11	patients	O
12	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	acetazolamide	O
11	and	O
12	disinfection	O
13	of	O
14	the	O
15	conjunctiva	O
16	,	O
17	50	O
18	micrograms	O
19	rt	B
20	-	I
21	PA	I
22	in	O
23	0	O
24	.	O
25	1	O
26	ml	O
27	(	O
28	BSS	O
29	)	O
30	and	O
31	0	O
32	.	O
33	5	O
34	ml	O
35	SF6	O
36	were	O
37	injected	O
38	intravitreally	O
39	.	O

1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	O
15	ODC	O
16	mRNA	O
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	differences	O
7	in	O
8	the	O
9	binding	O
10	of	O
11	nuclear	O
12	factors	O
13	from	O
14	shoots	O
15	versus	O
16	from	O
17	roots	O
18	,	O
19	in	O
20	agreement	O
21	with	O
22	the	O
23	different	O
24	activities	O
25	of	O
26	the	O
27	promoter	O
28	in	O
29	these	O
30	two	O
31	organs	O
32	.	O

1	Kidney	B
2	length	I
3	did	O
4	not	O
5	significantly	O
6	differ	O
7	between	O
8	right	O
9	and	O
10	left	O
11	,	O
12	however	O
13	,	O
14	kidney	O
15	width	O
16	,	O
17	cortical	O
18	thickness	O
19	and	O
20	size	O
21	did	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	ORF	I
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	O
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	I
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	O
30	16	O
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O

1	Azygos	B
2	vein	O
3	abutting	O
4	the	O
5	posterior	O
6	wall	O
7	of	O
8	the	O
9	right	O
10	main	O
11	and	O
12	upper	O
13	lobe	O
14	bronchi	O
15	:	O
16	a	O
17	normal	O
18	CT	O
19	variant	O
20	.	O

1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O

1	Reactive	B
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O

1	Allergenic	B
2	activity	O
3	of	O
4	allergen	O
5	extract	O
6	Ambrosia	O
7	elatior	O
8	(	O
9	AE	O
10	)	O
11	was	O
12	tested	O
13	in	O
14	fifteen	O
15	volunteers	O
16	extremely	O
17	sensitive	O
18	to	O
19	the	O
20	allergen	O
21	.	O

1	Detection	O
2	of	O
3	anti	B
4	-	I
5	lymphocyte	I
6	antibodies	I
7	using	O
8	the	O
9	immunoperoxidase	O
10	antiglobulin	O
11	technic	O
12	.	O

1	Preface	B
2	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	Fibrin	B
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Thus	O
2	,	O
3	the	O
4	bovine	O
5	PEDF	O
6	cDNA	O
7	isolated	O
8	here	O
9	codes	O
10	for	O
11	a	O
12	functional	O
13	soluble	O
14	secreted	O
15	PEDF	B
16	glycoprotein	I
17	.	O

1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O

1	On	O
2	a	O
3	separate	O
4	occasion	O
5	the	O
6	T1	O
7	weighted	O
8	and	O
9	T2	O
10	weighted	O
11	sagittal	O
12	and	O
13	T2	O
14	weighted	O
15	axial	O
16	sequences	O
17	were	O
18	reported	O
19	blind	O
20	in	O
21	relation	O
22	to	O
23	the	O
24	initial	O
25	assessment	O
26	.	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	O
17	IXa	O
18	by	O
19	factor	O
20	XIa	O
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	B
17	/	I
18	6	I
19	-	I
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	B
12	/	I
13	H1	I
14	domain	I
15	was	O
16	sufficient	O
17	for	O
18	coactivation	O
19	of	O
20	Zta	B
21	transcription	I
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	A	I
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	O
16	WWW	O
17	server	O
18	.	O

1	Seventy	O
2	-	O
3	two	O
4	hours	O
5	after	O
6	administration	O
7	of	O
8	vitamin	O
9	K1	O
10	,	O
11	plasma	O
12	concentrations	O
13	of	O
14	the	O
15	vitamin	O
16	were	O
17	not	O
18	different	O
19	from	O
20	normal	O
21	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	RNA	B
8	polymerase	I
9	II	I
10	activity	O
11	were	O
12	assayed	O
13	by	O
14	measuring	O
15	the	O
16	ability	O
17	of	O
18	mutant	O
19	genes	O
20	to	O
21	confer	O
22	alpha	B
23	-	I
24	amanitin	O
25	resistance	O
26	after	O
27	transfection	O
28	of	O
29	susceptible	O
30	rodent	O
31	cells	O
32	.	O

1	Particles	B
2	resembling	O
3	microbodies	O
4	in	O
5	normal	O
6	and	O
7	neoplastic	O
8	perianal	O
9	glands	O
10	of	O
11	dogs	O
12	.	O

1	Echinostomiasis	B
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	O
22	lack	O
23	of	O
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	Combination	B
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	B
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	we	O
6	used	O
7	a	O
8	series	O
9	of	O
10	plasmid	O
11	constructs	O
12	encoding	O
13	different	O
14	forms	O
15	of	O
16	the	O
17	envelope	B
18	glycoprotein	I
19	E	I
20	of	O
21	the	O
22	flavivirus	B
23	tick	I
24	-	I
25	borne	I
26	encephalitis	I
27	virus	I
28	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	Arm	B
2	function	O
3	tests	O
4	.	O

1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	GG	O
7	motifs	O
8	contributed	O
9	to	O
10	the	O
11	cell	O
12	-	O
13	specific	O
14	transcription	O
15	of	O
16	the	O
17	human	B
18	insulin	I
19	gene	I
20	in	O
21	association	O
22	with	O
23	the	O
24	binding	O
25	of	O
26	the	O
27	sequence	O
28	-	O
29	specific	O
30	nuclear	B
31	factor	I
32	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	O
25	.	O
26	5S	O
27	RNA	O
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	A	I
2	total	O
3	of	O
4	112	O
5	patients	O
6	received	O
7	anistreplase	O
8	and	O
9	119	O
10	received	O
11	heparin	O
12	within	O
13	a	O
14	mean	O
15	period	O
16	of	O
17	188	O
18	+/-	O
19	62	O
20	min	O
21	following	O
22	the	O
23	onset	O
24	of	O
25	symptoms	O
26	.	O

1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	O
8	(	O
9	maturation	O
10	promoting	O
11	factor	O
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	B
18	/	I
19	28	I
20	-	I
21	cyclin	I
22	B	I
23	complexes	I
24	.	O

1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	promoter	I
8	binding	I
9	protein	I
10	1	I
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O

1	The	O
2	Oct	B
3	and	O
4	HMG2	O
5	proteins	O
6	also	O
7	interact	O
8	in	O
9	vivo	O
10	.	O

1	Inactivation	B
2	of	O
3	Ulp2	O
4	also	O
5	suppresses	O
6	several	O
7	ulp1	O
8	(	O
9	ts	O
10	)	O
11	defects	O
12	,	O
13	and	O
14	the	O
15	double	O
16	mutant	O
17	accumulates	O
18	far	O
19	fewer	O
20	Smt3	B
21	-	I
22	protein	I
23	conjugates	O
24	than	O
25	either	O
26	single	O
27	mutant	O
28	.	O

1	In	O
2	canrenoate	O
3	-	O
4	treated	O
5	rats	O
6	,	O
7	ANP	B
8	infusion	O
9	caused	O
10	greater	O
11	increases	O
12	in	O
13	sodium	O
14	excretion	O
15	(	O
16	FENA	O
17	from	O
18	3	O
19	.	O
20	05	O
21	+/-	O
22	0	O
23	.	O
24	71	O
25	to	O
26	7	O
27	.	O
28	21	O
29	+/-	O
30	0	O
31	.	O
32	45	O
33	%;	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	;	O
40	n	O
41	=	O
42	8	O
43	)	O
44	than	O
45	saline	O
46	infusion	O
47	(	O
48	FENA	O
49	from	O
50	4	O
51	.	O
52	16	O
53	+/-	O
54	1	O
55	.	O
56	11	O
57	to	O
58	5	O
59	.	O
60	47	O
61	+/-	O
62	0	O
63	.	O
64	66	O
65	%;	O
66	n	O
67	=	O
68	6	O
69	),	O
70	despite	O
71	the	O
72	hypocapnia	O
73	.	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	B
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	This	O
2	laser	O
3	provided	O
4	sufficient	O
5	power	O
6	in	O
7	an	O
8	amniotic	O
9	fluid	O
10	medium	O
11	to	O
12	occlude	O
13	placental	O
14	vessels	O
15	as	O
16	large	O
17	as	O
18	7	O
19	mm	O
20	in	O
21	diameter	O
22	within	O
23	6	O
24	seconds	O
25	at	O
26	a	O
27	power	O
28	density	O
29	of	O
30	2000	O
31	W	O
32	/	O
33	cm2	O
34	.	O

1	Losartan	B
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	Transcriptional	O
2	blockade	O
3	was	O
4	reversed	O
5	by	O
6	co	O
7	-	O
8	transfections	O
9	of	O
10	a	O
11	wild	B
12	-	I
13	type	I
14	SRF	I
15	expression	O
16	vector	O
17	,	O
18	but	O
19	was	O
20	not	O
21	rescued	O
22	by	O
23	the	O
24	expression	O
25	of	O
26	other	O
27	myogenic	O
28	factors	O
29	,	O
30	such	O
31	as	O
32	MyoD	B
33	and	O
34	Mef	O
35	-	O
36	2C	O
37	.	O

1	This	O
2	investigation	O
3	was	O
4	undertaken	O
5	to	O
6	determine	O
7	whether	O
8	consuming	O
9	several	O
10	small	O
11	feedings	O
12	of	O
13	preexercise	O
14	carbohydrate	O
15	(	O
16	CHO	O
17	),	O
18	rather	O
19	than	O
20	a	O
21	single	O
22	bolus	O
23	,	O
24	would	O
25	affect	O
26	blood	O
27	glucose	O
28	and	O
29	insulin	B
30	responses	O
31	during	O
32	rest	O
33	and	O
34	exercise	O
35	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	O
12	suppressor	O
13	ING1	O
14	with	O
15	the	O
16	mSin3	O
17	/	O
18	HDAC1	O
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	full	B
9	-	I
10	length	I
11	cDNA	I
12	clone	O
13	coding	O
14	for	O
15	a	O
16	hitherto	O
17	undiscovered	O
18	isoform	O
19	of	O
20	the	O
21	bovine	B
22	C	I
23	-	I
24	subunit	I
25	.	O

1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	Hh	O
6	and	O
7	Patched	O
8	(	O
9	Ptc	O
10	)	O
11	act	O
12	through	O
13	those	O
14	Ci	B
15	binding	I
16	sites	I
17	to	O
18	modulate	O
19	the	O
20	level	O
21	of	O
22	Ci	O
23	-	O
24	dependent	O
25	transcriptional	O
26	activation	O
27	in	O
28	S2	O
29	cells	O
30	.	O

1	Although	O
2	pathological	O
3	thyroid	O
4	function	O
5	is	O
6	related	O
7	to	O
8	changes	O
9	in	O
10	energy	O
11	expenditure	O
12	and	O
13	body	O
14	composition	O
15	,	O
16	its	O
17	possible	O
18	influence	O
19	on	O
20	leptin	B
21	levels	O
22	remains	O
23	to	O
24	be	O
25	determined	O
26	.	O

1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	O
13	plasma	O
14	PSA	B
15	levels	O
16	.	O

1	DESIGN	O
2	:	O
3	Serum	O
4	aldosterone	O
5	and	O
6	plasma	B
7	renin	I
8	activity	O
9	were	O
10	measured	O
11	supine	O
12	prior	O
13	to	O
14	and	O
15	60	O
16	,	O
17	90	O
18	,	O
19	120	O
20	minutes	O
21	after	O
22	oral	O
23	captopril	O
24	,	O
25	25	O
26	mg	O
27	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	cerebrospinal	O
5	fluid	O
6	immunoglobulin	B
7	G	I
8	(	I
9	IgG	I
10	)	O
11	in	O
12	pediatric	O
13	neurological	O
14	diseases	O
15	.	O

1	The	O
2	clinical	O
3	and	O
4	laboratory	O
5	features	O
6	of	O
7	72	O
8	children	O
9	with	O
10	Henoch	O
11	-	O
12	Schonlein	O
13	purpura	O
14	(	O
15	HSP	O
16	)	O
17	were	O
18	examined	O
19	to	O
20	determine	O
21	if	O
22	there	O
23	were	O
24	associations	O
25	between	O
26	the	O
27	laboratory	O
28	indices	O
29	--	O
30	including	O
31	white	O
32	blood	O
33	cell	O
34	(	O
35	WBC	O
36	)	O
37	counts	O
38	,	O
39	serum	B
40	C	I
41	-	I
42	reactive	I
43	protein	I
44	(	I
45	CRP	I
46	)	O
47	levels	O
48	,	O
49	platelet	O
50	(	O
51	PLT	O
52	)	O
53	counts	O
54	--	O
55	and	O
56	the	O
57	clinical	O
58	manifestations	O
59	of	O
60	acute	O
61	HSP	O
62	.	O

1	Re	B
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	B
49	-	I
50	box	I
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	Human	B
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	GRE	O
8	sufficient	O
9	to	O
10	account	O
11	for	O
12	full	O
13	glucocorticoid	O
14	inducibility	O
15	and	O
16	an	O
17	HNF	B
18	-	I
19	1	I
20	site	I
21	close	O
22	to	O
23	the	O
24	promoter	O
25	that	O
26	are	O
27	major	O
28	determinants	O
29	of	O
30	transcriptional	O
31	control	O
32	of	O
33	the	O
34	Xenopus	B
35	fibrinogen	I
36	B	I
37	beta	I
38	subunit	I
39	gene	I
40	in	O
41	cells	O
42	from	O
43	normal	O
44	liver	O
45	tissue	O
46	.	O

1	Roux	B
2	-	I
3	en	I
4	-	I
5	Y	I
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O

1	AGO1	B
2	is	O
3	similar	O
4	to	O
5	QDE	B
6	-	I
7	2	I
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	B
13	-	I
14	1	I
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	ORF	I
2	2	I
3	potentially	O
4	encoded	O
5	a	O
6	hydrophobic	O
7	protein	O
8	of	O
9	29	O
10	,	O
11	705	O
12	Da	O
13	with	O
14	six	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	regions	O
20	.	O

1	The	O
2	experimental	O
3	design	O
4	incorporated	O
5	a	O
6	multiple	O
7	regression	O
8	model	O
9	,	O
10	sequential	O
11	treatments	O
12	and	O
13	a	O
14	proportional	O
15	end	O
16	point	O
17	(	O
18	95	O
19	%)	O
20	for	O
21	protection	O
22	time	O
23	.	O

1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	"	O
25	readthrough	O
26	"	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O

1	Cyclin	B
2	G2	O
3	is	O
4	highly	O
5	expressed	O
6	in	O
7	the	O
8	immune	O
9	system	O
10	where	O
11	immunologic	O
12	tolerance	O
13	subjects	O
14	self	O
15	-	O
16	reactive	O
17	lymphocytes	O
18	to	O
19	negative	O
20	selection	O
21	and	O
22	clonal	O
23	deletion	O
24	via	O
25	apoptosis	O
26	.	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	O
14	eIF	B
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	accuracy	O
7	of	O
8	working	O
9	casts	O
10	for	O
11	crown	O
12	and	O
13	bridge	O
14	restorations	O
15	made	O
16	from	O
17	twin	O
18	mix	O
19	putty	O
20	/	O
21	wash	O
22	silicone	O
23	elastomeric	O
24	impression	O
25	materials	O
26	using	O
27	different	O
28	types	O
29	of	O
30	stock	O
31	tray	O
32	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	indoramin	O
6	may	O
7	have	O
8	Class	O
9	III	O
10	antiarrhythmic	O
11	activity	O
12	.	O

1	The	O
2	results	O
3	suggest	O
4	followings	O
5	--	O
6	1	O
7	)	O
8	both	O
9	eosinophils	O
10	and	O
11	neutrophils	O
12	participate	O
13	in	O
14	hypersecretion	O
15	of	O
16	type	O
17	Ib	O
18	in	O
19	atopic	O
20	cases	O
21	,	O
22	and	O
23	only	O
24	eosinophils	O
25	in	O
26	non	O
27	-	O
28	atopic	O
29	cases	O
30	.	O

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	O
10	regardless	O
11	the	O
12	number	O
13	of	O
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	O
26	to	O
27	the	O
28	percentage	O
29	of	O
30	male	O
31	blood	O
32	donors	O
33	.	O

1	Polypyrimidine	B
2	and	O
3	ssDNA	O
4	binding	O
5	by	O
6	the	O
7	isolated	O
8	VH	B
9	domain	I
10	of	O
11	immunization	O
12	-	O
13	induced	O
14	anti	B
15	-	I
16	Z	I
17	-	I
18	DNA	I
19	Ab	I
20	resembles	O
21	the	O
22	activity	O
23	of	O
24	natural	O
25	autoantibodies	O
26	and	O
27	suggests	O
28	that	O
29	VH	B
30	-	I
31	dependent	I
32	binding	I
33	to	O
34	a	O
35	ligand	O
36	mimicked	O
37	by	O
38	polypyrimidines	O
39	may	O
40	play	O
41	a	O
42	role	O
43	in	O
44	B	O
45	cell	O
46	selection	O
47	before	O
48	immunization	O
49	with	O
50	Z	B
51	-	I
52	DNA	O
53	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	yeast	O
8	and	O
9	mammalian	O
10	mitochondrial	O
11	targeting	O
12	sequences	O
13	are	O
14	similar	O
15	but	O
16	less	O
17	related	O
18	than	O
19	the	O
20	mature	O
21	polypeptides	O
22	.	O

1	Serum	B
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	TBOH	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	140	O
37	in	O
38	finishing	O
39	heifers	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	MGA	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	heifer	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	Revalor	B
63	-	I
64	H	I
65	(	O
66	140	O
67	mg	O
68	TBA	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	Revalor	B
77	-	I
78	H	I
79	+	I
80	MGA	O
81	;	O
82	5	O
83	)	O
84	Finaplix	B
85	-	I
86	H	I
87	(	O
88	200	O
89	mg	O
90	TBA	O
91	);	O
92	and	O
93	6	O
94	)	O
95	Finaplix	B
96	-	I
97	H	I
98	+	I
99	MGA	O
100	.	O

1	Five	O
2	patients	O
3	developed	O
4	metastatic	O
5	spread	O
6	,	O
7	and	O
8	all	O
9	of	O
10	them	O
11	died	O
12	of	O
13	tumor	O
14	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	With	O
2	a	O
3	BMI	O
4	cutoff	O
5	of	O
6	27	O
7	,	O
8	mean	O
9	cardiac	O
10	NE	O
11	spillover	O
12	was	O
13	46	O
14	%	O
15	lower	O
16	in	O
17	the	O
18	obese	O
19	subjects	O
20	when	O
21	compared	O
22	with	O
23	the	O
24	lean	O
25	subjects	O
26	(	O
27	P	O
28	=.	O
29	017	O
30	).	O

1	Our	O
2	studies	O
3	extend	O
4	these	O
5	findings	O
6	and	O
7	show	O
8	that	O
9	the	O
10	E2	B
11	transactivation	I
12	gene	I
13	is	O
14	expressed	O
15	from	O
16	multiple	O
17	promoters	O
18	.	O

1	Pharmacoeconomic	B
2	assessment	O
3	of	O
4	HMG	B
5	-	I
6	CoA	I
7	reductase	I
8	inhibitor	I
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O

1	Response	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	heavily	O
21	pretreated	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Several	O
2	features	O
3	of	O
4	10	O
5	.	O
6	24	O
7	.	O
8	6	O
9	cells	O
10	suggest	O
11	that	O
12	the	O
13	mutation	O
14	disrupts	O
15	normal	O
16	intracellular	O
17	formation	O
18	of	O
19	peptide	O
20	/	O
21	DR	O
22	complexes	O
23	.	O

1	This	O
2	relatively	O
3	simple	O
4	and	O
5	easily	O
6	performed	O
7	technique	O
8	of	O
9	measuring	O
10	deep	O
11	muscle	O
12	temperature	O
13	appears	O
14	to	O
15	be	O
16	a	O
17	useful	O
18	adjunct	O
19	in	O
20	choosing	O
21	the	O
22	amputation	O
23	level	O
24	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	Re	B
2	-	I
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	specimen	O
8	from	O
9	the	O
10	right	O
11	hip	O
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	O
18	initial	O
19	operation	O
20	showed	O
21	areas	O
22	of	O
23	chondrosarcoma	O
24	arising	O
25	in	O
26	the	O
27	background	O
28	of	O
29	synovial	O
30	chondromatosis	O
31	.	O

1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O

1	The	O
2	full	B
3	-	I
4	length	I
5	N	I
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	O
24	-	O
25	8	O
26	.	O

1	The	O
2	two	O
3	methods	O
4	identify	O
5	the	O
6	same	O
7	patients	O
8	only	O
9	if	O
10	micturitional	O
11	pressures	O
12	are	O
13	normal	O
14	(	O
15	40	O
16	to	O
17	60	O
18	cmH2O	O
19	)	O
20	to	O
21	high	O
22	(	O
23	over	O
24	60	O
25	cmH2O	O
26	)	O
27	and	O
28	the	O
29	Sussett	O
30	formula	O
31	is	O
32	used	O
33	with	O
34	a	O
35	higher	O
36	(	O
37	95th	O
38	centile	O
39	)	O
40	cutoff	O
41	.	O

1	The	O
2	region	O
3	between	O
4	DXS52	O
5	and	O
6	Factor	B
7	VIII	I
8	gene	I
9	in	O
10	the	O
11	human	O
12	Xq28	O
13	chromosomal	O
14	band	O
15	contains	O
16	a	O
17	G	B
18	+	I
19	C	I
20	-	I
21	rich	O
22	isochore	O
23	to	O
24	which	O
25	many	O
26	genes	O
27	have	O
28	been	O
29	mapped	O
30	.	O

1	Eight	O
2	patients	O
3	with	O
4	ARC	O
5	and	O
6	renal	O
7	failure	O
8	were	O
9	recently	O
10	evaluated	O
11	.	O

1	Expression	O
2	of	O
3	various	O
4	FAK	B
5	mutants	I
6	in	O
7	the	O
8	FAK	B
9	-	I
10	cells	O
11	showed	O
12	that	O
13	FAK	B
14	kinase	I
15	activity	O
16	,	O
17	the	O
18	Tyr	O
19	-	O
20	397	B
21	/	I
22	SH2	I
23	domain	I
24	binding	I
25	site	I
26	,	O
27	and	O
28	the	O
29	first	O
30	proline	O
31	-	O
32	rich	O
33	SH3	B
34	binding	I
35	region	I
36	in	O
37	the	O
38	FAK	B
39	C	I
40	-	I
41	terminal	I
42	domain	I
43	were	O
44	individually	O
45	needed	O
46	to	O
47	promote	O
48	full	O
49	FAK	B
50	-	I
51	mediated	O
52	FAK	B
53	-	I
54	cell	O
55	migration	O
56	to	O
57	FN	B
58	whereas	O
59	direct	O
60	paxillin	B
61	binding	I
62	to	O
63	FAK	B
64	was	O
65	not	O
66	required	O
67	.	O

1	The	O
2	present	O
3	studies	O
4	compare	O
5	the	O
6	biochemical	O
7	characteristics	O
8	,	O
9	Kanagawa	O
10	hemolysin	O
11	reactions	O
12	,	O
13	and	O
14	plasmid	O
15	profiles	O
16	of	O
17	13	O
18	patient	O
19	and	O
20	221	O
21	environmental	O
22	isolates	O
23	of	O
24	the	O
25	organism	O
26	.	O

1	In	O
2	19	O
3	patients	O
4	vagotomy	O
5	not	O
6	only	O
7	curbed	O
8	the	O
9	bleeding	O
10	but	O
11	provided	O
12	definitive	O
13	therapy	O
14	(	O
15	Visick	B
16	I	I
17	-	I
18	II	I
19	);	O
20	4	O
21	patients	O
22	died	O
23	(	O
24	mortality	O
25	rate	O
26	16	O
27	%).	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	O
12	-	O
13	bp	O
14	BAL	O
15	cDNA	O
16	structure	O
17	.	O

1	In	O
2	1993	O
3	and	O
4	1994	O
5	and	O
6	infection	O
7	with	O
8	body	O
9	lice	O
10	was	O
11	registered	O
12	41	O
13	times	O
14	in	O
15	31	O
16	patients	O
17	at	O
18	the	O
19	clinic	O
20	for	O
21	homeless	O
22	of	O
23	the	O
24	Community	O
25	Health	O
26	Service	O
27	of	O
28	Utrecht	O
29	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	PKC	B
7	alpha	I
8	(	O
9	calcium	O
10	dependent	O
11	)	O
12	and	O
13	PKC	B
14	delta	I
15	(	O
16	calcium	O
17	independent	O
18	)	O
19	may	O
20	mediate	O
21	the	O
22	transcription	O
23	of	O
24	TPA	O
25	-	O
26	inducible	O
27	genes	O
28	through	O
29	both	O
30	AP	B
31	-	I
32	1	I
33	and	O
34	non	O
35	-	O
36	AP	B
37	-	I
38	1	I
39	sequences	I
40	.	O

1	Investigation	B
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	O
10	human	O
11	Igs	O
12	and	O
13	gp120	B
14	shows	O
15	that	O
16	the	O
17	viral	O
18	gp120	B
19	SAg	O
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	O
27	human	B
28	V	I
29	(	I
30	H	I
31	)	I
32	3	I
33	+	I
34	Igs	O
35	.	O

1	Evaluation	O
2	of	O
3	1	O
4	,	O
5	10	O
6	-	O
7	phenanthroline	O
8	as	O
9	a	O
10	reagent	O
11	for	O
12	sialic	O
13	acid	O
14	determinations	O
15	.	O

1	L	B
2	-	I
3	735	O
4	,	O
5	524	O
6	free	O
7	base	O
8	or	O
9	sulfate	O
10	salt	O
11	was	O
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	O
19	in	O
20	solid	O
21	dosage	O
22	forms	O
23	to	O
24	fasted	O
25	or	O
26	fed	O
27	Beagle	O
28	dogs	O
29	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	-	I
6	encoded	I
7	latent	I
8	membrane	I
9	protein	I
10	1	I
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	extreme	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	TRADD	B
25	and	O
26	TRAF2	B
27	.	O

1	Electrocardiograms	B
2	of	O
3	the	O
4	month	O
5	.	O

1	Codon	B
2	usage	O
3	in	O
4	C	O
5	.	O
6	reinhardtii	O
7	mitochondria	O
8	is	O
9	highly	O
10	biased	O
11	,	O
12	with	O
13	eight	O
14	codons	O
15	entirely	O
16	absent	O
17	from	O
18	all	O
19	protein	B
20	-	I
21	coding	I
22	genes	I
23	;	O
24	however	O
25	,	O
26	even	O
27	though	O
28	codon	O
29	usage	O
30	is	O
31	restricted	O
32	,	O
33	it	O
34	appears	O
35	that	O
36	C	O
37	.	O
38	reinhardtii	O
39	mtDNA	O
40	cannot	O
41	encode	O
42	the	O
43	minimum	O
44	number	O
45	of	O
46	tRNAs	O
47	needed	O
48	to	O
49	support	O
50	mitochondrial	O
51	protein	O
52	synthesis	O
53	.	O

1	CD4	B
2	lymphocyte	I
3	and	O
4	viral	O
5	load	O
6	levels	O
7	suggested	O
8	an	O
9	optimal	O
10	response	O
11	to	O
12	ARV	O
13	therapy	O
14	at	O
15	the	O
16	time	O
17	LD	O
18	developed	O
19	.	O

1	Among	O
2	these	O
3	360	O
4	ZFPs	O
5	,	O
6	a	O
7	novel	O
8	ZFP	B
9	cDNA	I
10	named	O
11	HFHZ	O
12	(	O
13	human	O
14	fetal	O
15	heart	O
16	ZFP	B
17	)	O
18	with	O
19	sequence	O
20	homology	O
21	to	O
22	a	O
23	Kruppel	B
24	-	I
25	associated	I
26	box	I
27	(	O
28	KRAB	B
29	)	O
30	was	O
31	identified	O
32	.	O

1	Enhancement	B
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O

1	It	O
2	bound	O
3	to	O
4	vitamin	B
5	D	I
6	receptor	I
7	(	O
8	VDR	B
9	)	O
10	but	O
11	not	O
12	retinoic	B
13	acid	I
14	Xalpha	I
15	receptor	I
16	(	O
17	RXRalpha	O
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	Each	O
2	immunoprecipitate	O
3	contained	O
4	a	O
5	complex	O
6	of	O
7	N1	O
8	(	O
9	deltaEC	O
10	)	O
11	and	O
12	CBF1	B
13	.	O

1	Antidepressant	B
2	-	I
3	like	I
4	properties	O
5	of	O
6	some	O
7	serotonin	B
8	receptor	I
9	ligands	O
10	and	O
11	calcium	O
12	channel	O
13	antagonists	O
14	measured	O
15	with	O
16	the	O
17	forced	O
18	swimming	O
19	test	O
20	in	O
21	mice	O
22	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	B
21	progesterone	I
22	receptor	I
23	(	O
24	hPR	O
25	).	O

1	The	O
2	dnaQ	O
3	-	O
4	lacZ	B
5	and	O
6	the	O
7	rnh	O
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O

1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	B
20	factor	I
21	binding	I
22	sites	I
23	.	O

1	Glucocorticoid	B
2	induced	O
3	hypertension	O
4	has	O
5	been	O
6	regarded	O
7	as	O
8	independent	O
9	of	O
10	sodium	O
11	(	O
12	Na	O
13	),	O
14	in	O
15	contrast	O
16	to	O
17	mineralocorticoid	O
18	induced	O
19	hypertension	O
20	,	O
21	which	O
22	is	O
23	Na	O
24	+-	O
25	dependent	O
26	.	O

1	The	O
2	role	O
3	of	O
4	DNA	O
5	rearrangement	O
6	and	O
7	alternative	O
8	RNA	O
9	processing	O
10	in	O
11	the	O
12	expression	O
13	of	O
14	immunoglobulin	B
15	delta	I
16	genes	I
17	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	size	O
6	,	O
7	the	O
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	B
22	finger	I
23	protein	I
24	,	O
25	Adx	B
26	factor	I
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	B
33	-	I
34	like	I
35	zinc	I
36	finger	I
37	protein	I
38	(	O
39	a	O
40	mouse	B
41	ZBP	I
42	-	I
43	89	I
44	homologue	I
45	).	O

1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	B
12	gene	I
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	Leads	B
2	from	O
3	the	O
4	MMWR	O
5	.	O

1	Specific	O
2	hyperimmune	B
3	globulins	I
4	to	O
5	pathogens	O
6	such	O
7	as	O
8	Haemophilus	O
9	influenzae	O
10	and	O
11	Streptococcus	O
12	pneumoniae	O
13	have	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	A	I
2	high	O
3	-	O
4	resolution	O
5	restriction	O
6	map	O
7	of	O
8	over	O
9	200	O
10	kb	O
11	of	O
12	contiguous	O
13	DNA	O
14	containing	O
15	N	B
16	-	I
17	myc	I
18	has	O
19	been	O
20	generated	O
21	by	O
22	subcloning	O
23	YACs	O
24	into	O
25	cosmids	O
26	.	O

1	Administration	O
2	of	O
3	growth	O
4	hormone	O
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O

1	Measurement	O
2	of	O
3	anti	B
4	-	I
5	HCV	I
6	IgM	I
7	antibodies	I
8	with	O
9	an	O
10	experimental	O
11	kit	O

1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	B
5	-	I
6	1	I
7	variant	I
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	O
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	B
26	-	I
27	1	I
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	B
36	-	I
37	selectin	I
38	.	O

1	A	I
2	chicken	I
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	O
21	paxil	O
22	-	O
23	lin	O
24	.	O

1	A	I
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	We	O
2	found	O
3	that	O
4	120	O
5	bp	O
6	of	O
7	the	O
8	enhancer	O
9	'	O
10	s	O
11	transcriptional	O
12	core	O
13	becomes	O
14	DNase	B
15	I	I
16	hypersensitive	I
17	early	I
18	in	O
19	B	O
20	-	O
21	cell	O
22	development	O
23	.	O

1	Altogether	O
2	,	O
3	our	O
4	results	O
5	indicate	O
6	that	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	Cut	O
12	proteins	O
13	is	O
14	modulated	O
15	by	O
16	PKC	B
17	.	O

1	The	O
2	R	O
3	.	O
4	meliloti	O
5	nifH	O
6	promoter	O
7	but	O
8	not	O
9	the	O
10	K	O
11	.	O
12	pneumoniae	O
13	nifH	O
14	promoter	O
15	showed	O
16	sigma	B
17	54	I
18	-	I
19	dependent	I
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	In	O
2	64	O
3	%	O
4	a	O
5	small	O
6	cardiac	O
7	vein	O
8	does	O
9	not	O
10	exist	O
11	,	O
12	but	O
13	its	O
14	origin	O
15	,	O
16	the	O
17	right	O
18	marginal	O
19	vein	O
20	,	O
21	joins	O
22	the	O
23	system	O
24	of	O
25	anterior	O
26	cardiac	O
27	veins	O
28	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	B
9	-	I
10	ended	I
11	double	I
12	-	I
13	stranded	I
14	DNA	I
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	amphibian	O
6	insulin	B
7	receptor	I
8	substrate	I
9	1	I
10	-	I
11	like	I
12	cDNA	I
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	B
17	3	I
18	-	I
19	kinase	I
20	in	O
21	insulin	B
22	-	I
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O

1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	B
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	O
18	--	O
19	phenylalanine	B
20	-	I
21	8	I
22	-	I
23	lysine	I
24	vasopressin	I
25	(	O
26	Octapressin	O
27	).	O

1	Nonreplicating	B
2	vaccinia	I
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	B
7	genes	I
8	.	O

1	The	O
2	variable	O
3	regions	O
4	of	O
5	vertebrate	O
6	striated	O
7	TnT	O
8	isoforms	O
9	reflect	O
10	the	O
11	subsequent	O
12	addition	O
13	and	O
14	modification	O
15	of	O
16	genomic	O
17	sequences	O
18	to	O
19	give	O
20	rise	O
21	to	O
22	members	O
23	of	O
24	the	O
25	TnT	O
26	multigene	B
27	family	I
28	.	O

1	Ketanserin	B
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	segments	O
6	of	O
7	C3	B
8	represented	O
9	by	O
10	amino	O
11	acid	O
12	residues	O
13	1082	O
14	-	O
15	1118	O
16	,	O
17	1117	O
18	-	O
19	1155	O
20	,	O
21	1234	O
22	-	O
23	1294	O
24	and	O
25	1312	O
26	-	O
27	1404	O
28	accommodate	O
29	C3	B
30	(	I
31	D	I
32	)	I
33	epitopes	I
34	that	O
35	are	O
36	expressed	O
37	by	O
38	erythrocyte	O
39	-	O
40	bound	O
41	C3	B
42	fragments	I
43	,	O
44	but	O
45	not	O
46	by	O
47	the	O
48	corresponding	O
49	fluid	O
50	-	O
51	phase	O
52	fragment	O
53	,	O
54	whereas	O
55	the	O
56	segments	O
57	spanning	O
58	residues	O
59	973	O
60	-	O
61	1026	O
62	and	O
63	1477	O
64	-	O
65	1510	O
66	contain	O
67	C3	B
68	(	I
69	D	I
70	)	I
71	epitopes	I
72	that	O
73	are	O
74	exposed	O
75	exclusively	O
76	in	O
77	denatured	O
78	C3	B
79	and	O
80	therefore	O
81	hidden	O
82	in	O
83	physiological	O
84	fragments	O
85	of	O
86	the	O
87	protein	O
88	.	O

1	The	O
2	influence	O
3	of	O
4	p53	B
5	on	O
6	cytokine	O
7	-	O
8	triggered	O
9	Janus	B
10	kinase	I
11	-	O
12	STAT	B
13	signaling	O
14	was	O
15	investigated	O
16	in	O
17	human	O
18	hepatoma	O
19	Hep3B	O
20	cell	O
21	lines	O
22	engineered	O
23	to	O
24	constitutively	O
25	express	O
26	the	O
27	temperature	O
28	-	O
29	sensitive	O
30	Val135	O
31	mutant	O
32	of	O
33	p53	B
34	.	O

1	A	I
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O

1	The	O
2	myeloproliferative	O
3	sarcoma	O
4	virus	O
5	(	O
6	MPSV	O
7	)	O
8	was	O
9	derived	O
10	by	O
11	passage	O
12	of	O
13	Moloney	O
14	sarcoma	O
15	virus	O
16	(	O
17	Mo	O
18	-	O
19	MuSV	O
20	)	O
21	in	O
22	adult	O
23	mice	O
24	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	O
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	O
33	domains	O
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	A	I
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	O
13	mRNA	O
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	Histological	O
2	examination	O
3	revealed	O
4	a	O
5	small	O
6	simple	O
7	renal	O
8	cyst	O
9	associated	O
10	with	O
11	renal	O
12	cell	O
13	carcinoma	O
14	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	Vesicles	B
2	could	O
3	be	O
4	induced	O
5	only	O
6	with	O
7	multiple	O
8	exposures	O
9	to	O
10	UVA	O
11	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	in	O
7	contrast	O
8	to	O
9	other	O
10	extracellular	O
11	matrix	O
12	molecules	O
13	pepsin	B
14	-	I
15	solubilized	I
16	collagen	I
17	VI	I
18	(	O
19	CVI	O
20	)	O
21	can	O
22	stimulate	O
23	DNA	O
24	synthesis	O
25	of	O
26	various	O
27	mesenchymal	O
28	cell	O
29	types	O
30	,	O
31	apparently	O
32	independent	O
33	of	O
34	integrin	B
35	-	I
36	mediated	O
37	signal	O
38	transduction	O
39	.	O

1	Despite	O
2	continuous	O
3	compliance	O
4	,	O
5	unexplained	O
6	resurgence	O
7	of	O
8	serum	O
9	ferritin	B
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	veteran	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O

1	Human	B
2	ZFM1	I
3	protein	I
4	is	O
5	a	O
6	transcriptional	O
7	repressor	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	transcription	O
13	activation	O
14	domain	O
15	of	O
16	stage	O
17	-	O
18	specific	O
19	activator	O
20	protein	O
21	.	O

1	According	O
2	to	O
3	the	O
4	results	O
5	of	O
6	assays	O
7	obtained	O
8	with	O
9	the	O
10	use	O
11	of	O
12	assay	O
13	systems	O
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	O
18	HCV	O
19	EIA	O
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	B
28	-	I
29	HCV	I
30	-	I
31	C100	I
32	-	I
33	3	I
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	B
53	carriers	O
54	(	O
55	1	O
56	.	O
57	8	O
58	%)	O
59	and	O
60	among	O
61	donors	O
62	with	O
63	anti	B
64	-	I
65	HCV	I
66	-	I
67	C100	I
68	-	I
69	3	I
70	in	O
71	the	O
72	blood	O
73	(	O
74	1	O
75	.	O
76	6	O
77	%)	O
78	(	O
79	p	O
80	<	O
81	0	O
82	.	O
83	01	O
84	).	O

1	The	O
2	Caenorhabditis	B
3	elegans	I
4	vitellogenin	I
5	genes	I
6	are	O
7	subject	O
8	to	O
9	sex	O
10	-,	O
11	stage	O
12	-,	O
13	and	O
14	tissue	O
15	-	O
16	specific	O
17	regulation	O
18	:	O
19	they	O
20	are	O
21	expressed	O
22	solely	O
23	in	O
24	the	O
25	adult	O
26	hermaphrodite	O
27	intestine	O
28	.	O

1	2	I
2	-	I
3	AP	I
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	B
19	-	I
20	1	I
21	constructs	I
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	B
28	gene	I
29	encoding	I
30	gamma	I
31	-	I
32	actin	I
33	or	I
34	glucose	I
35	6	I
36	-	I
37	phosphate	I
38	dehydrogenase	I
39	.	O

1	A	I
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	The	O
2	number	O
3	of	O
4	polymerases	O
5	active	O
6	in	O
7	vitro	O
8	at	O
9	the	O
10	E	O
11	strand	O
12	promoter	O
13	was	O
14	similar	O
15	to	O
16	the	O
17	number	O
18	of	O
19	polymerases	O
20	at	O
21	the	O
22	L	O
23	strand	O
24	promoter	O
25	.	O

1	Comparative	O
2	DNA	O
3	sequence	O
4	analysis	O
5	showed	O
6	the	O
7	Genethon	O
8	microsatellite	O
9	D19S596	O
10	lies	O
11	2	O
12	.	O
13	2	O
14	kb	O
15	downstream	O
16	of	O
17	the	O
18	coding	O
19	region	O
20	of	O
21	FUT1	O
22	,	O
23	indicating	O
24	that	O
25	the	O
26	cluster	O
27	comprising	O
28	the	O
29	closely	O
30	linked	O
31	FUT1	O
32	and	O
33	FUT2	O
34	genes	O
35	is	O
36	located	O
37	4	O
38	cM	O
39	distal	O
40	to	O
41	D19S412	O
42	(	O
43	lod	O
44	score	O
45	13	O
46	.	O
47	7	O
48	)	O
49	and	O
50	9	O
51	cM	O
52	proximal	O
53	to	O
54	D19S571	O
55	(	O
56	lod	O
57	score	O
58	11	O
59	.	O
60	7	O
61	).	O

1	To	O
2	derive	O
3	quantitative	O
4	concentration	O
5	changes	O
6	from	O
7	measurements	O
8	of	O
9	light	O
10	attenuation	O
11	,	O
12	the	O
13	optical	O
14	path	O
15	length	O
16	must	O
17	be	O
18	known	O
19	.	O

1	Mean	O
2	ROI	B
3	-	I
4	A	I
5	/	I
6	B	I
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O

1	This	O
2	protein	B
3	-	I
4	protein	I
5	interaction	O
6	does	O
7	not	O
8	require	O
9	the	O
10	simultaneous	O
11	binding	O
12	of	O
13	Oct	B
14	proteins	I
15	to	O
16	DNA	O
17	,	O
18	and	O
19	high	O
20	resolution	O
21	footprinting	O
22	of	O
23	the	O
24	Oct	B
25	-	I
26	DNA	O
27	interaction	O
28	reveals	O
29	that	O
30	binding	O
31	of	O
32	BOB	O
33	.	O
34	1	O
35	/	O
36	OBF	O
37	.	O
38	1	O
39	to	O
40	Oct1	O
41	or	O
42	Oct2	O
43	does	O
44	not	O
45	alter	O
46	the	O
47	interaction	O
48	with	O
49	DNA	O
50	.	O

1	ORFA	B
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Thus	O
2	,	O
3	in	O
4	stress	O
5	-	O
6	induced	O
7	arrhythmic	O
8	disease	O
9	as	O
10	well	O
11	as	O
12	in	O
13	ischemic	O
14	heart	O
15	disease	O
16	,	O
17	the	O
18	main	O
19	pathogenetic	O
20	links	O
21	are	O
22	outside	O
23	the	O
24	heart	O
25	,	O
26	but	O
27	they	O
28	differ	O
29	from	O
30	those	O
31	observed	O
32	in	O
33	ischemia	O
34	.	O

1	Moritta	B
2	)	O
3	and	O
4	contains	O
5	Bis	O
6	-	O
7	GMA	O
8	.	O

1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	I
27	c	I
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	O
13	mutations	O
14	in	O
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	B
20	activation	I
21	domain	I
22	.	O

1	Differential	O
2	expression	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blot	O
8	analysis	O
9	employing	O
10	multiple	O
11	normal	O
12	and	O
13	tumor	O
14	cell	O
15	lines	O
16	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	B
13	-	I
14	2	I
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Exons	B
2	III	I
3	to	O
4	VIII	O
5	,	O
6	which	O
7	cover	O
8	the	O
9	coding	O
10	region	O
11	and	O
12	the	O
13	3	O
14	'	O
15	untranslated	O
16	region	O
17	,	O
18	are	O
19	almost	O
20	identical	O
21	in	O
22	all	O
23	types	O
24	of	O
25	PST	O
26	or	O
27	AST	O
28	cDNAs	O
29	.	O

1	Conversely	O
2	,	O
3	activated	O
4	glucocorticoid	B
5	receptors	I
6	suppressed	O
7	the	O
8	transactivation	O
9	function	O
10	of	O
11	p53	B
12	,	O
13	while	O
14	transrepression	O
15	by	O
16	p53	B
17	was	O
18	largely	O
19	unaffected	O
20	.	O

1	In	O
2	the	O
3	second	O
4	case	O
5	,	O
6	an	O
7	epidermal	B
8	cyst	O
9	was	O
10	diagnosed	O
11	.	O

1	Notably	B
2	,	O
3	these	O
4	residues	O
5	are	O
6	located	O
7	in	O
8	different	O
9	domains	O
10	.	O

1	A	I
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	O
18	H	O
19	,	O
20	K	B
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	organization	O
7	of	O
8	functional	O
9	units	O
10	of	O
11	the	O
12	72	O
13	-	O
14	bp	O
15	repeat	O
16	required	O
17	for	O
18	transcriptional	O
19	enhancement	O
20	of	O
21	the	O
22	early	O
23	promoter	O
24	is	O
25	different	O
26	from	O
27	that	O
28	required	O
29	for	O
30	late	O
31	promoter	O
32	function	O
33	.	O

1	CONCLUSIONS	O
2	:	O
3	XCoe2	O
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	B
24	-	I
25	Notch	I
26	signalling	O
27	,	O
28	XCoe2	O
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	O
41	-	O
42	ngnr	B
43	-	I
44	1	I
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	O
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O

1	Clinicopathologic	B
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O

1	Vacuolar	B
2	membrane	I
3	vesicles	O
4	from	O
5	hum1	O
6	mutants	O
7	lack	O
8	all	O
9	Ca2	O
10	+/	O
11	H	O
12	+	O
13	antiport	O
14	activity	O
15	,	O
16	demonstrating	O
17	that	O
18	Hum1p	O
19	catalyzes	O
20	the	O
21	exchange	O
22	of	O
23	Ca2	O
24	+	O
25	for	O
26	H	O
27	+	O
28	across	O
29	the	O
30	yeast	O
31	vacuolar	O
32	membrane	O
33	.	O

1	This	O
2	study	O
3	indicated	O
4	that	O
5	the	O
6	Japanese	O
7	quail	O
8	was	O
9	less	O
10	sensitive	O
11	to	O
12	particulate	O
13	Mn3O4	O
14	exposure	O
15	than	O
16	rodents	O
17	treated	O
18	comparably	O
19	.	O

1	Three	O
2	high	B
3	mobility	I
4	group	I
5	-	I
6	like	I
7	sequences	I
8	within	O
9	a	O
10	48	O
11	-	O
12	base	O
13	pair	O
14	enhancer	O
15	of	O
16	the	O
17	Col2a1	B
18	gene	I
19	are	O
20	required	O
21	for	O
22	cartilage	O
23	-	O
24	specific	O
25	expression	O
26	in	O
27	vivo	O
28	.	O

1	The	O
2	appearance	O
3	of	O
4	dyskinetic	O
5	movement	O
6	disorders	O
7	in	O
8	humans	O
9	following	O
10	the	O
11	chronic	O
12	use	O
13	of	O
14	levodopa	O
15	or	O
16	amphetamine	O
17	may	O
18	be	O
19	a	O
20	manifestation	O
21	of	O
22	similarly	O
23	increased	O
24	dopamine	B
25	receptor	I
26	site	I
27	sensitivity	O
28	within	O
29	the	O
30	striatum	O
31	.	O

1	The	O
2	84	O
3	.	O
4	1C	B
5	mAb	I
6	recognizes	O
7	a	O
8	site	O
9	on	O
10	IgE	B
11	which	O
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	B
20	epsilon	I
21	R	I
22	binding	I
23	site	I
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	B
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	B
44	epsilon	I
45	R	I
46	binding	I
47	site	I
48	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	O
12	avian	O
13	integrins	O
14	was	O
15	obtained	O
16	.	O

1	This	O
2	protein	O
3	encoded	O
4	by	O
5	this	O
6	cDNA	O
7	,	O
8	which	O
9	we	O
10	have	O
11	termed	O
12	p150TSP	O
13	(	O
14	for	O
15	TPR	O
16	-	O
17	containing	O
18	,	O
19	SH2	B
20	-	I
21	binding	I
22	phosphoprotein	I
23	),	O
24	is	O
25	located	O
26	predominantly	O
27	in	O
28	the	O
29	nucleus	O
30	and	O
31	is	O
32	highly	O
33	conserved	O
34	in	O
35	evolution	O
36	.	O

1	Methyl	B
2	mercury	O
3	intoxication	O
4	in	O
5	rat	O
6	kidneys	O
7	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O

1	In	O
2	the	O
3	ISO	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	DEX	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	166	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	hypercapnia	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	).(	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O

1	GHB	B
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O

1	Intravenous	O
2	glucose	O
3	tolerance	O
4	tests	O
5	were	O
6	performed	O
7	before	O
8	operation	O
9	,	O
10	before	O
11	starting	O
12	CyA	O
13	and	O
14	after	O
15	3	O
16	weeks	O
17	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	technique	O
6	of	O
7	low	O
8	-	O
9	frequency	O
10	kindling	O
11	is	O
12	a	O
13	useful	O
14	experimental	O
15	model	O
16	in	O
17	assessing	O
18	the	O
19	effects	O
20	of	O
21	antipsychotic	O
22	or	O
23	antiepileptic	O
24	drugs	O
25	on	O
26	the	O
27	excitability	O
28	of	O
29	the	O
30	limbic	O
31	regions	O
32	.	O

1	The	O
2	cglIM	B
3	gene	I
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O

1	The	O
2	coordinated	O
3	expression	O
4	of	O
5	CD4	B
6	and	O
7	CD8	B
8	during	O
9	T	O
10	-	O
11	cell	O
12	development	O
13	is	O
14	tightly	O
15	coupled	O
16	with	O
17	the	O
18	maturation	O
19	state	O
20	of	O
21	the	O
22	T	O
23	cell	O
24	.	O

1	The	O
2	responsive	O
3	region	O
4	of	O
5	the	O
6	alpha	B
7	2	I
8	(	I
9	V	I
10	)	I
11	collagen	I
12	gene	I
13	was	O
14	localized	O
15	to	O
16	a	O
17	fragment	O
18	including	O
19	100	O
20	bp	O
21	of	O
22	basal	O
23	promoter	O
24	and	O
25	150	O
26	bp	O
27	of	O
28	exon	O
29	1	O
30	sequences	O
31	,	O
32	which	O
33	contained	O
34	two	O
35	CRE	O
36	-	O
37	like	O
38	elements	O
39	.	O

1	Among	O
2	the	O
3	v	B
4	-	I
5	myc	I
6	codons	O
7	,	O
8	the	O
9	first	O
10	5	O
11	are	O
12	derived	O
13	from	O
14	the	O
15	noncoding	O
16	5	O
17	'	O
18	terminus	O
19	of	O
20	the	O
21	second	O
22	c	B
23	-	I
24	myc	I
25	exon	O
26	,	O
27	and	O
28	412	O
29	codons	O
30	correspond	O
31	to	O
32	the	O
33	c	B
34	-	I
35	myc	I
36	coding	O
37	region	O
38	.	O

1	A	I
2	human	I
3	Raf	I
4	-	I
5	responsive	I
6	zinc	I
7	-	I
8	finger	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	divergent	O
14	sequences	O
15	.	O

1	Besides	B
2	,	O
3	it	O
4	was	O
5	considered	O
6	that	O
7	the	O
8	NPF	O
9	was	O
10	a	O
11	useful	O
12	tool	O
13	for	O
14	activation	O
15	of	O
16	velopharyngeal	O
17	activity	O
18	by	O
19	way	O
20	of	O
21	visual	O
22	feed	O
23	-	O
24	back	O
25	control	O
26	.	O

1	Thirty	O
2	-	O
3	one	O
4	age	O
5	-	O
6	matched	O
7	,	O
8	conscious	O
9	,	O
10	virgin	O
11	,	O
12	male	O
13	Sprague	O
14	-	O
15	Dawley	O
16	rats	O
17	and	O
18	spontaneously	O
19	hypertensive	O
20	rats	O
21	(	O
22	SHRs	O
23	)	O
24	were	O
25	individually	O
26	injected	O
27	with	O
28	a	O
29	single	O
30	subcutaneous	O
31	dose	O
32	of	O
33	85	O
34	mg	O
35	/	O
36	kg	O
37	dl	O
38	-	O
39	isoproterenol	O
40	to	O
41	determine	O
42	the	O
43	degree	O
44	and	O
45	time	O
46	course	O
47	of	O
48	drug	O
49	-	O
50	induced	O
51	cardiac	O
52	failure	O
53	and	O
54	functional	O
55	recovery	O
56	.	O

1	An	O
2	8	O
3	-	O
4	bp	O
5	sequence	O
6	(	O
7	ATTTCAAA	O
8	)	O
9	within	O
10	the	O
11	protected	O
12	region	O
13	shares	O
14	significant	O
15	homology	O
16	with	O
17	promoter	O
18	sequences	O
19	required	O
20	for	O
21	ethylene	O
22	responsiveness	O
23	from	O
24	the	O
25	tomato	O
26	fruit	B
27	-	I
28	ripening	I
29	E4	I
30	gene	I
31	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	B
13	.	O
14	1	O
15	and	O
16	PU	B
17	.	O
18	1	O
19	interaction	O
20	partner	O
21	(	O
22	PIP	O
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	O
38	'-	O
39	enhancer	O
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	Tumour	B
2	necrosis	I
3	factor	I
4	and	O
5	adult	O
6	respiratory	O
7	distress	O
8	syndrome	O
9	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	B
61	-	I
62	2	I
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	Either	B
2	a	O
3	UV	O
4	detector	O
5	set	O
6	at	O
7	268	O
8	nm	O
9	or	O
10	an	O
11	electrochemical	O
12	(	O
13	EC	B
14	)	O
15	detector	O
16	set	O
17	at	O
18	a	O
19	potential	O
20	of	O
21	+	O
22	0	O
23	.	O
24	9	O
25	V	O
26	(	O
27	versus	O
28	Ag	O
29	/	O
30	AgCl	O
31	/	O
32	3	O
33	M	O
34	NaCl	O
35	)	O
36	was	O
37	used	O
38	to	O
39	monitor	O
40	the	O
41	drug	O
42	.	O

1	Staphylococcal	B
2	enterotoxin	I
3	A	I
4	involvement	O
5	in	O
6	the	O
7	illness	O
8	of	O
9	a	O
10	20	O
11	-	O
12	month	O
13	-	O
14	old	O
15	burn	O
16	patient	O
17	.	O

1	Courses	B
2	were	O
3	repeated	O
4	monthly	O
5	upon	O
6	recovery	O
7	of	O
8	myelosuppression	O
9	.	O

1	Thrombolysis	B
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	155	B
2	aa	O
3	,	O
4	shares	O
5	78	O
6	%	O
7	identity	O
8	with	O
9	the	O
10	analogous	O
11	region	O
12	of	O
13	Xenopus	B
14	laevis	I
15	FGF3	O
16	and	O
17	72	O
18	%	O
19	identity	O
20	with	O
21	the	O
22	product	O
23	of	O
24	the	O
25	more	O
26	distantly	O
27	related	O
28	human	B
29	gene	I
30	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	successfully	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	metronidazole	O
11	(	O
12	a	O
13	tissue	O
14	amoebicide	O
15	)	O
16	and	O
17	diloxanide	O
18	(	O
19	a	O
20	lumenal	O
21	amoebicide	O
22	).	O

1	The	O
2	Trx	O
3	-	O
4	CT	O
5	fusion	O
6	protein	O
7	was	O
8	produced	O
9	less	O
10	efficiently	O
11	(	O
12	20	O
13	%	O
14	of	O
15	total	O
16	soluble	O
17	cellular	O
18	protein	O
19	).	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	zebrafish	O
6	egr1	O
7	coding	O
8	region	O
9	revealed	O
10	a	O
11	high	O
12	level	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	mouse	O
18	,	O
19	rat	O
20	,	O
21	and	O
22	human	B
23	Egr1	I
24	genes	I
25	with	O
26	the	O
27	notable	O
28	exception	O
29	of	O
30	a	O
31	polymorphic	O
32	,	O
33	triplet	O
34	nucleotide	O
35	repeat	O
36	sequence	O
37	in	O
38	the	O
39	region	O
40	coding	O
41	for	O
42	the	O
43	amino	O
44	terminus	O
45	of	O
46	the	O
47	Egr1	B
48	protein	I
49	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	requirements	O
6	of	O
7	the	O
8	CH	B
9	gene	I
10	switch	O
11	by	O
12	characterizing	O
13	two	O
14	rearranged	B
15	gamma	I
16	2b	I
17	genes	I
18	from	O
19	a	O
20	gamma	B
21	2b	I
22	producing	O
23	mouse	O
24	myeloma	O
25	(	O
26	MPC	O
27	-	O
28	11	O
29	).	O

1	Restriction	O
2	enzyme	O
3	and	O
4	heteroduplex	O
5	analyses	O
6	confirmed	O
7	that	O
8	sequences	O
9	unique	O
10	to	O
11	FeSV	B
12	(	I
13	src	I
14	sequences	I
15	)	O
16	are	O
17	located	O
18	at	O
19	the	O
20	center	O
21	of	O
22	the	O
23	FeSV	O
24	genome	O
25	and	O
26	are	O
27	approximately	O
28	1	O
29	.	O
30	5	O
31	kilobase	O
32	pairs	O
33	in	O
34	length	O
35	.	O

1	Studies	O
2	on	O
3	the	O
4	hereditary	O
5	nature	O
6	of	O
7	sole	O
8	prints	O
9	--	O
10	with	O
11	special	O
12	reference	O
13	to	O
14	interdigital	O
15	and	O
16	triradii	O

1	Therefore	O
2	the	O
3	prevalences	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	GDM	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O

1	We	O
2	examined	O
3	the	O
4	binding	O
5	of	O
6	purified	O
7	T3	B
8	receptor	I
9	alpha	I
10	(	O
11	T3R	B
12	alpha	I
13	),	O
14	overexpressed	O
15	in	O
16	Escherichia	O
17	coli	O
18	,	O
19	to	O
20	wild	B
21	-	I
22	type	I
23	and	O
24	up	O
25	and	O
26	down	O
27	mutations	O
28	of	O
29	the	O
30	rGH	O
31	T3RE	O
32	to	O
33	evaluate	O
34	whether	O
35	transcriptional	O
36	potency	O
37	correlates	O
38	with	O
39	changes	O
40	in	O
41	T3R	B
42	binding	I
43	.	O

1	METHODS	O
2	:	O
3	We	O
4	retrospectively	O
5	reviewed	O
6	242	O
7	adult	O
8	cadaveric	O
9	renal	O
10	transplant	O
11	recipients	O
12	treated	O
13	between	O
14	11	O
15	/	O
16	91	O
17	and	O
18	5	O
19	/	O
20	97	O
21	.	O

1	The	O
2	discussion	O
3	focuses	O
4	primarily	O
5	on	O
6	the	O
7	newer	O
8	drugs	O
9	like	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	,	O
15	alpha	B
16	-	I
17	adrenergic	I
18	receptor	I
19	blockers	O
20	,	O
21	and	O
22	calcium	O
23	antagonists	O
24	.	O

1	They	O
2	observed	O
3	depressed	O
4	protein	O
5	C	O
6	activity	O
7	that	O
8	significantly	O
9	(	O
10	p	O
11	<	O
12	0	O
13	.	O
14	005	O
15	)	O
16	increased	O
17	and	O
18	became	O
19	normal	O
20	immediately	O
21	after	O
22	hemodialysis	O
23	while	O
24	factor	B
25	X	I
26	and	I
27	factor	I
28	VII	I
29	increased	O
30	(	O
31	p	O
32	<	O
33	0	O
34	.	O
35	01	O
36	;	O
37	p	O
38	<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	despite	O
44	heparinization	O
45	together	O
46	with	O
47	amount	O
48	of	O
49	serum	B
50	lipoprotein	I
51	(	O
52	a	O
53	).	O

1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O

1	Identification	O
2	and	O
3	estimation	O
4	of	O
5	monosaccharides	O
6	and	O
7	disaccharides	O
8	in	O
9	urine	O
10	by	O
11	gas	O
12	-	O
13	liquid	O
14	chromatography	O
15	.	O

1	To	O
2	understand	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	increased	O
8	cell	O
9	surface	O
10	stability	O
11	compared	O
12	with	O
13	wild	B
14	-	I
15	type	I
16	peptide	I
17	and	O
18	to	O
19	understand	O
20	the	O
21	differences	O
22	in	O
23	T	O
24	cell	O
25	recognition	O
26	between	O
27	I1Y	O
28	and	O
29	I1F	O
30	,	O
31	we	O
32	determined	O
33	the	O
34	x	O
35	-	O
36	ray	O
37	crystal	O
38	structures	O
39	of	O
40	the	O
41	two	O
42	class	B
43	I	I
44	MHC	I
45	-	I
46	peptide	I
47	complexes	I
48	.	O

1	Hypothalamic	B
2	control	O
3	of	O
4	coronary	O
5	circulation	O
6	in	O
7	the	O
8	dog	O
9	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	All	O
2	patients	O
3	had	O
4	the	O
5	CA	B
6	125	I
7	assay	O
8	performed	O
9	within	O
10	one	O
11	week	O
12	before	O
13	their	O
14	second	O
15	-	O
16	look	O
17	operation	O
18	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	insulin	B
6	effect	O
7	to	O
8	increase	O
9	ras	B
10	GTP	I
11	formation	O
12	and	O
13	MAP	B
14	kinase	I
15	activity	O
16	was	O
17	negligible	O
18	in	O
19	A	O
20	/	O
21	K1018	O
22	cells	O
23	but	O
24	normal	O
25	,	O
26	or	O
27	supernormal	O
28	,	O
29	in	O
30	Y	O
31	/	O
32	F2	O
33	cells	O
34	.	O

1	TREB7	B
2	and	O
3	TREB36	O
4	protected	O
5	all	O
6	three	O
7	repeats	O
8	of	O
9	the	O
10	21	O
11	bp	O
12	,	O
13	but	O
14	TREB5	O
15	protected	O
16	only	O
17	the	O
18	second	O
19	repeat	O
20	.	O

1	Separation	B
2	of	O
3	malaria	O
4	-	O
5	infected	O
6	erythrocytes	O
7	from	O
8	whole	O
9	blood	O
10	:	O
11	use	O
12	of	O
13	a	O
14	selective	O
15	high	O
16	-	O
17	gradient	O
18	magnetic	O
19	separation	O
20	technique	O
21	.	O

1	Toxicity	B
2	was	O
3	mild	O
4	,	O
5	mainly	O
6	consisting	O
7	of	O
8	emesis	O
9	(	O
10	81	O
11	%	O
12	of	O
13	the	O
14	patients	O
15	;	O
16	66	O
17	%	O
18	of	O
19	the	O
20	courses	O
21	),	O
22	leukopenia	O
23	of	O
24	World	O
25	Health	O
26	Organization	O
27	(	O
28	WHO	O
29	)	O
30	grade	O
31	1	O
32	to	O
33	2	O
34	(	O
35	47	O
36	%	O
37	of	O
38	the	O
39	patients	O
40	;	O
41	18	O
42	%	O
43	of	O
44	the	O
45	courses	O
46	),	O
47	and	O
48	thrombocytopenia	O
49	(	O
50	12	O
51	%	O
52	of	O
53	the	O
54	patients	O
55	;	O
56	3	O
57	%	O
58	of	O
59	the	O
60	courses	O
61	).	O

1	Differential	O
2	screening	O
3	of	O
4	mitochondrial	O
5	cDNA	O
6	libraries	O
7	from	O
8	male	O
9	-	O
10	fertile	O
11	and	O
12	cytoplasmic	O
13	male	O
14	-	O
15	sterile	O
16	sugar	O
17	-	O
18	beet	O
19	reveals	O
20	genome	O
21	rearrangements	O
22	at	O
23	atp6	O
24	and	O
25	atpA	O
26	loci	O
27	.	O

1	A	I
2	further	O
3	subdivision	O
4	of	O
5	Category	O
6	pN1	O
7	into	O
8	pN1a	O
9	(	O
10	metastasis	O
11	in	O
12	single	O
13	node	O
14	)	O
15	and	O
16	pN1b	O
17	(	O
18	two	O
19	or	O
20	more	O
21	nodes	O
22	)	O
23	is	O
24	recommended	O
25	.	O

1	The	O
2	microphthalmia	O
3	-	O
4	TFE	O
5	(	O
6	MiT	O
7	)	O
8	subfamily	O
9	of	O
10	basic	B
11	helix	I
12	-	I
13	loop	I
14	-	I
15	helix	I
16	leucine	I
17	zipper	I
18	(	I
19	bHLH	I
20	-	I
21	ZIP	I
22	)	I
23	transcription	I
24	factors	I
25	,	O
26	including	O
27	TFE3	O
28	,	O
29	TFEB	O
30	,	O
31	TFEC	O
32	,	O
33	and	O
34	Mitf	O
35	,	O
36	has	O
37	been	O
38	implicated	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	tissue	B
44	-	I
45	specific	I
46	gene	I
47	expression	O
48	in	O
49	several	O
50	cell	O
51	lineages	O
52	.	O

1	However	O
2	,	O
3	a	O
4	cosmid	O
5	clone	O
6	containing	O
7	the	O
8	entire	O
9	mouse	B
10	alpha	I
11	1	I
12	(	I
13	I	I
14	)	I
15	gene	I
16	,	O
17	including	O
18	3	O
19	.	O
20	7	O
21	kb	O
22	of	O
23	5	O
24	'-	O
25	and	O
26	4	O
27	kb	O
28	of	O
29	3	O
30	'-	O
31	flanking	O
32	DNA	O
33	,	O
34	was	O
35	expressed	O
36	at	O
37	reduced	O
38	levels	O
39	in	O
40	fibroblasts	O
41	overexpressing	O
42	oncogenic	B
43	ras	I
44	.	O

1	In	O
2	a	O
3	randomized	O
4	study	O
5	on	O
6	150	O
7	patients	O
8	(	O
9	ASA	O
10	1	O
11	)	O
12	undergoing	O
13	induction	O
14	of	O
15	anaesthesia	O
16	,	O
17	the	O
18	effects	O
19	of	O
20	Fentanyl	O
21	(	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	),	O
27	the	O
28	combination	O
29	of	O
30	Fentanyl	O
31	(	O
32	0	O
33	.	O
34	1	O
35	mg	O
36	)	O
37	and	O
38	Droperidol	O
39	(	O
40	5	O
41	mg	O
42	)	O
43	(	O
44	Innovar	O
45	,	O
46	Thalamonal	O
47	)	O
48	and	O
49	Atropine	O
50	(	O
51	0	O
52	.	O
53	01	O
54	mg	O
55	/	O
56	kg	O
57	b	O
58	.	O
59	w	O
60	.)	O
61	alone	O
62	on	O
63	cardiocirculatory	O
64	parameters	O
65	were	O
66	studied	O
67	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	demonstrate	O
7	that	O
8	the	O
9	RP	O
10	,	O
11	like	O
12	the	O
13	20S	B
14	proteasome	I
15	,	O
16	is	O
17	functionally	O
18	and	O
19	structurally	O
20	conserved	O
21	among	O
22	eukaryotes	O
23	and	O
24	indicate	O
25	that	O
26	the	O
27	plant	O
28	RPT	O
29	subunits	O
30	,	O
31	like	O
32	their	O
33	yeast	O
34	counterparts	O
35	,	O
36	have	O
37	non	O
38	-	O
39	redundant	O
40	functions	O
41	.	O

1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O

1	39	I
2	-	I
3	47	O
4	.	O

1	Carbonic	B
2	anhydrase	I
3	V	I
4	(	I
5	CA	I
6	V	I
7	)	O
8	is	O
9	expressed	O
10	in	O
11	mitochondrial	O
12	matrix	O
13	in	O
14	liver	O
15	and	O
16	several	O
17	other	O
18	tissues	O
19	.	O

1	Proteinuria	B
2	--	O
3	selected	O
4	physiopathological	O
5	and	O
6	clinical	O
7	problems	O

1	Alena	B
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	O

1	Compensatory	B
2	renal	O
3	hypertrophy	O
4	in	O
5	parabiotic	O
6	rats	O
7	.	O

1	Significant	O
2	immunoglobulinuria	O
3	developed	O
4	prior	O
5	to	O
6	the	O
7	development	O
8	of	O
9	azotemia	O
10	,	O
11	significantly	O
12	decreased	O
13	creatinine	O
14	clearance	O
15	,	O
16	significant	O
17	proteinuria	O
18	(	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	3	O
25	+	O
26	dipstick	O
27	or	O
28	greater	O
29	than	O
30	or	O
31	equal	O
32	to	O
33	5	O
34	gm	O
35	per	O
36	24	O
37	-	O
38	hour	O
39	urine	O
40	collection	O
41	),	O
42	or	O
43	oliguria	O
44	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	B
6	-	I
7	2	I
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	By	O
2	Felix	O
3	Lagrange	O
4	,	O
5	1918	O
6	.	O

1	CONCLUSION	O
2	:	O
3	NBP	O
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	14DM	I
5	gene	I
6	,	O
7	encoding	O
8	cytochrome	B
9	P450	I
10	lanosterol	I
11	14	I
12	alpha	I
13	-	I
14	demethylase	O
15	(	O
16	14DM	O
17	),	O
18	was	O
19	overexpressed	O
20	in	O
21	various	O
22	S	O
23	.	O
24	cerevisiae	O
25	strains	O
26	under	O
27	the	O
28	control	O
29	of	O
30	three	O
31	strong	O
32	heterologous	O
33	yeast	O
34	transcription	O
35	promoters	O
36	(	O
37	pADC1	O
38	,	O
39	pGPD	O
40	,	O
41	pPHO5	O
42	)	O
43	and	O
44	under	O
45	the	O
46	control	O
47	of	O
48	its	O
49	own	O
50	promoter	O
51	.	O

1	JNK	B
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	O
7	Ras	B
8	-	I
9	related	I
10	G	I
11	proteins	I
12	Rac	I
13	and	O
14	Cdc42	B
15	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	trans	O
6	-	O
7	activation	O
8	from	O
9	the	O
10	prothymosin	O
11	intron	O
12	enhancer	O
13	is	O
14	a	O
15	faithful	O
16	reflection	O
17	of	O
18	the	O
19	transforming	O
20	properties	O
21	of	O
22	the	O
23	Myc	B
24	protein	I
25	.	O

1	Post	B
2	-	I
3	transcriptional	O
4	regulation	O
5	of	O
6	ribosomal	B
7	protein	I
8	gene	I
9	expression	O
10	during	O
11	development	O
12	in	O
13	Dictyostelium	O
14	discoideum	O
15	.	O

1	Quantitative	O
2	predictions	O
3	are	O
4	confirmed	O
5	for	O
6	the	O
7	positive	O
8	responses	O
9	,	O
10	but	O
11	not	O
12	for	O
13	the	O
14	negatives	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	SSTS	O
20	model	O
21	is	O
22	incorrect	O
23	.	O

1	Retrograde	B
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O

1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	O
13	11	O
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	Two	O
2	estrogen	B
3	receptor	I
4	(	I
5	ER	I
6	)	I
7	isoforms	I
8	with	O
9	different	O
10	estrogen	O
11	dependencies	O
12	are	O
13	generated	O
14	from	O
15	the	O
16	trout	B
17	ER	I
18	gene	I
19	.	O

1	During	O
2	coronary	O
3	stenosis	O
4	,	O
5	on	O
6	the	O
7	contrary	O
8	,	O
9	intracoronary	O
10	procaterol	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	deteriorated	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	LCX	O
23	flow	O
24	,	O
25	global	O
26	hemodynamics	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O

1	Visual	B
2	averaged	O
3	evoked	O
4	responses	O
5	and	O
6	platelet	B
7	monoamine	I
8	oxidase	I
9	in	O
10	patients	O
11	suffering	O
12	from	O
13	alcoholism	O
14	.	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	identified	O
6	between	O
7	groups	O
8	for	O
9	pH	O
10	,	O
11	PaCO2	O
12	,	O
13	intracranial	O
14	pressure	O
15	,	O
16	heart	O
17	rate	O
18	,	O
19	brain	O
20	temperature	O
21	,	O
22	or	O
23	glucose	O
24	levels	O
25	.	O

1	The	O
2	dominant	O
3	negative	O
4	mutant	O
5	of	O
6	SHP	B
7	-	I
8	2	I
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	the	O
14	induction	O
15	of	O
16	tyrosine	O
17	phosphorylation	O
18	and	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	m	B
25	-	I
26	Stat5a	I
27	,	O
28	m	B
29	-	I
30	Stat5b	I
31	,	O
32	and	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	O
37	deletion	O
38	variant	O
39	m	O
40	-	O
41	Stat5adelta749	O
42	,	O
43	as	O
44	well	O
45	as	O
46	the	O
47	transactivation	O
48	potential	O
49	of	O
50	m	B
51	-	I
52	Stat5a	I
53	and	O
54	m	B
55	-	I
56	Stat5b	I
57	.	O

1	Risks	B
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O

1	RESULTS	O
2	:	O
3	Auditory	O
4	thresholds	O
5	collected	O
6	during	O
7	audiometric	O
8	tests	O
9	increased	O
10	gradually	O
11	in	O
12	proportion	O
13	with	O
14	age	O
15	,	O
16	especially	O
17	in	O
18	the	O
19	hypertensive	O
20	group	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	One	O
2	group	O
3	(	O
4	n	O
5	=	O
6	9	O
7	)	O
8	was	O
9	premedicated	O
10	with	O
11	midazolam	O
12	,	O
13	0	O
14	.	O
15	1	O
16	mg	O
17	kg	O
18	-	O
19	1	O
20	,	O
21	and	O
22	atropine	O
23	0	O
24	.	O
25	2	O
26	-	O
27	0	O
28	.	O
29	4	O
30	mg	O
31	i	O
32	.	O
33	m	O
34	.	O

1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O

1	An	O
2	association	O
3	between	O
4	hSIE	O
5	and	O
6	Stat	B
7	-	I
8	3	I
9	after	O
10	MHC	B
11	-	I
12	I	I
13	ligation	O
14	was	O
15	directly	O
16	demonstrated	O
17	by	O
18	precipitating	O
19	Stat	B
20	-	I
21	3	I
22	from	O
23	nuclear	O
24	extracts	O
25	with	O
26	biotinylated	O
27	hSIE	O
28	probe	O
29	and	O
30	avidin	B
31	-	I
32	coupled	I
33	agarose	O
34	.	O

1	Dimerization	B
2	of	O
3	Myf	O
4	-	O
5	5	O
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	Ischemic	B
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O

1	Occupational	B
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	B
9	immunodeficiency	I
10	virus	I
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O

1	(	O
2	1995	O
3	)	O
4	J	O
5	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	total	O
6	cellular	O
7	RNA	O
8	indicated	O
9	that	O
10	xylP	O
11	encodes	O
12	a	O
13	1	O
14	.	O
15	3	O
16	-	O
17	kb	O
18	transcript	O
19	which	O
20	is	O
21	induced	O
22	by	O
23	xylan	O
24	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	liver	O
6	allograft	O
7	shortage	O
8	,	O
9	our	O
10	results	O
11	suggest	O
12	that	O
13	an	O
14	ELT	O
15	should	O
16	not	O
17	be	O
18	performed	O
19	in	O
20	patients	O
21	with	O
22	cardiac	O
23	failure	O
24	,	O
25	more	O
26	than	O
27	two	O
28	OSF	O
29	,	O
30	or	O
31	an	O
32	APACHE	O
33	II	O
34	score	O
35	higher	O
36	than	O
37	30	O
38	.	O

1	The	O
2	method	O
3	is	O
4	accurate	O
5	,	O
6	with	O
7	good	O
8	precision	O
9	and	O
10	adequate	O
11	sensitivity	O
12	.	O

1	Analysis	O
2	of	O
3	the	O
4	gag	B
5	and	O
6	rev	B
7	proteins	I
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	O
19	in	O
20	cells	O
21	transfected	O
22	with	O
23	the	O
24	tat	B
25	mutants	I
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	O
36	in	O
37	trans	O
38	with	O
39	a	O
40	tat	B
41	expression	O
42	vector	O
43	.	O

1	Members	O
2	of	O
3	the	O
4	meis1	O
5	and	O
6	pbx	O
7	homeodomain	B
8	protein	I
9	families	I
10	cooperatively	O
11	bind	O
12	a	O
13	cAMP	B
14	-	I
15	responsive	I
16	sequence	I
17	(	O
18	CRS1	O
19	)	O
20	from	O
21	bovine	O
22	CYP17	O
23	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	subjects	O
7	with	O
8	air	O
9	trapping	O
10	(	O
11	residual	O
12	volume	O
13	(	O
14	RV	O
15	)/	O
16	total	O
17	lung	O
18	capacity	O
19	(	O
20	TLC	O
21	)	O
22	>	O
23	37	O
24	%)	O
25	disclosed	O
26	not	O
27	only	O
28	a	O
29	higher	O
30	n	O
31	(	O
32	mit	O
33	)	O
34	(	O
35	0	O
36	.	O
37	63	O
38	+/-	O
39	0	O
40	.	O
41	17	O
42	versus	O
43	0	O
44	.	O
45	43	O
46	+/-	O
47	0	O
48	.	O
49	07	O
50	mt	O
51	x	O
52	microm	O
53	(-	O
54	2	O
55	),	O
56	p	O
57	<	O
58	0	O
59	.	O
60	05	O
61	)	O
62	but	O
63	shorter	O
64	sarcomeres	O
65	(	O
66	L	O
67	(	O
68	sar	O
69	))	O
70	than	O
71	subjects	O
72	without	O
73	this	O
74	functional	O
75	abnormality	O
76	(	O
77	2	O
78	.	O
79	08	O
80	+/-	O
81	0	O
82	.	O
83	16	O
84	to	O
85	2	O
86	.	O
87	27	O
88	+/-	O
89	0	O
90	.	O
91	15	O
92	microm	O
93	,	O
94	p	O
95	<	O
96	0	O
97	.	O
98	05	O
99	).	O

1	BRCA1	B
2	,	O
3	a	O
4	familial	O
5	breast	O
6	and	O
7	ovarian	O
8	cancer	O
9	susceptibility	O
10	gene	O
11	encodes	O
12	nuclear	O
13	phosphoproteins	O
14	that	O
15	function	O
16	as	O
17	tumor	O
18	suppressors	O
19	in	O
20	human	O
21	breast	O
22	cancer	O
23	cells	O
24	.	O

1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O

1	Our	O
2	laboratory	O
3	and	O
4	others	O
5	have	O
6	shown	O
7	alternative	O
8	splicing	O
9	of	O
10	up	O
11	to	O
12	ten	O
13	exons	O
14	at	O
15	a	O
16	discrete	O
17	extracellular	O
18	site	O
19	to	O
20	be	O
21	primarily	O
22	responsible	O
23	for	O
24	the	O
25	generation	O
26	of	O
27	CD44	B
28	variant	I
29	(	I
30	CD44v	I
31	)	I
32	isoforms	I
33	.	O

1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	B
23	beta	I
24	-	I
25	1b	I
26	in	O
27	RRMS	O
28	.	O

1	When	O
2	nifA	O
3	mRNA	O
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	I
43	were	O
44	observed	O
45	.	O

1	The	O
2	pheromone	O
3	response	O
4	pathway	O
5	activates	O
6	transcription	O
7	of	O
8	Ty5	O
9	retrotransposons	O
10	located	O
11	within	O
12	silent	O
13	chromatin	O
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	Previously	O
2	,	O
3	we	O
4	characterized	O
5	a	O
6	DNA	B
7	-	I
8	binding	I
9	protein	I
10	,	O
11	HS2NF5	O
12	,	O
13	that	O
14	bound	O
15	tightly	O
16	to	O
17	a	O
18	conserved	O
19	region	O
20	within	O
21	hypersensitive	O
22	site	O
23	2	O
24	(	O
25	HS2	O
26	)	O
27	of	O
28	the	O
29	human	B
30	beta	I
31	-	I
32	globin	I
33	locus	I
34	control	O
35	region	O
36	(	O
37	LCR	O
38	)	O
39	(	O
40	Lam	O
41	,	O
42	L	O
43	.	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	O
6	-	O
7	specific	O
8	and	O
9	MAP2	B
10	-	I
11	specific	I
12	mRNAs	I
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O

1	(	O
2	1997	O
3	)	O
4	Science	O
5	275	O
6	,	O
7	1927	O
8	-	O
9	1930	O
10	).	O

1	Laboratory	O
2	pyrolyses	O
3	have	O
4	indeed	O
5	shown	O
6	that	O
7	PCBs	O
8	give	O
9	significant	O
10	yields	O
11	of	O
12	PCDFs	O
13	,	O
14	and	O
15	chlorobenzenes	O
16	give	O
17	both	O
18	PCDFs	O
19	and	O
20	PCDDs	O
21	.	O

1	Receptors	B
2	for	O
3	interleukin	B
4	(	I
5	IL	I
6	)-	I
7	10	O
8	and	O
9	IL	B
10	-	I
11	6	I
12	-	I
13	type	I
14	cytokines	O
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	B
24	-	I
25	6	I
26	response	I
27	elements	I
28	.	O

1	A	I
2	724	I
3	-	I
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	B
17	-	I
18	box	I
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	B
24	-	I
25	specific	I
26	352	I
27	-	I
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	I
22	Rel	I
23	and	O
24	PI	B
25	-	I
26	3K	O
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	I
32	induced	O
33	proliferation	O
34	.	O

1	Comparison	O
2	of	O
3	the	O
4	nucleotide	O
5	sequences	O
6	between	O
7	the	O
8	human	O
9	and	O
10	bovine	O
11	DNA	O
12	showed	O
13	that	O
14	the	O
15	sequence	O
16	similarity	O
17	extended	O
18	2400	O
19	bp	O
20	downstream	O
21	from	O
22	the	O
23	coding	O
24	region	O
25	.	O

1	To	O
2	identify	O
3	factors	O
4	that	O
5	may	O
6	modify	O
7	the	O
8	heterosexual	O
9	transmission	O
10	of	O
11	human	O
12	T	O
13	cell	O
14	leukemia	O
15	/	O
16	lymphoma	O
17	virus	O
18	type	O
19	I	O
20	(	O
21	HTLV	B
22	-	I
23	I	I
24	),	O
25	534	O
26	married	O
27	couples	O
28	enrolled	O
29	in	O
30	the	O
31	Miyazaki	O
32	Cohort	O
33	Study	O
34	between	O
35	November	O
36	1984	O
37	and	O
38	April	O
39	1989	O
40	were	O
41	studied	O
42	:	O
43	95	O
44	husband	O
45	HTLV	B
46	-	I
47	I	I
48	-	I
49	seropositive	O
50	(	O
51	H	O
52	+)/	O
53	wife	O
54	seropositive	O
55	(	O
56	W	O
57	+),	O
58	33	O
59	H	O
60	+/	O
61	W	O
62	-,	O
63	64	O
64	H	O
65	-/	O
66	W	O
67	+,	O
68	and	O
69	342	O
70	H	O
71	-/	O
72	W	O
73	-.	O

1	A	I
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	O
7	1	O
8	insulin	B
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	I
18	IGF	I
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	Thus	O
2	,	O
3	hGRbeta	O
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	O
13	activity	O
14	.	O

1	Furthermore	O
2	,	O
3	synergistic	O
4	activation	O
5	of	O
6	ERK2	B
7	occurred	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	changes	O
13	in	O
14	intracellular	O
15	Ca2	O
16	+,	O
17	and	O
18	was	O
19	not	O
20	blocked	O
21	by	O
22	inhibition	O
23	of	O
24	protein	B
25	kinase	I
26	C	I
27	activity	O
28	and	O
29	represents	O
30	a	O
31	separate	O
32	pathway	O
33	by	O
34	which	O
35	CD19	O
36	regulates	O
37	B	O
38	cell	O
39	function	O
40	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	Some	O
2	of	O
3	them	O
4	produce	O
5	gigantic	O
6	sperm	O
7	several	O
8	times	O
9	the	O
10	total	O
11	male	O
12	body	O
13	length	O
14	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	O
12	functional	O
13	domains	O
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	B
20	polymerase	I
21	II	I
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O

1	Modeling	B
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	O
26	,	O
27	and	O
28	H11	O
29	.	O

1	CONCLUSION	O
2	:	O
3	We	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	features	O
9	of	O
10	disease	O
11	likely	O
12	to	O
13	be	O
14	associated	O
15	with	O
16	a	O
17	clinically	O
18	useful	O
19	response	O
20	to	O
21	inhaled	O
22	NO	O
23	therapy	O
24	using	O
25	the	O
26	parameters	O
27	studied	O
28	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	understand	O
6	Wee1	B
7	regulation	O
8	during	O
9	cell	O
10	cycle	O
11	,	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screening	O
17	was	O
18	used	O
19	to	O
20	identify	O
21	Wee1	B
22	-	I
23	binding	I
24	protein	I
25	(	O
26	s	O
27	).	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	B
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	Immediately	B
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	Comments	B
2	are	O
3	given	O
4	on	O
5	the	O
6	present	O
7	status	O
8	of	O
9	regulations	O
10	concerning	O
11	water	O
12	in	O
13	swimming	O
14	pools	O
15	and	O
16	baths	O
17	--	O
18	1991	O
19	--(	O
20	in	O
21	connection	O
22	with	O
23	the	O
24	KOK	O
25	regulations	O
26	--	O
27	1972	O
28	--	O
29	and	O
30	the	O
31	Federal	O
32	German	O
33	standard	O
34	[	O
35	DIN	O
36	]	O
37	No	O
38	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	B
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	well	O
8	established	O
9	polarity	O
10	of	O
11	RXR	B
12	heterodimer	O
13	binding	O
14	to	O
15	bipartite	O
16	hormone	O
17	response	O
18	elements	O
19	,	O
20	with	O
21	the	O
22	VDR	B
23	recognizing	O
24	the	O
25	3	O
26	'-	O
27	half	O
28	-	O
29	element	O
30	.	O

1	Myocardial	O
2	SPET	O
3	imaging	O
4	with	O
5	99Tcm	O
6	-	O
7	tetrofosmin	O
8	in	O
9	clinical	O
10	practice	O
11	:	O
12	comparison	O
13	of	O
14	a	O
15	1	O
16	day	O
17	and	O
18	a	O
19	2	O
20	day	O
21	imaging	O
22	protocol	O
23	.	O

1	Each	O
2	binding	O
3	site	O
4	,	O
5	however	O
6	,	O
7	was	O
8	different	O
9	in	O
10	its	O
11	preference	O
12	for	O
13	binding	O
14	partners	O
15	.	O

1	Genomic	O
2	DNA	O
3	hybridization	O
4	suggests	O
5	that	O
6	SpSHR2	O
7	is	O
8	a	O
9	single	O
10	-	O
11	copy	O
12	gene	O
13	in	O
14	the	O
15	S	O
16	.	O
17	purpuratus	O
18	genome	O
19	.	O

1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O

1	Coexpression	B
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	I
15	-	I
16	binding	I
17	domain	I
18	fusion	I
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	I
33	mutant	I
34	,	O
35	the	O
36	RNA	B
37	-	I
38	binding	I
39	-	I
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	O
47	)	O
48	K64E	O
49	/	O
50	K296R	O
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	B
56	-	I
57	type	I
58	mouse	I
59	PKR	I
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	B
68	-	I
69	length	I
70	PKR	I
71	-	O
72	Gal4	B
73	activation	I
74	domain	I
75	fusions	I
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O

1	Purified	B
2	PLB	O
3	showed	O
4	optimal	O
5	lyase	B
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	I
12	Rev	I
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	A	I
2	third	O
3	one	O
4	is	O
5	homologous	O
6	in	O
7	half	O
8	of	O
9	its	O
10	length	O
11	to	O
12	the	O
13	prokaryotic	O
14	hydantoinase	O
15	HyuA	O
16	and	O
17	in	O
18	the	O
19	other	O
20	half	O
21	to	O
22	hydatoinase	O
23	HyuB	O
24	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	O
19	to	O
20	induce	O
21	junB	B
22	transcription	I
23	.	O

1	The	O
2	ewes	O
3	were	O
4	returned	O
5	to	O
6	normoxia	O
7	,	O
8	and	O
9	monitoring	O
10	was	O
11	continued	O
12	for	O
13	1	O
14	h	O
15	.	O

1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O

1	A	I
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	Products	B
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	B
8	factor	I
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	B
21	-	I
22	stimulating	I
23	agents	O
24	.	O

1	Synthetic	B
2	ligands	O
3	have	O
4	been	O
5	identified	O
6	that	O
7	reset	O
8	and	O
9	amplify	O
10	the	O
11	cycle	O
12	of	O
13	pulsatile	O
14	GH	B
15	secretion	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	orphan	O
21	GH	B
22	-	I
23	secretagogue	I
24	receptor	I
25	(	I
26	GHS	I
27	-	I
28	R	I
29	).	O

1	The	O
2	bHLH	B
3	proteins	I
4	function	O
5	as	O
6	potent	O
7	transcriptional	O
8	activators	O
9	of	O
10	tissue	B
11	-	I
12	specific	I
13	genes	I
14	by	O
15	forming	O
16	heterodimers	O
17	between	O
18	ubiquitous	O
19	and	O
20	cell	O
21	-	O
22	restricted	O
23	family	O
24	members	O
25	.	O

1	They	O
2	also	O
3	discuss	O
4	the	O
5	existing	O
6	nomenclature	O
7	.	O

1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	O
8	families	O
9	Tydeidae	O
10	,	O
11	Nanorchestidae	O
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O

1	Mechanistically	B
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	GRR	O
8	appears	O
9	to	O
10	stop	O
11	further	O
12	degradation	O
13	of	O
14	p50	B
15	and	O
16	to	O
17	stabilize	O
18	the	O
19	molecule	O
20	.	O

1	Giant	B
2	pilomatrix	O
3	carcinoma	O
4	:	O
5	report	O
6	and	O
7	review	O
8	of	O
9	the	O
10	literature	O
11	.	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	The	O
2	effects	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	I
15	myc	I
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	O
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O

1	SELECTION	B
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	The	O
2	immune	O
3	system	O
4	is	O
5	closely	O
6	integrated	O
7	with	O
8	the	O
9	neuroendocrine	O
10	system	O
11	,	O
12	and	O
13	infection	O
14	-	O
15	induced	O
16	increases	O
17	in	O
18	cytokines	O
19	such	O
20	as	O
21	IL	B
22	-	I
23	1	I
24	,	O
25	IL	B
26	-	I
27	6	I
28	and	O
29	TNF	B
30	have	O
31	numerous	O
32	effects	O
33	on	O
34	the	O
35	central	O
36	nervous	O
37	system	O
38	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	The	O
2	gray	O
3	matter	O
4	NAA	O
5	/	O
6	mI	O
7	ratio	O
8	clearly	O
9	separated	O
10	the	O
11	two	O
12	groups	O
13	.	O

1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	O
7	AP	B
8	-	I
9	1	I
10	cis	I
11	-	I
12	response	I
13	elements	I
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	O
16	PWV	O
17	):	O
18	the	O
19	deduced	O
20	CP	O
21	sequence	O
22	is	O
23	only	O
24	distantly	O
25	related	O
26	to	O
27	CPs	O
28	of	O
29	other	O
30	sequenced	O
31	strains	O
32	of	O
33	PWV	O
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	requirements	O
8	for	O
9	induction	O
10	of	O
11	PEPCK	B
12	by	O
13	PKA	B
14	and	O
15	inhibition	O
16	by	O
17	insulin	B
18	include	O
19	:	O
20	1	O
21	)	O
22	the	O
23	CREB	B
24	activation	I
25	domain	I
26	,	O
27	2	O
28	)	O
29	the	O
30	PEPCK	B
31	TATA	O
32	sequence	O
33	,	O
34	and	O
35	3	O
36	)	O
37	insulin	B
38	-	I
39	responsive	I
40	hepatoma	O
41	cells	O
42	.	O

1	In	O
2	Xenopus	B
3	laevis	I
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	Recombination	B
2	,	O
3	replication	O
4	,	O
5	repair	O
6	:	O
7	from	O
8	complexity	O
9	to	O
10	harmony	O
11	.	O

1	The	O
2	ESEM	O
3	differs	O
4	from	O
5	conventional	O
6	SEM	O
7	in	O
8	that	O
9	no	O
10	sample	O
11	preparation	O
12	is	O
13	needed	O
14	,	O
15	eliminating	O
16	artifactual	O
17	changes	O
18	.	O

1	We	O
2	have	O
3	mapped	O
4	the	O
5	human	B
6	STAG3	I
7	gene	I
8	to	O
9	the	O
10	7q22	O
11	region	O
12	of	O
13	chromosome	O
14	7	O
15	;	O
16	six	O
17	human	B
18	STAG3	I
19	-	I
20	related	I
21	genes	I
22	have	O
23	also	O
24	been	O
25	mapped	O
26	:	O
27	two	O
28	at	O
29	7q22	O
30	near	O
31	the	O
32	functional	O
33	gene	O
34	,	O
35	one	O
36	at	O
37	7q11	O
38	.	O
39	22	O
40	,	O
41	and	O
42	three	O
43	at	O
44	7q11	O
45	.	O
46	23	O
47	,	O
48	two	O
49	of	O
50	them	O
51	flanking	O
52	the	O
53	breakpoints	O
54	commonly	O
55	associated	O
56	with	O
57	the	O
58	Williams	O
59	-	O
60	Beuren	O
61	syndrome	O
62	(	O
63	WBS	O
64	)	O
65	deletion	O
66	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	Further	O
2	observations	O
3	on	O
4	resorption	O
5	in	O
6	guinea	O
7	pigs	O
8	following	O
9	injections	O
10	of	O
11	trypan	O
12	blue	O
13	.	O

1	Cis	B
2	-	I
3	regulation	O
4	downstream	O
5	of	O
6	cell	O
7	type	O
8	specification	O
9	:	O
10	a	O
11	single	O
12	compact	O
13	element	O
14	controls	O
15	the	O
16	complex	O
17	expression	O
18	of	O
19	the	O
20	CyIIa	B
21	gene	I
22	in	O
23	sea	O
24	urchin	O
25	embryos	O
26	.	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	O
8	following	O
9	treatment	O
10	with	O
11	alpha	B
12	-	I
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O

1	With	O
2	the	O
3	increasing	O
4	use	O
5	of	O
6	ACE	B
7	inhibitors	O
8	,	O
9	the	O
10	incidence	O
11	of	O
12	rare	O
13	adverse	O
14	effects	O
15	such	O
16	as	O
17	potentially	O
18	lethal	O
19	pancreatitis	O
20	is	O
21	likely	O
22	to	O
23	increase	O
24	.	O

1	One	O
2	of	O
3	its	O
4	unique	O
5	features	O
6	appears	O
7	to	O
8	be	O
9	the	O
10	unusually	O
11	short	O
12	5	O
13	'-	O
14	untranslated	O
15	regions	O
16	(	O
17	UTR	O
18	)	O
19	(	O
20	1	O
21	-	O
22	6	O
23	nucleotides	O
24	(	O
25	nts	O
26	))	O
27	and	O
28	the	O
29	apparent	O
30	absence	O
31	of	O
32	5	O
33	'-	O
34	cap	O
35	structures	O
36	from	O
37	its	O
38	mRNAs	O
39	.	O

1	Which	B
2	cineangiographically	O
3	assessed	O
4	anatomic	O
5	variable	O
6	correlates	O
7	best	O
8	with	O
9	functional	O
10	measurements	O
11	of	O
12	stenosis	O
13	severity	O
14	?	O
15	A	O
16	comparison	O
17	of	O
18	quantitative	O
19	analysis	O
20	of	O
21	the	O
22	coronary	O
23	cineangiogram	O
24	with	O
25	measured	O
26	coronary	O
27	flow	O
28	reserve	O
29	and	O
30	exercise	O
31	/	O
32	redistribution	O
33	thallium	O
34	-	O
35	201	O
36	scintigraphy	O
37	.	O

1	The	O
2	normal	O
3	cell	O
4	cycle	O
5	is	O
6	regulated	O
7	by	O
8	several	O
9	molecules	O
10	,	O
11	such	O
12	as	O
13	the	O
14	tumor	B
15	-	I
16	suppressor	I
17	protein	I
18	pRb	I
19	,	O
20	the	O
21	G1	B
22	cyclins	I
23	,	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinases	I
29	,	O
30	and	O
31	their	O
32	inhibitors	O
33	.	O

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	B
35	deiodinase	I
36	system	O
37	.	O

1	Thus	O
2	,	O
3	the	O
4	B	B
5	-	I
6	S	I
7	mutant	I
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	O
14	GAPDHs	O
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	B
52	-	I
53	like	I
54	"	O
55	mutant	O
56	of	O
57	cytosolic	O
58	GAPDH	O
59	.	O

1	Organisms	B
2	were	O
3	recovered	O
4	from	O
5	the	O
6	conjunctiva	O
7	for	O
8	several	O
9	weeks	O
10	,	O
11	and	O
12	persistent	O
13	genital	O
14	and	O
15	gastrointestinal	O
16	infection	O
17	also	O
18	resulted	O
19	from	O
20	the	O
21	ocular	O
22	infection	O
23	in	O
24	some	O
25	cats	O
26	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	A	O
2	coiled	B
3	-	I
4	coil	I
5	related	I
6	protein	I
7	specific	I
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	The	O
2	available	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	NF	B
8	kappa	I
9	B2	I
10	nucleoprotein	I
11	complex	I
12	may	O
13	cooperate	O
14	with	O
15	DNA	O
16	-	O
17	bound	O
18	STAT6	O
19	to	O
20	achieve	O
21	IL	B
22	-	I
23	4	I
24	-	I
25	dependent	I
26	activation	O
27	of	O
28	the	O
29	human	B
30	IgE	I
31	germline	I
32	gene	I
33	.	O

1	TGF	B
2	beta	I
3	1	I
4	expression	O
5	is	O
6	largely	O
7	governed	O
8	by	O
9	three	O
10	AP	B
11	-	I
12	1	I
13	binding	I
14	sites	I
15	located	O
16	in	O
17	two	O
18	different	O
19	promoters	O
20	of	O
21	this	O
22	gene	O
23	.	O

1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	O
9	-	O
10	73	O
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	O
22	-	O
23	10	O
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O

1	A	I
2	region	I
3	approximately	O
4	100	O
5	bp	O
6	upstream	O
7	from	O
8	the	O
9	transcription	O
10	start	O
11	point	O
12	of	O
13	virB	O
14	was	O
15	identified	O
16	as	O
17	being	O
18	necessary	O
19	for	O
20	full	O
21	activation	O
22	of	O
23	this	O
24	promoter	O
25	by	O
26	VirF	O
27	.	O

1	Symposium	B
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	Homology	B
2	with	O
3	the	O
4	human	B
5	protein	I
6	is	O
7	only	O
8	34	O
9	%	O
10	in	O
11	the	O
12	tandem	O
13	repeat	O
14	domain	O
15	,	O
16	mainly	O
17	showing	O
18	conservation	O
19	of	O
20	serines	O
21	and	O
22	threonines	O
23	,	O
24	presumed	O
25	sites	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	attachment	O
32	.	O

1	A	I
2	cDNA	I
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	GA	B
9	20	I
10	-	I
11	oxidase	I
12	genomic	O
13	sequence	O
14	was	O
15	constructed	O
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	analyzing	O
35	the	O
36	capability	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	convert	O
47	GA53	O
48	to	O
49	GA44	O
50	and	O
51	GA19	O
52	to	O
53	GA20	O
54	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	internal	O
6	promoters	O
7	,	O
8	PmiaA	O
9	and	O
10	P1hfq	O
11	were	O
12	identified	O
13	and	O
14	mapped	O
15	to	O
16	201	O
17	and	O
18	837	O
19	nucleotides	O
20	upstream	O
21	from	O
22	the	O
23	respective	O
24	translation	O
25	start	O
26	sites	O
27	.	O

1	The	O
2	deduced	O
3	bovine	B
4	EFIA	I
5	#	I
6	1	I
7	amino	O
8	acid	O
9	(	O
10	aa	O
11	)	O
12	sequence	O
13	is	O
14	98	O
15	%	O
16	identical	O
17	to	O
18	rat	B
19	EFIA	I
20	and	O
21	100	O
22	%	O
23	identical	O
24	to	O
25	human	B
26	EFIA	I
27	/	I
28	DbpB	I
29	/	I
30	YB	I
31	-	I
32	1	I
33	family	I
34	member	I
35	DNA	I
36	-	I
37	binding	I
38	protein	I
39	B	I
40	(	O
41	DbpB	O
42	).	O

1	Comparable	B
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	I
23	-	I
24	binding	I
25	fragment	I
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Plasma	B
2	membranes	O
3	of	O
4	cultured	O
5	cells	O
6	contain	O
7	high	O
8	affinity	O
9	receptors	O
10	for	O
11	high	O
12	density	O
13	lipoprotein	O
14	(	O
15	HDL	B
16	)	O
17	that	O
18	appear	O
19	to	O
20	mediate	O
21	removal	O
22	of	O
23	excess	O
24	intracellular	O
25	cholesterol	O
26	.	O

1	As	O
2	the	O
3	components	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	at	O
9	least	O
10	five	O
11	TRBPs	O
12	(	O
13	p30	O
14	,	O
15	p37	O
16	,	O
17	p46	B
18	,	O
19	p50	B
20	,	O
21	and	O
22	p56	O
23	)	O
24	showing	O
25	specific	O
26	binding	O
27	to	O
28	the	O
29	TAR	O
30	RNA	O
31	were	O
32	detected	O
33	in	O
34	the	O
35	uv	O
36	cross	O
37	-	O
38	linking	O
39	assay	O
40	.	O

1	Patterns	B
2	defined	O
3	by	O
4	combinations	O
5	of	O
6	normal	O
7	and	O
8	abnormal	O
9	laboratory	O
10	results	O
11	had	O
12	decreased	O
13	the	O
14	likelihood	O
15	of	O
16	PEM	O
17	from	O
18	an	O
19	all	O
20	-	O
21	2	O
22	to	O
23	all	O
24	-	O
25	0	O
26	pattern	O
27	.	O

1	RESULTS	O
2	:	O
3	The	O
4	LV	O
5	maximum	O
6	brightness	O
7	and	O
8	area	O
9	under	O
10	the	O
11	curve	O
12	showed	O
13	significant	O
14	negative	O
15	correlations	O
16	(	O
17	p	O
18	=	O
19	<	O
20	0	O
21	.	O
22	004	O
23	)	O
24	with	O
25	the	O
26	FIO2	O
27	,	O
28	while	O
29	the	O
30	minimum	O
31	brightness	O
32	showed	O
33	a	O
34	significant	O
35	positive	O
36	correlation	O
37	(	O
38	p	O
39	=	O
40	<	O
41	0	O
42	.	O
43	002	O
44	).	O

1	Depth	B
2	-	I
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	TPBF	B
2	has	O
3	two	O
4	potential	O
5	coiled	O
6	-	O
7	coil	O
8	regions	O
9	,	O
10	a	O
11	basic	O
12	region	O
13	,	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	region	O
19	,	O
20	a	O
21	histidine	O
22	-	O
23	rich	O
24	N	O
25	terminus	O
26	,	O
27	and	O
28	a	O
29	nuclear	O
30	targeting	O
31	sequence	O
32	.	O

1	Here	O
2	we	O
3	investigate	O
4	the	O
5	role	O
6	of	O
7	c	B
8	-	I
9	Cbl	I
10	in	O
11	development	O
12	and	O
13	homeostasis	O
14	in	O
15	mice	O
16	by	O
17	targeted	O
18	disruption	O
19	of	O
20	the	O
21	c	B
22	-	I
23	Cbl	I
24	locus	I
25	.	O
26	c	B
27	-	I
28	Cbl	I
29	-	I
30	deficient	O
31	mice	O
32	were	O
33	viable	O
34	,	O
35	fertile	O
36	,	O
37	and	O
38	outwardly	O
39	normal	O
40	in	O
41	appearance	O
42	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	O
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	Virol	B
2	.	O

1	Identification	O
2	of	O
3	a	O
4	promoter	O
5	-	O
6	specific	O
7	transactivation	O
8	domain	O
9	in	O
10	the	O
11	herpes	B
12	simplex	I
13	virus	I
14	regulatory	I
15	protein	I
16	ICP4	I
17	.	O

1	In	O
2	acute	O
3	-	O
4	phase	O
5	livers	O
6	,	O
7	we	O
8	observed	O
9	a	O
10	dramatic	O
11	reduction	O
12	in	O
13	HNF	B
14	-	I
15	3	I
16	alpha	I
17	expression	O
18	which	O
19	correlates	O
20	with	O
21	a	O
22	decrease	O
23	in	O
24	the	O
25	expression	O
26	of	O
27	its	O
28	target	O
29	gene	O
30	,	O
31	the	O
32	TTR	B
33	gene	I
34	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	B
22	-	I
23	lactamase	I
24	.	O

1	These	O
2	losses	O
3	account	O
4	for	O
5	the	O
6	resistance	O
7	of	O
8	EDS	B
9	-	I
10	IV	I
11	collagen	I
12	to	O
13	cyanogen	O
14	bromide	O
15	and	O
16	mammalian	O
17	collagenase	O
18	digestion	O
19	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	B
19	-	I
20	type	I
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	O
27	SP1	B
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	O
45	E1A	B
46	/	I
47	E1B	I
48	-	I
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	B
54	LTR	I
55	.	O

1	The	O
2	management	O
3	of	O
4	the	O
5	"	O
6	chronic	O
7	"	O
8	patient	O
9	.	O

1	In	O
2	overdoses	O
3	up	O
4	to	O
5	2	O
6	g	O
7	fluvoxamine	O
8	no	O
9	lasting	O
10	toxic	O
11	effects	O
12	were	O
13	observed	O
14	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	Junctions	B
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O

1	These	O
2	results	O
3	may	O
4	suggest	O
5	involvement	O
6	of	O
7	peripheral	O
8	enkephalins	O
9	in	O
10	pain	O
11	modulation	O
12	in	O
13	patients	O
14	with	O
15	episodic	O
16	cluster	O
17	headache	O
18	.	O

1	Dopamine	B
2	SERS	O
3	spectra	O
4	from	O
5	these	O
6	electrodes	O
7	are	O
8	similar	O
9	to	O
10	those	O
11	obtained	O
12	at	O
13	uncoated	O
14	electrodes	O
15	.	O

1	Bupropion	B
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	4	I
2	)	I
3	PU	I
4	and	O
5	PD	O
6	lacked	O
7	the	O
8	canonical	O
9	TATA	O
10	or	O
11	CAAT	O
12	motifs	O
13	,	O
14	and	O
15	are	O
16	AT	O
17	-	O
18	rich	O
19	.	O

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	The	O
2	ANB1	O
3	locus	O
4	of	O
5	Saccharomyces	O
6	cerevisiae	O
7	encodes	O
8	the	O
9	protein	B
10	synthesis	I
11	initiation	I
12	factor	I
13	eIF	I
14	-	I
15	4D	O
16	.	O

1	Effect	O
2	of	O
3	ingestion	O
4	of	O
5	Norbiogest	O
6	during	O
7	the	O
8	quiescent	O
9	period	O
10	of	O
11	the	O
12	genital	O
13	organs	O

1	The	O
2	first	O
3	146	O
4	consecutive	O
5	patients	O
6	treated	O
7	with	O
8	EVL	O
9	during	O
10	the	O
11	period	O
12	from	O
13	August	O
14	,	O
15	1986	O
16	to	O
17	July	O
18	,	O
19	1989	O
20	are	O
21	reported	O
22	.	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Interestingly	O
2	,	O
3	the	O
4	positions	O
5	of	O
6	these	O
7	introns	O
8	have	O
9	been	O
10	conserved	O
11	in	O
12	comparison	O
13	with	O
14	the	O
15	genes	O
16	of	O
17	two	O
18	other	O
19	transglutaminase	O
20	-	O
21	like	O
22	activities	O
23	described	O
24	in	O
25	the	O
26	literature	O
27	,	O
28	but	O
29	the	O
30	TGM1	B
31	gene	I
32	is	O
33	by	O
34	far	O
35	the	O
36	smallest	O
37	characterized	O
38	to	O
39	date	O
40	because	O
41	its	O
42	introns	O
43	are	O
44	relatively	O
45	smaller	O
46	.	O

1	These	O
2	results	O
3	demonstrate	O
4	Ras	B
5	-	I
6	and	I
7	Raf	I
8	-	I
9	independent	O
10	ERK	B
11	MAPK	I
12	activation	O
13	maintains	O
14	cell	O
15	viability	O
16	following	O
17	heat	O
18	shock	O
19	.	O

1	Functional	O
2	recognition	O
3	of	O
4	5	O
5	'	O
6	splice	O
7	site	O
8	by	O
9	U4	B
10	/	I
11	U6	I
12	.	O
13	U5	B
14	tri	I
15	-	I
16	snRNP	I
17	defines	O
18	a	O
19	novel	O
20	ATP	O
21	-	O
22	dependent	O
23	step	O
24	in	O
25	early	O
26	spliceosome	O
27	assembly	O
28	.	O

1	Translation	B
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	O
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O

1	Animals	O
2	may	O
3	be	O
4	immunized	O
5	by	O
6	oral	O
7	vaccination	O
8	,	O
9	but	O
10	natural	O
11	mechanisms	O
12	that	O
13	also	O
14	can	O
15	terminate	O
16	outbreaks	O
17	are	O
18	discussed	O
19	.	O

1	Martin	B
2	Luther	O
3	and	O
4	his	O
5	physicians	O
6	.	O

1	The	O
2	order	O
3	of	O
4	the	O
5	helicase	B
6	motif	I
7	and	O
8	the	O
9	nsP3	O
10	homology	O
11	region	O
12	in	O
13	the	O
14	RUB	O
15	genome	O
16	is	O
17	reversed	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	alphavirus	O
23	genome	O
24	indicating	O
25	that	O
26	a	O
27	genetic	O
28	rearrangement	O
29	has	O
30	occurred	O
31	during	O
32	the	O
33	evolution	O
34	of	O
35	these	O
36	viruses	O
37	.	O

1	An	O
2	analysis	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	RNA	O
8	levels	O
9	in	O
10	T	O
11	-	O
12	lymphoid	O
13	cell	O
14	lines	O
15	showed	O
16	that	O
17	at	O
18	least	O
19	three	O
20	different	O
21	incomplete	O
22	proviral	O
23	transcripts	O
24	and	O
25	their	O
26	spliced	O
27	products	O
28	made	O
29	up	O
30	the	O
31	majority	O
32	of	O
33	expressed	O
34	RD	B
35	-	I
36	114	I
37	mRNA	I
38	,	O
39	and	O
40	further	O
41	demonstrated	O
42	that	O
43	partially	O
44	deleted	O
45	proviral	O
46	loci	O
47	have	O
48	the	O
49	potential	O
50	to	O
51	be	O
52	transcriptionally	O
53	vigorous	O
54	in	O
55	certain	O
56	feline	O
57	cell	O
58	types	O
59	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	The	O
2	major	O
3	phenotypes	O
4	resulting	O
5	from	O
6	Fab1p	B
7	kinase	I
8	inactivation	O
9	include	O
10	temperature	O
11	-	O
12	sensitive	O
13	growth	O
14	,	O
15	vacuolar	O
16	acidification	O
17	defects	O
18	,	O
19	and	O
20	dramatic	O
21	increases	O
22	in	O
23	vacuolar	O
24	size	O
25	.	O

1	Although	O
2	the	O
3	N13	O
4	-	O
5	N20	O
6	interpeak	O
7	interval	O
8	remained	O
9	stable	O
10	because	O
11	of	O
12	the	O
13	parallel	O
14	shift	O
15	of	O
16	the	O
17	2	O
18	peaks	O
19	,	O
20	the	O
21	central	O
22	conduction	O
23	time	O
24	measured	O
25	from	O
26	onset	O
27	latencies	O
28	of	O
29	N11	O
30	and	O
31	N20	O
32	significantly	O
33	increased	O
34	.	O

1	Whereas	O
2	p82	O
3	expression	O
4	had	O
5	no	O
6	effect	O
7	on	O
8	ERK2	B
9	activation	O
10	by	O
11	p126	O
12	,	O
13	p70	B
14	completely	O
15	abrogated	O
16	this	O
17	activity	O
18	.	O

1	Disruption	O
2	of	O
3	RB	B
4	/	I
5	E2F	I
6	-	I
7	1	I
8	interaction	O
9	by	O
10	single	O
11	point	O
12	mutations	O
13	in	O
14	E2F	B
15	-	I
16	1	I
17	enhances	O
18	S	O
19	-	O
20	phase	O
21	entry	O
22	and	O
23	apoptosis	O
24	.	O

1	Conversely	O
2	,	O
3	the	O
4	inactive	O
5	dAK	O
6	subunit	O
7	is	O
8	progressively	O
9	activated	O
10	by	O
11	1	O
12	)	O
13	association	O
14	with	O
15	a	O
16	dGK	O
17	or	O
18	dCK	O
19	subunit	O
20	and	O
21	2	O
22	)	O
23	the	O
24	conformationally	O
25	driven	O
26	heterotropic	O
27	affect	O
28	of	O
29	dGuo	O
30	or	O
31	dCyd	O
32	bound	O
33	to	O
34	the	O
35	opposing	O
36	subunit	O
37	.	O

1	A	I
2	2	I
3	.	I
4	4	I
5	-	I
6	kb	I
7	MAPKAPK	I
8	-	I
9	2	I
10	message	I
11	is	O
12	expressed	O
13	throughout	O
14	development	O
15	,	O
16	while	O
17	two	O
18	shorter	O
19	transcripts	O
20	of	O
21	2	O
22	.	O
23	3	O
24	and	O
25	1	O
26	.	O
27	8	O
28	kb	O
29	appear	O
30	to	O
31	be	O
32	specifically	O
33	expressed	O
34	in	O
35	the	O
36	germline	O
37	.	O

1	Differential	O
2	sensitivity	O
3	of	O
4	the	O
5	MMPI	B
6	-	I
7	2	I
8	depression	O
9	scales	O
10	and	O
11	subscales	O
12	.	O

1	During	O
2	ISO	O
3	+	O
4	AT	O
5	infusion	O
6	,	O
7	abdominal	O
8	fat	O
9	blood	O
10	flow	O
11	was	O
12	still	O
13	significantly	O
14	increased	O
15	as	O
16	compared	O
17	with	O
18	control	O
19	values	O
20	in	O
21	lean	O
22	and	O
23	obese	O
24	subjects	O
25	.	O

1	205	B
2	,	O
3	285	O
4	-	O
5	290	O
6	]	O
7	and	O
8	was	O
9	subsequently	O
10	cloned	O
11	and	O
12	sequenced	O
13	[	O
14	J	O
15	.	O

1	Two	O
2	such	O
3	genes	O
4	,	O
5	designated	O
6	hsiggll150	O
7	and	O
8	hsiggll295	O
9	,	O
10	were	O
11	cloned	O
12	and	O
13	sequenced	O
14	from	O
15	genomic	O
16	DNA	O
17	.	O

1	Five	O
2	concensus	O
3	poly	O
4	A	O
5	addition	O
6	sites	O
7	are	O
8	located	O
9	in	O
10	the	O
11	350	O
12	base	O
13	pairs	O
14	immediately	O
15	following	O
16	the	O
17	protein	B
18	IX	I
19	coding	O
20	region	O
21	.	O

1	Activity	B
2	of	O
3	palgD	O
4	in	O
5	the	O
6	cysB	O
7	mutant	O
8	,	O
9	in	O
10	CHA	O
11	and	O
12	in	O
13	the	O
14	non	O
15	-	O
16	mucoid	O
17	strain	O
18	PAO	O
19	was	O
20	assessed	O
21	by	O
22	the	O
23	use	O
24	of	O
25	a	O
26	transcriptional	O
27	algD	O
28	-	O
29	xylE	O
30	fusion	O
31	.	O

1	An	O
2	important	O
3	mechanism	O
4	by	O
5	which	O
6	the	O
7	tumor	O
8	suppressor	O
9	p53	B
10	maintains	O
11	genomic	O
12	stability	O
13	is	O
14	to	O
15	induce	O
16	cell	O
17	cycle	O
18	arrest	O
19	through	O
20	activation	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	O
28	p21	B
29	(	O
30	WAF1	B
31	/	O
32	Cip1	B
33	)	I
34	gene	I
35	.	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	O
27	3	O
28	N0	B
29	-	I
30	1	I
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	Shear	B
2	bond	O
3	strength	O
4	of	O
5	a	O
6	composite	O
7	resin	O
8	to	O
9	an	O
10	etched	O
11	glass	O
12	ionomer	O
13	.	O

1	Comparison	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequences	O
8	with	O
9	protein	O
10	sequences	O
11	of	O
12	T	O
13	.	O
14	pyriformis	O
15	H2As	O
16	showed	O
17	only	O
18	two	O
19	and	O
20	three	O
21	differences	O
22	respectively	O
23	,	O
24	in	O
25	a	O
26	total	O
27	of	O
28	137	O
29	amino	O
30	acids	O
31	for	O
32	H2A1	O
33	,	O
34	and	O
35	132	O
36	amino	O
37	acids	O
38	for	O
39	H2A2	O
40	,	O
41	indicating	O
42	the	O
43	two	O
44	genes	O
45	arose	O
46	before	O
47	the	O
48	divergence	O
49	of	O
50	these	O
51	two	O
52	species	O
53	.	O

1	The	O
2	CCAAT	B
3	core	I
4	sequence	I
5	mutants	I
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	These	O
2	data	O
3	may	O
4	also	O
5	aid	O
6	in	O
7	the	O
8	localization	O
9	of	O
10	other	O
11	disease	O
12	loci	O
13	mapped	O
14	to	O
15	this	O
16	region	O
17	,	O
18	including	O
19	the	O
20	gene	O
21	for	O
22	tricho	B
23	-	I
24	dento	I
25	-	I
26	osseous	O
27	syndrome	O
28	and	O
29	a	O
30	murine	B
31	locus	I
32	for	O
33	susceptibility	O
34	to	O
35	ozone	O
36	-	O
37	induced	O
38	acute	O
39	lung	O
40	injury	O
41	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	B
25	-	I
26	type	I
27	constructs	I
28	.	O

1	The	O
2	in	O
3	vitro	O
4	antibacterial	O
5	potency	O
6	is	O
7	greatest	O
8	when	O
9	the	O
10	1	O
11	-	O
12	substituent	O
13	is	O
14	2	O
15	,	O
16	4	O
17	-	O
18	difluorophenyl	O
19	and	O
20	the	O
21	7	O
22	-	O
23	substituent	O
24	is	O
25	a	O
26	3	B
27	-	I
28	amino	I
29	-	I
30	1	I
31	-	I
32	pyrrolidinyl	O
33	group	O
34	.	O

1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	I
6	IL6	I
7	beta	I
8	leucine	I
9	zipper	I
10	domain	I
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O

1	Mapping	O
2	of	O
3	RNA	B
4	-	I
5	temperature	I
6	-	I
7	sensitive	I
8	mutants	I
9	of	O
10	Sindbis	O
11	virus	O
12	:	O
13	complementation	O
14	group	O
15	F	O
16	mutants	O
17	have	O
18	lesions	O
19	in	O
20	nsP4	O
21	.	O

1	Evoked	B
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O

1	Groups	B
2	of	O
3	male	O
4	and	O
5	female	O
6	Fischer	O
7	344	O
8	rats	O
9	,	O
10	B6C3F1	O
11	mice	O
12	,	O
13	and	O
14	Hartley	O
15	guinea	O
16	pigs	O
17	were	O
18	exposed	O
19	once	O
20	for	O
21	6	O
22	hr	O
23	to	O
24	mean	O
25	concentrations	O
26	of	O
27	10	O
28	.	O
29	5	O
30	,	O
31	5	O
32	.	O
33	4	O
34	,	O
35	2	O
36	.	O
37	4	O
38	,	O
39	1	O
40	.	O
41	0	O
42	,	O
43	or	O
44	0	O
45	(	O
46	control	O
47	)	O
48	ppm	O
49	of	O
50	methyl	O
51	isocyanate	O
52	(	O
53	MIC	O
54	)	O
55	vapor	O
56	.	O

1	Praziquantel	B
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	neurocysticercosis	O
12	,	O
13	but	O
14	because	O
15	of	O
16	serious	O
17	side	O
18	effects	O
19	encountered	O
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O

1	Innervation	B
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	Piperacillin	B
2	-	I
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Effects	O
2	of	O
3	moderate	O
4	hypercapnia	O
5	on	O
6	hypothermia	O
7	induced	O
8	by	O
9	cold	O
10	He	O
11	-	O
12	O2	O
13	in	O
14	rats	O
15	.	O

1	Proprotein	B
2	processing	O
3	occurs	O
4	intracellularly	O
5	.	O

1	Limb	B
2	allografts	O
3	in	O
4	rats	O
5	immunosuppressed	O
6	with	O
7	cyclosporin	O
8	A	O
9	.	O

1	A	I
2	data	O
3	base	O
4	homology	O
5	search	O
6	revealed	O
7	that	O
8	the	O
9	predicted	O
10	ER1	O
11	amino	O
12	acid	O
13	sequence	O
14	contains	O
15	three	O
16	regions	O
17	of	O
18	similarity	O
19	to	O
20	the	O
21	rat	O
22	and	O
23	human	B
24	proteins	I
25	encoded	I
26	by	O
27	the	O
28	metastasis	O
29	-	O
30	associated	O
31	gene	O
32	,	O
33	mta1	O
34	,	O
35	and	O
36	two	O
37	regions	O
38	of	O
39	similarity	O
40	to	O
41	the	O
42	Caenorhabditis	O
43	elegans	O
44	sequence	O
45	that	O
46	is	O
47	similar	O
48	to	O
49	mta1	O
50	.	O

1	Mobilization	B
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	This	O
2	finding	O
3	is	O
4	the	O
5	first	O
6	example	O
7	of	O
8	utilization	O
9	of	O
10	noncomplementary	O
11	dinucleotide	O
12	primer	O
13	by	O
14	an	O
15	RNA	B
16	polymerase	I
17	.	O

1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O

1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O

1	Inspection	B
2	of	I
3	enhancer	I
4	mutants	I
5	suggests	O
6	that	O
7	trans	O
8	-	O
9	activation	O
10	by	O
11	hLEF	B
12	/	O
13	GAL4	B
14	is	O
15	especially	O
16	dependent	O
17	on	O
18	TCF	B
19	-	I
20	2	I
21	,	O
22	a	O
23	distinct	O
24	T	B
25	-	I
26	cell	I
27	-	I
28	enriched	I
29	protein	I
30	that	O
31	binds	O
32	to	O
33	sequences	O
34	flanking	O
35	the	O
36	hLEF	B
37	-	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	enhancer	O
43	.	O

1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	O
13	virally	O
14	encoded	O
15	proteases	O
16	which	O
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	O
23	factor	O
24	eIF4G	O
25	.	O

1	Intensification	B
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	In	O
2	addition	O
3	,	O
4	narZ	O
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O

1	When	O
2	the	O
3	cervical	O
4	Pap	O
5	smear	O
6	is	O
7	positive	O
8	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	The	O
2	PI3K_68D	O
3	cDNA	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	210	O
9	kDa	O
10	,	O
11	which	O
12	lacks	O
13	sequences	O
14	implicated	O
15	in	O
16	linking	O
17	p110	B
18	PI	I
19	3	I
20	-	I
21	kinases	I
22	to	O
23	p85	B
24	adaptor	I
25	proteins	I
26	,	O
27	but	O
28	contains	O
29	an	O
30	amino	O
31	-	O
32	terminal	O
33	proline	O
34	-	O
35	rich	O
36	sequence	O
37	,	O
38	which	O
39	could	O
40	bind	O
41	to	O
42	SH3	B
43	domains	I
44	,	O
45	and	O
46	a	O
47	carboxy	B
48	-	I
49	terminal	I
50	C2	I
51	domain	I
52	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	B
11	-	I
12	1	I
13	allergen	I
14	of	O
15	Ascaris	O
16	,	O
17	the	O
18	gp15	O
19	/	O
20	400	O
21	'	O
22	ladder	O
23	'	O
24	protein	O
25	of	O
26	Brugia	O
27	malayi	O
28	,	O
29	Brugia	O
30	pahangi	O
31	and	O
32	Wuchereria	O
33	bancrofti	O
34	,	O
35	and	O
36	a	O
37	15	B
38	-	I
39	kDa	I
40	antigen	I
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Second	O
2	report	O
3	of	O
4	the	O
5	Norwegian	O
6	Cancer	O
7	Society	O
8	.	O

1	The	O
2	study	O
3	included	O
4	139	O
5	eyes	O
6	with	O
7	presumed	O
8	ocular	O
9	histoplasmosis	O
10	syndrome	O
11	(	O
12	POHS	O
13	)	O
14	and	O
15	age	O
16	-	O
17	related	O
18	macular	O
19	degeneration	O
20	(	O
21	AMD	O
22	).	O

1	Typical	B
2	and	O
3	atypical	O
4	clinical	O
5	features	O
6	of	O
7	this	O
8	lacrimal	O
9	sac	O
10	cyst	O
11	are	O
12	emphasized	O
13	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	coat	B
6	protein	I
7	promoter	I
8	of	O
9	chloris	O
10	striate	O
11	mosaic	O
12	virus	O
13	is	O
14	enhanced	O
15	by	O
16	its	O
17	own	O
18	and	O
19	C1	B
20	-	I
21	C2	I
22	gene	I
23	products	I
24	.	O

1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O

1	Two	O
2	basic	O
3	patterns	O
4	of	O
5	locomotor	O
6	behavior	O
7	and	O
8	corresponding	O
9	torso	O
10	morphology	O
11	exist	O
12	among	O
13	extant	O
14	anthropoids	O
15	.	O

1	By	O
2	using	O
3	reporter	O
4	gene	O
5	constructs	O
6	,	O
7	it	O
8	is	O
9	shown	O
10	that	O
11	upstream	O
12	sequences	O
13	of	O
14	the	O
15	P1	O
16	promoter	O
17	contain	O
18	several	O
19	regions	O
20	that	O
21	modulate	O
22	the	O
23	expression	O
24	either	O
25	positively	O
26	or	O
27	negatively	O
28	.	O

1	Change	B
2	in	O
3	the	O
4	makeup	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	permanent	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O

1	CONCLUSIONS	O
2	:	O
3	Valproate	O
4	appears	O
5	to	O
6	inhibit	O
7	the	O
8	glucuronidation	O
9	of	O
10	carbamazepine	O
11	-	O
12	10	O
13	,	O
14	11	O
15	-	O
16	trans	O
17	-	O
18	diol	O
19	,	O
20	and	O
21	probably	O
22	also	O
23	inhibits	O
24	the	O
25	conversion	O
26	of	O
27	carbamazepine	O
28	-	O
29	10	O
30	,	O
31	11	O
32	-	O
33	epoxide	O
34	to	O
35	this	O
36	trans	O
37	-	O
38	diol	O
39	derivative	O
40	,	O
41	rather	O
42	than	O
43	simply	O
44	inhibiting	O
45	the	O
46	latter	O
47	reaction	O
48	only	O
49	.	O

1	PRL	B
2	-	I
3	1	I
4	is	O
5	able	O
6	to	O
7	dephosphorylate	O
8	phosphotyrosine	O
9	substrates	O
10	,	O
11	and	O
12	mutation	O
13	of	O
14	the	O
15	active	O
16	-	O
17	site	O
18	cysteine	O
19	residue	O
20	abolishes	O
21	this	O
22	activity	O
23	.	O

1	Thus	O
2	,	O
3	the	O
4	synergistic	O
5	effects	O
6	of	O
7	HNF	B
8	-	I
9	1beta	I
10	and	O
11	the	O
12	GR	B
13	on	O
14	dexamethasone	O
15	-	O
16	stimulated	O
17	promoter	O
18	activity	O
19	require	O
20	that	O
21	they	O
22	are	O
23	bound	O
24	to	O
25	the	O
26	HNF	B
27	-	I
28	1	I
29	site	I
30	and	O
31	the	O
32	GRE	O
33	,	O
34	respectively	O
35	,	O
36	and	O
37	may	O
38	involve	O
39	protein	B
40	-	I
41	protein	I
42	interactions	O
43	between	O
44	the	O
45	transcription	O
46	factors	O
47	,	O
48	or	O
49	between	O
50	them	O
51	and	O
52	the	O
53	basal	O
54	transcription	O
55	machinery	O
56	or	O
57	a	O
58	steroid	B
59	receptor	I
60	coactivator	I
61	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	B
6	gene	I
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	B
12	(+)	I
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	Sulfhydryl	B
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	O
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	O
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	The	O
2	beta	B
3	subunit	I
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	B
22	-	I
23	terminal	I
24	alpha	I
25	-	I
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	B
37	-	I
38	Asp	I
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O

1	Structural	O
2	and	O
3	evolutionary	O
4	studies	O
5	on	O
6	sterol	B
7	14	I
8	-	I
9	demethylase	I
10	P450	I
11	(	O
12	CYP51	O
13	),	O
14	the	O
15	most	O
16	conserved	O
17	P450	B
18	monooxygenase	O
19	:	O
20	I	O
21	.	O

1	A	I
2	"	O
3	Level	O
4	A	O
5	"	O
6	in	O
7	vitro	O
8	/	O
9	in	O
10	vivo	O
11	correlation	O
12	was	O
13	established	O
14	for	O
15	a	O
16	sustained	O
17	release	O
18	theophylline	O
19	(	O
20	CAS	O
21	58	O
22	-	O
23	55	O
24	-	O
25	9	O
26	)	O
27	preparation	O
28	(	O
29	Bronchoretard	O
30	)	O
31	under	O
32	investigation	O
33	.	O

1	Phylogenetic	B
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	O
14	rDNA	O
15	and	O
16	rbcL	O
17	sequences	O
18	.	O

1	This	O
2	paper	O
3	summarises	O
4	the	O
5	experimental	O
6	evidence	O
7	upon	O
8	which	O
9	the	O
10	clinical	O
11	trials	O
12	of	O
13	aldose	B
14	reductase	I
15	inhibitors	O
16	in	O
17	diabetic	O
18	patients	O
19	have	O
20	been	O
21	initiated	O
22	and	O
23	the	O
24	results	O
25	of	O
26	published	O
27	drug	O
28	trials	O
29	in	O
30	these	O
31	patients	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	I
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	O
15	mutation	O
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	B
5	phosphoinositide	I
6	3	I
7	-	I
8	kinase	I
9	with	O
10	a	O
11	C2	B
12	domain	I
13	that	O
14	displays	O
15	reduced	O
16	sensitivity	O
17	to	O
18	the	O
19	inhibitor	O
20	wortmannin	O
21	.	O

1	Bacterial	B
2	metabolism	O
3	of	O
4	4	O
5	-	O
6	chlorophenoxyacetate	O
7	.	O

1	The	O
2	csbA	O
3	fusion	O
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	The	O
2	factor	O
3	which	O
4	binds	O
5	to	O
6	the	O
7	TR	B
8	promoter	I
9	co	O
10	-	O
11	sedimented	O
12	with	O
13	SV40	O
14	chromosomes	O
15	extracted	O
16	late	O
17	in	O
18	infection	O
19	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	genetic	O
6	evidence	O
7	in	O
8	Saccharomyces	O
9	cerevisiae	O
10	for	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	the	O
16	DEAH	O
17	protein	O
18	Prp16	O
19	,	O
20	and	O
21	the	O
22	U6	B
23	and	I
24	U2	I
25	spliceosomal	O
26	snRNAs	O
27	.	O

1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	O
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	Deletion	O
2	and	O
3	mutational	O
4	analyses	O
5	revealed	O
6	two	O
7	positive	O
8	cis	O
9	-	O
10	regulatory	O
11	elements	O
12	in	O
13	this	O
14	region	O
15	that	O
16	are	O
17	essential	O
18	for	O
19	CSX1	O
20	expression	O
21	in	O
22	cardiomyocytes	O
23	.	O

1	Echo	B
2	modulation	O
3	in	O
4	Pr3	O
5	+:	O
6	YAlO3	O
7	.	O

1	PNT	B
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O

1	One	O
2	of	O
3	the	O
4	sequelae	O
5	of	O
6	the	O
7	antiphospholipid	B
8	-	I
9	antibodies	I
10	is	O
11	an	O
12	impaired	O
13	uteroplacental	O
14	circulation	O
15	.	O

1	Signaling	B
2	by	O
3	tyrosine	B
4	kinases	I
5	involves	O
6	direct	O
7	associations	O
8	between	O
9	proteins	O
10	with	O
11	Src	B
12	homology	I
13	2	I
14	(	I
15	SH2	I
16	)	I
17	domains	I
18	and	O
19	sites	O
20	of	O
21	tyrosine	O
22	phosphorylation	O
23	.	O

1	Degradation	B
2	of	O
3	the	O
4	soybean	B
5	ribulose	I
6	-	I
7	1	I
8	,	O
9	5	O
10	-	O
11	bisphosphate	O
12	carboxylase	O
13	small	B
14	-	I
15	subunit	I
16	mRNA	I
17	,	O
18	SRS4	O
19	,	O
20	initiates	O
21	with	O
22	endonucleolytic	O
23	cleavage	O
24	.	O

1	Intracavitary	B
2	irradiation	O
3	was	O
4	carried	O
5	out	O
6	with	O
7	a	O
8	microSelectron	O
9	HDR	O
10	afterloading	O
11	device	O
12	and	O
13	usually	O
14	22	O
15	.	O
16	5	O
17	Gy	O
18	was	O
19	given	O
20	in	O
21	three	O
22	fractions	O
23	repeated	O
24	weekly	O
25	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	O
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	B
19	-	I
20	helical	O
21	structures	O
22	.	O

1	The	O
2	cellular	O
3	rate	O
4	of	O
5	anticoagulant	O
6	heparan	O
7	sulfate	O
8	proteoglycan	O
9	(	O
10	HSPGact	O
11	)	O
12	generation	O
13	is	O
14	determined	O
15	by	O
16	the	O
17	level	O
18	of	O
19	a	O
20	kinetically	O
21	limiting	O
22	microsomal	O
23	activity	O
24	,	O
25	HSact	O
26	conversion	O
27	activity	O
28	,	O
29	which	O
30	is	O
31	predominantly	O
32	composed	O
33	of	O
34	the	O
35	long	O
36	sought	O
37	heparan	B
38	sulfate	I
39	D	I
40	-	I
41	glucosaminyl	I
42	3	I
43	-	I
44	O	I
45	-	I
46	sulfotransferase	I
47	(	I
48	3	I
49	-	I
50	OST	O
51	)	O
52	(	O
53	Shworak	O
54	,	O
55	N	O
56	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	MADS	B
17	domains	I
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	MADS	B
48	domain	I
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	O
16	-	O
17	89	O
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	O
26	(	O
27	Mn1	O
28	)	O
29	seed	B
30	locus	I
31	that	O
32	encodes	O
33	a	O
34	seed	O
35	-	O
36	specific	O
37	cell	O
38	wall	O
39	invertase	O
40	,	O
41	INCW2	O
42	.	O

1	The	O
2	novel	O
3	Notch	B
4	homologue	I
5	mouse	I
6	Notch	I
7	3	I
8	lacks	O
9	specific	O
10	epidermal	B
11	growth	I
12	factor	I
13	-	I
14	repeats	O
15	and	O
16	is	O
17	expressed	O
18	in	O
19	proliferating	O
20	neuroepithelium	O
21	.	O

1	Diuresis	B
2	was	O
3	induced	O
4	by	O
5	scheduled	O
6	drinking	O
7	of	O
8	tea	O
9	(	O
10	150	O
11	ml	O
12	/	O
13	h	O
14	).	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	I
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O

1	BRCA1	B
2	protein	I
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	B
9	finger	I
10	motif	I
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O

1	However	O
2	,	O
3	the	O
4	ratio	O
5	M	O
6	/	O
7	Pc	O
8	provides	O
9	a	O
10	useful	O
11	index	O
12	that	O
13	seems	O
14	to	O
15	be	O
16	independent	O
17	of	O
18	the	O
19	metabolic	O
20	demand	O
21	.	O

1	When	O
2	comparing	O
3	the	O
4	barley	B
5	PSI	I
6	-	I
7	K	I
8	and	O
9	PSI	B
10	-	I
11	G	I
12	with	O
13	the	O
14	reported	O
15	PSI	B
16	-	I
17	K	I
18	sequence	I
19	from	O
20	Synechococcus	O
21	vulcanus	O
22	,	O
23	the	O
24	degree	O
25	of	O
26	similarity	O
27	is	O
28	equal	O
29	,	O
30	suggesting	O
31	that	O
32	an	O
33	ancestral	O
34	gene	O
35	has	O
36	been	O
37	duplicated	O
38	in	O
39	a	O
40	chloroplast	O
41	progenitor	O
42	but	O
43	not	O
44	in	O
45	a	O
46	cyanobacterial	O
47	.	O

1	The	O
2	central	O
3	(	O
4	R	O
5	)	O
6	domain	O
7	is	O
8	responsible	O
9	for	O
10	receptor	O
11	-	O
12	binding	O
13	activity	O
14	whereas	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	(	O
20	T	O
21	)	O
22	domain	O
23	mediates	O
24	translocation	O
25	,	O
26	the	O
27	process	O
28	by	O
29	which	O
30	the	O
31	C	O
32	-	O
33	terminal	O
34	cytotoxic	O
35	domain	O
36	is	O
37	transported	O
38	from	O
39	the	O
40	receptor	O
41	to	O
42	the	O
43	site	O
44	of	O
45	its	O
46	cytotoxicity	O
47	.	O

1	BCR	B
2	-	I
3	ABL	I
4	and	O
5	v	B
6	-	I
7	abl	I
8	oncogenes	I
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	thymic	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	subsets	O
19	.	O

1	The	O
2	microdensitometric	O
3	scores	O
4	and	O
5	their	O
6	side	O
7	-	O
8	to	O
9	-	O
10	side	O
11	differences	O
12	in	O
13	patients	O
14	correlated	O
15	negatively	O
16	with	O
17	the	O
18	serum	O
19	25	O
20	-	O
21	OHD	O
22	concentration	O
23	and	O
24	positively	O
25	with	O
26	the	O
27	degree	O
28	of	O
29	paralysis	O
30	.	O

1	Endorphins	B
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O

1	Statement	B
2	on	O
3	the	O
4	development	O
5	of	O
6	guidelines	O
7	for	O
8	the	O
9	prevention	O
10	of	O
11	AIDS	O
12	transmission	O
13	in	O
14	the	O
15	workplace	O
16	.	O

1	Ophthalmosonographic	B
2	evaluation	O
3	of	O
4	blood	O
5	flow	O
6	velocity	O
7	in	O
8	arteriocavernous	O
9	fistula	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	B
8	-	I
9	binding	I
10	domain	I
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	B
9	gene	I
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	B
18	-	I
19	1	I
20	LTR	I
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	B
40	mitochondrial	I
41	gene	I
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	B
59	gene	I
60	.	O

1	Genetic	O
2	abnormalities	O
3	that	O
4	could	O
5	lead	O
6	to	O
7	mutagenesis	O
8	include	O
9	chromosomal	O
10	abnormalities	O
11	and	O
12	single	O
13	-	O
14	gene	O
15	mutations	O
16	.	O

1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	B
5	-	I
6	amanitin	O
7	conserved	O
8	domain	O
9	of	O
10	the	O
11	largest	O
12	subunit	O
13	of	O
14	yeast	B
15	RNA	I
16	polymerase	I
17	III	I
18	affect	O
19	pausing	O
20	,	O
21	RNA	O
22	cleavage	O
23	and	O
24	transcriptional	O
25	transitions	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	I
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	O
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	O
27	or	O
28	Stat3	B
29	.	O

1	Elimination	O
2	of	O
3	ETH1	O
4	in	O
5	apn1	O
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	B
5	ornithine	I
6	decarboxylase	I
7	-	I
8	related	I
9	sequence	I
10	family	I
11	.	O

1	The	O
2	cDNA	O
3	sequence	O
4	has	O
5	an	O
6	813	O
7	-	O
8	bp	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	whose	O
16	predicted	O
17	amino	O
18	acid	O
19	sequence	O
20	is	O
21	97	O
22	.	O
23	6	O
24	%	O
25	identical	O
26	to	O
27	the	O
28	272	O
29	carboxy	O
30	-	O
31	terminal	O
32	amino	O
33	acids	O
34	of	O
35	the	O
36	human	B
37	ets	I
38	-	I
39	1	I
40	protein	I
41	.	O

1	The	O
2	pCMBS	B
3	-	I
4	reactive	I
5	sulfhydryl	O
6	groups	O
7	were	O
8	located	O
9	exclusively	O
10	in	O
11	the	O
12	exofacial	O
13	half	O
14	of	O
15	the	O
16	plasma	O
17	membrane	O
18	and	O
19	,	O
20	when	O
21	presented	O
22	in	O
23	a	O
24	helical	O
25	model	O
26	,	O
27	lie	O
28	along	O
29	one	O
30	side	O
31	of	O
32	the	O
33	helices	O
34	.	O

1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	B
8	-	I
9	binding	I
10	sequence	I
11	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	although	O
6	218leu	O
7	retains	O
8	normal	O
9	transactivation	O
10	activity	O
11	on	O
12	a	O
13	p53	B
14	promoter	I
15	in	O
16	yeast	O
17	at	O
18	physiological	O
19	temperatures	O
20	,	O
21	it	O
22	is	O
23	not	O
24	capable	O
25	of	O
26	normal	O
27	p53	B
28	function	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	a	O
34	248trp	O
35	allele	O
36	in	O
37	SNU	O
38	-	O
39	C5	O
40	cells	O
41	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	O
9	/	O
10	Smarcal1	O
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	O
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	Nonlocal	B
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	Plasma	B
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	O
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	O
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	We	O
2	have	O
3	been	O
4	studying	O
5	the	O
6	interaction	O
7	of	O
8	the	O
9	oncogenic	O
10	human	O
11	polyomavirus	B
12	BK	O
13	(	O
14	BKV	O
15	)	O
16	with	O
17	the	O
18	tumor	B
19	-	I
20	suppressor	I
21	protein	I
22	p53	I
23	to	O
24	understand	O
25	the	O
26	biology	O
27	of	O
28	this	O
29	virus	O
30	as	O
31	well	O
32	as	O
33	to	O
34	understand	O
35	the	O
36	basic	O
37	mechanisms	O
38	of	O
39	p53	B
40	transactivation	O
41	.	O

1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	O
14	TR2	O
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O

1	Baseline	B
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	The	O
2	standard	O
3	dosage	O
4	of	O
5	anti	B
6	-	I
7	D	I
8	currently	O
9	given	O
10	at	O
11	all	O
12	gestational	O
13	ages	O
14	is	O
15	1	O
16	ampoule	O
17	containing	O
18	125	O
19	micrograms	O
20	of	O
21	anti	B
22	-	I
23	D	I
24	.	O

1	The	O
2	relevance	O
3	of	O
4	these	O
5	elements	O
6	in	O
7	conferring	O
8	anaerobic	O
9	induction	O
10	of	O
11	gpc4	B
12	gene	I
13	expression	O
14	is	O
15	discussed	O
16	.	O

1	Propranolol	B
2	also	O
3	effectively	O
4	controlled	O
5	her	O
6	familial	O
7	tremor	O
8	.	O

1	Characterization	O
2	of	O
3	a	O
4	human	O
5	alternatively	O
6	spliced	O
7	truncated	O
8	reduced	O
9	folate	O
10	carrier	O
11	increasing	O
12	folate	O
13	accumulation	O
14	in	O
15	parental	O
16	leukemia	O
17	cells	O
18	.	O

1	The	O
2	isolated	O
3	plasmin	O
4	fragments	O
5	of	O
6	VEGF	B
7	were	O
8	compared	O
9	with	O
10	respect	O
11	to	O
12	heparin	O
13	binding	O
14	,	O
15	interaction	O
16	with	O
17	soluble	O
18	VEGF	B
19	receptors	I
20	,	O
21	and	O
22	ability	O
23	to	O
24	promote	O
25	endothelial	O
26	cell	O
27	mitogenesis	O
28	.	O

1	The	O
2	presence	O
3	of	O
4	cutaneous	O
5	xanthomas	O
6	with	O
7	normal	O
8	serum	O
9	lipid	O
10	levels	O
11	is	O
12	due	O
13	to	O
14	the	O
15	antibetalipoproteic	O
16	activity	O
17	of	O
18	the	O
19	monoclonal	O
20	immunoglobulin	B
21	.	O

1	The	O
2	N1	O
3	and	O
4	P2	O
5	were	O
6	comparable	O
7	in	O
8	amplitude	O
9	and	O
10	both	O
11	had	O
12	prolonged	O
13	refractory	O
14	periods	O
15	.	O

1	The	O
2	Nur77	O
3	protein	O
4	can	O
5	act	O
6	as	O
7	a	O
8	potent	O
9	transcription	O
10	activator	O
11	and	O
12	may	O
13	function	O
14	to	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	downstream	O
20	genes	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	.	O

1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O

1	A	I
2	transformation	O
3	-	O
4	competent	O
5	mutant	O
6	,	O
7	like	O
8	the	O
9	wild	B
10	-	I
11	type	I
12	E5	I
13	protein	I
14	,	O
15	bound	O
16	the	O
17	receptor	O
18	and	O
19	induced	O
20	receptor	O
21	tyrosine	O
22	phosphorylation	O
23	and	O
24	down	O
25	-	O
26	regulation	O
27	.	O

1	The	O
2	2	O
3	cDNAs	O
4	differed	O
5	in	O
6	the	O
7	length	O
8	of	O
9	their	O
10	respective	O
11	3	O
12	'	O
13	untranslated	O
14	regions	O
15	,	O
16	of	O
17	577	O
18	bp	O
19	in	O
20	Cp	B
21	.	O
22	F6	O
23	and	O
24	72	O
25	bp	O
26	in	O
27	Cp	B
28	.	O
29	F10	O
30	,	O
31	in	O
32	both	O
33	of	O
34	which	O
35	a	O
36	putative	O
37	polyadenylation	O
38	signal	O
39	was	O
40	identified	O
41	.	O

1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O

1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	O
8	repair	O
9	enzyme	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O

1	The	O
2	beta	B
3	subunit	I
4	of	O
5	the	O
6	Fc	B
7	epsilon	I
8	R1	I
9	is	O
10	a	O
11	33	O
12	-	O
13	kDa	O
14	tyrosine	O
15	phosphoprotein	O
16	,	O
17	but	O
18	the	O
19	p33	O
20	Grb2	B
21	-	I
22	binding	I
23	protein	I
24	described	O
25	in	O
26	the	O
27	present	O
28	report	O
29	is	O
30	not	O
31	the	O
32	Fc	B
33	epsilon	I
34	R1	I
35	beta	I
36	chain	I
37	and	O
38	its	O
39	identity	O
40	is	O
41	unknown	O
42	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	402	O
6	consecutive	O
7	autopsies	O
8	,	O
9	parietal	O
10	pleural	O
11	plaques	O
12	(	O
13	PP	O
14	)	O
15	were	O
16	found	O
17	in	O
18	68	O
19	individuals	O
20	above	O
21	40	O
22	years	O
23	of	O
24	age	O
25	.	O

1	Wave	B
2	cybernetics	O
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	O
9	,	O
10	Fli1	O
11	,	O
12	GABPalpha	O
13	,	O
14	SAP1	O
15	,	O
16	Elk1	O
17	,	O
18	and	O
19	PE1	O
20	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	O
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	O
16	-	O
17	cortisol	O
18	release	O
19	.	O

1	Alternating	B
2	proline	O
3	/	O
4	alanine	O
5	sequence	O
6	of	O
7	beta	B
8	B1	I
9	subunit	I
10	originates	O
11	from	O
12	a	O
13	repetitive	O
14	DNA	O
15	sequence	O
16	.	O

1	Results	O
2	of	O
3	the	O
4	official	O
5	inspection	O
6	of	O
7	the	O
8	commercial	O
9	anti	B
10	-	I
11	inflammatory	O
12	enzyme	O
13	preparations	O
14	containing	O
15	chymotrypsin	O
16	and	O
17	trypsin	B
18	by	O
19	means	O
20	of	O
21	modified	O
22	NF	B
23	13	O
24	methods	O

1	Interleukin	B
2	-	I
3	12	O
4	(	O
5	IL	B
6	-	I
7	12	O
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	O
23	interferon	B
24	-	I
25	gamma	I
26	(	I
27	IFN	I
28	-	I
29	gamma	I
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	The	O
2	use	O
3	of	O
4	specific	O
5	antibodies	O
6	allowed	O
7	the	O
8	identification	O
9	of	O
10	at	O
11	least	O
12	RAR	B
13	beta	I
14	in	O
15	some	O
16	of	O
17	the	O
18	DNA	B
19	-	I
20	protein	I
21	complexes	I
22	,	O
23	although	O
24	the	O
25	four	O
26	sequences	O
27	bind	O
28	single	O
29	RARs	O
30	transfected	O
31	in	O
32	COS	O
33	cells	O
34	much	O
35	less	O
36	efficiently	O
37	,	O
38	or	O
39	not	O
40	at	O
41	all	O
42	,	O
43	when	O
44	compared	O
45	to	O
46	a	O
47	canonical	O
48	RAR	B
49	responsive	I
50	element	I
51	.	O

1	KRN2391	B
2	and	O
3	cromakalim	O
4	produced	O
5	a	O
6	dose	O
7	-	O
8	dependent	O
9	increase	O
10	in	O
11	aortic	O
12	and	O
13	coronary	O
14	blood	O
15	flow	O
16	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Anu2p	O
6	is	O
7	the	O
8	yeast	O
9	homologue	O
10	of	O
11	mammalian	B
12	epsilon	I
13	-	I
14	COP	O
15	and	O
16	the	O
17	abrupt	O
18	accumulation	O
19	of	O
20	the	O
21	ER	O
22	membrane	O
23	caused	O
24	by	O
25	a	O
26	blockage	O
27	of	O
28	the	O
29	early	O
30	protein	O
31	transport	O
32	pathway	O
33	leads	O
34	to	O
35	alteration	O
36	of	O
37	nuclear	O
38	morphology	O
39	of	O
40	the	O
41	budding	O
42	yeast	O
43	cells	O
44	.	O

1	Amino	O
2	acid	O
3	residues	O
4	of	O
5	beta	B
6	1	I
7	',	I
8	alpha	I
9	A	I
10	',	I
11	alpha	I
12	B	I
13	',	O
14	and	O
15	the	O
16	loop	O
17	containing	O
18	His539	O
19	of	O
20	the	O
21	RNase	B
22	H	I
23	domain	I
24	interact	O
25	with	O
26	the	O
27	primer	O
28	strand	O
29	of	O
30	the	O
31	dsDNA	O
32	.	O

1	Parasitological	B
2	post	O
3	-	O
4	mortem	O
5	examination	O
6	of	O
7	all	O
8	seropositive	O
9	animals	O
10	showed	O
11	five	O
12	and	O
13	seven	O
14	false	O
15	-	O
16	positive	O
17	animals	O
18	when	O
19	E	O
20	/	O
21	S	O
22	and	O
23	CWE	O
24	antigens	O
25	were	O
26	used	O
27	,	O
28	respectively	O
29	.	O

1	High	B
2	-	I
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O

1	Polymyxin	B
2	B	I
3	was	O
4	given	O
5	intravenously	O
6	for	O
7	1	O
8	week	O
9	postburn	O
10	in	O
11	doses	O
12	designed	O
13	to	O
14	neutralize	O
15	circulating	O
16	endotoxemia	O
17	.	O

1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	O
21	Lytic	O
22	Factor	B
23	and	O
24	Phospholipase	O
25	-	O
26	A	O
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	A	I
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	O
7	receptors	O
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O

1	A	I
2	unified	O
3	approach	O
4	to	O
5	the	O
6	standardization	O
7	of	O
8	allergens	O
9	.	O

1	A	I
2	medical	O
3	-	O
4	geographical	O
5	review	O

1	Regional	B
2	insertional	I
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	O
10	/	O
11	CIC2B9	O
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	B
21	/	I
22	Ds	I
23	transposon	I
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	The	O
2	Aie1	O
3	locus	O
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	B
10	-	I
11	A3	I
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	JPEG	B
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	Lead	B
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O

1	The	O
2	indoor	O
3	radon	O
4	concentration	O
5	in	O
6	the	O
7	summer	O
8	(	O
9	1990	O
10	)	O
11	period	O
12	ranged	O
13	between	O
14	8	O
15	and	O
16	81	O
17	Bq	O
18	m	O
19	-	O
20	3	O
21	,	O
22	while	O
23	in	O
24	the	O
25	winter	O
26	(	O
27	1989	O
28	-	O
29	1990	O
30	)	O
31	it	O
32	ranged	O
33	between	O
34	20	O
35	and	O
36	143	O
37	Bq	O
38	m	O
39	-	O
40	3	O
41	for	O
42	the	O
43	first	O
44	year	O
45	of	O
46	measurements	O
47	or	O
48	between	O
49	8	O
50	and	O
51	92	O
52	Bq	O
53	m	O
54	-	O
55	3	O
56	in	O
57	the	O
58	summer	O
59	(	O
60	1991	O
61	)	O
62	period	O
63	and	O
64	between	O
65	12	O
66	and	O
67	119	O
68	Bq	O
69	m	O
70	-	O
71	3	O
72	in	O
73	the	O
74	winter	O
75	(	O
76	1990	O
77	-	O
78	1991	O
79	)	O
80	for	O
81	the	O
82	second	O
83	year	O
84	of	O
85	measurements	O
86	.	O

1	We	O
2	conclude	O
3	that	O
4	administration	O
5	of	O
6	the	O
7	calcium	O
8	antagonist	O
9	Verapamil	O
10	is	O
11	of	O
12	no	O
13	additional	O
14	value	O
15	in	O
16	tocolytic	O
17	treatment	O
18	with	O
19	beta	B
20	-	I
21	mimetics	O
22	.	O

1	Examination	O
2	of	O
3	neurohumoral	O
4	factors	O
5	revealed	O
6	a	O
7	hyperactive	O
8	sympathetic	O
9	nervous	O
10	system	O
11	and	O
12	an	O
13	increase	O
14	in	O
15	plasma	B
16	renin	I
17	activity	O
18	.	O

1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O

1	Pseudocontact	B
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O

1	Some	O
2	users	O
3	will	O
4	willingly	O
5	comply	O
6	with	O
7	management	O
8	measures	O
9	,	O
10	other	O
11	users	O
12	will	O
13	comply	O
14	in	O
15	response	O
16	to	O
17	education	O
18	,	O
19	but	O
20	there	O
21	will	O
22	be	O
23	another	O
24	group	O
25	who	O
26	will	O
27	only	O
28	respond	O
29	to	O
30	enforcement	O
31	activities	O
32	.	O

1	A	I
2	fluoroimmunoassay	O
3	for	O
4	the	O
5	determination	O
6	of	O
7	serum	O
8	of	O
9	plasma	O
10	levels	O
11	of	O
12	propranolol	O
13	was	O
14	developed	O
15	using	O
16	antibodies	O
17	to	O
18	propranolol	O
19	coupled	O
20	to	O
21	magnetizable	O
22	solid	O
23	-	O
24	phase	O
25	particles	O
26	and	O
27	fluorescein	O
28	-	O
29	labeled	O
30	propranolol	O
31	as	O
32	tracer	O
33	.	O

1	HEED	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	to	O
7	MA	B
8	protein	I
9	in	O
10	vitro	O
11	,	O
12	as	O
13	efficiently	O
14	as	O
15	in	O
16	vivo	O
17	in	O
18	yeast	O
19	cells	O
20	.	O

1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	B
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O

1	Vivid	B
2	visual	O
3	hallucinations	O
4	without	O
5	other	O
6	psychopathology	O
7	have	O
8	been	O
9	reported	O
10	for	O
11	several	O
12	hundred	O
13	years	O
14	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	O
6	PHO8	O
7	promoter	O
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	O
14	promoter	O
15	.	O

1	Seventy	O
2	-	O
3	two	O
4	of	O
5	73	O
6	negative	O
7	controls	O
8	and	O
9	all	O
10	positive	O
11	blocks	O
12	as	O
13	seen	O
14	on	O
15	soft	O
16	tissue	O
17	radiographs	O
18	(	O
19	STRs	O
20	)	O
21	were	O
22	correctly	O
23	coded	O
24	(	O
25	specificity	O
26	98	O
27	.	O
28	6	O
29	%,	O
30	sensitivity	O
31	100	O
32	%).	O

1	Biohydrogenation	B
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O

1	These	O
2	observations	O
3	link	B
4	actin	I
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	Disruption	O
2	demonstrates	O
3	that	O
4	CDC14	O
5	is	O
6	an	O
7	essential	O
8	gene	O
9	.	O

1	Analysis	O
2	of	O
3	1	O
4	Mb	O
5	of	O
6	published	O
7	sequence	O
8	from	O
9	the	O
10	region	O
11	of	O
12	conserved	O
13	synteny	O
14	on	O
15	human	O
16	chromosome	O
17	5q31	O
18	-	O
19	q33	O
20	identified	O
21	45	O
22	gene	O
23	candidates	O
24	,	O
25	including	O
26	35	O
27	expressed	O
28	genes	O
29	in	O
30	the	O
31	human	O
32	IL	B
33	-	I
34	4	I
35	cytokine	I
36	gene	I
37	cluster	I
38	.	O

1	Responsibility	B
2	matters	O
3	--	O
4	this	O
5	is	O
6	a	O
7	scientific	O
8	council	O

1	No	O
2	drop	O
3	in	O
4	oxygen	O
5	saturation	O
6	(	O
7	SaO2	O
8	)	O
9	or	O
10	visual	O
11	evidence	O
12	of	O
13	transient	O
14	electroencephalographic	O
15	(	O
16	EEG	O
17	)	O
18	arousals	O
19	can	O
20	be	O
21	found	O
22	at	O
23	repeat	O
24	polysomnography	O
25	.	O

1	The	O
2	progression	O
3	of	O
4	acute	O
5	bronchitis	O
6	is	O
7	associated	O
8	with	O
9	elevated	O
10	blood	O
11	concentrations	O
12	of	O
13	acute	O
14	-	O
15	phase	O
16	proteins	O
17	,	O
18	KKS	O
19	activation	O
20	in	O
21	the	O
22	blood	O
23	and	O
24	high	O
25	serotonin	O
26	and	O
27	lactic	O
28	acid	O
29	content	O
30	in	O
31	the	O
32	humor	O
33	condensated	O
34	from	O
35	the	O
36	exhaled	O
37	air	O
38	.	O

1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	B
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	B
57	.	O

1	A	I
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	O
12	(	O
13	1990	O
14	)	O
15	is	O
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	O

1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O

1	Subjects	B
2	were	O
3	16	O
4	male	O
5	chronic	O
6	schizophrenics	O
7	consisting	O
8	of	O
9	8	O
10	DST	O
11	suppressors	O
12	and	O
13	8	O
14	nonsuppressors	O
15	.	O

1	A	I
2	deletion	I
3	mutation	I
4	analysis	O
5	of	O
6	the	O
7	recombinant	B
8	protein	I
9	has	O
10	shown	O
11	that	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	region	O
17	and	O
18	the	O
19	two	O
20	leucine	O
21	zippers	O
22	are	O
23	necessary	O
24	for	O
25	the	O
26	binding	O
27	.	O

1	After	O
2	a	O
3	survey	O
4	of	O
5	the	O
6	anatomical	O
7	and	O
8	physiological	O
9	basis	O
10	of	O
11	operative	O
12	treatment	O
13	of	O
14	behaviour	O
15	disorders	O
16	by	O
17	stereotactic	O
18	lesions	O
19	in	O
20	the	O
21	amygdala	O
22	and	O
23	the	O
24	posterior	O
25	medial	O
26	hypothalamus	O
27	the	O
28	author	O
29	describes	O
30	his	O
31	own	O
32	experiences	O
33	with	O
34	603	O
35	operations	O
36	for	O
37	control	O
38	of	O
39	conservatively	O
40	untreatable	O
41	aggressiveness	O
42	.	O

1	Static	O
2	lung	O
3	function	O
4	in	O
5	puppies	O
6	after	O
7	pneumonectomy	O
8	.	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	O
8	at	O
9	one	O
10	year	O
11	(	O
12	SPK	B
13	1	I
14	.	O
15	8	O
16	,	O
17	KTA	O
18	1	O
19	.	O
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	O
29	WORDS	O
30	)	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	describe	O
6	properties	O
7	of	O
8	the	O
9	cdc10	O
10	-	O
11	C4	B
12	mutant	I
13	of	O
14	the	O
15	fission	O
16	yeast	O
17	Schizosaccharomyces	O
18	pombe	O
19	.	O

1	CONCLUSION	O
2	:	O
3	Patients	O
4	wit	O
5	clinically	O
6	palpable	O
7	neck	O
8	disease	O
9	(	O
10	N1	O
11	-	O
12	3	O
13	),	O
14	histological	O
15	evidence	O
16	of	O
17	metastatic	O
18	nodal	O
19	disease	O
20	,	O
21	extracapsular	O
22	spread	O
23	,	O
24	and	O
25	three	O
26	or	O
27	more	O
28	positive	O
29	lymph	O
30	nodes	O
31	are	O
32	at	O
33	greater	O
34	risk	O
35	of	O
36	developing	O
37	failure	O
38	at	O
39	distant	O
40	sites	O
41	.	O

1	Marker	B
2	rescue	O
3	analysis	O
4	has	O
5	localized	O
6	ts8	O
7	to	O
8	a	O
9	910	O
10	-	O
11	bp	O
12	internal	O
13	segment	O
14	of	O
15	rpoB	O
16	that	O
17	encodes	O
18	the	O
19	Rif	O
20	domain	O
21	.	O

1	These	O
2	include	O
3	the	O
4	CACCC	O
5	and	O
6	CAAT	O
7	motifs	O
8	.	O

1	Injection	B
2	of	O
3	double	O
4	-	O
5	stranded	O
6	RNA	O
7	into	O
8	C	O
9	.	O
10	elegans	O
11	results	O
12	in	O
13	embryonic	O
14	lethality	O
15	;	O
16	thus	O
17	,	O
18	the	O
19	SF1	B
20	gene	I
21	is	O
22	essential	O
23	not	O
24	only	O
25	in	O
26	yeast	O
27	but	O
28	also	O
29	in	O
30	at	O
31	least	O
32	one	O
33	metazoan	O
34	.	O

1	Clones	B
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	B
8	-	I
9	dependent	I
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	O
17	SF	B
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	B
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	B
30	-	I
31	dependent	I
32	transcription	I
33	.	O

1	The	O
2	human	B
3	gp39	I
4	promoter	I
5	.	O

1	Drug	O
2	inhibition	O
3	of	O
4	whole	O
5	blood	O
6	aspirin	B
7	esterase	I
8	.	O

1	The	O
2	DNA	O
3	sequences	O
4	predict	O
5	proteins	O
6	for	O
7	SRP54sc	O
8	and	O
9	SRP54sp	O
10	that	O
11	are	O
12	47	O
13	%	O
14	and	O
15	52	O
16	%	O
17	identical	O
18	to	O
19	SRP54mam	O
20	,	O
21	respectively	O
22	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	different	O
6	models	O
7	of	O
8	intestinal	O
9	ischemia	O
10	have	O
11	different	O
12	cytokine	O
13	profiles	O
14	and	O
15	that	O
16	the	O
17	early	O
18	TNF	B
19	response	I
20	associated	I
21	with	O
22	SMA	O
23	occlusion	O
24	model	O
25	is	O
26	primarily	O
27	due	O
28	to	O
29	the	O
30	laparotomy	O
31	.	O

1	Antithrombin	B
2	III	I
3	prevents	O
4	60	O
5	min	O
6	warm	O
7	intestinal	O
8	ischemia	O
9	reperfusion	O
10	injury	O
11	in	O
12	rats	O
13	.	O

1	In	O
2	vitro	O
3	expression	O
4	of	O
5	four	O
6	different	O
7	naturally	O
8	occurring	O
9	nonsense	O
10	and	O
11	missense	O
12	mutations	O
13	revealed	O
14	a	O
15	dramatically	O
16	altered	O
17	subcellular	O
18	location	O
19	of	O
20	the	O
21	protein	O
22	in	O
23	cultured	O
24	cells	O
25	.	O

1	The	O
2	remaining	O
3	RAD	O
4	+	O
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O

1	However	O
2	,	O
3	little	O
4	was	O
5	understood	O
6	about	O
7	the	O
8	normal	O
9	function	O
10	of	O
11	CREB	B
12	-	I
13	2	I
14	in	O
15	mammalian	O
16	development	O
17	or	O
18	organ	O
19	physiology	O
20	.	O

1	This	O
2	motif	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	mediate	O
8	protein	O
9	interactions	O
10	in	O
11	the	O
12	case	O
13	of	O
14	ankyrin	B
15	as	O
16	well	O
17	as	O
18	several	O
19	other	O
20	repeat	O
21	-	O
22	bearing	O
23	proteins	O
24	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	O
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	Surprisingly	O
2	,	O
3	calf	O
4	thymus	O
5	CstF	O
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	O
14	64	B
15	-	I
16	kDa	I
17	subunit	I
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	B
8	-	I
9	type	I
10	Fus3	O
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	O
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O

1	2	I
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	The	O
2	associations	O
3	between	O
4	sex	B
5	-	I
6	hormone	I
7	-	I
8	binding	I
9	globulin	I
10	capacity	O
11	(	O
12	SHBG	O
13	),	O
14	age	O
15	,	O
16	body	O
17	mass	O
18	index	O
19	(	O
20	BMI	O
21	),	O
22	and	O
23	physical	O
24	fitness	O
25	have	O
26	been	O
27	studied	O
28	in	O
29	34	O
30	men	O
31	and	O
32	36	O
33	women	O
34	.	O

1	Influence	O
2	of	O
3	diet	O
4	on	O
5	urinary	O
6	VMA	O
7	excretion	O
8	.	O

1	Two	O
2	BASIC	O
3	computer	O
4	programs	O
5	using	O
6	logit	O
7	transformation	O
8	for	O
9	the	O
10	analysis	O
11	of	O
12	S	O
13	-	O
14	shaped	O
15	curves	O
16	are	O
17	presented	O
18	.	O

1	Electromobility	B
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	O
9	,	O
10	but	O
11	not	O
12	HNF4	O
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	I
23	expression	O
24	.	O

1	The	O
2	protein	O
3	mixtures	O
4	of	O
5	sesame	O
6	flour	O
7	and	O
8	soybean	O
9	flour	O
10	were	O
11	well	O
12	accepted	O
13	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	B
11	protein	I
12	C	I
13	-	I
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O

1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	B
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	rat	B
7	chromosomal	I
8	gene	I
9	for	O
10	a	O
11	polypeptide	O
12	(	O
13	pS1	O
14	)	O
15	antigenically	O
16	related	O
17	to	O
18	statin	O
19	.	O

1	Radiogallium	B
2	imaging	O
3	is	O
4	thus	O
5	of	O
6	limited	O
7	use	O
8	in	O
9	evaluation	O
10	of	O
11	suspected	O
12	giant	O
13	cell	O
14	tumors	O
15	of	O
16	bone	O
17	.	O

1	The	O
2	femoral	O
3	artery	O
4	/	O
5	vein	O
6	and	O
7	the	O
8	soleus	O
9	and	O
10	gastrocnemius	O
11	muscles	O
12	were	O
13	examined	O
14	in	O
15	healthy	O
16	human	O
17	male	O
18	volunteers	O
19	.	O

1	The	O
2	central	O
3	visual	O
4	fields	O
5	of	O
6	2165	O
7	normal	O
8	and	O
9	106	O
10	glaucoma	O
11	eyes	O
12	were	O
13	measured	O
14	using	O
15	a	O
16	threshold	O
17	related	O
18	suprathreshold	O
19	strategy	O
20	.	O

1	Collectively	O
2	,	O
3	the	O
4	results	O
5	suggest	O
6	that	O
7	ARF	B
8	binding	I
9	to	O
10	Mdm2	O
11	induces	O
12	a	O
13	conformational	O
14	change	O
15	that	O
16	facilitates	O
17	nucleolar	O
18	import	O
19	of	O
20	the	O
21	ARF	B
22	-	I
23	Mdm2	I
24	complex	I
25	and	O
26	p53	B
27	-	I
28	dependent	I
29	cell	O
30	cycle	O
31	arrest	O
32	.	O

1	It	O
2	was	O
3	subsequently	O
4	shown	O
5	that	O
6	Tip60	O
7	had	O
8	histone	B
9	acetyltransferase	I
10	(	O
11	HAT	O
12	)	O
13	activity	O
14	.	O

1	Cloning	O
2	of	O
3	higher	O
4	plant	B
5	omega	I
6	-	I
7	3	I
8	fatty	I
9	acid	I
10	desaturases	O
11	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	O
11	and	O
12	TbetaRII	O
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	O
28	.	O

1	An	O
2	exon	O
3	that	O
4	prevents	O
5	transport	O
6	of	O
7	a	O
8	mature	O
9	mRNA	O
10	.	O

1	Unlike	O
2	ARF	B
3	,	O
4	the	O
5	ARP	O
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O

1	In	O
2	addition	O
3	to	O
4	a	O
5	previously	O
6	characterized	O
7	promoter	O
8	(	O
9	P1	O
10	),	O
11	we	O
12	now	O
13	show	O
14	the	O
15	existence	O
16	of	O
17	a	O
18	second	O
19	promoter	O
20	for	O
21	the	O
22	human	O
23	IL	B
24	-	I
25	5Ralpha	I
26	gene	I
27	.	O

1	To	O
2	facilitate	O
3	manipulation	O
4	of	O
5	large	O
6	genomic	O
7	sequences	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	method	O
13	of	O
14	converting	O
15	Escherichia	O
16	coli	O
17	P1	O
18	artificial	O
19	chromosomes	O
20	(	O
21	PACs	O
22	)	O
23	into	O
24	yeast	O
25	artificial	O
26	chromosomes	O
27	(	O
28	YACs	O
29	).	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	O
14	triose	B
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	of	O
5	one	O
6	human	O
7	liver	O
8	clone	O
9	(	O
10	HL	O
11	-	O
12	14	O
13	)	O
14	was	O
15	identical	O
16	to	O
17	the	O
18	rabbit	B
19	skeletal	I
20	muscle	I
21	phosphatase	I
22	2A	I
23	cDNA	I
24	(	O
25	with	O
26	97	O
27	%	O
28	nucleotide	O
29	identity	O
30	).	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	unique	O
7	suppository	O
8	formulation	O
9	of	O
10	CZX	B
11	-	I
12	S	I
13	is	O
14	useful	O
15	in	O
16	the	O
17	treatment	O
18	of	O
19	infections	O
20	in	O
21	children	O
22	with	O
23	heavy	O
24	psychophysiologic	O
25	disorders	O
26	and	O
27	in	O
28	children	O
29	who	O
30	cannot	O
31	take	O
32	oral	O
33	drugs	O
34	because	O
35	of	O
36	severe	O
37	vomiting	O
38	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	O
6	protein	O
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	B
10	beta	I
11	revealed	O
12	that	O
13	SR	B
14	beta	I
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	O
20	,	O
21	like	O
22	SR	B
23	alpha	I
24	and	O
25	SRP54	O
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	B
33	superfamily	I
34	.	O

1	The	O
2	hyperacute	O
3	phase	O
4	of	O
5	posterolateral	O
6	myocardial	O
7	infarction	O
8	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	study	O
5	documents	O
6	that	O
7	regression	O
8	of	O
9	choroidal	O
10	neovascularization	O
11	that	O
12	occurred	O
13	with	O
14	alpha	B
15	interferon	I
16	treatment	O
17	was	O
18	minimal	O
19	.	O

1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O

1	SSF	B
2	experiments	O
3	were	O
4	carried	O
5	out	O
6	in	O
7	bench	O
8	-	O
9	scale	O
10	bioreactors	O
11	(	O
12	equipped	O
13	with	O
14	CO2	O
15	and	O
16	volatile	O
17	organic	O
18	traps	O
19	)	O
20	containing	O
21	a	O
22	mixture	O
23	of	O
24	lignocellulosic	O
25	materials	O
26	and	O
27	a	O
28	radiolabeled	O
29	pesticide	O
30	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	the	O
8	PERE	O
9	formed	O
10	three	O
11	major	O
12	complexes	O
13	(	O
14	P1	O
15	,	O
16	P2	O
17	and	O
18	P3	O
19	)	O
20	with	O
21	proteins	O
22	in	O
23	nuclear	O
24	extracts	O
25	from	O
26	HeLa	O
27	or	O
28	293	O
29	cells	O
30	.	O

1	Deglycosylation	B
2	with	O
3	endoglycosidase	O
4	H	O
5	showed	O
6	that	O
7	the	O
8	mutant	O
9	receptors	O
10	had	O
11	mainly	O
12	high	O
13	-	O
14	mannose	O
15	oligosaccharide	O
16	chains	O
17	.	O

1	Scapulae	B
2	with	O
3	a	O
4	Type	O
5	I	O
6	configuration	O
7	were	O
8	found	O
9	to	O
10	have	O
11	low	O
12	values	O
13	for	O
14	the	O
15	coraco	O
16	-	O
17	glenoid	O
18	angle	O
19	and	O
20	coracoid	O
21	overlap	O
22	,	O
23	which	O
24	are	O
25	known	O
26	to	O
27	be	O
28	associated	O
29	with	O
30	a	O
31	short	O
32	coraco	O
33	-	O
34	humeral	O
35	distance	O
36	.	O

1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O

1	63	O
2	.	O
3	3	O
4	micromol	O
5	/	O
6	1	O
7	,	O
8	p	O
9	<	O
10	0	O
11	.	O
12	01	O
13	)	O
14	and	O
15	area	O
16	under	O
17	the	O
18	plasma	O
19	concentration	O
20	-	O
21	time	O
22	curve	O
23	extrapolated	O
24	to	O
25	infinity	O
26	AUC	O
27	9	O
28	(	O
29	0	O
30	-	O
31	infinity	O
32	)(	O
33	518	O
34	.	O
35	7	O
36	vs	O
37	.	O

1	Acute	O
2	decrease	O
3	in	O
4	body	O
5	temperature	O
6	(	O
7	TB	O
8	)	O
9	lowered	O
10	PaCO2	O
11	(	O
12	32	O
13	.	O
14	5	O
15	to	O
16	14	O
17	.	O
18	5	O
19	mmHg	O
20	)	O
21	and	O
22	[	O
23	HCO3	O
24	-]	O
25	a	O
26	(	O
27	24	O
28	.	O
29	20	O
30	mEq	O
31	/	O
32	L	O
33	to	O
34	17	O
35	.	O
36	56	O
37	mEq	O
38	/	O
39	L	O
40	),	O
41	increased	O
42	pHa	O
43	(	O
44	7	O
45	.	O
46	481	O
47	to	O
48	7	O
49	.	O
50	608	O
51	)	O
52	and	O
53	diminished	O
54	the	O
55	[	O
56	OH	O
57	-]/[	O
58	H	O
59	+]	O
60	ratio	O
61	,	O
62	but	O
63	had	O
64	no	O
65	significant	O
66	effect	O
67	on	O
68	[	O
69	SID	O
70	]	O
71	or	O
72	[	O
73	Atot	O
74	],	O
75	although	O
76	both	O
77	total	O
78	phosphorus	O
79	[	O
80	PT	O
81	]	O
82	and	O
83	inorganic	O
84	phosphate	O
85	[	O
86	Pi	O
87	]	O
88	increased	O
89	.	O

1	Mutations	O
2	in	O
3	UPF1	B
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	Addition	O
2	of	O
3	Rap	O
4	or	O
5	KN62	O
6	after	O
7	exposure	O
8	of	O
9	cells	O
10	to	O
11	progesterone	O
12	agonist	O
13	Org	O
14	2058	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	induction	O
20	of	O
21	CAT	B
22	activity	O
23	.	O

1	Multiple	O
2	regression	O
3	analyses	O
4	revealed	O
5	that	O
6	WAIS	B
7	-	I
8	R	I
9	factor	I
10	scores	O
11	Verbal	O
12	Comprehension	O
13	and	O
14	Freedom	O
15	from	O
16	Distractibility	O
17	accounted	O
18	for	O
19	up	O
20	to	O
21	42	O
22	%	O
23	of	O
24	the	O
25	variance	O
26	in	O
27	WMS	B
28	-	I
29	R	I
30	and	O
31	CVLT	O
32	indices	O
33	.	O

1	MSSPs	B
2	are	O
3	believed	O
4	to	O
5	regulate	O
6	DNA	O
7	replication	O
8	,	O
9	transcription	O
10	,	O
11	apopotosis	O
12	and	O
13	cell	O
14	cycle	O
15	progression	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	C	B
21	-	I
22	MYC	I
23	protein	I
24	.	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	The	O
2	murine	O
3	Htf9	O
4	-	O
5	a	O
6	/	O
7	RanBP1	O
8	and	O
9	Htf9	B
10	-	I
11	c	I
12	genes	I
13	are	O
14	divergently	O
15	transcribed	O
16	from	O
17	a	O
18	shared	O
19	TATA	O
20	-	O
21	less	O
22	promoter	O
23	.	O

1	Strontium	B
2	chloride	O
3	Sr	O
4	89	O
5	is	O
6	costly	O
7	,	O
8	but	O
9	preliminary	O
10	analysis	O
11	indicates	O
12	that	O
13	it	O
14	may	O
15	reduce	O
16	management	O
17	expenditures	O
18	overall	O
19	.(	O
20	ABSTRACT	O
21	TRUNCATED	O
22	AT	O
23	250	O
24	WORDS	O
25	)	O

1	The	O
2	baroreflex	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	MSNA	O
15	burst	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	synchronicity	O
34	was	O
35	maintained	O
36	.	O

1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	O
12	184	O
13	HNF	B
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O

1	The	O
2	regions	O
3	of	O
4	the	O
5	tooth	O
6	fracture	O
7	are	O
8	determined	O
9	.	O

1	Copyright	O
2	2000	O
3	The	O
4	Royal	O
5	College	O
6	of	O
7	Radiologists	O
8	.	O

1	Chemical	B
2	uptake	O
3	into	O
4	human	O
5	stratum	O
6	corneum	O
7	in	O
8	vivo	O
9	from	O
10	volatile	O
11	and	O
12	non	O
13	-	O
14	volatile	O
15	solvents	O
16	.	O

1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	O
7	-	O
8	SMase	O
9	can	O
10	abrogate	O
11	Ox	O
12	-	O
13	LDL	B
14	-	I
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	I
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O

1	A	I
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O

1	This	O
2	and	O
3	previous	O
4	results	O
5	suggest	O
6	that	O
7	the	O
8	CRE	O
9	and	O
10	Sp1	B
11	site	I
12	may	O
13	synergistically	O
14	activate	O
15	TH	O
16	transcription	O
17	in	O
18	a	O
19	promoter	O
20	context	O
21	-	O
22	dependent	O
23	manner	O
24	.	O

1	E	I
2	50	O
3	,	O
4	843	O
5	(	O
6	1994	O
7	)].	O

1	Papers	B
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	Ha	B
2	-	I
3	RasV12	I
4	and	I
5	activated	I
6	proteins	I
7	in	O
8	both	O
9	the	O
10	extra	B
11	-	I
12	cellular	I
13	regulated	I
14	kinase	I
15	(	O
16	ERK	B
17	)	O
18	and	O
19	the	O
20	stress	B
21	-	I
22	activated	I
23	protein	I
24	kinase	I
25	(	O
26	SAPK	B
27	)	O
28	or	O
29	Jun	B
30	N	I
31	-	I
32	terminal	I
33	kinase	I
34	(	O
35	JNK	B
36	)	I
37	cascades	I
38	independently	O
39	stimulated	O
40	PEA3	B
41	-	I
42	mediated	I
43	gene	I
44	expression	O
45	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	revealed	O
5	that	O
6	dMax	O
7	contains	O
8	a	O
9	deletion	O
10	spanning	O
11	the	O
12	basic	O
13	region	O
14	and	O
15	helix	O
16	1	O
17	and	O
18	the	O
19	loop	O
20	of	O
21	the	O
22	helix	B
23	-	I
24	loop	I
25	-	I
26	helix	I
27	region	I
28	,	O
29	presumably	O
30	as	O
31	a	O
32	result	O
33	of	O
34	alternative	O
35	splicing	O
36	of	O
37	max	O
38	RNA	O
39	.	O

1	Abnormalities	B
2	of	O
3	plasma	O
4	cholecystokinin	O
5	were	O
6	observed	O
7	only	O
8	in	O
9	patients	O
10	with	O
11	delayed	O
12	gastric	O
13	emptying	O
14	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	B
13	prolactin	I
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	Lymphocytes	B
2	from	O
3	all	O
4	3	O
5	species	O
6	yielded	O
7	maximum	O
8	responses	O
9	with	O
10	a	O
11	48	O
12	-	O
13	hour	O
14	prelabel	O
15	and	O
16	12	O
17	-	O
18	to	O
19	-	O
20	16	O
21	hour	O
22	postlabel	O
23	incubation	O
24	period	O
25	at	O
26	41	O
27	C	O
28	and	O
29	1	O
30	:	O
31	20	O
32	blood	O
33	dilution	O
34	.	O

1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	O
22	.	O

1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O

1	Autotransplantation	B
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	O
20	.	O
21	8Ss	B
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	Xenopus	B
2	Ran	I
3	-	I
4	binding	I
5	protein	I
6	1	I
7	:	O
8	molecular	O
9	interactions	O
10	and	O
11	effects	O
12	on	O
13	nuclear	O
14	assembly	O
15	in	O
16	Xenopus	B
17	egg	I
18	extracts	O
19	.	O

1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O

1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	I
15	beta	I
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	B
27	-	I
28	terminal	I
29	regulatory	I
30	domain	I
31	of	O
32	p53	B
33	.	O

1	Contraction	B
2	of	O
3	the	O
4	tracheal	O
5	muscle	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	stretch	O
11	receptors	O
12	in	O
13	the	O
14	trachea	O

1	Following	O
2	seizure	O
3	induction	O
4	,	O
5	MABP	O
6	increased	O
7	to	O
8	105	O
9	mm	O
10	Hg	O
11	and	O
12	brain	O
13	pHi	O
14	fell	O
15	to	O
16	6	O
17	.	O
18	79	O
19	+/-	O
20	0	O
21	.	O
22	03	O
23	within	O
24	15	O
25	min	O
26	and	O
27	remained	O
28	at	O
29	this	O
30	level	O
31	for	O
32	1	O
33	h	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	001	O
40	).	O

1	Large	B
2	interpatient	O
3	variation	O
4	in	O
5	peak	O
6	PCZ	O
7	plasma	O
8	levels	O
9	(	O
10	91	O
11	-	O
12	3215	O
13	ng	O
14	/	O
15	ml	O
16	)	O
17	was	O
18	seen	O
19	,	O
20	with	O
21	the	O
22	plasma	O
23	half	O
24	-	O
25	life	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	alpha	O
31	)	O
32	being	O
33	approximately	O
34	57	O
35	min	O
36	in	O
37	patients	O
38	given	O
39	135	O
40	-	O
41	180	O
42	mg	O
43	/	O
44	m2	O
45	PCZ	O
46	.	O

1	The	O
2	amplitude	O
3	of	O
4	detrusor	O
5	contractions	O
6	at	O
7	6	O
8	,	O
9	12	O
10	,	O
11	and	O
12	24	O
13	hours	O
14	showed	O
15	no	O
16	significant	O
17	difference	O
18	from	O
19	that	O
20	in	O
21	the	O
22	controls	O
23	.	O

1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O

1	Thus	O
2	,	O
3	the	O
4	CCAAT	B
5	box	I
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	B
20	-	I
21	subunit	I
22	gene	I
23	to	O
24	trophoblasts	O
25	.	O

1	Overall	O
2	prevalences	O
3	of	O
4	antibody	O
5	were	O
6	70	O
7	per	O
8	cent	O
9	in	O
10	cattle	O
11	,	O
12	67	O
13	per	O
14	cent	O
15	in	O
16	sheep	O
17	and	O
18	76	O
19	per	O
20	cent	O
21	in	O
22	goats	O
23	as	O
24	assessed	O
25	by	O
26	an	O
27	immunodiffusion	O
28	test	O
29	.	O

1	Critique	B
2	of	O
3	"	O
4	Interactive	O
5	Effects	O
6	of	O
7	Test	O
8	Anxiety	O
9	and	O
10	Credit	O
11	/	O
12	No	O
13	Credit	O
14	or	O
15	A	O
16	-	O
17	F	O
18	Grade	O
19	Condition	O
20	upon	O
21	Short	O
22	-	O
23	term	O
24	and	O
25	Long	O
26	-	O
27	term	O
28	Recall	O
29	of	O
30	Course	O
31	Information	O
32	.	O

1	Transcription	O
2	start	O
3	sites	O
4	of	O
5	the	O
6	plastid	O
7	ACCase	O
8	genes	O
9	were	O
10	estimated	O
11	from	O
12	the	O
13	longest	O
14	cDNA	O
15	clones	O
16	obtained	O
17	by	O
18	5	O
19	'-	O
20	RACE	O
21	(	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	).	O

1	Together	O
2	with	O
3	a	O
4	considerably	O
5	shortened	O
6	and	O
7	interrupted	O
8	aromatic	O
9	aa	O
10	stretch	O
11	in	O
12	this	O
13	region	O
14	,	O
15	these	O
16	differences	O
17	are	O
18	discussed	O
19	in	O
20	terms	O
21	of	O
22	the	O
23	peculiar	O
24	affinity	O
25	of	O
26	cyanobacterial	B
27	cytochrome	I
28	oxidases	O
29	for	O
30	acidic	O
31	c	B
32	-	I
33	type	I
34	cytochromes	O
35	.	O

1	Direct	B
2	binding	I
3	and	O
4	competition	O
5	assays	O
6	using	O
7	30	O
8	-	O
9	mer	O
10	oligonucleotide	O
11	probes	O
12	representing	O
13	the	O
14	individual	O
15	CBF1	B
16	binding	I
17	sites	I
18	indicated	O
19	that	O
20	CBF1	B
21	bound	O
22	less	O
23	efficiently	O
24	to	O
25	the	O
26	CD23	B
27	promoter	I
28	and	O
29	the	O
30	EBV	O
31	LMP	B
32	-	I
33	1	I
34	promoter	I
35	sites	I
36	than	O
37	to	O
38	the	O
39	Cp	B
40	site	I
41	.	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	but	O
6	similar	O
7	elevation	O
8	of	O
9	mean	O
10	O2	O
11	uptake	O
12	during	O
13	40	O
14	min	O
15	postexercise	O
16	by	O
17	13	O
18	.	O
19	6	O
20	%	O
21	in	O
22	both	O
23	the	O
24	fasted	O
25	(	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	)	O
33	and	O
34	fed	O
35	state	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	O
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	B
17	-	I
18	1	I
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	O
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	B
41	-	I
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	The	O
2	test	O
3	for	O
4	alpha	B
5	-	I
6	naphthyl	I
7	esterase	I
8	and	O
9	quantitation	O
10	of	O
11	macrophages	O
12	(	O
13	absolute	O
14	number	O
15	)	O
16	per	O
17	infiltration	O
18	area	O
19	unit	O
20	adjacent	O
21	to	O
22	the	O
23	abscess	O
24	suggest	O
25	a	O
26	direct	O
27	correlation	O
28	between	O
29	the	O
30	absolute	O
31	number	O
32	of	O
33	macrophages	O
34	and	O
35	the	O
36	width	O
37	of	O
38	the	O
39	capsule	O
40	.	O

1	In	O
2	order	O
3	to	O
4	screen	O
5	for	O
6	such	O
7	cofactors	O
8	,	O
9	we	O
10	have	O
11	used	O
12	a	O
13	transcriptionally	O
14	inactive	O
15	mutant	O
16	of	O
17	Xenopus	O
18	MEF2D	O
19	in	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	screen	O
26	.	O

1	In	O
2	serum	O
3	-	O
4	stimulated	O
5	cells	O
6	,	O
7	the	O
8	binding	O
9	of	O
10	NF	B
11	-	I
12	Y	I
13	/	I
14	CBF	O
15	to	O
16	TKC1	O
17	increased	O
18	gradually	O
19	,	O
20	reaching	O
21	a	O
22	plateau	O
23	at	O
24	the	O
25	S	O
26	phase	O
27	.	O

1	There	O
2	were	O
3	9	O
4	patients	O
5	in	O
6	NYHA	B
7	class	I
8	III	I
9	and	O
10	8	O
11	in	O
12	class	O
13	IV	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	A	I
2	.,	O
3	Swift	O
4	,	O
5	A	O
6	.	O

1	Two	O
2	polyadenylation	O
3	sites	O
4	were	O
5	used	O
6	,	O
7	one	O
8	at	O
9	the	O
10	end	O
11	of	O
12	the	O
13	early	O
14	(	O
15	E	O
16	)	O
17	region	O
18	of	O
19	the	O
20	viral	O
21	DNA	O
22	,	O
23	the	O
24	other	O
25	at	O
26	the	O
27	end	O
28	of	O
29	the	O
30	late	O
31	(	O
32	L	O
33	)	O
34	region	O
35	.	O

1	Nonreturn	B
2	rates	O
3	can	O
4	be	O
5	used	O
6	to	O
7	derive	O
8	more	O
9	elementary	O
10	biological	O
11	measures	O
12	for	O
13	reproductive	O
14	efficiency	O
15	,	O
16	such	O
17	as	O
18	conception	O
19	rate	O
20	and	O
21	calving	O
22	rate	O
23	,	O
24	which	O
25	separately	O
26	might	O
27	be	O
28	more	O
29	reliable	O
30	than	O
31	nonreturn	O
32	rate	O
33	itself	O
34	to	O
35	evaluate	O
36	the	O
37	fertility	O
38	of	O
39	a	O
40	bull	O
41	or	O
42	the	O
43	performance	O
44	of	O
45	an	O
46	AI	O
47	technician	O
48	.	O

1	Technique	B
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O

1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O

1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O

1	Ganciclovir	B
2	and	O
3	foscarnet	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	polyradiculopathy	O
11	.	O

1	Multiresistant	B
2	strains	O
3	isolated	O
4	from	O
5	humans	O
6	in	O
7	enteral	O
8	toxico	O
9	-	O
10	infections	O
11	kill	O
12	orally	O
13	infected	O
14	mice	O
15	more	O
16	frequently	O
17	than	O
18	strains	O
19	isolated	O
20	in	O
21	hospital	O
22	infections	O
23	.	O

1	Non	O
2	-	O
3	complement	O
4	-	O
5	dependent	O
6	sperm	O
7	-	O
8	immobilizing	O
9	activity	O
10	was	O
11	also	O
12	detected	O
13	in	O
14	the	O
15	cervical	O
16	mucus	O
17	of	O
18	several	O
19	patients	O
20	.	O

1	Poliomyelitis	B
2	from	O
3	a	O
4	vaccine	O
5	.	O

1	Since	O
2	electrical	O
3	stimulation	O
4	of	O
5	neurones	O
6	may	O
7	activate	O
8	not	O
9	only	O
10	cell	O
11	bodies	O
12	but	O
13	also	O
14	neuronal	O
15	fibres	O
16	,	O
17	this	O
18	study	O
19	aimed	O
20	to	O
21	test	O
22	a	O
23	selectively	O
24	cholinergic	O
25	neurochemical	O
26	stimulation	O
27	of	O
28	the	O
29	rat	O
30	substantia	O
31	innominata	O
32	(	O
33	SI	O
34	)	O
35	by	O
36	the	O
37	local	O
38	microinjection	O
39	of	O
40	carbachol	O
41	;	O
42	the	O
43	effects	O
44	of	O
45	this	O
46	acetylcholine	O
47	agonist	O
48	were	O
49	compared	O
50	with	O
51	glutamate	O
52	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	C	O
6	-	O
7	terminal	O
8	portion	O
9	of	O
10	Sec31A	O
11	co	O
12	-	O
13	precipitate	O
14	Sec13	O
15	and	O
16	inhibit	O
17	ER	B
18	-	I
19	Golgi	O
20	transport	O
21	of	O
22	temperature	O
23	-	O
24	arrested	O
25	vesicular	O
26	stomatitis	B
27	G	I
28	protein	I
29	in	O
30	a	O
31	semi	O
32	-	O
33	intact	O
34	cell	O
35	assay	O
36	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	O
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	O
31	the	O
32	weakest	O
33	.	O

1	Eight	O
2	hr	O
3	of	O
4	acidosis	O
5	caused	O
6	a	O
7	significant	O
8	(	O
9	P	O
10	less	O
11	than	O
12	0	O
13	.	O
14	01	O
15	)	O
16	decrease	O
17	in	O
18	P50	O
19	in	O
20	vitro	O
21	which	O
22	fell	O
23	from	O
24	29	O
25	.	O
26	0	O
27	to	O
28	24	O
29	.	O
30	4	O
31	torr	O
32	.	O

1	Ime1	B
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	We	O
2	enrolled	O
3	253	O
4	HIV	B
5	-	I
6	antibody	I
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	B
12	-	I
13	related	I
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O

1	Eight	O
2	rabbits	O
3	were	O
4	exposed	O
5	to	O
6	0	O
7	.	O
8	7	O
9	+/-	O
10	0	O
11	.	O
12	4	O
13	mg	O
14	/	O
15	m3	O
16	Co2	O
17	+	O
18	as	O
19	CoCl2	O
20	and	O
21	1	O
22	.	O
23	2	O
24	+/-	O
25	0	O
26	.	O
27	7	O
28	mg	O
29	/	O
30	m3	O
31	Cr3	O
32	+	O
33	as	O
34	Cr	O
35	(	O
36	NO3	O
37	)	O
38	3	O
39	(	O
40	group	O
41	Co	O
42	+	O
43	Cr	O
44	),	O
45	eight	O
46	to	O
47	0	O
48	.	O
49	6	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	mg	O
55	/	O
56	m3	O
57	Co2	O
58	+	O
59	(	O
60	group	O
61	Co	O
62	),	O
63	and	O
64	eight	O
65	to	O
66	filtered	O
67	air	O
68	(	O
69	control	O
70	group	O
71	),	O
72	for	O
73	4	O
74	months	O
75	,	O
76	5	O
77	days	O
78	/	O
79	week	O
80	,	O
81	and	O
82	6	O
83	hr	O
84	/	O
85	day	O
86	.	O

1	There	O
2	were	O
3	3	O
4	/	O
5	32	O
6	(	O
7	9	O
8	.	O
9	4	O
10	per	O
11	cent	O
12	)	O
13	adverse	O
14	reactions	O
15	(	O
16	ADRs	O
17	),	O
18	and	O
19	one	O
20	case	O
21	each	O
22	of	O
23	nausea	O
24	,	O
25	dizziness	O
26	and	O
27	increased	O
28	menstrual	O
29	flow	O
30	.	O

1	The	O
2	open	O
3	reading	O
4	frames	O
5	of	O
6	rbsD	O
7	,	O
8	rbsA	O
9	,	O
10	and	O
11	rbsC	O
12	encode	O
13	proteins	O
14	of	O
15	139	O
16	,	O
17	501	O
18	,	O
19	and	O
20	321	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	respectively	O
26	.	O

1	Efferent	B
2	projections	O
3	of	O
4	the	O
5	ventral	O
6	portion	O
7	of	O
8	the	O
9	putamen	O
10	to	O
11	the	O
12	frontal	O
13	,	O
14	parietal	O
15	and	O
16	temporal	O
17	regions	O
18	of	O
19	the	O
20	cat	O
21	cerebral	O
22	cortex	O

1	A	I
2	gene	I
3	in	O
4	Drosophila	B
5	melanogaster	I
6	that	O
7	maps	O
8	cytologically	O
9	to	O
10	2C1	B
11	-	I
12	3	I
13	on	O
14	the	O
15	distal	O
16	portion	O
17	of	O
18	the	O
19	X	O
20	-	O
21	chromosome	O
22	encodes	O
23	a	O
24	member	O
25	of	O
26	the	O
27	steroid	B
28	/	I
29	thyroid	I
30	hormone	I
31	receptor	I
32	superfamily	I
33	.	O

1	Carcinoembryonic	B
2	antigen	I
3	(	I
4	CEA	I
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	A	I
2	limited	O
3	study	O
4	in	O
5	a	O
6	glassware	O
7	factory	O
8	(	O
9	As2O3	O
10	exposure	O
11	)	O
12	involving	O
13	the	O
14	measurement	O
15	of	O
16	total	O
17	airborne	O
18	arsenic	O
19	,	O
20	the	O
21	determination	O
22	of	O
23	urinary	O
24	arsenic	O
25	,	O
26	and	O
27	the	O
28	evaluation	O
29	of	O
30	hand	O
31	and	O
32	mouth	O
33	contamination	O
34	by	O
35	arsenic	O
36	before	O
37	and	O
38	after	O
39	the	O
40	workshift	O
41	suggests	O
42	that	O
43	the	O
44	high	O
45	urinary	O
46	arsenic	O
47	levels	O
48	(	O
49	300	O
50	microgram	O
51	/	O
52	g	O
53	creatinine	O
54	)	O
55	are	O
56	likely	O
57	to	O
58	be	O
59	more	O
60	related	O
61	to	O
62	an	O
63	increased	O
64	oral	O
65	intake	O
66	from	O
67	contaminated	O
68	hands	O
69	than	O
70	to	O
71	an	O
72	increased	O
73	absorption	O
74	from	O
75	the	O
76	lungs	O
77	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	O
16	and	O
17	serum	B
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	O
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O

1	Factors	O
2	associated	O
3	with	O
4	afterdrop	O
5	included	O
6	age	O
7	,	O
8	end	O
9	-	O
10	of	O
11	-	O
12	surgery	O
13	temperature	O
14	(	O
15	both	O
16	positively	O
17	)	O
18	and	O
19	body	O
20	mass	O
21	(	O
22	negatively	O
23	).	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	B
35	transposon	I
36	-	I
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	The	O
2	mMIWC1	O
3	promoter	O
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	B
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	O
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	O
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	Ten	O
2	weeks	O
3	after	O
4	reconstruction	O
5	,	O
6	the	O
7	regenerating	O
8	nerves	O
9	already	O
10	resembled	O
11	normal	O
12	nerves	O
13	.	O

1	A	I
2	comparative	O
3	study	O
4	was	O
5	undertaken	O
6	between	O
7	an	O
8	enzymatic	O
9	immunohistochemical	O
10	technique	O
11	(	O
12	EIT	O
13	)	O
14	developed	O
15	for	O
16	the	O
17	diagnosis	O
18	of	O
19	human	O
20	trichinellosis	O
21	and	O
22	the	O
23	indirect	O
24	immunofluorescence	O
25	test	O
26	(	O
27	IIF	O
28	),	O
29	analysing	O
30	sera	O
31	from	O
32	outbreaks	O
33	of	O
34	human	O
35	trichinellosis	O
36	in	O
37	Argentina	O
38	.	O

1	Plasmid	B
2	pAL618	O
3	contains	O
4	the	O
5	genetic	O
6	determinants	O
7	for	O
8	H2	O
9	uptake	O
10	(	O
11	hup	O
12	)	O
13	from	O
14	Rhizobium	O
15	leguminosarum	O
16	bv	O
17	.	O
18	viciae	O
19	,	O
20	including	O
21	a	O
22	cluster	O
23	of	O
24	17	O
25	genes	O
26	named	O
27	hupSLCDEFGHIJK	O
28	-	O
29	hypABFCDE	O
30	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	salsolinol	O
11	into	O
12	N	O
13	-	O
14	methylsalsolinol	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O

1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O

1	The	O
2	other	O
3	model	O
4	was	O
5	a	O
6	continuous	O
7	exponential	O
8	plus	O
9	constant	O
10	of	O
11	the	O
12	form	O
13	La	B
14	-	I
15	=	O
16	a	O
17	+	O
18	b	O
19	[	O
20	exp	O
21	(	O
22	cVO2	O
23	)].	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O

1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O

1	The	O
2	structure	O
3	of	O
4	these	O
5	genes	O
6	suggests	O
7	a	O
8	common	O
9	ancestor	O
10	for	O
11	all	O
12	viperid	O
13	PLA2	O
14	genes	O
15	.	O

1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	O
9	-	O
10	phosphoglycerate	B
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O

1	Inhibition	O
2	assays	O
3	performed	O
4	with	O
5	over	O
6	30	O
7	different	O
8	natural	O
9	and	O
10	synthetic	O
11	sialylated	O
12	and	O
13	/	O
14	or	O
15	sulfated	O
16	compounds	O
17	are	O
18	utilized	O
19	to	O
20	define	O
21	in	O
22	greater	O
23	detail	O
24	specific	O
25	structural	O
26	features	O
27	involved	O
28	in	O
29	oligosaccharide	B
30	-	I
31	protein	I
32	binding	I
33	.	O

1	Expression	O
2	of	O
3	neuronal	O
4	traits	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O

1	P	B
2	.,	O
3	Peyron	O
4	,	O
5	J	O
6	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	histopathological	O
6	findings	O
7	,	O
8	the	O
9	origin	O
10	of	O
11	amyloid	O
12	appeared	O
13	to	O
14	be	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	fibroblasts	O
20	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	The	O
2	effect	O
3	of	O
4	lithium	O
5	on	O
6	the	O
7	osmoregulation	O
8	of	O
9	arginine	B
10	vasopressin	I
11	secretion	O
12	.	O

1	Glomerular	B
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	Growth	I
2	factor	I
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	O
15	activation	O
16	domain	O
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	A	I
2	new	O
3	variant	O
4	of	O
5	the	O
6	EMG	O
7	-	O
8	BFB	O
9	method	O
10	(	O
11	multichannel	O
12	)	O
13	is	O
14	offered	O
15	which	O
16	has	O
17	made	O
18	it	O
19	possible	O
20	to	O
21	use	O
22	the	O
23	method	O
24	not	O
25	only	O
26	for	O
27	training	O
28	weakened	O
29	muscles	O
30	and	O
31	reducing	O
32	spasticity	O
33	in	O
34	their	O
35	antagonists	O
36	but	O
37	also	O
38	for	O
39	improving	O
40	motor	O
41	coordination	O
42	.	O

1	Alveolar	B
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O

1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	O
41	lipase	B
42	inhibitor	I
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O

1	11	I
2	-	I
3	Aminoundecanoyl	I
4	-	I
5	SK	O
6	-	O
7	NH2	O
8	and	O
9	11	O
10	-	O
11	aminoundecanoyl	O
12	-	O
13	SH	B
14	-	I
15	NH2	I
16	establish	O
17	that	O
18	a	O
19	simple	O
20	alkyl	O
21	backbone	O
22	can	O
23	maintain	O
24	an	O
25	appropriate	O
26	distance	O
27	between	O
28	three	O
29	elements	O
30	critical	O
31	for	O
32	recognition	O
33	by	O
34	the	O
35	fungal	B
36	enzyme	I
37	'	I
38	s	I
39	peptide	I
40	-	I
41	binding	I
42	site	I
43	:	O
44	a	O
45	simple	O
46	omega	O
47	-	O
48	terminal	O
49	amino	O
50	group	O
51	,	O
52	a	O
53	beta	B
54	-	I
55	hydroxyl	O
56	,	O
57	and	O
58	an	O
59	epsilon	B
60	-	I
61	amino	O
62	group	O
63	or	O
64	an	O
65	imidazole	O
66	.	O

1	The	O
2	"	O
3	tobacco	O
4	issue	O
5	".	O

1	In	O
2	the	O
3	control	O
4	group	O
5	the	O
6	histological	O
7	picture	O
8	resembled	O
9	osteoarthritis	O
10	.	O

1	Univariate	B
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	B
7	-	I
8	Meier	I
9	-	I
10	estimates	O
11	and	O
12	Log	B
13	-	I
14	Rank	I
15	-	I
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	O
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	B
51	alkaline	I
52	phosphatase	I
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	B
68	albumin	I
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O

1	Mutations	O
2	of	O
3	the	O
4	AP	B
5	-	I
6	1	I
7	site	I
8	of	O
9	the	O
10	TIMP	B
11	-	I
12	1	I
13	promoter	I
14	that	O
15	prevented	O
16	formation	O
17	of	O
18	HMAP	B
19	-	I
20	1	I
21	caused	O
22	a	O
23	70	O
24	%	O
25	loss	O
26	of	O
27	activity	O
28	in	O
29	transfected	O
30	activated	O
31	HSCs	O
32	.	O

1	The	O
2	structure	O
3	of	O
4	digiprogenin	O
5	.	O

1	The	O
2	recombinant	B
3	protein	I
4	was	O
5	purified	O
6	to	O
7	homogeneity	O
8	by	O
9	(	O
10	NH4	O
11	)	O
12	2SO4	O
13	-	O
14	precipitation	O
15	and	O
16	affinity	O
17	chromatography	O
18	on	O
19	5	O
20	'	O
21	AMP	O
22	-	O
23	Sepharose	O
24	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	O
11	and	O
12	cdc14	O
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	Four	O
2	p53	B
3	DNA	I
4	-	I
5	binding	I
6	domain	I
7	peptides	I
8	bind	O
9	natural	O
10	p53	B
11	-	I
12	response	I
13	elements	I
14	and	O
15	bend	O
16	the	O
17	DNA	O
18	.	O

1	Penicillin	B
2	-	I
3	G	I
4	degradation	O
5	products	O
6	inhibit	O
7	in	O
8	vitro	O
9	granulopoiesis	O
10	.	O

1	Southern	O
2	blot	O
3	hybridization	O
4	experiments	O
5	suggest	O
6	the	O
7	presence	O
8	of	O
9	one	O
10	copy	O
11	of	O
12	Atcys1	O
13	,	O
14	Athyp1	O
15	and	O
16	AKin10	O
17	per	O
18	haploid	O
19	genome	O
20	,	O
21	and	O
22	Northern	O
23	blot	O
24	analysis	O
25	demonstrates	O
26	that	O
27	the	O
28	three	O
29	genes	O
30	are	O
31	differentially	O
32	expressed	O
33	in	O
34	roots	O
35	,	O
36	shoots	O
37	and	O
38	leaves	O
39	.	O

1	Although	O
2	YopH	O
3	is	O
4	a	O
5	highly	O
6	active	O
7	PTP	B
8	,	O
9	it	O
10	preferentially	O
11	targets	O
12	a	O
13	subset	O
14	of	O
15	tyrosine	O
16	-	O
17	phosphorylated	O
18	proteins	O
19	in	O
20	host	O
21	cells	O
22	,	O
23	including	O
24	p130Cas	O
25	.	O

1	The	O
2	minimal	O
3	promoter	O
4	of	O
5	the	O
6	RII	B
7	beta	I
8	gene	I
9	was	O
10	composed	O
11	of	O
12	two	O
13	adjacent	O
14	functional	O
15	elements	O
16	.	O

1	Moreover	O
2	,	O
3	the	O
4	effect	O
5	exerted	O
6	by	O
7	TIS1	O
8	appeared	O
9	to	O
10	be	O
11	selective	O
12	for	O
13	the	O
14	MCK	B
15	promoter	I
16	.	O

1	e	O
2	.	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	These	O
2	genes	O
3	are	O
4	expressed	O
5	within	O
6	a	O
7	few	O
8	hours	O
9	of	O
10	the	O
11	initiation	O
12	of	O
13	development	O
14	;	O
15	their	O
16	mRNAs	O
17	accumulate	O
18	to	O
19	a	O
20	peak	O
21	at	O
22	12	O
23	hr	O
24	and	O
25	persist	O
26	until	O
27	culmination	O
28	.	O

1	Glomerular	B
2	mesangial	O
3	cells	O
4	expressed	O
5	an	O
6	abundant	O
7	1	O
8	.	O
9	1	O
10	kb	O
11	mRNA	O
12	transcript	O
13	for	O
14	Id1	O
15	,	O
16	but	O
17	in	O
18	contrast	O
19	to	O
20	other	O
21	cell	O
22	types	O
23	Id1	O
24	mRNA	O
25	was	O
26	expressed	O
27	in	O
28	both	O
29	randomly	O
30	cycling	O
31	cells	O
32	and	O
33	in	O
34	serum	O
35	-	O
36	deprived	O
37	,	O
38	quiescent	O
39	cultures	O
40	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	preformed	O
6	triplexes	O
7	are	O
8	quite	O
9	stable	O
10	when	O
11	precipitated	O
12	with	O
13	ethanol	O
14	and	O
15	resuspended	O
16	in	O
17	water	O
18	.	O

1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O

1	OBJECTIVE	O
2	--	O
3	To	O
4	assess	O
5	the	O
6	risk	O
7	of	O
8	hepatitis	O
9	A	O
10	in	O
11	international	O
12	travelers	O
13	and	O
14	to	O
15	recommend	O
16	preventive	O
17	measures	O
18	.	O

1	E	I
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O

1	In	O
2	HeLa	O
3	x	O
4	fibroblast	O
5	cell	O
6	hybrids	O
7	its	O
8	expression	O
9	correlates	O
10	with	O
11	tumorigenicity	O
12	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	169	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	fields	O
17	,	O
18	and	O
19	132	O
20	glaucomatous	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	qualitative	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	optic	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O

1	Chronic	O
2	E	B
3	-	I
4	B	I
5	virus	I
6	infection	O
7	terminated	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	O
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	O
15	.	O
16	cerevisiae	O
17	FBP1	B
18	gene	I
19	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	O
19	contrapsin	O
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	B
33	alpha	I
34	1	I
35	-	I
36	protease	I
37	inhibitor	I
38	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	O
4	(	O
5	GGTP	O
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	I
17	IL	I
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	B
46	).	O

1	Ammonia	B
2	concentration	O
3	dropped	O
4	significantly	O
5	in	O
6	all	O
7	treatments	O
8	,	O
9	a	O
10	finding	O
11	which	O
12	suggests	O
13	a	O
14	protective	O
15	effect	O
16	on	O
17	protein	O
18	nitrogen	O
19	degradation	O
20	to	O
21	non	O
22	-	O
23	protein	O
24	nitrogen	O
25	(	O
26	NH3	O
27	).	O

1	Neural	B
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	O
11	knuckle	O
12	9G8	O
13	variant	O
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	O
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	O
30	and	O
31	SRp20	O
32	are	O
33	similar	O
34	.	O

1	HupI	B
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	O
7	and	O
8	rubredoxin	B
9	-	I
10	like	I
11	proteins	I
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	I
11	like	I
12	GTPases	O
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	O
21	,	O
22	beta1D	O
23	,	O
24	or	O
25	IL2R	O
26	-	O
27	beta1A	O
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	O

1	To	O
2	determine	O
3	which	O
4	sequences	O
5	in	O
6	the	O
7	rat	O
8	P450c17	O
9	promoter	O
10	may	O
11	be	O
12	responsible	O
13	for	O
14	basal	O
15	and	O
16	cAMP	B
17	-	I
18	stimulated	I
19	gene	I
20	transcription	I
21	,	O
22	deletion	O
23	constructs	O
24	containing	O
25	between	O
26	-	O
27	1	O
28	,	O
29	560	O
30	and	O
31	-	O
32	53	O
33	base	O
34	pairs	O
35	of	O
36	5	O
37	'-	O
38	flanking	O
39	DNA	O
40	from	O
41	the	O
42	rat	B
43	P450c17	I
44	gene	I
45	were	O
46	ligated	O
47	to	O
48	plasmids	O
49	expressing	O
50	the	O
51	reporter	O
52	gene	O
53	luciferase	B
54	and	O
55	transfected	O
56	into	O
57	two	O
58	mouse	O
59	cell	O
60	lines	O
61	,	O
62	adrenal	O
63	Y	O
64	-	O
65	1	O
66	cells	O
67	,	O
68	and	O
69	testicular	O
70	Leydig	B
71	MA	I
72	-	I
73	10	O
74	cells	O
75	.	O

1	Labile	B
2	LTR	I
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	B
27	-	I
28	binding	I
29	proteins	I
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	2	I
2	new	O
3	Algerian	O
4	cases	O

1	This	O
2	analysis	O
3	revealed	O
4	an	O
5	intact	O
6	gene	O
7	(	O
8	arg4	O
9	)	O
10	showing	O
11	a	O
12	high	O
13	degree	O
14	of	O
15	homology	O
16	with	O
17	the	O
18	Saccharomyces	B
19	cerevisiae	I
20	CPA2	I
21	gene	I
22	encoding	O
23	the	O
24	large	O
25	subunit	O
26	of	O
27	carbamoyl	B
28	-	I
29	phosphate	I
30	synthetase	I
31	(	I
32	CPS	I
33	-	I
34	A	I
35	).	O

1	The	O
2	protein	O
3	was	O
4	associated	O
5	with	O
6	purified	O
7	vaccinia	O
8	virus	O
9	particles	O
10	and	O
11	with	O
12	membranes	O
13	of	O
14	immature	O
15	and	O
16	mature	O
17	virions	O
18	that	O
19	were	O
20	visualized	O
21	by	O
22	electron	O
23	microscopy	O
24	of	O
25	infected	O
26	cells	O
27	.	O

1	Inclusion	B
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	originally	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	B
20	factor	I
21	Lef	I
22	-	I
23	1	I
24	.	O

1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O

1	Consistent	O
2	with	O
3	the	O
4	hepatic	O
5	and	O
6	epidermal	B
7	expression	O
8	of	O
9	histidase	O
10	,	O
11	this	O
12	finding	O
13	suggests	O
14	that	O
15	histidase	O
16	transcription	O
17	may	O
18	be	O
19	regulated	O
20	by	O
21	these	O
22	factors	O
23	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	silymarin	O
9	may	O
10	exert	O
11	a	O
12	strong	O
13	anticarcinogenic	O
14	effect	O
15	against	O
16	PCA	O
17	and	O
18	that	O
19	this	O
20	effect	O
21	is	O
22	likely	O
23	to	O
24	involve	O
25	impairment	O
26	of	O
27	erbB1	B
28	-	I
29	SHC	I
30	-	I
31	mediated	O
32	signaling	O
33	pathway	O
34	,	O
35	induction	O
36	of	O
37	CDKIs	O
38	,	O
39	and	O
40	a	O
41	resultant	O
42	G1	O
43	arrest	O
44	.	O

1	Serum	B
2	levels	O
3	of	O
4	albumin	B
5	,	I
6	globulin	I
7	,	O
8	and	O
9	coagulation	B
10	protein	I
11	activity	O
12	were	O
13	measured	O
14	preshock	O
15	,	O
16	postshock	O
17	,	O
18	and	O
19	daily	O
20	for	O
21	3	O
22	days	O
23	;	O
24	skin	O
25	lymph	O
26	levels	O
27	were	O
28	measured	O
29	on	O
30	Day	O
31	3	O
32	.	O

1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O

1	FK506	O
2	is	O
3	10	O
4	-	O
5	to	O
6	100	O
7	-	O
8	fold	O
9	more	O
10	potent	O
11	than	O
12	cyclosporin	O
13	A	O
14	in	O
15	preventing	O
16	organ	O
17	rejection	O
18	and	O
19	in	O
20	toxicity	O
21	.	O

1	Effects	O
2	of	O
3	thromboxane	B
4	synthetase	I
5	inhibition	O
6	on	O
7	postburn	O
8	mesenteric	O
9	vascular	O
10	resistance	O
11	and	O
12	the	O
13	rate	O
14	of	O
15	bacterial	O
16	translocation	O
17	in	O
18	a	O
19	chronic	O
20	porcine	O
21	model	O
22	.	O

1	Blood	O
2	glucose	O
3	and	O
4	plasma	O
5	insulin	B
6	were	O
7	measured	O
8	at	O
9	zero	O
10	time	O
11	and	O
12	then	O
13	at	O
14	15	O
15	,	O
16	30	O
17	,	O
18	60	O
19	,	O
20	90	O
21	and	O
22	120	O
23	min	O
24	after	O
25	ingestion	O
26	of	O
27	25	O
28	g	O
29	glucose	O
30	,	O
31	fructose	O
32	or	O
33	lactose	O
34	,	O
35	or	O
36	30	O
37	g	O
38	honey	O
39	,	O
40	50	O
41	g	O
42	white	O
43	bread	O
44	,	O
45	125	O
46	g	O
47	white	O
48	rice	O
49	or	O
50	potatoes	O
51	,	O
52	150	O
53	g	O
54	apples	O
55	or	O
56	260	O
57	g	O
58	carrots	O
59	.	O

1	If	O
2	hnRNP	B
3	K	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	,	O
9	then	O
10	interactions	O
11	with	O
12	the	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcription	I
17	apparatus	O
18	are	O
19	predicted	O
20	.	O

1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	B
24	-	I
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	analyze	O
9	the	O
10	common	O
11	cause	O
12	of	O
13	asthenopia	O
14	,	O
15	mixed	O
16	astigmatism	O
17	.	O

1	The	O
2	distribution	O
3	of	O
4	their	O
5	fibrinogen	B
6	levels	O
7	was	O
8	Gaussian	O
9	,	O
10	but	O
11	more	O
12	wide	O
13	-	O
14	based	O
15	than	O
16	the	O
17	distribution	O
18	of	O
19	our	O
20	normal	O
21	controls	O
22	.	O

1	The	O
2	calcitonin	B
3	-	I
4	induced	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	HEF1	B
9	increased	O
10	in	O
11	a	O
12	time	O
13	-	O
14	and	O
15	dose	O
16	-	O
17	dependent	O
18	manner	O
19	.	O

1	Alignment	B
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	surrounding	O
8	Tyr	O
9	-	O
10	766	O
11	with	O
12	corresponding	O
13	regions	O
14	of	O
15	other	O
16	FGFRs	O
17	revealed	O
18	conserved	O
19	tyrosine	O
20	residues	O
21	in	O
22	all	O
23	known	O
24	members	O
25	of	O
26	the	O
27	FGFR	B
28	family	I
29	.	O

1	The	O
2	study	O
3	of	O
4	calcium	O
5	metabolism	O
6	in	O
7	ten	O
8	thalassaemic	O
9	children	O
10	comperatively	O
11	with	O
12	controls	O
13	after	O
14	oral	O
15	administration	O
16	of	O
17	47Ca	O
18	has	O
19	shown	O
20	diminished	O
21	intestinal	O
22	absorption	O
23	.	O

1	Conjugated	B
2	estrogens	O
3	shorten	O
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O

1	Allagille	B
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	Clone	B
2	pSRc200	O
3	hybrid	O
4	selected	O
5	an	O
6	mRNA	O
7	that	O
8	on	O
9	cell	O
10	-	O
11	free	O
12	translation	O
13	produced	O
14	a	O
15	38	O
16	-	O
17	kDa	O
18	polypeptide	O
19	.	O

1	The	O
2	structural	O
3	genes	O
4	encoding	O
5	glyceraldehyde	B
6	-	I
7	3	I
8	-	I
9	phosphate	I
10	dehydrogenase	I
11	(	O
12	GAPDH	O
13	),	O
14	3	O
15	-	O
16	phosphoglycerate	B
17	kinase	I
18	(	O
19	PGK	O
20	)	O
21	and	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	triosephosphate	B
29	isomerase	I
30	(	O
31	TIM	O
32	)	O
33	from	O
34	mesophilic	O
35	Bacillus	O
36	megaterium	O
37	DSM319	O
38	have	O
39	been	O
40	cloned	O
41	as	O
42	a	O
43	gene	O
44	cluster	O
45	(	O
46	gap	B
47	operon	I
48	)	O
49	by	O
50	complementation	O
51	of	O
52	an	O
53	Escherichia	O
54	coli	O
55	gap	B
56	amber	I
57	mutant	I
58	.	O

1	Following	O
2	chondroitinase	O
3	AC	O
4	and	O
5	ABC	O
6	digestion	O
7	,	O
8	staining	O
9	reactions	O
10	suggested	O
11	that	O
12	the	O
13	highest	O
14	levels	O
15	of	O
16	dermatan	O
17	sulfate	O
18	were	O
19	in	O
20	the	O
21	diabetes	O
22	resistant	O
23	group	O
24	(	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	compared	O
32	to	O
33	diabetic	O
34	,	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	001	O
41	compared	O
42	to	O
43	diabetes	O
44	prone	O
45	)	O
46	and	O
47	the	O
48	highest	O
49	levels	O
50	of	O
51	chondroitin	O
52	sulfates	O
53	were	O
54	in	O
55	the	O
56	diabetes	O
57	prone	O
58	group	O
59	(	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	001	O
66	).	O

1	To	O
2	address	O
3	this	O
4	issue	O
5	,	O
6	the	O
7	gene	O
8	for	O
9	factor	O
10	Y	O
11	has	O
12	been	O
13	cloned	O
14	molecularly	O
15	and	O
16	its	O
17	DNA	O
18	sequence	O
19	has	O
20	been	O
21	determined	O
22	.	O

1	Collectively	O
2	,	O
3	these	O
4	and	O
5	previously	O
6	published	O
7	data	O
8	suggest	O
9	a	O
10	model	O
11	where	O
12	NS1	B
13	recruits	O
14	eIF4GI	O
15	specifically	O
16	to	O
17	the	O
18	5	O
19	'	O
20	untranslated	O
21	region	O
22	(	O
23	5	O
24	'	O
25	UTR	O
26	)	O
27	of	O
28	the	O
29	viral	O
30	mRNA	O
31	,	O
32	allowing	O
33	for	O
34	the	O
35	preferential	O
36	translation	O
37	of	O
38	the	O
39	influenza	O
40	virus	O
41	messengers	O
42	.	O

1	Partial	O
2	correction	O
3	of	O
4	anemia	O
5	with	O
6	recombinant	O
7	human	B
8	erythropoietin	I
9	likely	O
10	reduces	O
11	left	O
12	ventricular	O
13	mass	O
14	and	O
15	volume	O
16	.	O

1	In	O
2	experiment	O
3	2	O
4	,	O
5	no	O
6	difference	O
7	in	O
8	gastric	O
9	emptying	O
10	of	O
11	40	O
12	%	O
13	peptone	O
14	or	O
15	25	O
16	%	O
17	glucose	O
18	was	O
19	found	O
20	between	O
21	rats	O
22	receiving	O
23	TPN	O
24	and	O
25	those	O
26	receiving	O
27	intragastric	O
28	nutrition	O
29	for	O
30	10	O
31	to	O
32	12	O
33	days	O
34	.	O

1	Liquid	O
2	chromatography	O
3	with	O
4	amperometric	O
5	detection	O
6	(	O
7	LC	O
8	/	O
9	AD	O
10	)	O
11	is	O
12	used	O
13	to	O
14	determine	O
15	fluazifop	O
16	acid	O
17	produced	O
18	from	O
19	the	O
20	metabolism	O
21	or	O
22	base	O
23	hydrolysis	O
24	of	O
25	fluazifop	O
26	-	O
27	butyl	O
28	in	O
29	soybeans	O
30	and	O
31	soybean	O
32	oil	O
33	.	O

1	Similar	O
2	to	O
3	the	O
4	mouse	B
5	gene	I
6	,	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	of	O
13	human	B
14	CD79	I
15	alpha	I
16	lacks	O
17	a	O
18	TATA	O
19	box	O
20	;	O
21	however	O
22	,	O
23	unlike	O
24	mouse	B
25	CD79	I
26	alpha	I
27	,	O
28	a	O
29	classical	O
30	octamer	O
31	motif	O
32	could	O
33	not	O
34	be	O
35	identified	O
36	in	O
37	the	O
38	human	B
39	gene	I
40	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	O
38	locus	O
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O

1	Haycocknema	B
2	perplexum	O
3	n	O
4	.	O
5	g	O
6	.,	O
7	n	O
8	.	O
9	sp	O
10	.	O

1	Northern	O
2	blotting	O
3	showed	O
4	that	O
5	MDMX	O
6	,	O
7	like	O
8	MDM2	O
9	,	O
10	is	O
11	expressed	O
12	in	O
13	all	O
14	tissues	O
15	tested	O
16	,	O
17	and	O
18	that	O
19	several	O
20	mRNAs	O
21	for	O
22	MDMX	O
23	can	O
24	be	O
25	detected	O
26	.	O

1	Remarkably	B
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	O
21	region	O
22	of	O
23	SRC1	O
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	The	O
2	derivatives	O
3	of	O
4	the	O
5	latter	O
6	two	O
7	cell	O
8	lines	O
9	showed	O
10	increased	O
11	expression	O
12	of	O
13	the	O
14	p27Kip1	O
15	protein	O
16	and	O
17	inhibition	O
18	of	O
19	cell	O
20	growth	O
21	.	O

1	Domains	B
2	I	I
3	and	I
4	II	I
5	of	O
6	B	O
7	"	O
8	are	O
9	buried	O
10	upon	O
11	assembly	O
12	of	O
13	the	O
14	TFIIIB	O
15	-	O
16	DNA	O
17	complex	O
18	,	O
19	as	O
20	determined	O
21	by	O
22	protein	O
23	footprinting	O
24	.	O

1	Among	O
2	genes	O
3	induced	O
4	by	O
5	added	O
6	pMesogenin1	O
7	is	O
8	Xwnt	O
9	-	O
10	8	O
11	,	O
12	a	O
13	signaling	O
14	factor	O
15	that	O
16	induces	O
17	a	O
18	similar	O
19	repertoire	O
20	of	O
21	marker	O
22	genes	O
23	and	O
24	a	O
25	similar	O
26	cellular	O
27	phenotype	O
28	.	O

1	1	I
2	.	O

1	All	O
2	the	O
3	women	O
4	received	O
5	13	O
6	.	O
7	5	O
8	mg	O
9	plain	O
10	bupivacaine	O
11	via	O
12	subarachnoid	O
13	injection	O
14	at	O
15	the	O
16	L2	O
17	-	O
18	3	O
19	interspace	O
20	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bovine	O
5	cDNA	O
6	insert	O
7	sequence	O
8	was	O
9	273	O
10	nucleotides	O
11	in	O
12	length	O
13	for	O
14	the	O
15	entire	O
16	mRNA	O
17	coding	O
18	region	O
19	,	O
20	212	O
21	nucleotides	O
22	in	O
23	the	O
24	5	O
25	'	O
26	untranslated	O
27	region	O
28	,	O
29	83	O
30	nucleotides	O
31	in	O
32	the	O
33	3	O
34	'	O
35	untranslated	O
36	region	O
37	and	O
38	a	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	tail	O
44	.	O

1	It	O
2	contains	O
3	three	O
4	putative	O
5	TATA	O
6	boxes	O
7	far	O
8	upstream	O
9	of	O
10	the	O
11	main	O
12	start	O
13	sites	O
14	region	O
15	,	O
16	one	O
17	AP	B
18	-	I
19	1	I
20	box	I
21	,	O
22	one	O
23	AP	B
24	-	I
25	2	I
26	box	I
27	,	O
28	one	O
29	Malt	O
30	box	O
31	,	O
32	one	O
33	GAGA	O
34	box	O
35	,	O
36	one	O
37	half	O
38	serum	B
39	-	I
40	responsive	I
41	element	I
42	,	O
43	and	O
44	putative	O
45	binding	O
46	sites	O
47	for	O
48	Sp1	B
49	(	O
50	five	O
51	),	O
52	GC	B
53	-	I
54	rich	I
55	binding	I
56	factor	I
57	(	O
58	five	O
59	),	O
60	CTF	B
61	-	I
62	NF1	I
63	(	O
64	one	O
65	),	O
66	Myb	B
67	(	O
68	one	O
69	),	O
70	p53	B
71	(	O
72	two	O
73	),	O
74	Ets	B
75	-	I
76	1	I
77	(	O
78	one	O
79	),	O
80	NF	B
81	-	I
82	IL6	I
83	(	O
84	two	O
85	),	O
86	MyoD	B
87	(	O
88	two	O
89	),	O
90	Zeste	O
91	(	O
92	one	O
93	),	O
94	and	O
95	hepatocyte	B
96	nuclear	I
97	factor	I
98	-	I
99	5	O
100	(	O
101	one	O
102	).	O

1	These	O
2	results	O
3	were	O
4	superior	O
5	to	O
6	those	O
7	in	O
8	24	O
9	patients	O
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	sutures	O
18	on	O
19	clinical	O
20	testing	O
21	.	O

1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	98	O
8	%	O
9	identity	O
10	to	O
11	the	O
12	human	O
13	cellular	O
14	transglutaminase	O
15	sequence	O
16	.	O

1	Between	B
2	acoR	O
3	and	O
4	acoXABC	O
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	B
29	)-	I
30	ACA	I
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	O
41	and	O
42	NifA	B
43	upstream	I
44	activator	I
45	sequences	I
46	,	O
47	respectively	O
48	.	O

1	The	O
2	relationships	O
3	between	O
4	the	O
5	partial	O
6	pressures	O
7	of	O
8	O2	O
9	and	O
10	CO2	O
11	as	O
12	well	O
13	as	O
14	between	O
15	their	O
16	gradients	O
17	,	O
18	become	O
19	stronger	O
20	with	O
21	the	O
22	increase	O
23	of	O
24	the	O
25	ventilation	O
26	-	O
27	perfusion	O
28	ratio	O
29	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	O
26	deletions	O
27	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	the	O
6	structure	O
7	of	O
8	the	O
9	decorin	B
10	gene	I
11	promoter	I
12	is	O
13	different	O
14	from	O
15	that	O
16	of	O
17	any	O
18	other	O
19	proteoglycan	O
20	promoter	O
21	characterized	O
22	so	O
23	far	O
24	and	O
25	indicate	O
26	that	O
27	the	O
28	pur	O
29	/	O
30	pyr	O
31	segment	O
32	plays	O
33	a	O
34	role	O
35	in	O
36	the	O
37	regulation	O
38	of	O
39	gene	O
40	transcription	O
41	.	O

1	The	O
2	final	O
3	screening	O
4	yielded	O
5	a	O
6	clone	O
7	containing	O
8	a	O
9	2	O
10	kilobase	O
11	(	O
12	kb	O
13	)	O
14	insert	O
15	.	O

1	The	O
2	peptide	O
3	sequences	O
4	reveal	O
5	that	O
6	the	O
7	factor	O
8	consists	O
9	of	O
10	GABP	B
11	alpha	I
12	and	O
13	GABP	B
14	beta	I
15	1	I
16	with	O
17	Ets	B
18	and	O
19	Notch	B
20	motifs	O
21	,	O
22	respectively	O
23	.	O

1	The	O
2	viral	B
3	oncoprotein	I
4	E1A	I
5	inhibits	O
6	NFAT	B
7	-	I
8	dependent	I
9	transactivation	O
10	in	O
11	a	O
12	p300	B
13	-	I
14	dependent	I
15	manner	O
16	.	O

1	Both	O
2	tear	O
3	volume	O
4	and	O
5	tear	O
6	flow	O
7	were	O
8	found	O
9	to	O
10	be	O
11	significantly	O
12	(	O
13	P	O
14	less	O
15	than	O
16	0	O
17	.	O
18	001	O
19	)	O
20	decreased	O
21	up	O
22	to	O
23	6	O
24	h	O
25	after	O
26	instillation	O
27	,	O
28	reaching	O
29	a	O
30	minimum	O
31	90	O
32	min	O
33	after	O
34	application	O
35	(	O
36	tear	O
37	volume	O
38	:	O
39	-	O
40	63	O
41	%;	O
42	tear	O
43	flow	O
44	:	O
45	-	O
46	71	O
47	%).	O

1	Systemic	O
2	lupus	O
3	erythematosus	O
4	was	O
5	diagnosed	O
6	.	O

1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O

1	Aneurysmal	B
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	The	O
2	intensity	O
3	of	O
4	the	O
5	SSTEs	O
6	is	O
7	an	O
8	order	O
9	of	O
10	magnitude	O
11	larger	O
12	than	O
13	that	O
14	of	O
15	the	O
16	MSEs	O
17	and	O
18	determines	O
19	the	O
20	signal	O
21	contrast	O
22	if	O
23	both	O
24	effects	O
25	are	O
26	selected	O
27	simultaneously	O
28	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	mutant	O
5	EphB1	B
6	receptors	I
7	(	O
8	Y594F	O
9	)	O
10	blocked	O
11	Nck	O
12	recruitment	O
13	to	O
14	EphB1	O
15	,	O
16	attenuated	O
17	downstream	O
18	JNK	B
19	activation	O
20	,	O
21	and	O
22	blocked	O
23	cell	O
24	attachment	O
25	responses	O
26	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	O
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	O
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	Feeding	B
2	behavior	O
3	,	O
4	circannual	O
5	body	O
6	weight	O
7	and	O
8	hibernation	O
9	rhythms	O
10	in	O
11	European	O
12	hamsters	O
13	lesioned	O
14	in	O
15	the	O
16	noradrenergic	O
17	ascending	O
18	bundles	O

1	Transabdominal	B
2	repair	I
3	of	I
4	type	I
5	IV	I
6	thoraco	I
7	-	I
8	abdominal	O
9	aortic	O
10	aneurysms	O
11	.	O

1	For	O
2	the	O
3	first	O
4	group	O
5	,	O
6	the	O
7	maximal	O
8	decrease	O
9	in	O
10	plasma	O
11	potassium	O
12	elicited	O
13	by	O
14	salbutamol	O
15	was	O
16	0	O
17	.	O
18	80	O
19	+/-	O
20	0	O
21	.	O
22	19	O
23	,	O
24	0	O
25	.	O
26	48	O
27	+/-	O
28	0	O
29	.	O
30	22	O
31	,	O
32	and	O
33	0	O
34	.	O
35	78	O
36	+/-	O
37	0	O
38	.	O
39	46	O
40	mmol	O
41	/	O
42	l	O
43	,	O
44	and	O
45	for	O
46	the	O
47	second	O
48	group	O
49	,	O
50	maximal	O
51	decrement	O
52	was	O
53	1	O
54	.	O
55	31	O
56	+/-	O
57	0	O
58	.	O
59	37	O
60	,	O
61	0	O
62	.	O
63	70	O
64	+/-	O
65	0	O
66	.	O
67	24	O
68	,	O
69	and	O
70	0	O
71	.	O
72	84	O
73	+/-	O
74	0	O
75	.	O
76	17	O
77	mmol	O
78	/	O
79	l	O
80	for	O
81	the	O
82	iv	O
83	,	O
84	po	O
85	,	O
86	and	O
87	it	O
88	routes	O
89	,	O
90	respectively	O
91	.	O

1	The	O
2	mobility	O
3	of	O
4	the	O
5	upper	O
6	and	O
7	lower	O
8	premolars	O
9	under	O
10	load	O
11	was	O
12	investigated	O
13	in	O
14	relation	O
15	to	O
16	the	O
17	interproximal	O
18	contact	O
19	and	O
20	occlusal	O
21	facets	O
22	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	Is	O
2	leishmaniasis	O
3	endemic	O
4	on	O
5	the	O
6	island	O
7	of	O
8	Minorca	O
9	(	O
10	Spain	O
11	)?	O
12	A	O
13	human	O
14	visceral	O
15	case	O
16	after	O
17	living	O
18	13	O
19	years	O
20	in	O
21	Minorca	O
22	.	O

1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O

1	Gng3lg	B
2	transcripts	I
3	are	O
4	expressed	O
5	in	O
6	a	O
7	variety	O
8	of	O
9	tissues	O
10	including	O
11	both	O
12	brain	O
13	and	O
14	testes	O
15	.	O

1	These	O
2	mutants	O
3	grow	O
4	normally	O
5	in	O
6	3T6	O
7	mouse	O
8	fibroblast	O
9	cells	O
10	,	O
11	and	O
12	they	O
13	do	O
14	not	O
15	complement	O
16	the	O
17	wild	B
18	-	I
19	type	I
20	virus	I
21	in	O
22	coinfection	O
23	experiments	O
24	of	O
25	C2	O
26	myoblasts	O
27	.	O

1	Percent	B
2	identities	O
3	of	O
4	the	O
5	mouse	O
6	PP2	O
7	to	O
8	mouse	O
9	Y1	O
10	,	O
11	mouse	O
12	Y4	O
13	/	O
14	PP1	O
15	and	O
16	human	B
17	Y2	I
18	receptors	I
19	are	O
20	53	O
21	,	O
22	42	O
23	,	O
24	and	O
25	31	O
26	,	O
27	respectively	O
28	.	O

1	The	O
2	promoter	O
3	region	O
4	(	O
5	P1	O
6	)	O
7	corresponding	O
8	to	O
9	the	O
10	main	O
11	group	O
12	of	O
13	transcription	O
14	initiation	O
15	sites	O
16	is	O
17	devoid	O
18	of	O
19	TATA	O
20	and	O
21	CAAT	O
22	boxes	O
23	but	O
24	has	O
25	putative	O
26	binding	O
27	sites	O
28	for	O
29	the	O
30	transcription	B
31	factor	I
32	SP1	I
33	and	O
34	is	O
35	embedded	O
36	in	O
37	a	O
38	large	O
39	G	B
40	+	I
41	C	I
42	-	I
43	rich	I
44	domain	I
45	of	O
46	a	O
47	CpG	O
48	island	O
49	,	O
50	features	O
51	shared	O
52	by	O
53	the	O
54	promoters	O
55	of	O
56	constitutively	O
57	expressed	O
58	housekeeping	O
59	genes	O
60	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	neonate	O
7	differs	O
8	from	O
9	the	O
10	adult	O
11	in	O
12	respect	O
13	of	O
14	both	O
15	the	O
16	nature	O
17	of	O
18	effects	O
19	of	O
20	the	O
21	drug	O
22	and	O
23	sensitivity	O
24	to	O
25	it	O
26	.	O

1	A	I
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	AIMS	B
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	role	O
7	of	O
8	environmental	O
9	intra	O
10	-	O
11	uterine	O
12	factors	O
13	in	O
14	determining	O
15	the	O
16	birthweights	O
17	of	O
18	twins	O
19	with	O
20	increased	O
21	susceptibility	O
22	to	O
23	diabetes	O
24	and	O
25	discordant	O
26	for	O
27	abnormal	O
28	responses	O
29	to	O
30	the	O
31	oral	O
32	glucose	O
33	tolerance	O
34	test	O
35	(	O
36	OGTT	O
37	)	O
38	and	O
39	verify	O
40	the	O
41	possible	O
42	association	O
43	of	O
44	within	O
45	-	O
46	pair	O
47	birthweight	O
48	differences	O
49	and	O
50	metabolic	O
51	abnormalities	O
52	in	O
53	adult	O
54	life	O
55	.	O

1	A	I
2	cDNA	I
3	encoding	O
4	the	O
5	NF	B
6	-	I
7	4FB	I
8	enhancer	I
9	binding	I
10	protein	I
11	has	O
12	been	O
13	cloned	O
14	by	O
15	screening	O
16	a	O
17	lambda	O
18	gt11	O
19	cDNA	O
20	library	O
21	with	O
22	a	O
23	rabiolabelled	O
24	oligonucleotide	O
25	corresponding	O
26	to	O
27	the	O
28	NF	B
29	-	I
30	4FB	I
31	recognition	I
32	sequence	I
33	.	O

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	O
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	O
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	Ly	B
2	-	I
3	49	O
4	is	O
5	a	O
6	family	O
7	type	B
8	II	I
9	transmembrane	I
10	proteins	I
11	encoded	I
12	by	O
13	a	O
14	gene	O
15	cluster	O
16	on	O
17	murine	O
18	chromosome	O
19	6	O
20	.	O

1	Oscillatory	B
2	exchange	I
3	of	O
4	atoms	O
5	between	O
6	traps	O
7	containing	O
8	Bose	O
9	condensates	O
10	.	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	I
18	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	B
10	gene	I
11	.	O

1	All	O
2	other	O
3	normal	O
4	and	O
5	transformed	O
6	lymphoid	O
7	and	O
8	nonlymphoid	O
9	cell	O
10	lines	O
11	and	O
12	normal	O
13	tissues	O
14	were	O
15	negative	O
16	for	O
17	PANG	O
18	expression	O
19	except	O
20	for	O
21	the	O
22	brain	O
23	,	O
24	wherein	O
25	unique	O
26	4	O
27	.	O
28	0	O
29	-	O
30	and	O
31	6	O
32	.	O
33	1	O
34	-	O
35	kb	O
36	transcripts	O
37	were	O
38	detected	O
39	.	O

1	Azithromycin	B
2	is	O
3	a	O
4	new	O
5	generation	O
6	macrolide	O
7	antibiotic	O
8	with	O
9	unusual	O
10	and	O
11	favorable	O
12	pharmacokinetics	O
13	,	O
14	and	O
15	seems	O
16	to	O
17	be	O
18	a	O
19	very	O
20	promising	O
21	agent	O
22	for	O
23	innovative	O
24	anti	B
25	-	I
26	H	I
27	.	O
28	pylori	O
29	regimens	O
30	.	O

1	Their	O
2	function	O
3	is	O
4	not	O
5	only	O
6	to	O
7	recruit	O
8	Pho2	O
9	to	O
10	the	O
11	promoter	O
12	but	O
13	to	O
14	allow	O
15	cooperative	O
16	binding	O
17	of	O
18	Pho4	O
19	together	O
20	with	O
21	Pho2	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	alpha	B
6	-	I
7	subunit	I
8	of	O
9	the	O
10	telomere	B
11	-	I
12	binding	I
13	protein	I
14	,	O
15	like	O
16	many	O
17	transcription	O
18	factors	O
19	,	O
20	has	O
21	separable	B
22	DNA	I
23	-	I
24	binding	I
25	and	I
26	protein	I
27	-	I
28	protein	I
29	interaction	O
30	domains	O
31	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	vacuolar	B
6	H	I
7	(+)-	I
8	ATPase	I
9	B2	I
10	subunit	I
11	gene	I
12	in	O
13	differentiating	O
14	THP	B
15	-	I
16	1	I
17	cells	O
18	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	Evaluation	O
2	of	O
3	the	O
4	Du	O
5	Pont	O
6	aca	O
7	ammonia	O
8	procedure	O
9	.	O

1	Insertional	B
2	inactivation	O
3	of	O
4	sms	O
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	Althoug	B
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	Hepatitis	B
2	B	I
3	virus	I
4	and	O
5	hepatoma	O
6	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	O
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	B
18	factor	I
19	binding	I
20	sites	I
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	B
26	-	I
27	responsive	I
28	element	I
29	)	O
30	were	O
31	found	O
32	.	O

1	ENV	B
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	O
12	.	O
13	cerevisiae	O
14	alpha	B
15	-	I
16	factor	I
17	prepro	O
18	secretion	O
19	leader	O
20	and	O
21	the	O
22	S	O
23	.	O
24	cerevisiae	O
25	invertase	O
26	signal	O
27	sequence	O
28	.	O

1	We	O
2	calculated	O
3	differences	O
4	in	O
5	late	O
6	occlusion	O
7	rates	O
8	by	O
9	the	O
10	chi2	O
11	(	O
12	chi	O
13	-	O
14	square	O
15	)	O
16	test	O
17	,	O
18	and	O
19	found	O
20	these	O
21	differences	O
22	were	O
23	significant	O
24	(	O
25	P	O
26	=.	O
27	04	O
28	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	c	B
7	-	I
8	met	I
9	gene	I
10	is	O
11	also	O
12	a	O
13	target	O
14	of	O
15	p53	B
16	gene	I
17	regulation	O
18	.	O

1	Intermediate	B
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	I
12	E	I
13	-	I
14	boxes	I
15	derived	I
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	We	O
2	conducted	O
3	a	O
4	prospective	O
5	,	O
6	randomized	O
7	controlled	O
8	trial	O
9	of	O
10	metoprolol	O
11	,	O
12	a	O
13	selective	O
14	beta	B
15	-	I
16	blocker	O
17	for	O
18	prevention	O
19	of	O
20	gastrointestinal	O
21	bleeding	O
22	from	O
23	portal	O
24	hypertension	O
25	in	O
26	29	O
27	non	O
28	-	O
29	selected	O
30	patients	O
31	with	O
32	liver	O
33	disease	O
34	and	O
35	previous	O
36	gastrointestinal	O
37	bleeding	O
38	.	O

1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O

1	Catecholamines	B
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	carp	B
5	JAK1	I
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	B
12	JAK1	I
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	O
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	O
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	Processing	B
2	of	O
3	the	O
4	NS3	B
5	'-	I
6	5B	I
7	polyprotein	I
8	was	O
9	complex	O
10	and	O
11	occurred	O
12	rapidly	O
13	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	sought	O
8	to	O
9	investigate	O
10	whether	O
11	constitutive	O
12	NF	B
13	-	I
14	kappaB	I
15	activity	O
16	in	O
17	chronically	O
18	HIV	B
19	-	I
20	1	I
21	-	I
22	infected	O
23	promonocytic	O
24	U937	O
25	(	O
26	U9	B
27	-	I
28	IIIB	I
29	)	O
30	and	O
31	myeloblastic	O
32	PLB	O
33	-	O
34	985	O
35	(	O
36	PLB	B
37	-	I
38	IIIB	I
39	)	O
40	cells	O
41	affects	O
42	apoptotic	O
43	signaling	O
44	.	O

1	Identical	B
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	B
22	gene	I
23	is	O
24	expressed	O
25	.	O

1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	O
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	O
24	in	O
25	vivo	O
26	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	identified	O
6	two	O
7	Sp1	B
8	binding	I
9	sites	I
10	within	O
11	this	O
12	element	O
13	.	O

1	Histamine	O
2	reactivity	O
3	had	O
4	returned	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	factories	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	worker	O
23	who	O
24	had	O
25	moved	O
26	within	O
27	her	O
28	original	O
29	factory	O
30	.	O

1	The	O
2	DNA	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	1520	O
9	amino	O
10	acids	O
11	with	O
12	sequence	O
13	homology	O
14	to	O
15	the	O
16	human	O
17	c	B
18	-	I
19	abl	I
20	proto	I
21	-	I
22	oncogene	I
23	product	I
24	,	O
25	beginning	O
26	at	O
27	the	O
28	amino	O
29	terminus	O
30	and	O
31	extending	O
32	656	O
33	amino	O
34	acids	O
35	through	O
36	the	O
37	region	O
38	essential	O
39	for	O
40	tyrosine	B
41	kinase	I
42	activity	O
43	.	O

1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	O
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	O
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	B
45	-	I
46	31	I
47	-	I
48	8220	O
49	.	O

1	For	O
2	E2	O
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	itraconazole	O
25	/	O
26	kg	O
27	(	O
28	capsules	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O

1	Thus	O
2	,	O
3	the	O
4	PCE	O
5	binds	O
6	a	O
7	Pbx	O
8	dimer	O
9	partner	O
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	I
15	Hox	I
16	proteins	I
17	.	O

1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O

1	Defective	B
2	provirus	O
3	genomes	O
4	of	O
5	human	B
6	T	I
7	-	I
8	cell	I
9	leukemia	I
10	virus	I
11	type	I
12	I	I
13	are	O
14	frequently	O
15	detected	O
16	in	O
17	lymphocytes	O
18	from	O
19	infected	O
20	individuals	O
21	and	O
22	in	O
23	infected	O
24	cell	O
25	lines	O
26	.	O

1	In	O
2	vivo	O
3	association	O
4	between	O
5	Shb	O
6	-	O
7	SH3	B
8	domain	I
9	proteins	I
10	v	I
11	-	I
12	Src	I
13	and	O
14	Eps8	O
15	was	O
16	detected	O
17	by	O
18	coimmunoprecipitation	O
19	.	O

1	Thrombophlebitis	B
2	and	O
3	pulmonary	O
4	embolism	O
5	in	O
6	congenital	O
7	factor	O
8	XII	O
9	deficiency	O

1	Cardiac	B
2	endothelin	I
3	release	O
4	and	O
5	infarct	O
6	size	O
7	,	O
8	myocardial	O
9	blood	O
10	flow	O
11	,	O
12	and	O
13	ventricular	O
14	function	O
15	in	O
16	canine	O
17	infarction	O
18	and	O
19	reperfusion	O
20	.	O

1	We	O
2	have	O
3	identified	O
4	amino	O
5	acid	O
6	sequences	O
7	in	O
8	mammalian	O
9	and	O
10	Xenopus	O
11	NeuroD1	O
12	/	O
13	BETA2	O
14	that	O
15	are	O
16	necessary	O
17	for	O
18	insulin	B
19	gene	I
20	expression	O
21	and	O
22	ectopic	O
23	neurogenesis	O
24	.	O

1	Gastric	B
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O

1	US	O
2	-	O
3	Doppler	O
4	has	O
5	recently	O
6	gained	O
7	attention	O
8	as	O
9	a	O
10	noninvasive	O
11	method	O
12	for	O
13	the	O
14	functional	O
15	evaluation	O
16	of	O
17	arteriovenous	O
18	fistulas	O
19	(	O
20	FAV	O
21	).	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	Using	O
2	a	O
3	MOS	O
4	-	O
5	Hypersil	O
6	reversed	O
7	-	O
8	phase	O
9	column	O
10	with	O
11	a	O
12	phosphate	O
13	buffer	O
14	--	O
15	acetonitrile	O
16	mobile	O
17	phase	O
18	,	O
19	baseline	O
20	separation	O
21	of	O
22	antipyrine	O
23	,	O
24	its	O
25	metabolites	O
26	3	O
27	-	O
28	hydroxymethylantipyrine	O
29	,	O
30	norantipyrine	O
31	and	O
32	4	O
33	-	O
34	hydroxyantipyrine	O
35	,	O
36	and	O
37	the	O
38	internal	O
39	standard	O
40	,	O
41	phenacetin	O
42	,	O
43	was	O
44	achieved	O
45	within	O
46	6	O
47	min	O
48	.	O

1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	O
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	I
22	granulocyte	I
23	-	I
24	macrophage	I
25	CSF	I
26	,	I
27	macrophage	I
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O

1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O

1	Using	O
2	autoantibodies	O
3	from	O
4	a	O
5	Sjogren	O
6	'	O
7	s	O
8	syndrome	O
9	patient	O
10	,	O
11	we	O
12	have	O
13	previously	O
14	identified	O
15	a	O
16	230	O
17	-	O
18	kDa	O
19	peripheral	O
20	membrane	O
21	protein	O
22	associated	O
23	with	O
24	the	O
25	cytosolic	O
26	face	O
27	of	O
28	the	O
29	trans	O
30	-	O
31	Golgi	O
32	(	O
33	Kooy	O
34	,	O
35	J	O
36	.,	O
37	Toh	O
38	,	O
39	B	O
40	.	O

1	In	O
2	the	O
3	pRb	B
4	(-)	I
5	SAOS	I
6	-	I
7	2	I
8	cell	O
9	line	O
10	transiently	O
11	transfected	O
12	with	O
13	a	O
14	reporter	O
15	plasmid	O
16	containing	O
17	six	O
18	tal	B
19	-	I
20	1	I
21	binding	I
22	site	I
23	,	O
24	pRb	B
25	enhances	O
26	the	O
27	transcriptional	O
28	activity	O
29	of	O
30	tal	B
31	-	I
32	1	I
33	-	O
34	E12	B
35	-	I
36	Lmo2	O
37	and	O
38	tal	B
39	-	I
40	1	I
41	-	O
42	E12	B
43	-	I
44	Lmo2	I
45	-	I
46	Ldb1	I
47	complexes	I
48	but	O
49	not	O
50	that	O
51	of	O
52	a	O
53	tal	B
54	-	I
55	1	I
56	-	O
57	E12	B
58	heterodimer	O
59	.	O

1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	O
14	recovery	O
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O

1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O

1	Within	O
2	the	O
3	compartment	O
4	or	O
5	dimension	O
6	of	O
7	severity	O
8	of	O
9	depression	O
10	a	O
11	subscale	O
12	of	O
13	the	O
14	Hamilton	O
15	Depression	O
16	Scale	O
17	(	O
18	or	O
19	the	O
20	Melancholia	O
21	Scale	O
22	)	O
23	was	O
24	shown	O
25	to	O
26	have	O
27	reached	O
28	an	O
29	instrumental	O
30	perfection	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.	O
36	as	O
37	an	O
38	outcome	O
39	measure	O
40	of	O
41	antidepressant	O
42	treatment	O
43	.	O

1	However	O
2	,	O
3	the	O
4	BCH	O
5	group	O
6	showed	O
7	inferior	O
8	gross	O
9	motor	O
10	performance	O
11	on	O
12	the	O
13	Bruininks	O
14	-	O
15	Oseretsky	O
16	Test	O
17	of	O
18	Motor	O
19	Proficiency	O
20	(	O
21	Bruininks	O
22	1978	O
23	).	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	O
7	K1F	B
8	tail	I
9	gene	I
10	encoding	I
11	endo	I
12	-	I
13	N	I
14	-	I
15	acylneuraminidase	O
16	(	O
17	endo	O
18	-	O
19	N	O
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	B
26	-	I
27	N	I
28	homolog	I
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O

1	Bound	B
2	-	I
3	exciton	O
4	transfer	O
5	and	O
6	photoluminescence	O
7	undulation	O
8	spectra	O
9	for	O
10	acceptors	O
11	in	O
12	ZnTe	O
13	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	simple	O
7	respiration	O
8	-	O
9	control	O
10	device	O
11	has	O
12	been	O
13	developed	O
14	that	O
15	enables	O
16	the	O
17	patient	O
18	to	O
19	monitor	O
20	breath	O
21	-	O
22	holding	O
23	during	O
24	successive	O
25	scans	O
26	.	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	O
8	in	O
9	nmt1	O
10	-	O
11	451Dino2	O
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	B
37	protein	I
38	N	I
39	-	I
40	myristoy	I
41	-	I
42	lation	O
43	.	O

1	Prevention	O
2	by	O
3	a	O
4	heparin	O
5	-	O
6	antithrombin	B
7	III	I
8	combination	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	Selective	O
2	bronchial	O
3	intubation	O
4	in	O
5	the	O
6	management	O
7	of	O
8	unilateral	O
9	pulmonary	O
10	interstitial	O
11	emphysema	O
12	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	O
7	sigma	B
8	factor	I
9	,	O
10	RpoN	O
11	,	O
12	in	O
13	Rhodobacter	O
14	capsulatus	O
15	;	O
16	physiological	O
17	relevance	O
18	of	O
19	an	O
20	autoactivated	O
21	nifU2	O
22	-	O
23	rpoN	O
24	superoperon	O
25	.	O

1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O

1	Potentially	B
2	load	O
3	-	O
4	insensitive	O
5	measures	O
6	of	O
7	ventricular	O
8	performance	O
9	were	O
10	therefore	O
11	evaluated	O
12	in	O
13	10	O
14	open	O
15	-	O
16	and	O
17	closed	O
18	-	O
19	chested	O
20	,	O
21	anesthetized	O
22	rabbits	O
23	.	O

1	Urinary	B
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	O
17	sulphatase	O
18	deficiency	O
19	.	O

1	A	I
2	progressive	O
3	growth	O
4	of	O
5	blood	O
6	erythrocyte	O
7	membrane	O
8	injury	O
9	has	O
10	been	O
11	demonstrated	O
12	after	O
13	rats	O
14	were	O
15	exposed	O
16	to	O
17	gamma	B
18	-	I
19	irradiaton	O
20	at	O
21	a	O
22	dose	O
23	of	O
24	100	O
25	to	O
26	500	O
27	Gy	O
28	.	O

1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O

1	Thus	O
2	,	O
3	the	O
4	effects	O
5	of	O
6	father	O
7	absence	O
8	under	O
9	routine	O
10	conditions	O
11	in	O
12	relatively	O
13	healthy	O
14	samples	O
15	may	O
16	exert	O
17	no	O
18	significant	O
19	effects	O
20	independent	O
21	of	O
22	intervening	O
23	family	O
24	stressors	O
25	or	O
26	maternal	O
27	psychopathology	O
28	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	per	O
10	se	O
11	of	O
12	keratan	O
13	sulfate	O
14	on	O
15	native	O
16	G1	O
17	-	O
18	G2	O
19	does	O
20	not	O
21	affect	O
22	the	O
23	activity	O
24	of	O
25	atrolysin	O
26	C	O
27	toward	O
28	the	O
29	two	O
30	sites	O
31	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	B
9	-	I
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	B
34	-	I
35	helical	O
36	stalk	O
37	.	O

1	An	O
2	additional	O
3	advantage	O
4	is	O
5	that	O
6	the	O
7	resin	O
8	can	O
9	be	O
10	removed	O
11	and	O
12	the	O
13	immunoperoxidase	O
14	technique	O
15	carried	O
16	out	O
17	on	O
18	thin	O
19	sections	O
20	.	O

1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O

1	Update	B
2	on	O
3	maternal	O
4	-	O
5	fetal	O
6	infections	O
7	by	O
8	hepatitis	O
9	C	O
10	,	O
11	HIV	O
12	and	O
13	cytomegalovirus	O

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	Spores	B
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	O
7	serum	B
8	CRP	I
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	The	O
2	effects	O
3	of	O
4	anabolic	O
5	implants	O
6	on	O
7	rate	O
8	,	O
9	composition	O
10	and	O
11	energetic	O
12	efficiency	O
13	of	O
14	growth	O
15	were	O
16	determined	O
17	in	O
18	steers	O
19	fed	O
20	diets	O
21	varying	O
22	in	O
23	forage	O
24	and	O
25	grain	O
26	content	O
27	.	O

1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O

1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	O
30	kHz	O
31	.	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	New	O
2	Langevin	O
3	equations	O
4	for	O
5	a	O
6	translating	O
7	and	O
8	simultaneously	O
9	rotating	O
10	asymmetric	O
11	top	O
12	.	O

1	CONCLUSION	O
2	:	O
3	Presence	O
4	of	O
5	APOE	O
6	epsilon4	O
7	/*	O
8	seems	O
9	to	O
10	increase	O
11	the	O
12	risk	O
13	for	O
14	dementia	O
15	and	O
16	AD	O
17	independently	O
18	of	O
19	its	O
20	effect	O
21	on	O
22	dyslipidemia	O
23	and	O
24	atherogenesis	O
25	.	O

1	One	O
2	hundred	O
3	twenty	O
4	units	O
5	of	O
6	deglycerolized	O
7	red	O
8	blood	O
9	cells	O
10	,	O
11	some	O
12	with	O
13	glycerol	O
14	added	O
15	so	O
16	as	O
17	to	O
18	exceed	O
19	an	O
20	acceptable	O
21	1	O
22	%	O
23	glycerol	O
24	content	O
25	,	O
26	had	O
27	measurements	O
28	made	O
29	of	O
30	the	O
31	post	O
32	-	O
33	wash	O
34	supernatant	O
35	fluid	O
36	by	O
37	refractive	O
38	index	O
39	and	O
40	osmometry	O
41	.	O

1	CONCLUSION	O
2	:	O
3	Twice	O
4	daily	O
5	treatment	O
6	with	O
7	inhaled	O
8	fluticasone	O
9	propionate	O
10	50	O
11	micrograms	O
12	or	O
13	100	O
14	micrograms	O
15	was	O
16	significantly	O
17	more	O
18	effective	O
19	than	O
20	theophylline	O
21	in	O
22	the	O
23	treatment	O
24	of	O
25	mild	O
26	-	O
27	to	O
28	-	O
29	moderate	O
30	asthma	O
31	.	O

1	Effects	O
2	of	O
3	a	O
4	new	O
5	antihypertensive	O
6	agent	O
7	,	O
8	SGB	O
9	-	O
10	1534	O
11	,	O
12	on	O
13	rat	O
14	platelet	O
15	aggregation	O
16	.	O

1	Based	O
2	on	O
3	the	O
4	estimated	O
5	values	O
6	of	O
7	divergence	O
8	of	O
9	apobec1	O
10	sequences	O
11	in	O
12	terms	O
13	of	O
14	the	O
15	numbers	O
16	of	O
17	synonymous	O
18	and	O
19	non	O
20	-	O
21	synonymous	O
22	suhstitutions	O
23	per	O
24	site	O
25	,	O
26	we	O
27	found	O
28	that	O
29	apobec1	O
30	is	O
31	a	O
32	fairly	O
33	rapidly	O
34	evolving	O
35	protein	O
36	.	O

1	Our	O
2	analysis	O
3	of	O
4	nonsense	O
5	mutations	O
6	indicates	O
7	that	O
8	the	O
9	C	O
10	terminus	O
11	of	O
12	eIF2Bepsilon	O
13	(	O
14	residues	O
15	518	O
16	to	O
17	712	O
18	)	O
19	is	O
20	required	O
21	for	O
22	both	O
23	catalytic	O
24	activity	O
25	and	O
26	interaction	O
27	with	O
28	eIF2	O
29	.	O

1	The	O
2	Jem	O
3	peptide	O
4	sequence	O
5	shows	O
6	a	O
7	'	O
8	leucine	O
9	-	O
10	zipper	O
11	'	O
12	dimerisation	O
13	motif	O
14	with	O
15	limited	O
16	homology	O
17	to	O
18	Fos	B
19	/	I
20	Jun	I
21	and	O
22	ATF	B
23	/	I
24	CREB	I
25	proteins	I
26	and	O
27	several	O
28	putative	O
29	phosphorylation	O
30	sites	O
31	.	O

1	(	I
2	2	I
3	)	O
4	The	O
5	inappropriateness	O
6	of	O
7	adaptive	O
8	segmentation	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	spikes	O
14	and	O
15	sharp	O
16	waves	O
17	,	O
18	which	O
19	had	O
20	been	O
21	anticipated	O
22	in	O
23	view	O
24	of	O
25	the	O
26	short	O
27	duration	O
28	of	O
29	such	O
30	transients	O
31	in	O
32	relation	O
33	to	O
34	the	O
35	length	O
36	of	O
37	the	O
38	window	O
39	(	O
40	1	O
41	.	O
42	2	O
43	sec	O
44	)	O
45	used	O
46	for	O
47	the	O
48	autocorrelation	O
49	functions	O
50	employed	O
51	in	O
52	the	O
53	segmentation	O
54	algorithm	O
55	,	O
56	was	O
57	confirmed	O
58	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	telomeres	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O

1	Thromboplastin	B
2	time	O
3	,	O
4	partial	O
5	thromboplastin	B
6	time	O
7	,	O
8	thrombin	B
9	time	O
10	,	O
11	heat	O
12	-	O
13	dependent	O
14	fibrin	B
15	,	O
16	clot	O
17	retraction	O
18	,	O
19	and	O
20	clotting	B
21	factors	I
22	II	I
23	,	O
24	V	O
25	,	O
26	VIII	O
27	,	O
28	IX	O
29	,	O
30	X	O
31	,	O
32	and	O
33	the	O
34	platelet	O
35	count	O
36	were	O
37	determined	O
38	.	O

1	Handling	B
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	Filter	B
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O

1	Synthesis	B
2	of	O
3	antisense	O
4	RNA	O
5	and	O
6	S	O
7	phase	O
8	-	O
9	dependent	O
10	binding	O
11	of	O
12	E2F	B
13	complexes	I
14	in	O
15	intron	O
16	1	O
17	.	O

1	A	I
2	proportion	O
3	of	O
4	APC	O
5	wild	B
6	-	I
7	type	I
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	I
20	beta	I
21	-	I
22	catenin	I
23	complexes	I
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	O
52	/	O
53	Conductin	O
54	.	O

1	Furthermore	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	both	O
8	p46	B
9	and	O
10	p54	O
11	subunits	O
12	markedly	O
13	altered	O
14	the	O
15	subcellular	O
16	distribution	O
17	of	O
18	p46	B
19	;	O
20	co	O
21	-	O
22	expressed	O
23	p46	B
24	was	O
25	transported	O
26	into	O
27	the	O
28	nucleus	O
29	as	O
30	efficiently	O
31	as	O
32	p54	O
33	.	O

1	RESULTS	O
2	:	O
3	Each	O
4	year	O
5	,	O
6	on	O
7	average	O
8	39	O
9	%	O
10	of	O
11	cases	O
12	seen	O
13	in	O
14	Sardinia	O
15	are	O
16	notified	O
17	;	O
18	646	O
19	(	O
20	40	O
21	%)	O
22	of	O
23	the	O
24	1591	O
25	patients	O
26	notified	O
27	during	O
28	the	O
29	study	O
30	period	O
31	were	O
32	never	O
33	seen	O
34	by	O
35	regional	O
36	medical	O
37	centres	O
38	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	two	O
7	treatment	O
8	groups	O
9	were	O
10	found	O
11	,	O
12	but	O
13	rapid	O
14	responders	O
15	had	O
16	a	O
17	smaller	O
18	mean	O
19	initial	O
20	platelet	B
21	-	I
22	associated	I
23	IgG	I
24	index	O
25	which	O
26	returned	O
27	more	O
28	rapidly	O
29	and	O
30	more	O
31	permanently	O
32	to	O
33	normal	O
34	than	O
35	that	O
36	of	O
37	slow	O
38	responders	O
39	.	O

1	The	O
2	computer	O
3	-	O
4	programmed	O
5	cytocentrifuge	O
6	is	O
7	currently	O
8	most	O
9	popular	O
10	.	O

1	The	O
2	histological	O
3	grading	O
4	was	O
5	certified	O
6	in	O
7	68	O
8	cases	O
9	:	O
10	12	O
11	G1	O
12	,	O
13	39	O
14	G2	O
15	,	O
16	17	O
17	G3	O
18	;	O
19	extracapsular	O
20	spread	O
21	was	O
22	found	O
23	in	O
24	20	O
25	/	O
26	54	O
27	cases	O
28	(	O
29	37	O
30	%).	O

1	Treatment	O
2	also	O
3	led	O
4	to	O
5	a	O
6	significant	O
7	dose	O
8	dependent	O
9	reduction	O
10	in	O
11	the	O
12	sum	O
13	of	O
14	ST	O
15	segment	O
16	depression	O
17	at	O
18	both	O
19	trough	O
20	and	O
21	peak	O
22	concentrations	O
23	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	O
17	to	O
18	block	O
19	EIB	O
20	.	O

1	With	O
2	histology	O
3	and	O
4	Evans	O
5	blue	O
6	injections	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	alterations	O
13	were	O
14	seen	O
15	as	O
16	early	O
17	as	O
18	4	O
19	days	O
20	after	O
21	a	O
22	dose	O
23	of	O
24	50	O
25	Gy	O
26	.	O

1	The	O
2	revertant	O
3	TATA	O
4	boxes	O
5	accelerated	O
6	the	O
7	kinetics	O
8	of	O
9	HIV	O
10	replication	O
11	when	O
12	present	O
13	in	O
14	the	O
15	context	O
16	of	O
17	an	O
18	LTR	O
19	containing	O
20	a	O
21	Sp1	B
22	mutation	I
23	(	O
24	deletion	O
25	or	O
26	site	O
27	specific	O
28	);	O
29	no	O
30	effect	O
31	was	O
32	observed	O
33	on	O
34	the	O
35	infectivity	O
36	of	O
37	wild	B
38	-	I
39	type	I
40	HIV	I
41	.	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	findings	O
5	imply	O
6	that	O
7	eotaxin	O
8	either	O
9	is	O
10	mechanistically	O
11	involved	O
12	in	O
13	acute	O
14	asthma	O
15	or	O
16	serves	O
17	as	O
18	a	O
19	biomarker	O
20	for	O
21	activity	O
22	of	O
23	the	O
24	CCR3	B
25	receptor	I
26	ligand	O
27	system	O
28	,	O
29	which	O
30	is	O
31	functionally	O
32	linked	O
33	to	O
34	asthma	O
35	.	O

1	Experimental	O
2	pancreatitis	O
3	in	O
4	pigs	O
5	.	O

1	The	O
2	rat	B
3	aldolase	I
4	C	I
5	gene	I
6	encodes	O
7	a	O
8	glycolytic	O
9	enzyme	O
10	strongly	O
11	expressed	O
12	in	O
13	adult	O
14	brain	O
15	.	O

1	A	I
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	O
7	1	O
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

